<SEC-DOCUMENT>0001104659-24-045216.txt : 20240524
<SEC-HEADER>0001104659-24-045216.hdr.sgml : 20240524
<ACCEPTANCE-DATETIME>20240409160848
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-24-045216
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20240409
<PUBLIC-REL-DATE>20240524
DATE AS OF CHANGE:		20240409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACTUATE THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001652935
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473044785
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07119
		FILM NUMBER:		24832802

	BUSINESS ADDRESS:	
		STREET 1:		1751 RIVER RUN
		STREET 2:		SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107
		BUSINESS PHONE:		847-986-4190

	MAIL ADDRESS:	
		STREET 1:		1751 RIVER RUN
		STREET 2:		SUITE 400
		CITY:			FORT WORTH
		STATE:			TX
		ZIP:			76107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apotheca Therapeutics, Inc.
		DATE OF NAME CHANGE:	20150911
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
submitted confidentially to the Securities and Exchange Commission on April 9, 2024</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <B>This Amendment No.
1 to draft registration statement has not been publicly filed with the Securities and Exchange Commission</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>and all information herein
remains strictly confidential.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Actuate Therapeutics,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8731</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-3044785</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State or other jurisdiction of<BR>
incorporation or organization)</I></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary Standard Industrial<BR>
Classification Code Number)</I></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S. Employer <BR>
Identification Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1751 River Run, Suite&nbsp;400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fort Worth, Texas 76107<BR>
(817) 887-8455</B></P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, including
zip code, and telephone number, including area code, of registrant&rsquo;s principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Daniel Schmitt</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1751 River Run, Suite&nbsp;400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fort Worth, Texas 76107<BR>
(817) 887-8455</B></P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name, address,
including zip code, and telephone number, including area code, of agent for service)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Janet Spreen,&nbsp;Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Asim Grabowski-Shaikh,&nbsp;Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Baker&nbsp;&amp; Hostetler LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>127 Public Square, Suite&nbsp;2000</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cleveland, Ohio 44114</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (216) 621-0200</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stephen E. Older,&nbsp;Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Andrew Terjesen,&nbsp;Esq.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>McGuireWoods LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1251 Avenue of the Americas</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20th Floor</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10020</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (212) 548-2100</B>&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B></FONT> As soon as practicable after this Registration Statement is declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If any of the securities
being registered on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933 check the following box: <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If this Form&nbsp;is
filed to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If this Form&nbsp;is
a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If this Form&nbsp;is
a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company&rdquo;
and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 21%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 35%; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 27%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 17%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Wingdings"> </FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a)&nbsp;of the
Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said
Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">The information in this preliminary
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>PRELIMINARY PROSPECTUS, DATED &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm247121d1_drs-sp1img002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is the initial public offering of shares
of common stock of Actuate Therapeutics,&nbsp;Inc. We are offering&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&emsp;&emsp;shares of our
common stock. It is currently estimated that the initial public offering price per share of common stock will be between $&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;and
$&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been no public
market for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to list our common stock on the
Nasdaq Capital Market under the symbol &ldquo;ACTU&rdquo;. We believe that upon the completion of this offering, we will meet the standards
for listing on the Nasdaq Capital Market, and the closing of this offering is contingent upon such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 and have elected to comply with certain reduced public company reporting
requirements in this prospectus and may elect to do so in future filings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Investing in our common stock is highly
speculative and involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;12.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify; padding-left: 0in">Public offering price</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in">Proceeds, before expenses, to us</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;Underwriting&rdquo; for additional disclosure regarding the underwriting discounts and commissions and estimated offering expenses, as well as a complete description of the compensation payable to the underwriters.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriters an option for
a period of 30 days to purchase up to an additional&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
of our common stock at the initial public offering price, less the underwriting discounts and commissions solely to cover over-allotments,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters expect to deliver the shares
on or about&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Partners Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>a division of American Capital Partners</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 96%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 4%; border-bottom: Black 1pt solid; text-align: center"> Page </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_001">1</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_002">12</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDUSTRY AND MARKET DATA</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_004">70</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_005">71</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_006">72</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAPITALIZATION</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_007">73</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_008">75</A> </TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 96%"> <A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE
    REGARDING FORWARD-LOOKING STATEMENTS</FONT></A> </TD>
    <TD STYLE="text-align: right; width: 4%"> <A HREF="#b_001">78</A> </TD></TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 96%"> <A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; width: 4%"> <A HREF="#a_009">79</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_010">91</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_011">136</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_012">144</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED
    PARTY TRANSACTIONS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_013">154</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL SECURITYHOLDERS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_014">158</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL</FONT> STOCK</A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_015">161</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SHARES ELIGIBLE FOR FUTURE SALE</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_016">167</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL U.S. FEDERAL INCOME TAX
    CONSEQUENCES FOR NON-U.S. HOLDERS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_017">170</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_018">174</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_019">183</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_020">183</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_021">183</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL
    STATEMENTS</FONT></A> </TD>
    <TD STYLE="text-align: right"> <A HREF="#a_022">F-1</A> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in this prospectus. Neither we nor the underwriters have authorized anyone to provide you with different information
and, if provided, such information or representations must not be relied upon as having been authorized by us or the underwriters. This
prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which
it is unlawful for such person to make such an offering or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should read this prospectus
together with the additional information described below under the heading &ldquo;Where You Can Find More Information.&rdquo; We may also
provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information
contained in, this prospectus. The information contained in this prospectus, or any free writing prospectus is accurate only as of its
date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations
and prospects may have changed since that date. This prospectus does not contain all of the information included in the Registration Statement.
For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus includes our
trademarks, and trade names, including but not limited to Actuate and Actuate Therapeutics, which are protected under applicable intellectual
property laws. This prospectus also may contain trademarks, service marks, trade names, and copyrights of other companies, which are the
property of their respective owners. Solely for convenience, the trademarks, service marks, trade names, and copyrights referred to in
this prospectus are listed without the TM, SM, &copy;, and &reg; symbols, but we will assert, to the fullest extent under applicable law,
our rights or the rights of the applicable licensors, if any, to these trademarks, service marks, trade names, and copyrights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>PROSPECTUS
SUMMARY<SUP></SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>This summary contains
basic information about us and our business but does not contain all of the information that is important to your investment decision,
and is qualified in its entirety by the more detailed information and consolidated financial statements included elsewhere in this prospectus.
You should carefully read this summary together with the more detailed information contained elsewhere in this prospectus before making
an investment decision. Investors should carefully consider the information set forth under the caption &ldquo;Risk Factors&rdquo; appearing
elsewhere in this prospectus. Unless the context requires otherwise, references in this prospectus to &ldquo;Actuate,&rdquo; the &ldquo;Company,&rdquo;
 &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Actuate Therapeutics,&nbsp;Inc.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen
synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and
block the function of the enzyme GSK-3&beta;, a master regulator of complex biological signaling cascades, including those mediated by
oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3&beta; signaling ultimately
results in the death of the cancer cells and the regulation of anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The enzyme GSK-3&beta;, a
serine/threonine protein kinase, is understood to be an essential positive regulator of nuclear factor kappa B (NF-kB) transcriptional
activity. Studies have demonstrated that the inhibition of GSK-3&beta; decreases cancer cell survival via suppression of the transcriptional
activity of its downstream effector NF-kB. In light of these findings, we believe that the inhibition of GSK-3&beta; may overcome and/or
reverse NF-kB-mediated cancer cell survival and chemoresistance to conventional chemotherapeutic drugs in a range of human cancers. Research
has also demonstrated that aberrant nuclear GSK-3&beta; accumulation is limited to cancer cells, making GSK-3&beta; a potential candidate
for specific and targeted cancer therapy. Additionally, GSK-3 regulates the expression of immune modulators such as pro-inflammatory cytokines
and checkpoint molecules in tumor and immune cells. We believe blocking GSK-3 in these cells leads to improved immune cell function, which
can ultimately result in better, longer clinical responses in patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Lead Product Candidate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have exclusively licensed
a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University
(NU). The lead drug in our portfolio is called elraglusib (9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients
with metastatic pancreatic cancer, our most advanced clinical indication to date. Elraglusib represents a broad opportunity for us to
potentially initiate and advance multiple drug development programs around our lead asset based on data emerging from completed or ongoing
Phase 1/2 trials in pediatric and adult patients with advanced, refractory cancers. Many of the pathological processes that drive cancer
are controlled by GSK-3&beta; and thus, by targeting GSK-3&beta;, we are pursuing the development of products designed to intervene in
the progression of multiple cancer types. Animal tumor model data and Phase 1/2 clinical data have identified a number of areas of unmet
clinical need in cancer where elraglusib may play an interventional role, including pancreatic, colon, lung, breast, renal, ovarian,
leukemias and lymphomas, and melanoma, as well as some pediatric cancers including Ewing sarcoma, neuroblastoma and pediatric leukemias. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our lead program, Elraglusib
Injection, is an intravenous solution of elraglusib that we are evaluating for the treatment of metastatic pancreatic ductal adenocarcinoma
(mPDAC). Elraglusib Injection has been evaluated in a Phase 1 dose escalation study (Actuate-1801 Part 1) in 238 adult patients with
refractory advanced cancers when given as a single agent (n=67) or in combination with chemotherapy (n=171). The objective of this study
was to establish the safety profile of elraglusib when used alone or in combination with chemotherapy and to identify either a maximum
tolerated dose (MTD) or recommended phase 2 dose (RP2D) to then inform the design of exploratory efficacy studies in Phase 2. Subjects
in this study were diagnosed with a variety of cancer types and most patients had received two or more previous lines of chemotherapy
prior to enrollment in the study. Objective responses and durable disease control were observed in both the single agent and combination
treatment arms of the study. The most common treatment-emergent adverse events (TEAEs) attributed to elraglusib were transient visual
disturbance (patients described lights as brighter and skin tones darker, which resolved spontaneously) and fatigue across both study
parts. The majority (&gt;99%) of TEAEs that occurred in &ge; 20% of patients were reported as Grade 1 or 2 (mild or moderate). In combination
with chemotherapy, no new safety signals were observed. Based on the results of the Phase 1 study, which established 15 mg/kg as the
RP2D when combined with chemotherapy, we initiated a single arm Phase 2 study (Actuate-1801 Part 2) in patients with previously untreated
mPDAC. This study was originally designed as a single arm exploratory Simon two-stage trial (and therefore not designed or powered to
demonstrate statistical significance), but after an analysis conducted following the completion of Stage 1, which showed a median overall
survival (mOS) of 15.3 months in the efficacy evaluable (n=29) patient population, we amended and expanded the Stage 2 of the study to
a randomized, controlled trial now powered for statistical significance (Actuate-1801 Part 3A) that would allow a comparison of the safety
and efficacy of the combination of Elraglusib Injection plus gemcitabine/nab-paclitaxel (GnP) as compared to GnP alone. Elraglusib is
currently being evaluated as a weekly intravenous (IV)&nbsp;infusion in combination with the approved dosing regimen for GnP. This study
completed enrollment four months faster than predicted and top line results are expected in the first quarter of 2025. The primary endpoint
is overall survival (OS). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> According to the American
Cancer Society, the annual incidence of pancreatic cancer is expected to exceed 66,000 patients in the United States this year and approximately
70% of these patients will present with metastatic disease. The mOS in patients with mPDAC is 9-11 months and the ability to extend survival
by even a few months would be considered meaningful in this patient population. Elraglusib has been granted Fast Track and Orphan Drug
Designations from the U.S. Food and Drug Administration (FDA) for pancreatic cancer in the United States. Based on our meetings with
the FDA to discuss our development plan in pancreatic cancer, the current Phase 2 study design cannot be used to support accelerated
approval. However, if the future mOS data is positive in favor of the elraglusib/GnP combination, we would initiate further conversations
with the FDA to discuss possible registration. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Two additional exploratory,
single arm Phase 2 studies are ongoing in patients with pancreatic cancer evaluating novel drug combinations with elraglusib: the combination
of elraglusib/FOLFIRINOX/losartan in up to 65 patients with mPDAC and the combination of elraglusib/GnP/retinfanlimab in up to 32 patients
with advanced PDAC. Both studies are academic investigator-initiated trials (IITs) that are exploring the addition of immunomodulatory
drugs to an elraglusib/chemotherapy backbone. Enrollment in both of these investigator-initiated studies is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elraglusib
Injection has also been evaluated in pediatric cancer patients with recurrent/refractory solid cancers. This study, Actuate-1902, is
a Phase 1/2 study that evaluated escalating doses of elraglusib as a single agent as well as in combination with irinotecan or cyclophosphamide/topotecan
in the Phase 1 portion. This study was based off of the recommended Phase 2 dose (RP2D) from the Actuate-1801 adult cancer study using
twice weekly dosing of elraglusib. Patients in this Actuate-1902 study also experienced a number of objective responses in the combination
chemotherapy arms, and based on this data, we identified Ewing sarcoma as a potential second indication for further development of Elraglusib
Injection. Currently, the Actuate-1902 study is closed to accrual. However, we plan to submit an amendment to the protocol and seek to
re-open the Phase 2 portion of this study to enroll only Ewing sarcoma patients to further investigate the activity of elraglusib in
this patient population. We are also evaluating the potential for additional exploratory development of Elraglusib Injection in other
pediatric cancer indications, including leukemias, which we expect to explore through academic IITs.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have developed several
oral dosage forms of elraglusib, including an oral liquid (Elraglusib Oral Liquid) and several solid dosage forms including an Elraglusib
Oral Tablet product candidate, which we believe will allow us to expand the number of cancer indications that we are able to target and
allow us to further explore optimal dosing. A Phase 1 healthy volunteer study (Actuate-2203) was completed showing very favorable (&gt;50%)
bioavailability after a single dose of Elraglusib Oral Liquid. A clinical candidate tablet (Elraglusib Oral Tablet) has been developed
and selected. Subject to our receipt of the proceeds of this offering, the manufacture of Elraglusib Oral Tablet under current Good Manufacturing
Practices (cGMP) is expected to be available in the third quarter of 2024 and a first in human dose escalation study using Elraglusib
Oral Tablet is expected to begin in the fourth quarter of 2024. We are planning a Phase 1 study (Actuate-2401) to identify the MTD/ RP2D
for Elraglusib Oral Tablet in patients with advanced, refractory adult cancers subject to our receipt of the proceeds of this offering.
Several Phase 2 indications, including refractory, metastatic melanoma and refractory, metastatic colorectal cancer have been identified
for further clinical development of Elraglusib Oral Tablet based on data from the Actuate-1801 study once the MTD/RP2D for the oral tablet
has been established. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pipeline and Development Timeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our current pipeline consists
of a &ldquo;pipeline in a molecule&rdquo; for elraglusib, which is being evaluated in mPDAC and pediatric malignancies. We are currently
focused on advancing our trials in pancreatic cancer with Elraglusib Injection. Our ability to advance our planned trials listed in the
development table below will depend on our ability to raise sufficient capital to support those trials, as discussed under &ldquo;Use
of Proceeds&rdquo; below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d1_drs-sp1img001.jpg" ALT="" STYLE="height: 474px; width: 840px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to available financing,
we intend to develop elraglusib in a broad list of advanced cancer indications, initially in patients with refractory disease and with
an initial focus on metastatic pancreatic cancer. Our portfolio consists of two product candidates, Elraglusib Injection and Elraglusib
Oral Tablet, which we believe will provide us with two different dosage forms of drug with different attributes that will allow us to
tailor each dosage form to a specific cancer type to potentially improve outcomes and compliance. Key elements of our strategy to accomplish
this objective include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Build
    a sustainable oncology company. </I></B></FONT> <FONT STYLE="font-size: 10pt">Our goal is to build a leading oncology company
    with a sustainable pipeline of target indications revolving around a patented, active product candidate, elraglusib, that can be
    delivered in different ways to potentially treat a wide variety of cancers. To accomplish this, we are focused on rapid advancement
    of our currently active clinical trials while curating and preparing additional indications for future expansion of elraglusib development.
    This effort is led by Daniel Schmitt, our chief executive officer and founder, and Dr.&nbsp;Andrew Mazar, our scientific co-founder
    and chief operating officer, who have more than 60 years of combined experience in the management of biotechnology companies and
    healthcare investing.&nbsp;&nbsp;Mr.&nbsp;Schmitt has led and contributed to the successful development and launch of multiple pharmaceutical
    and health technology products and executed over approximately $1.0 billion in milestone value through licensing, acquisition, and
    development deals. Dr.&nbsp;Mazar has founded seven start-ups and is the co-founder and former chief scientific officer and director,
    of Monopar Therapeutics,&nbsp;Inc. (Nasdaq: MNPR) as well as the former chief scientific officer of Attenuon, LLC. Dr.&nbsp;Mazar
    has shepherded eleven drugs from discovery stage through Phase 2 and Phase 3 trials. Our board of directors, or Board, is comprised
    of experienced entrepreneurs, scientists, and investors in the biotechnology industry<B><I>.</I></B></FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance our lead product
    candidate, elraglusib, through clinical trials. </I></B></FONT>We have generated clinical data from over 500 patients that have been
    dosed with elraglusib to date. Under the innovative seamless study design of our Actuate-1801 Phase 1/2 clinical trial, we have
    initiated a Phase 2 trial testing Elraglusib Injection in combination with chemotherapy in pancreatic cancer under this Master
    protocol (Actuate-1801 Part 3A). We are also advancing an opportunity in Ewing Sarcoma as part of the Actuate-1902 Phase 1/2 study
    in pediatric refractory malignancies. Currently, the Phase 1 portion of the Actuate-1902 study is closed to accrual and we are
    working to amend the Phase 2 portion of this trial to focus on Ewing Sarcoma. We also intend to explore strategically identified
    investigator-initiated trials (IIT) that may identify additional indications and standard of care products to combine with
    elraglusib in indications that go beyond those already identified in Actuate 1801-Part 1 and 2, which allows us to further leverage
    our pipeline in a molecule. By collaborating with our network of oncology Key Opinion Leaders (KOLs) we anticipate partnering to
    access non-dilutive funding for our IITs through both Federal (e.g. National Institute of Health (NIH)) and non-federal (e.g.
    cancer-specific foundations, pharma partners) sources. For example, Actuate collaborated with Dr. Colin Weekes to obtain Lustgarten
    Foundation grant support for the IIT currently being run at Massachusetts General Hospital (MGH). Actuate provides financial and
    resource support for IITs in exchange for rights to the trial data, but Actuate has no control over or input into the design or
    conduct of an IIT. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance our lead product candidate,
    elraglusib, by obtaining regulatory development incentives to accelerate path to approval. </I></B></FONT>One of our strategic objectives
    is to obtain development incentives in the United States and in other countries that we believe may accelerate our path to drug approval:
    Orphan Drug Designation, Fast-Track designation and Breakthrough Therapy Designation (BTD) in the United States; Orphan and priority
    medicines (PRIME) designations in the European Union (EU); and Orphan designations in Japan and Australia. There is no guarantee
    that any such designation, if received, will actually lead to a faster development, regulatory review or approval process. </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Explore strategic partnerships that can accelerate and maximize the potential of GSK-3 inhibitors.</I></B></FONT> <FONT STYLE="font-size: 10pt">We will evaluate potential strategic (pharma) partnering opportunities which could further help us to accelerate development of elraglusib by providing expertise, guidance, and funding to expand the pipeline into different tumors and other diseases areas that could benefit from GSK-3 inhibitor therapy, as discussed above. We may also broaden the reach of our platform by selectively in-licensing technologies or novel product candidates. In addition, we will consider potentially out-licensing certain geographic rights to elraglusib or other product candidates in our target indications or for indications and industries that we are not currently pursuing ourselves.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leverage
    our academic and research partnerships. </I></B></FONT> <FONT STYLE="font-size: 10pt">We are actively engaging with regulators,
    KOLs, advocates and other stakeholders early and throughout the development process in each cancer indication being considered for
    development to enhance the probability of technical success.&nbsp;&nbsp;We currently have clinical partnerships with investigators
    conducting IITs with elraglusib at MGH, the University of Pittsburgh (UPMC), and the Dana-Farber Cancer Institute (DFCI) and we expect
    to expand these pending additional funding to explore indications beyond pancreatic cancer.&nbsp;&nbsp;&nbsp;We also have a research
    and development collaboration with Lantern Pharma to leverage their artificial intelligence platform to further understand the effects
    of elraglusib and identify patient subtypes that are particularly susceptible to GSK-3 inhibition. We expect to continue to leverage
    these partnerships and establish others to hone and expand our research and development efforts.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risk Factor Summary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
many significant risks, as more fully described in the section titled &ldquo;Risk Factors&rdquo; immediately following this prospectus
summary. You should read and carefully consider these summary risks, together with the risks set forth under the section titled &ldquo;Risk
Factors&rdquo; and all of the other information in this prospectus, including the financial statements and the related notes included
elsewhere in this prospectus, before deciding whether to invest in our common stock. If any of the risks discussed in this prospectus
actually occurs, our business, prospects, financial condition or operating results could be materially and adversely affected. In particular,
our risks include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> We
                                            have a limited operating history, have incurred significant operating losses since our inception
                                            and expect to incur significant operating losses for the foreseeable future. We have a high
                                            risk of never generating revenue or becoming profitable or, if we achieve profitability,
                                            we may not be able to sustain it. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Our
                                            financial condition raises substantial doubt as to our ability to continue as a going concern. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not have, and may never have, any approved products on the market. Our business is highly dependent upon receiving approvals from various U.S. and international governmental agencies and will be severely harmed if we are not granted approval to manufacture and sell our product candidates.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> We
                                            currently depend entirely on the success of elraglusib, which is our only product candidate.
                                            If we are unable to advance elraglusib in clinical development, obtain regulatory approval
                                            and ultimately commercialize elraglusib, or experience significant delays in doing so, our
                                            business will be materially harmed. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Even
                                            if we complete all planned clinical trials including a Phase 3 trial in the future, there
                                            is no guarantee that at the time of submission the FDA will accept our new drug application
                                            (NDA). </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Clinical
                                            and preclinical drug development involves a lengthy and expensive process with uncertain
                                            timelines and outcomes, and results of prior preclinical studies and early clinical trials
                                            are not necessarily predictive of future results. Elraglusib or any future product candidates
                                            may not achieve favorable results in clinical trials or preclinical studies or receive regulatory
                                            approval on a timely basis, if at all. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> We
                                            may not be successful in our efforts to investigate elraglusib in additional indications.
                                            We may expend our limited resources to pursue a new product candidate or a particular indication
                                            for elraglusib and fail to capitalize on product candidates or indications that may be more
                                            profitable or for which there is a greater likelihood of success. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Use
                                            of elraglusib or any future product candidates could be associated with side effects, adverse
                                            events or other properties or safety risks, which could delay or preclude regulatory approval,
                                            cause us to suspend or discontinue clinical trials, abandon elraglusib or any future product
                                            candidate, limit the commercial profile of an approved label or result in other significant
                                            negative consequences that could severely harm our business, financial condition, results
                                            of operations and prospects. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> The
                                            termination of third-party licenses could adversely affect our rights to important compounds
                                            or technologies. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Our
                                            current elraglusib drug substance (DS) manufacturer is in China, and it is unknown how current
                                            or future geopolitical relationships with China may affect our ability to obtain DS; however,
                                            if they are negatively impacted, this could increase our DS manufacturing costs and adversely
                                            impact our financial condition. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties
do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for
or commercialize our current product candidates or any future products and our financial condition will be adversely affected.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> We
                                            have a limited operating history and no products approved for commercial sale, which may
                                            make it difficult to evaluate our prospects and likelihood of success. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> If
                                            we experience delays or difficulties in the enrollment of subjects to our clinical trials,
                                            our receipt of necessary regulatory approvals could be delayed or otherwise adversely affected. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">If we and our third-party licensors do not obtain and preserve protection for our respective intellectual
property rights, our competitors may be able to take advantage of our development efforts to develop competing drugs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">If we lose key management leadership, and/or scientific personnel, and if we cannot recruit qualified
employees or other significant personnel, we may experience program delays and increased compensation costs, and our business may be materially
disrupted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> We
                                            face significant competition from other biotechnology and pharmaceutical companies. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Even if this offering is successful, we will require substantial additional capital to finance our operations
and fund our clinical trials. We may not be able to obtain this necessary capital when needed on acceptable terms, or at all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of ownership by our principal stockholders, the Bios Equity Affiliated Funds (as defined below), which are affiliated with our Chairman, Aaron G.L. Fletcher, and </FONT><FONT STYLE="font-size: 10pt">our director, Les Kreis, Jr., limits the ability of others to influence the outcome of director elections and other transactions requiring stockholder approval, creates the potential for conflicts of interest, may negatively impact our stock price and may deter or prevent efforts by others to acquire us, which could prevent our stockholders from realizing a control premium.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate History and Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Delaware
on January&nbsp;16, 2015, as Apotheca Therapeutics,&nbsp;Inc. and changed our name to Actuate Therapeutics,&nbsp;Inc. on October&nbsp;1,
2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were formed with seed capital
from Bios Partners, LP, to commercialize the technology invented in the labs of Dr.&nbsp;Alan Kozikowski at UIC and developed under the
scientific leadership of Dr.&nbsp;Andrew Mazar and Dr.&nbsp;Andrey Ugolkov, each at NU. Daniel Schmitt was hired as chief executive officer
in April&nbsp;2015 and led the negotiation of the exclusive license for the portfolio of GSK-3 inhibitors invented at UIC and developed
in a collaboration with NU, providing the technology and know-how which is our foundational intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 1751 River Run, Suite&nbsp;400, Fort Worth, Texas 76107. Our telephone number is (817) 887-8455. Our website address is
www.actuatetherapeutics.com. Information contained on our website or connected thereto does not constitute part of, and is not incorporated
by reference into, this prospectus or the Registration Statement of which it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). As an emerging growth company, we
may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not
emerging growth companies. These include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; disclosure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">not being required to comply with the auditor attestation requirements in the assessment of our internal
control over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditors&rsquo; report providing additional information
about the audit and the financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reduced disclosure obligations regarding executive compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Additionally, under the
JOBS Act, an emerging growth company can delay adopting new or revised accounting standards issued subsequent to the enactment of the
JOBS Act until such time as those standards apply to private companies. We irrevocably elected to avail ourselves of this exemption from
new or revised accounting standards, and, therefore, are not subject to the same new or revised accounting standards as public companies
who are not emerging growth companies. As a result, our consolidated financial statements may not be comparable to companies that comply
with new or revised accounting pronouncements as of public company effective dates. We intend to rely on other exemptions provided by
the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b)&nbsp;of
the Sarbanes-Oxley Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will remain an emerging
growth company until the earliest of (i)&nbsp;the last day of the fiscal year in which the market value of our common stock that is held
by non-affiliates exceeds $700.0 million as of June&nbsp;30th of that fiscal year, (ii)&nbsp;the last day of the fiscal year in which
we have total annual gross revenue of $1.235 billion or more during such fiscal year (as indexed for inflation), (iii)&nbsp;the date on
which we have issued more than $1 billion in non-convertible debt in the prior three-year period, and (iv)&nbsp;the last day of the fiscal
year following the fifth anniversary of the date of the first sale of equity securities in our initial public offering, or December&nbsp;31,
2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a &ldquo;smaller
reporting company&rdquo; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer
an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will
be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is
less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million
during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million
measured on the last business day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 6.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock offered by us</B></FONT></TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assumed offering
    price</B></FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share of common stock</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option to purchase additional shares </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have granted the underwriters an option for a period of 30 days to purchase from us up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock at the public offering price per share, to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common stock outstanding immediately after this offering</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their over-allotment option to purchase additional shares in full).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that we will receive net proceeds
    from this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the underwriters exercise their over-allotment option in
    full, based on a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (which
    is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus), after deducting underwriting discounts and commissions
    and estimated offering expenses.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We intend to use the net proceeds from
    this offering, along with our existing cash and cash equivalents, for clinical trials and product development, research and development,
    clinical manufacturing as well as for working capital and other general corporate purposes. See the section titled &ldquo;Use of
    Proceeds&rdquo; in this prospectus for a more complete description of the intended use of proceeds from this offering. </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Nasdaq listing</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;ACTU&rdquo;. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-up agreements</B></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We, our successors, all of
    our directors, officers and holders of more than 1.0% of our outstanding common stock have agreed with the underwriters, subject to
    certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities
    convertible into or exercisable or exchangeable for our common stock for a period of 180 days after the date of this prospectus. See
    &ldquo;Underwriting&rdquo; for more information.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt; font-size: 10pt; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s warrant</B></FONT></TD>
    <TD STYLE="width: 67%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the closing of this offering, we have agreed
to issue to Titan Partners Group LLC, a division of American Capital Partners, LLC, as representative of the underwriters, warrants that
will be exercisable for the period commencing 180 days from the effective date of the registration statement of which this prospectus
forms a part and expiring three years after such date, entitling the representative to purchase up to 5% of the number of shares of common
stock sold in this offering (including any shares of common stock sold pursuant to the exercise of the underwriter&rsquo;s option), at
an exercise price per share equal to 125% of the public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement of which this prospectus
    forms a part also covers the representative&rsquo;s warrants and the common stock issuable upon the exercise thereof.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information regarding our arrangement
    with the underwriters, see the section titled &ldquo;Underwriting.&rdquo;</P></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.25pt; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our common stock involves a high degree of risk. See the section titled &ldquo;Risk Factors&rdquo; and other information included in this prospectus for a discussion of factors you should consider before investing in our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Except as otherwise indicated,
the information contained in this prospectus is based on &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
of our common stock outstanding as of March&nbsp;31, 2024 (which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock, which are unvested and subject to forfeiture)<FONT STYLE="background-color: white">, after giving effect to </FONT>the
following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing and effectiveness of our sixth amended and restated certificate of incorporation&nbsp;(the amended and restated certificate of incorporation) and the adoption of our amended and restated bylaws, each of which will occur immediately prior to the closing of this offering;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the conversion of all outstanding shares of our redeemable convertible preferred stock into
 &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; shares
of our common stock immediately prior to the closing of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
    of common stock issuable upon the conversion of our Series&nbsp;B-1 redeemable preferred stock to be issued upon the automatic net
    exercise of warrants outstanding as of March 31, 2024, with an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, immediately prior to the completion
    of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
    share of common stock, the midpoint of the price range set forth on the cover of this prospectus;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[ &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
    of common stock issuable upon the conversion of our Series&nbsp;B-1 redeemable preferred stock to be issued upon the automatic net
    exercise of warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share of common stock, the midpoint of the price range set forth on the cover of this prospectus;]</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
    of our common stock issuable upon the conversion of our Series&nbsp;C redeemable preferred stock to be issued upon the automatic
    net exercise of warrants (the Series&nbsp;C Warrants) outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share of common stock, the midpoint of the price range set forth on the cover of this prospectus;]</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
                                            of our common stock issuable to our chief executive officer upon the closing of this offering,
                                            pursuant to his employment agreement, based on an assumed initial public offering price of
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock,
                                            the midpoint of the price range set forth on the cover page&nbsp;of this prospectus; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
                                            of our common stock issuable upon the automatic conversion of our convertible notes issued
                                            in February&nbsp;2024 (the Bridge Note), based on an assumed initial public offering price
                                            of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, the
                                            midpoint of the price range set forth on the cover of this prospectus; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> [no
                                            exercise of our warrants to purchase&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
                                            &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;of
                                            redeemable preferred stock outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share, which will terminate unexercised immediately prior to the completion of this offering,
                                            based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover of this
                                            prospectus;] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">[a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
reverse stock split of our common stock, which we effected on &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;,
2024];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">no exercise of the outstanding stock options described below; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">no exercise by the underwriters of their over-allotment option to purchase up to&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;additional
shares of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares of common
stock outstanding does not include the shares issuable under our options outstanding as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of common stock issuable upon the exercise of stock options outstanding as of March 31, 2024,
                                            with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
                                            of common stock reserved for future issuance under our 2024 Stock Incentive Plan (the 2024
                                            Plan), which will become effective in connection with this offering (which number includes
                                            shares of common stock reserved for issuance under our 2015 Stock Incentive Plan (the 2015
                                            Plan) as of March 31, 2024, which shares will be added to the number of shares available
                                            for issuance under the 2024 Plan upon its effectiveness. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables set forth
a summary of our historical financial data as of, and for the periods ended on, the dates indicated. We have derived the summary consolidated
statements of operations for the years ended December&nbsp;31, 2022 and 2023 from our audited consolidated financial statements included
elsewhere in this prospectus. You should read these data together with our consolidated financial statements and related notes included
elsewhere in this prospectus and the section titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations.&rdquo; Our historical results for any prior period are not necessarily indicative of our future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="white-space: nowrap; font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="6" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Year Ended</B> <B><BR> December&nbsp;31,</B></TD>
<TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD>
<TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations:</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: -0.125in">Operating expenses:</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: left; text-indent: 8.1pt; padding-left: -0.125in">Research and development</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,387,216</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,708,332</TD>
<TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 8.1pt; padding-left: -0.25in">General and administrative</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,819,591</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,265,497</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total operating expenses</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,206,807</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,973,829</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0in">Loss from operations</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,206,807</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,973,829</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Other income (expense):</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 8.1pt; padding-left: -0.5in">Change in fair value of warrant liability</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">36,579</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">(79,822</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 8.1pt; padding-left: -0.375in">Interest expense</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">(16,200</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">)</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">(43,641</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 8.1pt; padding-left: -0.375in">Interest income</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">27,027</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; padding-bottom: 1pt; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; text-align: right">352,672</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: -0.5in; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total other income,&nbsp;&nbsp;net</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,406</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">229,209</TD>
<TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: -0.125in">Net loss</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Net loss per share attributable to common stockholders, basic and diluted</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9.25</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9.58</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 0in">Weighted-average shares of common stock outstanding, basic and diluted</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,179,037</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,582,876</TD>
<TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Actual</TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma<SUP>(1)(3)</SUP></B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro Forma As<BR>
 Adjusted<SUP>(2)(3)</SUP></B></FONT></TD><TD STYLE="text-align: center; white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: -0.125in; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD COLSPAN="7" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif">(unaudited)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Balance Sheet Data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left; text-indent: -0.2pt; padding-left: 0in">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,958,659</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working capital deficit<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,925,028</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,995,566</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,443,675</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Redeemable convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,178,404</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0in">Total stockholders&rsquo; (deficit) equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(99,626,513</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: justify">Pro forma amounts give effect to the  conversion of all outstanding shares of our redeemable
convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock, including the conversion of shares of our redeemable convertible preferred stock issuable upon the exercise
of all outstanding in-the-money warrants to purchase redeemable convertible preferred stock (assuming an initial public offering price
of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock, the midpoint of the
price range set forth on the cover page&nbsp;of this prospectus), and the related reclassification of the carrying value of the redeemable
convertible preferred stock to permanent equity immediately prior to the closing of this offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD><TD STYLE="text-align: justify">Pro forma as adjusted amounts give effect to (i)&nbsp;the pro forma adjustments set forth in footnote
(1)&nbsp;above, and (ii)&nbsp;the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock in this offering at an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock, the midpoint of the price range set forth on the cover page&nbsp;of this prospectus, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common
stock would increase or decrease, as applicable, the pro forma as adjusted amount of each of our cash, cash equivalents and marketable
securities, working capital, total assets and total stockholders&rsquo; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
assuming that the number of shares of common stock offered by us, as set forth on the cover page&nbsp;of this prospectus, remains the
same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase
or decrease of 1.0 million shares in the number of shares offered by us at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock would increase or decrease, as applicable, the pro forma as adjusted amounts of each of our cash, cash equivalents
and marketable securities, working capital, total assets and total stockholders&rsquo; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD><TD STYLE="text-align: justify">The pro forma and pro forma as adjusted information discussed above is illustrative only and will be adjusted
based on actual initial public offering price and other terms of this offering determined at pricing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD><TD STYLE="text-align: justify">We define working capital deficit as current assets less current liabilities. See our consolidated financial
statements and the related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our common
stock is speculative and involves a high degree of risk. You should consider carefully the risks described below, together with the other
information contained in this prospectus, including our financial statements and the related notes included elsewhere in this prospectus
and in the section titled &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; before
deciding whether to invest in our common stock. If any of the following risks occur, our business, financial condition, results of operations
and future growth prospects could be materially and adversely affected. Additional risks and uncertainties not presently known to us or
that we currently deem immaterial also may impair our business operations. In these circumstances, the market price of our common stock
could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements that involve
risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result
of a number of factors, including the risks described below. See the section titled &ldquo;Special Note Regarding Forward-Looking Statements&rdquo;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Limited Operating History,
Financial Condition and Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have a limited operating history, have
incurred significant operating losses since our inception and expect to incur significant operating losses for the foreseeable future.
We have a high risk of never generating revenue or becoming profitable or, if we achieve profitability, we may not be able to sustain
it.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biopharmaceutical product
development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company
with a relatively limited operating history upon which you can evaluate our business and prospects. We commenced operations in January&nbsp;2015
and have not generated revenue from the sale of our products. Therefore, there is limited historical financial or operational information
upon which to evaluate our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties
frequently encountered by companies in their early stages of operations. Many if not most companies in our industry at our stage of development
never become profitable and are acquired or go out of business before successfully developing any product that generates revenue from
commercial sales or enables profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception in January&nbsp;2015
through December 31, 2023, we have incurred losses of approximately $105.1 million. Substantially all of our losses have resulted from
expenses incurred in connection with our research and development activities and from general and administrative costs associated with
our operations. We expect to continue to incur substantial and increasing operating losses over the next several years as we continue
the clinical development of, seek regulatory approval for and potentially commercialize elraglusib and any future product candidates,
as well as operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of future losses and
when, if ever, we will become profitable are uncertain. We do not have any products that have generated any revenues from commercial sales,
and do not expect to generate revenues from the commercial sale of products in the near future, if ever. If we are unable to successfully
develop, obtain requisite approval for and commercialize elraglusib or any future product candidates, we may never generate revenue. Our
ability to generate revenue and achieve profitability will depend on, among other things, successful completion of the development of
our product candidates; obtaining necessary regulatory approvals from the FDA and international regulatory agencies; establishing manufacturing,
sales, and marketing arrangements with third parties; obtaining adequate reimbursement by third-party payers; and raising sufficient funds
to finance our activities. If we are unsuccessful at some or all of these undertakings, our business, financial condition, and results
of operations are expected to be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To become and remain profitable,
we must succeed in developing, obtaining regulatory approvals for, and eventually commercializing products that generate significant revenue.
This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies
of elraglusib and any future product candidates, acquiring or developing additional product candidates, obtaining regulatory approval
for elraglusib and any future product candidates, and manufacturing, marketing, and selling any products for which we may obtain regulatory
approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we
do, may never generate revenue that is significant enough to achieve profitability. In addition, we have not yet demonstrated an ability
to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly
in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development,
we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability.
Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure
to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital,
expand our business, maintain our research and development efforts, diversify our product candidates, achieve our strategic objectives
or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Our financial condition raises substantial
doubt as to our ability to continue as a going concern.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December&nbsp;31,
2023, we had approximately $3.0 million in cash and cash equivalents and a working capital deficiency of approximately $3.9 million,
and we have incurred and expect to continue to incur significant costs in pursuit of our sole drug candidate, elraglusib. Our consolidated
financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. To date, we have not generated product revenues from
our activities and have incurred substantial operating losses. We expect that we will continue to generate substantial operating losses
for the foreseeable future until we complete development and approval of our product candidates. We will continue to fund our operations
primarily through utilization of our current financial resources and additional raises of capital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> These conditions raise
substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public accounting firm included
in its audit opinion for the year ended December&nbsp;31, 2023 an explanatory paragraph that there is substantial doubt as to our ability
to continue as a going concern. We plan to address these conditions by raising funds from this public offering, from subsequent public
or private offerings of equity or debt securities and other funding sources. However, there can be no assurance that such funding will
be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our objectives. The reaction
of investors to the inclusion of a going concern statement by our auditors and our potential inability to continue as a going concern
may materially adversely affect our ability to raise new capital or enter into partnerships. If we become unable to continue as a going
concern, we may have to liquidate our assets and the value we receive for our assets in liquidation or dissolution could be significantly
lower than the value reflected in our consolidated financial statements. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if this offering is successful, we
will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable
terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of biopharmaceutical
product candidates, including conducting preclinical studies and clinical trials, is a very time-consuming, capital-intensive and uncertain
process. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to substantially increase in
connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of elraglusib and potentially
seek regulatory approval for elraglusib and any future product candidates we may develop. In addition, if we are able to progress elraglusib
through development and commercialization, we expect to be required to make milestone and royalty payments pursuant to various license
or collaboration agreements with third parties. If we obtain regulatory approval for elraglusib or any future product candidates, we also
expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. Because the
outcome of any clinical trial or preclinical study is highly uncertain, we cannot reliably estimate the actual amount of capital necessary
to successfully complete the development and commercialization of elraglusib or any future product candidates. Furthermore, following
the completion of this offering, we expect to incur additional costs associated with operating as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Based on our current operating
plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to
fund our operations for at least the next &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months. In particular, we expect that the net proceeds from this offering and our existing
cash and cash equivalents will allow us to complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B); complete
the existing pediatric refractory cancer Phase 1 dose escalation trial and continue exploring development opportunities and potentially
initiate the Phase 2 portion of this study in patients with refractory Ewing Sarcoma (Actutate-1902); satisfy the Company&rsquo;s funding
commitments for ongoing IIT studies for the use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate
trial to treat recurrent salivary gland cancer; to finalize development plans for and potentially initiate and complete a Phase 1 dose
escalation study with Elraglusib Oral Tablet in patients with advanced, refractory solid cancer; and to finalize development plans for
and potentially initiate a Phase 2 study with Elraglusib Oral Tablet in refractory metastatic melanoma. If we were to receive additional
proceeds of at least $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million from this offering, or other funding, if and to the extent such funds are
received, we anticipate that such funding would allow us to also initiate a Phase 3 mPDAC trial and finalize development plans for an
additional randomized Phase 2 trial in metastatic refractory colorectal cancer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently
expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and
we may need to seek additional funds sooner than planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds of this offering,
together with our existing capital, may not be sufficient to complete development of elraglusib in any form, or any future product candidates,
and after this offering, we will require substantial capital in order to advance elraglusib and any future product candidates through
clinical trials, regulatory approval and commercialization. Accordingly, we will need to obtain substantial additional funding in connection
with our continuing operations. Our ability to raise additional funds may be adversely impacted by global economic conditions, disruptions
to, and volatility in, the credit and financial markets in the United States and worldwide, and diminished liquidity and credit availability.
If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more
dilutive. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research
and development programs or any future commercialization efforts, or even cease operations. We expect to finance our cash needs through
public or private equity or debt financings or other capital sources, including potential collaborations, licenses, and other similar
arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe
we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management
from our day-to-day activities, which may adversely affect our ability to develop elraglusib or any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
will depend on many factors, including without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the initiation, type, number, scope, progress, expansions, results, costs and timing of clinical trials
and preclinical studies of elraglusib and any future product candidates we may choose to pursue, including the costs of modification to
clinical development plans (including an increase in the number, size, duration and/or complexity of a trial) based on feedback that we
may receive from regulatory authorities and any third-party products used as combination agents in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the costs and timing of manufacturing for elraglusib or any future product candidate, including commercial
manufacturing at sufficient scale and encountering higher than expected costs to manufacture our current and future active pharmaceutical
ingredients, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">slower than expected progress in developing elraglusib or a future product candidate, including without
limitation, additional costs caused by such program delays;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the costs, timing and outcome of regulatory meetings and reviews of elraglusib and developing certain
formulations of elraglusib or any future product candidates in any jurisdictions in which we or our current or any future collaborators
may seek approval for elraglusib or any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as
a public company, including enhanced internal control over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the timing and payment of milestone, royalty or other payments we must make pursuant to our existing and
potential future license or collaboration agreements with third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the costs and timing of establishing or securing sales and marketing capabilities and commercial compliance
programs if elraglusib or any future product candidate is approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">higher than expected personnel, consulting or other costs, such as adding personnel or industry expert
consultants or pursuing the licensing/acquisition of additional assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">higher than expected costs to obtain, maintain, enforce and protect our patents and other intellectual
property and proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party
payors and adequate market share and revenue for any approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our ability and strategic decision to develop future product candidates other than elraglusib, and the
timing of such development, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">patients&rsquo; willingness to pay out-of-pocket for any approved products in the absence of coverage
and/or adequate reimbursement from third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise sufficient funds when, and if, required.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Conducting clinical trials
and preclinical studies and potentially identifying future product candidates is a time-consuming, expensive and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize
elraglusib or any future product candidates. If approved, elraglusib and any future product candidates may not achieve commercial success.
We expect that our commercial revenue, if any, will initially be derived from sales of elraglusib, which we do not expect to be commercially
available for several years, if at all. Commercial success in the United States may depend upon acceptance and coverage by federal healthcare
program and third-party payors, and it can be time consuming and costly to demonstrate that any of our products should be covered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we will need
to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to
us on acceptable terms, or at all, including as a result of financial and credit market deterioration or instability, market-wide liquidity
shortages, geopolitical events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Raising additional capital may cause dilution
to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights
to our technologies or product candidates. In addition, any capital obtained by us may be obtained on terms that are unfavorable to us,
our investors, or both.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Until such time, if ever,
as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other
capital sources, including potential collaborations, licenses and other similar arrangements. We do not have any committed external source
of funds. If we attempt to raise additional financing, there can be no assurance that we will be able to secure such additional financing
in sufficient quantities or at all. We may be unable to raise additional capital for reasons including, without limitation, our operational
and/or financial performance, investor confidence in us and the biopharmaceutical industry, credit availability from banks and other
financial institutions, the status of current projects and our prospects for obtaining any necessary regulatory approvals. Potential
investors&rsquo; capital investments may have shifted to other opportunities with perceived greater returns and/or lower risk thereby
reducing capital available to us, if available at all. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, any additional
financing might not be available, and even if available, may not be available on terms favorable to us or our then-existing investors.
We may seek to raise funds through public or private equity offerings, debt financings, corporate collaboration or licensing arrangements,
mergers, acquisitions, sales of intellectual property or other financing vehicles or arrangements. To the extent that we raise additional
capital by issuing equity securities or other securities (including convertible debt), our then-existing investors will experience dilution,
and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder.
If we raise funds through debt financings or bank loans, we may become subject to restrictive covenants, such as incurring additional
debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations
and execute our business plan. Moreover, if we raise funds through debt financings or bank loans, our assets may be pledged as collateral
for the debt, and the interests of our then-existing investors would be subordinated to the debt holders or banks. In addition, our use
of and ability to exploit assets pledged as collateral for debt or loans may be restricted or forfeited. To the extent that we raise
additional funds through collaboration or licensing arrangements, we may be required to relinquish valuable rights to our future revenue
streams, product candidates, research programs, intellectual property or proprietary technology, or grant licenses on terms that are
not favorable to us and/or that may reduce the value of our common stock. If we are not able to raise needed funding when needed under
acceptable terms or at all, then we would be required to delay, limit, reduce, curtail, abandon or terminate our product development
or future commercialization efforts, or grant rights to develop and market product candidates that we might otherwise prefer to develop
and market ourselves, or on less favorable terms than we would otherwise choose, or sell assets, or cease operations entirely. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Clinical Development and Regulatory
Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not have and may never have any approved
products on the market. Our business is highly dependent upon receiving approvals from various U.S. and international governmental agencies
and will be severely harmed if we are not granted approval to manufacture and sell our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order for us to commercialize
elraglusib for the treatment of mPDAC or for any other disease indication, or any other product candidate, we must obtain regulatory approvals
of such treatment for the applicable indication. Satisfying regulatory requirements is an expensive process that typically takes many
years and involves extensive compliance with requirements covering research and development, testing, manufacturing, quality control,
labeling, and promotion of drugs for human use. To obtain necessary regulatory approvals, we must, among other requirements, complete
clinical trials demonstrating that our products are safe and effective for a particular indication. In addition, before we can initiate
clinical development for any future preclinical product candidates, we must submit the results of preclinical studies to the FDA or comparable
foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and
controls and our proposed clinical trial protocol, as part of an IND or similar regulatory submission, and we are also required to submit
comparable applications to foreign regulatory authorities for clinical trials outside of the United States. The FDA or comparable foreign
regulatory authorities may require us to conduct additional preclinical studies for any future product candidates before it allows us
to initiate clinical trials under any IND or similar regulatory submission, which may lead to delays or increase the costs of developing
future product candidates. There can be no assurance that our products will prove to be safe and effective, that our preclinical or clinical
trials will demonstrate the necessary safety and effectiveness of our product candidates, or that we will succeed in obtaining regulatory
approval for any treatment we develop even if such safety and effectiveness are demonstrated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delays or difficulties
we encounter in our clinical trials may delay or preclude regulatory approval from the FDA or from international regulatory organizations.
Any delay or preclusion of regulatory approval would be expected to delay or preclude the commercialization of our products. Examples
of delays or difficulties that we may encounter in our clinical trials include without limitation the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trials may not yield sufficiently conclusive results for regulatory agencies to approve the use of our products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products may fail to be more effective than current therapies, or to be effective at all;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may discover that our products have adverse side effects, which could cause our products to be delayed or precluded from receiving regulatory approval or otherwise expose us to significant commercial and legal risks;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it may
take longer than expected to determine whether or not a treatment is effective;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients involved in our clinical trials may suffer severe adverse side effects even up to death, whether as a result of treatment with our products, the withholding of such treatment, or other reasons (whether within or outside of our control);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to be able to enroll a sufficient number of patients in our clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients enrolled in our clinical trials may not have the characteristics necessary to obtain regulatory approval for a particular indication or patient population;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to produce sufficient quantities of product to complete the clinical trials;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the sites who conduct our clinical trials may fail to follow the trial protocols correctly, or there may be concerns regarding data integrity from one or more sites, which could require us to exclude certain data from our results, which may prolong the length of our trials and delay submissions to regulatory authorities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if we are successful in our clinical trials, any required governmental approvals may still not be obtained or, if obtained, may not be maintained; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if approval for commercialization is granted, it is possible the authorized use will be more limited than is necessary for commercial success, or that approval may be conditioned on completion of further clinical trials or other activities, which will cause a substantial increase in costs and which we might not succeed in performing or completing; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if granted, approval may be withdrawn or limited if problems with our products emerge or are suggested by the data arising from their use or if there is a change in law or regulation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any success we may achieve
at a given stage of our clinical trials does not guarantee that we will achieve success at any subsequent stage, including without limitation
final FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may encounter delays or
rejections in the regulatory approval process because of additional government regulation resulting from future legislation or administrative
action, or from changes in the policies of the FDA or other regulatory bodies during the period of product development, clinical trials,
or regulatory review. Failure to comply with applicable regulatory requirements may result in criminal prosecution, civil penalties, recall
or seizure of products, total or partial suspension of production, or an injunction preventing certain activity, as well as other regulatory
action against our product candidates or us. As a company, we have no experience in successfully obtaining regulatory approval for a product
and thus may be poorly equipped to gauge, and may prove unable to manage, risks relating to obtaining such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States.,
our ability to market a product is contingent upon receiving clearances from appropriate non-U.S. regulatory authorities. Non-U.S. regulatory
approval typically includes all of the risks associated with FDA clearance discussed above as well as geopolitical uncertainties and the
additional uncertainties and potential prejudices faced by U.S. pharmaceutical companies conducting business abroad. In certain cases,
pricing restrictions and practices can make achieving even limited profitability very difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently depend entirely on the success
of elraglusib, which is our only product candidate. If we are unable to advance elraglusib in clinical development, obtain regulatory
approval and ultimately commercialize elraglusib, or experience significant delays in doing so, our business will be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently only have one
product candidate, elraglusib, which is in Phase 2 clinical development. Our business presently depends entirely on our ability to successfully
develop, obtain regulatory approval for, and commercialize elraglusib in a timely manner. This may make an investment in our company riskier
than similar companies that have multiple product candidates in active development and may be able to better sustain the delay or failure
of a lead product candidate. The success of elraglusib will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">successful initiation and enrollment of clinical trials and completion of clinical trials with favorable
results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">acceptance of regulatory submissions by the FDA or comparable foreign regulatory authorities for the conduct
of clinical trials of elraglusib and of our proposed designs of planned clinical trials of elraglusib;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the frequency and severity of adverse events observed in clinical trials and preclinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">maintaining and establishing relationships with contract research organizations (CROs) and clinical sites
for the clinical development of elraglusib, and ability of such CROs and clinical sites to comply with clinical trial protocols, Good
Clinical Practices (GCPs) and other applicable requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">demonstrating the safety, purity and potency (or efficacy) of elraglusib to the satisfaction of applicable
regulatory authorities, including by establishing a safety database of a size satisfactory to regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">receipt and maintenance of regulatory approvals from applicable regulatory authorities, including approvals
of new drug applications (NDAs) from the FDA;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">maintaining relationships with our third-party manufacturers and their ability to comply with cGMPs as
well as entering into agreements with our third-party manufacturers for, or establishing our own, commercial manufacturing capabilities
at a cost and scale sufficient to support commercialization;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">establishing sales, marketing and distribution capabilities and launching commercial sales of elraglusib,
if and when approved, whether alone or in collaboration with others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">obtaining, maintaining, protecting and enforcing patent and any potential trade secret protection or regulatory
exclusivity for elraglusib;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">maintaining an acceptable safety profile of elraglusib following regulatory approval, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">maintaining and growing an organization of people who can develop and, if approved, commercialize, market
and sell elraglusib; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">acceptance and coverage of our products, if approved, by patients, the medical community and federal healthcare
program and other third-party payors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to develop,
obtain regulatory approval for, or if approved, successfully manufacture and commercialize elraglusib, or if we experience delays as a
result of any of the above factors or otherwise, our business would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Even if we complete all planned clinical
trials including a Phase 3 trial in the future, there is no guarantee that at the time of submission the FDA will accept our NDA.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulation and control
of new drugs in the United States is based on the NDA, and every new drug is the subject of an approved NDA before U.S. commercialization.
Through the NDA application, the developer of a drug candidate formally proposes that the FDA approve a new pharmaceutical for sale and
marketing in the United States. The data gathered during the animal studies and human clinical trials of an investigational new drug (IND)
become part of the NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials must be conducted
in accordance with the FDA and other applicable regulatory authorities&rsquo; legal requirements, regulations or guidelines, and are subject
to oversight by these governmental agencies and ethics committees (ECs) or one or more institutional review board (IRBs) at the medical
institutions and clinical trial sites where the clinical trials are conducted. We could also encounter delays if a clinical trial is suspended
or terminated by us, by the IRBs of the institutions in which such trials are being conducted, or by a data safety monitoring board for
such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension, including a clinical
hold, or termination due to a number of factors, including, among other reasons, failure to conduct the clinical trial in accordance with
GCP and other regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site, or investigation
of principal or sub-investigators conducting our clinical trials, by the FDA or comparable foreign regulatory authorities resulting in
the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition,
changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes.
Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful
completion of a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Failure by us or any of our
third party vendors, manufacturers, or trial sites to comply with applicable regulatory requirements may result in criminal prosecution,
civil penalties, recall or seizure of products, total or partial suspension of production, or an injunction preventing certain activity,
as well as other regulatory action against our product candidates or us. As a company, we have no experience in successfully obtaining
regulatory approval for a product and thus may be poorly equipped to gauge, and may prove unable to manage, risks relating to obtaining
such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
our ability to market a product is contingent upon receiving clearances from appropriate non-U.S. regulatory authorities. Non-U.S. regulatory
approval typically includes all of the risks associated with FDA clearance discussed above as well as the failure of enrolled patients
in foreign countries to adhere to clinical protocols as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war or embargoes, relevant
to such foreign countries. In certain cases, pricing restrictions and practices can make achieving even limited profitability very difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical and preclinical drug development
involves a lengthy and expensive process with uncertain timelines and outcomes, and the results of preclinical studies and early clinical
trials are not necessarily predictive of future results. Elraglusib or any future product candidates may not achieve favorable results
in clinical trials or preclinical studies or receive regulatory approval on a timely basis, if at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug development is expensive
and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials or preclinical
studies will be conducted as planned, including whether we are able to meet expected timeframes for data readouts, or completed on schedule,
if at all, and failure can occur at any time during the trial or study process, including due to factors that are beyond our control.
Despite promising preclinical or clinical results, elraglusib or any other future product candidate can unexpectedly fail at any stage
of clinical or preclinical development. The historical failure rate for product candidates in our industry is high.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results from preclinical
studies or clinical trials of elraglusib, any future product candidate, or a competitor&rsquo;s product candidate in the same class may
not predict the results of later clinical trials of elraglusib or any future product candidate, and interim, topline or preliminary results
of a clinical trial are not necessarily indicative of final results. Elraglusib or any future product candidate in later stages of clinical
trials may fail to show the desired characteristics despite having progressed through preclinical studies and initial clinical trials.
It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and
many product candidates fail in clinical trials despite very promising early results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, preclinical and
clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology
industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Such
setbacks have occurred and may occur for many reasons, including, but not limited to: clinical sites and investigators may deviate from
clinical trial protocols, whether due to lack of training or otherwise, and we may fail to detect any such deviations in a timely manner;
patients may fail to adhere to any required clinical trial procedures, including any requirements for post-treatment follow-up; our product
candidates may fail to demonstrate safety, purity or potency (or efficacy) in certain patient subpopulations, which has not been observed
in earlier trials due to limited sample size, lack of analysis or otherwise; or our clinical trials may not adequately represent the patient
populations we intend to treat, whether due to limitations in our trial designs or otherwise, such as where one patient subgroup is overrepresented
in the clinical trial. There can be no assurance that we will not suffer similar setbacks despite the data we observed in earlier or ongoing
studies. Based upon negative or inconclusive results, we or any current or any future collaborator may decide, or regulators may require
us, to conduct additional preclinical studies or clinical trials, which would cause us to incur additional operating expenses and delays
and may not be sufficient to support regulatory approval on a timely basis or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We may not be successful in our efforts
to investigate elraglusib in additional indications. We may expend our limited resources to pursue a new product candidate or a particular
indication for elraglusib and fail to capitalize on product candidates or indications that may be more profitable or for which there
is a greater likelihood of success.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"> Because we have limited financial and managerial
resources, we focus on the development of elraglusib for specific indications. We may fail to generate additional clinical development
opportunities for elraglusib for a number of reasons, including that elraglusib may, in indications we are seeking or may seek in the
future, be shown to have harmful side effects, limited to no efficacy or other characteristics that suggest it is unlikely to receive
marketing approval and/or achieve market acceptance in such potential indications. Our resource allocation and other decisions may cause
us to fail to identify and capitalize on viable potential product candidates or additional indications for elraglusib. Our spending on
current and future research and development programs for new product candidates or additional indications for elraglusib may not yield
any commercially viable product candidates or indications. If we do not accurately evaluate the commercial potential or target market
for a particular indication or product candidate, we may fail to develop such product candidate or indication, or relinquish valuable
rights to that product candidate through collaborations, license agreements and other similar arrangements in cases where it would have
been more advantageous for us to retain sole development and commercialization rights to such indication or product candidate, or negotiate
less advantageous terms for any such arrangements than is optimal. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Additionally, we may pursue
additional in-licenses or acquisitions of development-stage assets or programs, which entails additional risk to us. Identifying, selecting
and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so
may not result in the actual acquisition or license of a particular product candidate, potentially resulting in a diversion of our management&rsquo;s
time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately
result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products
that ultimately do not provide a return on our investment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Use of elraglusib or any future product
candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory
approval, cause us to suspend or discontinue clinical trials, abandon elraglusib or any future product candidate, limit the commercial
profile of an approved label or result in other significant negative consequences that could severely harm our business, financial condition,
results of operations and prospects.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As is the case with oncology
drugs generally, it is likely that there may be side effects and adverse events associated with use of elraglusib or any future product
candidates&rsquo; use. Results of our, our collaborators&rsquo; or any future collaborators&rsquo; clinical trials could reveal a high
and unacceptable severity and prevalence of expected or unexpected side effects or unexpected characteristics. Undesirable side effects
caused by our product candidates when used alone or in combination with approved or investigational drugs could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or lead to the delay or denial of
regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment
or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may
harm our business, financial condition, results of operations and prospects significantly. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Moreover, if elraglusib
or any future product candidates are associated with undesirable side effects in clinical trials or demonstrate characteristics that
are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the
undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective,
which may limit the commercial expectations for such product candidate if approved. Unacceptable enhancement of certain toxicities may
be seen when elraglusib or any future product candidates are combined with standard of care therapies, or when they are used as single
agents. We may also be required to modify our development and clinical trial plans based on findings in our ongoing clinical trials.
Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that
prevented further development of the compounds. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> It is possible that as
we, our collaborators or any future collaborators test elraglusib or any future product candidates in larger, longer and more extensive
clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following
any regulatory approval, more illnesses, injuries, discomforts and other adverse events than were observed in earlier trials, as well
as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later
in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects
significantly. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> With regard to our lead
product candidate, elraglusib, unforeseen side effects from elraglusib could arise either during clinical development or, if approved,
after elraglusib has been marketed. This could cause regulatory approvals for, or market acceptance of, elraglusib harder and costlier
to obtain. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> To date, elraglusib as
a single agent and in combination with a variety of chemotherapy has been shown in a Phase 1 trial to be well-tolerated. However, these
data were obtained in advanced cancer patients across many different cancer types and at different doses of elraglusib. The results of
our planned or any future clinical trials in single cancer types may show that the side effects of elraglusib are unacceptable or intolerable,
especially when compared with standard of care and in earlier stage patients, which could interrupt, delay or halt clinical trials. This
could result in delay of, or failure to obtain, marketing approval from the FDA or EMA and other regulatory authorities or result in
marketing approval from the FDA or EMA and other regulatory authorities with restrictive label warnings. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If elraglusib receives
marketing approval and we or others later identify undesirable or unacceptable side effects caused by the use of elraglusib: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">regulatory authorities may withdraw their approval
    of the product, which would force us to remove elraglusib from the market;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">regulatory authorities may require the addition
    of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">we may be required to change instructions regarding
    the way the product is administered, conduct additional clinical trials or change the labeling of the product;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">we may be subject to limitations on how we may
    promote the product;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">sales of the product may decrease significantly;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">we may be subject to litigation or product liability
    claims; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">our reputation may suffer.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Any of these events could
prevent us or our potential future collaborators from achieving or maintaining market acceptance of elraglusib and/or could substantially
increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the
sale of elraglusib. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>If we experience delays or difficulties
in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or otherwise adversely
affected, which could materially affect our financial condition.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Identifying, screening
and enrolling patients to participate in clinical trials of our product candidates is critical to our success, and we may not be able
to identify, recruit, enroll and dose a sufficient number of patients with the required or desired characteristics to complete our clinical
trials in a timely manner. We may not be able to initiate or continue certain clinical trials for elraglusib or any future product candidates
if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA
or similar regulatory authorities outside the United States. The timing of our clinical trials depends on our ability to recruit patients
to participate as well as to subsequently dose these patients and complete required follow-up periods. Patient enrollment, a significant
factor in the timing of clinical trials, is affected by many factors, including the size and characteristics of the patient population,
the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial,
the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate
competencies and experience, and competing clinical trials and clinicians&rsquo; and patients&rsquo; perceptions as to the potential
advantages and risks of the product candidates being studied in relation to other available therapies, including any new products that
may be approved for the indications we are investigating as well as any product candidates under development. We will be required to
identify and enroll a sufficient number of patients for each of our clinical trials and monitor such patients adequately during and after
treatment. Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we
are targeting, which could adversely impact the outcomes of our trials and could have safety concerns for the potential patients. Potential
patients for any planned clinical trials may also not meet the entry criteria for such trials. In particular, because our planned clinical
trials of elraglusib are focused on indications with relatively small patient populations, our ability to enroll eligible patients may
be limited or may result in slower enrollment than we anticipate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, we may experience
enrollment delays related to increased or unforeseen regulatory, legal and logistical requirements at certain clinical trial sites. These
delays could be caused by reviews by regulatory authorities and contractual discussions with individual clinical trial sites. Any delays
in enrolling and/or dosing patients in our planned clinical trials could result in increased costs, delays in advancing our product candidates,
delays in testing the effectiveness of our product candidates or in termination of the clinical trials altogether. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We may not be able to
fully enroll our clinical trials if other pharmaceutical companies with ongoing clinical trials for products with similar indications
as our product candidates recruit from these patient populations. The timing of our clinical trials depends, in part, on the speed at
which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. Patient enrollment may
also be affected by other factors, including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">coordination with clinical research organizations
    to enroll and administer the clinical trials;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">coordination and recruitment of collaborators and
    investigators at individual sites;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">size of the patient population and process for
    identifying patients;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">design of the clinical trial protocol;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">eligibility and exclusion criteria;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">perceived risks and benefits of the product candidates
    under study;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">availability of competing commercially available
    therapies and other competing products&rsquo; clinical trials;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">time of year in which the trials are initiated
    or conducted;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">severity of the diseases under investigation;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">ability to obtain and maintain subject consents;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">ability to enroll and treat patients in a timely
    manner;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">risk that enrolled subjects will drop out before
    completion of the trials;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">proximity and availability of clinical trial sites
    for prospective patients;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">ability to monitor subjects adequately during and
    after treatment; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">patient referral practices of physicians.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If patients are unwilling
or unable to participate in our trials for any reason, including the existence of concurrent clinical trials for similar target populations,
the availability of approved therapies, or the fact that enrolling in our trials may prevent patients from taking a different product,
or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and
obtaining regulatory approval of elraglusib or any future product candidates may be delayed. Our inability to enroll a sufficient number
of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Enrollment delays in these
clinical trials may result in increased time and development costs for our product candidates, which could materially affect our financial
condition. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>As a company, we have never completed
a clinical trial and have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect
our financial condition.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We will need to successfully
complete clinical trials in order to obtain FDA or comparable foreign regulatory approval to market elraglusib or any future product
candidates. Carrying out clinical trials and the submission of a successful NDA or other comparable foreign regulatory submission is
a complicated process. As a company, we have not yet completed any clinical trials of our product candidates, nor have we demonstrated
the ability to obtain marketing approvals, manufacture product candidates at a commercial scale, or conduct sales and marketing activities
necessary for the successful commercialization of a product. We may also choose to conduct a number of additional clinical trials of
elraglusib in parallel over the next several years, which may be a difficult process to manage with our limited resources and which may
divert attention of management. FDA or other regulatory authority could also require us to conduct additional trials which may further
delay approval of our product. Consequently, we have no historical basis as a company by which you can evaluate or predict reliably our
future success or viability. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have limited experience
with regulatory filings with agencies such as the FDA or EMA, and we have not yet completed any clinical trials for elraglusib or any
other product candidate. We also have limited experience as a company in preparing and submitting marketing applications and have not
previously submitted an NDA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited
interactions with the FDA and cannot be certain how many additional clinical trials of elraglusib or any future product candidate will
be required or how such additional trials should be designed. Consequently, we may be unable to successfully and efficiently execute
and complete necessary clinical trials in a way that leads to submission of an NDA and regulatory approval of any of our product candidates.
We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product
candidates that we develop. Failure to commence or complete, or delays in, our ongoing or planned clinical trials could prevent us from
or delay us in submitting NDAs or other comparable foreign regulatory submissions for and commercializing our product candidates. Any
delay in our regulatory filings for our product candidates, and any adverse development or perceived adverse development with respect
to the applicable regulatory authority&rsquo;s review of such filings, including, without limitation, the FDA&rsquo;s issuance of a &ldquo;refuse
to file&rdquo; letter or a request for additional information, could materially affect our financial condition. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, we cannot be
certain that our ongoing and planned clinical trials or preclinical studies will be successful. Any safety concerns observed in any one
of our clinical trials in our targeted indications could limit the prospects for regulatory approval of elraglusib in those and other
indications, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interim, topline, and preliminary data from
our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to
audit and verification procedures that could result in material changes in the final data.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
publicly disclose interim, topline, or preliminary data from our clinical trials, based on a preliminary analysis of then-available data,
and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to
the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and
we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline, or preliminary
results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results once additional data have been received and fully evaluated. Interim, topline, and preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, such data should be viewed with caution until the final data are available. From time to time, we may also disclose interim
data from our clinical trials. Interim, topline, and preliminary data from clinical trials that we may complete are subject to the risk
that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse differences between preliminary, interim or topline data and final data could significantly harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, others, including
regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret
or weigh the importance of data differently, which could impact the value of the particular program, the approvability, or commercialization
of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose
regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with
what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine
not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding
a particular product, product candidate, or our business. If the interim, topline, or preliminary data that we report differ from actual
results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize elraglusib and any future product candidates may be harmed, which could harm our business, operating results, prospects,
or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Serious adverse events, undesirable side
effects (including emergent drug-drug interactions between elraglusib and any of the other therapeutic agents given to the clinical trial
subjects) or other unexpected properties of our current or future product candidates may be identified during development or after approval,
which could halt their development or lead to the discontinuation of our clinical development programs, refusal by regulatory authorities
to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations
on the use of our product candidates thereby limiting the commercial potential of such product candidate.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, elraglusib is the
only product candidate we have tested in humans. As we continue our development of elraglusib and initiate clinical trials of any future
product candidates, serious adverse events, undesirable side effects or unexpected characteristics may emerge or be reported, causing
us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the serious adverse events,
undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.
Even if our product candidates initially show promise in early clinical trials, the side effects of therapies are frequently only detectable
after they are tested in large, Phase 2 or Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial
scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the
product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other
medications. If serious adverse or unexpected side effects are identified during development and are determined to be attributed to our
product candidates, or the result of drug-drug interactions between our product candidate and any of the concomitant therapies given to
the trial subjects, we, the FDA or comparable foreign regulatory authorities, or IRBs and other reviewing entities, could interrupt, delay,
or halt clinical trials and could result in a more restrictive label, a Risk Evaluation and Mitigation Strategy (REMS) or the delay or
denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities
may also require, or we may voluntarily develop strategies for managing adverse events during clinical development, which could include
restrictions on our enrollment criteria, the use of stopping criteria, adjustments to a study&rsquo;s design, or the monitoring of safety
data by a data monitoring committee, among other strategies. Any requests from the FDA or comparable foreign regulatory authority for
additional data or information could also result in substantial delays in the approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Drug-related side effects
could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability
claims. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, if one or more of
our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products,
a number of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">regulatory authorities may withdraw approvals of such product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">regulatory authorities may require additional warnings on the label;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">we may be required to create a medication guide outlining the risks of such side effects for distribution
to patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">we may be required to change the way the product is administered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">we could be sued and held liable for harm caused to patients; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the product may become less competitive, and our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The therapeutic-related side
effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability
claims. Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved,
and could significantly harm our business, financial condition, results of operations, stock price and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We anticipate that many of our product candidates
may be tested and, if approved, used in combination with third-party drugs and/or devices, some of which may still be in development,
and we have limited or no control over the supply, regulatory status or regulatory approval of such drugs and/or devices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate developing our
product candidates for use in combination with other oncology pharmaceutics, including chemotherapies and cellular and targeted therapies
(e.g., immune checkpoint inhibitors). We cannot be certain that current or potential future commercial relationships will provide us with
a steady supply of such drugs or devices on commercially reasonable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any failure to maintain or
enter into new successful commercial relationships, or the expense of purchasing platinum-based and other chemotherapies, or any other
combination products, or any devices in the market, may delay our development timelines, increase our costs and jeopardize our ability
to develop our product candidates as commercially viable therapies. If any of these occur, our business, financial condition, results
of operations, stock price and prospects may be materially harmed. Moreover, the development of product candidates for use in combination
with another product or product candidate may present challenges that are not faced for single agent product candidates. For our product
candidates that may be used in combination with other chemotherapies, or any other combination products or any devices, the FDA may require
us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed
effects. It is possible that the results of these trials could show that there are adverse events tied to the interaction of elraglusib
with any of the other therapies, or that any positive previous trial results are attributable to the combination therapy and not our product
candidates. Moreover, following product approval, the FDA may require that products or devices used in conjunction with each other be
cross labeled for combined use. To the extent that we do not have rights to the other product or device, this may require us to work with
a third party to satisfy such a requirement. The ability to obtain cooperation from the third party may impact our ability to respond
to the FDA&rsquo;s requests which could impact our ability to achieve regulatory approval. Moreover, developments related to the other
product or device may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments
may include changes to the safety or efficacy profile of the other product or device, changes to the availability of the approved product
or device, and changes to the standard of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any future
collaborator or supplier of other chemotherapies, or any other products administered in combination, or any devices used, with our product
candidates does not supply their products on commercially reasonable terms or in a timely fashion, we would need to identify alternatives
for accessing these products. This could cause our clinical trials to be delayed and limit the commercial opportunities for our product
candidates, in which case our business, financial condition, results of operations, stock price and prospects may be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We may seek additional Orphan Drug,
Fast Track, Breakthrough or PRIME designations for one or more of our current and future product candidates, but we might not receive
any such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval
process.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate,
elraglusib, has been given Fast Track designation from the FDA for development in the treatment of pancreatic cancer, and we may seek
Fast Track designations for other indications or future product candidates. The Fast Track program is intended to expedite or facilitate
the process for reviewing product candidates that meet certain criteria. Specifically, biologics are eligible for Fast Track designation
if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition
and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination
of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has
opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted,
the application may be eligible for priority review. An NDA submitted for a Fast Track product candidate may also be eligible for rolling
review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if
the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. Fast Track
designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe or
at all. We may not experience a faster development, regulatory review or approval process with fast track designation compared to conventional
FDA procedures. Additionally, the FDA may withdraw Fast Track designation, for reasons such as it comes to believe a drug candidate no
longer adequately addresses an unmet medical need or that the designation is no longer supported by data from our clinical development
program. Fast Track designation alone does not guarantee qualification for the FDA&rsquo;s priority review procedures. If we seek Fast
Track designation for other indications, or if we pursue breakthrough or PRIME designations from FDA or EMA, respectively, we may not
receive such designations. Many product candidates that have received Fast Track designation have ultimately failed to obtain approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We, or any future collaborators, may not
be able to obtain and maintain orphan drug exclusivity for our product candidates in the United States and Europe.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Elraglusib has been granted
orphan drug designation for the treatment of pancreatic cancer, glioblastomas (GBM) and neuroblastoma (NB) in the United States. We may
seek additional orphan drug designations or regulatory incentives for other indications, for the oral dosage form of elraglusib, or for
future product candidates in the United States, EU, Japan or Australia. We may not be able to obtain such designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While elraglusib currently
has been granted orphan drug designation from the FDA for limited indications, we may not be able to maintain this orphan drug exclusivity.
Further, even if we obtain orphan drug designation for a future product candidate or for elraglusib with respect to a different indication,
we may not be able to maintain orphan drug exclusivity for that drug or indication. For example, orphan drug designation may be removed
if the prevalence of an indication increases beyond the patient number limit required to maintain designation. Generally, if a drug with
an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the
drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application
for the same product in the same indication for that time period. Orphan drug exclusivity may be lost if the FDA or EMA determines that
the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to
meet the needs of patients with the rare disease or condition. Moreover, even after an orphan drug is approved, the FDA can subsequently
approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to
be safer, more effective or makes a major contribution to patient care compared to our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may reevaluate the
Orphan Drug Act and its regulations and policies, and similarly the EMA may reevaluate its policies and regulations. We do not know if,
when, or how the FDA or EMA may change their orphan drug regulations and policies in the future, and it is uncertain how any changes might
affect our business. Depending on what changes the FDA and/or EMA may make to their orphan drug regulations and policies, our business
could be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on third parties for the manufacture
and shipping of elraglusib for clinical development and expect to continue to do so for the foreseeable future. If we or our licensees,
development collaborators, or suppliers are unable to manufacture our products in sufficient quantities or at defined quality specifications,
or are unable to obtain regulatory approvals for the manufacturing facility, we may be unable to develop and/or meet demand for our products
and lose time to market and potential revenues.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of our clinical
trials and commercialization of our product candidates require access to, or development of, facilities to manufacture a sufficient supply
of our product candidates. We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale
manufacturing capabilities. We rely on a third-party manufacturer for the production of elraglusib and expect to continue to rely on third-party
manufacturers for commercial manufacture if elraglusib or any future product candidates receive regulatory approval. The facilities used
by third-party manufacturers to manufacture elraglusib or any future product candidate must be approved for the manufacture of such product
candidate by the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit an
NDA to the FDA or any comparable submission to a foreign regulatory authority. We do not control the manufacturing process of, and are
completely dependent on, third-party manufacturers for compliance with cGMP requirements for the manufacture of products. In addition,
we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified
personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or any comparable
foreign regulatory authority does not approve these facilities for the manufacture of elraglusib or any future product candidates or if
it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact
our ability to develop, obtain regulatory approval for or market elraglusib or any future product candidates, if approved. Our failure,
or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of elraglusib
or any future product candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect
supplies of elraglusib or any future product candidates. We may not be successful in identifying additional or replacement third-party
manufacturers, or in negotiating acceptable terms with any we do identify. We may face competition for access to these manufacturers&rsquo;
facilities and may be subject to manufacturing delays if the manufacturers give other clients higher priority than they give to us. Even
if we are able to identify an additional or replacement third-party manufacturer, the delays and costs associated with establishing and
maintaining a relationship with such manufacturer may have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before we can begin to commercially
manufacture elraglusib or any other product candidate, we must obtain regulatory approval of the manufacturing facility and process by
the FDA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit an NDA to the FDA
or any comparable submission to a foreign regulatory authority. Manufacturing of drugs for clinical and commercial purposes must comply
with cGMP. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with
cGMP requirements for the manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms
to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not
be able to secure and/or maintain regulatory approval for their manufacturing facilities. The cGMP requirements govern quality control
and documentation policies and procedures. Complying with cGMP and non-U.S. regulatory requirements will require that we expend time,
money, and effort in production, recordkeeping, and quality control to ensure that the product meets applicable specifications and other
requirements. We, or our contracted manufacturing facility, must also pass a pre-approval inspection prior to FDA approval. Failure to
pass a pre-approval inspection may significantly delay or prevent FDA approval of our products. If we fail to comply with these requirements,
we would be subject to possible regulatory action and may be limited in the jurisdictions in which we are permitted to sell our products
and will lose time to market and potential revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We depend on a third-party manufacturer
for certain drug substances, drug products, raw materials, samples, components, and other materials used in our product candidates. We
obtain our supplies on a purchase order basis and do not have any long-term supply agreements in place. If we are unable to source these
supplies on a timely basis, or establish longer-term contracts with suppliers, we will not be able to complete our clinical trials or
studies on time and the development of our product candidates may be delayed.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We depend on a third-party manufacturer for
certain drug substances, drug products, raw materials, samples, components and other materials used in our product candidates. We obtain
our supplies on a purchase order basis and do not currently have long-term supply contracts with our supplier, and our supplier is not
obligated to supply drug products to us for any period, in any specified quantity or at any certain price beyond the delivery contemplated
by the relevant purchase orders. As a result, our supplier could stop selling to us at commercially reasonable prices, or at all. While
we intend to enter into long-term supply agreements in the future as we advance our clinical trials or commercialization plans, we may
not be successful in negotiating such agreements on favorable terms, or at all. If we do enter into such long-term supply agreements,
we could be subject to binding long-term purchase obligations that are less favorable than purchasing on a purchase order basis, and
which may be harmful to our business, including in the event that we do not conduct our trials on planned timelines or utilize the drug
products that we are required to purchase. Any change in our relationship with our supplier or changes to our arrangement with our supplier
could adversely affect our business, financial condition, results of operations and prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Furthermore, our supplier could stop producing our supplies, cease
operations or be acquired by, or enter into exclusive arrangements with, our competitors. Establishing additional or replacement suppliers
for these supplies, and obtaining regulatory clearance or approvals that may result from adding or replacing suppliers, could take a
substantial amount of time, result in increased costs and impair our ability to produce our products or conduct timely trials, which
would adversely impact our business, financial condition, results of operations and prospects. Any such interruption or delay may force
us to seek similar supplies from alternative sources, which may not be available at reasonable prices, or at all. Any interruption in
the supply of source components for our product candidates would adversely affect our ability to meet scheduled timelines and budget
for the development and commercialization of our product candidates, could result in higher expenses and would harm our business. Although
we have not experienced any significant disruption as a result of our reliance on our supplier, we have a limited operating history and
cannot assure you that we will not experience disruptions in our supply chain in the future as a result of such reliance or otherwise. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is uncertain whether product liability
insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available
on acceptable terms in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical research involves
the testing of new drugs on human volunteers pursuant to a clinical trial protocol. Such testing involves a risk of liability for personal
injury to or death of patients due to, among other causes, adverse side effects, improper administration of the new drug, or improper
volunteer behavior. Claims may arise from patients, clinical trial volunteers, consumers, physicians, hospitals, companies, institutions,
researchers, or others using, selling, or buying our products, as well as from governmental bodies. In addition, product liability and
related risks are likely to increase over time, in particular upon the commercialization or marketing of any products by us or parties
with which we enter into development, marketing, or distribution collaborations. Although we are contracting for general liability insurance
in connection with our ongoing business, there can be no assurance that the amount and scope of such insurance coverage will be appropriate
and sufficient in the event any claims arise, that we will be able to secure additional coverage should we attempt to do so, or that our
insurers would not contest or refuse any attempt by us to collect on such insurance policies. Furthermore, there can be no assurance that
suitable product liability insurance (at the clinical stage and/or commercial stage) will continue to be available on terms acceptable
to us or at all, or that, if obtained, the insurance coverage will be appropriate and sufficient to cover any potential claims or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 01 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the market opportunities for our current
and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues may be adversely affected
and our business may suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The potential market opportunities
for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are
co-administered and the success of competing therapies and therapeutic approaches. Our projections of both the number of people who have
the cancers we are targeting, as well as the subset of people with these cancers in a position to receive therapy and who have the potential
to benefit from treatment with elraglusib or any future product candidate are predicated on many assumptions, which may include industry
knowledge and publications, third-party research reports, and other surveys. Although we believe that our internal assumptions are reasonable,
these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness
has not been assessed by an independent source. These estimates may prove to be incorrect and new studies may change the estimated incidence
or prevalence of these diseases. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected,
and patients may not be amenable to treatment with our product, or new patients may become increasingly difficult to identify or gain
access to, all of which would adversely affect our business, financial condition, results of operations and prospects. If any of the
assumptions prove to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential
market opportunities. Further, even if we obtain significant market share for elraglusib or any future product candidate, because some
of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Reliance on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>The termination of third-party licenses
could adversely affect our rights to important compounds or technologies.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In connection with our
efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future
pertaining to the in-license of rights to additional candidates. Such agreements may impose various diligence, milestone payment, royalty,
insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the
right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed
intellectual property. Our existing licensing agreements with UIC and NU contain diligence obligations to maintain each license agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Moreover, disputes may
arise regarding intellectual property subject to a licensing agreement, including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the scope of rights granted under the license agreement
    and other interpretation-related issues;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the extent to which our product candidates, technology
    and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the sublicensing of patent and other rights under
    our collaborative development relationships;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">our diligence obligations under the license agreement
    and what activities satisfy those diligence obligations;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the inventorship and ownership of inventions and
    know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the priority of invention of patented technology.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, the agreements
under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our
consolidated financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our
business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed
prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully
develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions,
results of operations and prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We may also have limited
control over the maintenance and prosecution of these in-licensed patents and patent applications, or any other intellectual property
that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors
have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and
other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding
against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to
us. It is possible that the licensors&rsquo; infringement proceeding or defense activities may be less vigorous than had we conducted
them ourselves. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Our current elraglusib drug substance
(DS) manufacturer is in China, and it is unknown how future geopolitical relationships with China may affect our ability to obtain DS;
however, if they are negatively impacted, this could increase our DS manufacturing costs and adversely impact our financial condition.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We rely upon a single
company located in China to manufacture the DS for our sole product candidate, elraglusib. This company manufactures DS under cGMP that
is suitable for formulating into a therapeutic used in humans. We do not have any exclusive contractual commitments for this company
to manufacture for us in the future or to ever become a sole provider of DS and thus, we do have the ability to seek out other GMP manufacturers
if needed. However, if we do not maintain this manufacturing and service relationship that is important to us and are not able to identify
replacement suppliers, vendors and laboratories, our ability to obtain manufacture elraglusib for clinical trials and to regulatory approval
could be impaired or delayed and our costs could substantially increase, adversely impacting our financial condition. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We may be unable to identify
additional manufacturers with whom we might establish appropriate arrangements on acceptable terms, if at all. Even if we are able to
find replacement manufacturers, suppliers, vendors and service providers when needed, we may not be able to enter into agreements with
them on terms and conditions favorable to us or there could be a substantial delay before such manufacturer, vendor or supplier, or a
related new facility is properly qualified and registered with the FDA or other foreign regulatory authorities. A new manufacturer currently
not qualified with the FDA would have to be educated in, or develop substantially equivalent processes for, production of our approved
products after receipt of FDA approval. To qualify and receive regulatory approval for a new manufacturer could take as long as two years.
The process of changing a supplier could have an adverse impact on our current clinical development programs if supplies of DS or materials
on hand are insufficient to satisfy demand. Such delays could have a material adverse effect on our development activities and our business.
Adverse changes in the political and economic policies of the Chinese government could have a material adverse effect on the overall
economic growth of China, which could adversely affect our ability to conduct business in China. We are unable to predict the frequency
and scope of such policy changes, any of which could materially and adversely affect our liquidity, access to capital and our ability
to conduct business in China. Any failure on our part to comply with changing government regulations and policies could result in the
loss of our ability to manufacture and develop our product candidates in China. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We rely on third parties to conduct
our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet
expected deadlines, we may be unable to obtain regulatory approval for or commercialize our current product candidates or any future
products, on a timely basis or at all, and our financial condition will be adversely affected.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We do not have the ability
to independently conduct non-clinical studies and clinical trials. We rely on medical institutions, clinical investigators, contract
laboratories, collaborative partners and other third parties, such as contract research organizations or clinical research organizations,
to conduct non-clinical studies and clinical trials on our product candidates. The third parties with whom we contract for execution
of our non-clinical studies and clinical trials play a significant role in the conduct of these studies and trials and the subsequent
collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations,
we have limited ability to control the amount or timing of resources that they devote to our programs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Although we rely on third
parties to conduct our non-clinical studies and clinical trials, we remain responsible for ensuring that each of our non-clinical studies
and clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA, EMA and other foreign regulatory
authorities require us to comply with regulations and standards, including regulations commonly referred to as good clinical practices
(GCPs), for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically
credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, the execution
of non-clinical studies and clinical trials, and the subsequent compilation and analyses of the data produced, requires coordination
among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties
communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities,
some of which may compete with us. Under certain circumstances, these third parties may be able to terminate their agreements with us
upon short notice. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience
work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy
of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other
reason, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and
our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may
not be able to obtain, on a timely basis or at all, regulatory approval for or to commercialize the product candidate being tested in
such trials, and as a result, our financial condition will be adversely affected. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our reliance on third parties requires us
to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade
secrets will be misappropriated or disclosed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we currently rely
on third parties to manufacture elraglusib and to perform quality testing, we must, at times, share our proprietary technology and confidential
information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality
and non-disclosure agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements
or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary
information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite
the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information
increases the risk that such trade secrets become known by our competitors or other third parties, are intentionally or inadvertently
incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position
is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&rsquo;s or other
third party&rsquo;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure of such
technology or information would impair our competitive position and may have a material adverse effect on our business, financial condition,
results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Corporate, non-profit, and academic collaborators
may take actions (including lack of effective actions) to delay, prevent, or undermine the success of our products. We may continue to
seek new collaborations or alliances in the future with respect to elraglusib or any future product candidates, but we may be unable to
do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization
plans.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating and financial
strategy for the development, clinical testing, manufacture, and commercialization of product candidates is heavily dependent on us entering
into collaborations with corporations, non-profit organizations, academic institutions, licensors, licensees, and other parties. There
can be no assurance that we will be successful in establishing such collaborations. Current and future collaborations are and may be terminable
at the sole discretion of the collaborator. The activities of any collaborator will not be within our direct control and may not be in
our power to influence. There can be no assurance that any collaborator will perform its obligations to our satisfaction or at all; that
we will derive any revenue, profits, or benefit from such collaborations; or that any collaborator will not compete with us. If any collaboration
is not pursued, we may require substantially greater capital to undertake development and commercialization of our proposed products,
and we may not be able to develop and commercialize such products effectively, if at all. In addition, a lack of development and commercialization
collaborations may lead to significant delays in introducing proposed products into certain markets and/or reduced sales of proposed products
in such markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also face significant competition
in seeking appropriate strategic partners, and the negotiation process can be time-consuming, costly and complex. Even if we are successful
in our efforts to establish or maintain such collaborations, the terms that we agree upon may not be favorable to us. As a result, we
may need to relinquish valuable rights to our future revenue streams, research programs, intellectual property, elraglusib or any future
product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements
may restrict us from entering into additional agreements with other potential collaborators. In addition, our current collaborations limit,
and potential future collaborations may limit, our control over the amount and timing of resources that our collaborators will dedicate
to the development or commercialization of elraglusib or any future product candidates. Our ability to generate revenue from these arrangements
will depend on any current or future collaborators&rsquo; abilities to successfully perform the functions assigned to them in these arrangements.
We cannot be certain that, following a collaboration, license, or strategic transaction, we will achieve an economic benefit that justifies
such transaction, and such transaction may not yield additional development product candidates for our pipeline. Furthermore, we may not
be able to maintain such collaborations if, for example, the development or approval of elraglusib or any future product candidate is
delayed, the safety of any such product candidate is questioned, or the sales of elraglusib, if approved, or an approved future product
candidate, are unsatisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our current collaborations
are, and potential future collaborations may be, terminable by our strategic partners, and we may not be able to adequately protect our
rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development
and, if approved, commercialization of elraglusib or any future product candidates, and may not conduct those activities in the same manner
as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to elraglusib
or any future product candidates, could delay the development and, if approved, commercialization of such product candidates, and reduce
their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Data provided by collaborators and other
parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third-party vendors,
scientists, clinical trial investigators, and collaborators to provide us with significant data and other information related to our projects,
clinical trials, and business. We do not independently verify or audit all of such data (including possibly material portions thereof).
As a result, such data may be inaccurate, misleading, or incomplete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>In certain cases, we may need to rely on
a single supplier for a particular manufacturing material or service, and any interruption in or termination of service by such supplier
could delay or disrupt the commercialization of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on third-party suppliers
for the materials used to manufacture our compounds. Some of these materials may at times only be available from one supplier. Any interruption
in or termination of service by such single source suppliers could result in a delay or disruption in manufacturing until we locate an
alternative source of supply, which could, among other things, adversely impact our clinical trials and ability to obtain approval from
the FDA for elraglusib or a future product candidate. There can be no assurance that we would be successful in locating an alternative
source of supply or in negotiating acceptable terms with such prospective supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>We may also rely on certain third party vendors located in
China or who are owned by or are associated with certain Chinese companies to assist in non-clinical or clinical trials or provide laboratory
services. It is unknown how current or future geopolitical relationships with China or specific Chinese-owned or associated vendors may
affect our ability to complete our non-clinical or clinical trials.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We may rely upon one or more companies located
in China, or are owned or operated by Chinese companies to provide non-clinical or clinical trial support services. If so, the process
of changing these vendors could have an adverse impact on our current clinical development programs if they were no longer permitted
to provide services or products due to geopolitical pressures, including legislative activities or executive orders aimed at prohibiting
certain Chinese or Chinese-owned biotechnology companies from engaging in biotechnology or biopharmaceutical research activities. We
could experience delays in finding suitable replacement service providers located outside China or not otherwise owned by or associated
with Chinese companies, which could have a material adverse effect on our development activities and our business. We are unable to predict
whether or when proposed legislative or executive actions would be effective, and whether such changes would materially and adversely
affect our liquidity, access to capital and our ability to conduct business. Any failure on our part to comply with changing government
regulations and policies could result in the loss of our ability to manufacture and develop our product candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Risks Related to Commercialization of Elraglusib
and any Future Product Candidates</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We have a limited operating history
and no products approved for commercial sale, which may make it difficult to evaluate our prospects and likelihood of success.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We are a clinical-stage
biopharmaceutical company with a limited operating history. We were originally incorporated in 2015, have no products approved for commercial
sale and have not generated any revenue to date. Our operations to date have been limited to organizing and staffing our company, business
planning, raising capital, establishing our intellectual property portfolio and performing clinical trials and research and development
of our product candidates. Our approach to the research and development of product candidates is unproven, and we do not know whether
we will be able to develop any products of commercial value. In addition, our lead product candidate, elraglusib, will require substantial
additional development and clinical research time and resources before we would be able to apply for or receive regulatory approvals
and begin generating revenue from product sales. We have not yet demonstrated the ability to progress any product candidate beyond Phase
2 clinical trials, obtain regulatory approvals, manufacture products at commercial scale or arrange for a third party to do so on our
behalf, or conduct sales and marketing activities necessary for successful product commercialization. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential
product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially
viable. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications,
delays and other known and unknown factors and risks frequently experienced by early stage biopharmaceutical companies in rapidly evolving
fields. Consequently, we have no meaningful history of operations upon which to evaluate our business, and predictions about our future
success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing
and commercializing drug products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we receive regulatory approval for
elraglusib or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which
may result in significant additional expense.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals that
we may receive for elraglusib or any future product candidates will require the submission of reports to regulatory authorities, subject
us to surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a REMS as a condition of approval of elraglusib or any future product candidates, which
could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the FDA or
a comparable foreign regulatory authority approves elraglusib or any future product candidates, the manufacturing processes, labeling,
packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will
be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing
information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we
conduct post-approval. Manufacturers of approved products and their facilities are subject to continual review and periodic, unannounced
inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. Failure to comply with regulatory
requirements or later discovery of previously unknown problems with our products, including adverse events of unanticipated severity or
frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market
or voluntary or mandatory product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical
trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing
or planned trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">fines, restitutions, disgorgement of profits or revenue, warning letters, untitled letters, adverse publicity
requirements or holds on clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved
applications submitted by us or suspension or revocation of approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">product seizure or detention, or refusal to permit the import or export of our products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">injunctions and the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The occurrence of any event
or penalty described above may inhibit our ability to commercialize elraglusib or any future product candidates and generate revenue and
could require us to expend significant time and resources in response and could generate negative publicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&rsquo;s and other
regulatory authorities&rsquo; policies may change and additional government regulations may be promulgated that could prevent, limit or
delay marketing authorization of elraglusib or any future product candidates. We also cannot predict the likelihood, nature or extent
of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The FDA and other regulatory agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and other regulatory
agencies strictly regulate the promotional claims that may be made about prescription products, such as elraglusib or any future product
candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory
agencies as reflected in the product&rsquo;s approved labeling. If we receive regulatory approval for elraglusib or any future product
candidates, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we
are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied
large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from
engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions
under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of elraglusib or any
future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our
business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is highly dependent on the
success of our lead product candidate, elraglusib, and any other future product candidates that we advance into clinical development.
All of our product candidates will require significant additional clinical and preclinical development before we can seek regulatory approval
for and launch a product commercially.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no products
that are approved for commercial sale and may never be able to develop marketable products. We have one clinical product candidate, elraglusib,
in clinical development. Because elraglusib is our only product candidate, if elraglusib encounters safety or efficacy problems, development
delays, regulatory issues or other problems, our development plans and business would be significantly harmed. For each product candidate,
we must demonstrate its safety and efficacy in humans, obtain regulatory approval in one or more jurisdictions, obtain manufacturing supply,
capacity and expertise, and substantially invest in marketing efforts before we will be able to generate any revenue from such product
candidate. These efforts will require substantial investment, and we may not have the financial resources to continue development of our
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience setbacks
that could delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">negative or inconclusive results from our clinical trials or preclinical studies or the clinical trials
or preclinical studies of others for product candidates similar to ours, leading to a decision or requirement to conduct additional clinical
trials or preclinical studies or to abandon a program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">drug-related side effects experienced by subjects in our clinical trials or by individuals using drugs
or therapeutics similar to our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">delays in submitting Investigational New Drug applications, or INDs, or comparable foreign regulatory
applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or
termination of a clinical trial once commenced;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">conditions imposed by FDA or comparable foreign authorities regarding the scope or design of our clinical
trials or our drug development strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">delays in enrolling subjects in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">high drop-out rates of subjects from clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">inadequate or delayed supply or quality of product candidates or other materials necessary for the conduct
of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">greater than anticipated clinical trial costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">inability to compete with other therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">failure of our third-party manufacturers, contractors or investigators to comply with regulatory requirements
or otherwise meet their contractual obligations in a timely manner, or at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">delays in obtaining any pre-market inspections required by FDA or other regulatory agencies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional
regulatory oversight around clinical testing generally or with respect to our technology in particular; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">varying interpretations of data by FDA and similar foreign regulatory agencies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have complete control
over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats
to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product development efforts are at an
early stage. We have not yet undertaken any marketing efforts, and there can be no assurance that future anticipated market testing and
analyses will validate our marketing strategy. We may need to modify the products, or we may not be successful in either developing or
marketing those products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a company, we have not
completed the development or clinical trials of any product candidates and, accordingly, have not yet begun to market or generate revenue
from the commercialization of any products. Obtaining approvals of these product candidates will require substantial additional research
and development as well as costly clinical trials. There can be no assurance that we will successfully complete the development of our
product candidates or successfully market them. We may encounter problems and delays relating to research and development, regulatory
approval, intellectual property rights of product candidates, or other factors. There can be no assurance that our development programs
will be successful, that our product candidates will prove to be safe and effective in or after clinical trials, that the necessary regulatory
approvals for any product candidates will be obtained, or, even if obtained, will be as broad as sought or will be maintained for any
period thereafter, that patents will issue on our patent applications, that any intellectual property protections we secure will be adequate,
or that our collaboration arrangements will not diminish the value of our intellectual property through licensing or other arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, elraglusib and
any future product candidates may not be commercially successful. Even if elraglusib or any future product candidates receive regulatory
approval, they may not gain market acceptance among physicians, patients, healthcare payors, or the medical community. The commercial
success of elraglusib or any future product candidates will depend significantly on the broad adoption and use of the resulting product
by these individuals and organizations for approved indications., and there can be no assurance that competitive products will not perform
better and/or be marketed more successfully. Additionally, there can be no assurances that any future market testing and analyses will
validate our marketing strategies. We may need to seek to modify the product labels through additional studies in order to be able to
market them successfully to reach their commercial potential. If elraglusib or any future product candidates is approved but does not
achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue
from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding
the benefits of our products may require significant resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We currently have no marketing and sales
organization and have no experience as a company in commercializing products, and we may need to invest significant resources to develop
these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market,
sell and distribute our products, we may not be able to generate product revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no internal sales,
marketing or distribution capabilities, nor have we ever commercialized a product. If elraglusib or any future product candidate ultimately
receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities
to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that
have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu
of our own sales force and distribution systems. For example, if elraglusib is approved, we will need to scale up a cost-effective and
reliable cold chain distribution and logistics network, which we may be unable to accomplish and which will require us to rely on third-party
distributors. Failure to scale up our cold chain supply logistics, by us or third parties, could in the future lead to additional manufacturing
costs and delays in our ability to supply required quantities for commercial supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no prior experience
as a company with the marketing, sale or distribution of biopharmaceutical products and there are significant risks involved in the building
and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient
sales leads, provide adequate training to and develop appropriate compliance programs for sales and marketing personnel and effectively
manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and
distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations
or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial
terms, or at all. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions
than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third
parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are
not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be
able to generate any future product revenue and we would incur significant additional losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to establish relationships
with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and
distribution capabilities, we will be unable to market our products successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy may
include selling product candidates, out-licensing product candidates to or collaborating with larger firms with experience in marketing
and selling pharmaceutical products. There can be no assurance that we will successfully be able to establish marketing, sales, or distribution
relationships with any third-party, that such relationships, if established, will be successful, or that we will be successful in gaining
market acceptance for any products we might develop. To the extent that we enter into any marketing, sales, or distribution arrangements
with third parties, our product revenues per unit sold are expected to be lower than if we marketed, sold, and distributed our products
directly, and any revenues we receive will depend upon the efforts of such third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The successful commercialization of elraglusib
or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers
establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate
reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The availability of coverage
and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other
third-party payors are essential for most patients to be able to afford prescription medications such as elraglusib or any future product
candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors
will have an effect on our ability to successfully commercialize those products. Accordingly, we will need to successfully implement a
coverage and reimbursement strategy for any approved product candidate. Even if we obtain coverage for a given product by a third-party
payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we participate in the Medicaid
Drug Rebate Program or other governmental pricing programs, in certain circumstances, our products would be subject to ceiling prices
set by such programs, which could reduce the revenue we may generate from any such products. Participation in such programs would also
expose us to the risk of significant civil monetary penalties, sanctions and fines should we be found to be in violation of any applicable
obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-party payors increasingly
are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage
and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a
third-party payor may consider our products as substitutable and offer to reimburse patients only for the less expensive product. Even
if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing
drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given
product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return
on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able
to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is significant uncertainty
related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including
private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which
new drugs will be covered. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies
before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors
will decide with respect to the coverage and reimbursement for elraglusib or any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining and maintaining
reimbursement status is time-consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how
private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for
coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for
products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&nbsp;and
regulations regarding reimbursement change frequently, and, in some cases, at short notice, and we believe that changes in these rules&nbsp;and
regulations are likely. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement
may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for
the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the
increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing
and usage of elraglusib or any future product candidates, if approved in these jurisdictions. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their
own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing
regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the
reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable
revenue and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, increasing efforts
by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations
to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate
payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend
toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward
pressure on healthcare costs in general, and prescription drugs, surgical procedures and other treatments in particular, has become very
intense. As a result, increasingly high barriers are being erected to the entry of new products. See the section titled &ldquo;<I>Risk
Factors&mdash;Risks Related to Our Business Operations and Industry&mdash;Current and future healthcare reform legislation or regulation
may increase the difficulty and cost for us to obtain coverage for and commercialize elraglusib or any future product candidates and may
adversely affect the prices we may set</I>&rdquo; for additional related information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we obtain FDA approval for any of our
product candidates, we will be subject to various federal and state fraud and abuse laws; these laws may impact, among other things, our
proposed sales, marketing and education programs. Fraud and abuse laws are expected to increase in breadth and in detail, which will likely
increase our operating costs and the complexity of our programs to ensure compliance with such enhanced laws.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain FDA approval
for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly
through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse laws, including,
without limitation, anti-kickback statutes and false claims statutes which may increase our operating costs. These laws may impact, among
other things, our proposed sales, marketing and education programs. In addition, we may be subject to data privacy and security regulation
by both the federal government and the states in which we conduct business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our operations are found to be in violation
of any of the federal and state fraud and abuse laws or any other governmental regulations that apply to us, we may be subject to criminal
actions and significant civil monetary penalties, which would adversely affect our ability to operate our business and our results of
operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any of the federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes and false
claims statutes or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant
civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, and the curtailment
or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
To the extent that any of our product candidates are ultimately sold in a foreign country, we may be subject to similar foreign laws and
regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse
laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we and our third-party licensors do not
obtain and preserve protection for our respective intellectual property rights, our competitors may be able to take advantage of our (and
our licensors&rsquo;) development efforts to develop competing drugs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We rely, and may in the
future rely, upon a combination of patent, trade secret and trademark protection for elraglusib and any future product candidates and
proprietary technologies to prevent third parties from exploiting our achievements, thus eroding our competitive position in our market.
These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and
proprietary information to our detriment. Our commercial success will depend in part on our ability to obtain, maintain, expand, enforce,
and defend the scope, ownership or control, validity and enforceability of our intellectual property protection in the United States
and other countries with respect to elraglusib and any future product candidates and other proprietary technologies we may develop. We
may also seek to protect our proprietary position by acquiring or in-licensing relevant issued patents or pending patent applications
from third parties. We have licensed patents on the original composition of matter patents covering elraglusib from UIC. In addition,
we own and have filed several new composition of matter patent applications that cover elraglusib polymorphs, which expire in 2038, with
possibility for patent term extensions (PTEs). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent process is subject
to numerous risks and uncertainties, and there can be no assurance that we will be successful in obtaining and defending patents. See
 &ldquo;Business - Intellectual Property&rdquo;. These risks and uncertainties include without limitation the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents that may be issued or licensed may be challenged, invalidated, or circumvented; or may not provide any competitive advantage for other reasons;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our licensors may terminate or breach our existing or future license agreements, thereby reducing or preventing our ability to exclude competition; termination of such license agreements may also subject us to risk of patent infringement of patents to which we no longer have a license;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our competitors, many of whom have substantially greater resources than we do and have made significant investments in competing technologies, may seek, or may already have obtained, patents that will limit, interfere with, or eliminate our ability to make, use, and sell our potential products either in the United States or in international markets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">intellectual property rights may subject to the risk of U.S. government 'march-in' rights under the Bayh-Dole Act. This legislation allows the federal government to intervene and grant licenses to third parties or take ownership of patents developed from federally funded research if it determines that such action is necessary to meet public health or safety needs, or if we fail to meet the requirements of the Act. Such government action could limit our exclusive rights, potentially reducing the commercial value of our potential products;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a matter of public policy regarding worldwide health concerns, there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of domestic and international patent protection for cancer treatments that prove successful; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries other than the United States may have less restrictive patent laws than those upheld by the U.S. courts; therefore, non-U.S. competitors could exploit these laws to create, develop, and market competing products. In some countries, the legal compliance with pharmaceutical patents, patent applications and other intellectual property regulations is very weak or actively evaded in some cases with government aid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the U.S. Patent
and Trademark Office (USPTO) and patent offices in other jurisdictions have often required that patent applications concerning pharmaceutical
and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations exemplified in the
patent application, thereby limiting their scope of protection against competitive challenges. Thus, even if we or our licensors are able
to obtain patents, the patents may be substantially narrower than anticipated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we permit our patents to
lapse or expire, we will not be protected and will have less of a competitive advantage. The value of our products may be greatly reduced
if this occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our patents expire at
different times and are subject to the laws of multiple countries. Some of our patents are currently near expiration and we may pursue
PTEs for these where appropriate. See &ldquo;Business - Intellectual Property&rdquo;. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents, we
also rely on trade secrets and proprietary know-how. While we take measures to protect this information by entering into confidentiality
and invention agreements with our consultants and collaborators, we cannot provide any assurances that these agreements will be fully
enforceable and will not be breached, that we will be able to protect ourselves from the harmful effects of disclosure if they are not
fully enforceable or are breached, that any remedy for a breach will adequately compensate us, that these agreements will achieve their
intended aims, or that our trade secrets will not otherwise become known or be independently discovered by competitors. If any of these
events for which we cannot provide assurances occurs, or we otherwise lose protection for our trade secrets or proprietary know-how, the
value of this information may be greatly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The patent protection we obtain and preserve
for our product candidates may not be sufficient enough to provide us with any competitive advantage.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to competition
despite the existence of intellectual property we license or own. We can give no assurances that our intellectual property claims will
be sufficient to prevent third parties from designing around patents we own or license and developing and commercializing competitive
products. The existence of competitive products that avoid our intellectual property could materially adversely affect our operating results
and financial condition. Furthermore, limitations, or perceived limitations, in our intellectual property may</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property disputes could require
us to spend time and money to address such disputes and could limit our intellectual property rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent position of biopharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in
recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.
Our current and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection
of elraglusib or any future product candidates or their intended uses against competitors, nor can there be any assurance that the issued
patents will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive
technologies, products or elraglusib or any future product candidates. Further, even if these patents are granted, they may be difficult
to enforce. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, information
disclosure, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or
eliminated if we fail to comply with these requirements. In the event we experience noncompliance events that cannot be corrected, and
we lose our patent rights, competitors could enter the market, which would have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biopharmaceutical industry
has been characterized by extensive litigation regarding patents and other intellectual property rights, and companies have employed intellectual
property litigation and USPTO post-grant proceedings to gain a competitive advantage. We may become subject to infringement claims or
litigation arising out of patents and pending applications of our competitors, or additional interference proceedings declared by the
USPTO to determine the priority and patentability of inventions. The defense and prosecution of intellectual property suits, USPTO proceedings,
and related legal and administrative proceedings are costly and time-consuming to pursue, and their outcome is uncertain. Grounds for
a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory
obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double
patenting or the loss of patent term, including a patent term adjustment granted by the USPTO. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO,
or made a misleading statement, during prosecution. Litigation may be necessary to enforce our issued patents, to protect our trade secrets
and know-how, or to determine the enforceability, scope, and validity of the proprietary rights of others. An adverse determination in
litigation or USPTO post-grant and interference proceedings to which we may become a party could subject us to significant liabilities,
require us to obtain licenses from third parties, or restrict or prevent us from selling our products in certain markets. Even if a given
patent or intellectual property dispute were settled through licensing or similar arrangements, our costs associated with such arrangements
may be substantial and could include the payment by us of large, fixed payments and ongoing royalties. Furthermore, the necessary licenses
may not be available on satisfactory terms or at all. Even where we have meritorious claims or defenses, the costs of litigation may prevent
us from pursuing these claims or defenses and/or may require extensive financial and personnel resources to pursue these claims or defenses.
In addition, it is possible there may be defects of form in our current and future patents that could result in our inability to defend
the intended claims. Intellectual property disputes arising from the aforementioned factors, or other factors, may materially harm our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to enforce our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The laws of some foreign countries
do not protect intellectual property rights to the same extent as the laws of the United States. Companies have encountered significant
problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those
relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our
other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must
grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government
agencies or government contractors. In these countries, patents may provide limited or no benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Proceedings to enforce
our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention
from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant
markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market
elraglusib or any future products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.
In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain
and enforce adequate intellectual property protection for our products and technology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to seeking patent
protection, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our
competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements
with parties who have access to them. Despite these efforts, these parties may breach the agreements and disclose our proprietary information,
including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally
disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition,
some courts inside and outside the United States, including in foreign jurisdictions, are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently
developed by a competitor, our competitive position would be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes to the patent law in the United
States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As is the case with other
biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Changes in either the patent
laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our intellectual property,
obtain, maintain, expand, enforce and defend our intellectual property rights and, more generally, could affect the value of our intellectual
property or narrow the scope of our protection. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological
and legal complexity. We cannot predict whether the patent applications we currently or may in the future pursue or may in-license will
issue as patents in any particular jurisdiction, whether the claims of any issued patents will provide sufficient protection against competitors
or other third parties, or if these patents are challenged by our competitors, whether the patents will be found to be invalid, unenforceable,
or not infringed or not owned or controlled by us. The patent prosecution process is expensive, time-consuming, and complex, and we may
not be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patent applications or patents at a reasonable
cost or in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research
and development output in time to obtain patent protection. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time
consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide ranging patent
reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection
available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty
with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value
of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, as well as other jurisdictions
around the world, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
new patents or to enforce our existing patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USPTO and various foreign
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the
patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market
earlier than would otherwise have been the case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to protect
the competitive position of elraglusib or any future product candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents have a limited lifespan.
In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest
U.S. non-provisional or international patent application filing date. The patent term of a U.S. patent may be lengthened by patent term
adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent
is terminally disclaimed over an earlier-filed patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various extensions may be
available, but the life of a patent, and the protection it affords, is limited. Even if patents covering elraglusib or any future product
candidates are obtained, once the patent has expired, we may be vulnerable to competition from competitive products, including generics.
Given the amount of time required for the development, testing and regulatory review of elraglusib or any future product candidates, patents
protecting such product candidates might expire before or shortly after such product candidates are commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Drug Price Competition and Patent Term Restoration Act of 1984 permits a Patent Term Extension (PTE) of up to five years beyond the normal
expiration of the patent to compensate patent owners for loss of enforceable patent term due to the lengthy regulatory approval process.
A PTE grant cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product approval. Further, PTE
may only be applied once per product, and only with respect to an approved indication&thinsp;-&thinsp;in other words, only one patent
(for example, covering the product itself, an approved use of said product, or a method of manufacturing said product) can be extended
by PTE. We anticipate applying for PTE in the United States. Similar extensions may be available in other countries where we are prosecuting
patents, and we likewise anticipate applying for such extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The granting of such PTEs
is not guaranteed and is subject to numerous requirements. We might not be granted an extension because of, for example, failure to apply
within applicable periods, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous
applicable requirements. In addition, to the extent we wish to pursue PTE based on a patent that we in-license from a third party, we
would need the cooperation of that third party. Moreover, the applicable authorities, including the FDA and the USPTO in the United States,
and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available,
and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors
may be able to obtain approval of competing products following our patent expiration by referencing our clinical and preclinical data
and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on
our ability to generate revenue. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual
property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates
or we could lose certain rights to grant sublicenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any license, collaboration
or other intellectual property-related agreements impose, and any future license, collaboration or other intellectual property-related
agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing,
insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual
property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate
the license. In spite of our best efforts, any of our future licensors might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technologies
covered by these license agreements. Any license agreements we enter into may be complex, and certain provisions in such agreements may
be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what
we believe to be the scope our rights to the relevant intellectual property or technology, or increase what we believe to be our financial
or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek to obtain licenses
from licensors in the future, however, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at
all. In addition, if any of our future licensors terminate any such license agreements, such license termination could result in our inability
to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the
licensed technology. Any of these events could have a material adverse effect on our competitive position, business, financial condition,
results of operations, and ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we may not have
the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that
we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted,
maintained, enforced and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute,
maintain, enforce and defend patents we may in-license, or lose rights to licensed patents or patent applications, our license rights
may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or drug candidates that
is the subject of such licensed rights could be materially adversely affected. In certain circumstances, our licensed patent rights are
subject to our reimbursing our licensors for their patent prosecution and maintenance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, our licensors may
own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their
merit, that we are infringing, misappropriating or otherwise violating the licensor&rsquo;s intellectual property rights and the amount
of any damages or future royalty obligations that would result, if any such claims were successful, would depend on the technology and
intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop
and commercialize products, due to such obligations, we may be unable to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims challenging
the inventorship or ownership of our patents and other intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, consultants, licensees, collaborators or other third parties have an interest in our patent rights, trade secrets,
or other intellectual property as an inventor, co-inventor or owner of trade secrets. For example, we may have inventorship or ownership
disputes arise from conflicting obligations of consultants or others who are involved in developing elraglusib or any future product candidates
and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship
or ownership or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights, such as ownership of, or the right to use intellectual
property that is important to elraglusib or any future product candidates and other proprietary technologies we may develop. Even if we
are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and
other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may initiate legal proceedings
alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse impact on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends,
in part, upon our ability or the ability of any of our future collaborators to develop, manufacture, market and sell our current or any
future drug candidates and to use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary
and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and
complex litigation regarding patents and other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or any of our future licensors
or strategic partners, may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights
with respect to our current or any potential future drug candidates and technologies, including derivation, reexamination, inter partes
review, post-grant review or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United
States such as opposition proceedings. If we or our licensors or strategic partners are unsuccessful in any interference proceedings or
other priority or validity disputes (including through any patent oppositions) to which we or they are subject, we may lose valuable intellectual
property rights through the loss of one or more patents or our patent claims may be narrowed, invalidated, or held unenforceable. In some
instances, we may be required to indemnify our licensors or strategic partners for the costs associated with any such adversarial proceedings
or litigation. Third parties may also assert infringement, misappropriation or other claims against us, our licensors or our strategic
partners based on existing patents or patents that may be granted in the future, as well as other intellectual property rights, regardless
of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors
or our strategic partners to enforce or otherwise assert their patent rights or other intellectual property rights. Even if we believe
such claims are without merit, a court of competent jurisdiction could hold that these third-party patents and other intellectual property
rights are valid, enforceable and infringed, which could have a material adverse impact on our ability to utilize our developed technologies
or to commercialize our current or any future drug candidates deemed to be infringing. In order to successfully challenge the validity
of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and convincing evidence
of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and
convincing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property rights of third parties
could adversely affect our ability to commercialize our current or future technologies or drug candidates, and we might be required to
litigate or obtain licenses from third parties to develop or market our current or future technologies or drug candidates, which may not
be available on commercially reasonable terms, or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are numerous companies
that have pending patent applications and issued patents broadly covering small molecules directed against the same targets as, or targets
similar to, those we are pursuing. Our competitive position may materially suffer if patents issued to third parties or other third-party
intellectual property rights cover our current or future technologies, drug candidates or elements thereof, or our manufacture or uses
relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies
or drug candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property rights concerned,
or enter into a license agreement with the intellectual property rights holder, if available on commercially reasonable terms. There may
be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be
infringed by our current or future technologies or drug candidates. There also may be pending patent applications of which we are not
aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should such an infringement
claim be successfully brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies
or drug candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially
reasonable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third-party intellectual property
rights holders may also actively bring infringement, misappropriation or other claims alleging violations of intellectual property rights
against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming
litigation and may be prevented from, or experience substantial delays in, marketing our drug candidates. If we fail in any such dispute,
in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or
future technologies or drug candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual
property rights. We might, if possible, also be forced to redesign current or future technologies or drug candidates so that we no longer
infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail,
could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which
could have a material adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims that our employees,
consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting
ownership of what we regard as our own intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our employees, consultants
and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed
intellectual property, including trade secrets or other proprietary information, of any such individual&rsquo;s current or former employer.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation
could result in substantial costs and be a distraction to our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while it is our
policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact,
conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing,
or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may
bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse
effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Some intellectual property which we own
or have licensed, or which may acquire or license in the future, may have been, or may be, discovered through government funded programs
and thus may be subject to federal regulations such as &ldquo;march-in&rdquo; rights, certain reporting requirements, and a preference
for United States industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with
respect to reporting requirements and limit our ability to contract with non-U.S. manufacturers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the intellectual property rights we own
or have licensed, or which we may acquire or license in the future, have been or may be generated using U.S. government funding and may
therefore be subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property
embodied in our current or future products and product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights
in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license
to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially
exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been
taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action
is necessary to meet requirements for public use under federal regulations (also referred to as &ldquo;march-in rights&rdquo;). The U.S.
government also has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file
an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire title
to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property generated
under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial
resources. In addition, the U.S. government requires that any products embodying the subject invention or produced using the subject invention
be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual
property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that
would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially
feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered
by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business Operations and
Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we lose key management leadership, and/or
scientific personnel, and if we cannot recruit qualified employees, managers, directors, officers, or other significant personnel, we
may experience program delays and increases in compensation costs, and our business may be materially disrupted.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success is highly
dependent on the continued service of principal members of our management, leadership, and scientific personnel, who are able to terminate
their employment with us at any time and may be able to compete with us. The loss of any of our key management, leadership, or scientific
personnel including, in particular, Daniel M, Schmitt, our President and CEO, and Andrew P. Mazar, our Chief Operating Officer, could
materially disrupt our business and materially delay or prevent the successful product development and commercialization of our product
candidates. We have employment agreements with Mr.&nbsp;Schmitt and Dr.&nbsp;Mazar which have no term but are for at-will employment,
meaning the executives have the ability to terminate their employment at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future success will also
depend on our continuing ability to identify, hire, and retain highly skilled personnel for all areas of the organization. Competition
in the biopharmaceutical industry for scientifically and technically qualified personnel is intense, and we may be unsuccessful in identifying,
hiring, and retaining qualified personnel. Our continued requirement to identify, hire, and retain highly competent personnel may cause
our compensation costs to increase materially. As of December&nbsp;31, 2023, we had 5 full-time employees and as of February&nbsp;15,
2024, we had 9 full-time employees. As our clinical development and commercialization plans and strategies develop, we will need to expand
our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing and legal capabilities or contract with
third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships
with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant added responsibilities
on members of management, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">identifying, recruiting, integrating, maintaining and motivating additional employees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">managing our development and commercialization efforts effectively, while complying with our contractual
obligations to contractors and other third parties; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">improving our operational, financial and management controls, reporting systems and procedures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to continue to
develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth.
Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a
substantial amount of time to managing these growth activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently rely, and for
the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide
certain services, including contract manufacturers and companies focused on research and development activities. There can be no assurance
that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed,
or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality,
accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be extended, delayed or terminated,
and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of our product candidates or otherwise
advance our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>We face significant competition from
other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The development and commercialization
of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or
commercialize in the future from major biopharmaceutical companies, specialty biopharmaceutical companies and biotechnology companies
worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations
that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing, and
commercialization. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> A highly effective treatment
for cancer is a desirable target for the pharma industry. There is significant activity in this space as indicated by the partial listing
of current products in clinical trials included elsewhere in this prospectus. Although none of the active pharmaceutical ingredients
in current clinical trials are directed toward the mechanism of action of elraglusib, there can be no assurance that a large biopharmaceutical
or biotechnology company will not pursue the commercialization or development of products competitive with elraglusib in the future.
Many of these potential competitors, either alone or with their strategic partners, have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals,
and marketing approved products than we do. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Mergers and acquisitions
in the biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of
our potential competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors
develop and commercialize products that are safer, more effective, more convenient, or less expensive than any products that we may develop.
Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours,
which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products
or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful
in marketing any product candidates we may develop against competitors. The availability of competitive products could limit the demand,
and the price we are able to charge, for any products that we may develop and commercialize. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>As a recently established entity, we
have a limited operating history.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of February&nbsp;1,
2024, we have engaged exclusively in licensing rights to product candidates and entering into collaboration agreements with respect to
key services or technologies for our drug product development, and have not received any governmental approvals, brought any product
to market, manufactured products in clinical or commercial quantities or sold any pharmaceutical products. As a company we have limited
experience in negotiating, establishing, and maintaining strategic relationships, conducting clinical trials, and managing the regulatory
approval process, all of which will be necessary if we are to be successful. Our lack of experience in these critical areas makes it
difficult for a prospective investor to evaluate our abilities and increases the risk that we will fail to successfully execute our strategies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Furthermore, if our business
grows rapidly, our operational, managerial, legal, and financial resources will be strained. Our development will require continued improvement
and expansion of our management team and our operational, managerial, legal, and financial systems and controls. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In the normal course of
business, we have evaluated and expect to evaluate potential acquisitions and/or licenses of patents, compounds, and technologies that
our management believes could complement or expand our business. We have a limited history of conducting acquisitions and negotiating
and acquiring licenses. In the event that we identify an acquisition or license candidate we find attractive, there is no assurance that
we will be successful in negotiating an agreement to acquire or license, or in financing or profitably exploiting, such patents, compounds,
or technologies. Furthermore, such an acquisition or license could divert management time and resources away from other activities that
would further our current business development. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to various U.S. federal,
state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and
regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business operations and
current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and
customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute any products for which we obtain regulatory approval. Such laws include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly
or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or
order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be
made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have
actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws,
which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government,
claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or
statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease
or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil
False Claims Act;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal
and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement,
in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute,
a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a
violation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain
exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), information related to payments and other
 &ldquo;transfers of value&rdquo; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists,
anesthesiology assistants and certified nurse-midwives), and teaching hospitals and other healthcare providers, as well as ownership and
investment interests held by physicians and their immediate family members; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which
may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party
payors, including private insurers; some state laws require biopharmaceutical companies to comply with the biopharmaceutical industry&rsquo;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers
to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
some state laws that require biopharmaceutical companies to report information on the pricing of certain drug products; and some state
and local laws that require the registration or pharmaceutical sales representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure that our
current and future business arrangements with third parties will comply with applicable healthcare and privacy laws and regulations will
involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain
consulting agreements and advisory board agreements we have entered into with physicians who are paid, in part, in the form of stock or
stock options, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. Due to the breadth of these laws, the narrowness of statutory exceptions and regulatory safe harbors available,
and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged
under one or more of these laws. If our operations are found to be in violation of any of these laws or any other governmental regulations
that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity
oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment
or restructuring of our operations. Defending against any such actions can be costly and time-consuming and may require significant financial
and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our
business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business
are found not to be in compliance with applicable laws or regulations, they may be subject to significant criminal, civil or administrative
sanctions, including exclusions from government-funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an emerging growth company and a
smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies
may make our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging growth
company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth
anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including
if we become a &ldquo;large accelerated filer&rdquo;, as defined under the Securities and Exchange Act of 1934, as amended (the Exchange
Act), our annual gross revenue exceeds $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period,
we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth
company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies
that are not emerging growth companies. These exemptions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo; disclosure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">not being required to comply with the auditor attestation requirements in the assessment of our internal
control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information
about the audit and the financial statements, unless the Securities and Exchange Commission (SEC) determines the new rules&nbsp;are necessary
for protecting the public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reduced disclosure obligations regarding executive compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have taken advantage of
reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial
statements and have not included all of the executive compensation-related information that would be required if we were not an emerging
growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended
transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption
of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected to avail ourselves of
this exemption and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being
required to comply with the auditor attestation requirements of Section&nbsp;404(b)&nbsp;of Sarbanes-Oxley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a smaller reporting
company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth
company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take
advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0
million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most
recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured
on the last business day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competition and technological change may
make our product candidates less competitive or obsolete.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biopharmaceutical industry
is subject to rapid technological change. We have many potential competitors, including major drug and chemical companies, specialized
biopharmaceutical firms, universities and other research institutions. These companies, firms, and other institutions may develop products
that are more effective than our product candidates or that would make our product candidates less competitive or obsolete. Many of these
companies, firms, and other institutions have greater financial resources than us and may be better able to withstand and respond to adverse
market conditions within the biopharmaceutical industry, including without limitation the lengthy regulatory approval process for product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may engage in strategic transactions
that could impact our liquidity, increase our expenses and present significant distractions to our management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
consider strategic transactions, such as acquisitions of companies, asset purchases, and out-licensing or in-licensing of products, product
candidates or technologies. Additional potential transactions that we may consider include a variety of different business arrangements,
including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any
such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose
significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results.
For example, these transactions may entail numerous operational and financial risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">exposure to unknown liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">disruption of our business and diversion of our management's time and attention in order to develop acquired
products, product candidates or technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">higher-than-expected acquisition and integration costs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">write-downs of assets, goodwill or impairment charges;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">increased amortization expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations
and personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">impairment of relationships with key suppliers or customers of any acquired businesses due to changes
in management and ownership; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">inability to retain key employees of any acquired businesses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, although there
can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that
we do complete may be subject to the foregoing or other risks, and could have a material adverse effect on our business, results of operations,
financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our interim chief financial officer is not
a full-time employee.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our interim chief financial
officer, Paul Lytle, was appointed in February&nbsp;2024 and provides such services as a consultant rather than as a full-time employee,
which appointment follows his consulting engagement to assist with our finance and accounting matters from December&nbsp;20, 2023. There
can be no assurance that we will be able to successfully manage our finance and accounting matters without a full time chief financial
officer. In addition, Mr.&nbsp;Lytle is also co-founder of a private biopharmaceutical company, where he currently also serves as its
chief financial officer, as well as a co-founder of a public development-stage biotechnology company, where he currently serves on its
board of directors and as its executive vice president, chief financial officer. While we believe that Mr.&nbsp;Lytle will devote adequate
time to our business to perform the role and duties of our Interim Chief Financial Officer, we cannot guarantee that he will continue
to do so in the future. Additionally, while we do not believe that Mr.&nbsp;Lytle currently faces any conflicts of interest, including
conflicts in allocating time to our business, Mr.&nbsp;Lytle may face conflicts of interest in the future. If Mr.&nbsp;Lytle cannot devote
adequate time to us to fulfill his role and duties as Interim Chief Financial Officer or if any conflicts of interest arise, it could
have a material adverse impact on our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If product liability lawsuits are brought
against us, we may incur substantial costs to defend them and address any damages awarded, and demand for our products could be reduced
as a result of such lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The testing and marketing
of medical products is subject to an inherent risk of product liability claims, including a possibility in some states for product liability
claims being made based on generic copies of our drugs. While we do have liability insurance coverage, regardless of their merit or eventual
outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">withdrawal of clinical trial volunteers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">decreased demand for our products when approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">injury to our reputation and significant, adverse media attention; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">potentially significant litigation costs, including without limitation, any damages awarded to the plaintiffs
if we lose or settle claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our information technology
systems, or those of any of our service providers, may fail or suffer security incidents and other disruptions, which could result in
a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing
critical information, potentially exposing us to liability or otherwise adversely affecting our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary and
confidential business information and personal information). Our information technology systems and those of our third-party service providers,
strategic partners and other contractors or consultants are vulnerable to attack, damage and interruption from computer viruses and malware
(e.g. ransomware), malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks,
phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service
attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization,
or persons with access to systems inside our organization. In addition, attacks upon information technology systems are increasing in
their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and
individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or
to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these
techniques or implement adequate preventative measures. We may also experience security incidents that may remain undetected for an extended
period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly
using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and certain of our service
providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any material
system failure, accident or security breach to date, if any such event, whether actual or perceived, were to occur, it could impact our
reputation and/or operations, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion
into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial
data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. We also rely on a third party to manufacture elraglusib, and similar events relating to their computer systems could
also have a material adverse effect on our business. To the extent that any actual or perceived disruption or security incident affects
our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of
or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or
damage to, our confidential or proprietary data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur liability, the further development and commercialization of elraglusib or any future product candidates could be delayed,
and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also outsourced elements
of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential
information. If our third-party vendors fail to protect their information technology systems and our confidential and proprietary information,
we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information and we could incur
liability and reputational damage. If the information technology systems of our third-party vendors and other contractors and consultants
become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend
significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this
nature from occurring. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals
of security breaches involving particular categories of personally identifiable information, which could result from incidents experienced
by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Our contracts may not contain
limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient
to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Although we currently hold cybersecurity
insurance, the costs related to significant security breaches or disruptions could be material and cause us to incur significant expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with health privacy and
other data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties),
private litigation or adverse publicity and could negatively affect our operating results and business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and our service providers
maintain and will maintain a large quantity of sensitive and/or regulated information, including confidential business and patient health
information, personal data about our employees and collaborators, and information relating to our clinical trials. The global data protection
landscape is rapidly evolving, and we, our service providers and our collaborators may be affected by or subject to existing, amended,
or new laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These
laws and regulations may be subject to differing interpretations, thus creating potentially complex compliance issues for us and our service
providers, strategic partners and future customers. The cost of compliance with these laws, regulations and standards is high and is likely
to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal
policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government
investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, numerous
federal and state laws and regulations, including federal health information privacy laws (e.g., the Health Insurance Portability and
Accountability Act (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH)), state data
breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&nbsp;5 of
the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information
could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties
(including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under
HIPAA, as amended by HITECH, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to
criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered
entity in a manner that is not authorized or permitted by HIPAA. State legislatures in Washington, Nevada, and Connecticut have recently
enacted legislation to protect consumer health information that is not covered by HIPAA. In addition to detailed and specific requirements
for the collection, use, disclosure, retention, and safeguarding of consumer health data, the Washington My Health My Data Act (MHMDA)
(effective March 31, 2024) provides a private right of action to consumers for violations of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our uses of personal data
may also be subject to state comprehensive data privacy laws, including, without limitation, the California Consumer Privacy Act and regulations
promulgated thereunder (CCPA), which came into effect in 2020. At the start of 2023, the CCPA was expanded in several ways, including
by extending its application to employees, job applicants and business-to-business contacts in addition to consumers. The CCPA requires
us to make disclosures about our data collection, use, and sharing practices with respect to personal information, and allows California
residents to request access, deletion and correction of their personal data, as well as providing the right to opt out of certain data
use and sharing practices. The CCPA is primarily enforced by the California Privacy Protection Agency and the California Attorney General,
which have the power to seek penalties of up to $7,500 per violation. The CCPA also allows the recovery of statutory damages in the event
of a data breach. Ongoing rulemaking by the California Privacy Protection Agency is likely to result in additional requirements, increasing
the level of risk associated with CCPA compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several other U.S. states
have also passed comprehensive data privacy laws, which are currently in effect or will take effect over the next few years. Generally,
these laws apply to consumer personal data. For example, Virginia enacted the Virginia Consumer Data Protection Act (VCDPA), which came
into effect on January 1, 2023; Colorado enacted the Colorado Privacy Act (CPA), which came into effect on July 1, 2023; Connecticut enacted
the Connecticut Data Privacy Act (CTDPA), which came into effect on July 1, 2023; and Utah enacted the Utah Consumer Privacy Act (UCPA),
which came into effect on December 31, 2023. Other states have enacted similar laws that will come into effect on future dates: Texas
has enacted the Texas Data Privacy and Security Act (TDPSA) (effective July 1, 2024); Florida has enacted the Florida Digital Bill of
Rights (FDBR) (effective July 1, 2024); Oregon has passed the Oregon Consumer Privacy Act (OCPA) (effective July 1, 2024); Montana has
enacted the Montana Consumer Data Privacy Act (MCDPA) (effective October 1, 2024); Iowa has enacted the Iowa Consumer Data Protection
Act (ICDPA) (effective January 1, 2025); the New Hampshire Legislature has passed the New Hampshire Privacy Act (NHPA) (effective January
1, 2025); Delaware has enacted the Delaware Personal Data Privacy Act (DPDPA) (effective January 1, 2025); New Jersey has enacted New
Jersey S332/A1971 (effective January 15, 2025); Tennessee has enacted the Tennessee Information Protection Act (TIPA) (effective July
1, 2025); and Indiana has enacted the Indiana Consumer Data Protection Act (INCDPA) (effective January 1, 2026). Similar legislation is
pending in several other states. At a high level, these comprehensive state privacy laws require us to make new disclosures about personal
data collection, use, and sharing practices and to adjust or develop internal compliance measures, such as those related to personal data
security, vendor contracting, personal data retention and privacy assessments. They grant certain privacy rights to consumers, including
the rights to access, collect and delete personal data. Consumers also have opt-in and opt-out rights that vary based on the applicable
state law and the type of personal data, but broadly include the ability to tell a company not to use personal data for targeted advertising
or not to sell personal data, which can include sales for monetary or other valuable consideration in most states. These state comprehensive
privacy laws are generally enforced by state attorneys general, and typically provide for fines of up to $7,500 per violation, with higher
penalties in some states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, several states
and localities have enacted statutes restricting the collection and use of biometric information. For example, the Illinois Biometric
Information Privacy Act (BIPA), Texas Biometric Privacy Act (TBPA), the Washington Biometric Privacy Law, and the Washington MHMDA regulate
the collection, use, safeguarding, and storage of biometric information and provide for substantial penalties and statutory damages, with
BIPA and MHMDA also creating a private right of action for violations. Since its enactment, BIPA has generated significant class action
activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International data protection
laws may also apply to health-related and other personal information we collect. In the EU, the collection, use, disclosure, transfer,
and other processing of personal data is governed by the EU General Data Protection Regulation 2016/679 (EU GDPR), which came into effect
in May 2018. The GDPR has also been implemented in the UK (UK GDPR, and together with the EU GDPR, the GDPR). The GDPR, among other things,
imposes: (i) accountability and transparency requirements, which require controllers to demonstrate and record compliance with the GDPR
and provide detailed information to data subjects regarding processing of personal data; (ii) requirements for obtaining valid consent;
(iii) obligations to consider data protection as new products or services are developed and to limit the amount of personal data processed;
(iv) obligations to comply with data protection rights of data subjects including a right of access to and rectification of personal data,
a right to obtain restriction of processing or to object to processing of personal data, and a right to ask for a copy of personal data
to be provided to a third party in a useable format and erasing personal data in certain circumstances; (v) obligations to implement appropriate
technical and organizational security measures to safeguard personal data; and (vi) obligations to report certain personal data breaches
to the relevant supervisory authority without undue delay (and no later than 72 hours where feasible). Both the EU GDPR and the UK GDPR
prohibit the transfer of personal data to other countries that are not recognized as having &ldquo;adequate&rdquo; data protection laws.
For personal data transfers from the EU or UK to the United States, additional safeguards such as adoption of standard contractual clauses
(SCCs) or compliance with the Trans-Atlantic Data Privacy Framework (DPF) and the UK and Swiss extensions of the DPF are required. Data
transfers from the EU to the US have been the subject or repeated legal challenges, including a July 2020 decision by the Court of Justice
of the EU that invalidated a prior transfer mechanism known as Privacy Shield. The EU GDPR provides for fines for violations of up to
the higher of 4% of annual worldwide turnover or &euro;20,000,000 (and in respect of the UK GDPR, GBP17,500,000). The GDPR identifies
a list of points to consider when determining the level of fines to impose (including the nature, gravity and duration of the infringement).
Data subjects also have a right to compensation for financial or non-financial losses (e.g., distress).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other countries in which we
have or plan to do business have also enacted laws regulating the collection, use, disclosure, transfer and processing of personal data.
For example, China has enacted the Personal Information Protection Law (PIPL) and Cybersecurity Law, Canada the Personal Information Protection
and Electronic Documents Act (PIPEDA), Australia the Privacy Act 1988 (the Privacy Act), Japan the Act on the Protection of Personal Information
(APPI), Brazil the General Data Protection Law (LGPD), and Mexico the Federal Law on the Protection of Personal Data held by Private Parties
(FLPPDPP), all of which govern the collection, use, disclosure and transfer of personal data. Other countries have already enacted, or
considering enacting, similar legislation. To the extent that the GDPR, PIPL, Chinese Cybersecurity Law, PIPEDA, Australian Privacy Act,
APPI, LGPD, FLPPDPP, and similar laws apply or will in the future apply to us, complying with their requirements may require substantial
amendments to our procedures and policies. The changes could adversely impact our business by increasing its operational and compliance
costs, and further, there is a risk that the measures will not be implemented correctly or that individuals within the business will not
be fully compliant with the new procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legal framework around
privacy issues is rapidly evolving, as various federal, state and foreign government bodies are considering adopting new privacy laws
and regulations and providing guidance on current laws and regulations, which could result in significant limitations on or changes to
the ways in which we can collect, use, host, store, or transmit personal data. Compliance with U.S. and international data protection
laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose
data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection
laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation
or adverse publicity and could negatively affect our operating results and business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not comply with laws regulating
the protection of the environment and health and human safety, our business could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
and drug candidates and future commercial manufacturing may involve the use of hazardous materials and various chemicals. We currently
do not maintain a research laboratory, but we engage third-party research organizations and manufacturers to conduct our preclinical studies,
clinical trials and manufacturing. These third-party laboratories and manufacturers are subject to federal, state and local laws and regulations
governing the use, manufacture, storage, handling and disposal of these hazardous materials. We must rely on the third parties&rsquo;
procedures for storing, handling and disposing of these materials in their facilities to comply with the relevant guidelines of the states
in which they operate and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that
their safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the
risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, this could result in significant
delays in our development. We are also subject to numerous environmental, health and workplace safety laws and regulations. Although we
maintain workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, this
insurance may not provide adequate coverage against potential liabilities. Additional federal, state and local laws and regulations affecting
our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate,
any of these laws or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Current and future healthcare reform legislation
or regulation may increase the difficulty and cost for us to obtain coverage for and commercialize elraglusib or any future product candidates
and may adversely affect the prices we may set.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and some
foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the
healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and
affect our ability to profitably sell elraglusib or any future product candidates for which we obtain regulatory approval. In particular,
there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and
improve the quality of healthcare.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, in March&nbsp;2010,
the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (ACA) was enacted
in the United States. The ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
drugs and biologic agents; extended manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled
in Medicaid managed care organizations; expanded eligibility criteria for Medicaid programs; expanded the entities eligible for discounts
under the 340B drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness
research, along with funding for such research; and established a Center for Medicare&nbsp;&amp; Medicaid Innovation at CMS to test innovative
payment and service delivery models to lower Medicare and Medicaid spending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its enactment, there
have been executive, judicial and Congressional challenges to certain aspects of the ACA. On June&nbsp;17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality
of the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted since the ACA was enacted. For example, beginning April&nbsp;1, 2013, Medicare payments to providers
were reduced under the sequestration required by the Budget Control Act of 2011, which will remain in effect until 2032, unless additional
Congressional action is taken. Additionally, on January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which,
among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
On March&nbsp;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory cap on the Medicaid drug
rebate, beginning January&nbsp;1, 2024. The rebate was previously capped at 100% of a drug&rsquo;s average manufacturer price. Further,
there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of
prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient assistance programs, and reform government program reimbursement methodologies for products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, on August&nbsp;16,
2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress
with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA (i)&nbsp;directs the U.S. Department
of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under
Medicare and (ii)&nbsp;imposes rebates under Medicare Part&nbsp;B and Medicare Part&nbsp;D to penalize price increases that outpace inflation.
The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial
years. HHS has and will continue to issue and update guidance as these programs are implemented. On August&nbsp;29, 2023, HHS announced
the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently
subject to legal challenges. The impact of the IRA on the pharmaceutical industry cannot yet be fully determined but is likely to be significant.
Additional drug pricing proposals could appear in future legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the state level, legislatures
have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including
price or reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment
amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects.
In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for elraglusib and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect
our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these existing
laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other
healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive
for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction
in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being
able to generate revenue, attain profitability or commercialize elraglusib or any future product candidates, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we are able to commercialize any
drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies,
which would harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related
treatments will be available from third-party payors, such as government authorities, private healthcare insurers and health maintenance
organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse
all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs,
such as Medicare and Medicaid, and private healthcare insurers are critical to new product acceptance. Patients are unlikely to use our
future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost-containment is a priority
in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control
costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring
that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.
Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company
to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Commercial third-party payors
often rely upon Medicare coverage policy and payment limitations in setting their reimbursement rates, but also have their own methods
and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the United
States can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for
any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement
may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If coverage and reimbursement are
not available or are available only at limited levels, we may not be able to successfully commercialize any drug candidate for which we
obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the regulations
that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country.
Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the
pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for
a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly
for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse
pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain
regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disruptions at the FDA and other government
agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and
other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or
at all, which could negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA and
other government agencies to review and approve new products can be affected by a variety of factors, including government budget and
funding levels, statutory, regulatory and policy changes, a government agency&rsquo;s ability to hire and retain key personnel and accept
the payment of user fees, and other events that may otherwise affect the government agency&rsquo;s ability to perform routine functions.
Average review times at the FDA and other government agencies have fluctuated in recent years as a result. In addition, government funding
of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid
and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to approved
or licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For
example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA,
have had to furlough critical employees and stop critical activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Separately, in response to
the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though
the FDA has since resumed standard inspection operations of domestic facilities where feasible, future pandemics may lead to similar inspectional
or administrative delays. If any future prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory
authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability
of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse
effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is subject to risks arising
from pandemics and epidemic diseases.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The COVID-19 worldwide pandemic
presented substantial public health and economic challenges and affected our employees, patients, physicians and other healthcare providers,
communities and business operations, as well as the U.S. and global economies and financial markets. Any future pandemic or epidemic disease
outbreaks could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for elraglusib
or any future product candidates for use in our, our collaborators&rsquo; or any future collaborators&rsquo; clinical trials and research
and preclinical studies and, delay, limit or prevent our employees and CROs from continuing research and development activities, impede
our clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, alter the results of the clinical
trial based on participants contracting the disease or otherwise increasing the number of observed adverse events, impede testing, monitoring,
data collection and analysis and other related activities, any of which could delay our preclinical studies and clinical trials and increase
our development costs, and have a material adverse effect on our business, financial condition, results of operations and prospects. Any
future pandemic or epidemic disease outbreak could also potentially further affect the business of the FDA, EMA or other regulatory authorities,
which could result in delays in meetings related to our planned clinical trials, as well have an adverse impact on global economic conditions
which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Effective collaboration with the FDA&rsquo;s
Center for Drug Evaluation and Research (CDER) for the approval of drug candidates is a highly demanding process which can result in increased
time and expense to gain approvals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead drug development
program, elraglusib, will be reviewed by CDER. Efficient and professional collaboration with the FDA&rsquo;s CDER is essential for the
timely clinical testing, test evaluations, analysis and approval of our drug candidates. CDER has an outstanding record of drug approvals
and substantial funds to operate a highly professional organization but is also very demanding as to the quality of clinical research
and applications for marketing approvals for drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have in-house expertise
and experience in the management of drug approvals, though members of our management team have gained certain drug-approval expertise
and experience in their prior roles at other companies. We may also rely on qualified consultants and drug research organizations to aid
in our drug approval process; however, there is a meaningful risk that discussions and interactions inherent in the drug approval process
and future developments or new improvements will result in delays, added expenses and new scientific/medical requirements which will cause
adverse financial results and will likely impact the price of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to use net operating loss carryforwards
and other tax attributes may be limited in connection with this offering or other ownership changes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred substantial
losses during our history, do not expect to become profitable in the near future and may never achieve profitability. As of December&nbsp;31,
2023, we had net operating loss (NOL) carryforwards, which may be available to offset our future taxable income, if any. Our NOL carryforwards
and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service (IRS) and state tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under Section&nbsp;382
of the U.S. Internal Revenue Code of 1986, as amended (the Code), our federal NOL carryforwards may be or become subject to an annual
limitation in the event we have had or have in the future an &ldquo;ownership change.&rdquo; For these purposes, an &ldquo;ownership change&rdquo;
generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&rsquo;s stock increase their ownership
by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. The amount of the annual
limitation is determined based on the Company&rsquo;s value immediately prior to the ownership change. Similar rules&nbsp;may apply under
state tax laws. Although we believe there have been one or more ownership changes resulting from past transactions, we have not determined
the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations
on our ability to utilize our NOL carryforwards and other tax attributes. However, we believe that our ability to utilize our NOL carryforwards
and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including
potential changes in connection with this offering. If we earn taxable income, such limitations could result in increased future income
tax liability to us and our future cash flows could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have recorded a full valuation
allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future
benefits of those assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign currency exchange rates may adversely
affect our consolidated financial statements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our primary operations are
transacted in U.S. Dollars, but certain service agreements with third parties are denominated in currencies other than the U.S. Dollar,
primarily the British pound and the Euro. All of our employees and operations are currently located in the United States and our expenses
are generally denominated in U.S. Dollar. As we continue to develop our business, our results of operations and cash flows will likely
be more affected by fluctuations in foreign currency exchange rates, including the British pound, Euro and other currencies, which could
adversely affect our results of operations. Sales and purchases in currencies other than the U.S. Dollar expose us to fluctuations in
foreign currencies relative to the U.S. Dollar and may adversely affect our consolidated financial statements. Increased strength of the
U.S. Dollar increases the effective price of our future drug products sold in U.S. Dollars into other countries, which may require us
to lower our prices or adversely affect sales to the extent we do not increase local currency prices. Decreased strength of the U.S. Dollar
could adversely affect the cost of materials, products and services we purchase overseas. Sales and expenses of our non-U.S. businesses
are also translated into U.S. Dollars for reporting purposes and the strengthening or weakening of the U.S. Dollar could result in unfavorable
foreign currency translation and transaction effects. In addition, certain of our businesses may in the future invoice customers in a
currency other than the business&rsquo; functional currency, and movements in the invoiced currency relative to the functional currency
could also result in unfavorable foreign currency translation and transaction effects. We also face exchange rate risk from our investments
in subsidiaries owned and operated in foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our anticipated operating expenses and capital
expenditures over the next year are based upon our management&rsquo;s estimates of possible future events. Actual amounts could differ
materially from those estimated by our management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Development of pharmaceuticals
and cancer drugs is extremely risky and unpredictable. We have estimated operating expenses and capital expenditures over the next year
based on certain assumptions. Any change in the assumptions could and will cause the actual results to vary substantially from the anticipated
expenses and expenditures and could result in material differences in actual versus forecasted expenses or expenditures. Furthermore,
all of the factors are subject to the effect of unforeseeable future events. The estimates of capital expenditures and operating expenses
represent forward-looking statements within the meaning of the federal securities laws. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may
differ materially from those discussed in the forward-looking statements as a result of various factors, including the risk factors set
forth under this &ldquo;Risk Factors&rdquo; section in this prospectus. In view of the foregoing, investors should not rely on these estimates
in making a decision to invest in us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our present and potential future international
operations may expose us to business, political, operational, and financial risks associated with doing business outside of the United
States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
risks associated with conducting business internationally. Some of our suppliers and clinical research organizations and clinical trial
sites are located outside of the United States. Furthermore, if we or any future collaborator succeeds in developing any products, we
anticipate marketing them in the EU and other jurisdictions in addition to the United States. If approved, we or our collaborator may
hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business
internationally involves a number of risks, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export
and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits and licenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">additional potentially relevant third-party patent and other intellectual property rights that may be
necessary to develop and commercialize our products and drug candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">complexities and difficulties in obtaining, maintaining, enforcing and defending our patent and other
intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">difficulties in staffing and managing foreign operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">complexities associated with managing multiple payor reimbursement regimes, government payors or patient
self-pay systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">limits in our ability to penetrate international markets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact
of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">natural disasters, political and economic instability, including wars, terrorism and political unrest,
outbreak of disease, boycotts, curtailment of trade and other business restrictions, implementation of tariffs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">certain expenses including, among others, expenses for travel, translation and insurance; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may
fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions
of anti-corruption or anti-bribery laws in other countries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and,
consequently, our business, financial condition, prospects and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future growth may depend, in part, on
our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future growth may depend,
in part, on our ability to develop and commercialize elraglusib or any future drug candidates in foreign markets for which we may rely
on partnering with third parties. We will not be permitted to market or promote elraglusib or any future drug candidate before we receive
regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval for
elraglusib or any future drug candidate. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous
and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials
and commercial sales, pricing and distribution of elraglusib or any future drug candidate, and we cannot predict success in these jurisdictions.
Approval procedures may be more onerous than those in the United States and may require that we conduct additional preclinical studies
or clinical trials. If we obtain approval of any of our current or potential future drug candidates and ultimately commercialize any such
drug candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and
changing foreign regulatory, tax, accounting and legal requirements, foreign reimbursement, pricing, and insurance regimes, workforce
uncertainty in countries where labor unrest is common, production shortages resulting from any events affecting raw material supply or
manufacturing capabilities abroad, business interruptions resulting from geopolitical actions, including war and terrorism, public health
pandemics or epidemics, or natural disasters including earthquakes, typhoons, floods and fires, and the reduced protection of intellectual
property rights in some foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated to our Common Stock and this
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B><I>Concentration of
ownership by our principal stockholder limits the ability of others to influence the outcome of director elections and other transactions
requiring stockholder approval, creates the potential for conflicts of interest, may negatively impact our stock price and may deter
or prevent efforts by others to acquire us, which could prevent our stockholders from realizing a control premium</I>.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> A majority percentage
of our outstanding stock is currently held by the Bios Equity Affiliated Funds, which are affiliated with our chairman, Aaron G.L. Fletcher,
and our director, Les Kreis, Jr., and, after giving effect to the offering, we expect that the Bios Equity Affiliated Funds will still
beneficially own approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock outstanding
as of the date of this offering. As a result, the Bios Equity Affiliated Funds have control over corporate actions requiring stockholder
approval, including the following actions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">to elect or defeat the election of our directors;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">to amend or prevent amendment of our certificate
    of incorporation or bylaws;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">to effect or prevent a merger, sale of assets or
    other corporate transaction; and</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">to control the outcome of any other matter submitted
    to our stockholders for vote.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Bios Equity Affiliated
Funds&rsquo; controlling interest in us also creates the potential for conflicts of interest which may be viewed unfavorably by minority
stockholders, thereby hurting our stock price. In addition, the Bios Equity Affiliated Funds are not subject to any contractual restrictions
on their ability to acquire additional shares of common stock, and any such purchases, including purchases of equity securities in connection
with any rights offerings or any alternative equity or equity-linked offering that we may conduct, could result in them continuing to
maintain beneficial ownership of a majority of our common stock. As a result of the Bios Equity Affiliated Funds&rsquo; controlling ownership
and Messr.&nbsp;Fletcher&rsquo;s and Kreis&rsquo; position as our Chairman and a director, respectively, others may be less inclined
to pursue an acquisition of us and therefore we may not have the opportunity to be acquired in a transaction that stockholders might
otherwise deem favorable, including transactions in which our stockholders might realize a substantial premium for their shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Existing and new investors will experience
dilution as a result of future sales or issuances of our common stock and future option exercises or other award grants under our stock
incentive plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our directors, employees,
and certain of our consultants have been and will be issued equity and/or granted options that vest with the passage of time. Up to a
total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock may be issued pursuant to new awards granted under the 2024 Plan, and stock options for the purchase of up
to shares of our common stock have already been granted ( stock options are exercisable) and are outstanding under our 2015 Plan as of
March 31, 2024. In addition, upon the closing of this offering, our chief executive officer is entitled to receive &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock issuable pursuant to his employment agreement (assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, the midpoint of the price range set forth on the cover page&nbsp;of this prospectus) under the 2015 Plan,
which shares will vest immediately. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing and our new investors
will likely also experience substantial dilution resulting from the issuance by us of equity securities in connection with certain transactions,
including without limitation, future offering of shares, intellectual property licensing, acquisition, or commercialization arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our ability to list on Nasdaq will require
raising significant capital; failure to qualify to trade on Nasdaq will make it more difficult to raise capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that our common
stock will be listed on the Nasdaq Capital Market, a national securities exchange, upon consummation of this offering. We may need to
raise significant funds in the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
continue our clinical development plans and we believe that if our stock is trading on the Nasdaq Capital Market it will enable better
access to capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nasdaq has listing requirements
for inclusion of securities for trading on the Nasdaq Capital Market, including stockholders&rsquo; equity of $4 million (market value
standard) or $5 million (equity standard), market value of publicly held shares of $15 million, an operating history of two years under
the equity standard or a market value of listed securities of $50 million under the market value standard, one million publicly held shares,
300 shareholders, three market makers and a $4 bid price or a closing price of $3 (equity standard) or $2 (market value standard). If
we are unable to list on Nasdaq, it could make it harder for us to raise capital in both the immediate time frame and in the long-term.
If we are unable to raise capital when needed in the future, we may have to cease or reduce operations. There can be no assurance that
we will be successful in including our common stock for trading on Nasdaq or that a market will develop for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our shares become subject to the penny
stock rules, it would become more difficult to trade our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC has adopted rules&nbsp;that
regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a
price of less than $5.00 per share, other than securities registered on certain national securities exchanges or authorized for quotation
on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities
is provided by the exchange or system. If we do not obtain or retain a listing on the Nasdaq Capital Market and if the price of our common
stock is less than $5.00 per share, our common stock will be deemed a penny stock. The penny stock rules&nbsp;require a broker-dealer,
before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing
specified information. In addition, the penny stock rules&nbsp;require that before effecting any transaction in a penny stock not otherwise
exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the
purchaser and receive (i)&nbsp;the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&nbsp;a
written agreement to transactions involving penny stocks; and (iii)&nbsp;a signed and dated copy of a written suitability statement. These
disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There has been no prior public market for
our common stock. An active, liquid and orderly market for our common stock may not develop, or we may in the future fail to satisfy the
continued listing requirements of Nasdaq, and you may not be able to resell your shares at or above the initial public offering price
or at all.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been no public market
for our common stock prior to this offering. <FONT STYLE="background-color: white">Although we have applied to list our common stock</FONT>
on the Nasdaq Capital Market, an active trading market for our common stock may never develop or may not be sustained following this offering.
The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may
vary from the market price of our common stock following this offering. This price does not necessarily reflect the price at which investors
in the market will be willing to buy and sell our shares following this offering. If you purchase shares of our common stock in this offering,
you may not be able to resell those shares at or above the initial public offering price or at all. In addition, an active trading market
may not develop following the completion of this offering or, if it is developed, may not be sustained. The lack of an active market may
impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market
may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies
using our shares as consideration, which, in turn, could materially adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, after listing, we fail
to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price
requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our
common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we
can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become
listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the
Nasdaq minimum bid price requirement or prevent future non-compliance with the listing requirements of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The trading price of the shares of our common
stock could be highly volatile regardless of our operating performance, and purchasers of our common stock could incur substantial losses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our stock price is likely
to be volatile. The stock market in general and the market for securities of biotechnology and pharmaceutical companies in particular
have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that
are unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell
their common stock at or above the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our common
stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">results of our clinical trials and preclinical studies, and the results of trials of our competitors or
those of other companies in our market sector;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our ability to obtain and maintain regulatory approval of elraglusib or any future product candidates
or additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays
in the regulatory review process;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">announcements concerning the progress and success of our clinical trials, our ability to obtain regulatory
approval for and commercialize elraglusib or any of our future product candidates, including any requests we receive from the FDA for
additional studies or data that result in delays in obtaining regulatory approval or launching elraglusib or any of our future product
candidates, if approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology sectors or the economy as a whole;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
or capital commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">price and volume fluctuations in the overall stock market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">our ability to enroll patients in future clinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the failure of elraglusib or any of our future product candidates, if approved, to achieve commercial
success;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">achievement of expected product sales and profitability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">announcements of the introduction of new products by us or our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">developments concerning product development results or intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">litigation or public concern about the safety of elraglusib of any of our future potential products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">actual fluctuations in our quarterly operating results, and concerns by investors that such fluctuations
may occur in the future;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">deviations in our operating results from the estimates of securities analysts or other analyst comments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">additions or departures of key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">sales of our stock by us, our insiders or our stockholders, as well as the anticipation of lock-up releases
or expiration of market stand-off or lock-up agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">healthcare reform legislation, including measures directed at controlling the pricing of pharmaceutical
products, and third-party coverage and reimbursement policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">developments concerning current or future strategic collaborations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">discussion of us or our stock price by the financial and scientific press and in online investor communities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in the past,
stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices
of these companies&rsquo; stock. Such litigation, if instituted against us, could cause us to incur substantial costs, divert our management&rsquo;s
attention and resources and damage our reputation, which could have a material adverse effect on our business, financial condition, results
of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors in this offering will suffer immediate
and substantial dilution of their investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you purchase shares of
our common stock in this offering, you will pay substantially more for your shares than our as adjusted net tangible book value per share.
Based upon an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share
of common stock, the midpoint of the price range on the cover page&nbsp;of this prospectus, you will incur immediate and substantial dilution
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing
the difference between our assumed initial public offering price and our as adjusted net tangible book value per share. In the past, we
issued options to acquire common stock at prices significantly below the midpoint of the range for this initial public offering price.
To the extent these outstanding options are ultimately exercised, investors purchasing common stock in this offering will sustain further
dilution. For a further description of the dilution that you will experience immediately after this offering, see the section titled &ldquo;Dilution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>After this offering, our executive officers,
directors, and principal stockholders, if they choose to act together, will continue to have the ability to significantly influence all
matters submitted to stockholders for approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion of
this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%
of our outstanding common stock (assuming no exercise of the underwriters&rsquo; over-allotment option and no exercise of outstanding
options and without giving effect to any potential purchases by such persons in this offering). As a result, such persons, acting together,
will have the ability to significantly influence all matters submitted to our board of directors or stockholders for approval, including
the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management
and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding
a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender
offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The grant of registration rights to our
existing stockholders may adversely affect the market price of our shares of common stock and make it more difficult to complete a strategic
transaction.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our existing stockholders
hold demand and piggyback registration rights for a total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares. These stockholders and their permitted transferees can demand that we register their shares in accordance with certain conditions,
including with respect to the timing of demand, aggregate sales price of shares being registered, and form of registration statement available.
We will bear the cost of registering these securities. The registration and availability of such a significant number of securities for
trading in the public market may have an adverse effect on the market price of our shares of common stock. In addition, the existence
of the registration rights may make our ability to execute a strategic transaction, such as a merger, more costly or difficult to conclude.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Substantial amounts of our outstanding shares
may be sold into the market when lock-up or market standoff periods end. If there are substantial sales of shares of our common stock,
the price of our common stock could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Sales of a substantial
number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the
market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity or equity-linked
securities. After this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;outstanding
shares of our common stock, based on the number of shares outstanding as of March 31, 2024, assuming no exercise of the underwriters&rsquo;
over-allotment option sold in this offering and no exercise of outstanding options. Of these shares, only the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&rsquo; over-allotment option, will
be freely tradable, without restriction, in the public market immediately following this offering, unless they are purchased by one of
our affiliates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our directors and executive
officers and our securityholders holding &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
have entered into lock-up agreements with the representatives pursuant to which they may not, with limited exceptions, for a period of
180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our securities, without the prior written
consent of the representative of the underwriters. Sales of these shares, or perceptions that they will be sold, could cause the trading
price of our common stock to decline. After the lock-up agreements expire, up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock will be eligible for sale in the public market, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
will be held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule&nbsp;144 under
the Securities Act of 1933, as amended (the Securities Act), in each case based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock outstanding as of March 31, 2024, and without giving effect to any potential purchases by such persons in this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, as of March
31, 2024, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock that are subject to outstanding options under our employee benefit plans became eligible for sale in the public
market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule&nbsp;144 and Rule&nbsp;701
under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public
market, the trading price of our common stock could decline. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> After this offering, the
holders of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our outstanding common stock,
or approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our total outstanding common stock based
on shares outstanding as of March 31, 2024, will be entitled to rights with respect to the registration of their shares of common stock
(and the shares of common stock underlying certain securities convertible or exercisable into shares of our common stock) under the Securities
Act, subject to vesting and the 180-day lock-up agreements described above. See the section titled &ldquo;Description of Capital Stock&mdash;Registration
Rights.&rdquo; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction
under the Securities Act, except for shares held by affiliates, as defined in Rule&nbsp;144 under the Securities Act. Any sales of securities
by these stockholders could have a material adverse effect on the trading price of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the use of the
net proceeds from this offering, and our use of those proceeds may not yield a favorable return on your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will have broad
discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled
 &ldquo;Use of Proceeds.&rdquo; Because of the number and variability of factors that will determine our use of the net proceeds from this
offering, their ultimate use may vary substantially from their currently intended use. We intend to use the remaining net proceeds from
the sale of the shares in the offering, along with available cash, for general corporate purposes, which may include advancing our other
pipeline programs, supporting the requirements of being a public company, including legal, audit, investor relations and board fees and
providing competitive salaries and benefits to attract and retain highly qualified employees. We have not specifically allocated the amount
of net proceeds that will be used for these purposes, and our management will have broad discretion over how these proceeds are used and
could spend the proceeds in ways with which you may not agree. In addition, we may not use the proceeds of this offering effectively or
in a manner that increases our market value or enhances our profitability. We have not established a timetable for the effective deployment
of the proceeds, and we cannot predict how long it will take to deploy the proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends in the
foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our
common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our capital stock and we do not intend to pay any cash dividends in the foreseeable future. We currently anticipate
that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying
any cash dividends for the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. Any determination
to pay dividends in the future will be at the discretion of our Board. Accordingly, investors must rely on sales of their common stock
after price appreciation, which may never occur, as the only way to realize any future gains as a return on their investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There can be no assurance that we will ever
provide liquidity to our investors through a sale of our Company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While acquisitions of pharmaceutical
companies like ours are not uncommon, potential investors are cautioned that no assurances can be given that any form of merger, combination,
or sale of our company will take place or that any merger, combination, or sale, even if consummated, would provide liquidity or a profit
for our investors. You should not invest in our company with the expectation that we will be able to sell the business in order to provide
liquidity or a profit for our investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delaware law and provisions in our amended
and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the potential trading price of our
common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated certificate
of incorporation and amended and restated bylaws that will be in effect immediately prior to the completion of this offering will contain
provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes
in our management without the consent of our board of directors. The provisions in our charter documents will include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders
to change the membership of a majority of our board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">no cumulative voting in the election of directors, which limits the ability of minority stockholders to
elect director candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the exclusive right of our board of directors, unless the board of directors grants such right to the
stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal
of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause,
and the prohibition on removal of directors without cause;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine
the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used
to significantly dilute the ownership of a hostile acquiror;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder
approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our
amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and
removal of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at
an annual or special meeting of our stockholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the
exclusive forum for certain actions and proceedings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the requirement that a special meeting of stockholders may be called only by the board of directors, which
may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">advance notice procedures that stockholders must comply with in order to nominate candidates to our board
of directors or to propose matters to be acted upon at a stockholders&rsquo; meeting, which may discourage or deter a potential acquiror
from conducting a solicitation of proxies to elect the acquiror&rsquo;s own slate of directors or otherwise attempting to obtain control
of us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject to the
anti-takeover provisions contained in Section&nbsp;203 of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation
may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the
stock for three years or, among other exceptions, the board of directors has approved the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Our amended and restated certificate
of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes
between us and our stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint
asserting a cause of action arising under the Securities Act, which could limit our stockholders&rsquo; ability to obtain a favorable
judicial forum for disputes with us or our directors, officers or employees or the underwriters of any offering giving rise to such claim</I></B>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Our amended and restated certificate of incorporation
that will be in effect immediately prior to the completion of this offering will provide that, unless we consent in writing to the selection
of an alternative forum, the Court of Chancery of the State of Delaware (the Court of Chancery) (or, in the event the Court of Chancery
does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will
be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative
action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty by any of our directors,
officers or stockholders; (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation
Law or our amended and restated certificate of incorporation or amended and restated bylaws; or (iv) any action asserting a claim governed
by the internal affairs doctrine, in all cases to the fullest extent permitted by law; provided, that, this provision would not apply
to suits brought to enforce a duty or liability created by the Exchange Act. or any other claim for which the federal courts have exclusive
jurisdiction. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing
to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution
of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant
to such complaint. These choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that
it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us
and our directors, officers and other employees and result in increased costs for investors to bring a claim. By agreeing to this provision,
however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations
thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&rsquo; certificates of incorporation
has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or
unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be
inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
which could adversely affect our business and financial condition. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unstable market and economic conditions
may have serious adverse consequences on our ability to raise funds, which may cause us to cease or delay our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the global
credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability.
The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict,
including the conflicts between Russia and Ukraine and in the Middle East, terrorism or other geopolitical events. Sanctions imposed by
the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial
markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic
instability. In addition, in 2023 the closures of financial institutions and their placement into receivership with the FDIC created bank-specific
and broader financial institution liquidity risk and concerns. Future adverse developments with respect to specific financial institutions
or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term
working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial
market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely
affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market
conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may
cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect
to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable
terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay,
limit, reduce or abandon product development or future commercialization efforts or grant rights to develop and market our product candidates
even if we would otherwise prefer to develop and market such product candidates ourselves. In addition, there is a risk that one or more
of our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing
risks, which could directly affect our ability to attain our operating goals on schedule and on budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur increased costs as a result
of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate
governance practices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we will
incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank
Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Capital Market and other applicable securities
rules&nbsp;and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount
of time to these compliance initiatives. Moreover, these rules&nbsp;and regulations will increase our legal and financial compliance costs
and will make some activities more time-consuming and costly. For example, we expect that these rules&nbsp;and regulations may make it
more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult
for us to attract and retain qualified members of our board of directors. However, these rules&nbsp;and regulations are often subject
to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve
over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance
matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to U.S. and foreign anti-corruption
and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability
and harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to export control
and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic
and trade sanctions regulations administered by the U.S. Treasury Department&rsquo;s Office of Foreign Assets Controls and anti-corruption
and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic
bribery statute contained in 18 U.S.C. &sect; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery
and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit
companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing,
soliciting or receiving, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private
sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad if and when we enter
a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have
direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and
other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and
other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities, and any training
or compliance programs or other initiatives we undertake to prevent such activities may not be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any violations of the laws
and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, U.S. export control
laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by
U.S. sanctions. U.S. sanctions that have been or may be imposed may impact our ability to continue activities at future clinical trial
sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties
could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions
could also adversely affect our supply chain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes in tax law may materially adversely
affect our financial condition, results of operations and cash flows, or adversely impact the value of an investment in our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New income, sales, use or
other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied
adversely to us, any of which could adversely affect our business operations and financial performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts do not
publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our
market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no
securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the
event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, or if we fail
to meet the expectations of one or more of these analysts, our stock price would likely decline. If one or more of these analysts ceases
to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading
volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to maintain proper and effective
internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors
may lose confidence in our financial reporting and the trading price of our common stock may decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section&nbsp;404
of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning
with the second annual report following the completion of this offering. When we lose our status as an &ldquo;emerging growth company&rdquo;
and do not otherwise qualify as a &ldquo;smaller reporting company&rdquo; with less than $100.0 million in annual revenue, our independent
registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The
rules&nbsp;governing the standards that must be met for our management to assess our internal control over financial reporting are complex
and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company
under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls,
reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to
conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and
the trading price of our common stock may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December&nbsp;31,
2023, we identified a material weakness in internal control over financial reporting as a result of an inadequate review of our CRO accrual
analysis that resulted in improper accruals of expenses. A material weakness is a deficiency or combination of deficiencies in internal
control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial
statements would not be prevented or detected on a timely basis. In order to remediate the material weakness, management will be implementing
additional processes to properly review and monitor clinical research organization accrual analysis at the end of each period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure you that
there will not be further material weaknesses or significant deficiencies in our internal control over financial reporting in the future.
Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial
condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective,
or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal
control over financial reporting once that firm begins its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and
completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations
by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting,
or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the
capital markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We could be subject to securities class
action litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, securities class
action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially
relevant for us because biotechnology and biopharmaceutical companies have experienced significant stock price volatility in recent years.
If we face such litigation, even if ultimately decided in our favor, it could result in substantial costs and a diversion of our management&rsquo;s
attention and resources, which could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain market, industry and
competitive data included in this prospectus were obtained from our own internal estimates and research, as well as from publicly available
information, reports of governmental agencies and industry publications and surveys in addition to research, surveys and studies conducted
by third parties. The content of these third-party sources, except to the extent specifically set forth in this prospectus, does not constitute
a portion of this prospectus and is not incorporated herein. Internal estimates are derived from publicly available information released
by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by
us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly
refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any
paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise
expressly stated or the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while we are
responsible for all of the disclosure contained in this prospectus and we believe the industry, market and competitive position data included
in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change
based on various factors, including those discussed in the sections titled &ldquo;Risk Factors&rdquo; and &ldquo;Special Note Regarding
Forward-Looking Statements.&rdquo; These and other factors could cause results to differ materially from those expressed in the estimates
made by the independent parties and by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_005"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We estimate that the net proceeds
to us from the issuance and the sale of shares of our common stock will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
<FONT STYLE="background-color: white">(or approximately $</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">million
if the underwriters exercise in full their over-allotment option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares)</FONT>, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, <FONT STYLE="background-color: white">which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus,
</FONT>after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Each
$1.00 increase (decrease) in the assumed initial public offering price of $</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white">per
share, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus, would increase (decrease) the net
proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us, by approximately $</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="background-color: white">million, assuming that the number of shares of common stock offered by us, as set forth on the cover
page&nbsp;of this prospectus, remains the same. We may also increase or decrease the number of shares of common stock we are offering.
An increase (decrease) of 1,000,000 in the number of shares of common stock we are offering would increase (decrease) the net proceeds
to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable
by us, by approximately $</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT STYLE="background-color: white">million,
assuming the initial public offering price stays the same. The information discussed above is illustrative only and will adjust based
on the actual initial public offering price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="background-color: white">The
principal purposes of this offering are to obtain additional capital to support our operations, to create a public market for our common
stock and to facilitate our future access to the public equity markets. </FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We currently intend to
use approximately $ million of the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the
research and development of elraglusib, including certain manufacturing activities, and the remainder, if any, for working capital and
other general corporate purposes. We expect the net proceeds from this offering and our existing cash and cash equivalents will allow
us to complete the ongoing Elraglusib Injection Phase 2 mPDAC trial (Actuate-1801 Part 3B); fund the existing pediatric refractory cancer
Phase 1 dose escalation trial and continue exploring development opportunities and potentially initiate the Phase 2 portion of this study
in patients with refractory Ewing Sarcoma (Actuate-1902); satisfy the company&rsquo;s funding commitments for ongoing studies for the
use of Elraglusib Injection with other chemotherapy agents to treat mPDAC and a separate trial to treat recurrent salivary gland cancer;
to finalize development plans and to potentially initiate and complete a Phase 1 dose escalation study in patients with advanced, refractory
solid cancer; and to finalize development plans for and potentially initiate a Phase 2 study in refractory metastatic melanoma. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If we were to receive
additional proceeds of at least $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million from this offering, or other funding, if and to the extent such
funds are received, we anticipate that such funding would allow us to also initiate a Phase 3 mPDAC trial and finalize development plans
for an additional randomized Phase 2 trial in patients with metastatic refractory colorectal cancer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We believe, based on our
current operating plan, that the net proceeds from this offering and our existing cash, cash equivalents and short-term investments,
together with interest thereon, will be sufficient to fund our operations through at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months
following the date of this prospectus, although there can be no assurance in that regard. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have based these estimates
on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Additionally, our expected
use of existing cash, cash equivalents and marketable securities and our net proceeds from this offering represent our intentions based
upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts
and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress and costs of our development
activities, the status of and results from clinical trials, the amount of cash used in our operations and any unforeseen cash needs as
well as other factors described in the sections titled &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations&rdquo; and &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo; The net proceeds
from this offering, together with our existing cash, cash equivalents, and marketable securities will not be sufficient to complete development
in all potential indications of elraglusib and any future product candidates, and after this offering, we will require substantial capital
in order to advance elraglusib and any future product candidates through clinical trials, regulatory approval and commercialization. Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt
financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be
unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="background-color: white">Our
management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the
judgment of our management regarding the application of those net proceeds. Pending the uses described above, we plan to invest the net
proceeds in a variety of capital preservation instruments, including short-term, interest-bearing obligations, investment-grade instruments,
certificates of deposit and direct or guaranteed obligations of the United States government.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our common stock to date. We may retain future earnings, if any, for future operations, expansion and debt repayment
and have no current plans to pay cash dividends for the foreseeable future. Any decision to declare and pay dividends in the future will
be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition,
cash requirements, contractual restrictions and other factors that the board may deem relevant <FONT STYLE="background-color: white">and
subject to applicable laws and the restrictions contained in any future financing instruments</FONT>. We do not anticipate declaring any
cash dividends to holders of the common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following table sets
forth our cash, cash equivalents and investment securities and our capitalization as of March 31, 2024: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on an actual basis;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">on a pro forma basis to give effect to</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">o</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">the conversion of all outstanding shares of our
    redeemable convertible preferred stock as of March 31, 2024 into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of our common stock immediately prior to the closing of this offering;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">o</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock issuable upon the conversion of our Series B-1 redeemable preferred stock to be issued upon the automatic net exercise
    of the Series&nbsp;B-1 Warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share of common stock, the midpoint of the price range set forth on the cover of this prospectus;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">o</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock issuable upon the conversion of our Series B-1 redeemable preferred stock to be issued upon the automatic net exercise
    of the Series&nbsp;B-1 Warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share of common stock, the midpoint of the price range set forth on the cover of this prospectus;]</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">o</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of our common stock issuable upon the conversion of our Series C redeemable preferred stock to be issued upon the automatic net exercise
    of Series&nbsp;C Warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share of common stock, the midpoint of the price range set forth on the cover of this prospectus];</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable to our chief executive officer upon the closing of this offering,
pursuant to his employment agreement, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, the midpoint of the price range set forth on the cover page&nbsp;of this prospectus;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="text-align: justify">the issuance and sale of a convertible promissory note in February&nbsp;2024 in the amount of $3.0 million
that is convertible into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which will occur immediately
prior to the closing of the offering; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering[, and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">o</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    reverse stock split of our common stock, which we effected on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024]; and</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">on a pro forma as adjusted basis to give further effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock (the midpoint of the price range set forth on the cover page&nbsp;of this prospectus), after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This pro forma and pro forma
as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering
determined at pricing. The following table should be read together with the sections of this prospectus titled &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; and our financial statements and the related notes included
elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> As
    of December&nbsp;31, 2023 </TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Actual </TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Pro
    Forma </TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Pro
    Forma As<BR> Adjusted<SUP>(1)(2)</SUP> </TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 1pt">&nbsp;</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-size: 10pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; font-size: 10pt"> <B>(unaudited)</B> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> (in thousands, except share and per<BR>
    share amounts) </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Cash
    and cash equivalents </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> 2,958,659 </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> &#8239;&#8239;&#8239;&#8239;&#8239; </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </TD><TD STYLE="padding-bottom: 2.5pt; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Redeemable convertible
    preferred stock, $0.000001 par value; 33,463,018 shares authorized, 24,678,355 shares issued and outstanding, actual; no shares authorized,
    issued or outstanding, pro forma and pro forma as adjusted </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 94,178,404 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Stockholders&rsquo;
    (deficit) equity: </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"> Common stock, $0.000001
    par value; 38,108,584 shares authorized, 3,043,309 shares issued and outstanding (3), actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    issued and outstanding, pro forma as adjusted </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 3 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Additional paid-in
    capital </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,468,005 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> Accumulated
    deficit </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (105,094,521 </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"> Total
    stockholders&rsquo; (deficit) equity </TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"> (99,626,513 </TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common (the midpoint of the price range set forth on the cover page&nbsp;of this prospectus) would increase or decrease, as applicable,
the pro forma as adjusted amounts of each of our cash, cash equivalents and investment securities, common stock and additional paid-in
capital, total stockholders&rsquo; (deficit) equity, and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming the number of shares of common stock offered by us, as set forth on the cover page&nbsp;of this prospectus, remains the same
and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
increase or decrease of 1.0 million shares in the number of shares of common stock offered by us would increase or decrease, as applicable,
the pro forma as adjusted amounts of each of our cash, cash equivalents and investment securities, common stock, and additional paid-in
capital, total stockholders&rsquo; (deficit) equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">This pro forma as adjusted information is illustrative only and will depend on the actual initial public
offering price and other terms of this offering determined at pricing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">The number of shares of common stock actually issued
    and outstanding excludes 304,251 shares outstanding that are unvested and subject to forfeiture as of December&nbsp;31, 2023 and
    which are therefore not considered outstanding for accounting purposes.</FONT> </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
the underwriters&rsquo; over-allotment option to purchase additional shares of our common stock is exercised in full, our pro forma as
adjusted cash, cash equivalents and marketable securities, additional&nbsp;paid-in&nbsp;capital, total stockholders&rsquo; (deficit) equity,
and total capitalization as of December&nbsp;31, 2023, would be $</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">&nbsp;million,
$</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">million,
$</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">million,
and $</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">million,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The number of shares of
our common stock to be outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock outstanding as of March 31, 2024 after giving effect to the pro forma adjustments described above (after giving effect
to the conversion of all of our shares of redeemable convertible preferred stock outstanding as of March 31, 2024), and excludes: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock issuable upon the exercise of stock options outstanding as of March 31, 2024, with a weighted-average exercise price
    of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share;</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock reserved for future issuance under the 2024 Plan which will become effective in connection with this offering (which
    number includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock reserved for issuance under the 2015 Plan) as of March 31, 2024, which shares will be added to the number of shares
    available for issuance under the 2024 Plan upon its effectiveness[; and]</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of our common stock issuable upon exercise of our warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of redeemable preferred stock as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, which will terminate unexercised immediately prior to the completion of this offering, based on an assumed initial public
    offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, the midpoint of the price range
    set forth on the cover of this prospectus.]</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you invest in our common
stock in this offering, your interest will be immediately diluted to the extent of the difference between the public offering price per
share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after
the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of March 31, 2024,
our historical net tangible book value was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of our common stock. Our historical net tangible book value per share represents total tangible assets less total liabilities
<FONT STYLE="background-color: white">and redeemable convertible preferred stock, which is not included within permanent equity,</FONT>
divided by the number of shares of our common stock outstanding on March 31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On a pro forma basis,
after giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to permanent
equity immediately prior to the closing of this offering, our pro forma net tangible book value (deficit) as of March 31, 2024 would
have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our as adjusted net tangible
book value represents our historical net tangible book value as adjusted to give effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus, and after deducting
the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We determine dilution per share to
investors participating in this offering by subtracting as adjusted net tangible book value per share after this offering from the assumed
initial public offering price per share of common stock paid by investors participating in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table illustrates
this per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 86%; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Assumed initial public offering price
    per share of common stock a</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 5%; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 5%"> <FONT STYLE="font-size: 10pt">$</FONT> </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Historical net tangible book value (deficit)
    per share as of March 31, 2024</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-size: 10pt">$</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Pro forma increase in historical net tangible
    book value per share as of March 31, 2024 attributable to the pro forma adjustments described above</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Pro forma net tangible book value per share as
    of March 31, 2024</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Increase in as adjusted net tangible book value
    per share attributable to new investors participating in this offering</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Pro forma as adjusted net tangible book value
    per share after this offering</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-size: 10pt">Dilution per share to new investors participating
    in this offering</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-size: 10pt">$</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Each $1.00 increase or
decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share of common stock, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus, would increase or
decrease, as applicable, our as adjusted net tangible book value as of March 31, 2024 after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and would increase or decrease dilution
to investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, assuming that the
number of shares of common stock offered by us, as set forth on the cover page&nbsp;of this prospectus, remains the same and after deducting
the underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number
of shares of common stock we are offering. Each increase of 1.0 million shares in the number of shares of common stock we are offering
would increase our as adjusted net tangible book value as of March 31, 2024 after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and would decrease dilution of investors
in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share assuming the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock remains the same, and after deducting
the underwriting discount and commissions and estimated offering expenses payable by us. Each decrease of 1.0 million shares in the number
of shares of common stock we are offering would decrease our as adjusted net tangible book value as of March 31, 2024 after this offering
by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share and would increase dilution of investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share assuming the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common
stock remains the same, and after deducting the underwriting discount and commissions and estimated offering expenses payable by us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If the underwriters fully
exercise their over-allotment option to purchase additional shares of our common stock, as adjusted net tangible book value after this
offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in as adjusted net
tangible book value per share to existing stockholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, and the decrease in dilution to investors in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, in each case assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The dilution information above
is for illustration purposes only. Our pro forma as adjusted net tangible book value following the closing of this offering will depend
on the actual initial public offering price and other terms of this offering determined at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes,
on the pro forma as adjusted basis described above, the differences between the number of shares of common stock purchased from us, the
total consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of
common stock in this offering. The calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock (the midpoint of the price range set forth on the cover page&nbsp;of this prospectus), before deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Purchased</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Total</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consideration</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-<BR> Average Price</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Percent</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Per Share</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">Existing stockholders before this offering</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Investors purchasing securities in this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8239;&#8239;&#8239;&#8239;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8239;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each $1.00 increase or decrease
in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share (the midpoint of the price range set forth on the cover page&nbsp;of this prospectus) would increase or decrease, as applicable,
the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and,
in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points, assuming that the number of shares offered by us, as set forth on the cover page&nbsp;of this prospectus, remains the
same. Similarly, each increase or decrease of 1.0 million shares in the number of shares offered by us, as set forth on the cover page&nbsp;of
this prospectus, would increase or decrease, as applicable, the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
and, in the case of an increase, would increase the percentage of total consideration paid by new investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage
points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
percentage points, assuming that the assumed initial public offering price remains the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The foregoing tables and
calculations (other than the historical net tangible book value calculation) are based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock outstanding as of March 31, 2024, after giving effect to the conversion of all outstanding shares of our redeemable
convertible preferred stock into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock immediately prior to the closing of this offering, <FONT STYLE="background-color: white">after giving effect
to </FONT>the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock issuable upon the conversion of our Series B-1 redeemable preferred stock to be issued upon the automatic net exercise
    of the Series&nbsp;B-1 Warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share of common stock, the midpoint of the price range set forth on the cover of this prospectus;</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-size: 10pt">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    of common stock issuable upon the conversion of our Series B-1 redeemable preferred stock to be issued upon the automatic net exercise
    of the Series&nbsp;B-1 Warrants outstanding as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    per share, immediately prior to the completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
    share of common stock, the midpoint of the price range set forth on the cover of this prospectus;]</FONT> </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock issuable upon the conversion of our Series C redeemable preferred stock
                                            to be issued upon the automatic net exercise of Series&nbsp;C Warrants outstanding as of
                                            March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share, immediately prior to the completion of this offering, based on an assumed initial
                                            public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
                                            share of common stock, the midpoint of the price range set forth on the cover of this prospectus]; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock issuable to our chief executive officer upon the closing of this offering,
                                            pursuant to his employment agreement, based on an assumed initial public offering price of
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock,
                                            the midpoint of the price range set forth on the cover page&nbsp;of this prospectus;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> the
                                            issuance and sale of a convertible promissory note in February&nbsp;2024 in the amount of
                                            $3.0 million that is convertible into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock, which will occur immediately prior to the closing of the offering; [and] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing
    and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering[, and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            reverse stock split of our common stock, which we effected on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
                                            2024].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of shares of
common stock outstanding does not include the shares issuable under our options outstanding as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of common stock issuable upon the exercise of stock options outstanding as of March 31, 2024,
                                            with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of common stock reserved for future issuance under the 2024 Plan which will become effective
                                            in connection with this offering (which number includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of common stock reserved for issuance under the 2015 Plan) as of March 31, 2024, which shares
                                            will be added to the 2024 Plan upon its effectiveness;[; and] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock issuable upon exercise of our warrants to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of redeemable preferred stock as of March 31, 2024, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share, which will terminate unexercised immediately prior to the completion of this offering,
                                            based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover of this
                                            prospectus.] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that outstanding
options or warrants are exercised, new options or other securities are issued under our equity incentive plans, or we issue additional
shares of our common stock in the future, there will be further dilution to investors participating in this offering. In addition, we
may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient
funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="b_001"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus contains
forward-looking statements about us and our industry. In addition, from time to time we or our representatives have made or will make
forward-looking statements. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements
related to present facts or current conditions or of historical facts, contained in this prospectus, including statements regarding our
strategy, future operations, future financial position, future revenues, and projected costs, prospects, plans and objectives of management,
research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical trials and preclinical
studies for elraglusib and any future product candidates, the timing and likelihood of regulatory filings and approvals for elraglusib
and any future product candidates, our ability to commercialize elraglusib and any future product candidates, if approved, the pricing
and reimbursement of elraglusib and any future product candidates, if approved, the potential to develop future product candidates, the
potential benefits of strategic collaborations and potential to enter into any future strategic arrangements, the timing and likelihood
of success, plans and objectives of management for future operations, and future results of anticipated product development efforts,
are forward-looking statements. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual
results to differ materially from those expressed in them. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;ongoing,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
 &ldquo;will,&rdquo; &ldquo;would,&rdquo; or the negative of these terms or other comparable terminology are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are qualified
in their entirety by reference to the factors discussed under the heading &ldquo;Risk Factors&rdquo; in this prospectus or in any related
free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should assume that the
information appearing in this prospectus or any related free writing prospectus is accurate as of its date only. Because the risk factors
referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements
made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which
factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All written or oral
forward-looking statements attributable to us or any person acting on our behalf made after the date of this prospectus are expressly
qualified in their entirety by the risk factors and cautionary statements contained in this prospectus. Unless legally required, we do
not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances
after the date of this prospectus or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, statements that
 &ldquo;we believe&rdquo; and similarly qualified statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain
and you are cautioned not to rely unduly upon them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion
and analysis of the financial condition and results of our operations should be read in combination with our consolidated financial statements
and the notes to those statements appearing elsewhere in this prospectus. This discussion and analysis contains forward-looking statements
reflecting our management&rsquo;s current expectations that involve risks, uncertainties and assumptions. See the section entitled &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo; Our actual results and the timing of events may differ materially from those described
in or implied by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this prospectus,
particularly those set forth under &ldquo;Risk Factors.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We are a clinical stage
biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition
of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer
cells and block the function of the enzyme GSK-3&beta;, a master regulator of complex biological signaling cascades, including those
mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3&beta;
signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. Our lead program, Elraglusib
Injection, is an intravenous injection solution of elraglusib that we are evaluating for the treatment of mPDAC (Actuate-1801). Elraglusib
Injection has also been evaluated in pediatric cancer patients with recurrent/refractory solid cancers and the data from this study,
Actuate-1902, also identified Ewing sarcoma as a potential second indication for further development of Elraglusib Injection. We are
currently advancing a Phase 2 clinical trial for the treatment of mPDAC and a Phase 1/2 clinical trial in refractory pediatric malignancies.
We are also evaluating the potential for additional exploratory development of Elraglusib Injection in other pediatric cancer indications,
including neuroblastoma and leukemias, which we expect to explore through academic IITs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have developed several
oral dosage forms of elraglusib, which we believe will allow us to expand the number of cancer indications that we are able to target
and allow us to further explore optimal dosing. A clinical candidate tablet (Elraglusib Oral Tablet) has been selected for further development
and the Company is planning a Phase 1 study (Actuate-2401) to identify the MTD/ RP2D for Elraglusib Oral Tablet in patients with advanced,
refractory adult cancers subject to our receipt of the proceeds of this offering. Several Phase 2 indications, including refractory,
metastatic melanoma and refractory, metastatic colorectal cancer have been identified for further clinical development of Elraglusib
Oral Tablet based on data from the Actuate-1801 study once the RP2D has been identified. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2015,
we have focused substantially all of our resources on organizing and staffing our company, business planning, raising capital, establishing
and maintaining our intellectual property portfolio, conducting research, preclinical studies, and clinical trials, establishing arrangements
with third parties for the manufacture of elraglusib, and providing general and administrative support for these operations. We do not
have any products approved for sale and have not generated any revenue from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred significant
operating losses and negative cash flows from operations since our inception. Our net losses were approximately $24.7 million and $20.2
million for the years ended December&nbsp;31, 2023 and 2022, respectively. As of December&nbsp;31, 2023, we had an accumulated deficit
of approximately $105.1 million. Substantially all of our net losses have resulted from costs incurred in connection with our research
and development programs and, to a lesser extent, from general and administrative costs associated with our operations. We expect to
continue to incur significant expenses and operating losses in the foreseeable future, and we anticipate these losses will increase substantially
as we continue our development of, seek regulatory approval for, and potentially commercialize elraglusib, and potentially seek to discover
and develop additional product candidates, utilize third parties to manufacture elraglusib, hire additional personnel, expand and protect
our intellectual property, and incur additional costs associated with being a public company. If we obtain regulatory approval for elraglusib,
we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing and
distribution. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately
predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are
able to generate product sales, we may not become profitable. If we do not become profitable or are unable to sustain profitability on
a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce or terminate our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have primarily
funded our operations with proceeds from the sale of shares of our redeemable convertible preferred stock and the issuance of convertible
notes that were converted into redeemable convertible preferred stock. Through December&nbsp;31, 2023, we have received aggregate net
proceeds of approximately $94.2 million from the sale of shares of our redeemable convertible preferred stock and the issuance of convertible
notes that were converted into redeemable convertible preferred stock. As of December&nbsp;31, 2023, we had cash and cash equivalents
of approximately $3.0 million. During February&nbsp;2024, we received net proceeds of $3.0 million from the issuance of convertible notes
to a related party (see Note 13 to our consolidated financial statements included elsewhere in this prospectus). Our ability to generate
any product revenue and, in particular, our ability to generate product revenue sufficient to achieve profitability, will depend on the
successful development and eventual commercialization of elraglusib and any future product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current operating
plan, we estimate that our existing cash and cash equivalents as of the date of this prospectus, together with the estimated net proceeds
from this offering, will be sufficient to fund our projected operating expenses and capital expenditure requirements through at least
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many
factors currently unknown to us. In addition, we could utilize our available capital resources sooner than we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will not generate revenue
from product sales unless and until we successfully complete clinical development and obtain regulatory approval for elraglusib or any
future product candidates, which we expect will take a number of years and may never occur. As a result, we will need substantial additional
funding in addition to the net proceeds from this offering to support our continuing operations and pursue our growth strategy. Until
such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through equity offerings,
debt financings, or other capital sources, including potential future collaborations, licenses, and other similar arrangements and non-dilutive
arrangements to the extent available through licensing partner funding, foundations and grants. However, we may be unable to raise additional
funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter
into such agreements or arrangements as, and when needed, we may delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves, or even cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own or operate,
and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for
the manufacture of elraglusib for clinical testing, as well as for commercial manufacture if we obtain marketing approval. In addition,
we rely on third parties to package, label, store, and distribute elraglusib, and we intend to rely on third parties for our commercial
products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating
the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise
and resources on the development of elraglusib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Components of Our Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating expenses consist
of (i)&nbsp;research and development expenses and (ii)&nbsp;general and administrative expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses consist primarily of external and internal costs incurred in performing clinical and preclinical development activities. Our
external research and development costs primarily consists of the cost incurred under agreements with hospitals to treat and monitor
patients enrolled in our clinical trials, contract manufacturers, consultants and other third parties to conduct and support our clinical
trials and preclinical studies. Our internal research and development costs primarily include research and development personnel-related
expenses such as salaries, employer taxes, group insurance benefits, and stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expense research and development
costs as incurred.&nbsp;We currently only have one product candidate, elraglusib. Therefore, since our inception, substantially all of
our research and development costs were related to the development of elraglusib. We track research and development expenses on an aggregate
basis and not on an indication-by-indication or treatment setting-by-treatment setting basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although research and development
activities are central to our business model, the successful development of elraglusib and any future product candidates is highly uncertain.
There are numerous factors associated with the successful development of any product candidate such as elraglusib, including future trial
design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development.
In addition, future regulatory factors beyond our control may impact our clinical development programs. Product candidates in later stages
of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to
the increased patient size and duration of later-stage clinical trials. As a result, we expect our research and development expenses
will increase substantially in connection with our ongoing and planned clinical and preclinical development activities in the near term
and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary
to complete the preclinical and clinical development of elraglusib and any future product candidates. Our future research and development
expenses may vary significantly based on a wide variety of factors such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            results of our clinical trials and preclinical studies of elraglusib and any future product
                                            candidates we may choose to pursue, including any modifications to clinical development plans
                                            based on feedback that we may receive from regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">per
                                            patient trial costs;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            number of trials required for approval;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            number of sites included in the trials and the number of countries in which the trials are
                                            conducted;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            number of patients that participate in the trials, the drop-out or discontinuation rates
                                            of patients, and the length of time required to enroll eligible patients;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            number of doses that patients receive;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            potential additional safety monitoring requested by regulatory agencies;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            duration of patient participation in the trials and&nbsp;follow-up;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            cost and timing of manufacturing elraglusib and any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs, if any, of obtaining third-party drugs for use in our combination trials;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            extent of changes in government regulation and regulatory guidance;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            efficacy and safety profile of elraglusib and any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            timing, receipt, and terms of any approvals from applicable regulatory authorities; and</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            extent to which we establish additional collaboration, license, or other arrangements.</TD></TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in the outcome of
any of these variables with respect to the development of elraglusib or any future product candidates could significantly change the
costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for
any product candidate.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Selling,
General and Administrative Expenses</I></B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">General
and administrative expenses consist primarily of personnel-related expenses such as salaries, benefits, and stock-based compensation,
for our personnel in executive and other administrative functions. General and administrative expenses also include legal fees relating
to patent and corporate matters and professional fees paid for accounting, auditing, consulting and tax services, as well as other costs
such as insurance costs, investor and public relations, and travel expenses.</FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
anticipate our general and administrative expenses will increase substantially in the future as we expand our operations, including increasing
our headcount to support our continued </FONT>research and development <FONT STYLE="background-color: white">activities and preparing
for later-stage clinical trials and potential commercialization of elraglusib. We also anticipate we will incur increased accounting,
audit, legal, regulatory, compliance, director and officer insurance, and investor and public relations expenses associated with operating
as a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Other
Income (Expense)</I></B></FONT></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Change in Fair Value of
Warrant Liability</I></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June&nbsp;30, 2023, in
connection with issuance of the Series&nbsp;C redeemable convertible preferred stock, we issued the placement agent warrants to purchase
up to 32,796 shares of Series&nbsp;C redeemable convertible preferred stock at an exercise price of $5.23 per share. The initial estimated
fair value of these warrants of $93,863 was calculated using the Black-Scholes valuation model and recorded as a reduction to redeemable
convertible preferred stock and a corresponding increase in the warrant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, in connection with
convertible promissory note payable agreements, we issued the noteholders warrants to purchase shares of Series&nbsp;B-1 redeemable convertible
preferred stock, of which, warrants to purchase up to 137,465 shares of redeemable convertible preferred stock were issued at an exercise
price of $2.93 per share and warrants to purchase up to 137,465 shares of redeemable convertible preferred stock were issued at an exercise
price of $5.86 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The redeemable convertible
preferred stock warrants require liability classification as the underlying redeemable convertible preferred stock is considered contingently
redeemable and may obligate us to transfer assets to the holders at a future date upon occurrence of a deemed liquidation event. The
warrants are recorded at fair value upon issuance and are subject to remeasurement to fair value at each balance sheet date, with any
changes in fair value recognized in other income (expense), net. We will continue to adjust the warrant liability for changes in fair
value until the earlier of (i)&nbsp;the exercise or expiration of the redeemable convertible preferred stock warrants, (ii)&nbsp;the
occurrence of a deemed liquidation event or (iii)&nbsp;the conversion of redeemable convertible preferred stock into common stock (see
Note 8 to the accompanying consolidated financial statements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest expense represents
interest owed to UIC under our license agreement with UIC, whereby UIC agreed to defer amounts owed to UIC under a former sublicense
agreement in the amount of $404,991 (see Note 6 to the accompanying consolidated financial statements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Interest Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest income represents
interest earned on our cash and cash equivalents at the then prevailing market rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Comparison of the Years Ended December&nbsp;31,
2023 and 2022</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our results of operations for the years ended December&nbsp;31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">21,708,332</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">16,387,216</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,321,116</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,265,497</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,819,591</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(554,094</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total operating
    expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,973,829</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,206,807</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,767,022</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,973,829</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,206,807</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,767,022</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(79,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(116,401</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(43,641</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(27,441</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,672</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,027</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">325,645</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Total other income,
    net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">229,209</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,406</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">181,803</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,585,219</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Research and Development
Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our research and development expenses for the years ended December&nbsp;31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">External clinical trial expenses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">13,986,355</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">10,513,275</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,473,080</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Personnel and consulting expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,675,373</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,028,258</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,647,115</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Preclinical and biomarker research</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,800,324</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,934,217</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(133,893</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">CMC related costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,246,280</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,911,466</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">334,814</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,708,332</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,387,216</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,321,116</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The increase in research
and development expenses of approximately $5.3 million for the year ended December&nbsp;31, 2023 was primarily due to an increase of
approximately $3.5&nbsp;million in clinical trial expenses related to increased patient enrollment, an increase of approximately $1.6
million in personnel and consulting expenses to support increased enrollment and other clinical, regulatory, and Chemistry, Manufacturing
and Control (CMC) activities, and an increase of approximately $0.3 million in CMC expenses due to an increase in formulation and stability
studies to support the oral formulation of elraglusib. These were partially offset by a decrease in preclinical and biomarker research
CMC expenses of $0.1 million primarily due to fewer toxicology and preclinical experiments completed in 2023 as compared to 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>General and Administrative
Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our general and administrative expenses for the years ended December&nbsp;31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Personnel-related expenses</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,827,250</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,579,222</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(751,972</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Professional and consulting fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,083,243</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">945,845</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">137,398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">355,004</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">294,524</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">60,480</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total general and administrative expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,265,497</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,819,591</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(554,094</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The decrease in general and
administrative expenses of approximately $0.6&nbsp;million for the year ended December&nbsp;31, 2023 compared to the same prior year
period was primarily due to a decrease in personnel-related expenses of approximately $0.8 million resulting from lower stock-based compensation
expense in the current period as fewer awards were subject to vesting as compared to the same prior year period combined with a decrease
in payroll costs due to a temporary decline in executive roles in the current year, which amount was offset with an increase in professional
and consulting fees of approximately $0.1 million primarily related to fees associated with maintaining our intellectual property and
an increase in other expenses of approximately $0.1 million primarily due to an increase in travel and related expenses to support investor
and public relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Income (Expense)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income (expense), net,
for the years ended December&nbsp;31, 2023 and 2022 is comprised of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Change
                                            in fair value of warrant liability</I> - During 2018 and June&nbsp;2023, we issued warrants
                                            to purchase shares of redeemable convertible preferred stock. The redeemable convertible
                                            preferred stock warrants require liability classification as the underlying redeemable convertible
                                            preferred stock is considered contingently redeemable and may obligate us to transfer assets
                                            to the holders at a future date upon occurrence of a deemed liquidation event. The warrants
                                            are recorded at fair value upon issuance and are subject to remeasurement to fair value at
                                            each balance sheet date, with any changes in fair value recognized in other income (expense),
                                            net. The following table represents the change in fair value of the redeemable convertible
                                            preferred stock warrants using the Black-Scholes valuation model, which amounts are included
                                            in other income (expense) in the accompanying consolidated financial statements for the years
                                            ended December&nbsp;31, 2023 and 2022:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Redeemable
    <BR> Convertible <BR> Preferred Stock <BR> Warrant Liability</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: justify">Fair value as of January&nbsp;1, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">850,943</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Change in fair
    value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair value as of December&nbsp;31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Estimated fair
    market value of warrants issued to placement agent in connection with issuance of redeemable convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93,863</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Change in fair
    value</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">79,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Fair value as of December&nbsp;31,
    2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
    expense</I></FONT> <FONT STYLE="font-size: 10pt">- Interest expense for the years ended December&nbsp;31, 2023 and 2022 represents
    interest accrued on amounts owed under a license agreement with UIC, whereby UIC agreed to defer amounts payable to UIC under a former
    sublicense agreement in the amount of $404,991 in exchange for an interest-bearing license payable (see Note 6 to the accompanying
    consolidated financial statements).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Interest
                                            income</I> &ndash; Interest income for the years ended December&nbsp;31, 2023 and 2022 represents
                                            interest earned on cash and cash equivalents based on the prevailing market rates. The increase
                                            in interest income in 2023 compared to the same prior year period is primarily due to higher
                                            rates of interest earned on money market funds during the current year period as compared
                                            to the prior year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sources of Liquidity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from operations.
We expect to incur significant expenses and operating losses in the foreseeable future as we advance the clinical development of elraglusib
and any future product candidates. To date, we have primarily funded our operations with proceeds from the sale of shares of our redeemable
convertible preferred stock and the issuance of convertible notes that were converted into redeemable convertible preferred stock. Through
December&nbsp;31, 2023, we have received aggregate net proceeds of approximately $94.2 million from the sale of shares of our redeemable
convertible preferred stock and the issuance of convertible notes that were converted into redeemable convertible preferred stock. As
of December&nbsp;31, 2023, we had cash and cash equivalents of approximately $3.0 million. During February&nbsp;2024, we received net
proceeds of $3.0 million from the issuance of convertible notes to a related party (see Note 13 to the accompanying consolidated financial
statements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future Funding Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our expenses to
increase substantially in connection with our ongoing activities, particularly as we continue our development of, seek regulatory approval
for, and potentially commercialize elraglusib and potentially seek to discover and develop additional product candidates, conduct our
ongoing and planned clinical trials and preclinical studies, continue our research and development activities, utilize third parties
to manufacture elraglusib, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated
with being a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash used to fund our operating
expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding prepaid expenses, accounts
payable, and other accrued expenses. The timing and amount of our funding requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs and timing of clinical trials and preclinical studies of elraglusib and any future
                                            product candidates we may choose to pursue, including the costs of modification to clinical
                                            development plans based on feedback that we may receive from regulatory authorities and any
                                            third-party products used as combination agents in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs, timing and outcome of regulatory meetings and reviews of elraglusib or any future
                                            product candidates, including requirements of regulatory authorities in any additional jurisdictions
                                            in which we may seek approval for elraglusib and any future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs of obtaining, maintaining, enforcing and protecting our patents and other intellectual
                                            property and proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            efforts to enhance operational systems and hire additional personnel to satisfy our obligations
                                            as a public company, including enhanced internal control over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs associated with hiring additional personnel and consultants as our business grows,
                                            including additional executive officers and clinical development, regulatory, CMC quality
                                            and commercial personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            timing and payment of milestone, royalty or other payments we must make pursuant to our existing
                                            and potential future license or collaboration agreements with third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            costs and timing of establishing or securing sales and marketing capabilities if elraglusib
                                            or any future product candidate is approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability to achieve sufficient market acceptance, coverage, and adequate reimbursement from
                                            third-party payors and adequate market share and revenue for any approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            ability and strategic decision to develop future product candidates other than elraglusib,
                                            and the timing of such development, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            terms and timing of establishing and maintaining collaborations, licenses and other similar
                                            arrangements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">costs
                                            associated with any products or technologies that we may in-license or acquire.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Based upon our current
operating plan, we estimate that our existing cash and cash equivalents as of the date of this prospectus, together with the estimated
net proceeds from this offering, will be sufficient to fund our projected operating expenses and capital expenditure requirements for
at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;months.
However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many
factors currently unknown to us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no other committed
sources of capital. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through
equity offerings, debt financings, or other capital sources, including current or potential future collaborations, licenses, and other
similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable
terms or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights
as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition,
merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain
investments or declaring dividends. If we raise additional funds through collaborations or license agreements with third parties, we
may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant
licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant
rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, or even cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Material Cash Requirements for Known Contractual
and Other Obligations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Research and Development
Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are continuing to invest
in our elraglusib clinical trials and have entered into contractual obligations with each clinical trial site. Each contract shall continue
until the completion of the trial at that site. Our clinical trial costs are dependent on, among other things, the size, number and length
of our clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Other Capital Requirements
and Additional Royalty Obligations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into agreements
in the normal course of business with various vendors, which are generally cancellable upon notice. Payments due upon cancellation typically
consist only of payments for services provided or expenses incurred, including&nbsp;non-cancellable&nbsp;obligations of service providers,
up to the date of cancellation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding our cash flows for the years ended December&nbsp;31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,625,167</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,794,093</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,134,516</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,255,569</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net change in cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,490,651</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,461,476</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Operating Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December&nbsp;31, 2023 consisted of our net loss of $24,744,620, which amount was offset by (i)&nbsp;non-cash
stock-based compensation expense of $423,539, (ii)&nbsp;a non-cash increase in the fair value of our warrant liability of $79,822, (iii)&nbsp;an
increase in accrued interest on license payable of $43,641, and (iv)&nbsp;cash provided by a net change in operating assets and liabilities
of $2,572,451.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December&nbsp;31, 2022 consisted of our net loss of $20,159,401 combined with a non-cash decrease in the
fair value of our warrant liability of $36,579, which amounts were offset by (i)&nbsp;non-cash stock-based compensation expense of $654,066,
(ii)&nbsp;an increase in accrued interest on license payable of $16,200, and (iii)&nbsp;cash provided by a net change in operating assets
and liabilities of $1,731,621.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the years ended December&nbsp;31,
2023 and 2022, net cash provided by financing activities of $4,134,516 and $19,255,569, respectively, was related to net proceeds received
from the issuance of Series&nbsp;C redeemable convertible preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies and Significant
Judgments and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements
are prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP). The preparation of our financial
statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical
experience, known trends and events, and various other factors we believe are reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions
or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our significant accounting
policies are described in more detail in Note 2 to the accompanying consolidated financial statements included elsewhere in this prospectus,
we believe the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Expenses and Related
Accrued Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the process of
preparing our consolidated financial statements, we are required to estimate our research and development expenses as of each balance
sheet date. This process involves reviewing open contracts, including clinical site contracts, and communicating with our personnel to
identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred
for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our research and development
expenses as of each balance sheet date based on facts and circumstances known to us at that time. The significant estimates in our research
and development expenses include the costs incurred for services performed by our vendors in connection with services for which we have
not yet been invoiced. We base our expenses related to research and development activities on our estimates of the services received
and efforts expended pursuant to quotes and contracts with contractors and vendors that conduct research and development on our behalf.
The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment
flows. Advance payments for goods and services that will be used in future research and development activities are expensed when the
activity has been performed or when the goods have been received rather than when the payment is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we do not expect
our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed
differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low
in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually
incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We periodically grant equity-based
awards in the form of restricted common stock awards (RSAs) and, beginning in 2023, options to purchase common stock, to employees, directors
and&nbsp;non-employees&nbsp;and record stock-based compensation expense for awards of stock-based payments based on their estimated fair
value at the grant date. We recognize stock-based compensation expense for all equity-based payments. The fair value of service-based
RSAs is measured at the grant date based on the fair market value of our common stock on the date of grant (see the subsection titled
 &ldquo;&mdash;Determination of Fair Value of Our Common Stock&rdquo; below) and is recognized as expense over the requisite service period,
which is generally the awards&rsquo; vesting period. The fair value of performance-based RSAs is measured at the grant date, based on
the fair value of shares expected to be earned at the end of the performance period, and is recognized as expense ratably over the performance
period based upon the probable number of shares expected to vest. RSAs are subject to forfeiture if the requisite service period is not
completed or the performance obligation is not achieved and are recognized as a reduction of stock-based compensation expense as they
occur. We classify stock-based compensation expense in the consolidated statements of operations in the same manner in which the recipient&rsquo;s
services are classified. We expect to continue to grant equity-based awards in the future, and to the extent that we do, our stock-based
compensation expense recognized in future periods will likely increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Determination of Fair
Value of Our Common Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">As there has been no public
market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as of
the date of grant of each option or restricted common stock award, with input from management, considering our most recently available
third-party valuations of common stock and our board of directors&rsquo; assessment of additional objective and subjective factors that
it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These
third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&rsquo;
Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common stock
valuations were prepared using either an option pricing method (OPM) or a hybrid method, both of which used market approaches to estimate
our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise
prices based on the value thresholds at which the allocation among the various holders of a company&rsquo;s securities changes. Under
this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred
stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted
expected return method (PWERM) where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based
methodology that estimates the fair value of common stock based upon an analysis of future values for us, assuming various outcomes.
In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective
factors to determine the fair value of our common stock as of each grant date, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            prices at which we sold shares of preferred stock and the superior rights and preferences
                                            of the preferred stock relative to our common stock at the time of each grant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            progress of our research and development programs, including the status of preclinical studies
                                            and clinical trials for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            stage of development and business strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">external
                                            market conditions affecting the biotechnology industry and trends within the biotechnology
                                            industry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            financial position, including cash on hand, and our historical and forecasted performance
                                            and operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            lack of an active public market for our common stock and our preferred stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or
                                            sale of our company in light of prevailing market conditions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            analysis of IPOs and subsequent market performance of similar companies in the biotechnology
                                            industry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            assumptions underlying these valuations represented management&rsquo;s best estimate, which
                                            involved inherent uncertainties and the application of management&rsquo;s judgment. As a
                                            result, if we had used significantly different assumptions or estimates, the fair value of
                                            our common stock and our stock-based compensation expense could have been materially different.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are significant judgments
and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions
regarding our future operating performance, the time to complete an initial public offering or other liquidity event, and the determination
of the appropriate valuation methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our early stage
of development, the difficulty in predicting the range of specific outcomes (and their likelihood), and other relevant factors, the market
approach was considered most appropriate for valuations prior to December&nbsp;2023. The recent transactions method was utilized to determine
the value of the equity and the OPM allocated the equity value to the respective share classes. In determining the estimated fair value
of our common stock, our board of directors also considered the fact that our stockholders could not freely trade our common stock in
the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average
expected time to liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a public trading market
for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our
board of directors to estimate the fair value of our common stock in connection with our accounting for granted equity-based awards or
for any other such awards we may grant, as the fair value of our common stock will be determined based on the closing price of our common
stock as reported on the date of grant on the primary stock exchange on which our common stock is traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Authoritative guidance requires
disclosure of the fair value of financial instruments. The carrying amount of certain of our financial instruments, including cash and
cash equivalents, accounts payable and accrued liabilities, approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The redeemable convertible preferred
stock warrant liability is carried at fair value based on unobservable market inputs. We measure the fair value of certain of its financial
liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine
fair values. Financial assets and liabilities carried at fair value which is not equivalent to cost will be classified and disclosed
in one of the following three categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            1 &mdash; Quoted prices (unadjusted) in active markets for identical assets and liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            2 &mdash; Inputs other than Level 1 that are observable, either directly or indirectly, such
                                            as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices
                                            in the markets that are not active, or other inputs that are observable or can be corroborated
                                            by observable market data for substantially the full term of the assets or liabilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            3 &mdash; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The redeemable convertible
preferred stock warrant liability is valued using the using the Black-Scholes model, which requires the use of highly subjective assumptions
to determine the appropriate fair value of each warrant, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Fair
                                            Value of Common Stock - See the subsection titled &ldquo;&mdash;Determination of Fair Value
                                            of Our Common Stock&rdquo; above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                            Volatility -</I> Since we are not yet a public company and do not have any trading history
                                            for our common stock, the expected volatility was estimated based on the historical volatilities
                                            of common stock of comparable publicly traded companies, for a look-back period commensurate
                                            with the expected term of the warrant. The comparable companies were chosen based on their
                                            size, stage of their life cycle or area of specialty. We will continue to apply this process
                                            until enough historical information regarding the volatility of our stock price becomes available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Risk-Free
                                            Interest Rate -</I> The risk-free interest rate used is based on the published U.S. Department
                                            of Treasury interest rates in effect at each measurement date for zero coupon U.S. Treasury
                                            notes with maturities approximating the expected remaining term of each warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                            Dividend Yield -</I> The expected dividend yield is zero as we have not paid dividends and
                                            do not anticipate paying a cash dividend in the foreseeable future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Expected
                                            Term -</I> The expected term of each warrant represents the remaining contractual term of
                                            the underlying warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance&nbsp;Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not have, during the
periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&nbsp;and regulations of
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of recently
issued accounting standards that may potentially impact our financial position, results of operations, and cash flows is included in
Note 2 to our consolidated financial statements included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Emerging Growth Company Status and Smaller
Reporting Company Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an emerging growth
company, as defined in the JOBS Act. The JOBS Act permits an emerging growth company such as us to take advantage of an extended transition
period to comply with new or revised accounting standards. We have elected to avail ourselves of such extended transition period, which
means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt
the new or revised standard at the time private companies adopt the new or revised standard and may do so until such time that we either
(i)&nbsp;irrevocably elect to opt out of such extended transition period or (ii)&nbsp;no longer qualify as an emerging growth company.
We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.
We will continue to remain an emerging growth company until the earliest of the following: (1)&nbsp;the last day of the fiscal year following
the fifth anniversary of the date of the completion of this offering; (2)&nbsp;the last day of the fiscal year in which our total annual
gross revenue is equal to or more than $1.235 billion; (3)&nbsp;the date on which we have issued more than $1.0 billion in nonconvertible
debt during the previous three years; or (4)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules&nbsp;of
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also a smaller reporting
company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth
company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take
advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0
million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the
most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured
on the last business day of our second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about
Market Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Interest Rate Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cash and cash equivalents
consist of cash held in readily available checking and money market accounts. Our primary exposure to market risk is interest rate sensitivity,
which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments
in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition
or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our investment policy,
we invest in highly rated securities, issued by the U.S. government or liquid money market funds. We do not invest in financial instruments
for trading or speculative purposes, nor do we use leveraged financial instruments. A hypothetical 10% change in interest rates would
not have a material impact on the value of our cash, cash equivalents, marketable securities and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign Currency Exchange Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not currently exposed
to significant market risk related to changes in foreign currency exchange rates. As we continue to develop our business, our results
of operations and cash flows will likely be more affected by fluctuations in foreign currency exchange rates, including the Euro and
other currencies, which could adversely affect our results of operations. All of our employees and operations are currently located in
the United States and our expenses are generally denominated in U.S. Dollar. To date, we have not entered into any foreign currency hedging
contracts to mitigate our exposure to foreign currency exchange risk. We do not believe that a hypothetical 10% increase or decrease
in exchange rates during any of the periods presented would have had a material impact on our financial statements included elsewhere
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Effects of Inflation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation could affect us
by increasing our cost of labor and research and development costs. We do not believe inflation has had a material effect on our business,
financial condition or results of operations, or on our financial statements included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen
synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells
and block the function of the enzyme GSK-3&beta;, a master regulator of complex biological signaling cascades, including those mediated
by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3&beta; signaling
ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The enzyme GSK-3&beta;, a
serine/threonine protein kinase, is understood to be an essential positive regulator of nuclear factor kappa B (NF-kB) transcriptional
activity. Studies have demonstrated that the inhibition of GSK-3&beta; decreases cancer cell survival via suppression of the transcriptional
activity of its downstream effector NF-kB. In light of these findings, we believe that the inhibition of GSK-3&beta; may overcome and/or
reverse NF-kB-mediated cancer cell survival and chemoresistance to conventional chemotherapeutic drugs in a range of human cancers. Research
has also demonstrated that aberrant nuclear GSK-3&beta; accumulation is limited to cancer cells, making GSK-3&beta; a potential candidate
for specific and targeted cancer therapy. Additionally, GSK-3 regulates the expression of immune modulators such as pro-inflammatory
cytokines and checkpoint molecules in tumor and immune cells. We believe blocking GSK-3 in these cells leads to improved immune cell
function, which can ultimately result in better, longer clinical responses in patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Lead Product Candidate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have exclusively licensed
a portfolio of GSK-3 inhibitors developed in a collaboration between UIC and NU. The lead drug in our portfolio is called elraglusib
(9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, our most advanced clinical
indication to date. Elraglusib represents a broad opportunity for us to potentially initiate and advance multiple drug development programs
around our lead asset based on data emerging from completed or ongoing Phase 1/2 trials in pediatric and adult patients with advanced,
refractory cancers. Many of the pathological processes that drive cancer are controlled by GSK-3&beta; and thus, by targeting GSK-3&beta;,
we are pursuing the development of products designed to intervene in the progression of multiple cancer types. Animal tumor model data
and Phase 1/2 clinical data have identified a number of areas of unmet clinical need in cancer where elraglusib may play an interventional
role, including pancreatic, colon, lung, breast, renal, ovarian, leukemias and lymphomas, and melanoma as well as some pediatric cancers
including Ewing sarcoma, neuroblastoma and pediatric leukemias. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our lead program, Elraglusib
Injection, is an intravenous injection solution of elraglusib for the treatment of mPDAC. Elraglusib Injection has been evaluated in
a Phase 1 dose escalation study (Actuate-1801 Part 1) in 238 adult patients with refractory advanced cancers when given as a single agent
(n=67) or in combination with chemotherapy (n=171). The objective of this study was to establish the safety profile of elraglusib when
used alone or in combination with chemotherapy and to identify either an MTD or RP2D to then inform the design of exploratory efficacy
studies in Phase 2. Subjects in this study were diagnosed with a variety of cancer types and most patients had received two or more previous
lines of chemotherapy prior to enrollment in the study. Objective responses and durable disease control were observed in both the single
agent and combination treatment arms of the study. The most common treatment-emergent adverse events (TEAEs) attributed to elraglusib
were transient visual disturbance (patients described lights as brighter and skin tones darker, which resolved spontaneously) and fatigue
across both study parts. The majority (&gt;99%) of TEAEs that occurred in &ge; 20% of patients were reported as Grade 1 or 2 (mild or
moderate). In combination with chemotherapy, no new safety signals were observed. Based on the results of the Phase 1 study, which established
15 mg/kg as the RP2D when combined with chemotherapy, we initiated a single arm Phase 2 study (Actuate-1801 Part 2) in patients with
previously untreated mPDAC. This study was originally designed as a single arm exploratory Simon two-stage trial (and therefore not designed
or powered to demonstrate statistical significance), but after an analysis conducted following the completion of Stage 1, which showed
a median overall survival (mOS) of 15.3 months in the efficacy evaluable (n=29) patient population, we amended and expanded the Stage
2 of the study to a randomized, controlled trial now powered for statistical significance (Actuate-1801 Part 3A) that would allow a comparison
of the safety and efficacy of the combination of Elraglusib Injection plus gemcitabine/nab-paclitaxel (GnP) as compared to GnP alone.
Elraglusib is currently being evaluated as a weekly intravenous (IV)&nbsp;infusion in combination with the approved dosing regimen for
GnP. This study completed enrollment four months faster than predicted and top line results are expected in the first quarter of 2025.
The primary endpoint is overall survival (OS). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> According to the American
Cancer Society, the annual incidence of pancreatic cancer is expected to exceed 66,000 patients in the United States this year and approximately
70% of these patients will present with metastatic disease. The mOS in patients with mPDAC is 9-11 months and the ability to extend survival
by even a few months would be considered meaningful in this patient population. Elraglusib has been granted Fast Track and Orphan Drug
Designations from the U.S. Food and Drug Administration (FDA) for pancreatic cancer in the United States. Based on our meetings with
the FDA to discuss our development plan in pancreatic cancer, the current Phase 2 study design cannot be used to support accelerated
approval. However, if the future mOS data is positive in favor of the elraglusib/GnP combination, we would initiate further conversations
with the FDA to discuss possible registration. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Two additional exploratory,
single arm Phase 2 studies are ongoing in patients with pancreatic cancer evaluating novel drug combinations with elraglusib: the combination
of elraglusib/FOLFIRINOX/losartan in up to 32 patients with mPDAC and the combination of elraglusib/GnP/retinfanlimab in up to 65 patients
with advanced PDAC. Both studies are academic (IITs that are exploring the addition of immunomodulatory drugs to an elraglusib/chemotherapy
backbone. Enrollment in both of these investigator-initiated studies is continuing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Elraglusib Injection has
also been evaluated in pediatric cancer patients with recurrent/refractory solid cancers. This study, Actuate-1902, is a Phase 1/2 study
that evaluated escalating doses of elraglusib as a single agent as well as in combination with irinotecan or cyclophosphamide/topotecan
in the Phase 1 portion. This study was based off the recommended Phase 2 dose (RP2D) from the Actuate-1801 adult cancer study using twice
weekly dosing of elraglusib. Patients in this Actuate-1902 study also experienced a number of objective responses in the combination
chemotherapy arms, and based on this data, we identified Ewing sarcoma as a potential second indication for further development of Elraglusib
Injection. Currently, the Actuate-1902 study is closed to accrual. However, we plan to submit an amendment to the protocol and seek to
re-open the Phase 2 portion of this study to enroll only Ewing sarcoma patients to further investigate the activity of elraglusib in
this patient population. We are also evaluating the potential for additional exploratory development of Elraglusib Injection in other
pediatric cancer indications, including leukemias, which we expect to explore through academic IITs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have developed several
oral dosage forms of elraglusib, including an oral liquid (Elraglusib Oral Liquid) and several solid dosage forms including an Elraglusib
Oral Tablet product candidate, which we believe will allow us to expand the number of cancer indications that we are able to target and
allow us to further explore optimal dosing. A Phase 1 healthy volunteer study (Actuate-2203) was completed showing very favorable (&gt;50%)
bioavailability after a single dose of Elraglusib Oral Liquid. A clinical candidate tablet (Elraglusib Oral Tablet) has been developed
and selected. Subject to our receipt of the proceeds of this offering, the manufacture of Elraglusib Oral Tablet under current Good Manufacturing
Practices (cGMP) is expected to be available in the third quarter of 2024 and a first in human dose escalation study using Elraglusib
Oral Tablet is expected to begin in the fourth quarter of 2024. We are planning a Phase 1 study (Actuate-2401) to identify the MTD/ RP2D
for Elraglusib Oral Tablet in patients with advanced, refractory adult cancers subject to our receipt of the proceeds of this offering.
Several Phase 2 indications, including refractory, metastatic melanoma and refractory, metastatic colorectal cancer have been identified
for further clinical development of Elraglusib Oral Tablet based on data from the Actuate-1801 study once the MTD/RP2D for the oral tablet
has been established. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Pipeline and Development Timeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our initial focus is on the
development of GSK-3 inhibitors for the treatment of cancers with ineffective treatment options and poor survival. Given our ability
to formulate elraglusib for both intravenous (IV)&nbsp;and oral administration if adequate funding is secured, and given the potential
to use it in different ways depending on the cancer type, we believe that elraglusib represents a pipeline in a molecule, as shown in
the figure below. We are currently focused on advancing our trials in pancreatic cancer with Elraglusib Injection. Our ability to advance
our planned trials listed in Figure 1 below will depend on our ability to raise sufficient capital to support those trials, as discussed
under &ldquo;Use of Proceeds&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Figure
1. </I></B></FONT><I>Development Pipeline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our initial focus is on
advanced cancer indications with high unmet medical need where 1 and 2 year OS are currently low. We are developing two dosage forms
of its GSK-3 inhibitor, elraglusib, the continuation and completion of which depends on the amount of funding we are able to secure through
this offering or otherwise, as discussed under &ldquo;Use of Proceeds.&rdquo; Details and milestones are shown in Figure 1. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <I>Elraglusib Injection (IV), mPDAC. </I>Our lead program is developing Elraglusib
    Injection mPDAC, an intravenous injection solution of elraglusib for the treatment of mPDAC. mPDAC remains one of the highest unmet
    needs in oncology as the 5-year survival rate for PDAC (&lt;10%) is one of the lowest of any cancer type. We received Fast Track
    designation for elraglusib in PDAC by the FDA in 2021. We also received Orphan Drug Designation for elraglusib in PDAC from the FDA
    in 2023. A single arm Phase 2 study in patients with mPDAC has been completed and a randomized, controlled Phase 2 trial in the same
    patient population has finished accrual (Q1, 2024) (Actuate-1801). Several patients still remain on treatment and are being followed
    for OS. These are discussed in detail below. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <I>Elraglusib (IV), Ewing sarcoma</I>. We plan to amend the Actuate-1902 protocol
    to modify the Phase 2 portion to include only those patients with Ewing or Ewing-like sarcoma, with an initial objective response
    readout in approximately 12-18 months from commencement. We are in the process of engaging with the pediatric sarcoma community to
    discuss potential registration trials in the United States and the EU if Phase 2 is positive. We believe that pursuing this development
    could be an efficient and rapid path to registration in the United States and Marketing Authorization in the EU.&nbsp;&nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Elraglusib
    (IV), IITs<B>.</B></I> We have several exploratory investigator-initiated studies with elraglusib that are ongoing using several
    different drug combinations in patients with advanced and mPDAC and a trial in recurrent salivary gland cancer. These are summarized
    in Figure 14. &nbsp;We have also engaged in additional IIT discussions regarding pediatric leukemia and neuroblastoma and regarding
    biliary tract cancer, malignant brain cancer and lung cancer in adults. These studies are exploratory and not considered critical
    path for us at this stage and will not be discussed further beyond the summary of ongoing IITs in Figure 21. However, data from these
    studies could inform future company sponsored trials, be presented at scientific meetings and present the potential for positive
    news flow.<I>&nbsp;</I></FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <I>Elraglusib Oral Tablet (FIH dose escalation). </I>Several oral formulations
    of elraglusib have been manufactured. An oral liquid was evaluated for bioavailability in a Phase 1 healthy volunteer study (Actuate-2203).
    This is discussed briefly below. In addition, oral tablet dosage forms have also been developed and show even higher bioavailability
    than the oral liquid in dogs. An oral tablet dosage form has been chosen as the development candidate and has been advanced into
    cGMP manufacturing of clinical investigational drug product. Assuming the proceeds of this offering are secured, we expect that these
    tablets will be evaluated in a Phase 1 study (Actuate-2401) in patients with advanced cancer. As shown above, this trial would begin
    in the second half of 2024, assuming receipt of the proceeds of this offering. We have accumulated clinical pharmacology (e.g., anticancer
    activity and exposure-effect relationships) from the Actuate-1801 Phase 1 trial to guide the development of the oral tablet dosage
    form. Based on data obtained with the IV in the Actuate-1801 study (Figure B and C, Table 4), we believe that investigating Elraglusib
    Oral Tablet in patients with metastatic melanoma and colorectal cancer (CRC) once the MTD/RP2D for the tablet are identified would
    be justified based on data from Actuate-1801 Part 1 and Part 2. A solid tablet dosage form of elraglusib is expected to broaden the
    application of elraglusib in additional cancers and other diseases where standard of care therapy is taken orally and IV administration
    is less desirable. </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> Actuate-2203
                                            investigated the oral bioavailability of a liquid formulation of elraglusib at a single dose
                                            of drug using a cross-over design such that each subject on the study received IV, oral liquid
                                            after fasting and oral liquid with food. Elraglusib oral liquid was approximately 50% bioavailable
                                            when given with food and was very well tolerated by healthy volunteers (Figure 2). The oral
                                            liquid and several oral tablets formulations were also evaluated for bioavailability in dogs
                                            and a candidate oral tablet was identified that was essentially 100% orally bioavailable
                                            when given with food (Figure 3). This oral tablet (Elraglusib Oral Tablet) was further evaluated
                                            in a 28 day repeat daily dose toxicology study in dogs (Study 23-1471). This simulated the
                                            expected daily dosing that we plan to use in our FIH Phase 1 study. For the first time, an
                                            MTD was identified with any formulation or schedule of elraglusib. In the past, elraglusib
                                            had been given up to 3 times a week in animal toxicology studies to cover twice weekly and
                                            once weekly dosing of Elraglusib Injection in the Actuate-1801 and Actuate-1902 studies,
                                            but never daily. Daily dosing of Elraglusib Oral Tablets identified 25 mg/kg (one 250 mg
                                            tablet) daily as the MTD as a number of clinical and pathological signs of toxicity were
                                            observed at the next highest doses of 50 mg/kg. The 25 mg/kg daily dose in dogs corresponds
                                            to approximately the 9.3 mg/kg weekly dose currently being used in the Actuate-1801 Part
                                            3B study when scaled from dog to man. Based on these observations, we expect to also reach
                                            MTD in the Elraglusib Oral Tablet Phase 1 study in patients with refractory advanced cancer. </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
2. Bioavailability of Elraglusib Oral Liquid in Phase 1 Human Healthy Volunteer Study</I></B></FONT><I>.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Elraglusib
                                            Oral Tablet, Phase 2. </I></FONT>Once an MTD and RP2D dose are identified for the Elraglusib
                                            Oral Tablet and adequate proceeds of this offering or other funding is secured, Phase 2 studies
                                            will be initiated in patients with refractory metastatic colorectal cancer, refractory metastatic
                                            melanoma and possibly other indications. Management believes that the initial rationale for
                                            these indications is supported by the Actuate-1801 Parts 1 and 2 trial as discussed above
                                            and in Figures 9-12. </P>
<FONT STYLE="font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Figure 3. Bioavailability of Elraglusib
Oral Tablet in Dog Exploratory Toxicology Study 23-1471</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm247121d3_s1aimg002.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Elraglusib (9-ING-41)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no approved high-affinity inhibitors of GSK-3</FONT><FONT STYLE="font-family: Symbol">b</FONT> and we believe our lead drug, elraglusib,
is one of the most advanced GSK-3<FONT STYLE="font-family: Symbol">b</FONT> inhibitors in clinical development. Elraglusib was originally
known as 9-ING-41 but was granted the elraglusib International Nonproprietary Names (INN) and United States Adopted Names (USAN) generic
name in 2021. The known major mechanisms of action of elraglusib are summarized in Figure 4 and emphasize the therapeutic potential of
this drug in multiple cancer types. For these reasons, elraglusib represents a &ldquo;pipeline in a molecule&rdquo; depending on the
dosage form and how it is used in a particular cancer type. Our lead development program is seeking to treat mPDAC in combination with
gemcitabine/nab-paclitaxel GnP. Our clinical data to date and the development plan are also discussed below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Elraglusib
may exert anticancer activity through a variety of mechanisms that may be context and cancer type specific. For example, GSK-3</FONT><FONT STYLE="font-family: Symbol">b
</FONT>mediates signaling of oncogenic PI-3K but if this oncogene is not expressed in a particular tumor, this would not be a pathway
that could be targeted by elraglusib in that tumor. Potential antitumor activity through GSK-3<FONT STYLE="font-family: Symbol">b</FONT>
inhibition may occur through the following six mechanisms of action (Figure 4, below): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;Immune modulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;Inhibiting cell
proliferation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;Reducing tumor fibrosis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;Decreasing immune
evasion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;Increasing apoptosis
and disrupting DNA damage repair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;Inhibition of epithelial-mesenchymal
transitions (EMT)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
4: </I></B></FONT><I>Elraglusib mechanism of action</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="tm247121d1_drssplit2img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(1)&nbsp;Immune modulation
and inhibition of immune evasion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">GSK-3&beta; plays an important
role in immune cell function, as inhibition of GSK-3&beta; can facilitate immune cell expansion, differentiation and activation including
T and natural killer (NK) cells. GSK-3&beta; inhibition increases the ability of effector T cells to kill tumors in vivo through the
induction of effector proteins granzyme B and FasL in gastric cancer models. Additionally, inhibition of GSK-3, with both small molecules
and small interfering RNA (siRNA), downregulates programmed cell death protein 1 (PD-1) expression in CD8 and cytolytic T cells and enhances
their function. GSK-3&beta; inhibition also lowers PD-1 expression and promotes long-term survival and generation of memory CAR-T cells
in vivo. These memory T-cells enabled 100% clearance of cancer cells after rechallenging during tumor remission. Recently, inhibition
of GSK-3&beta; with small molecules was shown to reduce the expression of T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT)
and lymphocyte activation gene-3 (LAG-3), additional immune system suppressing molecules that work in concert with PDL-1 to reduce antitumor
surveillance by the system. another inhibitory receptor, LAG-3. Combining GSK-3&beta; inhibition and LAG-3 blockade significantly enhanced
clearance of melanoma tumors compared to either treatment alone. LAG-3 was recently validated as a cancer therapeutic target when the
first anti-LAG-3 antibody relatlimab was approved in March&nbsp;2022 by the FDA for treatment of patients with unresectable or metastatic
melanoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Blocking GSK-3 in NK cells
leads to enrichment of mature NK cells and primes them for enhanced cytokine production and anti-tumor function in vivo. GSK-3&beta;
expression was increased in the NK cells of patients with acute myeloid leukemia (AML) and inhibition of GSK-3&beta; led to increased
cell directed cytotoxicity in these patient-derived samples. Inhibition of GSK-3 also decreased LAG-3 expression on NK cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GSK-3&beta;
activity has also been tied to transforming growth factor </FONT>&beta; (TGF&beta;) expression. TGF&beta; released by cancer cells, stromal
fibroblasts and other cells in the tumor microenvironment further promotes cancer progression by shaping the architecture of the tumor
and by suppressing the antitumor activities of immune cells, thus generating an immunosuppressive environment that prevents or attenuates
the efficacy of anticancer immunotherapies. Therefore, blocking GSK-3&beta; may reduce TGF&beta;-mediated immunosuppression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Elraglusib has now been demonstrated
to decrease expression of PD-1, TIGIT and LAG-3 and to enhance the anti-tumor effects of anti-PD-1 checkpoint inhibition in animal tumor
models. Thus, elraglusib blockade of GSK-3&beta; activity may improve immune response to tumors by augmenting the responsiveness of a
patient&rsquo;s immune system in addition to the direct anti-tumor effects of elraglusib within the cancer cells themselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(2)&nbsp;Inhibiting cell
proliferation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inhibition of GSK-3&beta;
leads to inhibition of tumor cell proliferation. This has been shown in multiple tumor model systems using elraglusib. A number of pathways
have been implicated in the inhibition of cell proliferation mediated by GSK-3 inhibitors including MYC, Cyclin D1, TGF&alpha;, epidermal
growth factor receptor, Ras, PI3K/Akt, and NF-&kappa;B. Given GSK-3&rsquo;s role as an adapter of multiple signaling pathways, elraglusib
may exert its antiproliferative effects through the inhibition of one or more of these pathways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(3)&nbsp;Reducing tumor
fibrosis and (4)&nbsp;decreased immune evasion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A chronic inflammatory microenvironment
is conducive to tumorigenesis (e.g., pancreatitis patients are known to have increased risk of pancreatic cancer) and tumors can undergo
epithelial to mesenchymal transition (EMT), leading to increased metastasis, under inflammatory conditions. Moreover, several profibrotic
cytokines (e.g., TGF-&beta;, TNF-&alpha; and IL-1) secreted by inflammatory and tumor cells converge to activate pathways that regulate
EMT. Further, GSK-3 has also been demonstrated to be a mediator of epithelial-mesenchymal transitions. Therefore, the inflammatory response
designed to fight tumor progression also ends up promoting metastasis and tumor-associated fibrosis. Tumor fibrosis presents multiple
challenges to drug delivery and tumor immune recognition and contributes to drug resistance by presenting physical barriers in the tumor
microenvironment to drug and immune cell access. Elraglusib has been shown to reduce the inflammation and signaling that contribute to
immune system evasion in multiple animal models, including lung and liver, of fibrosis suggesting another mechanism through which elraglusib
may interfere in cancer growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(5)&nbsp;Increasing apoptosis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">GSK-3 inhibits apoptosis
pathways. A number of studies have suggested that the primary mechanism of GSK-3-mediated apoptosis is through the NF-&kappa;B pathway.
Apoptosis is a mechanism of cell death that is often suppressed in cancer cells leading to cancer cell survival and resistance even after
treatment with chemotherapeutic drugs or radiation. Studies have shown that eliminating or inhibiting GSK-3&beta; in cancer cells is
able to restore apoptosis to cells, leading to tumor cell death. These findings support GSK-3&beta; as a potential therapeutic target
to potentiate apoptosis in cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to GSK-3&beta;&rsquo;s
role in regulating NF-&kappa;B activity, it has also been shown to modulate DNA damage repair (DDR) pathways. DDR pathways are integral
in both normal and cancer cells to maintain genomic integrity by sensing and responding to DNA damage. In normal cells, DDR helps to
identify and repair mutations or breaks in DNA and restore the normal, intact sequence. If the cell is unable to repair a DNA lesion,
these DDR pathways can then initiate cell death signaling to prevent neoplastic growth. In cancer, DNA repair has been subverted to protect
tumor cells from repairing DNA damage that would otherwise lead to spontaneous apoptosis. Cancers will often have mutations in at least
one DNA repair pathways leading to dysregulated cell growth and replication. Our collaborators have shown that elraglusib inhibition
of GSK-3&beta; sensitizes pancreatic cancer cells to gemcitabine by disrupting TopBP1/ATR mediated cell-cycle arrest and DNA repair.
GSK-3&beta;&rsquo;s emerging role in regulating DDR pathways supports its use in combination with DNA damaging chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inhibition of DDR pathways
have also been shown to enhance tumor immune recognition by immune checkpoint inhibitors such as anti-PD-1, creating neoantigens in tumors
that lead to recruitment of tumor infiltrating immune cells, decreased immune evasion and increased anti-tumor immune response. This
provides the link that couples the various elraglusib-related mechanisms of action through the targeting of GSK-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(6)&nbsp;Inhibition of
epithelial-mesenchymal transition (EMT)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">GSK-3&beta;
has been shown to be a mediator of a number of signaling pathways that regulate the transition of tumor cells from an epithelial to mesenchymal
phenotype potentially contributing to tumor progression, a process known as epithelial-mesenchymal transition (EMT). Signaling through
Wnt, Notch, TGF-</FONT><FONT STYLE="font-family: Symbol">b</FONT> and Snail are known mediators of EMT and their signaling is regulated
through GSK-3&beta;. Several toolkit GSK-3&beta; inhibitors have been shown to inhibit EMT in tumor models suggesting that this is a
class effect and highlighting a similar mechanism for elraglusib. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Elraglusib Clinical Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Elraglusib has been dosed
in over 500 patients to date both as a single agent and in combination. The first adult study, Actuate-1801 was designed as a multiphase
seamless design trial that allowed us to dose-escalate elraglusib as a single agent and in combination with chemotherapy in tandem in
Phase 1 in patients with advanced, refractory cancers and then moving to single cancer types Phase 2 trials all under a single protocol.
The objective of these studies was to evaluate safety and look for initial evidence of anti-tumor activity of elraglusib. Once the highest
well-tolerated dose was identified (the recommended Phase 2 dose, RP2D), elraglusib was then moved into single cancer Phase 2 to begin
to look for efficacy. In contrast to many Phase 1 trials, no MTD was identified for elraglusib when it was given twice per week and thus
an RP2D was advanced into Phase 2 studies. We also opened two other studies once we had safety data, a Phase 1/2 study in pediatric patients
with refractory malignancies (NCT04239092) and a Phase 2 study in myelofibrosis (NCT04218071). The pediatric study has provided a rationale
for developing elraglusib in patients with refractory Ewing Sarcoma and possible neuroblastoma that are discussed further as part of
our development pipeline. Additional work in myelofibrosis has been deferred pending the availability of an oral dosage form. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Actuate-1801 Phase 1/2 Clinical Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We developed an innovative
Phase 1/2 adaptive design &ldquo;basket&rdquo; clinical study, the Actuate-1801 trials, to efficiently evaluate elraglusib safety and
initial anti-tumor activity across multiple tumor types. This trial design (called a &ldquo;basket&rdquo; study because many different
types of cancer are enrolled in the study) facilitated the rapid advancement of elraglusib through dose escalation and safety cohorts
while later enabling seamless transition into Phase 2 efficacy studies in patient populations that showed evidence of antitumor activity
during the safety portion of the study. We began recruitment and treated the first patient in Part&nbsp;1 of Actuate-1801 in January&nbsp;2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The study design is shown
in Figure 5 below and consists of three parts. Part&nbsp;1 and Part&nbsp;2 consist of the evaluation of the safety and tolerability of
elraglusib to determine the MTD and the recommended Phase 2 dose (RP2D) as both a monotherapy (Part&nbsp;1; n=67) and in combination
with various chemotherapy regimens (Part&nbsp;2; n=171). Part&nbsp;1 and 2 involve dose escalation of elraglusib to identify either the
MTD or RP2D if an MTD cannot be achieved. These are discussed together because they were run in tandem and interdigitated. Initial dose
escalation was performed using single agent elraglusib (Part&nbsp;1) but once Part&nbsp;1 opened the fourth dose level, Part&nbsp;2 was
allowed to open at the third dose level in combination with one of the chemotherapy backbones shown in Figure 3. Dose escalation was
then continued for Part&nbsp;1 and 2 in tandem until MTD or RP2D were identified, with Part&nbsp;2 always being one dose level behind
Part&nbsp;1. A key design element of Part&nbsp;2 is that all subjects enrolled in a chemotherapy basket must have previously failed that
chemotherapy such that each patient is re-challenged by a drug to which they are resistant. Thus, each patient acts as their own control
since any disease control must be due to the combination. Part&nbsp;3 is designed to assess the clinical benefit of elraglusib at the
RP2D from Part&nbsp;2 in combination with chemotherapy in specific cancer populations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
5: </I></B></FONT><I>Actuate-1801 Master Protocol Study Design.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg2.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Between January&nbsp;2019
and August&nbsp;2021, patients participating in the Actuate-1801 study received at least one dose of elraglusib as monotherapy (n=67;
Part&nbsp;1) or in combination with chemotherapy (n=171; Part&nbsp;2). In Part&nbsp;1, eight dose levels were evaluated. Of the 67 total
patients enrolled, 35 were treated at the three highest dose levels (9.3, 12.4, 15 mg/kg) based on initial analysis of pharmacokinetics
(PK) that showed that these three dose levels showed the longest plasma exposure of elraglusib after a single administration that exceeded
the in vitro IC<SUB>50 </SUB>for inducing tumor cell apoptosis for 24 hours or more. Patients enrolled in this study had advanced disease
and were heavily pre-treated (e.g. had already received multiple chemotherapy regimens). Patients had received a mean of three prior
systemic chemotherapy regimens in Part&nbsp;1 and four prior systemic chemotherapy regimens in Part&nbsp;2. Twenty-one different cancer
types were enrolled in Part&nbsp;1 (see Figure 6, below) and 26 in Part&nbsp;2 (see Figure 7, below). On average, patients had received
and failed at least three previous lines of chemotherapy regimens (Figure 6). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In Part&nbsp;2, six&nbsp;dose
levels of elraglusib were evaluated across eight different chemotherapy baskets (Figure 5, above). It is important to note that the vast
majority of patients in Part&nbsp;2 (89%) were treated with elraglusib in combination with a chemotherapy regimen that the patient had
previously received and had not benefited from, had failed treatment, or had disease progression during treatment prior to enrolment
in the Actuate-1801 study. For example, patients included in the irinotecan basked in Actuate-1801 Part&nbsp;2 had previously received
a regimen that had included irinotecan and were then re-challenged with irinotecan plus elraglusib on the Actuate-1801 study. Thus, each
patient served as their own control after chemotherapy re-challenge and no response or clinical benefit would have been expected. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Parts
1 and 2 comprised the Phase 1 portion of the Actuate-1801 trial and the results of this study were recently published in <I>Clinical
Cancer Research.</I></FONT><I> (Carneiro et. al 2024).</I> No dose-limiting toxicities (DLTs) related to elraglusib occurred in either
Part&nbsp;1 or Part&nbsp;2. Since the MTD was not reached in either part of the study, 15 mg/kg, the pre-specified highest dose evaluated
in both Actuate-1801 Part&nbsp;1 and 2, was named the recommended Phase 2 dose (RP2D). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
6. </I></B></FONT><I>Actuate-1801 Part&nbsp;1 tumor types and prior lines of treatment.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Histology</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of Subjects (n)</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average
    number of <BR>
    prior lines of&nbsp;treatment<BR>
    (range)</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; padding-bottom: 1pt">Amelosblastoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Anal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    (3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Appendix</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    (1-2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Bile Duct</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    (4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">CNS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    (0-1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Colorectal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">14</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5
    (0-13)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Endometrial</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    (0)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Esophageal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
    (3-5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Head and Neck</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    (3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Kidney</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    (0-3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Leukemia</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    (0)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Liver</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7
    (7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Lung</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    (2-3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Lymphoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    (0-3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Melanoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">13</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
    (0-6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0
    (0)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Pancreatic</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
    (0-7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Prostate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9
    (8-9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Sarcoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    (4-8)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Skin, non-melanoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1
    (1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Uterine</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    (4-7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
7. </I></B></FONT><I>Part&nbsp;2 Tumor Types by dose level</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="17" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number
    of Patients (%) by Elraglusib Dose Level (mg/kg)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Tumor Type</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.3<BR>
                                            </B>(N=21)</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.0<BR>
                                            (N=39)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.0<BR>
    (N=38)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.3<BR>
                                            (N=11)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.4<BR>
    (N=2)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.0<BR>
                                            (N=60)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total<BR>
                                            (N=171)</B></FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: left">Adrenal Gland</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Anaplastic oligodendroglioma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Astrocytoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Biliary Tract</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Breast</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Cervix/Uterus/Endometrium</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">CNS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Colorectal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Endometrial</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Esophageal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Fallopian Tube</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Gallbladder</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Glioblastoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Gliosarcoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">H&amp;N</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liposarcoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Liver</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Lung</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">11</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Melanoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Merkel Cell</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Mesothelioma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Ovarian</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Pancreas</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">19</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Sarcoma</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Unknown</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Despite the fact that
the patients enrolled on the Actuate-1801 study had already received and failed multiple chemotherapy regimens, the mOS was 7.7 months
(95% CI, 5.1-9.7) for elraglusib monotherapy (Part 1) and 6.9 months (95% CI, 5.7-8.9) for the combination of elraglusib and chemotherapy
across all the different chemotherapy baskets (Figure 8). The mOS of 7.7 months in Part 1 benchmarks favorably with mOS 8-10 months for
other active single agents evaluated in Phase 1. A summary of best overall response (BOR) observed in Actuate-1801 Part(s)&nbsp;1 and
2 is also presented (Figure 6). Complete response (CR), partial response (PR) and stable disease (SD) were determined using RECIST 1.1.
Only evaluable patients as defined per the Actuate-1801 Master Protocol experiencing stable disease &ge;4 cycles of treatment are counted
as &ldquo;stable.&rdquo; Our management believes that 51.6% of patients in Actuate-1801 Part&nbsp;1 and 49.3% in Actuate-1801 Part&nbsp;2
with a response or stable disease that are able to stay on for at least four cycles of treatment is encouraging given the advanced and
treatment-refractory nature of their cancers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Figure 8. </I></B><I>Best overall response of elraglusib
as monotherapy (Part&nbsp;1) and in combination with chemotherapy (Part&nbsp;2) in Study Actuate-1801</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 33%">Outcome</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Elraglusib
    monotherapy&#8239; <BR>Part&nbsp;1 (N=62)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 33%; text-align: center">Elraglusib
    with chemotherapy <BR>Part&nbsp;2 (N=138)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OS,
    median (95% CI), month<SUP>a</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">7.7 (5.1, 9.7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">6.9 (5.7, 8.4)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PFS,
    median (95% CI), month<SUP>a</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">1.6 (1.3, 2.2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">2.1 (2.0, 2.6)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Best overall response, n (%)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Complete response</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">1 (1.6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">0 (0.0)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Partial response</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">1 (1.6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">7 (5.1)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Stable disease</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">24 (38.7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">57 (41.3)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Progressive disease</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">30 (48.4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">70 (50.7)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Not reported</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">6 (9.7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">4 (2.9)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Abbreviations: CI, confidence interval; OS,
overall survival; PFS, progression-free survival </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><SUP>a&#8239;&#8239;&#8239;&#8239;&#8239;</SUP>Using
Kaplan-Meier method</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> To further demonstrate
that elraglusib shows single agent anti-tumor activity, the maximal amount of tumor size reduction is shown by subject enrolled in Figure
9, below. 15/51 patients evaluated for response demonstrated tumor size reduction even if they did not reach a level of reduction associated
with a RECIST response. Our management believes that the reason for this response is the administration of elraglusib since it is the
only anticancer drug given in this part of the trial. Of the enrolled patients in Part&nbsp;1, sixteen patients had rapid clinical deterioration
related to their disease. These patients were unable to stay on treatment long enough to reach their first tumor assessment and are therefore
not included in the Part 1 analyses as per the protocol. Several tumor types are represented with clinical data in Part&nbsp;1 including
melanoma, colorectal, appendix, and lung, providing initial rationale for future studies in these cancer types. Management believes that
any benefit in this part of the trial may be due to elraglusib, as it was only cancer drug administered. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure&nbsp;9</B></FONT>.
<I>Best overall response in Actuate-1801 Part&nbsp;1.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tumor
tissues from both Actuate-1801 Part&nbsp;1 and Part&nbsp;2 were analyzed for the expression (presence) of GSK-3</FONT><FONT STYLE="font-family: Symbol">b
</FONT>using a validated immunohistochemical method. Archival and fresh pre-dose samples of tumor tissue were analyzed with 59.4% of
tumor samples in Part&nbsp;1 and &gt;80% of samples in Part&nbsp;2 immunostaining positive for GSK-3<FONT STYLE="font-family: Symbol">b</FONT>,
demonstrating that the target for elraglusib is present in a large portion of tumors across all the cancer types enrolled in this study.
Our management believes that this broad expression of GSK-3<FONT STYLE="font-family: Symbol">b </FONT>supports the development of elraglusib
in several different cancer types.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Actuate-1801 study was ongoing, studies in pre-clinical tumor models from several collaborating laboratories that were evaluating
elraglusib reported that elraglusib was also able to regulate expression of immune checkpoints such as PD-1/PD-L1, LAG-3 and TIGIT. The
data further credentialed GSK-3</FONT><FONT STYLE="font-family: Symbol">b </FONT>as a novel target for mediating anti-tumor immunity,
which had been reported by a number of groups over the past decade, and demonstrated the potential for immune checkpoint modulatory activity
for elraglusib. These were novel observations for elraglusib in addition to previously described roles in attenuating anti-apoptotic
activity, NF-<FONT STYLE="font-family: Symbol">k</FONT>B and DDR mediated drug resistance and enhancing chemotherapy and suggested that
elraglusib may inhibit tumor progression through multiple mechanisms of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Circulating
tumor cells isolated from a patient with adult T-cell leukemia/lymphoma (ATLL) in the Actuate-1801 study (Part&nbsp;1) who experienced
a durable PR (406 days) while on single agent elraglusib also exhibited robust cytokine changes when treated with elraglusib <I>ex vivo.
</I>Further, Huntington et al showed that <FONT STYLE="background-color: white">plasma from elraglusib-treated patients in the Actuate-1801
Part&nbsp;1 clinical study demonstrated reduced VEGF and BAFF and elevated IL-1</FONT></FONT><FONT STYLE="font-family: Symbol; background-color: white">b</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">,
CCL22, and CCL4 concentrations that correlated with </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">longer <FONT STYLE="background-color: white">survival.
Using paired tumor biopsies from patients in the Actuate-1801 study, Huntington et al also showed that tumor-infiltrating immune cells
had reduced expression of inhibitory immune checkpoints (VISTA, PD-1, PD-L2) and elevated expression of T-cell activation markers (CTLA-4,
OX40L) after elraglusib treatment. </FONT>Taken together, our management believes that these early studies further support elraglusib&rsquo;s
multimodal mechanism of action including immune modulation and inhibition of immune evasion. <FONT STYLE="background-color: white">Given
that a number of recent reports have highlighted that drugs that modulate anti</FONT>-<FONT STYLE="background-color: white">tumor immune
response may improve mOS with little or no effect on ORR, </FONT>we re-analyzed all the Actuate-1801 Part&nbsp;1 and 2 data with respect
to OS. In addition to simply looking at mOS (Figure 8), patient level OS evaluated by cancer type in Actuate-1801 Part&nbsp;1 is shown
in Figure 10.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
10. </I></B></FONT><I>Actuate-1801 Part&nbsp;1 OS by cancer type.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm247121d3_s1aimg005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <I>Green bar = lost to follow up, last known
alive date used to determine OS; dark blue bar: patient still on treatment; light blue bar: patient deceased.</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Safety in Actuate-1801 Part&nbsp;1 and
2</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In both Part(s)&nbsp;1
and 2, all patients experienced treatment-emergent adverse events (TEAEs). TEAE broadly encompass all adverse events observed while a
patient is on study and could be due to the drug or drugs (if used in combination), the disease or something specific to a particular
patient such as other diseases or illness. It is then up to individual clinical investigator to decide which toxicities are due to elraglusib.
The most common TEAEs attributed to elraglusib were transient visual disturbance and fatigue across both study parts, and the majority
of TEAEs that occurred in &ge; 20% of patients were reported as Grade 1 or 2 (Figure 11). Visual disturbance affected 50.7% of patients
(n=34/67) receiving elraglusib monotherapy and 60.8% of patients (n=104/171) receiving elraglusib with chemotherapy. Commonly reported
symptoms were darkened vision, where patients described lights as brighter and skin tones darker. Greater than 99% of visual disturbance
cases were reported as mild or moderate (Grade 1 or 2). These visual disturbances were considered dose-dependent, occurring more frequently
and lasting longer at higher doses. All cases of visual disturbance were transient, resolved completely, and lacked any associated retinal,
ocular, or systemic toxicity. Fatigue, while also observed in &ge; 20% of patients, was also reported as mild or moderate (Grade 1 or
2) and did not interfere with daily life. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
11. </I></B><I> Treatment-Emergent Adverse Events of Any Grade Reported in </I></FONT><I><FONT STYLE="font-family: Symbol">&sup3;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">20%
of Patients Treated with Elraglusib in Actuate 1801 Part 1 and 2.</FONT></I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Development Rationale Based on Actuate-1801
Part&nbsp;1 and 2</I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Most of the patients
enrolled in Part&nbsp;1 had advanced disease and &gt;75% were heavily pre-treated (Figure 6). Our management believes that the
number of patients with OS &ge; 8 months (approximately 35 weeks and close to Part 1 mOS of 7.7. months) is noteworthy when taking
into account that, like most Phase 1 trials, the inclusion criteria for this study only required a life expectancy of &ge;3 months
(Figure 10). Several meta-analyses have shown that active cancer agents used in the setting of heavily pre-treated Phase 1 patients
show mOS of 8-10 months depending on the study and agent. Similarly, an analysis of the Actuate-1801 Part&nbsp;2 data for OS shows
many subjects with OS &ge; 8 months (Figure 12) including several mOS that are close to or exceed this benchmark (Figure 13). While
it is difficult to make broad conclusions across multiple cancer types, our management believes that an evaluation of each cancer
type that was analyzed as shown in Figure 10 and Figures 12 and 13 will allow us to prioritize further development of elraglusib
based on the Actuate 1801-Part&nbsp;1 and 2 outcomes. For example, the pancreatic patients in Actuate 1801 Part 2 were all
pancreatic cancer patients that had previously failed GnP and had a dismal prognosis but nevertheless had good outcomes for this
patient population when rechallenged with the elraglusib plus gemcitabine/nab-paclitaxel (GnP) combination (mPFS =3.1 months;
mOS=5.6 months; Figure 13). Given that elraglusib plus GnP was well-tolerated in these pre-treated patients, the Company decided
that moving the elraglusib plus gemcitabine/nab-paclitaxel (GnP) combination into 1st line metastatic pancreatic cancer was
justified. Thus, previously untreated metastatic pancreatic cancer was chosen as a lead indication based on the Part&nbsp;2
outcome. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
12. </I></B></FONT><I>Actuate-1801 Part&nbsp;2 OS by chemotherapy basket</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg008.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <I>Green bar = lost to
follow up, last known alive date used to determine OS; dark blue bar: patient still on treatment; light blue bar: patient deceased.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Figure 13. </I></B><I>Actuate-1801 Part&nbsp;2 PFS and OS
by chemotherapy basket.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border: black 1pt solid; padding: 2.15pt 0.05in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chemotherapy
    backbone/Cancer Types</B></FONT> </TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2.15pt 0.05in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>mPFS
    (months)</B></FONT> </TD>
    <TD STYLE="width: 20%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 2.15pt 0.05in; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>mOS
    (months)</B></FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2.15pt 0.05in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Doxorubicin
                                            (N=10) </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Sarcoma &ndash; 5 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Ovarian &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Breast &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Adrenal gland &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Esophageal &ndash; 1 </P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT> </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2.15pt 0.05in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Irinotecan
                                            (N=34) </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Colorectal &ndash; 20 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Pancreas &ndash; 11 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Gastric &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Gallbladder &ndash; 1 </P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT> </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2.15pt 0.05in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Any
                                            carboplatin group (N=50) </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Lung &ndash; 10 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Ovarian &ndash; 7 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Esophageal &ndash; 4 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Head and Neck &ndash; 4 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Uterine &ndash; 3 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Liver &ndash; 3 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Colorectal &ndash; 3 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Breast &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Cervix &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Endometrial &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Mesothelioma &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Unknown &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Melanoma &ndash; 2 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Gallbladder &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Merkel Cell &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Pancreas &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Fallopian tube &ndash; 1 </P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT> </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2.15pt 0.05in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> GnP
                                            (N=27) </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Pancreas &ndash; 26 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Osteosarcoma &ndash; 1 </P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT> </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 2.15pt 0.05in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> Lomustine
                                            (N=14) </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> CNS &ndash; 6 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Glioblastoma &ndash; 5 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Astrocytoma &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Gliosarcoma &ndash; 1 </P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12pt"> Anaplastic oligodendroglioma &ndash; 1 </P></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT> </TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 2.15pt 0.05in; border-right: black 1pt solid; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Support for planned Phase
2 indications is provided by data extracted from Actuate-1801 Part&nbsp;1 in patients with metastatic melanoma. Actuate-1801 Part 1 enrolled
11 patients with metastatic melanoma who received only single agent elraglusib and demonstrated an mOS of 9.1 months, which compares
favorably to the mOS of 6.9 months for salvage chemotherapy in a similar patient population. Our management believes that we have potentially
identified a method for enriching patients diagnosed with metastatic melanoma that are refractory to checkpoint inhibitors but will benefit
from elraglusib. Patient selection and enrichment could improve the probability of success in a future Phase 2 trial in melanoma. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">These
11 Actuate-1801 Part 1 patients were refractory to several lines of treatment including immune checkpoint inhibitors and would typically
be candidates for chemotherapy salvage with an expected mOS of 6.9 months based on a meta-analysis of many different chemotherapy regimens
tested in the salvage setting in this patient population. In Actuate-1801 Part 1, one metastatic melanoma patient with widely metastatic
disease to the brain, lungs, bones, muscles, stomach, lymph nodes, pancreas and adrenal glands received Elraglusib Injection as a single
agent. This patient was refractory to all FDA-approved standard therapies, including several checkpoint inhibitors and a BRAF/MEK inhibitor.
This patient reported a partial response at 6 weeks and after 12 weeks on elraglusib, the patient&rsquo;s brain MRI showed complete response
(CR) by RANO criteria and a PET scan showed complete metabolic response (&ldquo;CMR&rdquo;) for other lesions. This patient continues
to have a durable CMR ongoing (&gt;5.0 years as of 2/1/2024) and continues to receive the drug.</FONT> A second melanoma patient who
received single agent elraglusib has ongoing stable disease (SD; 3.1 years as of last documented alive date). This patient also failed
all FDA-approved standard therapies including immune checkpoint inhibitors and several experimental treatments. This is an extraordinary
result and should not be considered representative of all patients or all outcomes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Figure 14. 12 weeks (4 cycles) on elraglusib leads to Complete
Metabolic Response by PET-MRI. Cystic lesions were observed in place of prior tumor.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm247121d3_s1aimg009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Similarly, Actuate-1801
Part&nbsp;2 data in the irinotecan chemotherapy basket identified metastatic colorectal (in combination with irinotecan) (Figure 13)
as another potential Phase 2 indication for elraglusib based on mOS=6.9 months for patients that were heavily pre-treated and refractory
to chemotherapy. This compares favorably with mOS &lt;3 months for this same patient population treated with salvage chemotherapy or
best supportive care. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Elraglusib
Oral Tablet Development in Metastatic Melanoma, Colorectal Cancer and Other Promising Indications Identified In 1801 Parts 1 and 2. </I>We
have been developing several oral dosage forms of elraglusib in addition to Elraglusib Injection that will potentially allow for further
exploration of dose and potentially allow us to evaluate elraglusib as a single agent and in combination with additional chemotherapy
backbones. We believe that we will be able to administer the Elraglusib Oral Tablet daily, which may allow the drug to achieve steady
state levels in plasma in patients that will allow for continuous inhibition of the target GSK-3 in tumor and tumor-associated cells.
Pre-clinical studies have shown that persistent exposure of tumor cells (&gt;12 hours but longer exposures work better) is required to
observe induction of apoptosis in these tumor cell line models. A comparison of plasma exposure at different doses of elraglusib in patients
in 1801 Part 1 (Figure 15) shows that exposures of elraglusib that surpass the target of 1 </FONT><FONT STYLE="font-family: Symbol">m</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">M
(the <I>in vitro</I> IC<SUB>50</SUB> in cell viability assays needs to exceeded for at least 12 hours to induce apoptosis in tumor cells)
are dose dependent and that 24 hour inhibition would only be expected at doses of 9.3 mg/kg and higher, whereas at 5 mg/kg, target levels
are exceeded for approximately 12 hours and at 3.3 mg/kg, for 4-6 hours. Thus, the active dose range of Elraglusib Injection is hypothesized
to be &ge;5 mg/kg. Our management believes that this is consistent with the clinical data for Part 1 (Figure 16) where a trend to longer
OS is observed at higher doses. As shown in Figure 2 and 3, both the liquid and solid oral dosage forms of elraglusib are highly bioavailable.
However, we have chosen to advance the Elraglusib Oral Tablet into clinical development based on an assessment of potential compliance,
convenience of use and taste that favor the Oral Tablet. GMP investigational product has already been manufactured and we are planning
a First in Human (FIH) Phase 1 clinical trial (Actuate-2401). We plan to initiate a dose escalation Phase 1 trial in patients with advanced
solid cancer to identify the MTD/RP2D for the Elraglusib Oral Tablet. Our development plan would then be to pursue Phase 2 indications
such as metastatic melanoma and metastatic colorectal cancer using the oral tablet.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Figure 15. Elraglusib Injection Achieves Sufficient Plasma
Exposure for Prolonged Inhibition of the GSK-3 Target as a Function of Dose</I></B> <B><I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm247121d3_s1aimg010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Figure 16. Overall survival by elraglusib dose level in part
1.</I></B> <B><I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg011.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our management believes
that there is sufficient clinical pharmacology data to support moving Elraglusib Oral Tablet into FIH studies. The plasma exposure (AUC24)
of elraglusib when given IV is 62,376 ng&bull;h/mL at the highest dose of Elraglusib Injection administered in Part 1. Given IV, elraglusib
plasma levels fall below active levels of drug after 24 hours. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In a dog toxicology study,
the oral drug has an AUC24 of 77,000 ng&bull;h/mL after a single 250 mg oral tablet and 137,000 ng&bull;h/mL after oral administration
of 500 mg (2 x 250 mg tablets) (Figure 3). The 500 mg dose was toxic and not tolerated by dogs but the 250 mg dose was well-tolerated
when given daily for 28 days in this exploratory study. Our management expects that steady state exposures of 77,000 ng&bull;h/mL or
greater will be possible with the Elraglusib Oral Tablet at well-tolerated doses in humans. We believe that this will allow for additional
opportunity to explore the antitumor activity of elraglusib with the oral tablet that could not be achieved with Elraglusib Injection.
The injection pairs well with GnP since both are given once per week but the oral tablet may be more amenable to use with other, less
convenient chemotherapies as well as a single agent. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Business Strategies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to available financing,
we intend to develop elraglusib in a broad list of advanced cancer indications, initially in patients with refractory disease and with
an initial focus on metastatic pancreatic cancer. Our portfolio consists of two product candidates, Elraglusib Injection and Elraglusib
Oral Tablet, which we believe will provide us with two different dosage forms of drug with different attributes that will allow us to
tailor each dosage form to a specific cancer type to potentially improve outcomes and compliance. Key elements of our strategy to accomplish
this objective include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <B><I>Build
                                            a sustainable oncology company. </I></B>Our goal is to build a leading oncology company with
                                            a sustainable pipeline of target indications revolving around a patented, active product
                                            candidate, elraglusib, that can be delivered in different ways to potentially treat a wide
                                            variety of cancers. To accomplish this, we are focused on rapid advancement of our currently
                                            active clinical trials while curating and preparing additional indications for future expansion
                                            of elraglusib development. This effort is led by Daniel Schmitt, our chief executive officer
                                            and founder, and Dr.&nbsp;Andrew Mazar, our scientific co-founder and chief operating officer,
                                            who have more than 60 years of combined experience in the management of biotechnology companies
                                            and healthcare investing.&nbsp;&nbsp;Mr.&nbsp;Schmitt has led and contributed to the successful
                                            development and launch of multiple pharmaceutical and health technology products and executed
                                            over approximately $1 billion in milestone value through licensing, acquisition, and development
                                            deals. Dr.&nbsp;Mazar has founded seven start-ups and is the co-founder and former chief
                                            scientific officer and director, of Monopar Therapeutics,&nbsp;Inc. (Nasdaq: MNPR) as well
                                            as the former chief scientific officer of Attenuon, LLC. Dr.&nbsp;Mazar has shepherded eleven
                                            drugs from discovery stage through Phase 2 and Phase 3 trials. Our board of directors, or
                                            Board, is comprised of experienced entrepreneurs, scientists, and investors in the biotechnology
                                            industry<B><I>.</I></B> </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance
        our lead product candidate, elraglusib, through clinical trials. </I></B></FONT>We have generated clinical data from over 500
        patients that have been dosed with elraglusib to date. Under the innovative seamless study design of our Actuate-1801 Phase 1/2
        clinical trial (<B><I>Figure 5:&nbsp;</I></B><I>Actuate-1801 Master Protocol study design</I>), we have initiated a Phase 2 trial
        testing Elraglusib Injection in combination with chemotherapy in pancreatic cancer under this Master protocol (Actuate-1801 Part
        3A). We are also advancing an opportunity in Ewing Sarcoma as part of the Actuate-1902 Phase 1/2 study in pediatric refractory
        malignancies. Currently, the Phase 1 portion of the Actuate-1902 study is closed to accrual and we are working to amend the Phase
        2 portion of this trial to focus on Ewing Sarcoma. We also intend to explore strategically identified investigator-initiated
        trials (IIT) that may identify additional indications and standard of care products to combine with elraglusib in indications
        that go beyond those already identified in Actuate 1801-Part 1 and 2, which allows us to further leverage our pipeline in a molecule.
        By collaborating with our network of oncology KOLs we anticipate partnering to access non-dilutive funding for our IITs through
        both Federal (e.g. NIH) and non-federal (e.g. cancer-specific foundations, pharma partners) sources.
        For example, Actuate collaborated with Dr. Colin Weekes to obtain Lustgarten Foundation grant support for the IIT currently being
        run at MGH. Actuate provides financial and resource support for IITs in exchange for rights to the trial data, but Actuate has
        no control over or input into the design or conduct of an IIT.&nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Advance
        our lead product candidate, elraglusib, by obtaining regulatory development incentives to accelerate path to approval. </I></B></FONT>One
        of our strategic objectives is to obtain development incentives in the United States and in other countries that we believe may
        accelerate our path to drug approval: Orphan Drug Designation, Fast-Track designation and Breakthrough Therapy Designation (BTD)
        in the United States; Orphan and priority medicines (PRIME) designations in the EU; and Orphan designations in Japan and Australia.
        There is no guarantee that any such designation, if received, will actually lead to a faster development, regulatory review or
        approval process.&nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Explore
    strategic partnerships that can accelerate and maximize the potential of GSK-3 inhibitors.</I></B></FONT> <FONT STYLE="font-size: 10pt">We
    will evaluate potential strategic (pharma) partnering opportunities which could further help us to accelerate development of elraglusib
    by providing expertise, guidance, and funding to expand the pipeline into different tumors and other diseases areas that could benefit
    from GSK-3 inhibitor therapy, as discussed above. We may also broaden the reach of our platform by selectively in-licensing technologies
    or novel product candidates. In addition, we will consider potentially out-licensing certain geographic rights to elraglusib or other
    product candidates in our target indications or for indications and industries that we are not currently pursuing ourselves.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"> <B><I>Leverage
                                            our academic and research partnerships. </I></B>We are actively engaging with regulators,
                                            KOLs, advocates and other stakeholders early and throughout the development process in each
                                            cancer indication being considered for development to enhance the probability of technical
                                            success.&nbsp;&nbsp;We currently have clinical partnerships with investigators conducting
                                            IITs with elraglusib at MGH, UPMC, and DFCI and we expect to expand these pending additional
                                            funding to explore indications beyond pancreatic cancer.&nbsp;&nbsp;&nbsp;We also have a
                                            research and development collaboration with Lantern Pharma to leverage their artificial intelligence
                                            platform to further understand the effects of elraglusib and identify patient subtypes that
                                            are particularly susceptible to GSK-3 inhibition. We expect to continue to leverage these
                                            partnerships and establish others to hone and expand our research and development efforts. </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Developing Elraglusib for the Treatment of
mPDAC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Phase 2 trial was initiated
in patients with mPDAC that had not previously been treated with any systemic chemotherapy including GnP (first line study) building
on the results of Actuate-1801 Part&nbsp;2 as described above. By moving our development into the first line setting, we increase our
ability to deliver the elraglusib plus GnP combination to many more patients since more than 70% of patients with mPDAC never go on to
a second treatment once they have progression on first line treatment. In addition, our management believes that the safety profile of
elraglusib/GnP provides a strong basis for testing this combination in first line patients. We also received a number of commercialization
incentives (e.g. orphan-drug designation, Fast-Track) through registration for mPDAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Actuate-1801 Part&nbsp;3A</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
first Phase 2 study (Actuate-1801 Part&nbsp;3A) was initiated under the Actuate-1801 Master Protocol in patients with metastatic pancreatic
cancer that had not previously received systemic treatment for their metastatic disease (first line setting). This was a single arm exploratory
study using disease control rate (DCR), defined as the proportions of patients achieving stable disease &ge;16 weeks, confirmed CR, or
confirmed PR according to RECIST v1.1 criteria, as the primary endpoint for the study. Secondary endpoints consisted of OS, TEAEs, and
other endpoints of response typical for Phase 2 cancer trials (NCT03678883). Several analysis populations were also defined for the study.
The modified intention to treat (mITT) population consisted of patients who received at least one dose of elraglusib, gemcitabine, or
nab-paclitaxel. The efficacy evaluable (EE) population consisted of patients who had at least 1 post-baseline efficacy assessment while
receiving study treatment. Patients who discontinued</FONT> due to disease progression or elraglusib-related toxicity prior to having
an efficacy assessment were also included. In Part&nbsp;3A, the EE was pre-defined as the efficacy analysis population and the mITT was
the safety population. The elraglusib dose was started at the RP2D evaluated in Part&nbsp;2 (15 mg/kg, two times per week).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The original study design
proposed to enroll 23 consecutively evaluable patients that met the definition for the EE. These patients could be replaced at the discretion
of the data monitoring committee (IDMC). Consequently, six patients were replaced such that the EE=29 patients. No new safety signals
were observed with the elraglusib/GnP combination, but investigators observed that GnP toxicities may have occurred earlier and may have
been more intense in some patients than would be anticipated for GnP alone. For these reasons, the dose of elraglusib was proactively
reduced near the end of the study to 9.3&nbsp;mg/kg 2X/week, with the final four patients enrolled being treated at this dose. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
17. </I></B></FONT><I>Response of patients with mPDAC treated with elraglusib in combination with gemcitabine and nab-paclitaxel in Part&nbsp;3A
(data cut 3/2023).</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Response</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EE
    population<BR>
    (N=29)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CR, n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 (6.9)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PR, n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 (31)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SD &ge;16 weeks, n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4 (13.8)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SD &lt;16 weeks, n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11 (37.9)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progressive disease, n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 (10.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disease
    control rate (CR+PR+SD &ge;16 weeks), n (%)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15 (51.7)<BR>
    95% CI: (32.5, 70.6)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mPFS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4 months (4.9 months ITT)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mOS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3 months (11.9 months
    ITT)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abbreviations:
CI, confidence interval; EE, efficacy evaluable</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Tumor responses for Part&nbsp;3A
(which met the Simon&rsquo;s Stage 1 threshold of DCR&ge;50%) are shown in Figure 17. The mOS for the EE and ITT were 15.3 months and
11.9 months, respectively. These compare favorably with the mOS for GnP alone of 8.5 months in the MPACT trial or more recently 9.2 months
in NAPOLI-3, which evaluated irinotecan liposomal injection (Onivyde) compared to GnP, in the first line mPDAC setting. The elraglusib
mOS of 11.9 months for the ITT also compares favorably with the mOS of 11.2 months for FOLFIRINOX, the other first line regimen used
for patients with mPDAC or more recently with irinotecan liposomal injection (Onivyde) (mOS=11.1 months). The FDA recently approved irinotecan
liposomal injection (Onivyde) for the treatment of mPDAC based on the mOS=11.1 months in the NAPOLI-3 trial. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Actuate-1801 Part&nbsp;3B</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to Actuate-1801 Part&nbsp;3A, Actuate-1801 Part&nbsp;3B was also initiated under the Actuate-1801 Master Protocol in patients with mPDAC
that had not previously received systemic treatment for their metastatic disease. This study was designed as a randomized, controlled
study with a run-in to explore dosing schedule by comparing two different schedules of elraglusib/GnP (once weekly vs. twice weekly)
in the hope of potentially providing clinical support for moving to a more convenient, commercially viable elraglusib schedule. Pharmacokinetics
were also included in this study to address the potential for drug-drug interactions (DDI) between elraglusib and gemcitabine or nab-paclitaxel.
Management believes that confirmation of the Actuate-1801 Part&nbsp;3A result in an adequately powered, randomized study, would compare
favorably with the recently approved irinotecan liposomal injection and would complement the other first line regimens currently used
to treat mPDAC and provide a basis for approval for use </FONT>in patients with mPDAC that had not previously received systemic treatment
for their metastatic disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actuate-1801 Part&nbsp;3B
enrolled its first patients in October&nbsp;2021 and the run-in part of the trial demonstrated the weekly elraglusib was equivalent to
twice weekly elraglusib. All patients randomized to the elraglusib/GnP arm now receive weekly elraglusib in addition to GnP. The trial
accrued more readily than projected and enrollment was completed in January&nbsp;2024. An interim analysis is planned when the trial
achieves 50% of events in the GnP control arm and then again at 70% (for top line analysis). The primary endpoint was recently changed
to OS from a 1-year OS landmark but the analysis is unchanged (Kaplan-Meier). OS was previously a secondary endpoint and it has now been
promoted to primary to simplify regulatory discussions. The sample size calculation was based on the 1-year survival rate of 55% from
the Actuate-1801 Part&nbsp;3A study compared to a 35% historical one-year survival. The sample size needed to show this difference at
a two-sided alpha of 0.05 is 232 patients with 80% power. However, the formal hypothesis testing was always planned to compare the overall
survival between elraglusib/GnP to GnP alone and will be based on a nonparametric log-rank test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Part&nbsp;3B has now completed
accrual and due to interest in the study and a rapid increase in accrual from November&nbsp;2023 through January&nbsp;2024, has accrued
285 patients. It is too early to perform any comparative analysis between the elraglusib/GnP and GnP arms of the study. However, patients
in this study are showing some reduction of tumor burden in the elraglusib/GnP arm of the study (Figure 18). A swim plot showing survival
for both treatment arms in the mITT population (all patients who received at least one dose of drug) is shown in Figure 19. As noted,
a large number of patients are still on treatment (bars with arrows). Interim safety data is shown in Figure 20. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
18. </I></B></FONT><I>Actuate-1801 Part&nbsp;3B BOR response to date (for patients where tumor measurement data is available).</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm247121d3_s1aimg012.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg013.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
19. </I></B></FONT><I>Actuate-1801 Part&nbsp;3B OS-mITT swim plot</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg014.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Figure
20. </I></B><I>Treatment-Emergent Adverse Events of Any Grade Reported in </I></FONT><I><FONT STYLE="font-family: Symbol">&sup3;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">20%
of Patients Treated with Elraglusib (31Dec2023) in Actuate 1801 Part 3B (ongoing)</FONT></I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm247121d3_s1aimg015.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>** Includes PT terms anemia and hemoglobin decreased; ***Includes
PT terms thrombocytopenia and platelet count decreased; *Includes PT terms neutropenia and neutrophil count decreased </I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> This is an open-label
study and we and our collaborators have viewed the patient data throughout the study, which means the study could not be used to support
accelerated approval based on surrogate endpoints. However, there are administrative analyses planned for this study. PFS and OS will
be evaluated when 50% of events have been reached in the GnP arm of the study. We have projected a late second quarter of 2024 analysis
date for PFS and OS based on anticipated events in the GnP control arm. We plan to perform topline analysis when &gt;70% of events for
progression and survival have been reached in the GnP arm. We anticipate these will occur in late fourth quarter of 2024 to the first
quarter of 2025. Management expects that topline data will then be available in the first quarter of 2025 based on enrollment of the
last patients in the study in February 2024. We plan to disclose the results of these studies as they become available. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Summary of Investigator-Initiated Trials</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition to the company
sponsored trials referenced above, elraglusib is currently being evaluated in three IITs. We track serious adverse events (SAEs) in these
trials and report these to our IND. These trials are listed here (Figure 21) for awareness only and the IIT investigators have not yet
shared data from these studies. However, we will receive all final data from these studies, which are considered exploratory and may
inform future development of elraglusib. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 03 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Figure
21. </I></B></FONT><I>Elraglusib studies to date-studies conducted under investigator INDs</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; width: 6%; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IND#</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 5%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 14%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NCT
    # / Sponsor</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 21%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Title</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 16%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dosing
    Regimen</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 12%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt; text-indent: 0.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Study
    Population</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 5%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FVFP<SUP>1</SUP></B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 8%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Planned
    Enrolment</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 13%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Patients / Study Status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.15pt; padding-left: 4.3pt; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">156280 </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NCT05010629</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Glenn J. Hanna, MD</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3&beta;) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9-ING-41 is administered by intravenous infusion twice weekly in combination with carboplatin administered once every 21 days</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adults with incurable, recurrent or metastatic salivary gland carcinomas</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sep 2021</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35 subjects</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total: 23 / enrolment and treatment is ongoing</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.15pt; padding-left: 4.3pt; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157852</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NCT05239182</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Anwar Saeed, MD</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3-beta (GSK-3&beta;) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Gemcitabine/Nab-Paclitaxel as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9-ING-41 is administered by intravenous infusion twice weekly in combination with GnP on Days 1, 8 and 15 and with retifanlimab on Day 1 of a 28-day cycle.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adults with pancreatic cancer who have not received any prior systemic therapy for advanced disease</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feb 2022</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32 subjects</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total: 7 / enrolment and treatment is ongoing</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.15pt; padding-left: 4.3pt; text-indent: -4.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157435</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NCT05077800</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Colin D. Weekes, MD</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Phase 2 Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 &beta;) Inhibitor 9-ING-41 and the Transforming Growth Factor-&beta; (TGF-&beta;) Inhibitor Losartan in Patients With Untreated Metastatic Adenocarcinoma</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9-ING-41 is administered by intravenous infusion twice weekly in combination with FOLFIRINOX administered once every 14 days and daily losartan </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adults with untreated metastatic pancreatic adenocarcinoma</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 2022</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70 subjects</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.15pt; padding-left: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total: 25 / enrolment and treatment is ongoing</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
FVFP=First Visit First Patient</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The annual incidence of pancreatic
cancer is expected to exceed 66,000 patients in the United States this year. Approximately 70% of these patients will present with mPDAC.
The mOS in patients with mPDAC is 9-11 months and our management believes that the ability to extend survival by even a few months would
be considered meaningful in this patient population. Elraglusib has been granted Fast Track and orphan drug designations from the FDA
for pancreatic cancer in the United States. Based on our meetings with the FDA to discuss our development plan in pancreatic cancer, the
current Phase 2 study design cannot be used to support accelerated approval. However, if the future OS data is positive in favor of the
elraglusib/GnP combination we would initiate further discussion with the FDA to discuss registration for accelerated approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Two additional exploratory
single arm Phase 2 studies are ongoing, subject to receipt of the proceeds of this offering, in patients with pancreatic cancer evaluating
novel drug combinations with elraglusib: the combination of elraglusib/FOLFIRINOX/losartan in patients with mPDAC and the combination
of elraglusib/GnP/retinfanlimab in patients with advanced PDAC. Both studies are academic IITs that are exploring the addition of immunomodulatory
drugs to an elraglusib/chemotherapy backbone. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing elraglusib
in patients with mPDAC that have not previously received systemic treatment for their metastatic disease. Due to lack of early symptoms,
approximately 80-90% of all patients with pancreatic cancer are unresectable and not able to be able to be treated with surgery, and present
with advanced or metastatic disease. 80-90% of PDAC cases do not have a high mutational burden. However, frequent mutations in KRAS and
TP53 confer a survival benefit on pancreatic tumors, making PDAC chemo-resistant and often refractory to chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Current first-line therapies
for mPDAC consist of FOLFIRINOX, GnP or irinotecan liposomal injection given with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX).
NALIRIFOX was recently approved (February&nbsp;13, 2024) and may provide an alternative to FOLFIRINOX with a better safety profile. FOLFIRINOX
is a combination of four drugs: folinic acid, fluorouracil, irinotecan, and oxaliplatin. Fluorouracil (5-FU) is a nucleoside analog that
prevents the replication of DNA, which is essential for dividing cells. Folinic acid enhances 5-FU activity. Irinotecan and oxaliplatin
inhibit DNA uncoiling and repair, respectively. Gemcitabine is also a nucleoside analog with a similar mechanism to 5-FU. Paclitaxel interferes
with the normal dynamics of the cellular cytoskeleton, which interferes with DNA segregation and cell division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The mOS in mPDAC patients
is 11.1 months for NALIRIFOX, 11.2 months with FOLFIRINOX and 8.5-9.2 months with GnP respectively in the first-line setting. NALIRIFOX
demonstrated superiority to GnP in the NAPOLI-3 trial (mOS 11. 1 vs 9.2 months). However, safety profiles between these three chemotherapy
backbones are quite different: FOLFIRINOX leads to higher rates of neutropenia and nausea, NALIRIFOX has more gastrointestinal and constitutional
toxicity such as nausea, diarrhea and fatigue, and GnP treatment leads to increased myelosuppression and neurotoxicity. An analysis of
an insurance claims database indicated that first line treatment from 2014-2018 was split between FOLFIRINOX and GnP. Our management believes
it is too early to predict how NALIRIFOX will fit into clinical use in patients with mPDAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Development Plan for Elraglusib Injection in mPDAC</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the conclusion of Actuate-1801
Part&nbsp;3B, we expect to have survival data on the elraglusib plus GnP combination in patients with mPDAC that had not previously received
systemic treatment for their metastatic disease. At the completion of this study, we plan to meet with FDA and discuss the design and
execution of a Phase 3 registration study, if justified by the results of Actuate-1801 Part&nbsp;3B. In addition, we plan to discuss the
use of the Actuate-1801 Part&nbsp;3B data for regulatory support and to support registration if the study achieves its primary endpoint
of showing improved survival over GnP alone. We have also been granted a parallel EMA-HTAb scientific advice meeting in October 2024 to
discuss a priority medicine (PRIME) designation and conditional approval in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Developing Elraglusib for the Treatment of
Ewing Sarcoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Actuate-</I></B></FONT><B><I>1902 Pediatric Cancer Phase 1/2 Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An estimated 9,620 children
(ages 0-14 years) and 5,280 adolescents (ages 15-19 years) are expected to be diagnosed with cancer in the United States in 2024. It is
also estimated that 1,040 children and 550 adolescents will die from the disease in the United States in 2024. While death rates for pediatric
and adolescent cancers have declined by more than 50% over the last five decades due to improved treatment options, there is still room
for improvement. Despite the improved survival offered by current therapies, approximately 40% of childhood cancer survivors have severe,
life-threatening or fatal complications within 30 years of diagnosis and up to 90% of survivors will have a chronic health condition by
the age of 45. These long-term effects are related to the type of treatment used such as chemotherapy and radiation which can have a material
adverse impact on developing organs. Work is ongoing to determine how to more effectively identify underlying mechanisms of pediatric
cancers in an effort to develop and administer more targeted, more effective and less toxic treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Based on extensive preclinical
work in pediatric malignancies showing excellent synergy between elraglusib and standard of care chemotherapy in neuroblastoma, sarcoma,
glioma and others, we initiated a Phase 1 study to determine the safety of elraglusib +/- chemotherapy in pediatric patients with refractory
malignancies in 2020. The dose escalation part of the study assigned patients to elraglusib alone, elraglusib/irinotecan or elraglusib/cyclophosphamide
and topotecan (CT). The RP2D was confirmed as 15 mg/kg twice weekly and additional patients were added to the elraglusib/irinotecan or
elraglusib/CT to explore initial signals of anticancer activity. As of February&nbsp;2, 2024, 36 patients had been enrolled and received
at least one dose of elraglusib. No serious adverse events were observed with elraglusib monotherapy at the first two dose levels. One
patient treated with elraglusib in combination with chemotherapy showed a Grade 4 hypotension/infusion reaction. Six patients (26.1%)
achieved stable disease and a patient with refractory, metastatic Ewing Sarcoma had a radiographic and pathologic CR after 3 cycles of
elraglusib/CT. Recently, a second CR was observed in a 5-year-old boy with treatment resistant neuroblastoma that has completed 9 cycles
of elraglusib in combination with CT. Upon determination of RP2D for monotherapy and combinations, we had originally intended to initiate
a Phase 2 study in neuroblastoma. However, recently approved anti-GD2 antibodies have shown considerable improvement of response rate,
PFS, and survival making development in this population much more challenging. Based on the response from the Ewing Sarcoma patient,
six additional patients with metastatic, refractory Ewing and Ewing-like sarcoma were enrolled in the elraglusib/CT arm. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> All seven Ewing patients
enrolled in our Actuate-1902 trial appear to have metastatic disease and had disease progression prior to joining the study despite previous
chemotherapy and radiation (4/7 patients had received two or more previous chemotherapy regimens). There are currently no known treatment
regimens that meaningfully extend life in Ewing sarcoma patients with metastatic, refractory disease. All patients received the combination
of elraglusib and cyclophosphamide/topotecan. The Ewing patient with the CR described above stopped all treatments after 4 months to
return to school and continues to be in complete remission with no evidence of disease almost 2 years after termination of treatment.
A second Ewing patient had a partial response with 52% reduction of tumor and a third patient has a partial response with 96% reduction
in tumor and complete disappearance of non-target lesions. Two additional Ewing patients have stable disease as the best overall response,
one patient had progressive disease, and one patient withdrew from treatment prior to evaluation of response. Four (4/7) patients remain
alive and three continue on treatment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Development Plan in Ewing Sarcoma</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The five years survival rate for patients that have recurrent
(relapsed) disease is &lt;30%. Patients that are refractory and have metastasis and disease progression despite two or more chemotherapy
regimens have very short survival of 3-8 months. There are currently no treatment regimens that meaningfully extend life in Ewing sarcoma
patients with metastatic, refractory disease. We believe that this exploratory Ewing sarcoma data is sufficiently positive in this orphan
pediatric cancer indication to consider additional development in Ewing sarcoma. The Actuate-1902 study is currently still active but
closed to accrual. If we have sufficient funding from the proceeds of this offering, we plan to amend the Phase 2 portion of the Actuate-1902
protocol to include only those patients with Ewing sarcoma. The proposed primary endpoint would be overall response rate (ORR), with
an initial efficacy readout in approximately 12-18 months from commencement. We anticipate that the study would be designed using a Simon&rsquo;s
two-stage design with an objective response (ORR) success endpoint that could be achieved in this time frame. This design is based on
the objective responses seen in the small cohort of Ewing patients enrolled in Actuate-1902 and will be benchmarked against the recently
published ORR in the rEECur phase 3 trial of 21% for CT to establish a success threshold for our study. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in the process of engaging
with the pediatric sarcoma community to discuss potential registration trials in the United States and the EU if Phase 2 is positive.
Given that Ewing Sarcoma is a very rare pediatric cancer, an international consortium of investigators and sites will be needed to advance
this program to registration. In addition, we plan to pursue a number of development incentives including orphan drug, Fast-track, a pediatric
rare disease waiver in the United States and parallel programs in the EU. The ability to engage in further development in pediatric cancers
will depend on our ability to raise sufficient capital through this offering or otherwise to support this path. We believe that pursuing
this development could be an efficient and rapid path to registration in the United States and Marketing Authorization in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Northwestern University License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The exclusive worldwide
rights to materials and non-exclusive rights to certain know-how relating to the use for therapeutic, diagnostic and commercial research
purposes of elraglusib and related compounds in cancer and combination therapies are licensed to us by NU pursuant to that certain royalty-free
license agreement between us and NU, dated March&nbsp;31, 2015, as amended on April&nbsp;29, 2019 (as amended, the NU License Agreement). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Pursuant to the NU License
Agreement, NU granted us (i)&nbsp;a nonexclusive license to certain technical information developed in the laboratory of Dr.&nbsp;Mazar,
and (ii)&nbsp;an exclusive license to all results obtained by Dr.&nbsp;Mazar and his collaborators at NU on the use of the GSK-3&beta;
inhibitor 9-ING-41 and related compounds used for the treatment of cancer and combination therapies. No patent rights are licensed by
us under the NU License Agreement. The term of the NU License Agreement continues in effect, unless earlier terminated by NU due to our
making a general assignment for the benefit of creditors, initiation of bankruptcy proceedings by or against us or the appointment of
a receiver or trustee to take possession of our property, or by either party following 90 days&rsquo; notice of a material breach of
the NU License Agreement that is not then cured. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of the license
granted by NU, we issued 50,000 shares of our common stock to NU, which represented 5% of our then-outstanding fully-diluted shares and
agreed to customary confidentiality and progress update obligations and to indemnify NU for any claims arising from our use of the licensed
rights under the NU License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>University of Illinois-Chicago Exclusive
License Agreement with Equity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The exclusive rights to
Patent Rights (as defined in the UIC License Agreement and described further below) and Technical Information (as defined in the UIC
License Agreement) surrounding GSK-3 inhibitors for Neurodegenerative Disorders were licensed through an Exclusive License Agreement
with Equity between us and UIC, dated April&nbsp;6, 2015, as amended on April&nbsp;24, 2019 (as amended, the UIC License Agreement).
Under the UIC License Agreement, the Patent Rights relate to certain patents relating to 3-Benzofuranyl-4-Indolyl Maleimides, the last
of which is scheduled to expire on March 16, 2028, not including any PTE, which we may apply for under Title II of the Drug Price Competition
and Patent Term Restoration Act of 1984 (&ldquo;Hatch-Waxman&rdquo;), 35 U.S.C. &sect;156. The following summarizes the key terms set
forth in the UIC License Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the UIC License Agreement, UIC granted us (i)&nbsp;an exclusive, nontransferable license, with the right to sublicense under UIC&rsquo;s
rights in the Patent Rights, and (ii)&nbsp;a non-exclusive, non-transferable license, with the right to sublicense, to use UIC&rsquo;s
rights in the Technical Information within the specified territory (which is where the Patent Rights exist for such rights and worldwide
for the Technical Information) for all uses other than rights reserved by UIC for non-commercial purposes, including teaching, research
and public service and publishing information included in the Patent Rights and the Technical Information. The term of the UIC License
Agreement continues in effect until the later of (x) expiration of the last to expire of the Patent Rights, (y) notice from us that the
use of the Technical Information has ceased, and (z) the expiration of the last form of market exclusivity for products using the licensed
technology. The UIC License Agreement may also be earlier terminated by UIC in the event of certain breaches of its terms that are not
cured following a notice period or initiation of bankruptcy proceedings by or against us or the imposition of any lien or encumbrance
on the licensed technology. We may also terminate in the UIC License Agreement</FONT> for any reason following 90 days&rsquo; notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
consideration of the license granted under the UIC License Agreement, we issued 83,750 shares of our common stock to UIC, which represented
5% of our capital stock on a fully diluted basis as of as defined in the UIC License Agreement, and agreed to pay UIC (i)&nbsp;development
milestones of up to $1.3 million, of which, up to $0.3 million is due upon the progress of clinical trials and $1.0 million is due upon
the initiation of commercial sales (ii)&nbsp;annual minimum royalty payments of $5,000 beginning on the three-year anniversary of the
UIC License Agreement and increasing to $15,000 in year four, $35,000 in year five, and $50,000 in year six and thereafter, (iii)&nbsp;royalty
on net sales for product covered under the Patent Rights in the low single digits with a 50% reduction in royalties for products solely
utilizing Technical Information, (iv)&nbsp;a declining percentage of sublicensing revenue based on the escalating stage of development
upon a sublicensing event, and (v)&nbsp;the reimbursement of all patent and related expenses incurred by UIC covering the Patent Rights.</FONT>
We also agreed to customary confidentiality and progress update obligations, to indemnify UIC for any claims arising from our use of the
licensed rights under the NU License Agreement and to certain co-sale and piggy-back registration rights with respect to the shares of
our common stock issued to UIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The UIC License Agreement
obligates us or a sublicensee to commercialize the licensed technology, including to achieve the development events specified in the agreement,
including progress through clinical trials and achieving commercialization. UIC may also identify feasible uses of the licensed technology
and, unless we demonstrate that we are pursuing such development or is not feasible within a specified period, UIC may terminate the UIC
License Agreement or the exclusivity of the licensed rights. As of the date hereof, we have met all existing milestones as provided for
in the UIC License Agreement. We are also responsible for the prosecution and maintenance of the licensed patents, at our expense and
using commercially reasonable efforts. We have the sole right to enforce the licensed patents, at our expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company has
an obligation to UIC related to a sub-license and collaboration agreement dated August&nbsp;28, 2017 with an unrelated entity, which agreement
was later terminated on January&nbsp;31, 2018. Under the agreement, the Company initially paid UIC a portion of the sublicense fees in
the amount of $44,999 with the remaining unpaid balance due and payable to UIC in two installments with 50% due and payable on the one-year
anniversary from the first commercial sale and the remaining balance is due on the second-year anniversary from the first commercial sale.
The unpaid balance of $404,991 as of December&nbsp;31, 2023 and 2022 continues to accrue interest at a rate of 5% per annum, representing
the prime rate as of the date of the agreement plus 1%. Interest payable to UIC was $130,041 and $86,400 as of December&nbsp;31, 2023
and 2022, respectively, and is included in the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property<SUP></SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December&nbsp;31,
2023, we own or have licensed 76 issued patents and pending patent applications worldwide, two pending international Patent Cooperation
Treaty (PCT) patent applications and one U.S. provisional patent application, which are material to the programs described below. Three
issued patents worldwide and no pending patent applications are owned by UIC, which have granted us exclusive license rights to the technology.
Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important
to the development of our business. We seek U.S. and foreign patent protection for a variety of technologies. We also intend to seek
patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and
identify and develop novel products. We seek protection, in part, through confidentiality and proprietary information agreements. We
are a party to various other license agreements that give us rights to use specific technologies in our research and development. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hold an exclusive license
for the portfolio of GSK-3&beta; inhibitors developed in a collaboration between UIC and NU. This intellectual property portfolio is exclusively
licensed through two licensing agreements between us and each UIC and NU, as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In particular, as discussed
below, we rely on the patents as critical to our development. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> With respect to our elraglusib
program, as of March 31, 2024, we own or exclusively in-license three patent families focused on the elraglusib molecule and/or related
compounds. The exclusively in-licensed patent family for elraglusib and related compounds (the original patent in-licensed from UIC)
includes one granted U.S. patent, one granted European patent and one granted Canadian patent, which are directed to 3-Benzofuranyl-4-Indolyl
Maleimides compounds. The U.S. patent is expected to expire in 2028. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Actuate subsequently discovered
that elraglusib exists as one of only two polymorphs and filed composition of matter patents covering both polymorphs. The patent family
covering &ldquo;Polymorph I&rdquo; is based on PCT/US2018/046203 9-ING-41 Polymorph I Composition of Matter and includes one granted
U.S. patent (US 11,136,334), one granted patent in each of Australia, Europe (with validation in 19 countries), Japan, and Mexico, one
non-provisional U.S. patent application, an expired PCT patent application, and pending patent applications in Australia, Brazil, Canada,
China, Israel, Japan, Mexico, South Korea and South Africa, which are directed to a polymorph of a GSK-3&beta; inhibitor, compounds,
pharmaceutical compositions, methods of preparing and uses for treating cancers. The U.S. patent is expected to expire in 2038. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The patent family we own
that covers elraglusib &ldquo;Polymorph II&rdquo; is based on PCT/US2018/056083 9-ING-41 Polymorph II Composition of Matter and includes
one granted U.S. patent (US 11,407,759), one granted patent in each of China, Mexico and Macao, one non-provisional U.S. patent application,
an expired PCT patent application and pending patent applications in Australia, Brazil, Canada, European Patent Office, Israel, Japan,
Mexico, South Korea and South Africa, which are directed to a polymorph of a GSK-3&beta; inhibitor, compounds, pharmaceutical compositions,
methods of preparing and uses for treating cancers. The U.S. patent is expected to expire in 2040. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We intend to file additional
patent applications for the liquid and solid formulations of these elraglusib compositions covering the liquid and solid oral dosage
forms of elraglusib that we expect to develop. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The term of individual
patents depends upon the legal term of the patents in the countries in which they are obtained. In the United States, the patent term
is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent&rsquo;s term may be
shortened if a patent is terminally disclaimed over another patent or as a result of delays in patent prosecution by the patentee, and
a patent&rsquo;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO
in granting a patent. Patent term may also be extended up to five years due to regulatory delay. We may apply for PTE under Title II
of Hatch-Waxman. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to continue to regularly
assess opportunities for seeking patent protection for those aspects of our discoveries in the clinic, technology, designs and methodologies
that we believe provide a meaningful competitive advantage. However, because patent filings can be time-consuming and expensive, our ability
to do so may be limited until such time as we are able to generate cash flow from operations or otherwise raise sufficient capital to
continue to invest in our intellectual property. For example, maintaining patents in the United States and other countries requires the
payment of maintenance fees which, if we are unable to pay, may result in loss of our patent rights. If we are unable to do so, our ability
to protect our intellectual property or prevent others from infringing our proprietary rights may be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We work with a third-party
manufacturer to support the manufacturing of elraglusib for clinical studies and our research activities and, if we receive regulatory
approval, we intend to rely on such third party for commercial manufacture. We do not own or operate, and currently have no plans to establish,
any manufacturing facilities. We currently obtain our supplies from this manufacturer on a purchase order basis and do not have any long-term
supply agreements in place. In order to de-risk our supply chain, and as we advance toward potential commercialization, we may enter into
long-term supply agreements as well as evaluate additional product manufacturing sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Elraglusib in Actuate-1801
Part&nbsp;1 and 2 has shown the ability to combine with components of GnP, and FOLFIRINOX/NALIRIFOX (irinotecan, platinums). We are presently
developing elraglusib combined with GnP for first line mPDAC but the ongoing IIT (Figure 13) will provide exploratory data on the elraglusib/FOLFIRINOX
combination which would also provide a rationale for combining elraglusib with NALIRIFOX in the clinic. mPDAC patients either have primary
resistance to these chemotherapy backbones (e.g., do not respond at all when treated to these chemotherapy backbones) or develop resistance
quickly (responses with GnP, FOLFIRINOX and NALRIFOX are transient and not very durable). Our management believes that elraglusib may
improve outcomes in first line mPDAC regardless of the chemotherapy backbone used, although the clinical data does not yet support this
hypothesis. Nevertheless, as either GnP or FOLFIRINOX are used to treat &gt;90% of patients with mPDAC and there is potential for combining
elraglusib with either of these chemotherapy backbones based on Actuate-1801 Parts 1 and 2, our management believes that elraglusib has
the potential to treat a large segment of patients diagnosed with mPDAC. Thus, our plan is to develop elraglusib in combination with the
present first line chemotherapy regimens used in the treatment of mPDAC, as exemplified by its lead program of elraglusib/GnP and later
moving to combinations with either FOLFIRINOX or NALIRIFOX pending results of the IITs. If shown to be clinically active, elraglusib chemotherapy
combinations could eventually be used to treat a large segment of mPDAC patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Several other targeted
therapies are also being evaluated in mPDAC but these are all being tested for the treatment of small subpopulations of mPDAC. There
are many studies combining immune checkpoint inhibitors, PARP inhibitors, various chemotherapies and certain RAS inhibitors in patients
with mPDAC. However, other targeted agents besides elraglusib are only able to target a low percentage of mPDAC patients. Ongoing studies
with other targeted agents in mPDAC are generally non-randomized at one or a limited number of sites, are too early to assess for commercial
potential and would not be considered as a competitor to elraglusib because of their lack of broad suitability for most mPDAC patients.
For example, the PARP inhibitor Lynparza (olaparib) was recently approved as a maintenance therapy as it has been shown to significantly
improve PFS and duration of response in patients with BRCA-mutated mPDAC that have not progressed following first-line platinum-based
chemotherapy. However, BRCA mutations are only present in 4-7% of all PDAC patients. Olaparib is currently being evaluated as a therapeutic
intervention in combination with a checkpoint inhibitor, pembrolizumab, in patients with mPDAC in BRCA1 mutated patients.&#9;Similarly,
the RAS mutation targeted by clinical RAS inhibitors is only present in a low percentage of all PDAC and thus, of the current PDAC inhibitors
available in the clinic, few PDAC patients would be expected to benefit from their treatment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Thus, the vast majority
of mPDAC patients still do not have an approved targeted therapy that can treat their tumor. If successful, we believe the elraglusib/chemotherapy
combination would introduce the first broadly targeted agent, elraglusib, as a treatment option for patients with mPDAC and would have
the potential to treat the majority (80-90%) of patients with mPDAC. A review of clinicaltrials.gov reveals that there are very few randomized
studies for any novel drug or drug combination (not just targeted) in previously untreated patients with mPDAC: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Onivyde
                                            (Ipsen Pharmaceuticals)-Recently approved for 1st line mPDAC when used as part of the NAIRIFOX
                                            regimen based on a survival improvement of 1.9 months (NALRIFOX 11.1 months vs GNP 9.2 months). </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">SBP-101 (Panbela Therapeutics, Inc.)-A randomized, double-blind, placebo-controlled, multicenter study
of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for mPDAC.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #171716; background-color: white">Zolbetuximab (IMAB362)-A phase 2, open-label, randomized study to assess the
efficacy and safety of zolbetuximab (imab362) in combination with nab-paclitaxel and gemcitabine as first line treatment in subjects with
claudin 18.2 (cldn18.2) positive,&nbsp;</FONT>metastatic<FONT STYLE="color: #171716; background-color: white">&nbsp;</FONT>pancreatic<FONT STYLE="color: #171716; background-color: white">&nbsp;adenocarcinoma.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; color: #171716"><FONT STYLE="background-color: white">There
are very few drugs in late stage clinical development for mPDAC and this may reflect the rapid accrual experienced in Actuate-1801 Part
3B, which accrued ahead of schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> There are several treatments
in development for locally advanced or mPDAC. The tables below focus on select first line treatments that are in clinical trials in mPDAC.
Quite a few of these are very early stage and therefore little information is available on clinical activity to date. With the initial
success of biomarker driven and targeted therapies, there is an effort to test additional targeted agents in mPDAC patients to determine
if there is any synergy with standard chemotherapy regimens in the first line setting. For instance, KRAS is mutated in over 90% of PDAC
patients and there are several KRAS targeted agents in development; however, several agents are specifically targeting the G12C mutation
which only accounts for 1-2% of KRAS mutations in PDAC. Other agents are being tested in KRAS mutant cancers more broadly by targeting
other MAPK pathway members such as MEK and ERK1/2, though treatment-related toxicity has been reported with these agents. Additionally,
these MAPK targeted agents are currently being evaluated in second-line and later settings. In the future, targeted/ immunotherapy agents
may be able to be combined or used in series to provide a more flexible and tailored therapeutic approach for each individual patient.
Additionally, the multifaceted and differentiated mechanism of action of elraglusib is likely to be synergistic with both cytotoxic and
immunomodulatory therapeutics that may be approved in the future. Our management believes that this potential for combining elraglusib
with future multi-therapy regimens is also feasible given elraglusib&rsquo;s favorable safety profile as a single agent. Mechanistically,
some of the targets inhibited by competitors e.g., KRAS intersect with the GSK-3 pathways and provide a rationale for potentially prioritizing
these combinations with elraglusib. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of <FONT STYLE="background-color: white">December&nbsp;31,
2023, we had five regular full-time employees, four of whom were engaged in research and development activities, and seven contract workers,
four of whom were engaged in research and development activities. </FONT>We currently have nine full-time employees that manage and oversee
all aspects of our pre-clinical and clinical development. In addition, we currently work with numerous  highly experienced consultants
and contractors that provide management and oversight in manufacturing, analytical, clinical supply chain, regulatory, pharmacovigilance
and safety, clinical operations, data management, statistics, non-clinical toxicology, nonclinical and clinical pharmacology, and medical
affairs. Thus, we currently operate as a semi-virtual pharmaceutical company with expertise in numerous aspects of preclinical and clinical
development. Many of our consultants and contractors have extensive experience specifically in the development of cancer drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">None
of our employees are represented by a labor union, and we believe we maintain good relations with our</FONT> employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our human capital resources
objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors
and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the
granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating
such individuals to perform to the best of their abilities and achieve our objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located in Fort Worth, Texas, utilizing space made available by our largest investor for administrative purposes. We are working on
entering into a lease for office space to establish a new headquarters in the Chicago, Illinois area. We believe that our current arrangement
and plans to establish our new headquarters location are sufficient to meet our needs for the foreseeable future and that any additional
space we may require will be available on commercially reasonable terms. All research and development activities are undertaken at CROs
or with academic collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation and Product Approval</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities in
the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research,
development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical
product candidates that we develop must be approved by the U.S. Food and Drug Administration (FDA) before they may be legally marketed
in the United States. See &ldquo;Risk Factors &ndash; Risks Related to Clinical Development and Regulatory Approval&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Pharmaceutical Product Development
Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates pharmaceutical products under the Federal Food, Drug and Cosmetic Act (FDCA) and implementing regulations. Pharmaceutical
products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process,
approval process or after approval, may subject an applicant to administrative or judicial enforcement. FDA noncompliance enforcement
could include a refusal to review and or approve pending applications, withdrawal of an approval, a clinical study hold, warning letters,
product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties. Any regulatory enforcement action could have a material adverse effect
on us. The process required by the FDA before a non-biological pharmaceutical product may be marketed in the United States generally involves
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory
Practices (GLP), and other applicable regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Submission of an Investigational New Drug application (IND), which must become effective before human
clinical studies may begin;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Conduct of adequate and well-controlled human clinical studies according to current Good Clinical Practices
(GCP), to establish the safety and efficacy of the proposed pharmaceutical product for its intended use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> Submission
                                            to the FDA of an NDA for a new pharmaceutical product; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical
product is produced to assess compliance with current Good Manufacturing Practice standards (cGMP), to assure that the facilities, methods
and controls are adequate to preserve the pharmaceutical product&rsquo;s identity, strength, quality and purity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Potential FDA inspection of the preclinical and clinical study sites that generated the data in support
of the NDA; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">FDA review and approval of the NDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The lengthy process of seeking
required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial
resources and approvals are inherently uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before testing any pharmaceutical
product with potential therapeutic value in humans, the pharmaceutical product candidate enters the preclinical testing stage. Preclinical
tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential
safety and activity of the pharmaceutical product candidate. These early studies are conducted using sound scientific procedures and require
thorough documentation. The conduct of a single and repeat dose toxicology and toxicokinetic studies in animals must comply with federal
regulations and requirements including GLP. The pharmaceutical product sponsor must submit the results of the preclinical tests, together
with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA
as part of the IND. The IND becomes effective 30 days after receipt by the FDA, unless the FDA has concerns and notifies the sponsor.
In such a case, the IND sponsor must resolve any outstanding concerns before the clinical study can begin. If resolution cannot be reached
within the 30-day review period, the FDA can place the IND on clinical hold or the sponsor may withdraw the application. The FDA may also
impose clinical holds on a pharmaceutical product candidate at any time before or during clinical studies due to safety concerns or regulatory
non-compliance. Accordingly, it is not certain that submission of an IND will result in the FDA allowing clinical studies to begin, or
that, once begun, issues will not arise that can lead to suspension or termination of such clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the development of
a new drug, sponsors are given opportunities to meet with the FDA to discuss progress. These meetings may occur prior to submission of
an IND, at the end of Phase 2 clinical development, and before an NDA is submitted. Meetings at other times may be requested. These meetings
can provide an opportunity for the sponsor to share information about the data gathered to date, for the sponsor to ask specific questions
of the FDA, for the FDA to provide advice, and for the sponsor and FDA to reach agreement on the next phase of development. Sponsors typically
use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical (registration)
trial(s)&nbsp;that they believe will support approval of the new drug. A sponsor may be able to request a Special Protocol Assessment
(SPA), the purpose of which is to reach agreement with the FDA on the Phase 3 clinical trial protocol design and analyses that will form
the primary basis of an efficacy claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Conducting Clinical Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical studies are voluntary
research studies involving the administration of the pharmaceutical product candidate to healthy volunteers or patients under the supervision
of qualified investigators, typically physicians independent of the clinical study sponsor&rsquo;s control. Clinical studies are conducted
according to protocols detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion
criteria, how the results will be analyzed and presented and the parameters to be used to monitor subject safety. Each protocol must be
submitted to the FDA as part of the IND. Clinical studies must be conducted in accordance with GCP requirements. Further, each clinical
study must be reviewed and approved by an independent institutional review board (IRB), at, or servicing, each institution at which the
clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and is tasked with considering
such items as whether the safety risks to individuals participating in the clinical studies are minimized and are reasonable in relation
to anticipated benefits. The IRB approves the informed consent that must be provided to each clinical study subject or his or her legal
representative and will also monitor the clinical study to ensure patient safety until completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical studies are
typically conducted in three sequential phases that may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Phase 1. The pharmaceutical product is initially administered to healthy volunteers and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Phase 2. The pharmaceutical product is studied in a limited patient population with the disease or condition
to evaluate its effectiveness for a particular indication or indications and to determine the common short-term side effects and risks
associated with the product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Phase 3. Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an
expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall
risk/benefit of the product and provide an adequate basis for product labeling. The studies must be well- controlled and usually include
a control arm for comparison. One or two Phase 3 studies may be required by the FDA for an NDA, depending on the disease severity and
other available treatment options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Post-approval studies, or Phase 4 clinical studies, may be conducted after initial marketing approval.
These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Progress reports detailing the results of the clinical studies must be submitted at least annually to
the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or
any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical
studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring
board may suspend a clinical study at any time on various grounds, including a finding that the research subjects or patients are being
exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if
the clinical study is not being conducted in accordance with the IRB&rsquo;s requirements or if the pharmaceutical product has been associated
with unexpected serious harm to patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical studies,
companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the pharmaceutical product as well as finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the pharmaceutical product candidate
and, among other things, must include methods for testing the identity, strength, quality and purity of the final pharmaceutical product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the pharmaceutical
product candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>U.S. Review and Approval
Processes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of product development,
preclinical studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry
of the pharmaceutical product, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting
approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may
be obtained under certain limited circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the Pediatric
Research Equity Act (PREA), an NDA or a supplement thereof must contain data to assess the safety and effectiveness of the pharmaceutical
product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.
Unless otherwise required by regulation, PREA does not apply to any pharmaceutical product for an indication for which orphan designation
has been granted. The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than
accepting an NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the goals
and policies agreed to by the FDA under the Prescription Drug User Fee Act (PDUFA), the FDA has 10 months in which to complete its initial
review of a standard NDA and respond to the applicant, and six months for a priority NDA. The FDA does not always meet its PDUFA goal
dates for standard and priority NDAs. The review process and the PDUFA goal date may be extended by three months if the FDA requests or
if the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission
within the last three months before the PDUFA goal date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After the NDA submission is
accepted for filing, the FDA reviews the NDA application to determine, among other things, whether the proposed product is safe and effective
for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s
identity, strength, quality and purity. The FDA may refer applications for novel pharmaceutical products or pharmaceutical products which
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the
pharmaceutical product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (REMS), is necessary
to assure the safe use of the pharmaceutical product. If the FDA concludes that a REMS is needed, the sponsor of the NDA must submit a
proposed REMS; the FDA will not approve the NDA without a REMS, if required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before approving an NDA, the
FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product
within required specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, before approving
an NDA, the FDA will typically inspect one or more clinical study sites to assure compliance with GCPs. If the FDA determines the application,
manufacturing process or manufacturing facilities, or clinical study sites are not acceptable, it will outline the deficiencies in the
submission and often will request additional testing or information. In addition, the FDA will require the review and approval of product
labeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NDA review and approval
process is lengthy and involved and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may
require additional clinical data or other data and information. Even if such data and information are submitted, the FDA may ultimately
decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and the
FDA may interpret data differently than the sponsor interprets the same data. The FDA will issue a complete response letter if the agency
decides not to approve the NDA. The complete response letter usually describes all of the specific deficiencies in the NDA identified
by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional
clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the complete
response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If
a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the
letter, or withdraw the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product receives regulatory
approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited,
which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions
be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical studies designed to further
assess pharmaceutical product safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved
products that have been commercialized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Expedited Development and
Review Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has a Fast Track program
that is intended to expedite or facilitate the process for reviewing new pharmaceutical products that meet certain criteria. Specifically,
new pharmaceutical products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. The Fast Track designation must be requested by the sponsor.
Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. With a Fast
Track designated product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted,
if the sponsor provides a schedule for the submission of the sections of the NDA, if the FDA agrees to accept sections of the NDA and
determines that the schedule is acceptable and if the sponsor pays any required user fees upon submission of the first section of the
NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product submitted to the
FDA for marketing approval, including a Fast Track program, may also be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential
to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment,
diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation
of an application for a new pharmaceutical product designated for priority review in an effort to facilitate the review. Additionally,
a product may be eligible for accelerated approval. Pharmaceutical products studied for their safety and effectiveness in treating serious
or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval,
which means that the products may be approved on the basis of adequate and well-controlled clinical studies establishing that the product
has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical
endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a pharmaceutical
product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, the FDA currently
requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the
commercial launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval
but may expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Breakthrough Therapy Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA is also required to
expedite the development and review of the application for approval of drugs that are intended to treat a serious or life-threatening
disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate
may request that the FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after,
the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for breakthrough therapy designation
within 60 days of receipt of the sponsor&rsquo;s request. Elraglusib IV and elraglusib oral dosage forms may all be eligible for breakthrough
therapy designation depending on the indication and pending additional data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Orphan Drug Designation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer than 200,000 individuals
in the United States, or in other limited cases. Orphan drug designation (ODD) provides for seven years of market exclusivity, independent
of patent protection, to the company with ODD that brings a particular product to market. In addition, companies developing orphan drugs
are eligible for certain incentives, including tax credits for qualified clinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To gain exclusivity, if a
product that has ODD subsequently receives the first FDA approval for the disease or condition for which it has such designation, the
product is entitled to the orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same
active moiety for the same indication for seven years, except in limited circumstances, such as another drug&rsquo;s showing of clinical
superiority over the drug with orphan exclusivity. In addition, doctors may prescribe products for off-label uses and undermine our exclusivity.
Orphan drug exclusivity could block the approval of one of our product candidates for seven years if a competitor obtains approval for
the same active moiety for the same indication before we do, unless we are able to demonstrate that our product is clinically superior.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor may request ODD
of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that
is otherwise the same product as an already approved orphan drug may seek and obtain ODD for the subsequent product for the same rare
disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first, approved product.
More than one sponsor may receive ODD for the same product for the same rare disease or condition, but each sponsor seeking ODD must file
a complete request for designation, and only the first sponsor that obtains approval for that drug for the orphan indication will obtain
market exclusivity, effectively preventing the FDA from approving products under development by competitors for the same drug and same
indication, unless the competitor is able to demonstrate that the product under development is clinically superior to the approved product
or the approved product is not available in sufficient quantities. To permit the FDA to end another manufacturer&rsquo;s orphan exclusivity
period, the FDA must determine that the manufacturer has demonstrated clinical superiority by showing the later drug is safer, more effective,
or otherwise makes a major contribution to patient care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The period of exclusivity
begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has
been designated. The FDA may approve a second application for the same product for a different use or a subsequent application for a different
drug for the same indication. ODD neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage
in the regulatory review or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We may plan to pursue
ODD and exclusivity for some of our product candidates in the United States, the EU, and other geographies of interest for specific products.
We cannot guarantee that we will obtain ODD for any products in any jurisdiction. Even if we are able to ODD for a product, we cannot
be sure that such product will be approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we
will be able to maintain any exclusivity that is granted. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulation Outside the United States</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market a pharmaceutical
product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries
and jurisdictions regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing authorization, commercial
sales and distribution. Whether or not we obtain FDA approval for a pharmaceutical product, we would need to obtain the necessary approvals
by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries
or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing
and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from
and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory
approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the
regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Regulation and Marketing
Authorization in the EU</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Medicines Agency
(EMA) is the scientific agency of the EU that coordinates the evaluation and monitoring of new and approved medicinal products such as
drugs and biologics. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development
of technical guidance and the provision of scientific advice to sponsors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process regarding approval
of medicinal products in the EU follows roughly the same lines as in the United States and likewise generally involves satisfactorily
completing each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with
the applicable EU Good Laboratory Practice regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">submission to the relevant regulatory agencies in EU member states, or national authorities, of a clinical
trial application (CTA) for each clinical trial, which must be approved before human clinical trials may begin;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the
product for each proposed indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">submission to the relevant national authorities of a Marketing Authorization Application, (MAA), which
includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in
clinical development and proposed labeling;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility
or facilities, including those of third parties, at which the product is produced to assess compliance with cGMP;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">potential audits of the non-clinical and clinical trial sites that generated the data in support of the
MAA; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">review and approval by the relevant national authority of the MAA before any commercial marketing, sale
or shipment of the product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Preclinical Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical tests include
laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential efficacy and toxicity
in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant EU regulations
and requirements. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted
as part of the CTA when seeking approval to start a clinical trial, and with the MAA when seeking marketing authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Clinical Trial Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Requirements for the conduct
of clinical trials in the EU including GCP, are implemented in the currently Clinical Trials Directive 2001/20/EC and the GCP Directive
2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical trials in the
EU has been implemented through national legislation of the EU member states. Under this system, approval must be obtained from the competent
national authority in which a trial is planned to be conducted, or in multiple member states if the clinical trial is to be conducted
in a number of member states. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier
(IMPD) and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable guidance documents.
Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial
application in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January&nbsp;31, 2022,
the Clinical Trials Regulation (EU) No.&nbsp;536/2014 repealed the Clinical Trials Directive 2001/20/EC. To ensure that the rules&nbsp;for
clinical trials are identical throughout the EU, the Clinical Trials Regulation (EU) No.&nbsp;536/2014 was passed as a regulation which
is directly applicable in all EU member states. The Clinical Trials Directive 2001/20/EC will, however, still apply three years from the
date of entry into application of the Clinical Trials Regulation to (i)&nbsp;clinical trials applications submitted before the entry into
application and (ii)&nbsp;clinical trials applications submitted within one year after the entry into application if the sponsor opts
for the old system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulation (EU) No 536/2014
aims to simplify and streamline the approval of clinical trial in the EU. The main characteristics of the regulation include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a streamlined application procedure via a single entry point, known as the Clinical Trials Information
System;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a single set of documents to be prepared and submitted for the application as well as simplified reporting
procedures which will spare sponsors from submitting broadly identical information separately to various and different national authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">strictly defined deadlines for the assessment of clinical trial application; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the involvement of the ethics committees in the assessment procedure in accordance with the national law
of the member state concerned but within the overall timelines defined by the Regulation (EU) No 536/2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Marketing Authorization</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Authorization to market a
product in the member states of the EU proceeds under one of four procedures: a centralized procedure, a mutual recognition procedure,
a decentralized procedure or a national procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Centralized Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure
enables applicants to obtain a marketing authorization that is valid in all EU member states based on a single application. Certain medicinal
products, including products developed by means of biotechnological processes must undergo the centralized authorization procedure for
marketing authorization, which, if granted by the European Commission, based on the opinion of the EMA, is automatically valid in all
EU member states. Sponsors may elect to file an MAA through the centralized procedures for other classes of products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure
is mandatory for certain types of products such as, medicines derived from biotechnology processes such as genetic engineering, advanced-therapy
medicines such as gene-therapy or tissue engineered medicine, orphan medicines, and medicinal products containing a new active substance
indicated for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative disorders, autoimmune and other immune dysfunctions, and
viral diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized authorization
procedure is optional for other medicinal products if they contain a new active substance, if the applicant shows that the medicinal product
concerned constitutes a significant therapeutic, scientific or technical innovation, or that the granting of authorization is in the public
interest of the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Administration Procedure</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized procedure,
the EMA&rsquo;s Committee for Human Medicinal Products (CHMP) serves as the scientific committee that renders opinions about the safety,
efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed of experts nominated by each member
state&rsquo;s national authority for medicinal products, with one of them appointed to act as Rapporteur for the co-ordination of the
evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s)&nbsp;continue
to monitor the product throughout its life cycle. The CHMP has 210 active days, to adopt an opinion as to whether a marketing authorization
should be granted. The process usually takes longer in case additional information is requested, which triggers clock-stops in the procedural
timelines. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of
experts. When an application is submitted for a marketing authorization in respect of a drug which is of major interest from the point
of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may, pursuant to Article&nbsp;14(9)&nbsp;Regulation
(EC) No 726/2004, request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced
to 150 days, but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure if it considers that
it is no longer appropriate to conduct an accelerated assessment. Once the procedure is completed, a European Public Assessment Report
(EPAR) is produced. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. After the
adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission, after consulting the EU member states,
which in total can take more than 60 days. After a drug has been authorized and launched, it is a condition of maintaining the marketing
authorization that all aspects relating to its quality, safety and efficacy must be kept under review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Conditional Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In specific circumstances,
EU legislation (Article&nbsp;14(7)&nbsp;Regulation (EC) No.&nbsp;726/2004 and Regulation (EC) No.&nbsp;507/2006 on Conditional Marketing
Authorizations for Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining
the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted
for products (including medicines designated as orphan medicinal products), if&thinsp; (1)&nbsp;the risk-benefit balance of the product
is positive, (2)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data,
(3)&nbsp;the product fulfills unmet medical needs, and (4)&nbsp;the benefit to public health of the immediate availability on the market
of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing
authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect
to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations
are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need
for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply
with respect to the review by the CHMP of applications for a conditional marketing authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Marketing Authorization
Under Exceptional Circumstances</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As per Article&nbsp;14(8)&nbsp;Regulation
(EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with the requirements laid down in
Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation) might be eligible
for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess the risk-benefit
balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under exceptional circumstances
is aimed at the provision of information on the safe and effective use of the product and will normally not lead to the completion of
a full dossier/approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Pediatric Studies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to obtaining a marketing
authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation
Plan (PIP) covering all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a
class waiver, or (3)&nbsp;a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing
authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement also applies
when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized.
The Pediatric Committee of the EMA (PDCO) may grant deferrals for some medicines, allowing a company to delay development of the medicine
in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when
development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before a marketing authorization
application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with
the agreed studies and measures listed in each relevant PIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Period of Authorization
and Renewals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
will be valid for five years in principle, and the marketing authorization may be renewed after five years on the basis of a re-evaluation
of the risk-benefit balance by the EMA or by a national authority. To this end, the marketing authorization holder must provide the EMA
or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations
introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid.
Once renewed, the marketing authorization will be valid for an unlimited period, unless the European Commission or the national authority
decides on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization that is
not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing
member state within three years after authorization will cease to be valid, the so-called &ldquo;sunset clause.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Orphan Drug Designation
and Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Commission can
grant orphan medicinal product designation to products for which the sponsor can establish that it is intended for the diagnosis, prevention,
or treatment of&thinsp;(1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 people
in the EU, or (2)&nbsp;a life threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives
it is unlikely that sales of the drug in the EU would generate a sufficient return to justify the necessary investment. In addition, the
sponsor must establish that there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition,
or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ODD
</FONT>provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized
EU marketing authorization, as well as 10 years of market exclusivity following a marketing authorization. During this market exclusivity
period, neither the EMA, nor the European Commission nor the Member States can accept an application or grant a marketing authorization
for a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and
which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may be
reduced to six years if, at the end of the fifth year, it is established that the ODD criteria are no longer met, including where it is
shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, a competing similar medicinal
product may be authorized prior to the expiration of the market exclusivity period, including if it is shown to be safer, more effective
or otherwise clinically superior to the already approved orphan drug or if the holder of the marketing authorization for the already approved
orphan drug is unable to supply sufficient quantities of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the MAA of a medicinal
product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed PIP, and a corresponding
statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity will be extended
to twelve years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Regulatory Data Protection</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EU legislation also provides
for a system of regulatory data and market exclusivity. Upon receiving marketing authorization, new chemical entities approved on the
basis of complete independent data package benefit from eight years of data exclusivity and an additional two years of market exclusivity.
Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&rsquo;s data to assess a generic or biosimilar
(abbreviated) application. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization
can be submitted, and the innovator&rsquo;s data may be referenced, but no generic or biosimilar medicinal product can be marketed until
the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first
eight years of those 10 years, the marketing authorization holder (MAH) obtains an authorization for one or more new therapeutic indications
which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with
existing therapies. Even if a compound is considered to be a new chemical entity and the innovator is able to gain the period of data
exclusivity, another company nevertheless could also market another version of the drug if such company obtained marketing authorization
based on an MAA with a complete independent data package of pharmaceutical test, preclinical tests and clinical trials. However, products
designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years of orphan market exclusivity.
Depending upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years&rsquo;
supplementary protection certificates (SPCs). Such SPCs extend the rights under the basic patent for the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Regulatory Requirements
After a Marketing Authorization Has Been Obtained</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain authorization
for a medicinal product in the EU, we will be required to comply with a range of requirements applicable to the manufacturing, marketing,
promotion and sale of medicinal products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will, for example, have
to comply with the EU&rsquo;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and
additional monitoring obligations can be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other requirements relate
to, for example, the manufacturing of products and active pharmaceutical ingredients in accordance with good manufacturing practice standards.
EU regulators may conduct inspections to verify our compliance with applicable requirements, and we will have to continue to expend time,
money and effort to remain compliant. Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements
related to the development of products for the pediatric population, can also result in significant financial penalties in the EU. Similarly,
failure to comply with the EU&rsquo;s requirements regarding the protection of individual personal data can also lead to significant penalties
and sanctions. Individual EU member states may also impose various sanctions and penalties in case we do not comply with locally applicable
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing of authorized
drugs, for which a separate manufacturer&rsquo;s license is mandatory, must be conducted in compliance with the EMA&rsquo;s cGMP requirements
and comparable requirements of other national authorities, which mandate the methods, facilities and controls used in manufacturing, processing
and packing of drugs to assure their safety and identity. The EMA enforces its cGMP requirements through mandatory registration of facilities
and inspections of those facilities. The EMA may have a coordinating role for these inspections while the responsibility for carrying
them out rests with the member states competent authority under whose responsibility the manufacturer falls. Failure to comply with these
requirements could interrupt supply and result in delays, unanticipated costs and lost revenues, and could subject the applicant to potential
legal or regulatory action, including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive
action or possible civil and criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketing and promotion
of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs
and/or the general public, are strictly regulated in the EU. The applicable regulations aim to ensure that information provided by holders
of marketing authorizations regarding their products is truthful, balanced and accurately reflects the safety and efficacy claims authorized
by the EMA or by the national authority of the authorizing member state. Failure to comply with these requirements can result in adverse
publicity, warning letters, corrective advertising and potential civil and criminal penalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Healthcare Laws</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to FDA restrictions
on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain business
practices in the biopharmaceutical industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Anti-Kickback Statute of
1972</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal Anti-Kickback
Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in
return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable
under Medicare, Medicaid, or other federally financed healthcare programs. The term &ldquo;remuneration&rdquo; has been broadly interpreted
to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments
of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute
has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary
managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and a company&rsquo;s practices may not in all cases meet all of
the criteria for statutory exemptions or safe harbor protection. Practices that involve remuneration that may be alleged to be intended
to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor.
Several courts have interpreted the statute&rsquo;s intent requirement to mean that if any one purpose of an arrangement involving remuneration
is to induce referrals of federal healthcare covered business, the statute has been violated. The reach of the Anti-Kickback Statute was
also broadened by the Patient Protection and Affordable Care Act (PPACA), which, among other things, amends the intent requirement of
the federal Anti-Kickback Statute. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of
this statute or specific intent to violate it in order to have committed a violation. In addition, the PPACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false
or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute, which imposes
penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the
person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>False Claims Act of 1986</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal False Claims Act
prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Recently,
several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers
with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing
false claims to be submitted because of the companies&rsquo; marketing of the product for unapproved, and thus non-reimbursable, uses.
Many states also have statutes or regulations similar to the federal Anti-Kickback Statute and False Claims Act, which state laws apply
to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Health Insurance Portability
and Accountability Act of 1996</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA created new federal
criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private
third-party payers and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious
or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Because of the breadth
of these laws and the narrowness of the federal Anti-Kickback Statute&rsquo;s safe harbors, it is possible that some of a company&rsquo;s
business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect
on a company&rsquo;s business, financial condition and results of operations. See &ldquo;Risk Factors &ndash; Risks Related to Commercialization
of Our Product Candidates&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Health Information Technology
for Economic and Clinical Health Act of 2009</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA, as amended by HITECH
and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable
health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security standards directly applicable to &ldquo;business
associates&rdquo;&mdash;independent contractors or agents of covered entities that receive or obtain protected health information in connection
with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against
covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions
for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&rsquo;s fees and costs associated with
pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and may not have the same effect, complicating compliance efforts. See &ldquo;Risk
Factors &ndash; Risks Related to Commercialization of Our Product Candidates&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Medicare Prescription
Drug,&nbsp;Improvement and Modernization Act of 2003 (MMA)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and foreign
jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system, in particular, there have been
and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. The MMA, imposed
new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries
may enroll in prescription drug plans offered by private entities, which will provide coverage of outpatient prescription drugs. Part&nbsp;D
plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans.
Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. Part&nbsp;D prescription drug plan sponsors are not required
to pay for all covered Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover
and at what tier or level. However, Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and
class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&nbsp;D
prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Moreover, while the MMA applies only to
drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their
own payment rates. Any reduction in payment that results from Medicare Part&nbsp;D may result in a similar reduction in payments from
non-governmental payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The American Recovery and
Reinvestment Act of 2009</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The American Recovery and
Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same
illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research
and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be
made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public
or private payers, it is not clear what effect, if any, the research will have on the sales of any product, if any such product or the
condition that it is intended to treat is the subject of a study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Physician Payments Sunshine
Act of 2010</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The federal Physician Payments
Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp;
Medicaid Services (CMS) information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable
manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians
and their immediate family members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Patent Protection and Affordable
Care Act of 2010</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March&nbsp;2010, the PPACA
was enacted, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers.
Among the provisions of the PPACA of importance to the pharmaceutical and biotechnology industry are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">extension of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals
who are enrolled in Medicaid managed care organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer
Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at
or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing manufacturers&rsquo; Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing
program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">new requirements under the federal Open Payments program, created under Section&nbsp;6002 of the PPACA
and its implementing regulations, that manufacturers of drugs, devices, biologics and medical supplies for which payment is available
under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions) report annually to the U.S. Department
of Health and Human Services (HHS), information related to &ldquo;payments or other transfers of value&rdquo; made or distributed to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and that applicable manufacturers
and applicable group purchasing organizations report annually to HHS ownership and investment interests held by physicians (as defined
above) and their immediate family members, with data collection required beginning August&nbsp;1, 2013 and reporting to CMS, required
by March&nbsp;31, 2014 and by the 90th day of each subsequent calendar year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a requirement to annually report drug samples that manufacturers and distributors provide to physicians,
effective April&nbsp;1, 2012;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">expansion of health care fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute,
new government investigative powers, and enhanced penalties for noncompliance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a licensure framework for follow-on biologic products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">creation of the Independent Payment Advisory Board which, beginning in 2014, will have authority to recommend
certain changes to the Medicare program that could result in reduced payments for prescription drugs and those recommendations could have
the effect of law even if Congress does not act on the recommendations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery
models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January&nbsp;1, 2011.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Budget Control Act of 2011</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August&nbsp;2011, the President
signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction, or
joint committee, to recommend proposals in spending reductions to Congress. The joint committee did not achieve its targeted deficit reduction
of at least $1.2 trillion and for the years 2013 through 2021, triggering automatic reductions to several government programs. These reductions
include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>American Taxpayer Relief
Act of 2012</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January&nbsp;2013, the
President signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers
and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These
new laws may result in additional reductions in Medicare and other healthcare funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Patent Term Restoration
and Marketing Exclusivity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Depending upon the timing,
duration and specifics of the FDA approval of the use of our pharmaceutical product candidates, some of our products to be licensed under
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984,
commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permits a patent restoration term of up to five years
as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND and the submission date of an NDA or Biologics License Application
(BLA) plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to
an approved pharmaceutical product is eligible for the extension and the application for the extension must be submitted prior to the
expiration of the patent. The U.S. Patent and Trademark Office (USPTO), in consultation with the FDA, reviews and approves the application
for any PTE or restoration. Market exclusivity provisions under the U.S. Food, Drug, and Cosmetic Act can also delay the submission or
the approval of certain applications of other companies seeking to reference another company&rsquo;s NDA or BLA. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Biologics Price Competition
and Innovation Act (BPCI Act)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Biologics Price Competition
and Innovation Act (BPCI Act) authorizes the FDA to license a biological product that is biosimilar to an FDA-licensed biologic through
an abbreviated pathway. The BPCI Act establishes criteria for determining that a product is biosimilar to an already-licensed biologic,
or reference product, and establishes a process by which an abbreviated BLA for a biosimilar product is submitted, reviewed and approved.
The BPCI Act provides periods of exclusivity that protect a reference product from biosimilars competition. Under the BPCI Act, the FDA
may not accept a biosimilar application for review until four years after the date of first licensure of the reference product, and the
biosimilar may not be licensed until at least 12 years after the reference product&rsquo;s approval. Additionally, the BPCI Act establishes
procedures by which the biosimilar applicant provides information about its application and product to the reference product sponsor,
and by which information about potentially relevant patents may be shared and litigation over patents may proceed in advance of approval.
The BPCI Act also provides a period of exclusivity for the first biosimilar determined by the FDA to be interchangeable with the reference
product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the contours
of the BPCI Act will continue to be defined as the statute is implemented over a period of years. This likely will be accomplished by
a variety of means, including decisions related to the statute by the relevant federal courts, FDA issuance of guidance documents, and
FDA decisions in the course of considering specific applications. The FDA has to date issued various guidance documents and other materials
indicating the agency&rsquo;s thinking regarding a number of issues implicated by the BPCI Act. Additionally, the FDA&rsquo;s approval
of several biosimilar applications in recent years has helped define the agency&rsquo;s approach to certain issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Coverage and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our product candidates
in the United States may depend, in part, on the extent to which the costs of the product candidates may be covered by third-party payers,
such as government health programs, commercial insurance and managed health care organizations. These third-party payers are increasingly
challenging the prices charged for medical products and services. Additionally, the containment of health care costs has become a priority
of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government, state legislatures
and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions
on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and
adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.
If these third-party payers do not consider our product candidates to be cost-effective compared to other available therapies, they may
not cover our product candidates after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient
to allow us to sell our product candidates on a profitable basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to secure coverage
and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA, EMA or other
comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. A payer&rsquo;s decision
to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement
may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pricing and reimbursement
schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price
has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product
candidate to currently available therapies. The conduct of such studies could be expensive and result in delays in our commercializing
efforts. The EU provides options for its member states to restrict the range of drug products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price
for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product
on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits.
The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly
high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets
exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls
or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketability of any products
for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate
coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase
the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. Even
if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Healthcare Reform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The PPACA contains provisions
that may reduce the profitability of drug products, including, for example, increased rebates for drugs subject to the Medicaid Drug Rebate
Program, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries
and annual fees based on pharmaceutical companies&rsquo; share of sales to federal health care programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its enactment, there
have been executive, judicial and Congressional challenges to certain aspects of the PPACA. On June&nbsp;17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the PPACA brought by several states without specifically ruling on the constitutionality
of the PPACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted since PPACA was enacted. On March&nbsp;11, 2021, President Biden signed the American Rescue Plan
Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, for single source and innovator multiple source drugs,
beginning January&nbsp;1, 2024. The rebate was previously capped at 100% of a drug&rsquo;s average manufacturer price. Additionally, there
has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription
drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries, presidential executive orders and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. Additional
changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&nbsp;1, 2013 and, due to
subsequent legislative amendments to the statute, will stay in effect through 2027, unless additional Congressional action is taken; however,
pursuant to the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and subsequent legislation. In January&nbsp;2013, the American
Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may
result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for
our drugs, if approved, and, accordingly, our financial operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recently there has
been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products. There have been
several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs
under Medicare, and reform government program reimbursement methodologies for drugs. The FDA published a final rule&nbsp;on October&nbsp;1,
2020, effective November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further,
on November&nbsp;20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers
to plan sponsors under Part&nbsp;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law.
The rule&nbsp;also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers. At the state level, legislatures have increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most recently, on August&nbsp;16,
2022, the&nbsp;Inflation&nbsp;Reduction&nbsp;Act&nbsp;of 2022 (the IRA) was signed into law. Among other things, the IRA directs the HHS
to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare. The negotiated prices, which
will first become effective in 2026, will be capped at a statutory ceiling price representing a significant discount from average prices
to wholesalers and direct purchasers. The law will also, beginning in 2023, penalize drug manufacturers that increase prices of Medicare
Part&nbsp;B and Part&nbsp;D drugs at a rate greater than the rate of inflation. Further, the IRA eliminates the &ldquo;donut hole&rdquo;
under the Medicare Part&nbsp;D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating
a new manufacturer discount program. The IRA permits the Secretary of the HHS, to implement many of these provisions through guidance,
as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented,
although the IRA may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant
impact on the pharmaceutical industry In addition, in response to the Biden administration&rsquo;s October&nbsp;2022 executive order,
on February&nbsp;14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation
which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear
whether the models will be utilized in any health reform measures in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a number of these,
and other proposed measures may require authorization through additional legislation to become effective, Congress has indicated that
it will continue to seek new legislative measures to control drug costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CMS issued a final rule, effective
on July&nbsp;9, 2019, that requires direct-to-consumer advertisements of prescription drugs and biological products, for which payment
is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of
that drug or biological product if it is equal to or greater than $35 for a monthly supply or usual course of treatment. Prescription
drugs and biological products that are in violation of these requirements will be included on a public list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any adopted health reform
measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the
United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state
and federal healthcare reform measures will be adopted in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that additional
state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted in the future, any of which
could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a Delaware corporation.
Our principal executive offices are located at 1751 River Run, Suite&nbsp;400, Fort Worth, Texas 76107, and our telephone number <FONT STYLE="background-color: white">is
(817) 887-8455. </FONT>We were formed on January&nbsp;16, 2015 as Apotheca Therapeutics,&nbsp;Inc. and changed our name to Actuate Therapeutics,&nbsp;Inc.
on October&nbsp;1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be involved in legal proceedings or subject to claims incident to the ordinary course of business. We are not party to or aware of any
proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition
or results of operations. Regardless of the outcome, such proceedings or claims can have an adverse impact on our business because of
defense and settlement costs, diversion of resources and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_011"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the
name, age and position of each of our executive officers and directors as of February&nbsp;1, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Executive Officers:</I></B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel M. Schmitt</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew P. Mazar, Ph.D.</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Lytle</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial Officer</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Non-Employee Directors:</I></B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron G.L. Fletcher, Ph.D.</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson and Director</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les Kreis,&nbsp;Jr. </FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director (2)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd Thomson</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director (2)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan Zabrowski, Ph.D.</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director (2)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
                            <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Member of the audit committee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Member</FONT>&#8239;<FONT STYLE="font-size: 10pt">of
the compensation committee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Member&#8239;of the nominating
and corporate governance committee.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Background of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Daniel
M. Schmitt.</I></B></FONT> Mr.&nbsp;Schmitt has served as our Chief Executive Officer and President since March&nbsp;2015 and our
director since April&nbsp;2015. He previously served as Chief Operating Officer of Genus Oncology LLC, a clinical stage company,
from 2009 to 2014. Prior to that, he served as Senior Vice President, Licensing and Commercial Development of Immtech
Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, from 2004 to 2009; General Manager, Academic and Government Institution
Markets of First Genetic Trust, a genomic technology company, from 2001 to 2004; and previously held positions with G.D. Searle
Inc., a pharmaceutical company, ILEX Oncology,&nbsp;Inc., a pharmaceutical company, Fujisawa USA,&nbsp;Inc., a pharmaceutical
company, and Burroughs Wellcome Co., a pharmaceutical company. Mr.&nbsp;Schmitt has also held research positions affiliated with the
National Foundation for Cancer Research in 1984 and the University of North Carolina School of Medicine from 1987 to 1988. He also
served as an Entrepreneur-In-Residence at Northwestern University in 2014 and as an external expert consultant for both the
University of Chicago and the University of Illinois-Chicago from 2011 to 2014. Mr.&nbsp;Schmitt is also a founding member of
Chicago Innovation Mentors. He earned his MBA and a BS in Chemistry with a concentration in Theoretical Mathematics from West
Virginia University. Mr.&nbsp;Schmitt is well qualified to serve as a director due to his pharmaceutical and biotechnology
experience, including his experience in operations management, new product development and business development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B><I>Andrew P. Mazar,
Ph.D. </I></B>Dr.&nbsp;Mazar has served as our Chief Operating Officer since June&nbsp;2022, and prior to joining the Company, he served
as an independent consultant from January 2022 to June 2022. Previously, Dr.&nbsp;Mazar was the Co-Founder, Chief Scientific Officer
and a director of Monopar Therapeutics,&nbsp;Inc., a public clinical-stage biopharmaceutical company, from September&nbsp;2016 to April&nbsp;2022.
Dr. Mazar is also a founder and managing member of Tactic Pharma, LLC, where he developed WTX-101/ALXN1840, a drug he co-invented for
the treatment of Wilson&rsquo;s disease.&nbsp; WTX-101/ALXN1840 was acquired by Alexion Pharmaceuticals for more than $800 million in
2018.&nbsp; Prior to Monopar, Dr.&nbsp;Mazar was a Professor of Pharmacology at the Feinberg School of Medicine at Northwestern University,
where he also served as the Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence from September&nbsp;2009
to September&nbsp;2016.&nbsp; During his tenure at Northwestern University, Dr, Mazar served as the Co-chair of the Animal Model Working
Group for the NCI Nanotechnology Alliance; was a charter member of the Developmental Therapeutics (DT) study section at the NIH Center
for Scientific review; and was a member of the editorial board of Clinical Cancer Research where he continues to serve. Prior to that,
Dr.&nbsp;Mazar served as the Chief Scientific Officer at Attenuon, LLC, a private clinical-stage biopharmaceutical company, from February&nbsp;2000
to July&nbsp;2009. Dr. Mazar earned his BS in Chemistry from the University of Wisconsin, Parkside and his Ph.D. in Biochemistry from
the University of Illinois College of Medicine, Chicago, Illinois. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B><I>Paul Lytle</I></B>.
Mr.&nbsp;Lytle has served as our Interim Chief Financial Officer since February&nbsp;2024. Mr.&nbsp;Lytle is the Co-Founder of Thendor
Therapeutics, LLC, a private biopharmaceutical company, and he has served as its Chief Financial Officer since September&nbsp;2023. Mr.&nbsp;Lytle
is also the Co-Founder of Mosaic ImmunoEngineering,&nbsp;Inc., a public development-stage biotechnology company, and he has served on
its board of directors and as its Executive Vice President, Chief Financial Officer since August&nbsp;2020. Previously, Mr.&nbsp;Lytle
served as Executive Vice President, Chief Financial Officer of Breathe Technologies,&nbsp;Inc., a private medical device company acquired
by Hillrom Holdings,&nbsp;Inc. in August&nbsp;2019, from September&nbsp;2018 to December&nbsp;2019. Prior to that, Mr.&nbsp;Lytle served
as Chief Financial Officer of Avid Bioservices,&nbsp;Inc. (Nasdaq: CDMO), a publicly traded biologics development company initially focused
on developing immunotherapies for the treatment of cancer while building a new biologics contract development and manufacturing organization,
from March&nbsp;1997 to May&nbsp;2018. Mr. Lytle received his B.S. in Business with an emphasis in Accounting from California State University
at Long Beach and is a Certified Public Accountant (inactive). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Aaron
G.L. Fletcher, Ph.D.</I></B></FONT> Dr.&nbsp;Fletcher has served as our director since April&nbsp;2015. Dr.&nbsp;Fletcher is the Founder
and has served as the President of Bios Research, a financial services firm, since 2012. Dr.&nbsp;Fletcher has also served as an independent
consultant in the biotechnology and healthcare equity industry for over 10 years, and a visiting professor at Dallas Baptist University
since 2008, where he teaches Biochemistry, Bioethics and Cell Biology. Dr.&nbsp;Fletcher earned his PhD in Biochemistry from Colorado
State University. Dr.&nbsp;Fletcher is well qualified to serve as a director due to his extensive experience in the healthcare industry,
particularly in the biotech and med-tech sub-sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Les
Kreis,&nbsp;Jr.</I></B></FONT> Mr.&nbsp;Kreis has served as our director since March&nbsp;2015. Mr.&nbsp;Kreis currently serves as the
Managing Principal of Steelhead Capital Management, a single-family office, since 2008. He is also a Co-Founder and has served as the
Managing Partner of Bios Partners, a venture capital firm focused on early-stage biotechnology investments, since 2013. Mr.&nbsp;Kreis
has served as a founding member of Cowtown Angels, an angel investment network, since 2012. Previously, Mr.&nbsp;Kreis was a Vice President
of HBK Investments, a private multi-strategy global hedge fund, from 1994 to 2005. Mr.&nbsp;Kreis earned a BBA in Finance from Texas Christian
University in 1994. He is well qualified to serve as a director due to his extensive experience in finance, including in both global public
and private equity markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Todd
Thomson.</I></B></FONT> Mr.&nbsp;Thomson has served as our director since September&nbsp;2022. Mr.&nbsp;Thomson has served as the Chief
Operating and Financial Officer of Kairos Ventures, a venture capital firm, since August&nbsp;2019. Previously, he co-founded and served
as Chairman of Dynasty Financial Partners, an investment and technology platform, from November&nbsp;2010 to August&nbsp;2019, and currently
serves on the board of directors. Prior to that, Mr.&nbsp;Thomson served as CEO of the Wealth Management Division of Citigroup and previously
Chief Financial Officer of Citigroup Inc., an investment bank and financial services corporation, from 1998 to 2007. Mr.&nbsp;Thomson
has served on the board of directors and as a member of the audit committee of Sivers Semiconductors, a public technology company, since
January&nbsp;2022, and on the board of directors and as a member of the Investment Committee for the Davidson College and World Resources
Institute Endowments. He earned his MBA with Distinction in Finance and Strategy from the Wharton School of Business and his BA in Economics
from Davidson College. Mr.&nbsp;Thomson is well qualified to serve as a director due to his extensive investing experience and years of
executive leadership, financial leadership, and experience in mergers and acquisitions and business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <B><I>Dan Zabrowski, Ph.D.
</I></B>Dr.&nbsp;Zabrowski has served as our director since March&nbsp;2021. Dr.&nbsp;Zabrowski has served as a Venture Partner of Decheng
Capital, a private investment firm, since July&nbsp;2016. Prior to that, Dr.&nbsp;Zabrowski served in a number of roles for Roche, a
healthcare company, from 1994 to 2016, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head
of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. Dr.&nbsp;Zabrowski also
previously held positions with Syntex, Fujisawa (now Astellas), a pharmaceutical company, and G.D. Searle, LLC, a pharmaceutical company,
and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois &mdash; Chicago. He also served on the board
of directors of Apexigen,&nbsp;Inc., a public biopharmaceutical company, from February&nbsp;2021 to August&nbsp;2023, including serving
as Chairman of its compensation committee and member of its audit committee, BeyondSpring Inc., a public biopharmaceutical company, from
January&nbsp;2020 to June&nbsp;2022, including serving as a member of its compensation committee, Nimble Therapeutics,&nbsp;Inc., a private
biotechnology company, since 2019, Ariagen,&nbsp;Inc., a private biotechnology company, since 2018, Endogena Therapeutics,&nbsp;Inc.,
a private biotechnology company, since 2018, and AccuraGen,&nbsp;Inc., a private biotechnology company, since 2013, and also as a board
observer for Encodia,&nbsp;Inc., a private biotechnology company, since 2018. Dr.&nbsp;Zabrowski earned his PhD in Organic Chemistry
from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University. Dr.&nbsp;Zabrowski is well qualified
to serve as a director due to his extensive experience on a variety of public and private boards in the biotechnology and biopharmaceutical
industries. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no familial relationships
among our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Composition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and affairs are
organized under the direction of the Board. The Board currently consists of five members. The primary responsibilities of the Board are
to provide oversight, strategic guidance, counseling, and direction to our management. The Board will meet on a regular basis and additionally
as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our fourth amended
and restated voting agreement, or the voting agreement, which will terminate upon the closing of this offering, the holders of the Series&nbsp;A
Preferred Stock, voting as a separate class, were entitled to elect one member of the Board, with the initial director being Dr.&nbsp;Fletcher,
the holders of the Series&nbsp;B Preferred Stock, voting as a separate class, were entitled to elect two members of the Board, with the
initial directors being Messrs.&nbsp;Kreis,&nbsp;Jr. and Thomson, and the holders of the Series&nbsp;C Preferred Stock, voting as a separate
class, were entitled to elect one were member of the Board (no director was selected by such holders to fill this seat). The holders of
common stock, voting as a separate class, were entitled to elect one member of the Board, with the initial director being Mr.&nbsp;Schmitt.
The holders of the Preferred Stock and the common stock voting together as a single class on an as-converted basis were also entitled
to elect one additional &ldquo;independent&rdquo; director, as such term is defined in the Exchange Act, with the initial director being
Dr.&nbsp;Zabrowski.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&nbsp;Fletcher currently
serves as our Chairperson of the Board. This structure ensures a greater role for non-management&nbsp;directors in the oversight of our
Company and active participation of these directors in setting agendas and establishing priorities and procedures for the work of the
Board. In addition, this structure allows the Chief Executive Officer to focus his attention on implementing our strategic plans, while
a separate Chairperson can devote full attention to Board leadership functions. The Board will continue to periodically review our leadership
structure and may make such changes in the future as it deems appropriate and in the best interests of us and our stockholders. While
the Board does not have a lead independent director, the independent directors meet in executive session regularly without the presence
of management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are seeking the listing
of our common stock on the Nasdaq Capital Market and will utilize the Nasdaq listing rules&nbsp;in determining whether a director is independent.
The Nasdaq rules&nbsp;generally define an &ldquo;independent director&rdquo; as a person, other than an executive officer of a company
or any other individual having a relationship which, in the opinion of the issuer&rsquo;s board of directors, would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&nbsp;Schmitt is not considered
to be independent due to his role as an executive officer of the Company. The Board has determined that each of Dr.&nbsp;Fletcher, Mr.&nbsp;Thomson,
Mr.&nbsp;Kreis,&nbsp;Jr., and Dr.&nbsp;Zabrowski qualifies as an independent director, and that the Board consists of a majority of independent
directors, as such term is defined under the Nasdaq rules. In making this determination, our Board considered the current and prior relationships
that each of Dr.&nbsp;Fletcher, Mr.&nbsp;Thomson, Mr.&nbsp;Kreis,&nbsp;Jr., and Dr.&nbsp;Zabrowski has with our Company and all other
facts and circumstances our Board deemed relevant in determining their independence, including their beneficial ownership of our capital
stock. In addition, we are subject to the rules&nbsp;of the SEC and Nasdaq relating to the membership, qualifications, and operations
of the audit committee, the compensation committee, and the nominating and corporate governance committee, as discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Classified Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the terms
of our amended and restated certificate of incorporation that will go into effect immediately prior to the closing of this offering, our
board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the directors
whose terms then expire will be eligible for reelection until the third annual meeting following reelection. Effective upon the closing
of this offering, our directors will be divided among the three classes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the Class&nbsp;I directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and their terms will expire at our first annual meeting of stockholders following this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the Class&nbsp;II directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and their terms will expire at our second annual meeting of stockholders following this offering; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">the Class&nbsp;III directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and their terms will expire at our third annual meeting of stockholders following this offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated certificate
of incorporation that will go into effect immediately prior to the closing of this offering will provide that the authorized number of
directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the
number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of
the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change
of our board of directors or a change in control of our Company. Our directors may be removed only for cause by the affirmative vote of
the holders of at least two-thirds of our outstanding voting stock then entitled to vote in an election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Meetings and Committees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal year ended
December&nbsp;31, 2023, the Board met four times. All of our directors attended 75% or more of the aggregate number of meetings of the
Board and committees on which they served. The directors are strongly encouraged to attend future meetings of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board has established
a standing audit committee, compensation committee, and nominating and corporate governance committee. The Board adopted a charter for
each of these committees, which complies with the applicable Nasdaq rules. Copies of the charters for each committee will be publicly
available upon the closing of the offering on our website at www.actuatetherapeutics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee was formed
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024 and consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(chairperson), &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The Board has determined that
each member of the audit committee is an independent director as defined by Nasdaq rules&nbsp;applicable to members of an audit committee,
including that each member meets the criteria for independence set forth in Rule&nbsp;10A-3(b)(1)&nbsp;under the Exchange Act. In addition,
as required by Nasdaq rules, each member of the audit committee is able to read and understand fundamental financial statements, including
a company&rsquo;s balance sheet, income statement, and statement of cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audit committee will meet
on at least a quarterly basis. Both our independent registered public accounting firm and management will periodically meet privately
with the audit committee. The audit committee will assist the Board in monitoring the integrity of our financial statements, our compliance
with legal and regulatory requirements, and the independence and performance of our internal and external auditors. The audit committee&rsquo;s
duties, which are specified in our audit committee charter, include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">selecting and retaining an independent registered public accounting firm to act as our independent auditors,
and evaluating the qualifications, performance and independence of the independent auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">selecting, retaining, overseeing and terminating, if necessary, any other registered public accounting
firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">approving the fees to be paid to the independent auditor for audit services and approving the retention
of independent auditors for non-audit services and all fees for such services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing periodic reports from the independent auditor regarding, among other things the auditor&rsquo;s
independence, including discussion of such reports with the auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">meeting with the independent auditor prior to the audit to review the scope, planning, and staffing of
the audit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">discussing with management and the independent auditor, as appropriate, our critical accounting policies
and practices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and discussing with management and the independent auditor the annual audit report, the annual
financial statements and related notes and management&rsquo;s discussion and analysis of financial condition and results of operations
proposed to be included in our annual report, and recommending to the Board whether the audited financial statements and related notes
and management&rsquo;s discussion and analysis of financial condition and results of operations should be included in our annual report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">producing the report of the audit committee, as required by the rules&nbsp;of the SEC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and discussing with management and the independent auditor our quarterly financial statements
prior to the filing of each quarterly report and management&rsquo;s discussion and analysis of financial condition and results of operations
proposed to be included in such quarterly report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and discussing with management and the independent auditor our major financial risk exposures
and the steps management has taken to monitor and control such exposures, including the our risk assessment and risk management policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> reviewing
                                            with management and our independent auditors the adequacy and effectiveness of our financial
                                            reporting process, internal control over financial reporting and disclosure controls and
                                            procedures; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> developing and recommending to the Board
    for approval a Company code of conduct, and monitoring, investigating and enforcing the provisions of such code against any alleged
    violations; and </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and approving all related-party transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Financial Experts on Audit
Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board determined that </FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;qualifies
as an audit committee financial expert within the meaning of the rules&nbsp;and regulations of the SEC.&nbsp;In making this determination,
the Board considered &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&rsquo;s
formal education and previous experience in financial roles. In addition, as required by Nasdaq rules, we have at least one member who
has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience
or background that results in the individual&rsquo;s financial sophistication. The Board determined &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
qualifies as financially sophisticated under the Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The compensation committee
currently consists of Dr.&nbsp;Zabrowski and Messrs.&nbsp;Kreis and Thomson, and, following the completion of the offering, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will
serve as chairperson. The Board has determined that each member of the compensation committee is an independent director as defined by
the Nasdaq rules&nbsp;applicable to members of a compensation committee. The compensation committee meets from time to time to consider
matters for which approval by the committee is desirable or is required by law. During the fiscal year ended December&nbsp;31, 2023,
the compensation committee met two times. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee&rsquo;s
duties, which are specified in our compensation committee charter, include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and making recommendations to the Board regarding the corporate goals and objectives relevant
to compensation of our Chief Executive Officer and other executive officers, annually evaluate such officers&rsquo; performance in light
of those goals and objectives and, based on this evaluation, make recommendations to the Board regarding such officers&rsquo; compensation
level;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations to the Board with respect to the adoption of, and amendments to, incentive compensation and equity-based plans, and where appropriate or required, recommend for approval by our stockholders, which includes the ability to adopt, amend and terminate such plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">administering our incentive and equity-based compensation plans, including designation of the employees
to whom the awards are to be granted, the amount of the award or equity to be granted and the terms and conditions applicable to each
award or grant, subject to the provisions of each plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">if required under Regulation&nbsp;S-K, reviewing our compensation discussion and analysis, discussing
it with our management, and determining whether to recommend it for inclusion in the our annual report or proxy statement and producing
the report of the compensation committee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing and making recommendations to the Board regarding any employment agreements and any severance
arrangements or plans, including any benefits to be provided in connection with a change in control, for the CEO and other executive officers,
which includes the ability to adopt, amend and terminate such agreements, arrangements or plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing our incentive compensation arrangements to determine whether they encourage excessive risk-taking,
reviewing and discussing at least annually the relationship between risk management policies and practices and compensation, and evaluating
compensation policies and practices that could mitigate any such risk; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">reviewing all director compensation and benefits for service on the Board and committees thereof and recommending
any changes to the Board, as necessary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
will consider the recommendations of the Chief Executive Officer when determining compensation for the other executive officers. Executive
officers do not determine any element or component of their own pay package or total compensation amount. The Chief Executive Officer
is not present for any discussions regarding his own compensation. The compensation committee retains sole authority to engage compensation
consultants, including determining the nature and scope of services and approving the amount of compensation for those services, and legal
counsel or other advisors. The compensation committee assesses the independence of any consultants pursuant to the rules&nbsp;and regulations
of the SEC and Nasdaq rules. We will provide for appropriate funding, as determined by the compensation committee, for payment of any
such investigations or studies and the compensation to any consulting firm, legal counsel or other advisors retained by the compensation
committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Nominating and Corporate Governance Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating and corporate
governance committee was formed on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024 and consists of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (chairperson),
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
The Board has determined that each member of the nominating and corporate governance committee is an independent director as defined by
the Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating and corporate
governance committee will meet from time to time to consider matters for which approval by the committee is desirable or is required by
law. The nominating and corporate governance committee&rsquo;s duties, which are specified in our nominating and corporate governance
committee charter, include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> periodically reviewing the size of the
    Board and assessing its ability to function effectively, and reviewing its committee structure, committee chairs and membership and
    making recommendations to the Board with respect to any changes thereto;&nbsp; </P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">determining the qualifications, qualities, skills and other expertise required to be a director, and developing
and recommending to the Board for its approval, criteria to be considered in selecting nominees for director;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">identifying, evaluating and making recommendations to the Board regarding nominees for election to the
Board and its committees;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and recommending to the Board for approval any director independence standards that are deemed appropriate in addition to those required
    by Nasdaq Rules and making recommendations to the Board with respect to whether a director has a relationship with the Company that
    would impair such director&rsquo;s independence</FONT><FONT STYLE="font-size: 10pt">;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">developing and recommending to the Board a set of corporate governance guidelines, and reviewing these
guidelines annually;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> overseeing the Company&rsquo;s corporate
    governance policies, practices and procedures, including identifying best practices and reviewing and recommending to the Board for
    approval any changes to the documents, policies and procedures in the Company's corporate governance framework;&nbsp; </P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    directorships in other public companies held by or offered to a director, and retirements or other changes to a director&rsquo;s
    principal occupation or business association, to determine whether they adversely affect his or her service on the Board and making
    recommendations to the Board with respect thereto; and</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> developing,
                                            subject to approval by the Board, a process for an annual evaluation of the performance of
                                            the Board and its committees, and overseeing such evaluation. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Guidelines for Selecting
Director Nominees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating and corporate
governance committee will consider persons identified by its stockholders, management, investment bankers and others. The nominating and
corporate governance committee will consider a number of qualifications relating to management and leadership experience, background and
integrity and professionalism in evaluating a person&rsquo;s candidacy for membership on the Board. The nominating and corporate governance
committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise
from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members.
The nominating and corporate governance committee does not distinguish among nominees recommended by stockholders and other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board&rsquo;s objective
is that its membership be comprised of a diverse group of experienced and dedicated individuals. Though the nominating and corporate governance
committee does not have specific guidelines on diversity, it is one of many criteria considered by the nominating and corporate governance
committee when evaluating candidates. The nominating and corporate governance committee does not have a written policy or formal procedural
requirements for stockholders to submit recommendations for director nominations. However, the nominating and corporate governance committee
will consider properly submitted recommendations for candidates to the Board from stockholders in accordance with our amended and restated
bylaws. Stockholders should communicate nominee suggestions directly to the nominating and corporate governance committee and accompany
the recommendation with biographical details and a statement of support for the nominee. The suggested nominee must also provide a statement
of consent to being considered for nomination. There have been no material changes to the procedures by which stockholders may recommend
nominees to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Oversight of Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Board&rsquo;s primary
function is one of oversight. The Board as a whole works with our management team to promote and cultivate a corporate environment that
incorporates enterprise-wide risk management into strategy and operations. Management periodically reports to the Board about the identification,
assessment and management of critical risks and management&rsquo;s risk mitigation strategies. Each committee of the Board is responsible
for the evaluation of elements of risk management based on the committee&rsquo;s expertise and applicable regulatory requirements. In
evaluating risk, the Board and its committees consider whether our programs adequately identify material risks in a timely manner and
implement appropriately responsive risk management strategies throughout the organization. The audit committee focuses on assessing and
mitigating financial risk, including risk related to internal controls and compliance. In setting compensation, the compensation committee
strives to create incentives that encourage behavior consistent with our business strategy, without encouraging undue risk-taking. The
nominating and corporate governance committee considers areas of potential risk within corporate governance. Each of the committees reports
to the Board as a whole as to their findings with respect to the risks they are charged with assessing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted a code of ethics
that applies to all of our directors, officers and employees. A copy of the code of ethics will publicly available upon the closing of
this offering on our website at www.actuatetherapeutics.com. We also intend to disclose future amendments to, or waivers of, its code
of ethics, as and to the extent required by SEC regulations, on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stockholder and Interested Party Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Stockholders and interested
parties may communicate with the Board, any committee or committee chairperson or the independent directors as a group by writing to
the Board, committee, committee chairperson or independent directors in care of the Chairman of the Board at Actuate Therapeutics, Inc.,
1751 River Run, Suite&nbsp;400, Fort Worth, Texas 76107. Each communication will be forwarded, depending on the subject matter, to the
Board, the appropriate committee or committee chairperson or all independent directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Liability and Indemnification
of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Delaware General Corporation
Law authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations
and their stockholders for monetary damages for breach of their fiduciary duties. Our amended and restated certificate of incorporation
limits the liability of our directors and officers to the fullest extent permitted by Delaware law. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have director and officer
liability insurance to cover liabilities our directors and officers may incur in connection with their services to us, including matters
arising under the Securities Act. Our amended and restated certificate of incorporation and bylaws also provide that we will indemnify
its directors and officers to the fullest extent permitted by Delaware law. Our bylaws further provide that we will indemnify any other
person whom it has the power to indemnify under Delaware law. In addition, we have entered into customary indemnification agreements with
each of our officers and directors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no pending litigation
or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required or permitted. We
are not aware of any threatened litigation or proceedings that may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons controlling us, in the opinion
of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_012"></A>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our executive officers for the year ended December&nbsp;31,
2023, whom we refer to in this prospectus as our named executive officers, were:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Daniel M. Schmitt, our President and Chief Executive Officer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify">Andrew P. Mazar, Ph.D., our Chief Operating Officer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Paul Lytle, our Interim Chief
Financial Officer, was appointed in February&nbsp;2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Summary Compensation Table</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information concerning the compensation of the named executive officers for the years ended December&nbsp;31, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Name </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bonus
                                            </B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock<BR>
                                            Award(1)</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
                                            Awards(1) </B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All
                                            Other<BR> Compensation</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 29%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    M. Schmitt<SUP>(2)</SUP></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"> 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> 400,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> 120,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"> 520,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font: italic 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"> President
    and Chief Executive Officer </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 2022 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 400,000 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 44,489 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 444,489 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: center"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    P. Mazar, Ph.D. <SUP>(3)</SUP></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 2023 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 450,000 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 157,500 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 58,612 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 666,112 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font: italic 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left"> Chief
    Operating Officer </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 2022 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 377,500 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 287,544 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 85,071 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: right"> 750,115 </TD><TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD STYLE="text-align: justify"> The dollar amounts listed reflect the value of the award as
                                       of the grant date calculated in accordance with ASC Topic 718 based upon the fair-market value
                                       of our common stock on the date of the grant and, therefore, do not necessarily reflect the actual
                                       value received by the individuals. The assumptions made in computing the estimated fair value
                                       of such awards are disclosed in Note 9 to our consolidated financial statements included in this
                                       prospectus for the fiscal year ended December&nbsp;31, 2023. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The terms of Mr.&nbsp;Schmitt&rsquo;s compensation are set forth in his employment agreement. See &ldquo;Employment
Agreements &ndash; Chief Executive Officer.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"> (3) </TD><TD STYLE="text-align: justify"> Dr.&nbsp;Mazar began consulting for the
                                            Company in January 2022, for which he received $15,000 per month. Dr. Mazar then assumed
                                            the role of Chief Operating Officer on April&nbsp;1, 2022 as a consultant and became our
                                            employee on June&nbsp;1, 2022. Pursuant to the COO Consulting Agreement (defined below),
                                            he received $35,000 per month for serving in that role and the COO Employment Agreement (defined
                                            below) provides for a base salary equal to $450,000 per year, the ability to earn a bonus
                                            of up to 50% of his base salary upon achievement of certain milestones mutually agreed to
                                            between us. Upon signing the COO Employment Agreement in 2022, Dr.&nbsp;Mazar received a
                                            signing bonus equal to $200,000 and 72,710 shares of restricted common stock awards, 25%
                                            of which vested on the first anniversary of the grant date and the remaining 75% of which
                                            vest in equal monthly installments during the 36 months following the first anniversary of
                                            the grant date. See &ldquo;Employment Agreements &ndash; Chief Operating Officer&rdquo; below.
                                            Dr. Mazar was granted 67,273 stocks options based on performance on October 23, 2023, of
                                            which, 25% vested on the grant date and the remaining 75% vest in equal installments on a
                                            monthly basis during the 36 months following the grant date. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Narrative Disclosure to Summary Compensation
Table</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For 2023 and 2022, the compensation
program for our named executive officers consisted of base salary and incentive compensation delivered in the form of cash bonuses and
equity awards. Base salary was set at a level that was commensurate with the executive&rsquo;s duties and authorities, contributions,
prior experience and sustained performance. Cash bonuses and equity awards were also set at a level that was commensurate with the executive&rsquo;s
duties and authorities, contributions, prior experience and sustained performance, in accordance with the employment or similar agreement
with the executive. We provide benefits to its named executive officers on the same basis as it provides them to all of its employees,
including health, dental and vision insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employment Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April&nbsp;15, 2015, we
entered into an employment agreement with Mr.&nbsp;Schmitt, which was amended on each of February&nbsp;5, 2016, September&nbsp;28, 2017,
September&nbsp;23, 2018, January&nbsp;29, 2019, September&nbsp;3, 2019, August&nbsp;1, 2022, January&nbsp;27, 2023, and December&nbsp;12,
2023 (the CEO Employment Agreement), that provides a base salary equal to $400,000 per year, and the ability to earn a bonus of up to
50% of his base salary, 70% of which shall be payable upon achievement of certain milestones mutually agreed to between the Company and
Mr.&nbsp;Schmitt and 30% of which shall be payable at the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event the Company is
sold on or before December&nbsp;31, 2026 for cash in a transaction valued at or above $29.56 per share, immediately prior to the consummation
of such transaction, Mr.&nbsp;Schmitt will also be (i)&nbsp;granted shares of common stock under the stock incentive plan of the Company
that is then in effect entitling Mr.&nbsp;Schmitt to receive that number of shares that would bring his total ownership (including the
shares he owned prior to calculation of the shares to be granted in the sale transaction) to 8.0% of the issued and outstanding shares
of common stock immediately prior to the closing of such transaction on a fully diluted basis, and (ii)&nbsp;entitled to receive a cash
bonus equal to 100% of his base salary. Further, in the event on or before December&nbsp;31, 2026 the Company receives between $10,000,000-100,000,000
or more in gross revenue pursuant to certain licensing arrangements between the Company and any third party or another non-dilutive capital
transaction, Mr.&nbsp;Schmitt will be (i)&nbsp;granted shares of common stock under the stock incentive plan of the Company that is then
in effect entitling Mr.&nbsp;Schmitt to receive that number of shares that would bring his total ownership (including the shares he owned
prior to calculation of the shares to be granted in the transaction) to 5.0-6.0% of the issued and outstanding shares of common stock
on a fully diluted basis, and (ii)&nbsp;entitled to receive a cash bonus equal to 25-50% of his base salary. If the Company closes a transaction
or series of related transactions occurring on or before December&nbsp;31, 2026 pursuant to which the Company issues and sells shares
of its common or preferred equity securities in exchange for aggregate gross proceeds of more than $10,000,000, excluding any gross proceeds
attributable to sales to Bios Partners L.P. or its affiliates, (a &ldquo;Qualified Financing&rdquo;), Mr.&nbsp;Schmitt will be granted
shares of common stock under the stock incentive plan of the Company that is then in effect entitling Mr.&nbsp;Schmitt to receive that
number of shares that would bring his total ownership (including the shares he owned prior to calculation of the shares to be granted
in the transaction) to 4.25-5.0% of the issued and outstanding shares of common stock on a fully diluted basis, depending on the per share
price of the shares sold in such Qualified Financing. The shares issued to Mr.&nbsp;Schmitt in such transactions will be fully vested
as of the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr.&nbsp;Schmitt&rsquo;s severance
amounts payable upon termination by the Company for any reason other than Mr.&nbsp;Schmitt&rsquo;s death, disability or for &ldquo;cause,&rdquo;
or termination by Mr.&nbsp;Schmitt for &ldquo;good reason,&rdquo; is set at a payment equal to one times his then current base salary
(the CEO Standard Severance Benefits). Upon termination upon a change in control, and if Mr.&nbsp;Schmitt&rsquo;s employment is terminated
by the Company for any reason other than Mr.&nbsp;Schmitt&rsquo;s death, disability or for &ldquo;cause,&rdquo; or termination by Mr.&nbsp;Schmitt
for &ldquo;good reason,&rdquo; in any such case within the six months immediately preceding or the twelve months immediately following
such change in control, Mr.&nbsp;Schmitt is entitled to a payment equal to one-half times his then current base salary reduced by the
CEO Standard Severance Benefits to which he would be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Chief Operating Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&nbsp;Mazar assumed the
role of Chief Operating Officer on April&nbsp;1, 2022 pursuant to a consulting agreement, dated March&nbsp;25, 2022 (the COO Consulting
Agreement), which entitled him to compensation equal to $35,000 per month for serving in that role. On June&nbsp;1, 2022, the COO Consulting
Agreement was superseded by an employment agreement (the COO Employment Agreement) that provides for a base salary equal to $450,000 per
year, the ability to earn a bonus of up to 50% of his base salary upon achievement of certain milestones mutually agreed to between the
Company and Dr.&nbsp;Mazar, and a signing bonus equal to $200,000. Upon execution of the Employment Agreement, the Company granted to
Dr.&nbsp;Mazar 72,710 shares of restricted common stock, 25% of which vested on the first anniversary of the grant date and the remaining
75% of which vest in equal monthly installments during the 36 months following the first anniversary of the grant date. In the event the
Company is sold on or before March&nbsp;31, 2024 for cash in a transaction valued at or above $29.56 per share, immediately prior to the
consummation of such transaction, Dr.&nbsp;Mazar will also be granted shares of common stock under the stock incentive plan of the Company
that is then in effect entitling Dr.&nbsp;Mazar to receive that number of shares that would bring his total ownership (including the shares
he owned prior to calculation of the shares to be granted in the sale transaction) to 2.0% of the issued and outstanding shares of common
stock on the day immediately prior to the closing of such transaction on a fully diluted basis. The shares issued to Dr.&nbsp;Mazar in
such transaction will be fully vested as of the date of grant. Dr.&nbsp;Mazar&rsquo;s severance amounts payable upon termination by the
Company for any reason other than Dr.&nbsp;Mazar&rsquo;s death, disability or for &ldquo;cause,&rdquo; or termination by Dr.&nbsp;Mazar
for &ldquo;good reason,&rdquo; is set at a payment equal to 100% of his then current base salary plus reimbursement of the cost associated
with his premiums for elected COBRA coverage up to $25,000 (the COO Standard Severance Benefits). Upon termination upon a change in control,
and if Dr.&nbsp;Mazar&rsquo;s employment is terminated by the Company for any reason other than Dr.&nbsp;Mazar&rsquo;s death, disability
or for &ldquo;cause,&rdquo; or termination by Dr.&nbsp;Mazar for &ldquo;good reason,&rdquo; in any such case within the six months immediately
preceding or the twelve months immediately following such change in control, Dr.&nbsp;Mazar is entitled to a payment equal to one times
his then current base salary reduced by the COO Standard Severance Benefits to which he would be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Interim Chief Financial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On February&nbsp;17, 2024,
we entered into a consulting agreement with Mr.&nbsp;Lytle (the Interim CFO Agreement), that provides a consulting fee equal to $20,000
per month for a term of one year for services covering of at least 50% of full-time, unless earlier terminated by us or Mr.&nbsp;Lytle
pursuant to the Interim CFO Agreement. The Company may terminate the Interim CFO Agreement at any time and for any reason upon written
notice to Mr. Lytle. Mr. Lytle may terminate the Interim CFO Agreement upon 30 days prior written notice to the Company or immediately
upon a material breach by the Company that has not been cured within 30 days after written notice to the Company of such breach. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Outstanding Equity Awards at Year End</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
information regarding the outstanding stock options and restricted common stock awards held by the Company&rsquo;s named executive officers
at December&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
    Awards</B></FONT> </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
                                            Awards</B></FONT> </TD><TD STYLE="padding-bottom: 1pt; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"> Name </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Date</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Exercisable</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of<BR> Securities<BR> Underlying<BR> Unexercised<BR> Options<BR> Unexercisable</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
                                            Exercise<BR> Price<BR> ($)</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option<BR>
                                            Expiration<BR> Date</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
                                            of<BR> Shares or<BR> Units&nbsp;of Stock&#8239;<BR>
                                            That Have<BR> Not Vested</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
                                            Value&#8239;<BR>
                                            of Shares of<BR> Units&nbsp;of Stock <BR>
                                            That Have <BR>
                                            Not Vested</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
                                            <BR>
                                            Incentive <BR>
                                            plan awards: <BR>
                                            number of<BR> unearned <BR>
                                            shares,<BR> units or other<BR> rights that <BR>
                                            have<BR> not vested</B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
                                            <BR>
                                            incentive<BR> plan awards:<BR> market or<BR> payout value<BR> of unearned<BR> shares, units<BR>
                                            or other <BR>
                                            rights<BR>
                                            &#8239;that have not&#8239;<BR>
                                            vested</B></FONT><B><FONT STYLE="font-size: 10pt">(1)</FONT></B> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt; width: 18%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    M. Schmitt<SUP>(2)</SUP></FONT> </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 2/5/16(3) </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 21,107 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 44,114 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2/22/21(4) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 193,892 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 405,234 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    P. Mazar, Ph.D.<SUP>(2)&nbsp;</SUP></FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 2/22/21(5) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 14,584 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 30,481 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 7/7/22(6) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 46,959 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 98,144 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-indent: -10pt; padding-left: 10pt"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 10/23/23(7) </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 67,273 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 1.19 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/23/33</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> &mdash; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify">The market value of the restricted stock as of December&nbsp;31, 2023 is calculated by multiplying the
number of unvested shares outstanding under the award by $2.09 per share, which is the fair value we used for financial reporting purposes
as of such date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Each of Mr.&nbsp;Schmitt and Dr.&nbsp;Mazar are also entitled to receive shares of common stock following
the consummation of certain transactions, including this offering with respect to Mr.&nbsp;Schmitt. See &ldquo;Employment Agreements &ndash;
Chief Executive Officer&rdquo; and &ldquo;&ndash; Chief Operating Officer&rdquo; above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">84,428
                                            restricted common stock awards were granted on February 5, 2016, of which, (i) 21,107 shares
                                            vested on the grant date, &nbsp;(ii) 21,107 shares vested on September 18, 2017 upon the
                                            hiring of the Company&rsquo;s Chief Medical Officer, &nbsp;(iii) 21,107 shares vested on
                                            January 11, 2018 upon the filing of the Company&rsquo;s &ldquo;Investigation of New Drug&rdquo;
                                            application with the FDA, &nbsp;and (iv) 21,107 shares will vest upon the achievement of
                                            strategic partnership or licensing transaction with anticipated gross proceeds of at least
                                            $25 million.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">664,771 restricted common stock awards were granted on February&nbsp;22, 2021, of which, 25% vested on
the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first
anniversary of the grant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">50,000 restricted common stock awards were granted on February&nbsp;22, 2021, of which, 25% vested on
the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first
anniversary of the grant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">72,710 restricted common stock awards were granted on July&nbsp;7, 2022, of which, 25% vested on the first
anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following the first anniversary
of the grant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD STYLE="text-align: justify">67,273 non-qualified stock option awards were granted on October&nbsp;23, 2023, of which, 25% of the option
vests on the first anniversary of the grant date and the remaining 75% vests in equal monthly installments during the 36 months following
the first anniversary of the grant date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Potential Payments upon Termination or Change
in Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our named executive officers
each have employment agreements with us, pursuant to which they are entitled to receive certain benefits upon qualifying termination.
See the section &ldquo;Employment Agreements&rdquo; above for additional information regarding these benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clawback Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We intend to adopt a clawback
policy that is compliant with the Nasdaq rules, as required by the Dodd-Frank Act, to be effective upon the closing of this offering,
the form of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this offering, <FONT STYLE="background-color: white">we
have provided annual grants of restricted stock or stock options to our non-employee directors for their service on the Board. On April&nbsp;30,
2023, each of our non-employee directors were granted options to purchase 28,695 shares of common stock. The options have an exercise
price of $1.19 per share, the fair market value on the date of grant as determined by our board of directors based on an independent third-party
valuation. The options vest as to 50% on the award date, and the remaining 50% vest on the first anniversary of the award date, subject
to such director&rsquo;s continued service. We also had a policy of reimbursing all of our non-employee directors for their reasonable
out-of-pocket&nbsp;expenses in connection with attending Board and committee meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
compensation earned during the year ended December&nbsp;31, 2023 by each director who is not a named executive officer and served during
the year ended December&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Name</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Stock Awards</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option Awards<SUP>(1)</SUP></B></FONT></TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">All Other<BR> Compensation</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 24%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron G.L. Fletcher, Ph.D.<SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les Kreis,&nbsp;Jr<SUP>.(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd Thomson<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan Zabrowski, Ph.D.<SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents an annual grant on April&nbsp;30, 2023 of an option to purchase 28,695 shares of common stock
with an exercise price of $1.19 per share. The dollar amounts listed reflect the value of the underlying shares as of the grant date calculated
in accordance with ASC Topic 718 based upon the fair-market value of our common stock on the date of the grant and, therefore, do not
necessarily reflect the actual value received by the individuals. The assumptions made in computing the estimated fair value of such awards
are disclosed in Note 9 to the our consolidated financial statements included in this prospectus&nbsp;for the fiscal year ended December&nbsp;31,
2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (2) </TD><TD STYLE="text-align: justify"> At December 31, 2023, 14,437 stock
                                            options remained outstanding. The stock options granted to each of Dr.&nbsp;Fletcher and
                                            Mr.&nbsp;Kreis are held by BP Directors, LP., which is a fund affiliated with Bios Partners. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (3) </TD><TD STYLE="text-align: justify"> At December 31, 2023, 14,437 stock
                                            options remained outstanding. The stock options granted to Mr.&nbsp;Thomson are held by Kairos
                                            Venture Partners II, L.P., which is a fund affiliated the Kairos Venture Affiliated Funds. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">(4)</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">At
                                            December 31, 2023, 14,437 stock options remained outstanding. The stock options granted to
                                            Dr.&nbsp;Zabrowski are held by the Catharine A. Zabrowski Irrevocable Trust, of which Catherine
                                            A. Zabrowski, the wife of Dr.&nbsp;Zabrowski, is the trustee. Dr. Zabrowski does not have
                                            any investment or voting power with respect to, and disclaims any beneficial ownership of
                                            securities of the Company held by, such trust.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
the Board has established, based upon the recommendation of the compensation committee, a compensation program for the non-employee&nbsp;members
of the Board. The compensation program is designed to align the directors&rsquo; compensation with our business objectives and the creation
of stockholder value. The compensation committee and the Board expect to review non-employee&nbsp;director compensation periodically to
ensure that such compensation remains competitive and enables us to recruit and retain qualified directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the non-employee&nbsp;directors&rsquo;
compensation program, beginning upon the closing of this offering, each non-employee director will receive an annual cash retainer and
will receive cash fees for serving as chair or as a member of the audit, compensation or nominating and corporate governance committees,
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: left">Annual Director Compensation Cash Retainer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Additional Annual Compensation for Committee Chairs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Compensation Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Nominating and Corporate Governance Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: left">Additional Annual Compensation for Committee Members (Other than Chairs)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Audit Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Compensation Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Nominating and Corporate Governance Committee</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In addition, each non-employee&nbsp;director,
upon their initial appointment or election, and on an annual basis, will receive a grant of stock options under our 2024 Plan with a
fair market value as of the grant date equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, respectively, with the initial grant vesting in three equal installments on the first, second, and third anniversary of the grant date,
and with the annual grants vesting in full on the first anniversary of the grant date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employee Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Incentive Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal features of
our stock incentive plans are summarized below. These summaries are qualified in their entirety by reference to the actual text of the
plans, which are filed as exhibits to the registration statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>2024 Equity Incentive Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
our board of directors has adopted and our stockholders have approved our 2024 Stock Incentive Plan, or the 2024 Plan, which becomes effective
upon the closing of this offering. Under the 2024 Plan, we may grant cash and equity incentive awards to eligible service providers in
order to attract, motivate and retain the talent for which we compete. The material terms of the 2024 Plan are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility
and administration.</I></FONT>&nbsp;Our employees, consultants and directors, and employees and consultants of any subsidiary, will be
eligible to receive awards under the 2024 Plan. Following this offering, the 2024 Plan will generally be administered by our Board with
respect to awards to&nbsp;non-employee&nbsp;directors and by our compensation committee with respect to other participants, each of which
may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator
below), subject to certain limitations that may be imposed under the 2024 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange
rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all
forms for use with, and adopt rules&nbsp;for the administration of, the 2024 Plan, subject to its express terms and conditions. The plan
administrator will also set the terms and conditions of all awards under the 2024 Plan, including any vesting and vesting acceleration
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Limitation on awards
and shares available.&nbsp;</I>The number of shares initially available for issuance under awards granted pursuant to the 2024 Plan will
be the sum of (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the number of &ldquo;pricing date
fully-diluted shares&rdquo; (as defined below), plus (2)&nbsp;any shares of our common stock which, as of the effective date of the 2024
Plan, remain available for issuance under the 2015 Plan, (3)&nbsp;any shares subject to outstanding awards under the 2015 Plan as of
the effective date of the 2024 Plan that become available for issuance under the 2024 Plan thereafter in accordance with its terms, and
(4) an annual increase on the first day of each calendar year beginning January&nbsp;1, 2025 and ending on and including January&nbsp;1,
2034, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately
preceding calendar year and (B)&nbsp;such smaller number of shares as is determined by the administrator. The entirety of the overall
share limit shall be available for awards of incentive stock options. Shares issued under the 2024 Plan may be authorized but unissued
shares, shares purchased on the open market or treasury shares. For purposes of the 2024 Plan, the &ldquo;pricing date fully-diluted
shares&rdquo; means, as of the <FONT STYLE="background-color: white">date on which the registration statement of which this prospectus
forms a part is declared effective, the sum of (1)&nbsp;the shares of our common stock outstanding on such date (calculated on an as-converted
basis after giving effect to the conversion of our outstanding securities into shares in connection with the initial public offering
and after giving effect to the issuance of the shares to be sold in this initial public offering and assuming the exercise in full of
the underwriters&rsquo; over-allotment option in such initial public offering), (2)&nbsp;the shares of our common stock subject to compensatory
equity awards (including stock options) outstanding on such date (with the number of shares subject to performance-based compensatory
equity awards calculated at the &ldquo;maximum&rdquo; level of performance), and (3)&nbsp;all shares of common stock available for future
issuance under the 2024 Plan as of such date.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an award under the 2024 Plan </FONT>or the 2015 Plan expires, lapses or is terminated, exchanged for or settled in cash, surrendered,
repurchased, cancelled without having been fully exercised or forfeited, in any case, in a manner that results in us acquiring shares
covered by the award at a price not greater than the price paid by the participant for such shares or not issuing any shares covered
by the award, any shares subject to such award will, as applicable, become or again be available for new grants under the 2024 Plan.
Awards granted under the 2024 Plan upon the assumption of, or in substitution for, awards authorized or outstanding under a qualifying
equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available
for grant under the 2024 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Awards.&nbsp;</I></FONT>The
2024 Plan provides for the grant of stock options, including incentive stock options (ISOs) within the meaning of Section&nbsp;422 of
the Code, and nonqualified stock options (NSOs); restricted stock; dividend equivalents; restricted stock units (RSUs); stock appreciation
rights (SARs); and other stock or cash-based awards. Certain awards under the 2024 Plan may constitute or provide for a deferral of compensation,
subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards
under the 2024 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable
vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares
of our common stock, but the plan administrator may provide for cash settlement of any award. A brief description of each award type
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Stock
                                            Options.&nbsp;</I>Stock options provide for the purchase of shares of our common stock in
                                            the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide
                                            tax deferral beyond exercise and favorable capital gains tax treatment to their holders if
                                            certain holding period and other requirements of the Code are satisfied. The exercise price
                                            of a stock option will not be less than 100% of the fair market value of the underlying share
                                            on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders),
                                            except with respect to certain substitute options granted in connection with a corporate
                                            transaction. The term of a stock option may not be longer than ten years (or five years in
                                            the case of ISOs granted to certain significant stockholders). Vesting conditions determined
                                            by the plan administrator may apply to stock options and may include continued service, performance
                                            and/or other conditions. ISOs generally may be granted only to our employees and employees
                                            of any subsidiary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>SARs.</I>&nbsp;SARs
                                            entitle their holder, upon exercise, to receive from us an amount equal to the appreciation
                                            of the shares subject to the award between the grant date and the exercise date. The exercise
                                            price of a SAR will not be less than 100% of the fair market value of the underlying share
                                            on the date of grant (except with respect to certain substitute SARs granted in connection
                                            with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting
                                            conditions determined by the plan administrator may apply to SARs and may include continued
                                            service, performance and/or other conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Restricted
                                            Stock and RSUs.</I>&nbsp;Restricted stock is an award of nontransferable shares of our common
                                            stock that remain forfeitable unless and until specified conditions are met, and which may
                                            be subject to a purchase price. RSUs are contractual promises to deliver shares of our common
                                            stock in the future, which may also remain forfeitable unless and until specified conditions
                                            are met. Delivery of the shares <FONT STYLE="background-color: white">underlying RSUs may
                                            be deferred under the terms of the award or at the election of the participant, if the plan
                                            administrator permits such a deferral. Conditions applicable to restricted stock and RSUs
                                            may be based on continuing service, the attainment of performance goals and/or such other
                                            conditions as the plan administrator may determine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Other
                                            Stock or Cash-Based Awards.</I>&nbsp;Other stock or cash-based awards are awards of cash,
                                            fully vested shares of our common stock and other awards valued wholly or partially by referring
                                            to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may
                                            be granted to participants and may also be available as a payment form in the settlement
                                            of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees,
                                            or other cash compensation otherwise payable to any individual who is eligible to receive
                                            awards. The plan administrator will determine the terms and conditions of other stock or
                                            cash-based awards, which may include vesting conditions based on continued service, performance
                                            and/or other conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Dividend
                                            Equivalents.</I>&nbsp;RSUs or other stock and cash-based awards may be accompanied by the
                                            right to receive the equivalent value of dividends paid on shares of our common stock prior
                                            to the delivery of the underlying shares. Such dividend equivalents will only be paid out
                                            to the extent that any vesting conditions are subsequently satisfied, unless otherwise determined
                                            by the plan administrator. No dividend equivalents will be payable on stock options or SARs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
Awards</I></FONT>. Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment based on
the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively
determinable. Performance criteria upon which performance goals are established by the plan administrator may include: net earnings or
losses (either before or after one or more of interest, taxes, depreciation, amortization and&nbsp;non-cash&nbsp;equity-based compensation
expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income;
profits (including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return
ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead
and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on
capital or invested capital; cost of capital; return on stockholders&rsquo; equity; total stockholder return; return on sales; costs,
reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share;
price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance;
implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones
or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer
satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human capital management (including
diversity and inclusion); supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios
(including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing
and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives,
any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may
be based solely by reference to our performance or the performance of a subsidiary, division, business segment or business unit, or based
upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance
of other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Director
Compensation</I></FONT>. The 2024 Plan provides that the plan administrator may establish compensation for&nbsp;non-employee&nbsp;directors
from time to time subject to the 2024 Plan&rsquo;s limitations. The initial terms of our&nbsp;non-employee&nbsp;director compensation
program is described below under the subsection titled &ldquo;&mdash;Director Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
Transactions</I></FONT>. In connection with certain transactions and events affecting our common stock, including a change in control
(as defined below), or change in any applicable laws or accounting principles, the plan administrator has broad discretion to act under
the 2024 Plan to prevent the dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such
change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other
property with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of such award
or realization of the participant&rsquo;s rights under the vested portion of such award, accelerating the vesting of awards, providing
for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares available, replacing awards
with other rights or property or terminating awards under the 2024 Plan. In the event of a change in control where the acquirer does
not assume awards granted under the 2024 Plan, the plan administrator may provide that awards issued under the 2024 Plan be subject to
accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable. In addition, in the event
of certain&nbsp;non-reciprocal&nbsp;transactions with our stockholders (an equity restructuring) the plan administrator will make equitable
adjustments to the 2024 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
purposes of the 2024 Plan, a &ldquo;change in control&rdquo; means the occurrence of (i)&nbsp;a sale, lease or other disposition of all
or substantially all of our assets, (ii)&nbsp;a merger or consolidation in which we are not the surviving corporation (except for a merger
or consolidation with an entity controlled by our stockholders), (iii)&nbsp;a reverse merger in which we are the surviving corporation
but the Shares outstanding immediately preceding the merger are converted by virtue of the merger into other property, whether in the
form of securities, cash or otherwise or (iv)&nbsp;the adoption of a plan of our dissolution or liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Participants, Clawback Provisions, Transferability, and Participant Payments.&nbsp;</I></FONT>With respect to foreign participants, the
plan administrator may modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share
limits described above. All awards will be subject to the provisions of any clawback policy implemented by us and to the extent set forth
in such clawback policy or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders,
certain beneficiary designations and the laws of descent and distribution, awards under the 2024 Plan are generally nontransferable prior
to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards
under the 2024 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2024 Plan, the
plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions
(a market sell order) or such other consideration as it deems suitable or any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Plan
amendment and termination.&nbsp;</I></FONT>Our board of directors may amend, suspend, or terminate the 2024 Plan at any time; however,
except in connection with certain changes in our capital structure, stockholder approval will be required for any amendment that increases
the number of shares available under the 2024 Plan. No award may be granted pursuant to the 2024 Plan after the tenth anniversary of
the date on which our board of directors adopted the 2024 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2015 Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April&nbsp;2015, the Board
and our stockholders approved the 2015 Plan, which was most recently amended in 2022. The 2015 Plan will be terminated prior to the completion
of this offering, and thereafter we will not grant any additional awards under our 2015 Plan. However, our 2015 Plan will continue to
govern the terms and conditions of the outstanding awards previously granted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility
and Administration</I></FONT>. Our employees, consultants and directors are eligible to receive awards under the 2015 Plan. The Board
or a committee or an officer delegated by the Board administers our 2015 Plan. Subject to the terms of our 2015 Plan, the administrator
has the power to, among other things, select the persons to whom awards may be granted, determine the type of award to be granted to
any person, determine the number and type of shares to be covered by each award, establish the terms and conditions of each award agreement,
determine whether and under what circumstances an option may be exercised without a payment of cash, and determine whether and to what
extent and under what circumstances shares and other amounts payable with respect to an award may be deferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitation
on Awards and Shares Available</I></FONT>. Subject to certain capitalization adjustments, the aggregate number of shares of our common
stock that may be issued pursuant to awards under our 2015 Plan is 3,670,566 shares. No more than 3,670,566 shares of common stock may
be issued upon the exercise of incentive stock options under the 2015 Plan. The shares issued pursuant to the 2015 Plan may be authorized
but unissued shares or may be shares issued pursuant to the 2015 Plan that have been reacquired by us. Shares subject to stock awards
granted under our 2015 Plan that expire or terminate without being exercised or otherwise issued in full or that are paid out in cash
rather than in shares and shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to
satisfy a tax with-holding obligation do not reduce the number of shares available for issuance under our 2015 Plan. If any shares of
our common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us, such shares revert to and
again become available for issuance under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Awards</I></FONT>.
The 2015 Plan provides for the grant of ISOs, NSOs and restricted common stock. All the our employees and any subsidiary employees (including
officers and directors who are also employees), as well as all of our non-employee directors and other consultants, advisors and other
persons who provide services to us are eligible to receive incentive awards under the 2015 Plan. All awards under the 2015 Plan will
be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment
terms and post-termination exercise limitations. Awards generally will be settled in shares of our common stock, but the plan administrator
may provide for cash settlement of any award. A brief description of each award type follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Stock
                                            Options</I>. ISOs and NSOs are granted pursuant to stock option agreements adopted by the
                                            administrator. ISOs may be granted only to our employees and our subsidiary corporations&rsquo;
                                            employees. All other awards may be granted to employees, directors and consultants of ours
                                            and to any of our subsidiary corporations&rsquo; employees or consultants. The administrator
                                            determines the exercise price for a stock option, provided that the exercise price of a stock
                                            option generally cannot be less than 100% of the fair market value of our common stock on
                                            the date of grant. Options granted under our 2015 Plan vest at the rate specified by the
                                            administrator. The administrator determines the term of stock options granted under our 2015
                                            Plan, up to a maximum of 10 years. Unless the terms of an optionholder&rsquo;s stock option
                                            agreement provide otherwise, if an optionholder&rsquo;s service relationship with us, or
                                            any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder
                                            may generally exercise any vested options for a period of 90 days following the cessation
                                            of service. If an optionholder&rsquo;s service relationship with us or any of our affiliates
                                            ceases due to disability or death, or an optionholder dies within a certain period following
                                            cessation of service, the optionholder or a beneficiary may generally exercise any vested
                                            options for a period of one year. In the event of a termination for cause, options generally
                                            terminate immediately upon the termination of the individual for cause. In no event may an
                                            option be exercised beyond the expiration of its term. Acceptable consideration for the purchase
                                            of our common stock issued upon the exercise of a stock option will be determined by the
                                            administrator and set forth in the award agreement and may include (1)&nbsp;cash, certified
                                            check, bank draft and wire transfer, (2)&nbsp;a cashless exercise, (3)&nbsp;the tender of
                                            shares of our common stock previously owned by the optionholder, (4)&nbsp;promissory note
                                            and shares pledged as collateral by the optionholder and (5)&nbsp;other legal consideration
                                            approved by the administrator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate fair market value, determined
at the time of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any
calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally
be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more
than 10% of our total combined voting power or that of any of our affiliates unless (1)&nbsp;the option exercise price is at least 110%
of the fair market value of the stock subject to the option on the date of grant and (2)&nbsp;the term of the ISO does not exceed five
years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>Restricted
                                            Stock Awards</I>. Restricted stock awards are granted pursuant to restricted stock award
                                            agreements adopted by the administrator. Restricted stock awards may be granted for such
                                            consideration as may be determined by the administrator and set forth in the award agreement
                                            and may include (1)&nbsp;cash, certified check, bank draft and wire transfer, (2)&nbsp;a
                                            cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by
                                            the award holder, (4)&nbsp;promissory note and shares pledged as collateral by the award
                                            holder and (5)&nbsp;other legal consideration approved by the administrator. Common stock
                                            acquired under a restricted stock award are subject to repurchase by us in accordance with
                                            the terms of any applicable stockholders&rsquo; agreement and such other conditions as set
                                            forth in the applicable award agreement. A restricted stock award may be transferred only
                                            upon such terms and conditions as set by the administrator. Except as otherwise provided
                                            in the applicable award agreement, restricted stock awards that have not vested may be forfeited
                                            or repurchased by us upon the participant&rsquo;s cessation of continuous service for any
                                            reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December&nbsp;31, 2023,
stock options covering 478,001 shares of our common stock with a weighted-average exercise price of $1.19 per share were outstanding,
restricted stock awards covering 304,251 shares of our common stock were unvested and outstanding, and 1,124,246 shares of our common
stock remained available for the future grant of awards under our 2015 Plan. In addition, any shares subject to options that expire or
terminate prior to exercise or are withheld to satisfy tax withholding obligations related to an option or the exercise price of an option
will be added to the number of shares then available for issuance under our 2024 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
Transactions</I></FONT>. In the event there is a specified type of change in our capital structure not involving receipt of consideration
(such as through a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, stock split or reverse stock
split), appropriate adjustments will be made to the number of shares available for issuance under our 2015 Plan and the number of shares
covered by and, as applicable, the exercise price of each outstanding award granted under our 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the 2015 Plan, a &ldquo;change of control&rdquo; means the occurrence of (i)&nbsp;a sale, lease or other disposition of all
or substantially all of our assets, (ii)&nbsp;a merger or consolidation in which we are</FONT> <FONT STYLE="font-size: 10pt">not the surviving
corporation (except for a merger or consolidation with an entity controlled by our </FONT>stockholders), (iii)&nbsp;a reverse merger
in which we are the surviving corporation but the shares of our common stock outstanding immediately preceding the merger are converted
by virtue of the merger into other property, whether in the form of securities, cash or otherwise or (iv)&nbsp;the adoption of a plan
of our dissolution or liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a &ldquo;change
of control&rdquo;, unless the administrator determines otherwise, then the following actions will occur with respect to outstanding awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            vesting of all of awards will accelerate as of the change in control date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            surviving or acquiring corporation will assume or continue such awards, or to substitute
                                            a similar stock award for such outstanding awards;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">The
                                            administrator may instead provide that awards are cancelled in exchange for cash or other
                                            consideration and/or provide a limited period for the exercise of stock options before they
                                            will terminate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The administrator need not
take the same action or actions with respect to all stock awards or portions thereof or with respect to all participants or with respect
to the vested or unvested portion of such stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transferability
and Participants Payments. </I></FONT>With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations
and the laws of descent and distribution, awards under the 2015 Plan are generally nontransferable prior to vesting and are exercisable
only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2015 Plan and exercise
price obligations arising in connection with the exercise of stock options under the 2015 Plan, the plan administrator may, in its discretion,
accept cash, wire transfer, or check, shares of our common stock that meet specified conditions (a market sell order) or such other consideration
as it deems suitable or any combination of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Plan
Amendment or Termination</I></FONT>. The Board may amend, modify or terminate our 2015 Plan at any time, provided that (1)&nbsp;such
action cannot impair the rights of holders of outstanding awards unless the majority of the impaired holders provide consent and (2)&nbsp;any
increase in the shares available for issuance, change in employees eligible to receive ISOs, or change in the identity of the granting
entity issuing ISOs or shares upon exercise thereof requires approval of our stockholders within 12 months thereafter. Unless terminated
sooner by the Board, the 2015 Plan will automatically terminate on August&nbsp;21, 2032. As discussed above, we will terminate our 2015
Plan prior to the completion of this offering and no new awards will be granted thereunder following such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_013"></A>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following includes a
summary of transactions since January&nbsp;1, 2021 and any currently proposed transactions, to which we were or are to be a participant,
in which (i)&nbsp;the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets
at year-end for the last two completed fiscal years; and (ii)&nbsp;any of our directors, executive officers or holders of more than 5%
of our capital stock, or any affiliate or member of the immediate family of the foregoing persons, had or will have a direct or indirect
material interest, other than compensation and other arrangements that are described under the section of this prospectus titled &ldquo;Executive
and Director Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Convertible Promissory Note, Preferred Stock
and Warrant Financings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From September&nbsp;2015 to October&nbsp;2019, we issued shares of
Series&nbsp;A redeemable convertible preferred stock, shares of Series&nbsp;B-1 redeemable convertible preferred stock and warrants to
purchase 137,465 shares of our Series&nbsp;B-1 redeemable convertible preferred stock at an exercise price of $2.93 per share and warrants
to purchase 137,465 shares of our Series&nbsp;B-1 redeemable convertible preferred stock at an exercise price of $5.86 per share, or the
Series&nbsp;B-1 warrants. The Series&nbsp;B-1 warrants terminate at the earlier of the ten-year anniversary from the issuance date, the
consummation of a change of control, or upon the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> In April&nbsp;2019, we
entered into a Series&nbsp;B preferred stock purchase agreement with various investors, pursuant to which we issued and sold in an initial
closing and subsequent closings in May&nbsp;2019, October&nbsp;2019 and December&nbsp;2020 an aggregate of 9,808,101 shares of our Series&nbsp;B-1,
B-2, B-3 and B-4 redeemable convertible preferred stock. The Series&nbsp;B-1 per share purchase price was $3.66, the Series&nbsp;B-2
per share purchase price was $3.83, the Series&nbsp;B-3 per share purchase price was $4.00 and the Series&nbsp;B-4 per share purchase
price was $4.18, and we received aggregate gross proceeds of approximately $38.6 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From August&nbsp;2022 to June&nbsp;2023, we entered into a Series&nbsp;C
preferred stock purchase agreement with various investors, pursuant to which, in seven separate tranches, we issued and sold an aggregate
of 5,570,200 shares of our Series&nbsp;C redeemable convertible preferred stock at a price per share of $4.36 for aggregate net proceeds
of $23.4 million. In connection with the Series&nbsp;C financing, we also issued warrants to the placement agent to purchase 32,796 shares
of our Series&nbsp;C redeemable convertible preferred stock at an exercise price of $5.23 per share (the Series&nbsp;C warrants). The
Series&nbsp;C warrants terminate at the earlier of the five-year anniversary from the issuance date, the consummation of a change of control,
or upon the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&nbsp;2024, we issued to Bios Clinical Opportunity Fund,
LP, which is a fund affiliated with the Bios Equity Affiliated Funds, a convertible promissory note (the Bridge Note) in the aggregate
principal amount of $3,000,000. The Bridge Note accrues interest at a rate of 7% per annum and is due and payable on June&nbsp;30, 2024,
subject to its earlier conversion as described below. The Bridge Note will automatically convert into (i)&nbsp;in the case of a qualified
financing (as defined in the Bridge Note), that number of shares of capital stock issued in such qualified financing equal to the quotient
obtained by dividing the outstanding principal amount of the Bridge Note plus all accrued and unpaid interest thereon by the price of
shares to be sold in the qualified financing multiplied by 0.80, and (ii)&nbsp;in the case of this offering, such number of shares of
common stock equal to the principal amount and the accrued but unpaid interest thereon, divided by 80% of the offering price, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock, at an assumed initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share of common stock, the midpoint of the price range set forth on the cover page&nbsp;of this prospectus. If a qualified financing or
this offering is not consummated prior to June&nbsp;30, 2024, the holder of the Bridge Note may elect to convert the Bridge Note into
such number of shares of Series&nbsp;C redeemable convertible preferred stock equal to the principal amount plus the accrued and unpaid
interest thereon divided by $4.36, rounded down to the nearest share, or elect that the Bridge Note become fully due and payable in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The table below sets forth
the number of shares of our Series&nbsp;A, B and C redeemable convertible preferred stock, Series&nbsp;B-1 and Series&nbsp;C warrants
and the Bridge Note held by holders of more than 5% of our capital stock and their affiliated entities, Bios Equity Affiliated Funds
and Kairos Venture Affiliated Funds, as of December&nbsp;31, 2023. As of March 31, 2024, assuming (i)&nbsp;the conversion of all outstanding
shares of our redeemable convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock in connection with the closing of this offering; (ii)&nbsp;the conversion of our redeemable preferred stock
into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock upon the net exercise of outstanding Series&nbsp;B Warrants and Series&nbsp;C Warrants, assuming an initial offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the termination of such warrants containing
an exercise price greater than the initial offering price per share of common stock, immediately prior to the closing of this offering,
(iii)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock to our chief executive officer pursuant to the CEO Employment Agreement upon the closing of this offering,
(iv)&nbsp;the conversion of the Bridge Note into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock upon the closing of this offering, (v)&nbsp;no exercise of the underwriters&rsquo; over-allotment option to
purchase additional shares of common stock; and (vi)&nbsp;no exercise of outstanding options, we will have outstanding an aggregate of
approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock, the Bios Equity Affiliated Funds beneficially hold approximately &nbsp;&nbsp;&nbsp;% of our outstanding shares
and the Kairos Venture Affiliated Funds beneficially own approximately &nbsp;&nbsp;&nbsp;% of our outstanding shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr.&nbsp;Fletcher, who has
served as our director and chairperson of the board since April&nbsp;2015, has served as the President of Bios Research since 2012. Mr.&nbsp;Kreis,
who has served as our director since March&nbsp;2015, is also a Co-Founder and has served as the Managing Partner of Bios Partners since
2013. Dr.&nbsp;Fletcher and Mr.&nbsp;Kreis are each deemed to beneficially own the shares and warrants held by the Bios Equity Affiliated
Funds. Mr.&nbsp;Thomson, our director since September&nbsp;2022, has served as the Chief Operating and Financial Officer of Kairos Ventures
since August&nbsp;2019. Mr.&nbsp;Thompson is deemed to beneficially own the shares and warrants held by the Kairos Venture Affiliated
Funds. In connection with this offering, holders of a majority of the outstanding shares of each series of convertible preferred stock
have agreed to cause the conversion of all outstanding shares of convertible preferred stock into common stock immediately prior to the
closing of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Greater
    than 5% stockholders<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><B>Series&nbsp;A<BR>
    Redeemable<BR>
    Convertible<BR>
    Preferred<BR>
    Stock<BR>
    (#)</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series&nbsp;B-1<BR>
    Redeemable<BR>
    Convertible<BR>
    Preferred<BR>
    Stock<BR>
    (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Series&nbsp;B-2</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Redeemable</B></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible<BR>
Preferred<BR>
Stock<BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Series&nbsp;B-3</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Redeemable</B></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible<BR>
Preferred<BR>
Stock<BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Series&nbsp;B-4</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Redeemable</B></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible<BR>
Preferred<BR>
Stock<BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series&nbsp;B-1
    Warrants (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Series&nbsp;C</B></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Redeemable</B></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible<BR>
Preferred<BR>
Stock<BR>
(#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series&nbsp;C<BR>
    Warrants<BR>
    (#)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Principal Amount of Bridge Note</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>($)</B></P></TD>
    <TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 28%; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bios Equity Affiliated Funds</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,500,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,474,352</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">722,167</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">862,595</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,555,060</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,620</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,178,894</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,000,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos Venture Affiliated Funds</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,904,972</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,307,093</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">639,365</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">654,306</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102,468</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">133,417</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional details regarding these stockholders and their equity holdings are provided in &ldquo;Principal Securityholders.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investors&rsquo; Rights, Voting and Right of
First Refusal and Co-Sale Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bios Equity Affiliated
Funds and Kairos Ventures Affiliated Funds are parties to the following agreements entered into in connection with the investments described
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investor Rights Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
entered into a fourth amended and restated investor rights agreement in November&nbsp;2022 (the Investor Rights Agreement) with the holders
of our redeemable convertible preferred stock, or the preferred stockholders. The Investor Rights Agreement provides for </FONT>certain
customary demand and &ldquo;piggy-back&rdquo; registration rights for a period of three years following our initial public offering, with
respect to the shares of common stock underlying the <FONT STYLE="background-color: white">redeemable convertible preferred stock </FONT>owned
by the preferred stockholders. All expenses incurred in connection with registrations, filings or qualifications, including (without limitation)
all registration, filing and qualification fees, printer&rsquo;s fees, accounting fees and fees and disbursements of our counsel and the
reasonable fees and disbursements of one counsel for the selling holders not to exceed $30,000 per registration, but excluding underwriting
discounts and commissions relating to registrable securities, will be borne by the us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preferred stockholders
also agreed, pursuant to the <FONT STYLE="background-color: white">Investor Rights Agreement</FONT>, subject to certain exceptions, not
to sell any registrable securities for a period of at least 180 days following the date of a final prospectus relating to the registration
by us of shares of our common stock or any other equity securities under the Securities Act on a registration statement on Form&nbsp;S-1
or Form&nbsp;S-3, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, pursuant to the
<FONT STYLE="background-color: white">Investor Rights Agreement</FONT>, we granted each of the preferred stockholders that, individually
or together with such preferred stockholder affiliates, holds at least 683,122 shares of registrable securities, a pro rata right, based
on their respective percentage equity ownership in us (assuming the conversion of all outstanding preferred stock into common stock and
the exercise of all options outstanding under our stock plans), to participate in subsequent issuances of our equity securities, not including
exempted securities (as defined in the fifth amended and restated certificate of incorporation) or shares of common stock issued in our
initial public offering. Such rights terminate immediately before the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a fourth amended
and restated voting agreement in November&nbsp;2022 (the Voting Agreement) with the preferred stockholders. Through the date of this offering,
our Board consisted of five members. The holders of the Series&nbsp;A Preferred Stock, voting as a separate class, were entitled to elect
one member of the Board, with the initial director being Dr.&nbsp;Fletcher, the holders of the Series&nbsp;B Preferred Stock, voting as
a separate class, were entitled to elect two members of the Board, with the initial directors being Messrs.&nbsp;Kreis,&nbsp;Jr. and Thomson,
and the holders of the Series&nbsp;C Preferred Stock, voting as a separate class, were entitled to elect one member of the Board. The
holders of common stock, voting as a separate class, were entitled to elect one member of the Board, with the initial director being Mr.&nbsp;Schmitt.
The holders of the Preferred Stock and the common stock voting together as a single class on an as-converted basis were also entitled
to elect one additional &ldquo;independent&rdquo; director, as such term is defined in the Exchange Act, with the initial director being
Dr.&nbsp;Zabrowski.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Voting Agreement will
terminate upon the closing of this offering, and members previously elected to the Board pursuant to the Voting Agreement will continue
to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition
of the Board is described in more detail in the section titled &ldquo;Management.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Right of First Refusal and Co-Sale Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
entered into a fourth amended and restated right of first refusal and&nbsp;co-sale&nbsp;agreement in November&nbsp;2022 (the ROFR and
Co-Sale Agreement) with Messrs.&nbsp;Schmitt and Mazar and Francis Giles, each referred to in the ROFR and Co-Sale Agreement as a key
holder, and certain holders of our preferred stock that individually or together with their respective affiliates, hold at least 683,122
shares of common stock, which holders are referred to in the ROFR and Co-Sale Agreement as major investors. Pursuant to the ROFR and Co-Sale
Agreement, the major investors have a right of first refusal on certain transfers of our shares by the key holders, and i</FONT>f any
shares proposed to be transferred by a key holder is not purchased pursuant to the major investors&rsquo; right of first refusal and is
to be sold to a prospective transferee, <FONT STYLE="background-color: white">the major investors have a right of&nbsp;co-sale&nbsp;in
respect of such transfers. The ROFR and Co-Sale Agreement will terminate upon the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in">We have entered into indemnification
agreements with certain of our current directors and executive officers, and intend to enter into new indemnification agreements with
each of our current directors and executive officers before the completion of this offering. Our amended and restated certificate of
incorporation and our amended and restated bylaws will provide that we will indemnify our directors and officers to the fullest extent
permitted by applicable law. See the section of this prospectus titled &ldquo;Management&mdash;Limitation on Liability and Indemnification
Matters.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Policies and Procedures for Related Party
Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to adopt a written
related-person transactions policy prior to the completion of this offering that sets forth our policies and procedures regarding the
identification, review, consideration and oversight of &ldquo;related-person transactions.&rdquo; For purposes of our policy only, a
 &ldquo;related-person transaction&rdquo; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements
or relationships) in which we and any &ldquo;related person&rdquo; are participants involving an amount that exceeds $120,000. Transactions
involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions
under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than five percent
of our common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the policy, where a
transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person
transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our
board of directors) for review. The presentation must include a description of, among other things, all of the parties thereto, the direct
and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to
us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from
unrelated third parties and management&rsquo;s recommendation. To identify related-person transactions in advance, we rely on information
supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our audit
committee or another independent body of our board of directors takes into account the relevant available facts and circumstances including,
but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            risks, costs and benefits to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            impact on a director&rsquo;s independence in the event the related person is a director,
                                            immediate family member of a director or an entity with which a director is affiliated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            terms of the transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            availability of other sources for comparable services or products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            terms available to or from, as the case may be, unrelated third parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event a director has
an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_014"></A>PRINCIPAL
SECURITYHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth information regarding the actual beneficial ownership of our common stock as of&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
, 2024 by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">each
                                            person or group of affiliated persons known by us to be the beneficial owner of more than
                                            5% of the outstanding shares of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">each
                                            of our named executive officers and directors; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">all
                                            of our executive officers and directors as a group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
according to the rules&nbsp;of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it
possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable
or exercisable within 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Applicable
percentage ownership is based on &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;shares
of common stock outstanding on </FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;,
<FONT STYLE="background-color: white">2024, which gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            filing and effectiveness of our amended and restated certificate of incorporation, which
                                            will occur immediately prior to the closing of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            conversion of all outstanding shares of our redeemable convertible preferred stock
                                            into shares of our common stock immediately prior to the closing of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of common stock issuable upon the conversion of our Series&nbsp;B-1 redeemable preferred
                                            stock to be issued upon the automatic net exercise of warrants outstanding as of December&nbsp;31,
                                            2023, with an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
                                            share, immediately prior to the completion of this offering, based on an assumed initial
                                            public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
                                            of common stock, the midpoint of the price range set forth on the cover of this prospectus; </P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the conversion of our Series&nbsp;B-1 redeemable
                                            preferred stock to be issued upon the automatic net exercise of warrants outstanding as of
                                            December&nbsp;31, 2023, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, immediately prior to the
                                            completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover of this
                                            prospectus;]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock issuable upon the conversion of our redeemable preferred stock
                                            to be issued upon the automatic net exercise of Series&nbsp;C Warrants outstanding as of
                                            December&nbsp;31, 2023, with an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, immediately prior to the
                                            completion of this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover of this
                                            prospectus;]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock issuable to our chief executive officer upon the closing of this offering,
                                            pursuant to his employment agreement (assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover page&nbsp;of
                                            this prospectus); [and] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD><TD STYLE="text-align: justify"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock issuable upon the automatic conversion of the Bridge Note, based on an
                                            assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per share of common stock, the midpoint of the price range set forth on the cover of this
                                            prospectus; [and] </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">[a
                                            &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reverse stock
                                            split of our common stock, which we effected on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
                                            2024].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
we believe that all persons named in the table have sole voting and investment power with respect to all our common stock beneficially
owned by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; padding-left: 0.25in"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of Shares Beneficially Owned</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    and Address of Beneficial Owner</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of<BR>
    Shares<BR>
    Beneficially<BR>
    Owned</B></FONT> </TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Before
    <BR>
    Offering</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>After
    <BR>
    Offering</B></FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors and
    Named Executive Officer</I></FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: right"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: right"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 54%; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    M. Schmitt(1)&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 17%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">961,875</FONT> </TD>
    <TD STYLE="vertical-align: top; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 2%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 1%"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 2%"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Mazar(2)</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">191,174</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Lytle</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    G.L. Fletcher(3)(4)</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,669,115</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd
    Thomson(5)</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,855,488</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les
    Kreis,&nbsp;Jr.(4)(6)</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,640,115</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Zabrowski</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and executive officers (7 individuals)(7)</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,677,652</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 9pt; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5%
    Beneficial Holders</I></FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bios
    Equity Affiliated Funds(4)&nbsp; </FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,429,878</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-indent: -9pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kairos
    Venture Affiliated Funds(5)&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,841,141</FONT> </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD STYLE="vertical-align: bottom"> &nbsp; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Represents
beneficial ownership less than 1%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> (1) </TD><TD STYLE="text-align: justify"> Includes (i)&nbsp;40,000 shares of common stock held by The Andrew
                                  Schmitt Irrevocable Trust, dated December&nbsp;31, 2019, of which Mr.&nbsp;Schmitt is trustee, (ii)&nbsp;40,000
                                  shares of common stock held by The Anna Schmitt Irrevocable Trust, dated December&nbsp;31, 2019, of
                                  which Mr.&nbsp;Schmitt is trustee, (iii)&nbsp;40,000 shares of common stock held by The Edward Schmitt
                                  Irrevocable Trust, dated December&nbsp;31, 2019, of which Mr.&nbsp;Schmitt is trustee, (iv)&nbsp;841,875
                                  shares of common stock held by The Schmitt Family Irrevocable Trust, dated December&nbsp;31, 2019,
                                  of which Mr.&nbsp;Schmitt is trustee, and (v)&nbsp;27,700 shares of restricted common stock that vest
                                  within 60 days. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> (2) </TD><TD STYLE="text-align: justify"> Includes 3,030 shares of restricted common stock that vest within
                                  60 days. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> (3) </TD><TD STYLE="text-align: justify"> Includes (i)&nbsp;109,750 shares of common stock held by Dr.&nbsp;Fletcher
                                  directly, (ii)&nbsp;152,846 shares of common stock and 57,391 shares of common stock underlying options
                                  that are or will be exercisable within 60 days held by BP Directors, LP, of which Dr.&nbsp;Fletcher
                                  is the general partner, (iii)&nbsp;14,500 shares of common stock held by the KF Legacy Trust U/A/D
                                  December&nbsp;7, 2016, of which Dr.&nbsp;Fletcher is the trustee, and (iv)&nbsp;14,500 shares of common
                                  stock held by the MF Legacy Trust U/A/D December&nbsp;7, 2016, of which Dr.&nbsp;Fletcher is the trustee. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> (4) </TD><TD STYLE="text-align: justify"> Includes (i)&nbsp;276,663 shares of common stock issuable upon the
                                  conversion of 276,663 shares of Series&nbsp;B-1 Preferred Stock and 264,684 shares of common stock
                                  issuable upon the conversion of 264,684 shares of Series&nbsp;B-2 Preferred Stock held by Bios Actuate
                                  Co-Invest I, LP, (ii)&nbsp;3,770,368 shares of common stock issuable upon the conversion of 3,770,368
                                  shares of Series&nbsp;C Preferred Stock held by Bios Actuate Co-Invest II, LP, (iii)&nbsp;1,032,108
                                  shares of common stock issuable upon the conversion of 1,032,108 shares of Series&nbsp;C Preferred
                                  Stock held by Bios Actuate Co-Invest III, LP, (iv)&nbsp;553,567 shares of common stock issuable upon
                                  the conversion of 553,567 shares of Series&nbsp;A Preferred Stock held by Bios Fund I QP, LP, (v)&nbsp;946,433
                                  shares of common stock issuable upon the conversion of 946,433 shares of Series&nbsp;A Preferred Stock
                                  held by Bios Fund I, LP, (vi)&nbsp;111,340 shares of common stock issuable upon the conversion of 111,340
                                  shares of Series&nbsp;B-1 Preferred Stock, 42,529 shares of common stock issuable upon the conversion
                                  of 42,529 shares of Series&nbsp;B-2 Preferred Stock, 80,206 shares of common stock issuable upon the
                                  conversion of 80,206 shares of Series&nbsp;B-3 Preferred Stock, and 12,700 shares of common stock issuable
                                  upon the exercise and conversion of securities underlying Series&nbsp;B Warrants held by Bios Fund
                                  II NT, LP, (vii)&nbsp;831,729 shares of common stock issuable upon the conversion of 831,729 shares
                                  of Series&nbsp;B-1 Preferred Stock, 317,697 shares of common stock issuable upon the conversion of
                                  317,697 shares of Series&nbsp;B-2 Preferred Stock, 599,159 shares of common stock issuable upon the
                                  conversion of 599,159 shares of Series&nbsp;B-3 Preferred Stock, and 94,876 shares of common stock
                                  issuable upon the exercise and conversion of 94,876 shares of securities underlying Series&nbsp;B Warrants
                                  held by Bios Fund II QP, LP, (viii)&nbsp;254,620 shares of common stock issuable upon the conversion
                                  of 254,620 shares of Series&nbsp;B-1 Preferred Stock, 97,257 shares of common stock issuable upon the
                                  conversion of 97,257 shares of Series&nbsp;B-2 Preferred Stock, 183,420 shares of common stock issuable
                                  upon the conversion of 183,420 shares of Series&nbsp;B-3 Preferred Stock, and 29,044 shares of common
                                  stock issuable upon the exercise and conversion of securities underlying Series&nbsp;B Warrants held
                                  by Bios Fund II, LP, (ix)&nbsp;587,784 shares of common stock issuable upon the conversion of 587,784
                                  shares of Series&nbsp;B-4 Preferred Stock and 140,878 shares of common stock issuable upon the conversion
                                  of 140,878 shares of Series&nbsp;C Preferred Stock held by Bios Fund III NT, LP, (x)&nbsp;3,639,650
                                  shares of common stock issuable upon the conversion of 3,639,650 shares of Series&nbsp;B-4 Preferred
                                  Stock and 872,346 shares of common stock issuable upon the conversion of 872,346 shares of Series&nbsp;C
                                  Preferred Stock held by Bios Fund III QP, LP, and (xi)&nbsp;557,258 shares of common stock issuable
                                  upon the conversion of 557,258 shares of Series&nbsp;B-4 Preferred Stock and 133,562 shares of common
                                  stock issuable upon the conversion of 133,562 shares of Series&nbsp;C Preferred Stock held by Bios
                                  Fund III, LP. Bios Equity Partners, LP is the general partner of Bios Actuate Co-Invest I, LP; Bios
                                  Equity Partners III, LP is the general partner of Bios Actuate Co-Invest II, LP, Bios Actuate Co-Invest
                                  III, LP, Bios Fund III NT, LP, Bios Fund III QP, LP, Bios Fund III, LP; Bios Equity Partners, LP is
                                  the general partner of Bios Fund I QP, LP and Bios Fund I, LP; and Bios Equity Partners II, LP is the
                                  general partner of Bios Fund II NT, LP, Bios Fund II QP, LP and Bios Fund II, LP (collectively, the
                                  &ldquo;Bios Equity Affiliated Funds&rdquo;). Cavu Management, LP, an entity managed and controlled
                                  by Mr.&nbsp;Kreis,&nbsp;Jr., and Bios Capital Management, LP, an entity managed and controlled by Dr.&nbsp;Fletcher,
                                  are the general partners of Bios Equity Partners, LP, Bios Equity Partners II, LP and Bios Equity Partners
                                  III, LP. Cavu Advisors LLC, an entity that is managed and controlled by Mr.&nbsp;Kreis,&nbsp;Jr., is
                                  the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled
                                  by Dr.&nbsp;Fletcher, is the general partner of Bios Capital Management, LP.&nbsp;The shares owned
                                  by Bios Equity Affiliated Funds are aggregated for purposes of reporting share ownership information.
                                  Mr.&nbsp;Kreis,&nbsp;Jr. and Dr.&nbsp;Fletcher share voting and investment control with respect to
                                  shares held by the Bios Equity Affiliated Funds. The address for Bios Equity Affiliated Funds is 1751
                                  River Run, Suite&nbsp;400, Fort Worth, Texas 76107. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 04 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"> (5) </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Includes
                                  (i)&nbsp;250,000 shares of common stock issuable upon the conversion of 250,000 shares of Series&nbsp;B-3
                                  Preferred Stock, 239,234 shares of common stock issuable upon the conversion of 239,234 shares of Series&nbsp;B-4
                                  Preferred Stock, and 89,970 shares of common stock issuable upon the conversion of 89,970 shares of
                                  Series&nbsp;C Preferred Stock held by Kairos SPV Fund LLC, (ii)&nbsp;1,307,093 shares of common stock
                                  issuable upon the conversion of 1,307,093 shares of Series&nbsp;B-2 Preferred Stock and 264,365 shares
                                  of common stock issuable upon the conversion of 264,365 shares of Series&nbsp;B-3 Preferred Stock held
                                  by Kairos Venture Opportunities I, L.P., (iii)&nbsp;85,172 shares of common stock issuable upon the
                                  conversion of 85,172 shares of common stock held directly, 1,904,972 shares of common stock issuable
                                  upon the conversion of 1,904,972 shares of Series&nbsp;B-1 Preferred Stock, 125,000 shares of common
                                  stock issuable upon the conversion of 125,000 shares of Series&nbsp;B-3 Preferred Stock, 102,468 shares
                                  of common stock issuable upon the exercise and conversion of securities underlying Series&nbsp;B Warrants,
                                  and 28,695 shares of common stock underlying options that are or will be exercisable within 60 days
                                  held by Kairos Venture Partners II, L.P., and (iv)&nbsp;415,072 shares of common stock issuable upon
                                  the conversion of 415,072 shares of Series&nbsp;B-4 Preferred Stock and 43,447 shares of common stock
                                  issuable upon the conversion of 43,447 shares of Series&nbsp;C Preferred Stock held by Kairos-Actuate
                                  SPV L.P. Kairos Venture Investments, LLC is the manager of Kairos SPV Fund LLC; Kairos Venture Opportunities
                                  GP I, LLC is the general partner of Kairos Venture Opportunities I, L.P.; and Kairos Venture Partners
                                  GP II, LLC is the general partner of Kairos-Actuate SPV L.P. and Kairos Venture Partners II, L.P. (collectively,
                                  the &ldquo;Kairos Venture Affiliated Funds&rdquo;). The shares owned by Kairos Venture Affiliated Funds
                                  are aggregated for purposes of reporting share ownership information. Mr.&nbsp;Thomson shares voting
                                  and investment control with </FONT>James Demetriades, CEO of Kairos Ventures, with respect to shares
                                  held by the Kairos Venture Affiliated Funds. The address for Kairos Venture Affiliated Funds is 9440
                                  S. Santa Monica Blvd., Ste. 710, Beverly Hills, CA 90210. </TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i)&nbsp;152,846 shares of common stock held by BP Directors, LP, of which Mr.&nbsp;Kreis,&nbsp;Jr. is the general partner, and (ii)&nbsp;57,391
    shares of common stock underlying options held by BP Directors, LP, of which Mr.&nbsp;Kreis,&nbsp;Jr. is the general partner, that
    are or will be exercisable within 60 days.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    86,086 shares of common stock underlying options that are or will be exercisable within 60 days and 30,730 shares of restricted common
    stock that will be vested within 60 days.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_015"></A>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and our amended and restated bylaws, which will
become effective immediately prior to the completion of this offering, the amended and restated investors&rsquo; rights agreement to
which we and certain of our stockholders are parties and of the Delaware General Corporation Law. Because it is only a summary, it does
not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated
certificate of incorporation, amended and restated bylaws and amended and restated investors&rsquo; rights agreement, copies of which
have been filed as exhibits to the registration statement of which this prospectus is part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of this
offering and the filing our amended and restated certificate of incorporation, our authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock, par value of $0.000001 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of preferred stock, par value $0.000001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Outstanding Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of March 31, 2024,
there were &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock outstanding, including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
subject to forfeiture, held of record by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;stockholders, assuming the
conversion of all of our outstanding shares of redeemable convertible preferred stock into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock immediately prior to the completion of this offering. The number of shares of common stock outstanding does not
include the shares issuable under our warrants, options, equity awards and plans, and other contractual rights to acquire common stock,
as described below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors,
and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to
vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that
holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters
shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders
present or represented and voting on such matter. Our amended and restated certificate of incorporation also provides that our directors
may be removed only for cause and only by the affirmative vote of the holders of at least&nbsp;two-thirds&nbsp;in voting power of the
outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least&nbsp;two-thirds&nbsp;in
voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision
inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See the subsection titled &ldquo;&mdash;Anti-Takeover
Effects of Delaware Law and Our Certificate of Incorporation and Bylaws-Amendment of Charter Provisions&rdquo; below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to preferences that
may apply to any outstanding preferred stock, the holders of our common stock are entitled to receive dividends, if and when declared
by our board of directors out of funds legally available therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a liquidation,
dissolution or winding up, our stockholders will be entitled to share ratably in all assets remaining available for distribution to them
after payment of liabilities and after provision is made for each class of stock, if any, having preference over the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights, Preferences and Privileges</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of our common stock
have no conversion, preemptive or other subscription rights, and there are no sinking fund or redemption provisions applicable to our
common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected
by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fully Paid and Nonassessable</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our outstanding shares
of common stock are fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion of this
offering, all of our currently outstanding shares of redeemable convertible preferred stock will convert into common stock and we will
not have any shares of preferred stock outstanding. Immediately prior to the completion of this offering, our amended and restated certificate
of incorporation will be amended and restated to delete all references to such shares of preferred stock. Our amended and restated certificate
grants our board of directors the authority, without further stockholder authorization, to issue from time to time up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of preferred stock in one or more series and to fix the terms, limitations, voting rights, relative rights and preferences and
variations of each series. Although we have no present plans to issue any shares of preferred stock, the issuance of shares of preferred
stock, or the issuance of rights to purchase such shares, could decrease the amount of earnings and assets available for distribution
to the holders of our common stock, could adversely affect the rights and powers, including voting rights, of the common stock and could
have the effect of delaying, deterring or preventing a change of control of our company or an unsolicited acquisition proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series&nbsp;B-1 Preferred Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of March 31, 2024,
there were outstanding warrants to purchase an aggregate of 274,930 shares of our Series&nbsp;B-1 redeemable convertible preferred stock,
consisting of warrants to purchase 137,465 shares of our Series&nbsp;B-1 redeemable convertible preferred stock at an exercise price
of $2.93 per share and warrants to purchase 137,465 shares of our Series&nbsp;B-1 redeemable convertible preferred stock at an exercise
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case subject to adjustment as set
forth in the warrants (collectively, the Series&nbsp;B Warrants). The Series&nbsp;B Warrants provide that to the extent such warrant
is not previously exercised, it will be deemed to have been automatically converted pursuant to the net exercise provision of the Series&nbsp;B
Warrants as of immediately before its expiration, involuntary termination or cancellation if the then-fair market value of a share issuable
under the warrant exceeds the exercise price, as adjusted. The Series&nbsp;B Warrants are exercisable until their expiration, which will
be triggered upon the closing of this offering. The Series&nbsp;B Warrants also include a cashless exercise feature allowing the holder
to receive shares underlying the applicable Series&nbsp;B Warrant in an amount reduced by the aggregate of the exercise price that would
have been payable upon exercise of the applicable Series&nbsp;B Warrant for such shares. In the event the Series&nbsp;B Warrants are
not exercised prior to the closing of this offering, and provided that such Series&nbsp;B Warrants&rsquo; exercise price per share is
less than the initial public offering price per share of common stock in this offering, such warrants will be automatically exercise
for and converted into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series&nbsp;B-1
redeemable convertible preferred stock, and such shares of Series&nbsp;B-1 redeemable convertible preferred stock shall subsequently
be converted into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock
upon the closing of this offering, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus. In the event
the Series&nbsp;B Warrants are not exercised prior to the closing of this offering and such Series&nbsp;B Warrants&rsquo; exercise price
per share exceeds the initial public offering price per share of common stock, such Series&nbsp;B Warrants will terminate automatically
and no shares of common stock shall be issued to the holders of such Series&nbsp;B Warrants. Upon exercise or conversion, the shares
underlying the Series&nbsp;B Warrants will be entitled to the registration rights set forth in our amended and restated investors&rsquo;
rights agreement. See &ldquo;&mdash;Registration Rights&rdquo; for additional information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series&nbsp;C Preferred Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of March 31, 2024,
there were outstanding warrants to purchase an aggregate of 32,796 shares of our Series&nbsp;C redeemable convertible preferred stock
at an exercise price of $5.23 per share, subject to adjustment as set forth in the warrants (the Series&nbsp;C Warrants). The Series&nbsp;C
Warrants provide that to the extent such warrant is not previously exercised, it will be deemed to have been automatically converted
pursuant to the net exercise provision of the Series&nbsp;C Warrants as of immediately before its expiration, involuntary termination
or cancellation if the then-fair market value of a share issuable under the warrant exceeds the exercise price, as adjusted. The Series&nbsp;C
Warrants are exercisable until their expiration, which will be triggered upon the closing of this offering. The Series&nbsp;C Warrants
also include a cashless exercise feature allowing the holder to receive shares underlying the applicable Series&nbsp;C Warrant in an
amount reduced by the aggregate of the exercise price that would have been payable upon exercise of the applicable Series&nbsp;C Warrant
for such shares. In the event the Series&nbsp;C Warrants are not exercised prior to the closing of this offering, and provided that the
Series&nbsp;C Warrants&rsquo; exercise price per share is less than the initial public offering price per share of common stock in this
offering, such warrants will be automatically exercise for and converted into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our Series&nbsp;C redeemable convertible preferred stock, and such shares of Series&nbsp;C redeemable convertible preferred stock
shall subsequently be converted into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock upon the closing of this offering, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share of common stock, which is the midpoint of the price range set forth on the cover page&nbsp;of this prospectus. In the event
the Series&nbsp;C Warrants are not exercised prior to the closing of this offering and such Series&nbsp;C Warrants&rsquo; exercise price
per share exceeds the initial public offering price per share of common stock, such Series&nbsp;C Warrants will terminate automatically
and no shares of common stock shall be issued to the holders of such Series&nbsp;C Warrants. Upon exercise or conversion, the shares
underlying the Series&nbsp;C Warrants will be entitled to the registration rights set forth in our amended and restated investors&rsquo;
rights agreement. See &ldquo;&mdash;Registration Rights&rdquo; for additional information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of March 31, 2024,
under our 2015 Plan, we have outstanding stock options to purchase approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock, which have an average remaining life of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
years and a weighted average exercise price of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and, since
March 31, 2024, we have issued stock options that remain outstanding to purchase approximately ________ shares of common stock, which
have an average remaining life of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years and a weighted
average exercise price of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Furthermore, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock are available for future issuance under the 2015 Plan, of which&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares are expected to be issued to our chief executive officer at the closing of this offering under the terms of his employment agreement.
As of the closing, the 2024 Plan will replace the 2015 Plan and provide for shares to be initially available for grants under such plan
after the closing, plus any remaining shares available under the 2015 Plan as of such date and any shares under awards under the 2015
that are subsequently cancelled, forfeited or expire will become available for grant under the 2024 Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion of this offering and subject to the lock-up agreements
entered into in connection with this offering and federal securities laws, certain holders of shares of our common stock, including those
shares of our common stock that will be issued upon the conversion of our redeemable convertible preferred stock and the exercise of our
outstanding preferred stock warrants in connection with this offering, will initially be entitled to certain rights with respect to registration
of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities
possess registration rights pursuant to the terms of our investors&rsquo; rights agreement and are described in additional detail below.
The registration of shares of our common stock pursuant to the exercise of the registration rights described below would enable the holders
to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We
will pay the registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered
pursuant to the demand, piggyback and Form&nbsp;S-3 registrations described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, in an underwritten
offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number of shares
the holders may include. The demand, piggyback and Form&nbsp;S-3 registration rights described below will terminate upon the earliest
of (i)&nbsp;with respect to each stockholder, such date, on or after the closing of this offering, on which all registrable shares held
by such stockholder may immediately be sold during any 90-day period pursuant to Rule&nbsp;144 of the Securities Act, or Rule&nbsp;144
and (ii)&nbsp;the occurrence of a deemed liquidation event, as defined in our amended and restated certificate of incorporation, as currently
in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Demand Registration Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the completion of this offering, holders of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock issuable upon conversion of outstanding redeemable convertible preferred stock and the exercise and subsequent conversion
of outstanding warrants to purchase our redeemable convertible preferred stock will be entitled to certain demand registration rights.
Beginning 180 days following the effectiveness of the registration statement of which this prospectus is a part, certain investors holding,
collectively, holding at least 50% of registrable securities may, on not more than two occasions, request that we register all or a portion
of their shares, subject to certain specified exceptions. If any of these holders exercises its demand registration rights, then holders
of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock issuable upon the shares of our redeemable convertible preferred stock and the exercise and subsequent conversion
of outstanding warrants to purchase redeemable convertible preferred stock in connection with this offering will be entitled to register
their shares, subject to specified conditions and limitations in the corresponding offering. Such request for registration must cover
shares with an anticipated offering price of at least $18.40 per share and an anticipated aggregate offering price of at least $60.0 million,
net of selling expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Piggyback Registration Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
holders of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock issuable upon conversion of outstanding redeemable convertible preferred stock and the exercise and subsequent conversion
of outstanding warrants to purchase redeemable convertible preferred stock are entitled to their rights to notice of this offering and
to include their shares of registrable securities in this offering. The requisite percentage of these stockholders are expected to waive
all such stockholders&rsquo; rights to notice of this offering and to include their shares of registrable securities in this offering.
In the event that we propose to register any of our securities under the Securities Act in another offering, either for our own account
or for the account of other security holders, the holders of registrable securities will be entitled to certain &ldquo;piggyback&rdquo;
registration rights allowing them to include their shares in such registration, subject to specified conditions and limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>S-3 Registration Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of this
offering, the holders of approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;registrable
securities will initially be entitled to certain Form&nbsp;S-3 registration rights. The holders of at least 25% of the shares entitled
to certain Form&nbsp;S-3 registration rights may, on not more than two registrations on Form&nbsp;S-3 within any 12-month period, request
that we register all or a portion of their shares on Form&nbsp;S-3 if we are qualified to file a registration statement on Form&nbsp;S-3,
subject to specified exceptions. Such request for registration on Form&nbsp;S-3 must cover securities with an aggregate offering price
which equals at least $1.0 million, net of selling expenses. The right to have such shares registered on Form&nbsp;S-3 is further subject
to other specified conditions and limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Indemnification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our investors&rsquo; rights
agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of registrable securities
in the event of material misstatements or omissions in a registration statement attributable to us, and they are obligated to indemnify
us for material misstatements or omissions attributable to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain Anti-Takeover Provisions of Delaware
Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some provisions of Delaware
law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the
following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest
or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult
to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests,
including transactions that provide for payment of a premium over the market price for our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased
protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure
us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of
their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Undesignated Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of our board
of directors, without action by the stockholders, to issue up to
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of undesignated preferred stock
with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change
control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or
management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stockholder Meetings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our amended and restated
certificate of incorporation and our amended and restated bylaws provide that a special meeting of stockholders may be called only by
our board of directors, chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority
of our board of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Requirements for Advance Notification of
Stockholder Nominations and Proposals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination
of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee
of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Elimination of Stockholder Action by Written
Consent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our amended and restated
certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Staggered Board of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our amended and restated
certificate of incorporation provide that our board of directors will be divided into three classes. The directors in each class will
serve for a three-year term, with one class being elected each year by our stockholders. For more information on the classified board
of directors, see the section titled &ldquo;Management&mdash;Classified Board of Directors.&rdquo; This system of electing directors
may tend to discourage a third party from attempting to obtain control of us, because it generally makes it more difficult for stockholders
to replace a majority of the directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Removal of Directors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
certificate of incorporation provides that no member of our board of directors may be removed from office except for cause and, in addition
to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding
voting stock then entitled to vote in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stockholders Not Entitled to Cumulative
Voting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated
certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders
of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors
standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delaware Anti-Takeover Statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to Section&nbsp;203
of the Delaware General Corporation Law, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo; from engaging in
a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the date these persons become
interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was,
approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status
did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo; includes a merger, asset
or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may
have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Choice of Forum</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Our amended and restated
certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware (the Court of Chancery) (or, in the event the Court of Chancery does not have jurisdiction, the federal district
court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for the following
types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf;
(ii)&nbsp;any action asserting a claim of breach of a fiduciary duty by any of our directors, officers or stockholders to us or our stockholders;
(iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our amended
and restated certificate of incorporation or amended and restated bylaws; or (iv)&nbsp;any action asserting a claim governed by the internal
affairs doctrine, in all cases to the fullest extent permitted by law. The provision would not apply to suits brought to enforce a duty
or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our
amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative
forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a
cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For
the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters
to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made
by that person or entity and who has prepared or certified any part of the documents underlying the offering. In any case, stockholders
will not be deemed to have waived our compliance with the federal securities laws and the rules&nbsp;and regulations thereunder. The
enforceability of similar choice of forum provisions in other companies&rsquo; certificates of incorporation has been challenged in legal
proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and
restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares
of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment of Charter Provisions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amendment of any of the
above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval
by holders of at least two thirds of the total voting power of all of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of Delaware
law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging
others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our
common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing
changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult
to accomplish transactions that stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Liability and Indemnification
of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &ldquo;Management &ndash;
Limitation on Liability and Indemnification of Directors and Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of this
offering, the transfer agent and registrar for our common stock will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
The transfer agent&rsquo;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have applied to list our
common stock on the Nasdaq Capital Market under the trading symbol &ldquo;ACTU&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_016"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this offering, there
has been no public market for our common stock, and a liquid trading market for our common stock may not develop or be sustained after
this offering. Future sales of our common stock, including shares issued upon the exercise of outstanding options, in the public market
after the completion of this offering, or the perception that those sales may occur, could adversely affect the prevailing market price
for our common stock from time to time or impair our ability to raise equity capital in the future. As described below, only a limited
number of shares of our common stock will be available for sale in the public market for a period of several months after the completion
of this offering due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public
market either before or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing
market price of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sale of Restricted Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Based on the number of
shares of our common stock outstanding as of March 31, 2024, upon the closing of this offering and assuming (i)&nbsp;the conversion of
all outstanding shares of our redeemable convertible preferred stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock in connection with the closing of this offering; (ii)&nbsp;the conversion of our redeemable preferred stock
into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of our common stock upon the net exercise of outstanding Series&nbsp;B Warrants and Series&nbsp;C Warrants, assuming an initial offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the termination of such warrants containing
an exercise price greater than the initial offering price per share of common stock, immediately prior to the closing of this offering,
(iii)&nbsp;the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock to our chief executive officer pursuant to the CEO Employment Agreement upon the closing of this offering,
(iv)&nbsp;the conversion of the Bridge Note into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock upon the closing of this offering, (v)&nbsp;no exercise of the underwriters&rsquo; over-allotment option to
purchase additional shares of common stock; and (vi)&nbsp;no exercise of outstanding options, we will have outstanding an aggregate of
approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of these shares, all shares
of common stock to be sold in this offering will be freely tradable in the public market without restriction or further registration
under the Securities Act, unless the shares are held by any of our &ldquo;affiliates&rdquo; as such term is defined in Rule&nbsp;144
or subject to lock-up agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All remaining shares of common
stock held by existing stockholders immediately prior to the consummation of this offering will be &ldquo;restricted securities,&rdquo;
as such term is defined in Rule&nbsp;144. These restricted securities were issued and sold by us in private transactions and are eligible
for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities
Act, including the exemptions provided by Rule&nbsp;144 or Rule&nbsp;701, which rules&nbsp;are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As a result of the lock-up
agreements referred to below and the provisions of Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act, based on the number of shares
of our common stock outstanding (calculated as of March 31, 2024 on the basis of the assumptions described above and assuming no exercise
of the underwriters&rsquo; option to purchase additional shares, if any, and no exercise of outstanding options), the shares of our common
stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
    Number of Shares</B></FONT></TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
    Date Available For Sale Into Public Market</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">181
    days after the date of this prospectus, upon expiration of the lock-up agreements referred to below, subject in some cases to applicable
    volume, manner of sale and other limitations under Rule&nbsp;144 and Rule&nbsp;701.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue shares of common
stock from time to time as consideration for future acquisitions, investments or other corporate purposes. In the event that any such
acquisition, investment or other transaction is significant, the number of shares of common stock that we may issue may in turn be significant.
We may also grant registration rights covering those shares of common stock issued in connection with any such acquisition and investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the shares of
common stock reserved for future issuance under our 2024 Plan will become eligible for sale in the public market to the extent permitted
by the provisions of various vesting schedules, the lock-up agreements, a registration statement under the Securities Act or an exemption
from registration, including Rule&nbsp;144 and Rule&nbsp;701.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule&nbsp;144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, persons who have
beneficially owned restricted shares of our common stock for at least six months, and any affiliate of the company who owns shares of
our common stock, are entitled to sell their securities without registration with the SEC under an exemption from registration provided
by Rule&nbsp;144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Rule&nbsp;144, as currently
in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90 days, and we are
current in our Exchange Act reporting at the time of sale, a person (or persons whose shares are required to be aggregated) who is not
deemed to have been one of our &ldquo;affiliates&rdquo; for purposes of Rule&nbsp;144 at any time during the 90 days preceding a sale
and who has beneficially owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including the holding
period of any prior owner other than one of our &ldquo;affiliates,&rdquo; is entitled to sell those shares in the public market (subject
to the lock-up agreement referred to below, if applicable) without complying with the manner of sale, volume limitations or notice provisions
of Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially
owned the shares proposed to be sold for at least 12 months, including the holding period of any prior owner other than &ldquo;affiliates,&rdquo;
then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule&nbsp;144
(subject to the lock-up agreement referred to above, if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;144,
as currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90 days,
our &ldquo;affiliates,&rdquo; as defined in Rule&nbsp;144, who have beneficially owned the shares proposed to be sold for at least six
months, are entitled to sell in the public market, upon expiration of any applicable lock-up agreements and within any three-month period,
a number of those shares of our common stock that does not exceed the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
    of the number of shares of common stock then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock immediately upon the closing of this offering (calculated as of March 31, 2024 on the basis of the assumptions
    described above and assuming no exercise of the underwriters&rsquo; over-allotment option, if any, and no exercise of outstanding
    options); or</FONT> </TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            average weekly trading volume of our common stock on the Nasdaq Capital Market during the
                                            four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to such
                                            sale</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Such sales under Rule&nbsp;144
by our &ldquo;affiliates&rdquo; or persons selling shares on behalf of our &ldquo;affiliates&rdquo; are also subject to certain manner
of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the availability
of Rule&nbsp;144, the holders of substantially all of our restricted securities have entered into lock-up agreements as referenced above
and their restricted securities will become eligible for sale (subject to the above limitations under Rule&nbsp;144) upon the expiration
of the restrictions set forth in those agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule&nbsp;701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, under Rule&nbsp;701
as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common stock from us in connection
with a written compensatory stock or option plan or other written agreement in compliance with Rule&nbsp;701 before the effective date
of the registration statement of which this prospectus is a part (to the extent such common stock is not subject to a lock-up agreement)
and who are not our &ldquo;affiliates&rdquo; as defined in Rule&nbsp;144 during the immediately preceding 90 days, is entitled to rely
on Rule&nbsp;701 to resell such shares beginning 90 days after the date of this prospectus in reliance on Rule&nbsp;144, but without
complying with the notice, manner of sale, public information requirements or volume limitation provisions of Rule&nbsp;144. Persons
who are our &ldquo;affiliates&rdquo; may resell those shares beginning 90 days after the date of this prospectus without compliance with
minimum holding period requirements under Rule&nbsp;144 (subject to the terms of the lock-up agreement referred to below, if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this offering,
we, our directors, our executive officers and holders of more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our of our other outstanding
shares of common stock or securities convertible into or exchangeable for shares of our common stock outstanding upon the closing of
this offering, have agreed, subject to certain limited exceptions, with the underwriters not to directly or indirectly offer, sell, contract
to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of or hedge any shares of our common stock or
any options to purchase shares of our common stock, or any securities convertible into or exchangeable for shares of common stock during
the period from the date of the lock-up agreement continuing through and including the date 180 days after the date of this prospectus,
except with the prior written consent of the representatives of the underwriters, and certain other limited exceptions. These agreements
are described in the section of this prospectus titled &ldquo;Underwriting.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the restrictions
contained in the lock-up agreements described above, we have entered into agreements with certain security holders, including the amended
and restated investors&rsquo; rights agreement and stock restriction agreements, that contain market stand-off provisions imposing restrictions
on the ability of such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the closing of this
offering, the holders of an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their
shares or to include their shares in registration statements that we may file for ourselves or other stockholders. After registration
pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. See the section of this
prospectus titled &ldquo;Description of Capital Stock&mdash;Registration Rights&rdquo; for additional information regarding these registration
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Incentive Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to file with the
SEC a registration statement on Form&nbsp;S-8 under the Securities Act covering the shares of common stock reserved for issuance under
outstanding options under the 2015 Plan and reserved for issuance under the 2024 Plan. The registration statement is expected to be filed
and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration
statement will be available for sale in the open market following its effective date, subject to Rule&nbsp;144 volume limitations and
the lock-up agreements described above, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_017"></A>MATERIAL
U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the acquisition, ownership and disposition
of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal income
tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income,
and does not address any estate or gift tax consequences or any tax consequences arising under any state, local or foreign tax laws,
or any other U.S. federal tax laws. This discussion is based on the Internal Revenue Code of 1986, as amended (the Code), and applicable
Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the Internal
Revenue Service (IRS), all as in effect as of the date hereof. These authorities are subject to differing interpretations and may change,
possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested
a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance
that the IRS or a court will agree with such statements and conclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion is limited
to non-U.S. holders who purchase our common stock pursuant to this offering and who hold our common stock as a &ldquo;capital asset&rdquo;
within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of
the U.S. federal income tax consequences that may be relevant to a particular holder in light of such holder&rsquo;s circumstances. This
discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special rules&nbsp;under
the U.S. federal income tax laws, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">certain
                                            former citizens or long-term residents of the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">partnerships
                                            or other pass-through entities (and investors therein);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;controlled
                                            foreign corporations;&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;passive
                                            foreign investment companies;&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">corporations
                                            that accumulate earnings to avoid U.S. federal income tax;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">banks,
                                            financial institutions, investment funds, insurance companies, brokers, dealers or traders
                                            in securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">tax-exempt
                                            organizations and governmental organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">tax-qualified
                                            retirement plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">&ldquo;qualified
                                            foreign pension funds&rdquo; as defined in Section&nbsp;897(l)(2)&nbsp;of the Code and entities
                                            all of the interests of which are held by qualified foreign pension funds</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">persons
                                            subject to the alternative minimum tax;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">persons
                                            that own, or have owned, actually or constructively, more than 5% of our common stock at
                                            any time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">accrual-method
                                            taxpayers subject to special tax accounting rules&nbsp;under Section&nbsp;451(b)&nbsp;of
                                            the Code; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">persons
                                            holding our common stock as part of a hedging or conversion transaction, straddle, synthetic
                                            security, constructive sale, or other risk reduction strategy or integrated investment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment
of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations
made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax
advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS DISCUSSION IS FOR INFORMATIONAL
PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME
TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE,
LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Definition of Non-U.S. Holder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this discussion,
a non-U.S. holder is any beneficial owner of our common stock that is not a &ldquo;U.S. person&rdquo; or a partnership (including any
entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal
income tax purposes, is or is treated as any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">an
                                            individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            corporation (or entity treated as a corporation for U.S. federal income tax purposes) created
                                            or organized in or under the laws of the United States, any state thereof or the District
                                            of Columbia;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">an
                                            estate, the income of which is subject to U.S. federal income tax regardless of its source;
                                            or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">a
                                            trust (i)&nbsp;whose administration is subject to the primary supervision of a U.S. court
                                            and which has one or more U.S. persons who have the authority to control all substantial
                                            decisions of the trust or (ii)&nbsp;that has a valid election in effect under applicable
                                            Treasury Regulations to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Distributions on Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable
future. However, if we do make cash or other property distributions on our common stock, such distributions will constitute dividends
for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S.
federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital
and will first be applied against and reduce a holder&rsquo;s tax basis in our common stock, but not below zero. Any excess will be treated
as gain realized on the sale or other disposition of our common stock and will be treated as described under the section titled &ldquo;Gain
on Disposition of Our Common Stock&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussions
below regarding effectively connected income, backup withholding and Sections 1471 through 1474 of the Code (commonly referred to as
FATCA), dividends paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of
30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a
reduced treaty rate, a non-U.S. holder must furnish us or our paying agent with a valid IRS Form&nbsp;W-8BEN or IRS Form&nbsp;W-8BEN-E
(or applicable successor form) and satisfy applicable certification and other requirements. This certification must be provided to us
or our paying agent before the payment of dividends and must be updated periodically. If the non-U.S. holder holds the stock through
a financial institution or other agent acting on the non-U.S. holder&rsquo;s behalf, the non-U.S. holder will be required to provide
appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly
or through other intermediaries. Prospective investors should consult their tax advisors concerning whether they may benefit from an
applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Non-U.S. holders that do
not provide the required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess
amounts withheld by timely filing an appropriate claim for refund with the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a non-U.S. holder holds
our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are
effectively connected with such holder&rsquo;s U.S. trade or business (and are attributable to such holder&rsquo;s permanent establishment
in the United States if required by an applicable tax treaty), the non-U.S. holder will be exempt from U.S. federal withholding tax.
To claim the exemption, the non-U.S. holder must generally furnish a valid IRS Form&nbsp;W-8ECI (or applicable successor form) to the
applicable withholding agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, any such effectively
connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular
U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a
foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable
income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Non-U.S. holders
should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Gain on Disposition of Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussions
below regarding backup withholding and FATCA, a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain
realized on the sale or other disposition of our common stock, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            gain is effectively connected with the non-U.S. holder&rsquo;s conduct of a trade or business
                                            in the United States, and if required by an applicable income tax treaty, is attributable
                                            to a permanent establishment maintained by the non-U.S. holder in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">the
                                            non-U.S. holder is a nonresident alien individual present in the United States for 183 days
                                            or more during the taxable year of the disposition, and certain other requirements are met;
                                            or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">our
                                            common stock constitutes a &ldquo;United States real property interest&rdquo; by reason of
                                            our status as a United States real property holding corporation (USRPHC) for U.S. federal
                                            income tax purposes at any time within the shorter of the five-year period preceding the
                                            disposition or the non-U.S. holder&rsquo;s holding period for our common stock, and our common
                                            stock is not &ldquo;regularly traded&rdquo; on an established securities market (as defined
                                            by applicable Treasury Regulations).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Determining whether we are
a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade or
business assets and our foreign real property interests. We believe that we are not currently and do not anticipate becoming a USRPHC
for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC. If we are or become
a USRPHC and the &ldquo;regularly traded&rdquo; exception noted above does not apply to the disposition, a non-U.S. holder will generally
be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that
the branch profits tax generally will not apply. Prospective investors are encouraged to consult their own tax advisors regarding the
possible consequences to them if we are, or were to become, a USRPHC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain described in the first
bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax
rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also
may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of
its effectively connected earnings and profits for the taxable year, as adjusted for certain items. A non-U.S. holder described in the
second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable
income tax treaty) on gain realized upon the sale or other taxable disposition of our common stock, but may be offset by certain U.S.-source
capital losses (even though the individual is not considered a resident of the United States), provided that the non-U.S. holder has
timely filed U.S. federal income tax returns with respect to such losses. Non-U.S. holders should consult their tax advisors regarding
any applicable income tax treaties that may provide for different rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Reporting and Backup Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Annual reports are required
to be filed with the IRS and provided to each non-U.S. holder indicating the amount of distributions on our common stock paid to such
holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if
no withholding was required because the distributions were effectively connected with the holder&rsquo;s conduct of a U.S. trade or business,
or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific
treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established. Backup withholding,
currently at a 24% rate, generally will not apply to payments to a non-U.S. holder of dividends on or the gross proceeds of a disposition
of our common stock provided the non-U.S. holder furnishes the required certification for its non-U.S. status, such as by providing a
valid IRS Form&nbsp;W-8BEN, W-8BEN-E or W-8ECI, or certain other requirements are met. Backup withholding may apply if the payor has
actual knowledge, or reason to know, that the holder is a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. If any amount is withheld under the backup withholding rules, the non-U.S. holder should consult with a U.S. tax advisor
regarding the possibility of and procedure for obtaining a refund or a credit against the non-U.S. holder&rsquo;s U.S. federal income
tax liability, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Withholding on Foreign Entities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FATCA imposes a U.S. federal
withholding tax of 30% on certain payments made to a &ldquo;foreign financial institution&rdquo; (as specially defined under these rules)
unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide
to the U.S. tax authorities certain information regarding certain U.S. account holders of such institution (which includes certain equity
and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption
applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a non-financial foreign entity
unless such entity provides the withholding agent a certification identifying certain direct and indirect U.S. owners of the entity or
an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements.
FATCA currently applies to dividends paid on our common stock. Under certain circumstances, a non-U.S. holder might be eligible for refunds
or credits of such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prospective investors are
encouraged to consult with their own tax advisors regarding the potential implications of FATCA on their investment in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>The preceding discussion
of U.S. federal tax considerations is for general information only. It is not tax advice. Each prospective investor should consult its
tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing
of our common stock, including the consequences of any proposed change in applicable laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_018"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Titan Partners Group&#8239;LLC,<I>&nbsp;</I>a
division of American Capital Partners, LLC,<I>&nbsp;</I>is acting as the representative of the underwriters of the offering (herein referred
to as the &ldquo;Representative&rdquo;). We have entered into an underwriting agreement dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024 with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter
named below and each underwriter named below has severally and not jointly agreed to purchase from us, at the public offering price per
share of common stock, less the underwriting discounts set forth on the cover page&nbsp;of this prospectus, the number of shares of common
stock listed next to its name in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number <BR> of Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Titan Partners Group&#8239;LLC, a division of American Capital Partners, LLC</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The underwriters are committed
to purchase all the shares of common stock offered by us other than those covered by the over-allotment&nbsp;option described below, if
any, are purchased. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting&nbsp;underwriters
may be increased, or the offering may be terminated. The underwriters are not obligated to purchase the securities covered by the underwriters&rsquo;
over-allotment&nbsp;option described below. The underwriters are offering the shares of common stock, subject to prior sale, when, as
and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting
agreement, such as the receipt by the underwriters of officer&rsquo;s certificates and legal opinions. The underwriters reserve the right
to withdraw, cancel or modify offers to the public and to reject orders in whole or in&nbsp;part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have granted to the Representative an option,
exercisable one or more times in whole or in part, not later than 30&nbsp;days after the date of this prospectus, to purchase from us
up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock at the public a price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share (which equals 15% of the shares of common stock initially sold in this offering, based on the midpoint of the price range set forth
on the cover of this prospectus), less the underwriting discounts and commissions set forth on the cover of this prospectus to cover
over-allotments, if any. To the extent that the Representative exercises this option, each of the underwriters will become obligated,
subject to conditions, to purchase approximately the same percentage of these additional shares of common stock as the number of shares
of common stock to be purchased by it in the above table bears to the total number of shares of common stock offered by this prospectus.
We will be obligated, pursuant to the option, to sell these additional shares of common stock to the underwriters to the extent the option
is exercised. If any additional shares of common stock are purchased, the underwriters will offer the additional shares of common stock
on the same terms as those on which the other shares of common stock are being offered hereunder. If this option is exercised in full,
the total offering price to the public will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and the total
net proceeds, before expenses and after the credit to the underwriting commissions described below, to us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(based on an assumed initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which
is the midpoint of the price range set forth on the cover of this prospectus). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discounts and Commissions; Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the public offering
price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the
Representative of the over-allotment&nbsp;option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Without <BR> Over-allotment <BR> Option</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total With Full <BR> Over-allotment <BR> Option</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; text-indent: -10pt; padding-left: 10pt">Public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Underwriting discounts and commissions (7.0%)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also paid an advance of $50,000 to the
Representative, which will be applied against the accountable expenses that will be paid by us to the Representative in connection with
this offering, or the Advance. The Advance will be returned to us to the extent not actually incurred by the Representative in accordance
with Financial Industry Regulation&nbsp;Authority (&ldquo;FINRA&rdquo;) Rule&nbsp;5110(g)(4)(A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters propose to offer the shares of
common stock offered by us to the public at the public offering price per share of common stock set forth on the cover of this prospectus.
In addition, the underwriters may offer some of the shares of common stock to other securities dealers at such price less a concession
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. After the initial public offering,
the public offering price and concession to dealers may be changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have also agreed to reimburse the Representative for reasonable
and accountable out-of-pocket&nbsp;expenses not to exceed $200,000 in the aggregate (up to $150,000 for legal fees, costs and expenses
and up to $50,000 of the underwriters&rsquo; non-legal&nbsp;expenses). We estimate that total expenses payable by us in connection with
this offering, other than the underwriting discount, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discretionary Accounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters do not intend to confirm sales
of the shares of common stock offered hereby to any accounts over which they have discretionary authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the underwriters against
specified liabilities, including liabilities under the Securities Act,&nbsp;and to contribute to payments the underwriters may be required
to make in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We and our officers and directors, and the holders
of 1.0% or more of the outstanding shares of our common stock as of the effective date of the registration statement of which this prospectus
is a part, have agreed, subject to limited exceptions, for a period of one hundred eighty (180)&nbsp;days with respect to us, and for
a period of one (1)&nbsp;year with respect to our officers, directors, and holders of 1.0% or more of the outstanding shares of our common
stock, after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short
sale or otherwise dispose of, directly or indirectly any shares of our common stock or any securities convertible into or exchangeable
for our common stock either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent
of the Representative. The Representative may, in its sole discretion and at any time or from time to time before the termination of the
lock-up&nbsp;period, without notice, release all or any portion of the securities subject to lock-up&nbsp;agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pricing of this Offering;&nbsp;Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been no public
market for our common stock. The initial public offering price was determined through negotiations between us and the Representative.
In addition to prevailing market conditions, the factors considered in determining the initial public offering price included the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the information included in this prospectus and otherwise available
to the Representative;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    valuation multiples of publicly-traded companies that the Representative believes to be comparable to us;</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our financial information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our prospects and the history and the prospects of the industry
in which we compete;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an assessment of our management, its past and present operations,
and the prospects for, and timing of, our future revenues;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the present state of our development; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the above factors in relation to market values and various valuation
measures of other companies engaged in activities similar to ours.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An active trading market for our common stock
may not develop. It is also possible that after the offering our common stock will not trade in the public market at or above the public
offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Representative&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We have agreed to issue to the Representative
(or its permitted designees) warrants to purchase up to a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock (5.0% of the shares of common stock issued in this offering, including the over-allotment, if any). The warrants will
be exercisable at any time, and from time to time, in whole or in part, during the three&nbsp;year period from the commencement of sales
of the common stock in this offering, which is also the effective date of the registration statement of which this prospectus is a part,
which period is in compliance with applicable FINRA rules. The warrants are exercisable at a per share price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, or 125% of the initial public offering price per share of common stock issued in this offering (based on the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover
page&nbsp;of this prospectus). The warrants have been deemed compensation by FINRA and are therefore subject to a 180-day&nbsp;lock-up&nbsp;pursuant
to Rule&nbsp;5110(e)(1)(A)&nbsp;of FINRA.&nbsp;The Representative (or permitted assignees under Rule&nbsp;5110(e)(2)) will not sell,
transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging,
short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying
securities for a period commencing 180&nbsp;days from the commencement of sales of the common stock in this offering.&nbsp;In addition,
the warrants provide for cashless exercise after the first 15 months and registration rights upon request, in certain cases. The Representative&rsquo;s
warrants will have one demand and unlimited piggyback registration rights at our expense for a period of three years from the commencement
of sales of the offering in compliance with applicable FINRA rules&nbsp;(provided such registration rights will not apply to any universal
shelf registration statement). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the
warrants. The exercise price and number of shares issuable upon exercise of the warrants may be adjusted in certain circumstances including
in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. However,
the warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock at a price below the warrant
exercise price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Subject to the closing of this offering in
an aggregate amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in gross proceeds, for a period of 18&nbsp;months
after the closing of the offering, the Representative shall have a right of first refusal to act as sole underwriter, sole book-runner
and/or sole placement agent for any and all future public or private equity and debt (excluding commercial bank debt and other customary
exceptions) offerings undertaken during such period by us, or any of our successors or subsidiaries. Such right of first refusal is also
subject to the rights of another unaffiliated investment bank. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nasdaq Capital Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to have our common stock listed
on the Nasdaq Capital Market under the symbol &ldquo;ACTU&rdquo;. No assurance can be given that our listing application will be approved
by the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar of our common
stock is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering the underwriters
may engage in stabilizing transactions, over-allotment&nbsp;transactions, syndicate covering transactions and penalty bids in accordance
with Regulation&nbsp;M under the Exchange&nbsp;Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Stabilizing transactions permit bids to purchase securities
so long as the stabilizing bids do not exceed a specified maximum.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Over-allotment&nbsp;involves sales by the underwriters of securities
in excess of the number of securities the underwriters are obligated to purchase, which creates a syndicate short position. The short
position may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted&nbsp;by
the underwriters is not greater than the number of securities that they may purchase in the over-allotment&nbsp;option. In a naked short
position, the number of securities involved is greater than the number of securities in the over-allotment&nbsp;option. The underwriters
may close out any covered short position by either exercising their over-allotment&nbsp;option and/or purchasing securities in the open
market.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Syndicate covering transactions involve purchases of the securities
in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of
securities to close out the short position, the underwriters will consider, among other things, the price of securities available for
purchase in the open market as compared to the price at which they may purchase securities through the over-allotment&nbsp;option. A
naked short position occurs if the underwriters sell more securities than could be covered by the over-allotment&nbsp;option. This position
can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters
are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely
affect investors who purchase in this offering.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Penalty bids permit the underwriters to reclaim a selling concession
from a syndicate member when securities originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction
to cover syndicate short positions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These stabilizing transactions, syndicate covering
transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding
a decline in the market price of the securities. As a result, the price of our shares of common stock may be higher than the price that
might otherwise exist in the open market. These transactions may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriters make any representation
or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our shares
of common stock. In addition, neither we nor the underwriters make any representation that the underwriters will engage in these transactions
or that any transaction, if commenced, will not be discontinued without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Passive Market Making</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, the underwriters
and selling group members may also engage in passive market making transactions in our common stock. Passive market making consists of
displaying bids limited by the prices of independent market makers and effecting purchases limited by those prices in response to order
flow. Rule&nbsp;103 of Regulation&nbsp;M promulgated by the SEC limits the amount of net purchases that each passive market maker may
make and the displayed size of each bid. Passive market making may stabilize the market price of the shares of common stock at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus in electronic format may be made
available on websites or through other online services maintained by the underwriters, or by their affiliates. Other than this prospectus
in electronic format, the information on the underwriters&rsquo; websites and any information contained in any other websites maintained
by the underwriters is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved
and/or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the underwriters and/or their
affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services
it has received and, may in the future receive, customary fees. Except for the services provided in connection with this offering and
other than as described below, the underwriters have not provided any investment banking or other financial services during the 180-day&nbsp;period
preceding the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offer Restrictions Outside the United&nbsp;States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than in the United&nbsp;States, no action
has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction
where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly,
nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities
be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules&nbsp;and
regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe
any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell
or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation
is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Australia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is not a disclosure document under
Chapter&nbsp;6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and
does not purport to include the information required of a disclosure document under Chapter&nbsp;6D of the Australian Corporations Act.
Accordingly, (i)&nbsp;the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities
without disclosure under Chapter&nbsp;6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the
Australian Corporations Act, (ii)&nbsp;this prospectus is made available in Australia only to those persons as set forth in clause (i)&nbsp;above,
and (iii)&nbsp;the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree
is such a person as set forth in clause (i)&nbsp;above, and, unless permitted under the Australian Corporations Act, agrees not to sell
or offer for sale within Australia any of the securities sold to the offeree within 12&nbsp;months after its transfer to the offeree under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities may be sold in Canada only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&nbsp;45-106 Prospectus
Exemptions or subsection 73.3(1)&nbsp;of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with
an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including
any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser
within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer
to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights
or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105),
the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in
connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cayman Islands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No invitation, whether directly or indirectly,
may be made to the public in the Cayman Islands to subscribe for our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>European Economic Area &mdash; Belgium, Germany,
Luxembourg and Netherlands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this document has been prepared
on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (&ldquo;Prospectus Directive&rdquo;),
as implemented in Member States of the European Economic Area (each, a &ldquo;Relevant Member State&rdquo;), from the requirement to produce
a prospectus for offers of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An offer to the public of securities has not been
made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive
as implemented in that Relevant Member State:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to legal entities that are authorized or regulated to operate
in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to any legal entity that has two or more of (i)&nbsp;an average
of at least 250 employees during its last fiscal year; (ii)&nbsp;a total balance sheet of more than &euro;43,000,000 (as shown on its
last annual unconsolidated or consolidated financial statements) and (iii)&nbsp;an annual net turnover of more than &euro;50,000,000
(as shown on its last annual unconsolidated or consolidated financial statements);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to fewer than 100 natural or legal persons (other than qualified
investors within the meaning of Article&nbsp;2(1)(e)&nbsp;of the Prospectus Directive) subject to obtaining the prior consent of the
Company or any underwriter for any such offer; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in any other circumstances falling within Article&nbsp;3(2)&nbsp;of
the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the Company
of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is not being distributed in the
context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article&nbsp;L.411-1
of the French Monetary and Financial Code (Code Mon&eacute;taire et Financier) and Articles&nbsp;211-1 et seq. of the General Regulation
of the French Autorit&eacute; des march&eacute;s financiers (&ldquo;AMF&rdquo;). The securities have not been offered or sold and will
not be offered or sold, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document and any other offering material
relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed
or caused to distributed, directly or indirectly, to the public in France.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such offers, sales and distributions have been
and shall only be made in France to (i)&nbsp;qualified investors (investisseurs qualifi&eacute;s) acting for their own account, as defined
in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1 ;and D.764-1 of the French Monetary and
Financial Code and any implementing regulation and/or (ii)&nbsp;a restricted number of non-qualified investors (cercle restreint d&rsquo;investisseurs)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-4, D.744-1, D.754-1; and D.764-1
of the French Monetary and Financial Code and any implementing regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Article&nbsp;211-3 of the General
Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public
by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary
and Financial Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ireland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this document does not constitute
a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority
as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish
Prospectus (Directive 2003/71/EC) Regulations&nbsp;2005 (the &ldquo;Prospectus Regulations&rdquo;). The securities have not been offered
or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i)&nbsp;qualified
investors as defined in Regulation&nbsp;2(l)&nbsp;of the Prospectus Regulations and (ii)&nbsp;fewer than 100 natural or legal persons
who are not qualified investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities offered by this prospectus have
not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale
in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus.
The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated
the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being
offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions
on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Italy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering of the securities in the Republic
of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&agrave; e la Borsa,
 &ldquo;CONSOB&rdquo; pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities
may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article&nbsp;1.1(t)&nbsp;of
Legislative Decree No.&nbsp;58 of 24 February&nbsp;1998 (&ldquo;Decree No.&nbsp;58&rdquo;), other than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to Italian qualified investors, as defined in Article&nbsp;100
of Decree no.58 by reference to Article&nbsp;34-ter of CONSOB Regulation no.&nbsp;11971 of 14 May&nbsp;1999 (&ldquo;Regulation no.&nbsp;1197l&rdquo;)
as amended (&ldquo;Qualified Investors&rdquo;); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in other circumstances that are exempt from the rules&nbsp;on
public offer pursuant to Article&nbsp;100 of Decree No.&nbsp;58 and Article&nbsp;34-ter of Regulation&nbsp;No.&nbsp;11971 as amended.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any offer, sale or delivery of the securities
or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an
offer from the issuer) under the paragraphs above must be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">made by investment firms, banks or financial intermediaries
permitted to conduct such activities in Italy in accordance with Legislative Decree No.&nbsp;385 of 1 September&nbsp;1993 (as amended),
Decree No.&nbsp;58, CONSOB Regulation&nbsp;No.&nbsp;16190 of 29 October&nbsp;2007 and any other applicable laws; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">in compliance with all relevant Italian securities, tax and
exchange controls and any other applicable laws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any subsequent distribution of the securities
in Italy must be made in compliance with the public offer and prospectus requirement rules&nbsp;provided under Decree No.&nbsp;58 and
the Regulation&nbsp;No.&nbsp;11971 as amended, unless an exception from those rules&nbsp;applies. Failure to comply with such rules&nbsp;may
result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for
any damages suffered by the investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Japan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities have not been and will not be registered
under Article&nbsp;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948), as amended (the &ldquo;FIEL&rdquo;)
pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional
Investors (as defined in and in accordance with Article&nbsp;2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly,
the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other
than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person
in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution
of an agreement to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Portugal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is not being distributed in the
context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios) in Portugal, within the meaning
of Article&nbsp;109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The securities have not been offered
or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material
relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&abreve;o do
Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly
or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese
Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &ldquo;qualified investors&rdquo;
(as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information
contained in it to any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sweden</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document has not been, and will not be, registered
with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available,
nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under
the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Swedish Financial Instruments Trading Act (1991:980)
(Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified
investors&rdquo; (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not
distribute it or the information contained in it to any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Switzerland</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities may not be publicly offered in
Switzerland and will not be listed on the SIX Swiss Exchange (&ldquo;SIX&rdquo;) or on any other stock exchange or regulated trading facility
in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or
art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules&nbsp;or
the listing rules&nbsp;of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering
material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this document nor any other offering material
relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document
will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document is personal to the recipient only
and not for general circulation in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>United Arab Emirates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither this document nor the securities have
been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority
in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab Emirates
or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This
document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including
the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No offer or invitation to subscribe for securities
is valid or permitted in the Dubai International Financial Centre.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the information in this document nor any
other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus
(within the meaning of section 85 of the Financial Services and Markets Act&nbsp;2000, as amended (&ldquo;FSMA&rdquo;) has been published
or is intended to be published in respect of the securities. This document is issued on a confidential basis to &ldquo;qualified investors&rdquo;
(within the meaning of section 86(7)&nbsp;of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United
Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication
of a prospectus pursuant to section 86(1)&nbsp;FSMA.&nbsp;This document should not be distributed, published or reproduced, in whole or
in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any invitation or inducement to engage in investment
activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated
or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which
section 21(1)&nbsp;of FSMA does not apply to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United Kingdom, this document is being
distributed only to, and is directed at, persons (i)&nbsp;who have professional experience in matters relating to investments falling
within Article&nbsp;19(5)&nbsp;(investment professionals) of the Financial Services and Markets Act&nbsp;2000 (Financial Promotions) Order
2005 (&ldquo;FPO&rdquo;), (ii)&nbsp;who fall within the categories of persons referred to in Article&nbsp;49(2)(a)&nbsp;to (d)&nbsp;(high
net worth companies, unincorporated associations,&nbsp;etc.) of the FPO or (iii)&nbsp;to whom it may otherwise be lawfully communicated
(together &ldquo;relevant persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer
or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely
on this document or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_019"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered by this prospectus will be passed upon for us by Baker&nbsp;&amp; Hostetler LLP, Cleveland, Ohio. McGuireWoods LLP, New York,
New York is representing the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_020"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of Actuate Therapeutics,&nbsp;Inc. as of December&nbsp;31, 2023 and 2022, and for each of the two years in the period ended
December&nbsp;31, 2023, included in this Prospectus and Registration Statement on Form&nbsp;S-1 have been audited by KMJ Corbin&nbsp;&amp;
Company LLP, an independent registered public accounting firm, as stated in their report (which contains an explanatory paragraph relating
to the Company&rsquo;s ability to continue as a going concern), which is included herein. Such consolidated financial statements have
been so included in reliance upon the report of such firm given upon their authority as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_021"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form&nbsp;S-1, including exhibits and schedules, under the Securities Act, with respect to the shares of
common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain
all of the information in the registration statement and its exhibits. For further information with respect to us and the common stock
offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to
the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the
copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all
respects by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may read our SEC filings,
including this registration statement, over the Internet at the SEC&rsquo;s website at www.sec.gov. Upon the closing of this offering,
we will be subject to the information reporting requirements of the Exchange Act and we will file reports, proxy statements and other
information with the SEC. These reports, proxy statements and other information will be available for review on the web site of the SEC
referred to above. We also maintain a website at www.actuatetherapeutics.com, at which, following the completion of this offering, you
may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to,
the SEC. Information contained on or accessible through our website is not a part of this prospectus or the registration statement of
which it forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_022"></A>ACTUATE
THERAPEUTICS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Balance Sheets as of December&nbsp;31, 2023 and 2022</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Operations for the years ended December&nbsp;31, 2023 and 2022</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Redeemable Convertible Preferred Stock and Stockholders&rsquo; Deficit for the years ended December&nbsp;31, 2023 and
    2022</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
    Statements of Cash Flows for the years ended December&nbsp;31, 2023 and 2022</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#F_6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#F_6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 187; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_1"></A>Report of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of<BR>
Actuate Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Actuate Therapeutics,&nbsp;Inc. and subsidiary (the &ldquo;Company&rdquo;) as of December&nbsp;31, 2023 and 2022, the
related consolidated statements of operations, redeemable convertible preferred stock and stockholders&rsquo; deficit and cash flows
for each of the two years in the period ended December&nbsp;31, 2023, and the related notes (collectively referred to as the &ldquo;consolidated
financial statements&rdquo;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December&nbsp;31, 2023 and 2022, and the results of its operations and its cash flows for each of the two
years in the period ended December&nbsp;31, 2023, in conformity with accounting principles generally accepted in the United States of
America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the Company has incurred recurring operating losses, has had negative operating cash flows and has not recognized any revenues since
its inception. In addition, the Company has an accumulated deficit of $105,094,521 as of December&nbsp;31, 2023 and is dependent on its
ability to raise capital. These matters raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s
plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules&nbsp;and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ KMJ Corbin&nbsp;&amp; Company LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company's auditor since 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Irvine, California<BR>
<FONT>February&nbsp;29, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_2"></A>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS OF DECEMBER 31, 2023 AND 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2,958,659</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">20,449,310</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Prepaid assets
    and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">36,907</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,746</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,995,566</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,483,056</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,995,566</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,483,056</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND
    STOCKHOLDERS&rsquo; DEFICIT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,421,840</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,130,847</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">277,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">132,033</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other accrued
    expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,221,254</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,082,102</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,920,594</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,344,982</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Long term liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">130,041</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">86,400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">License payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">404,991</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">404,991</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total long-term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,523,081</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,305,755</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,443,675</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,650,737</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Commitments and contingencies (Note 5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Redeemable convertible
    preferred stock $0.000001 par value, 33,463,018 shares authorized; 24,678,355 and 23,656,337 shares issued and outstanding as of
    December&nbsp;31, 2023 and 2022, respectively; liquidation value of $121,033,336 and $108,936,156 as of December&nbsp;31, 2023 and
    2022, respectively.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">94,178,404</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90,137,751</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; deficit:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock: $0.000001 par value,
    38,108,584 shares authorized; 3,043,309 shares issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,468,005</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,044,466</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,094,521</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(80,349,901</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo;
    deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(99,626,513</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(75,305,432</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total liabilities, redeemable convertible
    preferred stock and stockholders&rsquo; deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,995,566</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,483,056</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_3"></A>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,
    2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,
    2022</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">21,708,332</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">16,387,216</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,265,497</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,819,591</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total operating expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,973,829</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,206,807</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,973,829</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,206,807</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Change in estimated fair value of warrant
    liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(79,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(43,641</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">352,672</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">27,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Total other income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">229,209</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">47,406</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average shares of common stock outstanding, basic
    and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,582,876</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,179,037</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss per share attributable to common stockholders, basic
    and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9.58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(9.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_4"></A>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Redeemable Convertible</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>Additional</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Preferred Stock</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Paid-in</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accumulated</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;</B></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Amount</FONT></TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Capital</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Deficit</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Deficit</FONT></TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; font: 10pt Times New Roman, Times, Serif">Balances, January&nbsp;1, 2022</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">19,108,155</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,882,182</TD><TD STYLE="border-right: Black 1pt solid; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,092,858</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">4,390,400</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">(60,190,500</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">(55,800,097</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of restricted stock awards</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">187,231</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Cancellation
    of nonvested restricted stock awards</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(236,780</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">654,066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">654,066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from
    issuances of redeemable convertible preferred stock, net of issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,548,182</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,255,569</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balances, December&nbsp;31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,656,337</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90,137,751</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,043,309</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,044,466</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(80,349,901</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(75,305,432</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">423,539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">423,539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from
    issuances of redeemable convertible preferred stock, net of issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,022,018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,134,516</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair
    market value of warrants issued to placement agent in connection with issuance of redeemable convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(93,863</TD><TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Balances, December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,678,355</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">94,178,404</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,043,309</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,468,005</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,094,521</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(99,626,513</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_5"></A>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Adjustment to reconcile net loss to
    net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Stock-based compensation expense</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">423,539</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">654,066</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Change in estimated fair value of warrant
    liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">79,822</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(36,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Interest accrued on license payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,641</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Prepaid assets and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,161</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(25,304</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,290,993</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">586,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left">Accrued compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">145,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43,283</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Other accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,139,152</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,127,383</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: left; padding-bottom: 1pt">Net cash used in operating
    activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,625,167</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,794,093</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Proceeds from
    issuances of redeemable convertible preferred stock, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,134,516</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,255,569</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,134,516</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,255,569</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Net change in cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(17,490,651</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,461,476</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning
    of year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,449,310</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,987,834</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end
    of year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,958,659</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,449,310</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of non-cash financing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Estimated
    fair market value of warrants issued to placement agent in connection with issuance of redeemable convertible preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">93,863</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="F_6"></A>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;DESCRIPTION
OF BUSINESS AND BASIS OF PRESENTATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Actuate Therapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;)
was incorporated in the State of Delaware on January&nbsp;16, 2015. The Company is a clinical-stage biopharmaceutical company focused
on developing novel therapies for the treatment of cancers through the inhibition of glycogen synthase kinase-3 (&ldquo;GSK-3&rdquo;).
The Company&rsquo;s lead investigational product, elraglusib (formerly 9-ING-41), is a small molecule that is designed to enter cancer
cells and block the function of the enzyme GSK-3&beta;, thereby causing the death of the cancer cells and the regulation of anti-tumor
immunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a 100%-owned Irish subsidiary,
Actuate Therapeutics Limited, that is currently dormant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates as a semi-virtual biopharmaceutical
company with expertise in all aspects of preclinical and clinical development. In addition, the Company contracts with highly experienced
development, manufacturing, regulatory, and clinical consultants located in offices throughout the United States of America (&ldquo;U.S.&rdquo;),
Europe and Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s consolidated financial statements
are presented in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) and
reflect the financial position, results of operations and cash flows for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going Concern and Management&rsquo;s Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern. As of December&nbsp;31, 2023, the Company had cash and cash
equivalents of $2,958,659 and a working capital deficit of $3,925,028. The Company has not generated revenues since inception and has
incurred recurring operating losses since inception. The Company expects to continue to incur losses for the foreseeable future and therefore,
the Company&rsquo;s ability to continue its operations is highly dependent on its ability to raise additional capital to fund its future
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2023, the Company completed a private
placement and issued 1,022,018 shares of its Series&nbsp;C redeemable convertible preferred stock (see Note 7) at a purchase price of
$4.36 per share, for aggregate net proceeds of $4,134,516 after deducting placement agent and other offering expenses paid in the amount
of $321,500. On February&nbsp;20, 2024, the Company issued a convertible promissory note in the amount of $3,000,000 to a related party
(the &ldquo;Related Party Convertible Promissory Note&rdquo;), which accrues interest at a rate of 7% per annum and matures on June&nbsp;30,
2024 (&ldquo;Maturity Date&rdquo;) in exchange for gross proceeds of $3,000,000 (see Note 13).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2023, the Company&rsquo;s research and
development expenses continued to increase as it hired additional professional and scientific staff, advanced its clinical pipeline,
and continued to execute its manufacturing plans. Management expects to incur substantial additional expenditures in 2024 and beyond
for the development and potential commercialization of its product candidates, provided the Company is able to raise sufficient capital.
If the Company encounters unforeseen delays or expenses, management will have the ability to curtail its presently planned level of operations.
Management anticipates, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy
the Company&rsquo;s operational and capital requirements through twelve months from the issuance date of these consolidated financial
statements. Additionally, in view of the Company&rsquo;s expectation to incur significant losses for the foreseeable future, it will
be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company&rsquo;s
access to such resources, is not assured. The above matters raise substantial doubt regarding the Company&rsquo;s ability to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the accounts of Actuate Therapeutics,&nbsp;Inc. and its wholly owned subsidiary, Actuate Therapeutics Limited. All material intercompany
accounts and transactions have been eliminated in the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassification of prior period amounts
has been made to conform to the 2023 presentation. These reclassifications had no effect on net loss or net loss share attributable to
common stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets, liabilities,
expenses, and related disclosures in the accompanying notes. The Company bases its estimates, assumptions and judgements on historical
experience when available and on various factors that it believes to be reasonable under the circumstances as of the date of the accompanying
consolidated financial statements including the fair value of common stock, fair value of the warrant liability, stock-based compensation
expense, accrued expenses (including accrued expenses related to research and development (&ldquo;R&amp;D&rdquo;) as described below),
and the recoverability of the Company&rsquo;s net deferred tax assets and related valuation allowance. In addition, other factors may
affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions
used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process
often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that
falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the
preparation of the accompanying consolidated financial statements under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Accrued Expenses Related to R&amp;D Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the process of preparing our consolidated
financial statements, we are required to estimate our R&amp;D expenses as of each balance sheet date. This process involves reviewing
open contracts, including clinical site contracts, and communicating with our personnel to identify services that have been performed
on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been
invoiced or otherwise notified of the actual cost. We make estimates of our R&amp;D expenses as of each balance sheet date based on facts
and circumstances known to us at that time. The significant estimates in our R&amp;D expenses include the costs incurred for services
performed by our vendors in connection with services for which we have not yet been invoiced. We base our expenses related to R&amp;D
activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with contractors and vendors
that conduct R&amp;D on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract,
and may result in uneven payment flows. Advance payments for goods and services that will be used in future R&amp;D activities are expensed
when the activity has been performed or when the goods have been received rather than when the payment is made. Although we do not expect
our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed
differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low
in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually
incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Segment Reporting and Geographic Concentrations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company manages its operations as a single
operating segment for the purposes of assessing performance and making operating decisions. The Company conducts business in the U.S.
As Actuate Therapeutics Limited is a dormant entity, there are no assets, liabilities or operations in any foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments
acquired with a maturity of three months or less from the purchase date that can be liquidated without prior notice or penalty to be
cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Concentrations of Credit Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company deposits cash and
cash equivalents with high credit quality financial institutions in the U.S. These deposits are held in checking and money market accounts
and may, from time to time, exceed the federally insured amounts. The Company has not experienced any losses in such accounts. The Company
believes it is not exposed to any significant risk in its cash and cash equivalents. The primary objectives of the Company&rsquo;s investment
portfolio are the preservation of capital and maintenance of liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to risks common to companies
in the biopharmaceutical industry, including, but not limited to, risks related to the successful development and commercialization of
product candidates, fluctuations in operating results and financial risks, the ability to successfully raise additional funds when needed,
protection of proprietary rights and patent risks, patent litigation, compliance with government regulations, dependence on key personnel
and collaboration partners, and competition from competing products in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Authoritative guidance requires disclosure of
the fair value of financial instruments. The Company applies fair value measurements to record fair value adjustments to certain assets
and liabilities and to determine fair value disclosures. The carrying amount of certain of the Company&rsquo;s financial instruments,
including cash and cash equivalents, accounts payable and accrued liabilities, approximate their estimated fair values primarily due
to the short-term nature of the instruments or based on information obtained from market sources and management estimates. The redeemable
convertible preferred stock warrant liability is carried at fair value based on unobservable market inputs (see Note 3). The Company
measures the fair value of certain of its financial liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which is not
equivalent to cost will be classified and disclosed in one of the following three categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            1 &mdash; Quoted prices (unadjusted) in active markets for identical assets and liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            2 &mdash; Inputs other than Level 1 that are observable, either directly or indirectly, such
                                            as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices
                                            in the markets that are not active, or other inputs that are observable or can be corroborated
                                            by observable market data for substantially the full term of the assets or liabilities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Level
                                            3 &mdash; Unobservable inputs that are supported by little or no market activity and that
                                            are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities
                                            include those whose fair value measurements are determined using pricing models, discounted
                                            cash flow methodologies or similar valuation techniques and significant management judgment
                                            or estimation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Comprehensive Loss</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no differences between net loss and
comprehensive loss presented in the consolidated statements of operations for the years ended December&nbsp;31, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with authoritative guidance, the
Company charges research and development costs to operations as incurred. Research and development expenses consist primarily of personnel
and related costs, external costs of outside vendors engaged clinical trials, contract manufacturers, consultants and other third parties
to conduct and support our clinical trials and preclinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent fees and patent related costs in connection
with filing and prosecuting patent applications are expensed as incurred and are classified as general and administrative expenses in
the accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Redeemable Convertible Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records all shares of redeemable
convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred
stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in certain events considered not solely
within the Company&rsquo;s control, such as a merger, acquisition, or sale of all or substantially all of the Company&rsquo;s assets,
each referred to as a &ldquo;deemed liquidation event,&rdquo; the redeemable convertible preferred stock will become redeemable at the
option of the holders of at least a majority of the then outstanding preferred shares. The Company has not adjusted the carrying value
of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company
to pay the liquidation preference to holders of shares of redeemable convertible preferred stock is not probable of occurring as of the
issuance date of these consolidated financial statements. Subsequent adjustments to the carrying values to the liquidation preference
will be made only if it becomes probable that such a deemed liquidation event will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Redeemable Convertible Preferred Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s redeemable convertible preferred
stock warrants require liability classification and accounting as the underlying redeemable convertible preferred stock is considered
contingently redeemable and may obligate the Company to transfer assets to the holders at a future date upon occurrence of a deemed liquidation
event. The warrants are recorded at their estimated fair value upon issuance and are subject to remeasurement to estimated fair value
at each balance sheet date, with changes in the estimated fair value recognized as a component of other income (expense) in the accompanying
consolidated statements of operations. The Company will continue to adjust the warrant liability for changes in estimated fair value
until the earlier of the exercise or expiration of the redeemable convertible preferred stock warrants, the occurrence of a deemed liquidation
event or the conversion of redeemable convertible preferred stock into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
April&nbsp;2015, the Company&rsquo;s </FONT>Board of Directors (&ldquo;Board&rdquo;) <FONT STYLE="background-color: white">approved its
2015 Stock Incentive Plan (&ldquo;2015 Plan&rdquo;). The Company periodically grants equity-based payment awards under the 2015 Plan
in the form of restricted common stock awards </FONT>(&ldquo;RSAs&rdquo;) and <FONT STYLE="background-color: white">stock options to
employees, directors and non-employees and records stock-based compensation expenses for awards of stock-based payments based on their
estimated fair value at the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated fair value of service-based RSAs
is measured at the grant date based on the estimated fair market value of the Company&rsquo;s common stock on the date of grant and is
recognized as expense <FONT STYLE="background-color: white">over the requisite service period, which is generally the awards&rsquo; vesting
period. </FONT>The estimated fair value of performance-based RSAs is measured at the grant date <FONT STYLE="background-color: white">based
on the estimated fair value of shares expected to be earned at the end of the performance period, and is recognized as expense ratably
over the performance period based upon the probable number of shares expected to vest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company accounts
for the grant of stock options based on the estimated fair value of the underlying option using the Black-Scholes valuation model on
the date of grant and are recognized as expense in the consolidated statement of operations on a straight-line basis over the requisite
service period, which is the vesting period. The Black-Scholes valuation model requires the input of subjective assumptions, including
expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying
common stock on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We classify stock-based compensation expense
in the consolidated statements of operations in the same manner in which the award recipients&rsquo; payroll costs are classified or
in which the award recipients&rsquo; service payments are classified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes forfeitures related to
stock-based compensation awards as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Net Loss Per Share Attributable to Common
Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during
the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss
attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding
for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock, warrants to purchase
redeemable convertible preferred stock, unvested RSAs, and outstanding stock options are considered to be potentially dilutive securities
(see Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Basic and diluted net loss attributable to
common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable
convertible preferred stock and common stock subject to repurchase are considered participating securities. The redeemable convertible
preferred stock does not have a contractual obligation to share in the Company&rsquo;s losses, and unvested RSAs subject to forfeiture
is considered an unvested stock-based compensation award for accounting purposes. As such, the net loss is attributed entirely to common
stockholders. Because the Company has reported a net loss for the reporting periods presented, the diluted net loss per common share
is the same as basic net loss per common share for those periods. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes in accordance
with Accounting Standards Codification (&ldquo;ASC&rdquo;) 740, &ldquo;Income Taxes&rdquo; (&ldquo;ASC 740&rdquo;). In accordance with
authoritative guidance, deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and
tax bases of assets and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to
reverse. A valuation allowance is recorded on deferred tax assets unless realization is considered more likely than not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates its tax positions taken
or expected to be taken in the course of preparing the Company&rsquo;s tax returns to determine whether the tax positions are &ldquo;more-likely-than-not&rdquo;
of being sustained by the applicable tax authority. Tax positions not deemed to meet the &ldquo;more-likely-than-not&rdquo; threshold
are not recorded as a tax benefit or expense in the current year. The Company recognizes interest and penalties, if any, related to uncertain
tax positions in interest expense. No interest and penalties related to uncertain tax positions were accrued at either December&nbsp;31,
2023 or 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows authoritative guidance which
requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management has analyzed
all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those that are open for
examination by taxing authorities. Tax years covering the years from 2020 to 2023 are the only open years for the Company as of the issuance
date of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also has elected to utilize research
credits against the employer portion of payroll tax as it is considered a qualified small business under the Internal Revenue code. Due
to the uncertainty of utilizing the research credits, the Company accounts for the credits against research and development expenses
in the accompanying consolidated financial statements when the related expense is incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recently Issued Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting standards not listed below were assessed
and determined not to be applicable or are expected to have minimal impact on the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December&nbsp;2019, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Updates (&ldquo;ASU&rdquo;) 2019-12, <I>Simplifying the Accounting for
Income Taxes</I>. The guidance eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology
for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
clarifies and simplifies other aspects of the accounting for income taxes. The guidance was effective for fiscal years beginning after
December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. Early adoption was permitted.
The adoption of the guidance did not have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August&nbsp;2020, the FASB issued ASU 2020-06,
<I>Debt &mdash; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &mdash; Contracts in Entity&rsquo;s
Own Equity (Subtopic 815-40)</I>. The guidance simplifies the accounting for certain financial instruments, eliminates the current models
that require separation of beneficial conversion and cash conversion features from convertible instruments, and simplifies the derivative
scope exception guidance pertaining to equity classification of contracts in an entity&rsquo;s own equity. It also introduces additional
disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&rsquo;s own equity and amends
the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. The
guidance is effective for public business entities that meet the definition of a Securities and Exchange Commission filer, excluding
entities eligible to be smaller reporting companies as defined by the Securities and Exchange Commission, for fiscal years beginning
after December&nbsp;15, 2021, including interim periods within those fiscal years. For all other entities, the guidance is effective
for fiscal years beginning after December&nbsp;15, 2023, including interim periods within those fiscal years. Early adoption is permitted,
but no earlier than fiscal years beginning after December&nbsp;15, 2020, including interim periods within those fiscal years. The Company
adopted the guidance as of January&nbsp;1, 2024. The adoption of the guidance is not expected to have a material impact on the Company&rsquo;s
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;FAIR
VALUE MEASUREMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the&nbsp;Company&rsquo;s
liabilities measured at fair value as of December&nbsp;31, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value
    Measurements at December&nbsp;31,&nbsp;2023 Using</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fair Value
    at<BR> December&nbsp;31, <BR> 2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Quoted
    Prices<BR> in Active<BR> Markets for<BR> Identical Assets <BR> (Level 1)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant
    <BR>
    Other<BR> Observable <BR> Inputs <BR> (Level 2)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant<BR>
    Unobservable <BR> Inputs<BR> (Level 3)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Redeemable
    convertible preferred stock warrant liability</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid">Fair
    Value Measurements at December&nbsp;31,&nbsp;2022 Using</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fair Value
    at<BR> December&nbsp;31, <BR> 2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Quoted
    Prices<BR> in Active<BR> Markets for<BR> Identical Assets <BR> (Level 1)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant
    <BR>
    Other<BR> Observable <BR> Inputs <BR> (Level 2)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Significant<BR>
    Unobservable <BR> Inputs<BR> (Level 3)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Redeemable
    convertible preferred stock warrant liability</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the changes in
the fair value of the Company&rsquo;s Level&nbsp;3 financial instruments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series&nbsp;B
    <BR>
    Redeemable <BR>
    Convertible <BR>
    Preferred Stock Warrant Liability</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Series&nbsp;C
    Redeemable Convertible Preferred Stock Warrant <BR>
    Liability</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;<B>Total</B></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Fair value as of January&nbsp;1, 2022</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">850,943</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">850,943</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,579</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,579</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Fair value as of December&nbsp;31, 2022</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,364</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">Estimated fair
    market value of warrants issued to placement agent in connection with issuance of redeemable convertible preferred stock</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93,863</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93,863</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">76,691</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,131</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">79,822</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Fair value as of December&nbsp;31, 2023</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">891,055</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">96,994</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">988,049</TD>
    <TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series&nbsp;B redeemable convertible preferred
stock warrant liability was valued using the following assumptions using the Black-Scholes valuation model:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock price</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.78</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.18</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected term (in years)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82.53</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Weighted average risk-free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.99</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series&nbsp;C redeemable convertible preferred
stock warrant liability was valued using the following assumptions using the Black-Scholes valuation model as of December&nbsp;31, 2023
and June&nbsp;30, 2023 (Date of Grant):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Date of Grant</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock price</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.72</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">4.36</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected term (in years)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80.68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Weighted average risk-free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.80</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;OTHER
ACCRUED EXPENSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accrued expenses as of December&nbsp;31,
2023 and 2022 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued clinical trial costs</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,207,785</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,895,313</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Other accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,469</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,789</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total other
    accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,221,254</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,082,102</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;COMMITMENTS
AND CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Legal</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be involved, from time to time,
in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes
and are not predictable with assurance. While management believes that such matters are currently insignificant, matters arising in the
ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its
business and financial condition. To the Company&rsquo;s knowledge, the Company is not subject to any pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Indemnities and Guarantees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have made certain
indemnities and guarantees, under which we may be required to make payments to a guaranteed or indemnified party, in relation to certain
transactions. We indemnify our officers and directors to the maximum extent permitted under the laws of the State of Delaware. The duration
of these indemnities and guarantees varies and, in certain cases, is indefinite. These indemnities and guarantees do not provide for
any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make
any payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated
balance sheets<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;LICENSES
AND AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Northwestern License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March&nbsp;31, 2015, the Company entered into
an Exclusive License Agreement with Equity (the &ldquo;Northwestern License Agreement&rdquo;) with Northwestern University (&ldquo;Northwestern&rdquo;).
Pursuant to the Northwestern License Agreement, Northwestern granted the Company (a)&nbsp;a nonexclusive license to certain technical
information developed in the laboratory of Andrew Mazar, and (b)&nbsp;an exclusive license to all results obtained by Andrew Mazar and
his collaborators at Northwestern on the use of the GSK-3&beta; (formerly 9-ING-41) and related compounds used for the treatment of cancer
and combination therapies. In consideration of the license granted pursuant to the Northwestern License Agreement, the Company granted
Northwestern 50,000 shares of the Company&rsquo;s common stock, representing 5% of the Company&rsquo;s capital stock on a fully diluted
basis on the date of grant. In addition, the Company granted Northwestern the right to participate in future offerings of the Company&rsquo;s
capital securities on the same terms as offered to those participating in the offering. In 2019, Northwestern&rsquo;s right to participate
in future offerings expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>UIC License Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April&nbsp;6, 2015, the Company entered into
an Exclusive License Agreement with Equity (the &ldquo;UIC License Agreement&rdquo;) with The Board of Trustees of the University of
Illinois (&ldquo;UIC&rdquo;), whereby, UIC granted the Company (a)&nbsp;an exclusive, nontransferable license, with the right to sublicense
under UIC&rsquo;s rights in the Patent Rights (as defined in the UIC License Agreement), and (b)&nbsp;a non-exclusive, non-transferable
license, with the right to sublicense, to use UIC&rsquo;s rights in the Technical Information (as defined in the UIC License Agreement)
within the Territory and the Field as each such term is defined in the UIC License Agreement. In consideration of the license granted
under the UIC License Agreement, the Company issued 83,750 shares of the Company&rsquo;s common stock to UIC, which represented 5% of
the Company&rsquo;s capital stock on a fully diluted basis, as defined in the UIC License Agreement, and agreed to pay UIC (i)&nbsp;development
milestones of up to $1.3 million, of which, up to $0.3 million is due upon the progress of clinical trials and $1.0 million is due upon
the initiation of commercial sales (ii)&nbsp;annual minimum royalty payments of $5,000 beginning on the third anniversary year of the
UIC License Agreement and increasing to $15,000 in year four, $35,000 in year five, and $50,000 in year six and thereafter, (iii)&nbsp;royalty
on net sales for product covered under the Patent Rights in the low single digits with a 50% reduction in royalties for products solely
utilizing Technical Information, (iv)&nbsp;a declining percentage of sublicensing revenue based on the escalating stage of development
upon a sublicensing event, and (v)&nbsp;the reimbursement of all patent and related expenses incurred by UIC covering the Patent Rights.
For the years ended December&nbsp;31, 2023 and 2022, the Company incurred minimum royalties and reimbursable patent expenses to UIC in
the aggregate amount of $64,711 and $50,000, respectively, which amounts were included in general and administrative expenses in the
accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company has an obligation to
UIC related to a sub-license and collaboration agreement dated August&nbsp;28, 2017 with an unrelated entity, which agreement was later
terminated on January&nbsp;31, 2018. Under the agreement, the Company initially paid UIC a portion of the sublicense fees in the amount
of $44,999 with the remaining unpaid balance of $404,991 due and payable to UIC in two installments with 50% due and payable on the one-year
anniversary from the first commercial sale and the remaining balance is due on the second-year anniversary from the first commercial sale.
The unpaid balance of $404,991 as of December&nbsp;31, 2023 and 2022 continues to accrue interest at a rate of 5% per annum, representing
the prime rate as of the date of the agreement plus 1%. Interest payable to UIC was $130,041 and $86,400 as of December&nbsp;31, 2023
and 2022, respectively, and is included in the accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;STOCKHOLDERS&rsquo;
DEFICIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company authorized capital as of December&nbsp;31,
2023 consists of 38,108,584 shares of common stock, $0.000001 par value per share (&ldquo;Common Stock&rdquo;) and 33,463,018 shares
of preferred stock, $0.000001 par value per share, of which, the Company has designated multiple series of redeemable convertible preferred
stock (&ldquo;Preferred Stock&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Redeemable Convertible Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2023, the Company completed a private
placement and issued 1,022,018 shares of its Series&nbsp;C redeemable convertible preferred stock at a purchase price of $4.36 per share,
for net proceeds to the Company of $4,134,516 after deducting placement agent and other offering expenses paid in the amount of $321,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022, the Company completed a private
placement and issued 4,548,182 shares of its Series&nbsp;C redeemable convertible preferred stock at a purchase price of $4.36 per share,
for net proceeds to the Company of $19,255,569 after deducting placement agent and other offering expenses of $574,645.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2023, the redeemable
convertible preferred stock is comprised of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number
    of Shares Authorized</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number
    of Shares<BR>
    Issued and Outstanding</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Face Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Liquidation
    Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Original<BR>
    Issue Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; text-align: left">Series&nbsp;A</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,663</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,663</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,967,333</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,123,812</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.00000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,133,477</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,858,547</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,121,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">19,401,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.65967</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,307,017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,307,017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,824,986</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,046,258</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.82528</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,694,252</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.00000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,961,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,333,928</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,015,819</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48,356,709</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.18000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Series&nbsp;C</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,452,140</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,570,200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,286,072</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">26,411,200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.36000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,463,018</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,678,355</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">96,715,222</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">121,033,336</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2022, the redeemable
convertible preferred stock is comprised of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="RIGHT" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number
    of Shares Authorized</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number
    of Shares<BR>
    Issued and Outstanding</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Face Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Liquidation
    Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Original
    <BR>
    Issue Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif; text-align: left">Series&nbsp;A</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,663</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,663</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,967,333</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,806,426</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.00000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,133,477</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,858,547</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14,121,012</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">18,271,425</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.65967</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,307,017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,307,017</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,824,986</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,340,259</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.82528</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,625,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,174,252</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.00000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Series&nbsp;B-4</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,961,721</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,333,928</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">39,015,819</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,235,444</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.18000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Series&nbsp;C</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,452,140</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,548,182</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,830,214</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,108,350</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right">4.36000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,463,018</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,656,337</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">92,259,364</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">108,936,156</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE><BR STYLE="clear: both">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights, preferences, privileges and restrictions granted to or
imposed on the Company&rsquo;s redeemable convertible preferred stock or the holders thereof are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of redeemable convertible preferred
stock shall be entitled to receive dividends, out of any assets legally available therefore, prior and in preference to any declaration
or payment of any dividend to the common stockholders, at the rate of 8.0% per annum on each of the Series&nbsp;A, Series&nbsp;B-1, Series&nbsp;B-2,
Series&nbsp;B-3, Series&nbsp;B-4, and Series&nbsp;C original issue prices, payable when, and if declared by the Board. Such dividends
shall be cumulative and if less than the full amount of dividends payable on the redeemable convertible preferred stock if declared and
paid, any such payments shall be made ratably among the holders of the redeemable convertible preferred stock in proportion to the total
amount each holder would be entitled to receive if the full amount of dividends payable on the redeemable convertible preferred stock
had been declared. As of December&nbsp;31, 2023 and 2022, no dividends had been declared or paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company or deemed liquidation event (as defined in the certificate of incorporation), the
holders of shares of Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution
to its stockholders before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per
share equal to one times the original issue price, plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution
or winding up of the Company or deemed liquidation event, the assets of the Company available for distribution to its stockholders shall
be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled, the holders of shares
of Preferred Stock shall share ratable in any distribution of the assets available for distribution in proportion to the respective amounts
which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect
to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each share of redeemable convertible preferred
stock is convertible at the option of the holder at any time into a share of fully paid and non-assessable share of Common Stock. Each
share of convertible preferred stock is convertible into that number of common shares as is determined by dividing the applicable initial
purchase price (the &ldquo;Initial Purchase Price&rdquo;) of such share by the applicable conversion price. The conversion rates for
each series of redeemable convertible preferred stock as of December&nbsp;31, 2023 were as follows: Series&nbsp;A - $2.00; Series&nbsp;B-1
- $3.65967; Series&nbsp;B-2 - $3.82528; Series&nbsp;B-3 - $4.00; Series&nbsp;B-4 - $4.18; and Series&nbsp;C - $4.36.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The conversion price is subject to adjustment
upon the occurrence of certain events, including issuances of shares of Common Stock at a price, exercise price, or conversion price
lower than the conversion prices of the Preferred Stock, unless waived by a majority of the holders of the series of redeemable convertible
preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the closing of the sale of shares of common
stock to the public resulting in at least $100 million in gross proceeds, all outstanding shares of Preferred Stock shall automatically
be converted into shares of Common Stock at the then effective conversion rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of redeemable convertible preferred
stock shall have the right to one vote for each whole share of Common Stock into which such redeemable convertible preferred stock could
then be converted. With respect to such vote, the holder shall have full voting rights and powers equal to the voting rights and powers
of the holders of Common Stock, shall be entitled to notice of any stockholders&rsquo; meeting in accordance with the bylaws of the Company,
and shall be entitled to vote, together with holders of Common Stock, with respect to any matter upon which holders of Common Stock have
the right to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Redemption and Balance Sheet Classification</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The redeemable convertible preferred stock is
recorded within temporary equity because, while it is not mandatorily redeemable, it will become redeemable at the option of the holders
upon the occurrence of certain deemed liquidation events that are considered not solely within the Company&rsquo;s control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2023, there were 38,108,584
shares of Common Stock authorized, of which, 3,043,309 shares were issued and outstanding as of December&nbsp;31, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The voting, dividend, and liquidation rights
of the holders of Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reserved Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2023, the Company reserved
the following shares of Common Stock for issuance upon the (i)&nbsp;conversion of the outstanding redeemable convertible preferred stock,
(ii)&nbsp;exercise of outstanding redeemable convertible preferred stock warrants, (iii)&nbsp;exercise of issued and outstanding stock
options, and (iv)&nbsp;to reserve the remaining shares available for grant under the 2015 Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Conversion of redeemable convertible preferred
    stock</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">24,678,355</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise of Series&nbsp;C redeemable convertible preferred
    stock warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">32,796</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exercise of Series&nbsp;B redeemable convertible preferred
    stock warrants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">274,930</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock options outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">478,011</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Shares reserved for issuance under
    the 2015 Plan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,124,246</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,588,338</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Redeemable Convertible Preferred Stock
Warrant Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;30, 2023, in connection with issuance
of the Series&nbsp;C redeemable convertible preferred stock, the Company issued the placement agent warrants to purchase 32,796 shares
of Series&nbsp;C redeemable convertible preferred stock at an exercise price of $5.23 per share. The warrants terminate at the earlier
of (i)&nbsp;five (5)&nbsp;years from the issuance date, (ii)&nbsp;the consummation of a change of control, or (iii)&nbsp;upon the first
closing of an initial public offering of the Company&rsquo;s common stock. The warrants have a net exercise provision under which the
holders could, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the
fair market value of the Company&rsquo;s stock at the time of exercise of the warrants after deduction of the aggregate exercise price.
The warrants contain provisions for adjustment of the exercise price and number of shares issuable upon the exercise of warrants in the
event of certain stock dividends, stock splits, reorganizations, reclassifications, and consolidations. The initial estimated fair value
of the warrants of $93,863 was calculated using the Black-Scholes valuation model (see Note 3) and recorded as a reduction to redeemable
convertible preferred stock and a corresponding increase in the warrant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> On September&nbsp;7, 2018, in connection with
convertible promissory note payable agreements, the Company agreed to issue the noteholders warrants to purchase shares of Series&nbsp;B-1
redeemable convertible preferred stock. Warrants to purchase 137,465 shares of Series B-1 redeemable convertible preferred stock were
issued at an exercise price of $2.93 per share and warrants to purchase 137,465 shares of Series B-1 redeemable convertible preferred
stock were issued at an exercise price of $5.86 per share. The warrants terminate at the earlier of (i)&nbsp;ten (10)&nbsp;years from
the issuance date, (ii)&nbsp;the consummation of a change of control, or (iii)&nbsp;upon the first closing of an initial public offering
of the Company&rsquo;s common stock. The warrants have a net exercise provision under which the holders could, in lieu of payment of
the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the Company&rsquo;s
stock at the time of exercise of the warrants after deduction of the aggregate exercise price. The warrants contain provisions for adjustment
of the exercise price and number of shares issuable upon the exercise of warrants in the event of certain stock dividends, stock splits,
reorganizations, reclassifications, and consolidations. The initial estimated fair value of the warrants of $805,292 was recorded on
the closing date of a private placement in April&nbsp;2019, representing the initial date the warrants could be measured. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series&nbsp;B-1 and Series&nbsp;C warrants
had an aggregate fair value of $988,049 and $814,364 as of December&nbsp;31, 2023 and 2022, respectively (see Note 3). Changes in the
estimated fair value of the warrant liability were recognized as a component of other income (expense) in the accompanying consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;STOCK-BASED
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2015 Plan provides for the grant of incentive stock options, non-qualified
stock options and restricted common stock awards. As of December&nbsp;31, 2023, there were 3,670,566 shares authorized under the 2015
Plan, of which, 1,124,246 shares remained available for grant. All the Company&rsquo;s employees, as well as all of the Company&rsquo;s
non-employee directors and other consultants, advisors and other persons who provide services to the Company are eligible to receive
incentive awards under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Restricted Common Stock Awards (&ldquo;RSAs&rdquo;)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company did not grant RSAs during the year
ended December&nbsp;31, 2023. During the year ended December&nbsp;31, 2022, the Company granted&nbsp;187,231 RSAs. As of December&nbsp;31,
2023, the total estimated unrecognized compensation cost related to non-vested RSAs was approximately $367,000. This cost is expected
to be recognized over the remaining weighted average vesting period of 1.22 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restricted common stock activity for the two years ended&nbsp;December&nbsp;31,
2023 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Restricted
    <BR>
    Common Stock <BR>
    Award Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted
    <BR>
    Average Grant <BR>
    Fair Date Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    balance at January&nbsp;1, 2022</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,424,342</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.32</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">187,231</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.17</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(718,658</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.28</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(236,780</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    balance at December&nbsp;31, 2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">656,135</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.24</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(351,884</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.24</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested
    balance at December&nbsp;31, 2023</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">304,251</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.23</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">There were no stock
options granted during the year ended December&nbsp;31, 2022. The following table provides the assumptions used in determining the estimated
fair value of stock option awards for the year ended December&nbsp;31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended<BR>

    December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected volatility</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82.02%
                                            to 86.46%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.90
                                            to 4.84%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected dividend yield</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">0.00%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected term (in years)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00
                                            to 5.85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The weighted-average
grant-date fair value of the options granted was $0.84 for the year ended December&nbsp;31, 2023. The estimated fair value of shares
vested during the year ended December&nbsp;31, 2023 was $0.81.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
summarizes stock option activity for the year ended December&nbsp;31, 2023:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number<BR>
    of <BR>
    Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR>
    Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR>
    Average<BR> Remaining<BR> Contractual<BR> Term (in <BR>
    years)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR>
    Intrinsic<BR> Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Outstanding at December&nbsp;31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font: 10pt Times New Roman, Times, Serif; text-align: left">Options granted</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">478,011</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1.19</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Options exercised</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Options canceled and forfeited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December&nbsp;31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">478,011</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.19</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.31</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">430,210</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at December&nbsp;31,
    2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">478,011</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.19</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.31</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">430,210</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Exercisable at December&nbsp;31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">85,336</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1.19</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">9.31</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">76,802</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2023, total unrecognized
stock-based compensation cost related to stock options was approximately $252,000. This cost is expected to be recognized over the remaining
weighted average vesting period of 1.89 years. The aggregate intrinsic value is calculated as the difference between the option exercise
price and the estimated fair value of the underlying Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the stock-based
compensation expense recorded in the accompanying consolidated statements of operations during the years ended December&nbsp;31, 2023
and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31, 2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31, 2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: right">129,642</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: right">102,853</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">293,897</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">551,213</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">423,539</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">654,066</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not recognized and does not expect
to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation
allowance related to its net deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; NET
LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation
of basic and diluted net loss per share attributable to common stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended
    December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Numerator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,744,620</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,159,401</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Weighted-average shares of common stock outstanding, basic
    and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,582,876</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,179,037</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Net loss per share attributable to common stockholders,
    basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9.58</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(9.25</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential dilutive effect of redeemable convertible
preferred stock outstanding during the period is calculated using the if-converted method assuming the conversion of redeemable convertible
preferred stock as of the earliest period reported or at the date of issuance, if later, but are excluded if their effect is anti-dilutive.
The potential dilutive effect of options, unvested RSAs, and warrants outstanding during the period are calculated in accordance with
the treasury stock method, but are excluded if their effect is anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The potential shares of Common Stock that were excluded from the computation
of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an
antidilutive effect were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">Redeemable convertible preferred stock</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">24,678,355</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">23,656,337</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options issued and outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">478,011</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unvested restricted common stock awards (&ldquo;RSAs&rdquo;)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">304,251</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">656,135</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Warrants to purchase redeemable convertible
    preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">307,726</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">274,930</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25,768,343</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,587,402</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;INCOME
TAXES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had no income tax expense due to
operating losses incurred for the years ended December&nbsp;31, 2023 and 2022. The Company accounts for income taxes in accordance with
ASC 740, &ldquo;Income Taxes&rdquo; (&ldquo;ASC 740&rdquo;), which requires that the tax benefit of net operating losses, temporary differences
and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &ldquo;more likely than not.&rdquo;
Realization of the future tax benefits is dependent on the Company&rsquo;s ability to generate sufficient taxable income within the carryforward
period. Because of the Company&rsquo;s recent history of operating losses, management believes that recognition of the deferred tax assets
arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full valuation
allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provision (benefit) for income taxes for the years ended December&nbsp;31,
2023 and 2022 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: justify">Current</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Federal</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">State</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Foreign</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: justify">Total current</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: justify">Deferred</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">Federal</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,198,732</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,139,924</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">State</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(92,676</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Foreign</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Change in valuation
    allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,291,408</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,139,924</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: justify; padding-bottom: 1pt">Total deferred</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0in; text-align: justify; padding-bottom: 2.5pt">Income tax provision
    (benefit)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred tax assets and liabilities reflect the
net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts
used for income tax purposes. Significant components of our deferred tax assets as of December&nbsp;31, 2023 and 2022 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deferred tax assets (liabilities):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Capitalized R&amp;D, net of amortization</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,800,091</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,454,424</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33,579</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,050</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify">Net operating loss carryforwards</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,500,774</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10,875,920</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Research and development
    tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,420,432</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,132,074</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total deferred tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">31,754,875</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24,463,468</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(31,754,875</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,463,468</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reconciliation of the effective income tax
rate to the Federal statutory rate for the years ended December&nbsp;31, 2023 and 2022 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2023</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,
    2022</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Statutory federal income tax rate</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">21.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">21.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development tax credits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.45</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1.32</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.91</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(29.13</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(35.87</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Effective income tax rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2023 and 2022, the Company
had gross federal income tax net operating loss (&ldquo;NOL&rdquo;) carryforwards of $59,443,749 and $51,790,095, respectively, and federal
research tax credits of $12,420,432 and $10,132,074, respectively. Of the federal NOL carryforwards, $3,010,902 will expire beginning
in 2037 and $56,432,847 has an indefinite life while the federal research tax credits will expire by 2043. In addition, the Company has
state NOL carryovers of $319,752 that will carry forward indefinitely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Utilization of U.S. net operating losses and
tax credit carryforwards may be limited by &ldquo;ownership change&rdquo; rules, as defined in Sections&nbsp;382 and 383 of the Code.
Similar rules&nbsp;may apply under state tax laws. The Company has not conducted a study to date to assess whether a limitation would
apply under Sections&nbsp;382 and 383 of the Code as and when it starts utilizing its net operating losses and tax credits. The Company
will continue to monitor activities in the future. In the event the Company previously experienced an ownership change, or should experience
an ownership change in the future, the amount of net operating losses and research and development credit carryovers available in any
taxable year could be limited and may expire unutilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CARES Act was signed into law on March&nbsp;27,
2020 as a response to the economic challenges facing U.S. businesses caused by the COVID-19 global pandemic. The CARES Act allowed net
operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely, and to be fully utilized without
being subjected to the 80% taxable income limitation. Net operating losses incurred after December&nbsp;31, 2020 will be subjected to
the 80% taxable income limitation. In assessing the realization of deferred tax assets, management considers whether it is more likely
than not that some portion, or all, of the deferred tax asset will be realized. The ultimate realization of deferred tax assets is dependent
upon the Company attaining future taxable income during periods in which those temporary differences become deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the uncertainty surrounding the realization
of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance on its deferred
tax assets at December&nbsp;31, 2023 and 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;RELATED
PARTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2018, the Company entered into a master
service agreement with Pacific BioPharma Logistics,&nbsp;Inc. (&ldquo;PBL&rdquo;) to provide clinical support related to the packaging,
labeling, kitting, storage, distribution and inventory for the Company&rsquo;s investigational products. Mr.&nbsp;Richard Kenley, Vice
President of Manufacturing for the Company, is an unpaid advisor for PBL and his spouse is a shareholder in PBL. During the years ended
December&nbsp;31, 2023 and 2022 we incurred $853,574 and $636,727, respectively, in services provided by PBL, which amounts are included
in research and development expense in the accompanying consolidated statements of operations. As of December&nbsp;31, 2023 and 2022,
we had an outstanding balance owed to PBL of $52,206 and $52,298, respectively, which amounts are included in accounts payable in the
accompanying consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTUATE THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For The Years Ended December&nbsp;31, 2023
and 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;SUBSEQUENT
EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events after
the consolidated balance sheet date and through the issuance date of these consolidated financial statements, and based on our evaluation,
management has determined that no other subsequent events have occurred that would require recognition in the accompanying consolidated
financial statements or disclosure in the notes thereto other than as disclosed below and in the accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February&nbsp;20, 2024, the Company issued
a convertible promissory note in the amount of $3,000,000 to a related party (the &ldquo;Related Party Convertible Promissory Note&rdquo;),
which accrues interest at a rate of 7% per annum and matures on June&nbsp;30, 2024 (&ldquo;Maturity Date&rdquo;). Principal and accrued
interest are due and payable on the Maturity Date, subject to an automatic conversion upon a Qualified Financing (as defined below) or
an Initial Public Offering (as defined below) or at the option of the holder, convertible into shares of Series&nbsp;C redeemable convertible
preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the Company either completes a financing
of at least $5 million in gross proceeds (&ldquo;Qualified Financing&rdquo;) or closes the Company&rsquo;s first firm commitment underwritten
initial public offering (&ldquo;Initial Public Offering&rdquo;) of its Common Stock before the Maturity Date, the Related Party Convertible
Promissory Note will automatically convert into (i)&nbsp;in the case of a Qualified Financing, that number of shares of capital stock
issued in such Qualified Financing (the &ldquo;Qualified Financing Securities&rdquo;) equal to the quotient obtained by dividing the
outstanding principal amount of the Related Party Convertible Promissory Note plus all accrued and unpaid interest thereon by eighty
percent (80%) of the per share price at which shares are to be sold in such Qualified Financing or (ii)&nbsp;in the case of an Initial
Public Offering, such number of shares of Common Stock (as defined below) equal to the outstanding principal amount of the Related Party
Convertible Promissory Note plus all accrued and unpaid interest thereon, divided by eighty percent (80%) of the Initial Public Offering
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event a Qualified Financing or Initial
Public Offering does not occur prior to the Maturity Date, then on or after the Maturity Date, the holder may elect to either (i)&nbsp;convert
the Related Party Convertible Promissory Note into such number of shares of Series&nbsp;C redeemable convertible preferred stock equal
to the principal amount plus the accrued but unpaid interest thereon divided by $4.36 or (ii)&nbsp;elect that the Related Party Convertible
Promissory Note become fully due and payable in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 208; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm247121d1_drsimg007.jpg" ALT=""></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Partners Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>a division of American Capital Partners</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>,
2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to deliver a prospectus
when acting as an underwriter and with respect to an unsold allotment or subscription.</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 209 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART&nbsp;II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated expenses in connection with the
sale of the securities being registered hereby, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq listing fee</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer agent fees and
    expenses</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black medium double; padding-bottom: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* To be filed by amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14. Indemnification of Directors and
Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsection (a)&nbsp;of Section&nbsp;145 of the
General Corporation Law of the State of Delaware (the DGCL) empowers a corporation to indemnify any person who was or is a party or who
is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action,
suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best
interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&rsquo;s
conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsection (b)&nbsp;of Section&nbsp;145 empowers
a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in
any of the capacities set forth above, against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person
in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably
believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of
any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent
that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication
of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
which the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;145 further provides that to the
extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding
referred to in subsections (a)&nbsp;and (b)&nbsp;of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person
shall be indemnified against expenses (including attorneys&rsquo; fees) actually and reasonably incurred by such person in connection
therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified
party may be entitled; and the indemnification provided for by Section&nbsp;145 shall, unless otherwise provided when authorized or ratified,
continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&rsquo;s
heirs, executors and administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any
person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability
asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the
corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 210; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section&nbsp;102(b)(7)&nbsp;of the DGCL provides
that a corporation&rsquo;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director
to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision
shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of the director&rsquo;s duty of loyalty to the corporation
or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation
of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL or (iv)&nbsp;for any transaction from which the director derived an improper personal
benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
and our amended and restated bylaws, each of which will become effective immediately prior to the closing of this offering, will provide
that we shall indemnify our directors and officers, and may indemnify our employees and other agents, to the maximum extent permitted
by the DGCL, and our bylaws provide that we shall indemnify directors, officers, employees and other agents to the maximum extent permitted
by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have entered into indemnification
agreements with each of our directors and officers. These agreements require us to indemnify these individuals to the fullest extent
permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as
a result of any proceeding against them as to which they could be indemnified. We also intend to enter into indemnification agreements
with our future directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or
otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since January&nbsp;1, 2021, we have made the
following sales of unregistered securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    January&nbsp;2021, we issued and sold to certain investors an aggregate of 5,869,263 shares of our Series&nbsp;B-4 redeemable convertible
    preferred stock at a purchase price of $4.18 per share, for aggregate gross proceeds of approximately $24.5 million.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In multiple closings from August&nbsp;2022 to June&nbsp;2023, we issued and sold to certain investors an aggregate of 5,570,200 shares of our Series&nbsp;C redeemable convertible preferred stock at a purchase price of $4.36 per share, and received aggregate gross proceeds of approximately $23.4 million.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June&nbsp;2023, in connection with our Series&nbsp;C financing, we issued to the placement agent warrants to purchase an aggregate of 32,796 shares of our Series&nbsp;C redeemable convertible preferred stock at an exercise price of $5.23 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="font-size: 10pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    February&nbsp;2024, we issued and sold to a certain accredited investor a $3.0 million principal amount convertible promissory note
    that is subject to an automatic conversion upon a Qualified Financing (as defined below) or an Initial Public Offering (as defined
    below) or at the option of the holder, convertible into shares of Series&nbsp;C redeemable convertible preferred stock. In the event
    we either complete a financing of at least $5 million in gross proceeds (&ldquo;Qualified Financing&rdquo;) or close a firm commitment
    underwritten initial public offering (&ldquo;Initial Public Offering&rdquo;) of our common stock before June 30, 2024 (the Maturity
    Date), the note will automatically convert into (i)&nbsp;in the case of a Qualified Financing, that number of shares of capital stock
    issued in such Qualified Financing (the Qualified Financing Securities) equal to the quotient obtained by dividing the outstanding
    principal amount of the note plus all accrued and unpaid interest thereon by eighty percent (80%) of the per share price at which
    shares are to be sold in such Qualified Financing or (ii)&nbsp;in the case of an Initial Public Offering, such number of shares of
    common stock equal to the outstanding principal amount of the note plus all accrued and unpaid interest thereon, divided by eighty
    percent (80%) of the Initial Public Offering price. In the event a Qualified Financing or Initial Public Offering does not occur
    prior to the Maturity Date, then on or after the Maturity Date, the holder may elect to either (i)&nbsp;convert the note into such
    number of shares of Series&nbsp;C redeemable convertible preferred stock equal to the principal amount plus the accrued but unpaid
    interest thereon divided by $4.36 or (ii)&nbsp;elect that the note become fully due and payable in cash.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">From January&nbsp;1, 2021 through the date of this registration statement, we granted to certain of our directors, employees and consultants under our 2015 Stock Incentive Plan, as amended (the 2015 Plan), options to purchase 708,011 shares of our common stock, all of which remain outstanding, with per share exercise prices ranging from $1.19 to $2.60. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">From January&nbsp;1, 2021 to the effective
                                            date of this registration statement, we granted to certain of our directors, employees and
                                            consultants restricted stock awards under our 2015 Plan covering an aggregate of 2,135,167
                                            shares of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offers, sales and issuances of the securities
described in paragraphs (1)&nbsp;through (4)&nbsp;were deemed to be exempt from registration under the Securities Act in reliance on
Section&nbsp;4(a)(2)&nbsp;(or Regulation D promulgated thereunder) in that the issuance of securities to the accredited investors did
not involve a public offering. The recipients of securities in each of these transactions acquired the securities for investment only
and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities
issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor under Rule&nbsp;501
of Regulation D. No underwriters were involved in these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offers, sales and issuances of the securities
described in paragraphs (5)&nbsp;and (6)&nbsp;were deemed to be exempt from registration under the Securities Act in reliance on either
Rule&nbsp;701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under
Rule&nbsp;701 or Section&nbsp;4(a)(2)&nbsp;in that the issuance of securities to the accredited investors did not involve a public offering.
The recipients of such securities were our employees, directors or bona fide consultants and received the securities under the 2015 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Appropriate legends were affixed to the securities
issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment, business
or other relationships, to information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>(a)&nbsp;Exhibits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The exhibits listed below are filed as part of
this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
<U>Number</U></B></FONT></TD>
    <TD STYLE="padding: 0.25pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; white-space: nowrap; text-align: center; width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description of Document</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Underwriting Agreement</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1^</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt"> &nbsp; </TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth
    Amended and Restated Certificate of Incorporation, as currently in effect</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Sixth Amended and Restated Certificate of Incorporation to become effective immediately prior to the closing of this offering</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3^</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt"> &nbsp; </TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws,
    as currently in effect</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Amended and Restated Bylaws to become effective upon the closing of this offering</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Common Stock Certificate of the registrant</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2^</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt"> &nbsp; </TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Amended and Restated Investors&rsquo; Rights Agreement, by and between the registrant and certain of its stockholders, dated November
    30, 2022</FONT> </TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt; white-space: nowrap; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&dagger;</FONT> </TD>
    <TD STYLE="padding: 0.25pt; white-space: nowrap; vertical-align: top"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative Warrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Baker&nbsp;&amp; Hostetler LLP</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1^+</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt"> &nbsp; </TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actuate
    Therapeutics,&nbsp;Inc. 2015 Equity Incentive Plan, as amended, and form of grant agreements thereunder</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2+&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actuate Therapeutics,&nbsp;Inc. 2024 Equity Incentive Plan, and form of grant agreements thereunder</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+&dagger;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Employee Director Compensation Policy</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><A HREF="tm247121d3_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"><A HREF="tm247121d3_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement with Equity, dated April&nbsp;6, 2015, as amended, between The Board of Trustees of the University of Illinois and the Registrant</FONT></A></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5^*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt"> &nbsp; </TD>
    <TD STYLE="padding: 0.25pt; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement, dated March&nbsp;31, 2015, as amended, between Northwestern University and the Registrant</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 6%; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6^+</FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 92%; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement, effective April&nbsp;15, 2015 and as amended on each of February&nbsp;5, 2016, September&nbsp;28, 2017, September&nbsp;23,
    2018, January&nbsp;29, 2019, August&nbsp;1, 2022, January&nbsp;27, 2023 and December&nbsp;12, 2023, between Daniel Schmitt, and the
    Registrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7^+</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement, effective June&nbsp;1, 2022, between Andrew P. Mazar, Ph.D., and the Registrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8^+</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting
    Agreement, effective February&nbsp;17, 2024, between Paul Lytle, and the Registrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for Directors and Officers</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10^+</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    Agreement, effective February&nbsp;17, 2024, between Paul Lytle and the Registrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11^+</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification
    Agreement, effective March&nbsp;17, 2017, between each of the parties set forth on the schedule thereto and the Registrant</FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of KMJ Corbin&nbsp;&amp; Company LLP,&nbsp;Independent Registered Public Accounting Firm</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Baker&nbsp;&amp; Hostetler LLP (included in Exhibit&nbsp;5.1)</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page)</FONT></TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1+&dagger;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback
    Policy </FONT> </TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107&dagger;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"> ^ </TD>
    <TD STYLE="padding: 0.25pt"> Previously submitted </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&yen;</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules have been omitted
    pursuant to Item 601(a)(5)&nbsp;of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted
    schedules upon request by the SEC. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates management contract
    or compensatory plan. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain portions of this exhibit
    have been omitted pursuant to Item 601(b)(10)&nbsp;of Regulation S-K on the basis that they are not material and would likely cause
    competitive harm to the registrant if disclosed. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant hereby undertakes
to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered
in such names as required by the underwriters to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">For purposes of determining any liability
                                            under the Securities Act, the information omitted from the form of prospectus filed as part
                                            of this registration Statement in reliance upon Rule&nbsp;430A and contained in a form of
                                            prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1)&nbsp;or (4)&nbsp;or 497(h)&nbsp;under
                                            the Securities Act shall be deemed to be part of this Registration Statement as of the time
                                            it was declared effective.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">For the purpose of determining any liability
                                            under the Securities Act, each post-effective amendment that contains a form of prospectus
                                            shall be deemed to be a new registration statement relating to the securities offered therein,
                                            and the offering of such securities at that time shall be deemed to be the initial bona fide
                                            offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actuate Therapeutics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel M. Schmitt</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S_001"></A>SIGNATURES AND POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE
PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel M. Schmitt and Andrew P. Mazar, and each
of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or
her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments,
to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed
pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act of 1933, and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents,
or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 23%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 54%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief
    Executive Officer and Director</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel M. Schmitt</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim Chief Financial
    Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Lytle</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer
    and Principal Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairperson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron G.L. Fletcher, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les Kreis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Todd Thomson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
    2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel Zabrowski, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 214; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ACTUATE THERPEUTICS,&nbsp;INC. HAS DETERMINED THE INFORMATION (I)&nbsp;IS
NOT MATERIAL AND (II)&nbsp;WOULD LIKELY CAUSE COMPETITIVE HARM TO ACTUATE THERPEUTICS,&nbsp;INC. IF PUBLICLY DISCLOSED.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXCLUSIVE LICENSE AGREEMENT WITH EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">License Agreement (&ldquo;<B>Agreement</B>&rdquo;),
effective as of April&nbsp;6, 2015 (&ldquo;<B>Effective Date</B>&rdquo;) between The Board Of Trustees Of The University Of Illinois,
a body corporate and politic of the State of Illinois, 352 Henry Administration Building, 506 S. Wright St., Urbana,&nbsp;Illinois 61801
(&ldquo;<B>University</B>&rdquo;) and Apotheca Therapeutics a Delaware corporation, with a principal place of business at 1401 Foch Street,
Fort Worth, TX 76107 (&ldquo;<B>Licensee</B>&rdquo; or <B>&ldquo;Company&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">University holds certain
rights to the patent rights and technical information described below and desires to have the rights exploited for commercial purposes
for the public benefit. Licensee wishes to obtain the exclusive license to the patent rights and the non-exclusive license to the technical
information for such commercial purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, in consideration
of the obligations set forth below, University and Licensee hereby agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE&nbsp;1 - DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any entity that directly or indirectly controls, is controlled by, or is under common control with Licensee, and is identified
in writing to the University. For purposes of the preceding sentence, &ldquo;<B>control</B>&rdquo; means the right to control, or actual
control of, the management of the entity, whether by ownership of securities, by voting rights, by agreement or otherwise. While an entity
is entitled to the benefits of an Affiliate under this Agreement for only the period of time the entity qualifies as an Affiliate under
this definition, all obligations under this Agreement that accrued to the entity while an Affiliate shall survive until fulfilled even
though the entity no longer qualifies as an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Confidential Information</B>&rdquo;
means any information or material disclosed by one party, the &ldquo;<B>disclosing party</B>&rdquo; to the other party, the &ldquo;<B>receiving
party</B>&rdquo; that is identified in writing as confidential at the time of disclosure or, if disclosed orally or observed, is identified
as confidential at the time of disclosure or is summarized in a marked writing within <FONT STYLE="background-color: white">[***] </FONT>of
disclosure, and is not information or material that is: (a)&nbsp;already known to receiving party at the time of disclosure as evidenced
by receiving party&rsquo;s written records; (b)&nbsp;in the public domain other than through acts or omissions of receiving party, or
anyone that accessed the Confidential Information from receiving party; (c)&nbsp;lawfully disclosed without restriction to receiving
party by a third party; or (d)&nbsp;independently developed by receiving party without knowledge of or access to the Confidential Information
as evidenced by receiving party&rsquo;s written records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Equity
Rights</B></FONT>&rdquo; means the capital stock and related rights granted to the University by Licensee and its Affiliates and other
parties as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Field</B>&rdquo;
shall have the meaning set forth on <U>Schedule 1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>including</B>&rdquo;
means including, without limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>License Year</B>&rdquo;
means each successive one year term following the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;| </FONT><FONT STYLE="font-size: 10pt; color: rgb(50,62,79)">25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Market Exclusivity</B>&rdquo;
means an exclusive benefit by grant or an exclusion under or from any Regulatory Authority relating to a Product, including orphan drug
protection and data exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Sales</B>&rdquo;
means the gross invoice amounts for Product sold, transferred, practiced, performed or otherwise provided, less the following deductions,
but only to the extent included in the invoiced amount and documented as solely attributable to the Product:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;customary
trade, quantity or cash discounts and rebates actually given;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;refunds,
replacements or credits given to purchasers for return of Product; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;freight
and other transportation costs, including insurance charges, and unreimbursed duties, tariffs, sales and excise taxes actually paid,
excluding value-added taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
Sales on Product provided as part of a non-cash exchange or other than through an arms-length transaction shall mean the amount invoiced
in an arms-length sale of the same or equivalent Product in substantially the same quantity, time and place as the non-cash transfer,
and if no such sale </FONT>has occurred, shall be the fair market value of the transferred Product(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Patent
Rights</B>&rdquo; means: (a)&nbsp;the patents and patent applications listed on <U>Schedule 1;</U> (b)&nbsp;U.S., PCT and foreign patent
applications claiming priority therefrom, including division</FONT>al, and continuations; (c)&nbsp;patents issuing from any of the foregoing;
and (d)&nbsp;reissues, renewals, re-examinations, substitutions or extensions thereof, and supplementary protection certificates referencing
any of the foregoing, in each case only to the extent of the claimed subject matter that is fully disclosed and enabled by the disclosures
in (a)&nbsp;of this definition to satisfy 35 U.S.C. &sect;112.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Product(s)</B>&rdquo;
means any product or process: (a)&nbsp;claimed by the Patent Rights, or whose manufacture, use or production is claimed by the Patent
Rights; (b)&nbsp;the development, manufacture, reproduction, performance, use, sale or importation of which is, incorporates, uses or
is derived from any of the Technical Information; or (c)&nbsp;meeting the qualifications of both (a)&nbsp;and (b)&nbsp;of this definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Authority</B>&rdquo;
means the U.S. Food and Drug Administration, European Medicines Agency or other similar regulatory body, agency or entity, and their
respective successors anywhere in the world, that grants approvals, licenses, registrations or authorizations on behalf of any national,
multi-national, regional, state or local agency, department, administration, bureau, fund, commission, council or other governmental
entity necessary to test, make, market, distribute, use or sell products in its respective jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Royalty Period</B>&rdquo;
means each <FONT STYLE="background-color: white">[***]</FONT> of a License Year. The final Royalty Period shall end on the date of termination
or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sublicense</B>&rdquo;
means any agreement, however captioned, and regardless of how the conveyances are referred to, or how the parties are referred to therein,
in which Licensee directly or indirectly through privity of contract: (a)&nbsp;grants or otherwise conveys any of the rights licensed
hereunder; (b)&nbsp;agrees not to assert any of the rights licensed hereunder; (c)&nbsp;has obtained the agreement of the other party
thereto not to practice any right licensed hereunder; and/or (d)&nbsp;permits the making, offering for sale, using, selling and/or importing
of Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sublicensee</B>&rdquo;
means any third party, including an Affiliate, to which a Sublicense is conveyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Sublicense
Revenue</B>&rdquo; means all remuneration paid to Licensee under a Sublicense, including all up-front license fees, milestone payments,
maintenance fees or other sums, and the fair market value of any non-cash payments and/or in kind transfers, but excluding royalties
paid by Licensee to University hereunder based on Net Sales by Sublicensees.</FONT> Also excluded from Sublicense Revenue are payments
made to Company or Affiliates from Sublicensees that are (a)&nbsp;fees paid by Sublicensee for services rendered by Licensee employees
or consultants in support of Sublicensee&rsquo;s efforts in addition to, in excess of or outside of normal and customary support for
licensed programs, to the extent such services rendered are not required pursuant to any Sublicense; (b)&nbsp;equity investments from
third Parties so long as proceeds from said equity investments are not received from a Sublicensee as consideration for any Sublicense;
(c)&nbsp;bona fide funding in support of laboratory research, product development or clinical trials, so long as Licensee does not receive
such payments from a Sublicensee as consideration for any Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Technical Information</B>&rdquo;
means the information and/or material described on <U>Schedule 1</U>, and if provided in the form of: (a)&nbsp;biological materials,
then including all progeny, modifications and/or derivatives of the materials made by or on behalf of Licensee and/or any Sublicensee;
(b)&nbsp;software or other copyrightable work, then including all derivative works made by or on behalf of Licensee and/or any Sublicensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Term</B>&rdquo;
means the period of time from the Effective Date until the later of the date: (a)&nbsp;of the last to expire of the Patent Rights; or
(b)&nbsp;when Licensee provides notice that use of Technical Information has ceased in accordance with Section&nbsp;2.1</FONT>; or (c)&nbsp;of
the expiration of the last form of Market Exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Territory</B>&rdquo;
shall have the meaning set forth on <U>Schedule 1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;</B></FONT><B>2
- GRANT OF LICENSE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Grant</B>.
Subject to the terms and conditions of this Agreement and Licensee&rsquo;s continuing compliance therewith, University grants and Licensee
accepts: (a)&nbsp;an exclusive, non-transferable license, limited to the Field and the Territory, with the right to sublicense, under
the University&rsquo;s rights in the Patent Rights to make, have made, use, import, sell, and offer for sale royalty-bearing Product
solely within the Field and within the Territory; and (b)&nbsp;a non-exclusive, non-transferable license, limited to the Field and the
Territory, with the right to sublicense, to use the University&rsquo;s rights in the Technical Information to make and sell royalty-bearing
Product solely within the Field and within the Territory. Within <FONT STYLE="background-color: white">[***] </FONT>of the last signature
below, University shall provide Licensee with the Technical Information, selected by University in its sole discretion to transfer, for
Licensee to use solely as permitted in Section&nbsp;2.1(b), which constitutes University&rsquo;s entire obligation to Licensee regarding
the Technical Information. If the Technical Information includes tangible materials, then such Technical Information is provided in bailment
to Licensee solely as permitted in Section&nbsp;2.1(b), and nothing herein shall be construed as a sale thereof. Licensee shall notify
University when all use of Technical Information ceases, and all rights to Technical Information granted in Section&nbsp;2.1(b)&nbsp;shall
revert to University as of the date of the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Reservations</B>.&nbsp;
University reserves all rights, titles and interests not expressly granted in Section&nbsp;2.1, and the right to practice and have practiced
the Patent Rights for non-</FONT>commercial purposes, including teaching, research and public service, and to publish any information
included in the Patent Rights and Technical Information. Nothing in this Agreement or a party&rsquo;s performance hereunder shall be
construed as conferring, by implication, estoppel or otherwise, upon Licensee, any party in privity with Licensee, or any customer of
any of the foregoing, any right, title or interest under any of University&rsquo;s intellectual or tangible property right at any time,
except for those rights as expressly granted in Section&nbsp;2.1. Nothing in this Agreement shall be construed as University granting
any license under Patent Rights or Technical Information owned by any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Sublicenses</B>.
Subject to the terms and conditions of this Agreement and Licensee&rsquo;s and Sublicensee&rsquo;s continuing compliance therewith, Licensee
may grant Sublicenses provided each is: (a)&nbsp;in writing; (b)&nbsp;provides written notice to the University of the grant of each
Sublicense <FONT STYLE="background-color: white">[***]</FONT> after the execution of such Sublicense, the written notice identifying
the name and address of the Sublicensee; (c)&nbsp;on terms and conditions that are consistent with and not in conflict with this Agreement,
are no less protective of University&rsquo;s rights than those terms and conditions set forth herein, create no additional obligation
on University, terminate with the termination of this Agreement and designate University as a third party beneficiary thereunder. Licensee
shall be fully responsible to University for any breach of any Sublicense that would constitute a breach of this Agreement if the result
of actions or inactions of Licensee hereunder. For clarity, any Affiliate desiring to exercise any of the rights granted hereunder must
enter into a Sublicense. Licensee will provide University with a copy of each Sublicense, and each amendment, restatement and/or termination
thereof, within <FONT STYLE="background-color: white">[***]</FONT> of execution, and in no event any later than <FONT STYLE="background-color: white">[***]
</FONT>following University&rsquo;s request. Licensee will provide University with a copy of each report received by Licensee from each
Sublicensee. </FONT> Sublicensees shall have the right to further sublicense provided that each such further sublicensee shall be considered
a Sublicensee for all purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.4.<B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Federal
Funding</B>. Licensee understands that Patent Rights or Technical Information may have been conceived or first actually reduced to practice,
or during the Term may be first actually reduced to practice, with funding from the U.S. government. All rights granted in this Agreement
are limited by and subject to the rights of the United States government, including those set forth in 35 U.S.C. &sect;200 et seq. (&ldquo;<B>Bayh-Dole
Act</B>&rdquo;). Licensee agrees to comply and permit University to comply with the Bayh-Dole Act, including to provide the reporting
information required and to substantially manufacture Product and products produced through the use of Product in the United States,
unless waived. Licensee is a &ldquo;small business firm&rdquo; as defined in 15 U.S.C. &sect;632 and shall promptly notify University
of any changes during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;</B></FONT><B>3
- CONSIDERATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Signing
Fee</B>. Within <FONT STYLE="background-color: white">[***]</FONT> of the last signature to this Agreement, Licensee shall pay University
the amount set forth on <U>Schedule 1</U> listed as the &ldquo;<B>Signing Fee</B>&rdquo;. Licensee shall also issue and sell to University,
equity securities, on the price and terms for the number and type of equity securities of Licensee, and rights to acquire equity securities
of Licensee, and with such other related rights, preferences and privileges with respect to such equity securities, pursuant to the Equity
Rights Agreement executed contemporaneously therewith and attached in <U>Exhibit&nbsp;B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Net
Sales</B>. Net Sales accrue with the earlier of invoice or provision of Product, whether by sale, lease, transfer, performance or otherwise.
Within <FONT STYLE="background-color: white">[***]</FONT> after the end of each Royalty Period, Licensee shall pay University royalties
on Net Sales accruing in such Royalty Period in the percentages set forth on <U>Schedule 1</U>. Royalty payments on Net Sales made to
University may be credited toward the Annual Minimum for the License Year in which the royalty payment accrues, and only for that License
Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Sublicensee
Revenues. </B>Sublicensee Revenues accrue upon receipt by Licensee. Within <FONT STYLE="background-color: white">[***]</FONT> of the
Sublicensee&rsquo;s payment date to Licensee, Licensee shall pay University royalt</FONT>ies on Sublicensee Revenue as set forth on <U>Schedule
1</U>. Royalty Payments on Sublicensee Revenue made to University may be credited toward the Annual Minimum payment for the License Year
that the Sublicensee Revenue royalty payment accrues, and only for that License Year. Licensee shall not receive Sublicensee Revenue
other than in the form of cash payments without written approval from University and agreement with University on the fair market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Annual
Minimums</B>. If total amounts actually paid by Licensee to University under Sections 3.2 and 3.3 for any License Year are less than
the amount set forth on <U>Schedule 1</U> for that License Year (each an &ldquo;<B>Annual Minimum</B>&rdquo;), then within <FONT STYLE="background-color: white">[***]
</FONT>of the end of the License Year, Licensee shall pay University the amount equal to the shortfall. If this Agreement expires or
terminates for any reason, the Annual Minimum for that License Year shall be reduced pro-rata and due immediately upon such expiration
or termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Milestone
Payments</B>. Licensee shall pay University each milestone payment set forth on <U>Schedule 1</U> within <FONT STYLE="background-color: white">[***]
</FONT>after the occurrence of the corresponding milestone event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Payments
and Financial Reports</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
amounts due to University under this Agreement shall be paid in U.S. dollars, by check or other instrument representing immediately available
funds, payable as set forth on <U>Schedule 1</U>. Payments are non-refundable and unless expressly stated herein, non-creditable. If
Licensee or any Sublicensee receives payment in a currency other than U.S. dollars, such currency will be converted directly from the
currency in the country of sales origin to U.S. dollars on the date payment was made to Licensee or Sublicensee, without intermediate
conversions, based on the conversion rate applicable for exchange of Citibank, N.A., in New York, New York, on the date of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payments
due to the University under this Agreement, if not paid when due, shall be subject to a late payment charge of <FONT STYLE="background-color: white">[***]
</FONT>of the delinquent amount (or the maximum interest rate permitted by law if less) or $1.00, whichever is greater, per month on
the past due balance, and a past due penalty of <FONT STYLE="background-color: white">[***]</FONT> per month. In the event Licensee&rsquo;s
past due amount is referred for collection, Licensee shall pay a one-time collection fee of <FONT STYLE="background-color: white">[***]</FONT>.
Licensee hereby acknowledges that University may refer Client&rsquo;s past due accounts for collection and authorize legal action for
the collection of past due accounts, and Licensee shall be responsible for all reasonable costs of collection incurred by University
including reasonable attorney fees and court costs. The accrual or receipt by University of interest under this Section&nbsp;shall not
constitute a waiver by University of any right it may otherwise have to declare a breach of or default under this Agreement and to terminate
this Agreement. Licensee authorizes University and its agents to contact Licensee at any telephone number, wireless communication service
and/or email address Licensee provides to the University, using automated telephone dialing systems, artificial or pre-recorded voice
or text messages, or personal calls, regarding Licensee&rsquo;s obligation to repay any debt owed to University. Licensee understands
that others may be able to access University&rsquo;s messages and/or emails, and their content, which may include information regarding
Licensee&rsquo;s debt. The accrual or receipt by University of late payments and interest shall not waive any right or remedy University
may otherwise have, including to terminate this Agreement in accordance with Section&nbsp;6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Licensee
shall promptly notify University of Sublicensee Revenue that has accrued. In addition, Licensee shall deliver to University a true and
complete accounting within [***] days after the end of each Royalty Period, including the final Royalty Period showing all amounts that
have accrued to University during the Royalty Period, the calculation of such amounts on a Product-by-Product basis as set forth on <U>Exhibit&nbsp;A</U>.
If no payments are due in a Royalty Period, then Licensee shall submit a report to University so stating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Company upon advice of its patent counsel reasonably deems it necessary to obtain a license under a patent owned by a third party who
is not an Affiliate or a Sublicensee in order to avoid infringement thereof while practicing the Patent Rights to make Products hereunder,
then during such practice of the third party&rsquo;s patent in any particular country where such license is so required, Licensee may
deduct </FONT>[***] of the royalties paid by Licensee to such third party during the Royalty Period that are attributable to the use
of its patent for such Product in such country from the amount of royalties otherwise due to University pursuant to Section&nbsp;3.2
for such Product in such country, provided that in no event shall royalties otherwise due to University in such Royalty Period for such
Product in such country be less than <FONT STYLE="background-color: white">[***]</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Records</B>.
Licensee shall keep, and shall cause each Sublicensee to keep, complete, continuous and accurate records in sufficient and customary
detail such that the calculations and payment amounts may be verified. During the Term and for a period of <FONT STYLE="background-color: white">[***]
</FONT>following the expiration or termination of this Agreement, upon <FONT STYLE="background-color: white">[***] </FONT>prior written
notice and no more than once annually, Licensee shall permit, and shall ensure each Sublicensee shall permit, University and/or its representative
to audit and copy their respective books and records regarding any obligation under Article&nbsp;3, during normal business hours. The
examinations shall be made by a certified public accountant selected by the University and reasonably acceptable to the Company at University&rsquo;s
expense, unless the examination shows a shortage of <FONT STYLE="background-color: white">[***] </FONT>or more in the amount of payments
made to University prior to notice of the audit, in which case, Licensee shall reimburse University for all costs and expenses, including
attorneys&rsquo; or professionals fees incurred in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Diligence</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Licensee
shall bring or require its Sublicensees to bring Products to market within the Field and throughout the Territory, and develop such markets
through a thorough, vigorous and diligent program for the commercial exploitation of the Patent Rights and Technical Information. In
partial satisfaction of its obligations to bring Products to market, Licensee shall achieve the development events by the corresponding
dates as set forth in <U>Schedule 1</U>, and shall promptly notify University upon the achievement of each development event, identify
whether the Licensee or which of its Sublicensees are responsible for such achievement, and provide the actual date of such achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
University provides information to Licensee demonstrating: (i)&nbsp;potential feasibility of a particular Product or use in the Field;
or (ii)&nbsp;that a third party desires the right to develop, manufacture or sell a particular Product or a particular use in the Field;
and Licensee does not provide to University evidence that such Product or use is being diligently developed, manufactured or sold by
Licensee or one of its Sublicensees, and Licensee determines, in cooperation with University, that such development is commercially reasonable,
then Licensee shall promptly commence development of such Product or use, or Sublicense such third party the right to the particular
Product or use; at University&rsquo;s discretion, Licensee may be required to provide written documentation supporting a claim of lack
of commercial reasonability of a particular Product or particular use in the Field, such documentation to be produced by a third party
other than the third party identified in (ii)&nbsp;above as may be mutually agreed upon by University and Licensee. If within <FONT STYLE="background-color: white">[***]
</FONT>of such demonstration Licensee has not so performed, then University may either terminate this Agreement, or unilaterally convert
the grant of rights in Section&nbsp;2.1(a)&nbsp;to non-exclusive regarding such particular Product or use in the Field, as selected by
University in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;4
</B></FONT><B>- IP MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Responsibility</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">University
shall be responsible for filing, prosecuting, defending and maintaining the Patent Rights and Technical Information</FONT>, as set forth
in Schedule 1, in its sole discretion. At Licensee&rsquo;s request and expense, University shall instruct its patent counsel to provide
Licensee with copies of all official actions and other communications received from or submitted to the United States Patent and Trademark
Office (and corresponding foreign authorities) with respect to the Patent Rights in the Field and Territory. Provided Licensee is not
in breach of this Agreement, University shall reasonably consider Licensee&rsquo;s advice and comments regarding prosecution strategy
for Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Patent
Costs</B>. Within <FONT STYLE="background-color: white">[***]</FONT> receipt of each invoice, Licensee shall reimburse University for
all documented costs and expenses, including attorneys&rsquo; fees, whether incurred before, on or after the Effective Date in connection
with the Patent Rights, including the preparation, filing, prosecution, maintenance and defense thereof. From time to time, the anticipated
costs and expenses may be significant, including when nationalizing and paying annuities, or Licensee may have been or be in arrears,
and in either case Licensee shall, upon request, pay to University estimated costs and expenses in advance of such costs and expenses
being incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Discontinuation
of Support</B>. If Licensee desires to stop paying future costs or expenses associated with the filing or prosecution of any patent application,
or maintenance or defense of any patent, within the Patent Rights, then it shall give prompt written notice to University prior to University
incurring such costs or expenses, and all rights in and to such Patent Rights shall revert to University upon receipt of such notice.
If Licensee does not provide University with notice at least <FONT STYLE="background-color: white">[***] </FONT>prior to the date on
which the cost or expense may be incurred, then Licensee shall remain responsible therefor. If University, acting in reliance on such
notice, ceases to file or prosecute such patent application or maintain or defend such patent of the Patent Rights, then Licensee and/or
Sublicensee shall not sell any product or practice any processes that would have been covered by the claims of that patent application
or patent unless Licensee pays royalties on Net Sales in that country at the royalty rate set for Net Sales of Product defined under
subsection (b)&nbsp;of the definition of Product. For clarity, in addition to and not in lieu of any other rights and remedies, any patent
or patent application within the Patent Rights for which Licensee fails to pay any invoice when due shall revert to University, shall
be unilaterally removed from the Patent Rights along with all Patent Rights arising from such patent application or patent after the
date of exclusion without further obligation to Licensee, and may be freely licensed by University to others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Patent
Term Extension</B>. On a country-by-country basis, the parties shall cooperate in selecting the patent within the Patent Rights for which
to seek term extension, and as applicable, the Product for which to reference in a supplementary protection certificate, in accordance
with the applicable laws of each country where there are Patent Rights. Each party agrees to execute any documents and to take any additional
actions as the other party may reasonably request in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Marking</B>.
Licensee shall ensure all Product are marked with the: (a)&nbsp;Patent Rights in a manner provided for under applicable patent laws;
and (b)&nbsp;Field and Territory restrictions, including in a manner sufficient to prevent any implied license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Enforcement</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
Licensee becomes aware of the infringement of any patent under the Patent Rights, it shall immediately notify University, and provide
any available evidence of such infringement lawfully in its possession or that of its Sublicensees. Licensee shall have the first right
to abate the alleged infringement in the Field, provided that Licensee has standing to bring an action asserting the Patent Rights without
joining University, and evidences to University that it has sufficient resources to incur all associated costs and expenses. Licensee
may enforce the Patent Rights against the infringer in the Field by appropriate legal proceedings, provided that Licensee employs counsel
reasonably satisfactory to University, informs University of all developments in such proceedings, and provides University with all correspondence
between it and the infringer including pleadings related to any such action. Nothing in this Agreement is a waiver of sovereign immunity.
Should University elect to join in any abatement activity or enforcement proceeding it shall do so in its sole discretion, with the right
to be represented by counsel of its selection. Licensee shall not have any right to surrender or compromise the Patent Rights, to admit
the fault of University, its counsel or any inventor on the Patent Rights, to create an obligation on University, or to grant any infringer
any rights under the Patent Rights other than a Sublicense subject to the conditions which would apply to the grant of any other Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Licensee
shall be responsible for all costs and expenses of any abatement and/or enforcement activities, including legal proceedings, which Licensee
initiates, including paying all costs and expenses that University incurs in connection with any abatement activity and/or enforcement
proceedings. Recoveries collected by Licensee shall be paid (i)&nbsp;first, to Licensee in the amount of all documented and reasonable
out-of-pocket costs and expenses incurred by Licensee in such action, (ii)&nbsp;then to University to reimburse University for any of
its documented and reasonable out-of-pocket costs and expenses incurred that have not been previously reimbursed by Licensee, and (iii)&nbsp;the
remainder, if any, shall be </FONT>paid to University in the amount greater of either (a)&nbsp;the percent of the total direct billed
costs of litigation paid by University if University elects to join in and share the costs associated with abatement activity or enforcement
proceeding, or (b)&nbsp;the percent owed according to the Sublicensee Revenue schedule in Schedule 1; and the amount paid to Licensee
shall be the remainder not paid to University. Under no circumstances shall University&rsquo;s share fall below <FONT STYLE="background-color: white">[***]
</FONT>in recoveries collected by Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Licensee elects not to abate any alleged infringement or to enforce the Patent Rights, then it shall so notify University in writing.
Upon receipt of such notice, or in the event Licensee fails to abate or enforce the Patent Rights regarding such alleged infringer within
<FONT STYLE="background-color: white">[***]</FONT> of notice of the alleged infringement, University may, in its sole discretion, and
at its own expense, take steps to abate the alleged infringement and/or enforce any Patent Rights, to control, settle, and defend such
suit, and to recover for its own account any damages, awards or settlements. Licensee shall reasonably cooperate in any such actions,
including being joined as a party in such action upon University&rsquo;s written request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;</B></FONT><B>5
 &ndash; REPRESENTATIONS AND INDEMNIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>University&rsquo;s
Limited Representation</B>. As a state entity, University is not permitted to make any warranties. However, University represents solely
that it has the right, power and authority to enter into this Agreement.</FONT> The Patent Rights and Technical Information are provided
 &ldquo;AS IS; WHERE IS.&rdquo; EXCEPT AS SPECIFICALLY SET FORTH IN SECTION&nbsp;5.1, UNIVERSITY DISCLAIMS ANY AND ALL REPRESENTATIONS
AND WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS STATUTORY,&nbsp;IMPLIED OR OTHERWISE,&nbsp;INCLUDING RELATING TO PERFORMANCE, MARKETABILITY,
TITLE OR OTHERWISE IN ANY RESPECT RELATED TO THE PATENT RIGHTS, TECHNICAL INFORMATION OR PRODUCT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS, REGARDING THE MAKING, USING OR SELLING OR OTHER DISTRIBUTION OF PRODUCT
BY ANY PERSON OR ENTITY, THE VALIDITY, SCOPE, ENFORCEABILITY OR PATENTABILITY OF ANY OF THE PATENT RIGHTS, THE ACCURACY OF ANY INFORMATION
PROVIDED OR THE ACCURACY, SAFETY, OR USEFULNESS FOR ANY PURPOSE OF ANY OF THE PATENT RIGHTS, TECHNICAL INFORMATION OR PRODUCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Licensee
Representations</B>. Licensee represents and warrants that: (a)&nbsp;the execution and delivery of this Agreement has been duly authorized
and no further approval, corporate or otherwise, is required in order to execute, deliver and perform this valid and binding agreement
in accordance with the terms and conditions herein; (b)&nbsp;it and all Sublicensees shall comply with all court orders and applicable
international, national, or local laws and/or regulations in its performance under this Agreement, including export control laws and
HIPPA; (c)&nbsp;it shall diligently pursue the development, manufacture, and sale of Product in the Field and the Territory throughout
the Term and comply with the terms and conditions herein; (d)&nbsp;it now maintains and shall continue to maintain throughout the Term
and beyond insurance coverage in accordance with Section&nbsp;5.5; and (e)&nbsp;it is and shall be at all times during the Term a valid
legal entity existing under the law of its state of formation with the power to own all of its properties and assets and to carry on
its business as it is currently being conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Limitation
of Liability</B>. In no event shall University or its affiliates including their respective trustees, directors, officers, faculty, staff,
students, employees, independent contractors or agents (collectively, the &ldquo;<B>Representatives</B>&rdquo;), be responsible or liable
for any indirect, special, punitive, incidental, exemplary or consequential damages, loss of use or lost profits regardless of legal
theory or whether advised of the possibility of such damage. Licensee shall not, and shall require that its Sublicensees do not, imply
or make any statements, representations or warranties, or accept any liabilities or responsibilities whatsoever that are inconsistent
with this Article&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Indemnification</B>.
Licensee<I>, </I>on behalf of itself and Sublicensees, assumes the entire risk and responsibility for the safety, efficacy, performance,
design, marketability, title and quality of all Product. None of the University, its affiliates or any of their respective Representatives
(each an &ldquo;<B>Indemnified Person</B>&rdquo;) shall have any liability or responsibility whatsoever to Licensee or any Sublicensee
or any other person or entity for or on account of (and Licensee agrees and shall cause each of its Sublicensees to agree not to assert
any claim against any Indemnified Person in connection with) any injury, loss, or damage of any kind or nature, sustained by, or any
damage assessed or asserted against, or any other liability incurred by or imposed upon, Licensee, any of its Sublicensees, or any other
person or entity, whether direct, indirect, special, punitive, incidental, consequential or otherwise arising under any legal theory,
including attorneys&rsquo; fees, and Licensee shall indemnify and hold each Indemnified Person harmless from and against all claims,
demands, losses, damages or penalties, including attorneys&rsquo; fees, arising out of or in connection with or relating to: (a)&nbsp;Licensee&rsquo;s
breach of this Agreement and/or Sublicensees&rsquo; breach of their respective agreements pertaining to the subject matter of this Agreement;
(b)&nbsp;the exercise of any right granted, including when resulting in the exhaustion of University&rsquo;s rights in patents other
than the Patent Rights as licensed; (c)&nbsp;the advertising, promotion, marking, manufacture, sale, offer for sale, importation, exportation
or use of Product, and related product liability therefrom; (d)&nbsp;any act or omission of negligence or willful misconduct by Licensee,
and/or Sublicensees; and/or (e)&nbsp;the death of or injury to person(s)&nbsp;or property damage relating to the subject matter of this
Agreement; except to the extent of such losses that are attributable to University&rsquo;s breach of this Agreement, negligence or willful
malfeasance. Licensee shall not settle or compromise any claim or allegation subject to indemnification hereunder in a manner that imposes
any material obligation on, or makes any admission of fault by, any Indemnified Person (including compromising the validity or enforceability
of Patent Rights and/or Technical Information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Insurance</B>.
Licensee shall obtain and carry in full force and effect, and shall cause its Sublicensees to obtain and carry in full force and effect,
insurance with the coverages and limits as are reasonably adequate to ensure that Licensee can meet its obligations to University under
this Agreement, including pursuant to this Article&nbsp;5, the nature and extent of which insurance shall be commensurate with usual
and customary industry practices for similarly situated companies, but in any event not less than the amounts set forth on <U>Schedule
1</U>. Such insurance will be written by a reputable insurance company reasonably acceptable to the University authorized to do business
in the State of Illinois, will name the University as an additional insured under all general liability and product liability policies
and shall require <FONT STYLE="background-color: white">[***]</FONT> written notice to be given to University prior to any cancellation,
endorsement or other change. Licensee will provide University, for itself and on behalf of any Sublicensee, with appropriate certificates
of insurance from time to time as requested by University reflecting the obligations of Licensee pursuant to this Section&nbsp;5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;</B></FONT><B>6
 &ndash; TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Term</B>.
Unless terminated earlier under Sections 6.2 or 6.3, this Agreement shall expire at the end of the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>U</B></FONT><B>niversity
Right to Terminate</B>. University shall have the right (without prejudice to any of its other rights or remedies conferred on it by
this Agreement or otherwise) to terminate this Agreement only if Licensee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;fails
to pay any amount, provide any other consideration, or make any report when required to be made pursuant to this Agreement, and Licensee
does not cure such failure within thirty (30) days after notice thereof by University;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;is
in breach of any provision of this Agreement not covered by Section&nbsp;6.2(a), including failing to meet any requirement under Section&nbsp;3.8
of this Agreement, and Licensee fails to remedy any such breach within forty-five (45) days after notice thereof by University;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;is
in breach of any obligations that Licensee has to University under any other agreement between Licensee and University, including the
Equity Rights Agreement and Licensee fails to remedy any such breach or default within forty-five (45) days after written notice thereof
by University;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;makes
any materially false report, and such termination shall be upon written notice to Licensee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;to
the extent not prohibited by applicable law commences a voluntary case as a debtor under the Bankruptcy Code of the United States or
any successor statute (the &ldquo;<B>Bankruptcy Code</B>&rdquo;), or if an involuntary case is commenced against Licensee under the Bankruptcy
Code</FONT> by a third party other than the University or any of its affiliates, or if an order for relief shall be entered in such case,
or if the same or any similar circumstance shall occur under the laws of any foreign jurisdiction; and/or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;takes
any action that purports to cause or causes any of the Patent Rights or Technical Information to be subject to any lien or encumbrance,
and such termination shall be upon written notice to Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Licensee
Right to Terminate</B>. Licensee may terminate this Agreement at any time on written notice to University at least ninety (90) days prior
to the termination date specified in the notice and the notice shall include Licensee&rsquo;s justification for such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Effect
of Expiration or Termination</B>.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;Upon the expiration or termination of this Agreement, all rights
granted herein shall automatically revert to University. Unless this Agreement expires, Licensee shall immediately cease and cause its
Sublicensees to immediately cease practicing the Patent Rights and Technical Information, and Licensee shall return to University or
destroy, as University directs, all of University&rsquo;s Technical Information. Notwithstanding the expiration or termination of this
Agreement, neither party is relieved of its rights and obligations that have previously accrued. Terms and conditions of this Agreement
that by their nature prescribe continuing rights and obligations shall survive the termination or expiration of this Agreement, including:
(i)&nbsp;Licensee&rsquo;s obligation to pay any fees accrued or perform obligations remaining unpaid or unperformed under the terms of
this Agreement prior to such termination (including the delivery and continuing benefits, if any, under the Equity Rights Agreement);
and (ii)&nbsp;Licensee&rsquo;s obligations under Sections 3.4, 3.6, 3.7, 4.2,&nbsp;4.7 and, to the extent proceedings have been initiated,
Section&nbsp;4.6, Article&nbsp;5, this Section&nbsp;6.4 and Article&nbsp;7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE&nbsp;</B></FONT><B>7
 &ndash; MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Assignment
or Change of Control</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall not be assigned or transferred by Licensee without the prior written consent of University except in the event of the
sale of all or substantially all the assets of Licensee. Upon at least <FONT STYLE="background-color: white">[***] </FONT>prior notification
to Licensee, University may assign or transfer this Agreement, the Patent Rights, Technical Information and/or its obligations and/or
benefits hereunder without the consent of Licensee, so long as said assignment or transfer is not commercially deleterious to Licensee.
Any conveyance inconsistent with the terms and conditions of this Agreement shall be null and void. This Agreement shall be binding on
the parties and their respective successors and assigns and inure to the benefit of the parties and their respective permitted successors
and assigns. Notwithstanding anything to the contrary in this Agreement, this Agreement cannot be assumed or assigned by Licensee, any
trustee acting on behalf of the assets of Licensee, or otherwise including in connection with Licensee&rsquo;s insolvency, liquidation,
appointment over any assets related to this Agreement, voluntary or involuntary arrangement with any of its creditors, ceasing to carry
on its business or any similar event under the law of any foreign jurisdictions, unless such assignee provides evidence satisfactory
to University that such assignee has the capability to perform as required by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
(i)&nbsp;permitted assignment or transfer of this Agreement, or (ii)&nbsp;sale of all or substantially all stock or assets of Licensee
in any transaction or series of related transactions that results in the current equity holders of Licensee holding less than fifty percent
(50%) of the outstanding equity interests of Licensee, as measured by voting power; or the transfer of all or fifty (50%) or more of
the assets of Licensee to an entity that is not an Affiliate of the Licensee (each a &ldquo;<B>Change in Control</B>&rdquo;), Licensee
shall pay to University the applicable percentage as set forth in <U>Schedule 1</U> of any remuneration, including fair market value
of non-cash remuneration, received by Licensee and/or its equity holders&nbsp; for such assignment, transfer, or Change in Control, due
no later than <FONT STYLE="background-color: white">[***] </FONT>prior to the first to occur of the effective date or last signature
date of the assignment or transfer, or closing date of Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Participation
Rights</B>. If Licensee proposes to sell any equity securities or securities that are convertible into equity securities of the Licensee,
then the University and/or its Assignee (as defined below) will have the right to purchase up to </FONT><FONT STYLE="background-color: white">[***]
</FONT>of the securities issued in each offering on the same terms and conditions as are offered to the other purchasers in each such
financing. Licensee shall provide <FONT STYLE="background-color: white">[***]</FONT> advanced written notice of each such financing,
including reasonable detail regarding the terms and purchasers in the financing. The term &ldquo;Assignee&rdquo; means (a)&nbsp;any entity
to which the University&rsquo;s participation rights under this section have been assigned either by the University or another entity,
or (b)&nbsp;any entity that is controlled by the University. This paragraph shall survive the termination of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>No
Third Party Beneficiaries</B>. The representations, warranties, covenants and undertakings contained in this Agreement are for the sole
benefit of the parties and their permitted successors and assigns and shall not be construed as conferring any rights on any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Notices</B>.
All notices required or desired to be given under this Agreement, and all payments to be made to University under this Agreement, shall
be delivered to the parties at the addresses set forth on <U>Schedule 1</U>, as may be amended unilaterally upon notice in compliance
with this provision. Notices may be given by hand, electronically via email as long as the receiving party sends a confirmatory reply
to the sender or the sender otherwise receives an email receipt notification from the receiving party&rsquo;s email system, or by a nationally
recognized overnight delivery service. The date of personal delivery or electronic delivery confirmation, or one day after the date of
deposit with the overnight delivery service for next business day delivery, as the case may be, shall be the date the notice is deemed
delivered under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Severability</B>.
The provisions of this Agreement are severable, and if any provision is determined to be invalid or unenforceable in a given jurisdiction,
such invalidity or non-enforceability shall not in any way affect the validity and enforceability of the remaining provisions or the
validity or enforceability of those provisions in any other jurisdiction. Any invalid or unenforceable provision will be reformed promptly
by the parties to effectuate their intent as evidenced on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Governing
Law and Venue</B>. This Agreement is governed and interpreted under the laws of the state of Illinois, excluding any conflict of laws
provisions, and Licensee (a)&nbsp;consents to avail itself of the courts located within the state of Illinois and submits to the jurisdiction
of any local, state or federal court located within the state of Illinois; (b)&nbsp;shall not bring any action or claim against University
in any other jurisdiction; (d)&nbsp;shall require that its Affiliates and Sublicensees agree not to bring any action or claim against
University in any other jurisdiction; and (d)&nbsp;consents to delivery and service of process by means of the notice provisions established
in this Agreement. Nothing in this Agreement shall be construed as a waiver of sovereign immunity by or on behalf of University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Counterparts</B>.
This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute
one instrument. The parties agree that duplicated, electronic, or facsimile signatures shall be deemed original for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Relationship
of Parties</B>. There is no relationship of principal to agent, master to servant, employer to employee, or franchiser to franchisee
or joint venture or partnership between the parties created by this Agreement. Neither party has the authority on behalf of the other
to bind the other or incur any obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Headings</B>.
The headings of the articles, sections, subsections, and paragraphs of this Agreement including in Exhibits and the Schedule have been
added for convenience only and shall not affect the interpretation or construction of this Agreement in any manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Advertising</B>.
Licensee shall not use, and shall cause its Sublicensees to not use, the names or trademarks of University or its Representatives any
adaptation thereof, including any commercial activity, marketing, advertising or sales brochures without the prior written consent of
University in each instance, which consent may be granted or withheld in University&rsquo;s sole and complete discretion. Notwithstanding
the foregoing, Licensee may use the name of University in a factual manner in: (a)&nbsp;executive summaries, business plans, offering
memoranda and other similar documents used by Licensee for the purpose of raising financing for the operations of Licensee or entering
into commercial contracts with third parties, but in such case only to the extent necessary to inform a reader that the Patent Rights
and Technical Information have been licensed by Licensee from University, or to inform a reader of the identity and published credentials
of the University faculty members listed as inventors of the Patent Rights and Technical Information; (b)&nbsp;any securities reports
required to be filed with the Securities and Exchange Commission; and any reports required by any other federal or state regulatory agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>11.&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Conflicts</B>.
Licensee acknowledges and agrees that it will use reasonable efforts to avoid potential conflicts of interest between the University
and University employees who may also be employees, consultants, shareholders or directors of Licensee. Licensee agrees to cooperate
with University with respect to the University of Illinois Policy on Conflicts of Commitment and Interest, available at http://www.research.uiuc.edu/coi/index.asp,
and to work constructively with University to manage and mitigate any conflicts that may arise in the course of this and related agreements
between it and University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Confidentiality</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to Section&nbsp;7.11(</FONT>c), Licensee agrees to maintain, and shall cause its Sublicensees to maintain, <U>Schedule 1</U>, Technical
Information, and all Confidential Information provided by or on behalf of University hereunder in confidence, and only use Confidential
Information as required and permitted by Section&nbsp;2.1(b). Licensee may disclose Confidential Information to potential Sublicensees
or investors, provided that Licensee shall first obtain from the intended recipient(s)&nbsp;a valid and binding confidentiality agreement
which is at least as protective of the Confidential Information as the confidentiality agreement Licensee employs to protect its own
proprietary and confidential information, which shall reflect no less than those restrictions on Licensee herein. Licensee shall take,
and shall cause its Sublicensees to take, such actions as the University may reasonably request from time to time to safeguard the confidentiality
of Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to Section&nbsp;7.11(c), University agrees to maintain Confidential Information if provided by Licensee to the individual identified
in Schedule 1 as entitled to accept notices on behalf of the University, and to use such Confidential Information solely in relation
to this Agreement and for any reporting required hereon or regarding Section&nbsp;2.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(</FONT>c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
receiving party is required by law, regulation, or court order to disclose any of the Confidential Information, then it may do so provided
that it had promptly notified disclosing party, and discloses only such Confidential Information as is legally required. Licensee acknowledges
that University is subject to compliance with requests made under the Freedom of Information Act (&ldquo;FOIA&rdquo;). University shall
notify Licensee of all FOIA requests in connection with the Confidential Information, and Licensee shall have the right to intervene
and/or defend against the disclosure of the Confidential Information arising from such FOIA request at Licensee&rsquo;s sole expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(</FONT>d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Given
the nature of the University&rsquo;s Confidential Information licensed hereunder and the competitive damage that would result to University
upon unauthorized disclosure or use thereof, the parties hereby agree that monetary damages may not be sufficient remedy for any breach
of this Section&nbsp;7.11, and, therefore, in addition to and not in lieu of any other rights or remedies, University may seek specific
performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Section&nbsp;7.11 without
showing actual monetary damages in connection with such remedy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties may have entered into one or more confidentiality agreements with respect to some or all of the Confidential Information (collectively,
the &ldquo;<B>Confidentiality Agreements</B>&rdquo;) and agree that as of the Effective Date, the Confidentiality Agreements are terminated
and this Agreement shall govern the disclosure and use of Confidential Information. Any Confidential Information provided under the Confidentiality
Agreements will be treated as a disclosure made under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<B>Entire
Agreement, Amendment and Waiver</B>. The Schedule and Exhibits are attached hereto and incorporated herein by reference. This Agreement,
including all Exhibits and the Schedule, and any agreements between the parties referenced herein, contain the entire understanding of
the parties with respect to the subject matter of this Agreement and supersede any and all prior written or oral discussions, arrangements,
courses of conduct or agreements. Except as expressly stated herein, this Agreement may be amended only by an instrument in writing duly
executed by the parties. The waiver of a breach hereunder may be effected only by a writing signed by the waiving party and shall not
constitute a waiver of any other breach. The delay or failure to assert a right or to insist upon compliance with any term or condition
of this Agreement shall not constitute a waiver, or excuse a similar or subsequent failure to perform any such term or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this valid and binding agreement to be executed by their respective duly authorized officers or representatives on
the date indicated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">THE BOARD OF TRUSTEES</TD>
    <TD>&nbsp;</TD>
  <TD COLSPAN="2">LICENSEE</TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">OF THE UNIVERSITY OF ILLINOIS</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">/s/ Walter K. Knorr April&nbsp;13, 2015</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">/s/ Daniel M. Schmitt, CEO April&nbsp;14, 2015</TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">Walter K. Knorr, Comptroller &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Date</TD>
    <TD>&nbsp;</TD>
  <TD STYLE="padding-left: -0.25in; text-align: left">&nbsp;</TD>
  <TD STYLE="padding-left: 0.25in; text-align: left">Name/Title/Date</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2"></TD>
    <TD>&nbsp;</TD>
  <TD></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%">Attest:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 44%">/s/ Susan M. Kies 4/13/15</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2">Susan M. Kies, Secretary &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Date</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule 1 to Exclusive License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>ARTICLE&nbsp;1 DEFINITIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Patent Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 12%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">TECH ID#</FONT></TD>
    <TD STYLE="width: 26%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Invention</FONT></TD>
    <TD STYLE="width: 16%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">App #</FONT></TD>
    <TD STYLE="width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">COUNTRY</FONT></TD>
    <TD STYLE="width: 11%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Issue Date</FONT></TD>
    <TD STYLE="width: 11%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Issued #</FONT></TD>
    <TD STYLE="width: 12%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps">Status</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-Benzofuranyl-4-Indolyl Maleimides As Potent GSK3 Inhibitors for Neurodegenerative Disorders</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,207,216</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-Benzofuranyl-4-Indolyl Maleimides As Potent GSK3 Inhibitors for Neurodegenerative Disorders</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP07865893.7</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of allowance</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-Benzofuranyl-4-Indolyl Maleimides As Potent GSK3 Inhibitors for Neurodegenerative Disorders</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA2,673,368</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-Benzofuranyl-4-Indolyl Maleimides As Potent GSK3 Inhibitors for Neurodegenerative Disorders</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA2,669,877</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field
means </B></FONT>Exclusive for all uses with exception of those reserved for the University as outlined in Paragraph 2.2b</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory
means</B></FONT> For Patent Rights: Where patent rights exist; For Technical Information: Worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technical
Information:</B></FONT> The &ldquo;UIC Technical Information&rdquo; shall be as described in appendix 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>ARTICLE&nbsp;3 PAYMENTS AND REPORTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signing Fee:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;$10,000.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Royalty rate on Net Sales in territories where Patent Rights or
Market Exclusivity exist:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty
rate on Net Sales of Product defined by subsection (a)&nbsp;or (c)&nbsp;of the definition</FONT><FONT STYLE="font-size: 10pt">:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="background-color: white">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalty
rate on Net Sales of Product defined by subsection (b)&nbsp;of the definition</FONT><FONT STYLE="font-size: 10pt">:</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="background-color: white">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Royalty rates on Sublicensee Revenue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annual Minimums License
  Year</U></FONT></TD>
  <TD STYLE="width: 50%"><U>Minimum Payment per section 3.4</U></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 1: $0&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 2: $0&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 3: $5,000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 4: $15,000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 5: $35,000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Year 6 until first commercial sale: $50,000&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT> Years
after first commercial sale: $100,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><U>Milestone Event</U> &nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ 10,000.00</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ 50,000.00</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ 250,000.00</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ 1,000,000.00</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Patent Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Ongoing Patent costs: Licensee will pay upon
invoicing of the University</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Past Patent costs:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>
End of Year 1: None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> End of Year 2: 25%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> End of Year 3: 25%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> End of Year 4: 25%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> End of Year 5 : Remaining outstanding</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: Black 1pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Development Event</U></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 1.5pt; border-bottom: Black 1pt solid; text-align: right; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Achievement Due Date</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt 2pt 0.25in; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">[***]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 15%">Checks payable to:</TD>
  <TD STYLE="width: 85%">[***]</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Email notice:</TD>
  <TD>[***]</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Wire to:</TD>
  <TD>[***]</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>ARTICLE&nbsp;5 REPRESENTATIONS; INDEMNIFICATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Minimum Insurance Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">General Liability: (i)&nbsp;<FONT STYLE="background-color: white">[***]
</FONT>per occurrence, with an aggregate minimum of <FONT STYLE="background-color: white">[***] </FONT>for personal injury or death;
and an additional (ii)&nbsp;<FONT STYLE="background-color: white">[***] </FONT>per occurrence, with an aggregate minimum of <FONT STYLE="background-color: white">[***]
</FONT>for property damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Product Liability: Prior to the first
Product testing for or in human, or if such Product does not require such testing, then generation of the first Net Sale or <FONT STYLE="background-color: white">[***]
</FONT>per occurrence and <FONT STYLE="background-color: white">[***] </FONT>in aggregate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>ARTICLE&nbsp;7 MISCELLANEOUS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Assignment or Change of Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><U>Execution or Closing Date During</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Licensee shall pay to University</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]
</FONT>if Closing is at the same time or prior to 6 months after the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]
</FONT>if Closing occurs after 6 months from the Effective Date, and at the same time or prior to 12 months after Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]
</FONT>if Closing occurs after 12 months from the Effective Date, and at the same time or prior to 18 months after the Effective Date;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT> <FONT STYLE="background-color: white">[***]
</FONT>if Closing occurs after 18 months from the Effective Date, and at the same time or prior to 24 months after the Effective Date</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Symbol">&middot;</FONT> 0% after 24 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to University:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Office
of Technology Management&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">University of Illinois at Chicago (MC
682)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">1853 West Polk Street, Suite&nbsp;446&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Chicago,&nbsp;IL 60612-7335</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">FEIN:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Phone: 312-996-7018&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Fax: 312-996-1995</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With copy to: OTM Legal Counsel&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">1737 W. Polk Suite&nbsp;405 (mc/225)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Chicago,&nbsp;IL 60612</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to Licensee: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>CEO&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Apotheca Therapeutics Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">1401 Foch St, Suite&nbsp;140&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Fort Worth, TX. 76107</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">FEIN: 47-3044785&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Phone: 847-986-4190&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Fax: 847-986-4190&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify">Delaware Corporation File Number 5676683</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With copy to: BakerHostetler&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in">2929 Arch Street<BR>
Cira Centre, 12th Floor<BR>
Philadelphia, PA 19104-2891</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top"><TD STYLE="text-align: left; padding-left: 0in; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CZ061 UIC-Apotheca Pharmaceuticals</FONT></TD><TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%"><FONT STYLE="font-size: 10pt">Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT><FONT STYLE="font-size: 10pt; color: #323e4f"> | 25</FONT></TD></TR></TABLE><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A to Exclusive License Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Royalty Period _______, ____ to ________, ____</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Information from Licensee per Product:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Product
name, number and description, and applicable Patent Rights and/or Technical Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Units
of Product sold, transferred, practiced, performed or otherwise provided and in which country</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Units
of Product provided as part of non-case exchange or other than through an arms-length transaction</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Gross
invoice amount for Product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Application
of foreign currency conversion rate, shown for each currency received for Product</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Calculation
of Net Sales, including deductions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Royalty
rates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Total
royalty payment amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Sublicensee
Revenue accrued in Royalty Period</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Calculation
of Annual Minimum owed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">11. &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Milestone
Payments made during Royalty Period with specific reference to Milestones Event listed on <U>Schedule 1</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Information
per Sublicensee shall include the above plus</U></B></FONT><B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Name
and address of each Sublicensee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Total
amounts reported above, with respect to each Sublicensee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EQUITY RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Equity Rights Agreement
(the &ldquo;Agreement&rdquo;) is entered into as of <B>April&nbsp;6, 2015</B> (the &ldquo;Effective Date&rdquo;) by and between <B>[Apotheca
Therapeutics,&nbsp;Inc.]</B>, a Delaware corporation (the &ldquo;Company&rdquo;) and the Board of Trustees of the University of Illinois
(the &ldquo;University&rdquo;). Pursuant to that certain <B>[Exclusive Technology License Agreement with Equity]</B> dated as of the
date hereof (the &ldquo;License Agreement&rdquo;), the Company and the University hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;DELIVERY
OF SHARES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On or prior to the date of execution of this
Agreement, in consideration for the University&rsquo;s entry into the License Agreement, the Company has delivered to the University
50,000 shares or units of equity securities, representing 5 percent (5%) of all issued and outstanding equity securities, and rights
to acquire equity securities, of the Company on a Fully Diluted Basis (as defined in Section&nbsp;5(b)&nbsp;below) as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Co-Sale
Right.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except to the extent required to do so by law
or any existing agreement to which it is subject, the Company shall not cause or permit to be recorded in its stock transfer records
any Transfer (as defined below), or consent to any Transfer, of shares of its stock unless the Company has required that the Transfer
be conducted in accordance with the following procedure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at any time any holder of greater than five percent (5%) of the Company&rsquo;s stock on a Fully Diluted Basis (a &ldquo;Principal Stockholder&rdquo;)
desires to sell all or any part of its stock to any person other than any other stockholder or the Company (the &ldquo;Buyer&rdquo;),
such Principal Stockholder shall give notice in writing to the University of its intention to proceed with the transaction (the &ldquo;Co-Sale
Offer&rdquo;). The University shall have the right, exercisable by providing written notice within <FONT STYLE="background-color: white">[***]
</FONT>of the Co-Sale Offer, to sell to the Buyer, as a condition to the sale by such Principal Stockholder, at the same price per share
and on the same terms and conditions as involved in the sale by such Principal Stockholder, a number of shares of stock equal to the
product of (I)&nbsp;the quotient of (A)&nbsp;the number of shares of stock held by the University, divided by (B)&nbsp;the aggregate
number of shares of stock outstanding, on a fully-diluted basis; multiplied by (II)&nbsp;the aggregate number of shares of stock to be
sold in the contemplated Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Principal Stockholder and the University shall sell to the Buyer all, or at the option of the Buyer, any portion of the stock proposed
to be sold by them at the price and upon other terms and conditions not more favorable to the Buyer than those in the Co-Sale Offer provided
by such Principal Stockholder pursuant to Section&nbsp;1(a)&nbsp;above; provided, however, that any purchase of less than all of such
stock by the Buyer shall be made from any Principal Stockholder and the University pro rata based upon the relative number of shares
of stock that such Principal Stockholder and the University is otherwise entitled to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
purposes of this Section, a &ldquo;Transfer&rdquo; shall mean a sale, exchange, assignment, transfer, mortgage, pledge, encumbrance,
hypothecation, disposition, gift, devise, bequest, or other disposition or grant of rights or interests, whether voluntarily or involuntarily,
by operation of law or otherwise, but does not include a Permitted Transfer. A &ldquo;Permitted Transfer&rdquo; shall be: (A)&nbsp;any
transfer of stock to an inter-vivos trust created by an individual stockholder for the primary benefit of one or more of (i)&nbsp;such
stockholder, (ii)&nbsp;such stockholder&rsquo;s spouse, (iii)&nbsp;such stockholder&rsquo;s parents, siblings, descendants or the descendants
of any of the foregoing, and (iv)&nbsp;such stockholder&rsquo;s spouse&rsquo;s parents, siblings, descendants or the descendants of any
of the foregoing; (B)&nbsp;any testamentary Transfer of stock to or for the benefit of such stockholder&rsquo;s spouse, parent or descendants;
and (C)&nbsp;any transfer by an stockholder that is an entity to an entity controlling, controlled by or under common control with such
stockholder (an &ldquo;Affiliate&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Piggyback
Registration. After the initial public offering of the Company&rsquo;s stock, the University shall be entitled to have its shares registered
at the same time the Company registers shares of stock for its own or another&rsquo;s account under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;). If such registration relates to an underwritten offering of the stock and if, in the good faith judgment
of the managing underwriter of such offering, the inclusion of the University's stock would interfere with the successful marketing of
the stock offered by the Company and/or others, the number of shares of the University&rsquo;s stock included in such registration may
be reduced. Any reduction will be applied to each stockholder exercising registration rights in proportion to the number of shares of
stock such holder proposed to include in such registration; provided, further, that if there are reduction requirements contained in
an agreement or agreements between the Company and any holders of stock in the Company, then the University shall be subject to no more
restrictive provisions than those which are applicable to any holder of more than one percent (1%) of the Company&rsquo;s stock. The
Company shall give the University at least <FONT STYLE="background-color: white">[***] </FONT>prior written notice of its intention to
allow piggyback registration to University. The Company shall pay all expenses related to such registration, including all registration,
filing, qualification, printer&rsquo;s and Company attorney and accounting fees, but excluding underwriter commissions and discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Limitation
on Piggyback Registrations. Notwithstanding the foregoing, the Company shall not be obligated to register any of shares of stock held
by the University in a registration by the Company relating to any merger, acquisition, exchange offer, employee benefit plan of the
Company, dividend reinvestment plan of the Company or a registration on any form which does not include substantially the same information
as would be required to register the shares of stock held by the University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
</B></FONT><B><FONT STYLE="text-transform: uppercase">and Warranties of the Company</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company represents and warrants to the University
that, as of the Effective Date, and except as set forth in any Disclosure Schedule attached hereto and made a part hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Organization,
Qualifications and Corporate Power. The Company is a corporation duly incorporated, validly existing and in good standing under the laws
of the State of Delaware and is duly licensed or qualified to transact business as a foreign corporation and is in good standing in each
jurisdiction in which the nature of the business transacted by it or the character of the properties owned or leased by it requires such
licensing or qualification, except where the failure to be so licensed or qualified does not have a material adverse effect on the Company&rsquo;s
business or financial condition. The Company has provided the University with a true, correct and complete copy of the Company&rsquo;s
Certificate of Incorporation and By-Laws and any amendments thereto. The Company has the corporate power and authority to own and hold
its properties and to carry on its business as now conducted and as proposed to be conducted, to execute, deliver and perform this Agreement,
and to issue, sell and deliver the shares delivered pursuant to the License Agreement (the &ldquo;Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Authorization
of Agreements, Etc. The execution and delivery by the Company of this Agreement, the performance by the Company of its obligations hereunder
and under the License Agreement, and the issuance, sale and delivery of the Shares have been duly authorized by all requisite corporate
action and will not (i)&nbsp;violate any provision of law, any order of any court or other agency of government, or the terms of the
Certificate of Incorporation or the By-laws of the Company, as amended, or (ii)&nbsp;violate any provision of any indenture, agreement
or other instrument to which the Company or any of its properties or assets is bound, or (iii)&nbsp;conflict with, result in a breach
of or constitute (with due notice or lapse of time or both) a default under any such indenture, agreement or other instrument, or (iv)&nbsp;result
in the creation or imposition of any lien, charge, restriction, claim or encumbrance of any nature whatsoever upon any of the properties
or assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Due
Authorization. The Shares, when issued, will be duly authorized, validly issued, fully paid and nonassessable shares and will be free
and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the Company, except for transfer restrictions
imposed by applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Validity.
This Agreement has been duly executed and delivered by the Company and constitute legal, valid and binding obligations of the Company,
enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">e.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Capital
Stock. Immediately prior to the Effective Date the Company has 1,000,000 shares of common stock outstanding. The Company has no other
authorized or outstanding class or series of capital stock, and has not issued, and does not have any commitments to issue, any securities
exchangeable for or convertible into the Company&rsquo;s capital stock. After the issuance of shares to the University, the shareholders
of record, and the number of shares of stock held by each, will be as set forth in the attached Disclosure Schedule. The statutory designations,
powers, preferences, rights, qualifications, limitations and restrictions in respect of each class and series of authorized capital stock
of the Company are as set forth in the Certificate of Incorporation and Bylaws of the Company. All of the outstanding securities of the
Company were issued in compliance with all applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">f.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governmental
Approvals. No registration or filing with, or consent or approval of or other action by, any federal, state or other governmental agency
or instrumentality is or will be necessary for the valid execution, delivery and performance by the Company of this Agreement, or the
issuance, sale and delivery of the Shares, other than filings pursuant to federal and state securities laws (all of which filings have
been made by the Company, other than those which are required to be made after the Effective Date and which will be duly made on a timely
basis) in connection with the sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">g.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Offering
of the Shares. Neither the Company nor any person authorized or employed by the Company as agent, broker, dealer or otherwise in connection
with the offering or sale of the Shares has offered the Shares or any such similar security for sale to, or solicited any offer to buy
the Shares or any such similar security from, or otherwise approached or negotiated with respect thereto with, any person or persons
so as to subject the offering, issuance or sale of the Shares to the registration provisions of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;ANTI-DILUTION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If,
at any time, prior to such time as the Company has achieved the Funding Threshold (as defined below) (the &ldquo;Termination Event&rdquo;),
the Company issues Securities (as defined below) that would cause the University&rsquo;s shareholdings in the Company to drop below five
percent (5%), on a Fully Diluted Basis, the Company shall issue additional shares of common stock to the University such that the University&rsquo;s
shareholdings in the Company shall not fall below five percent (5%), on a Fully Diluted Basis, as calculated after giving effect to the
anti-dilutive issuance (the &ldquo;Anti-Dilution Shares&rdquo;). Any issuances of Anti-Dilution Shares shall be in partial consideration
for the licenses granted under the License Agreements and the University shall not be required to pay any further consideration for such
shares. All Anti-Dilution Shares, when issued pursuant to the terms hereof, shall, upon such issuance, be duly authorized, validly issued,
fully paid and nonassessable. Such issuances shall continue until the Termination Event. Thereafter, this Section&nbsp;4 shall terminate,
no additional Anti-Dilution Shares shall be due to the University pursuant to this Section&nbsp;4, and the University&rsquo;s shareholdings
in the company will be subject to ordinary dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Exempt Securities&rdquo; include: (i)&nbsp;shares
of capital stock, options or convertible securities of the Company issued by the Company by reason of a dividend, stock split, split-up
or other distribution on shares of common stock; (ii)&nbsp;shares of capital stock or options issued to employees or directors of, or
consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board
of Directors of the Company; (iii)&nbsp;shares of capital stock or convertible securities of the Company actually issued by the Company
upon the exercise of options or shares of capital actually issued upon the conversion or exchange of convertible securities, in each
case provided such issuance is pursuant to the terms of such option or convertible security; (iv)&nbsp;shares of capital stock, options,
warrants or convertible securities of the Company issued by the Company to banks, equipment lessors or other financial institutions,
or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board
of Directors of the Company; (v)&nbsp;shares of capital stock, options, warrants or convertible securities of the Company issued by the
Company to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions
approved by the Board of Directors of the Company; and (vi)&nbsp;shares of capital stock, options, warrants or convertible securities
of the Company issued by the Company pursuant to the strategic acquisition of the equity securities or assets of another business entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Fully Diluted Basis&rdquo; means, as of
a specified date (but in the case of convertible debt, only at the time that such convertible debt converts into capital stock, or at
such time specific conversion ratio is established pursuant to the operation of such instrument), the number of shares of Common Stock
then outstanding (assuming conversion of all outstanding stock other than common stock into common stock) plus the number of shares of
Common Stock issuable upon exercise or conversion of then outstanding convertible securities, options, rights or warrants of the Company
(which shall be determined without regard to whether such securities are then vested, exercisable or convertible), excluding any Exempt
Securities issued after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Funding Threshold&rdquo; means a cumulative
total of <FONT STYLE="background-color: white">[***] </FONT>in cash raised by the Company after the Effective Date in one or more financing
rounds in exchange for Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Securities&rdquo; means shares of capital
stock, convertible securities, warrants, options, convertible time or other rights to subscribe for, purchase or acquire from the Company
any capital stock of the Company, excluding any Exempt Securities. Convertible debt shall be deemed a &ldquo;Security&rdquo; only at
the time that such convertible debt converts into capital stock, or at such time specific conversion ratio is established pursuant to
the operation of such instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Financial
Information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company shall furnish to the University information
reports and rights no less favorable than those provided or granted to any other holder of stock of the Company, solely in respect of
such holder&rsquo;s stock. In any event the Company shall provide the University with unaudited quarterly balance sheets and statements
of income within <FONT STYLE="background-color: white">[***] </FONT>after the end of each quarter, and unaudited annual balance sheets
and statements of income within <FONT STYLE="background-color: white">[***] </FONT>after the end of each fiscal year, all certified as
accurate by an officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="text-transform: uppercase">Certain
Covenants</FONT></B></FONT><FONT STYLE="text-transform: uppercase">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notice
of Certain Events. The Company agrees to provide the University with at least <FONT STYLE="background-color: white">[***] </FONT>prior
written notice of the reasonably anticipated closing date for (i)&nbsp;any and all merger, consolidation or restructuring transactions
involving the Company or any of its Affiliates, (ii)&nbsp;any sale of all or substantially all of the assets of the Company and its Affiliates,
taken as a whole, (iii)&nbsp;any license of all or substantially all of the assets of the Company and its Affiliates, taken as a whole,
or (iv)&nbsp;any issuance of stock of the Company or its Affiliates, or any rights to acquire stock of the Company or any of its Affiliates,
or any related series of issuances, pursuant to which persons or entities will acquire or have the right to acquire forty percent (40%)
or more of the stock or interests, or voting rights, of the Company or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Certain
Interested Transactions. Except with respect to agreements in existence as of the date hereof, the Company will not enter into any transaction
with any person employed by or serving as an officer or director of the Company or any Affiliate, or any founding stockholder, unless
such transaction has been approved by a majority of disinterested directors who are not themselves employees or officers of the Company
or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Equity Rights Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 50%"><B>Apotheca Pharmaceuticals</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/s/ Daniel M. Schmitt</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Name:</TD>
  <TD STYLE="text-align: justify">Daniel M. Schmitt</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="text-align: justify">CEO</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -0.01pt; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0in; text-indent: -0.01pt; width: 50%"><B>THE BOARD OF TRUSTEES OF THE UNIVERSITY OF
  ILLINOIS</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/<FONT STYLE="font-size: 10pt">s/ Walter K. Knorr April&nbsp;13,
  2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify"></TD>
  <TD STYLE="text-align: justify">Walter K. Knorr, Comptroller</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">Attest:</TD>
  <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
  Susan M. Kies 4/13/15 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Susan Kies, Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT
WITH EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This AMENDMENT TO EXCLUSIVE
LICENSE AGREEMENT WITH EQUITY (this &ldquo;<U>Amendment</U>&rdquo;) is entered into as of the date (&ldquo;Execution Date&rdquo;) of
the last to be executed signature, by and between The Board of Trustees of the University of Illinois, a body corporate and politic of
the State of Illinois (&ldquo;<U>University</U>&rdquo;), and Actuate Therapeutics,&nbsp;Inc., a Delaware corporation (&ldquo;<U>Licensee</U>&rdquo;
or the &ldquo;<U>Company</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
on April&nbsp;6, 2015, the parties entered into an Exclusive License Agreement with Equity (the &ldquo;<U>Original Agreement</U>&rdquo;)
pursuant to which, among other things, University licensed to the Company certain rights to the patent rights and technical information
described in the Original Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS</B></FONT>,
the parties desire to amend the Original Agreement as set forth herein to enable Company to secure funding and utilize sublicensing revenue
for development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, in consideration of the foregoing, the mutual covenants and agreements herein contained, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties, the parties do hereby agree and
bind themselves as follows. Capitalized terms used, but not defined herein, shall have the meanings ascribed to them in the Original
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Article&nbsp;3.8(b)&nbsp;of
the Original Agreement is hereby deleted and restated in its entirety as follows:</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;(b)&nbsp;The Patent Rights and
Technical Information licensed from University under this Agreement were developed supported by funds from the United States Government
and thus any rights granted herein to Licensee (and subsequently by Licensee to its Sublicensees) are subject to, and shall in no way
restrict, the rights of the United States Government pursuant to 35 USC &sect;203.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>Section&nbsp;7.1(b)&nbsp;of
the Original Agreement is hereby deleted and restated in its entirety as follows:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;(b)</FONT>&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">Upon
(i)&nbsp;permitted assignment or transfer of this Agreement, or (ii)&nbsp;sale of all or substantially all stock or assets of Licensee
in any transaction or series of related transactions that results in the current equity holders of Licensee holding less than fifty percent
(50%) of the outstanding equity interests of Licensee, as measured by voting power; or the transfer of all or fifty percent (50%) or
more of the assets of Licensee to an entity that is not an Affiliate of the Licensee (each a &ldquo;<B>Change of Control</B>&rdquo;),
Licensee shall pay to University the applicable percentage as set forth in <U>Schedule 1</U> of any remuneration, including fair market
value of non-cash remuneration, received by Licensee and/or its equity holders for such assignment, transfer, or Change in Control, due
no later than </FONT><FONT STYLE="background-color: white">[***] </FONT><FONT STYLE="font-size: 10pt">after the first to occur of the
effective date or last signature date of the assignment or transfer, or closing date of Change in Control. Notwithstanding the foregoing,
in the event the Licensee effectuates a Change in Control, Sublicenses the Product, or secures cumulative financing equal to or exceeding
$100MM, then Licensee shall immediately pay the University all accrued but unpaid obligations of Licensee to University, including, but
not limited to any indebtedness of Licensee to University, inclusive of historic patent costs and deferred payable obligations, if any,
to the extent such amounts are not otherwise paid pursuant to the first sentence of this <U>Section&nbsp;7.1(b)</U>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Section&nbsp;7.2
of the Original Agreement is hereby amended to include the following language after the last sentence of Section&nbsp;7.2:</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;Notwithstanding the foregoing,
the participation right granted to University pursuant to this Section&nbsp;7.2 shall terminate and be of no further force and effect
in the event University&rsquo;s right to participate in any Licensee financing is triggered pursuant to this Section&nbsp;7.2 and University
does not elect to participate in such financing.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>A
new Article&nbsp;7.14 is hereby added to the Original Agreement as follows:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;7.14.</FONT><FONT STYLE="background-color: white">&#9;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt"><B>Force
Majeure</B>. If Licensee is prevented from performing any obligation hereunder by reason of fire, explosion, strike, labor dispute, casualty,
accident, lack or failure of transportation, manufacturing facilities, flood, war, civil commotion, acts of god, governmental law, order
or decree or any other cause beyond the reasonable control of Licensee, then Licensee shall be excused from performance hereunder to
the extent and for the duration of such prevention, provided it promptly notifies University in writing of such prevention.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B>Article&nbsp;3
of Schedule 1 to the Original Agreement is hereby amended to modify &ldquo;Royalty rates on Sublicensee Revenue&rdquo; as follows:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">Except
as expressly stated herein, the parties hereby acknowledge and agree that the terms and conditions of the Original Agreement shall remain
in full force and effect unchanged, and the same are hereby ratified, confirmed and reaffirmed by the parties in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">This
Amendment shall take effect (&rdquo;Amendment Effective Date&rdquo;) upon Licensee&rsquo;s payment of a nonrefundable </FONT><FONT STYLE="background-color: white">[***]
</FONT><FONT STYLE="font-size: 10pt">amendment fee. In the event, Licensee fails to complete the first tranche of fund-raising with commitments
totaling no less than $7,500,000 within 30 days of University&rsquo;s receipt of that payment, all changes under this Amendment shall
be nullified and the license will revert to previous business terms. The completion of the funding event shall be communicated to the
University in writing, and Licensee shall provide documentation evidencing such fund-raising.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">At
any time and from time to time, each party agrees, at Licensee&rsquo;s expense, to take such actions and to execute and deliver such
documents as may be reasonably necessary to effectuate the purposes of this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">This
Amendment, the Original Agreement, as amended hereby, and the exhibits and schedules thereto set forth the entire understanding of the
parties with respect to the subject matter hereof, and supersede all existing agreements among them concerning such subject matter. The
Parties acknowledge that no other documents shall have any effect on the construction or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;<FONT STYLE="font-size: 10pt">The
provisions of this Amendment shall be binding upon and inure to the benefit of the parties and their respective successors and assigns.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument binding on the parties. This Amendment shall be governed by and construed in accordance with the
laws of the State of Illinois, without giving effect to applicable conflict of laws principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>remainder of page&nbsp;intentionally left
blank</I>]&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signatures on next page</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>signature page&nbsp;to Amendment to Exclusive
License Agreement with Equity</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Amendment be executed as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ACTUATE THERAPEUTICS,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Daniel M. Schmitt &#8239;&#8239;4/24/19</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Daniel Schmitt&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Date</FONT></TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Chief Executive Officer</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE BOARD OF TRUSTEES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">OF THE UNIVERSITY OF ILLINOIS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Avijit Ghosh &#8239;&#8239;4/23/2019</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Avijit Ghosh, Comptroller &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Date</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 50%">/s/ Suseelan Pookote &#8239;&#8239;4/23/2019</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Signature of Comptroller Delegate &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Date</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">Suseelan Pookote,
Director, UIC-OTM</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">Printed Name and
Title of Comptroller Delegate</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 5%">Attest:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 45%">/s/ Dedra M. Williams 4/24/2019</TD>
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD COLSPAN="2" STYLE="text-align: justify">Dedra M. Williams, Secretary &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;Date</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm247121d1_drs-sp1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d1_drs-sp1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,X!;4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQXD'A?QMIJZ;JCOLBE"&-6;LK*2<9[,#@U25W9$MVU/8:***0PHHHH ****
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MKZ;CM_U?R],=*Z2FU9V)3N%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-.*TW_K\"M'+7;^OQ/4=-UFS\0^&8]6T^3?:W4!=">HXY!]P<@_2O,_V<_\
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MQ'\3O'V@VUSX:.GZ5:I$B/J%^H\RZE  D95"LH7=G^'\>PJ:7\6?%>A:Q?\
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MU]HOG,VZ7RU3.UB!PH Z#TKS?P1\1_B+XNT^72M)CMKO5$F9Y]3O(U2&WB(
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDVTY5L%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCV%7^5_<'UFC_.OO1U=%<I_PLKPC_P!!;_R6E_\ B:/^%E>$?^@M_P"2TO\
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M]!;_ ,EI?_B:/85?Y7]P?6:/\Z^]'5T5RG_"RO"/_06_\EI?_B:/^%E>$?\
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M'L*O\K^X/K-'^=?>CJZ*Y3_A97A'_H+?^2TO_P 31_PLKPC_ -!;_P EI?\
MXFCV%7^5_<'UFC_.OO1U=%<I_P +*\(_]!;_ ,EI?_B:/^%E>$?^@M_Y+2__
M !-'L*O\K^X/K-'^=?>CJZ*Y3_A97A'_ *"W_DM+_P#$T?\ "RO"/_06_P#)
M:7_XFCV%7^5_<'UFC_.OO1U=%<I_PLKPC_T%O_):7_XFC_A97A'_ *"W_DM+
M_P#$T>PJ_P K^X/K-'^=?>CJZ*Y3_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R
M6E_^)H]A5_E?W!]9H_SK[T=717*?\+*\(_\ 06_\EI?_ (FC_A97A'_H+?\
MDM+_ /$T>PJ_RO[@^LT?YU]Z.KHKE/\ A97A'_H+?^2TO_Q-'_"RO"/_ $%O
M_):7_P")H]A5_E?W!]9H_P Z^]'5T5RG_"RO"/\ T%O_ "6E_P#B:/\ A97A
M'_H+?^2TO_Q-'L*O\K^X/K-'^=?>CJZ*Y3_A97A'_H+?^2TO_P 31_PLKPC_
M -!;_P EI?\ XFCV%7^5_<'UFC_.OO1U=%<I_P +*\(_]!;_ ,EI?_B:/^%E
M>$?^@M_Y+2__ !-'L*O\K^X/K-'^=?>CJZ*Y3_A97A'_ *"W_DM+_P#$T?\
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M+?\ DM+_ /$T?\+*\(_]!;_R6E_^)H]A5_E?W!]9H_SK[T=717*?\+*\(_\
M06_\EI?_ (FC_A97A'_H+?\ DM+_ /$T>PJ_RO[@^LT?YU]Z.KHKE/\ A97A
M'_H+?^2TO_Q-'_"RO"/_ $%O_):7_P")H]A5_E?W!]9H_P Z^]'5T5RG_"RO
M"/\ T%O_ "6E_P#B:/\ A97A'_H+?^2TO_Q-'L*O\K^X/K-'^=?>CJZ*Y3_A
M97A'_H+?^2TO_P 34<GQ1\'1/$C:N<RMM7_1I>N"?[OL:3HU%]E_<"Q%%[27
MWG7T5RG_  LKPC_T%O\ R6E_^)H_X65X1_Z"W_DM+_\ $T_85?Y7]P?6:/\
M.OO1U=%<I_PLKPC_ -!;_P EI?\ XFC_ (65X1_Z"W_DM+_\31["K_*_N#ZS
M1_G7WHZNBN4_X65X1_Z"W_DM+_\ $T?\+*\(_P#06_\ ):7_ .)H]A5_E?W!
M]9H_SK[T=717*?\ "RO"/_06_P#):7_XFC_A97A'_H+?^2TO_P 31["K_*_N
M#ZS1_G7WHZNBN4_X65X1_P"@M_Y+2_\ Q-'_  LKPC_T%O\ R6E_^)H]A5_E
M?W!]9H_SK[T=717*?\+*\(_]!;_R6E_^)H_X65X1_P"@M_Y+2_\ Q-'L*O\
M*_N#ZS1_G7WHZNBN4_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:/85?Y
M7]P?6:/\Z^]'5T5RG_"RO"/_ $%O_):7_P")H_X65X1_Z"W_ )+2_P#Q-'L*
MO\K^X/K-'^=?>CJZ*Y3_ (65X1_Z"W_DM+_\31_PLKPC_P!!;_R6E_\ B:/8
M5?Y7]P?6:/\ .OO1U=%<I_PLKPC_ -!;_P EI?\ XFC_ (65X1_Z"W_DM+_\
M31["K_*_N#ZS1_G7WHZNBN4_X65X1_Z"W_DM+_\ $T?\+*\(_P#06_\ ):7_
M .)H]A5_E?W!]9H_SK[T=717*?\ "RO"/_06_P#):7_XFC_A97A'_H+?^2TO
M_P 31["K_*_N#ZS1_G7WHZNBN4_X65X1_P"@M_Y+2_\ Q-'_  LKPC_T%O\
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M?6JW\S#ZEA_Y%_7S/(HOAIH[^.[O1S>:A]EBTR"Z7]XF[>\LJGG9TPBUN?\
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M8_\ XBO0:*/K5;^9A]2P_P#(OZ^9Y]_PI[P__P _FI_]_8__ (BC_A3WA_\
MY_-3_P"_L?\ \17H-%'UJM_,P^I8?^1?U\SS[_A3WA__ )_-3_[^Q_\ Q%'_
M  I[P_\ \_FI_P#?V/\ ^(KT&BCZU6_F8?4L/_(OZ^9Y]_PI[P__ ,_FI_\
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M'_\ $5Z#11]:K?S,/J6'_D7]?,\^_P"%/>'_ /G\U/\ [^Q__$4?\*>\/_\
M/YJ?_?V/_P"(KT&BCZU6_F8?4L/_ "+^OF>??\*>\/\ _/YJ?_?V/_XBC_A3
MWA__ )_-3_[^Q_\ Q%>@T4?6JW\S#ZEA_P"1?U\SS[_A3WA__G\U/_O['_\
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MM5OYF'U+#_R+^OF>??\ "GO#_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\
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M'_\ $5Z#11]:K?S,/J6'_D7]?,\^_P"%/>'_ /G\U/\ [^Q__$4?\*>\/_\
M/YJ?_?V/_P"(KT&BCZU6_F8?4L/_ "+^OF>??\*>\/\ _/YJ?_?V/_XBC_A3
MWA__ )_-3_[^Q_\ Q%>@T4?6JW\S#ZEA_P"1?U\SS[_A3WA__G\U/_O['_\
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MA>#E!USQFO6ZY;Q7_P C#X._["K_ /I+/1]:K?S,/J6'_D7]?,Q_^%/>'_\
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M_P#/YJ?_ ']C_P#B*]!HH^M5OYF'U+#_ ,B_KYGGW_"GO#__ #^:G_W]C_\
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M'_\ $5Z#11]:K?S,/J6'_D7]?,\^_P"%/>'_ /G\U/\ [^Q__$4?\*>\/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*2TDGZ_BK#>S7];A1110 4444 %%%% !7*_#K_D3D_Z_K[_TKFKJJY7X=?\
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MO9 ]S$K-+M.0K,Q8J/IG%=31152?,[LE*RL%%%%(85RWBO\ Y&'P=_V%7_\
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M6M10!D^;XA_Y]-+_ / J3_XW1YOB'_GTTO\ \"I/_C=:U% &3YOB'_GTTO\
M\"I/_C='F^(?^?32_P#P*D_^-UK44 9/F^(?^?32_P#P*D_^-T>;XA_Y]-+_
M / J3_XW6M10!D^;XA_Y]-+_ / J3_XW1YOB'_GTTO\ \"I/_C=:U% &3YOB
M'_GTTO\ \"I/_C='F^(?^?32_P#P*D_^-UK44 9/F^(?^?32_P#P*D_^-T>;
MXA_Y]-+_ / J3_XW6M10!Q7F:Y_PL+/V73O-_LKI]H?;M\WUV=?PK?\ -\0_
M\^FE_P#@5)_\;JG_ ,U(_P"X1_[6KHJ ,GS?$/\ SZ:7_P"!4G_QNCS?$/\
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MD^;XA_Y]-+_\"I/_ (W1YOB'_GTTO_P*D_\ C=:U% &3YOB'_GTTO_P*D_\
MC='F^(?^?32__ J3_P"-UK44 9/F^(?^?32__ J3_P"-T>;XA_Y]-+_\"I/_
M (W6M10!D^;XA_Y]-+_\"I/_ (W1YOB'_GTTO_P*D_\ C=:U% &3YOB'_GTT
MO_P*D_\ C='F^(?^?32__ J3_P"-UK44 9/F^(?^?32__ J3_P"-T>;XA_Y]
M-+_\"I/_ (W6M10!D^;XA_Y]-+_\"I/_ (W1YOB'_GTTO_P*D_\ C=:U% &3
MYOB'_GTTO_P*D_\ C='F^(?^?32__ J3_P"-UK44 9/F^(?^?32__ J3_P"-
MT>;XA_Y]-+_\"I/_ (W6M10!D^;XA_Y]-+_\"I/_ (W1YOB'_GTTO_P*D_\
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MXH_XG_\ U#?_ ")6I10!E_\ $_\ ^H;_ .1*/^)__P!0W_R)6I10!E_\3_\
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MM2B@#+_XG_\ U#?_ ")1_P 3_P#ZAO\ Y$K4HH R_P#B?_\ 4-_\B4?\3_\
MZAO_ )$K4HH R_\ B?\ _4-_\B4?\3__ *AO_D2M2B@#+_XG_P#U#?\ R)1_
MQ/\ _J&_^1*U** ,O_B?_P#4-_\ (E'_ !/_ /J&_P#D2M2B@#+_ .)__P!0
MW_R)1_Q/_P#J&_\ D2M2B@#+_P")_P#]0W_R)1_Q/_\ J&_^1*U** ,O_B?_
M /4-_P#(E'_$_P#^H;_Y$K4HH R_^)__ -0W_P B4?\ $_\ ^H;_ .1*U**
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MEM3FH\O8[:$KQL=51117I&X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7*^,?^0GX0_P"PXO\ Z37%=57*^,?^0GX0_P"PXO\ Z37% '54444
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M44 %%%% !1110 4444 %%%% !1110 5ROC'_ )"?A#_L.+_Z37%=57*^,?\
MD)^$/^PXO_I-<4 =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7*^,?\ D)^$/^PXO_I-<5U5<KXQ_P"0GX0_[#B_^DUQ0!U5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <[_S4C_N$?^UJZ*N=_P":D?\ <(_]K5T5 ",P12S$!0,D
MGL*X'PM\8/#7B[Q(=#L([Z.Y(<QR7"(J2;>H4AR<XR1QT%3_ !<\2?\ "-?#
MO49XVVW-TOV2#G!W/D$CZ+N/X5XSJPT/PEX7\#ZWHNKZ9<ZSI<@-Y#;W<;R,
M'^=@0#G .5_X%1'66NVB^_\ RT')>[IOJ_N_S/IZL?Q1XCL_"7AZZUJ_CGDM
MK;;O6!07.Y@HP"0.I]:YGXD^-Y?#_P -SKFC2(9KSRTM9<;@N\9W>G"@XSWK
MS3QIX5\;Z/\ #*]U+5/&$FJ6]VL3WMC.A81;G4@QN6/1L# "C&:4KI/RT^8X
MI-KS/?-'U2#6]&LM4MED2"\A2>-9  P5AD9P2,\^M7:\)\4ZMJ6E?#/X;G3M
M0N[,S-;1RFWF:/>OECAMI&1[&NC^-.K:EI5OX:.G:A=V9FU-8Y3;S-'O7'1M
MI&1[&M))*;2_FM_7WF7-I=]K_G_D=?J7C;3=+\::9X6G@NVOM1C,D4B(IB4#
M=]XE@1]T] :NKXFTF3Q.WAV*Z635$A,\D*<^6@Q]X]B=PP.M>;>+_P#DXGP;
M_P!>C?\ M6N0TSPGJUQ^T!JMA'XIO8;BW NY+M0^^:/,;>2?GSMPP7J1A1Q4
MP]ZU^O-^#-)JR;71+\3Z/HHHI""BBB@ HHHH Y6W_P"2L:C_ -@.U_\ 1]Q7
M55RMO_R5C4?^P':_^C[BNJH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *Y7Q[_R#-(_[#FG?^E*5U5<KX^*K
MI.F.S!536+%SGOMG0X'N<8'N12;LKL#JJ*Q/^$JT[TF_[X'^-'_"5:=Z3?\
M? _QKG^MT/YT9^TAW-NBL3_A*M.])O\ O@?XT?\ "5:=Z3?]\#_&CZW0_G0>
MTAW-NBL3_A*M.])O^^!_C1_PE6G>DW_? _QH^MT/YT'M(=S;HK$_X2K3O2;_
M +X'^-'_  E6G>DW_? _QH^MT/YT'M(=S;HK$_X2K3O2;_O@?XT?\)5IWI-_
MWP/\:/K=#^=![2'<VZ*Q/^$JT[TF_P"^!_C1_P )5IWI-_WP/\:/K=#^=![2
M'<VZ*Q/^$JT[TF_[X'^-'_"5:=Z3?]\#_&CZW0_G0>TAW-NBL3_A*M.])O\
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MQE^96*L,, >"#5ZO$(-2US4/#/A.*+7]1MKB\\17%O+<I,6<QAI/E.[(( '
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MK^WH?PK2\8_\A+PA_P!AQ?\ TFN*^JP>(]M3N]UN>A2GS1.JHHHKL-0HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<[_S4C_N$?\ M:NBKG?^:D?]PC_VM714 %%%% !1110 4444 %%%% !1110
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M2KE'62\]?O)3T3*L/@CPW;:39:7!I<<5E97*7<$:.XVRKT<D'+'_ 'B<]ZZ
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MCJJ***]@Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5\8_\
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M9(IG5.I4'!YY&>F:K>$?AI%K-MK[:R=<TWS]:N"\,5Q);I>09!4.AX9#D\@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<KX]_P"09I'_ &'-
M._\ 2E*ZJN5\>_\ (,TC_L.:=_Z4I0!U5%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7+?#__ )%ZZ_["NH?^E4M=37+?#_\ Y%ZZ
M_P"PKJ'_ *52T =31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7->+XU:7P[(1\\6LPLAST)5U/Z,1^-=+7.^+?^8%_P!A>W_]FH Z*BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8\81LUYX7F&-L.
MM1LP[D-%*@Q^+C\,UT]<[XM_Y@7_ &%[?_V:@#HJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***\&UGXO^/4\8ZSHN@^';/48["X>,>593S2! V 6V/\
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M?\AQM))KK_E<]IJO>W]GIMH]W?W<%K;1XWS3R!$7)P,L>!S7EO\ PDFH7B^
M[#P7?/IVG:G!<I_Q,(%G<)$H +#=DD8.,-@\9XXK*\2:MK-_\)O&&GZY=1:A
M>:5J4=H+E(A%YZB2,@E1P#SVIM?U\TOU'%7MY_\ !_R9ZYIOB/0]9E>+2]9T
MZ^D0;F2UNDE*CU(4G%7;6[MKZW6XM+B*XA;(62)PZG!P<$<=017E6B>&-7O_
M !?HNI_\()IGA*WTYFDEEMKF*1[H,A79B)1QSD[JW_A_(;;Q#XST9,_9K35/
M.A'9?-0.RC_@63^-%OU_!K_,B_7T_&_^1WE%%%(H*Y7Q[_R#-(_[#FG?^E*5
MU5<QXYB>73=,V+GR]7LIG]D2978_@JD_A2;25V#=CIZ*SO[>TS_G[3\C_A1_
M;VF?\_:?D?\ "L_;TOYE]Z)YX]S1HK._M[3/^?M/R/\ A1_;VF?\_:?D?\*/
M;TOYE]Z#GCW-&BL[^WM,_P"?M/R/^%']O:9_S]I^1_PH]O2_F7WH.>/<T:*S
MO[>TS_G[3\C_ (4?V]IG_/VGY'_"CV]+^9?>@YX]S1HK._M[3/\ G[3\C_A1
M_;VF?\_:?D?\*/;TOYE]Z#GCW-&BL[^WM,_Y^T_(_P"%']O:9_S]I^1_PH]O
M2_F7WH.>/<T:*SO[>TS_ )^T_(_X4?V]IG_/VGY'_"CV]+^9?>@YX]S1HK._
MM[3/^?M/R/\ A1_;VF?\_:?D?\*/;TOYE]Z#GCW-&BL[^WM,_P"?M/R/^%']
MO:9_S]I^1_PH]O2_F7WH.>/<T:*SO[>TS_G[3\C_ (4?V]IG_/VGY'_"CV]+
M^9?>@YX]S1KEOA__ ,B]=?\ 85U#_P!*I:V/[>TS_G[3\C_A7/\ @Z^MM-T6
MX@O)EBE;4+R8*><H]Q(ZGCU5@?QI>WI?S+[T'/'N=C16=_;VF?\ /VGY'_"C
M^WM,_P"?M/R/^%/V]+^9?>@YX]S1HK._M[3/^?M/R/\ A1_;VF?\_:?D?\*/
M;TOYE]Z#GCW-&BL[^WM,_P"?M/R/^%']O:9_S]I^1_PH]O2_F7WH.>/<T:*S
MO[>TS_G[3\C_ (4?V]IG_/VGY'_"CV]+^9?>@YX]S1HK._M[3/\ G[3\C_A1
M_;VF?\_:?D?\*/;TOYE]Z#GCW-&BL[^WM,_Y^T_(_P"%2VVJ65W+Y4%PKOC.
M "*%6IMV4E]X<T>Y<HHHK4H**** "BBB@ KG?%O_ # O^PO;_P#LU=%7.^+?
M^8%_V%[?_P!FH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N=\6_P#,"_["]O\ ^S5T5<[XM_Y@7_87M_\ V:@#HJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ=WEG EQ(ME:>:#&>K9!X [EL#ZT[3?B?H&JZUI^G6L6H[-10FUO9+1DMY6
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MQQR7DMO9EX[$. 0)FS\IP>@S5C6OB-I.C:O'I9L=5OKJ6R%["EA:&8R(3C
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M'<4=.7^MK?HBKZM_UO<\9\,>!_$\'C'P_K>H:&8)+>*>&\N+C5C>2R,4($C
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M]#V_6O/:Z?Q7?Y*6*'I\\G]!_7\JYBOF\RJ1G6LNAPUY)RT"BBBO-, HHHH
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M4 %%%% !1110 4444 %%%% !7.^+?^8%_P!A>W_]FKHJYWQ;_P P+_L+V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_X173O6;_OL?X4?V97\OO#V$SBJ*[7_ (173O6;_OL?X4?\(KIWK-_WV/\
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M+UU_V%=0_P#2J6@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_A(])_Y^_\ R&_^% &I163_ ,))IOK=_P#@%-_\11_PDFF^MW_X!3?_ !%
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M .)H_P"$@M_^?+5/_ "7_P")H UJY;X?_P#(O77_ &%=0_\ 2J6M/_A(+?\
MY\M4_P# "7_XFN9\":RD>B7D(L=0D=-5O]VVV; S<R'&3CGGD=10!WE%9?\
M;?\ U#-2_P# ?_Z]']M_]0S4O_ ?_P"O0!J45E_VW_U#-2_\!_\ Z]']M_\
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M_1='VO7?^@1:?^!Q_P#C= &M163]KUW_ *!%I_X''_XW1]KUW_H$6G_@<?\
MXW0!K45D_:]=_P"@1:?^!Q_^-T?:]=_Z!%I_X''_ .-T :U<[XM_Y@7_ &%[
M?_V:K$UYXDVC[/HVFLV>?.U-T&/J(6Y_"N;\3W7BEO[&\[1M&3&J0%-FK2MN
M;YL YMQ@>_/T- '?45S_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-_P#(
MM '045S_ -L\8?\ 0"T/_P ',W_R+1]L\8?] +0__!S-_P#(M '045S_ -L\
M8?\ 0"T/_P ',W_R+5E)?$912]EI2L1RHO)& /IGRAGZX% &O163YOB'_GTT
MO_P*D_\ C='F^(?^?32__ J3_P"-T :U%9/F^(?^?32__ J3_P"-T>;XA_Y]
M-+_\"I/_ (W0!K45D^;XA_Y]-+_\"I/_ (W0'\0,<&#3(QZ^=(_Z;10!K45E
M_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!J45E_\ $_\ ^H;_ .1*/^)__P!0W_R)
M0!J45E_\3_\ ZAO_ )$H_P")_P#]0W_R)0!J45D^7XA//VK2U]OL\AQ^.\9H
M\KQ#_P _>E_^ LG_ ,<H UJ*R?*\0_\ /WI?_@+)_P#'*/*\0_\ /WI?_@+)
M_P#'* -:BLGRO$/_ #]Z7_X"R?\ QRCRO$/_ #]Z7_X"R?\ QR@#6HK%F@\3
MNH$.I:1"V>6>PDD&/3 F7\\U#]C\8?\ 0=T/_P $TW_R50!T%%<_]C\8?]!W
M0_\ P33?_)5'V/QA_P!!W0__  33?_)5 '045S_V/QA_T'=#_P#!--_\E4?8
M_&'_ $'=#_\ !--_\E4 =!17/_8_&'_0=T/_ ,$TW_R55A+3Q!L'F:Q8E\<E
M-/95S[ RDC\S0!L45D_9-=_Z"]I_X G_ ..4?9-=_P"@O:?^ )_^.4 :U%,A
M61846:19)  &=5VACZ@9./SHH ?1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '$ZUIEOJOQ1TR&XDNT1=%N7!M;N6W;(F@'WHV4D<],XZ>@
MK6_X0W2_^?K7/_![>_\ QZJMQ_R5C3O^P'=?^C[>NJH Y_\ X0W2_P#GZUS_
M ,'M[_\ 'J/^$-TO_GZUS_P>WO\ \>KH** ,!?!VEJP;[3K1P<X;7+U@?J#+
M@CV-6?\ A&]-]+O_ ,#9O_BZUJ* ,G_A&]-]+O\ \#9O_BZ/^$;TWTN__ V;
M_P"+K6HH R?^$;TWTN__  -F_P#BZ/\ A&]-]+O_ ,#9O_BZUJ* ,G_A&]-]
M+O\ \#9O_BZ4>&]+_B@D<^LEQ(Y_,L:U:* ,O_A'-)_Y]/\ R(_^-'_".:3_
M ,^G_D1_\:U** ,O_A'-)_Y]/_(C_P"-'_".:3_SZ?\ D1_\:U** .+_ +!T
MS_A87E?9OD_LK=CS&Z^;CUK?/AO22,&S!'H78@_K5+_FI'_<(_\ :U=%0!D_
M\(QH7_0)M/\ OT*/^$8T+_H$VG_?H5S>I_%&RT[6M1TN+PWXEU"33W"7$UA8
MB:)25#=0_'![@5JP>.M&NUT![1IYXM<=X[61$ "E5)8/D@CH1T/-"UU0/0O_
M /",:%_T";3_ +]"C_A&-"_Z!-I_WZ%:U% &3_PC&A?] FT_[]"C_A&-"_Z!
M-I_WZ%:U% &'-X,\,7)#7'AW2IR. 9K2-R/IN!J/_A!/!_\ T*FA_P#@NA_^
M)K7U#4+32K&:]O[B.WMH5+222-@**I>&?$5GXJ\/VVM6"3):W&[8)E"M\K%>
M0">X]:-P*O\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UNS
M2K!!),P)6-2Q ZX S7GMC\8]&NX8+N?0O$=CILQ&-2NM/Q;#)P"75CQGO0M7
M8#I?^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFM]65U#*05(R".A
M%+0!@+X&\(HX=/"VB*RG((T^($'_ +YJ]_PC^B_] BP_\!D_PK1HH SO^$?T
M7_H$6'_@,G^%'_"/Z+_T"+#_ ,!D_P *P/$?Q#L_#GB"/1/[$US4[U[<7.S3
M+4383<5R1N!ZCTQR*UO#?B+_ (2.REN?['U?2_+DV>5JEKY#MP#D#)R.>M"U
MU0/3<L_\(_HO_0(L/_ 9/\*/^$?T7_H$6'_@,G^%:-% &=_PC^B_] BP_P#
M9/\ "I(]&TN$$1:;9IGKM@49_2KM97AWQ!:>)M)_M&RCFCA\V2+;,H#91BIZ
M$\9% %O^S+#_ )\;;_OTO^%']F6'_/C;?]^E_P *@UO7+'P]IIO]0=D@$B1C
M:I8EF8*HP/4D4[^U/^)]_97V"^_X]_M'VOR?]'^]MV;\_?[XQTHW E_LRP_Y
M\;;_ +]+_A1_9EA_SXVW_?I?\*M44 5?[,L/^?&V_P"_2_X4?V98?\^-M_WZ
M7_"K5% $7V:#_GC'_P!\BC[-!_SQC_[Y%2T4 1?9H/\ GC'_ -\BC[-!_P \
M8_\ OD5+10!%]F@_YXQ_]\BC[-!_SQC_ .^14M% #4C2/.Q%7/7:,4ZBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;X@?\ (O6O_85T_P#]*HJZ
MFN;\<0-<:!"%95\N_M)B6/9)T<CZD*0/<BDVHJ[!NQTE%8/_  EMA_SQN?\
MOE?\:/\ A+;#_GC<_P#?*_XUS?7,/_.OZ^1G[6'<WJ*P?^$ML/\ GC<_]\K_
M (T?\);8?\\;G_OE?\:/KF'_ )U_7R#VL.YO45@_\);8?\\;G_OE?\:/^$ML
M/^>-S_WRO^-'US#_ ,Z_KY![6'<WJ*P?^$ML/^>-S_WRO^-'_"6V'_/&Y_[Y
M7_&CZYA_YU_7R#VL.YO45@_\);8?\\;G_OE?\:/^$ML/^>-S_P!\K_C1]<P_
M\Z_KY![6'<WJ*P?^$ML/^>-S_P!\K_C1_P );8?\\;G_ +Y7_&CZYA_YU_7R
M#VL.YO45@_\ "6V'_/&Y_P"^5_QH_P"$ML/^>-S_ -\K_C1]<P_\Z_KY![6'
M<WJ*P?\ A+;#_GC<_P#?*_XT?\);8?\ /&Y_[Y7_ !H^N8?^=?U\@]K#N;U%
M8/\ PEMA_P \;G_OE?\ &C_A+;#_ )XW/_?*_P"-'US#_P Z_KY![6'<WJ*P
M?^$ML/\ GC<_]\K_ (T?\);8?\\;G_OE?\:/KF'_ )U_7R#VL.YO5RO@+_D&
M:O\ ]AS4?_2EZZ.TNH[VUCN(L['&1GJ.U<YX"_Y!FK_]AS4?_2EZZ4TU=&B=
MSJJ***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XM_Y@7_
M &%[?_V:NBKG?%O_ # O^PO;_P#LU '14444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5SOBW_F!?]A>W_\ 9JZ*N=\6_P#,"_["]O\ ^S4
M=%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %<K\0@3X;@4,1NU.Q4D'L;F,']*ZJN6^('_(O6O_85T_\
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M7MW%9-Y2#RE1,J, ?-@^N:3=H\SZ7_!V&HW=EY?BCTBJT>H64U]-8Q7EN]W
MH:6!909(P>A9<Y /;->6IXN\4ZOI'@C2=.U&&UU77;5[BYU*6W1S&J#)VQX"
MDG/^>M9]C;>*K7QGX]5=1A?7H]+MWM[NWMU42[1E<QMN )Q@C\JIKE;OY_@2
MM5IY?BSVNBO,AXZO_$5QX'M=#N?(EU0&[U!EC5]D,8PZ'<#C+Y7(YXKHOB7J
MEWHWPZUN^L9&CN4@VI(O5-S!<CW .:4_=3?]=@C[S2-H:_HS:F=,&K6!U =;
M47*>;_WQG/Z5HUY'%\%?!D_A2TN!+/;7[11S'5ENFW%C@EL%MO)]JV_$&L:[
M<>*=-\%>'M5CL;@V'VRYU2>!9WV A1M4X4L3USZ\4VK/EZB3NKK;^O\ ,]!H
MKQ_4O'/B;2?"_C+3;N]A?7= $!BU"&!5$R2%<,4.5#8)R.G-++KGQ L/$WAW
M3Y]<TZ=O$-JQ5/L 5+)E0,6'S9D.#W(!/84EJ]/ZNF_T8WIO_5K?YH]?HKR:
MS\6>)[/POX\M;_4XKK4_#P(M]02V2,OE"P)CQMXQZ?G4'_"1>.-!T?PWXHU;
M6K._T[4&MX;FPCLUC\L2CB02 Y+>HX'/ II7_#\=A-_K^&YZO#J-E<WEQ9P7
MEO+=6VWSX4E5GBR,C<H.5R.F:LUXT?$)\*^,/BEK2Q++):Q6;1HW1G*87/MD
MBJOA/XH7EUXHTO3)?%MKK@U;<DD<>F-;'3Y2N5"D@"1<\<\\4+6UNR_&_P#D
M5+W;W_K;_,]GEOK."&XFENX(XK8$SN\@"Q #)W'^'CGFI+>X@N[>.XMIHYH)
M5#QRQL&5U/0@C@BO!O"%OK.G^$?B->S:S'=PP37L;VTEA$5EN H)F.<C!Z>7
M@K736WB/7K[3?!GAG0KJUTZ^U'2EN[B^-JC+!&J#B.(83)/;& *=M/N_%-_H
M)Z?C^%O\SU>BO*)O%_B71],\9:+J5]!<:OHU@+NTU*&W5/-5EX+1\J&![=/:
MJT?B7QMI4?@W6]2UJTNK#6Y;>UFL%LE3R_,7(D\P<ENY PH]*25]O+\;_P"3
M$W;\?PM_F>P445SWB;QQX<\'O;+KVH_9#<AC"/(DDW;<9^XIQU'6D,Z&J%GK
M>DZA=S6EEJEE<W,'$L,-PCO'_O*#D?C2:C9PZ_H-Q:?:9XH+V IYUNVR0*PZ
MJ2#@X/<5Y/9Z3H3_ !&\/Z/X+L8D'A]F;5=3BC +#;M\MW4#>Q.<_CZ&FE[U
MG_7_  P/X;K^O^'/7[74+*]DGCM+RWN'MY/+F6*4.8G_ +K '@^QI+;4["]2
M=[6^MIUMW:.8Q2JPB<=5;!X([@UX;I/C?7/"WB[QE;Z7X+U#7HYM7D=YK4OB
M,]-IVQMSWZBM+X<:3#XV\$^++35A>:;%>:Y++<112!)(_N,8V++TSP>!^%*/
MO1OY)_D.2Y7;SL>N:=K.EZPLC:9J5G>K&=KFVG63:?0[2<&JDGBWPU#?&QE\
M0Z2EVLGEFW:]C$@?.-NW=G.>U>=^$H-+U3XI/J/@_3H+30=,LGM+BYMHA%'>
M3$\ 8&&QC.[_ !%8,&FZQX&MY/$?BGPEX<NK*;4FFN9)56:^A,DG#JV"NT<8
M .?IV:5VO/\ SLOOW$[I/R_RO^&Q[W12*P90P.01D&EI %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <M?_P#)4=#_
M .P5>_\ HRWKJ3TKEK__ )*CH?\ V"KW_P!&6];.MZ4NMZ-=::UU<6JW";#-
M;/MD3G.5/8T <3\)/"^L^&+;7TUBS^S-=Z@TT(\U'W(1U^4G'XUZ)(BRQM&X
MRK J1Z@UYE_PI>W_ .AS\5_^!X_^)H_X4O;_ /0Y^*__  /'_P 30]5;RM^@
M=6_F<]IWA?XH?#Y[S1_"=OINHZ/<SM)#/<.H:WS@9(++SC'9AQTYQ77ZWX&U
MKQ3\,#H>OZO'=:X2)Q=")4C64'(4!5'RXXSC/)/M5'_A2]O_ -#GXK_\#Q_\
M31_PI>W_ .AS\5_^!X_^)H>JL_ZL"T=T<KK6@?&#Q)X,G\/:C9:8EM;JBJT<
MJ^=>[2,<[]H' /(7I^%:_C7P/XCU?X4^%-%L=.\W4;!H#<P^?&NS;$5;YBP!
MP3V)K3_X4O;_ /0Y^*__  /'_P 31_PI>W_Z'/Q7_P"!X_\ B:I2:U\T_F@\
MO5?>4/B)X%UK5/'&E>(K;1H?$5A;VXAETJ:Z$&&&[YLL=N,D?ET-0>%/!/B+
M1_BW'KTGAO3].TF:T,7E:?.A2V^7 ##Y2S97DA2/FZUK?\*7M_\ H<_%?_@>
M/_B:/^%+V_\ T.?BO_P/'_Q-3'W?Q_$35U;T_ H^'O"_C3PK\5M7NK*PL[C0
M-9NO.N+MY1OC3+-A5W [LMC[I'2M/X<^%=:T'QKXSU#4K+R+74KOS+23S4;S
M%WR'.%)(X8=<=:B_X4O;_P#0Y^*__ \?_$T?\*7M_P#H<_%?_@>/_B:<79+T
MM\OZ13=[^;3+#^%]9;X\1>)!9_\ $H73_)-QYJ??P>-N=WZ5@W/A3Q_X&\4:
MQJ'@>UL-3T_5IO.>VN7"F%R22>70<$GD'N..*UO^%+V__0Y^*_\ P/'_ ,31
M_P *7M_^AS\5_P#@>/\ XFI6B272_P"+N+JWWM^&AT/@#2_%>GZ7<2>+=4%Y
M>W$ID2%,%;=>?E#8R>ON!@ 5UU<=X3^'T7A/59;]/$&MZB9(##Y5_<B1!EE.
MX# Y^7&?0FNQJF[B2L<[_P U(_[A'_M:NBKG?^:D?]PC_P!K5T5(9X?X]T:7
M_A-]3U#Q/HFM:GI$D,8TJ\TQG?\ LY@OS,8U8<[L')XX'6NDMO&%[!X9\+Z7
MX;O;;Q!JVJ1ND-]>J\4>V(?,\B@ELC@$9R3FK^I_#W4?[>U#5?#7BJXT,ZG@
MWT(M$N$D8#&Y=Q&PXSR*&^%]I:Z!H]EHNJW6G:AI#2/::AL65MSYW[U/# YZ
M<41TC9^7Z_\  UW8Y:RO_73^K;=3 \3^)=1U7X=^,]&UVTMK;6=+AC$_V1V:
M&57PRNF[D#KP?2KLWB&V\/\ BW6]0DT^)VL?#<%PTJ,_F2@,V$.6V@9[A<\]
M36G_ ,*V\SPOKMA=ZU-=:MK87[9J<L"@DK@*%C4@!0!P,]^M7KCP';7NKZG=
MWET9;;4-*33)+<1[2 I)WAL]>>F.,=:'UMO_ /:V_/\ JPGK;U_5?U_P3B+N
M_P#%FH>+/ 5SXCT_3;>&>]>:W:RE<E T60D@8?>QW!Q["N]\;>)KSP];:=;Z
M7:0W.J:I="TM5G8K$K$$[GQS@ =!S6%8?#35(-5T*\U#QA=:C%HLI-M;R6B(
MOE[=H4E3DL/[QS]!72>+?"J>*;&V1+V:POK*<7-G=Q*&,,@! )4\,.>13=K6
M6U_PT_$2OUWM^.OX&6?$/BW2O"VJ7>NZ/IB:A9E1#+#>K':3@X^?,C!D"YY#
M<G'&<URND?%C5KK2_%2S_P!AWE]H]C]KAN=.,K6TG'W2'P3@]2#_ "KH+OX<
M7VJ^&KZPUCQ9?W^H74T<ZW;Q*L4+1G*[8 =@7U'>H1\,+R1=::]\3RWEQJVE
MBPFEDLD4(1T9%0J H!^Y_P"/4G?7T_3_ #'V_KK_ )!HWC3Q0?$VA66OZ9I<
M%GKEJTUM]DE=Y(F1 Y$FX <YZ#IZFDT;QAXQ\0W(U72M#TV?PX;MK81FX*W9
M57VM*"<)@8)V]:WY?!_F:SX8U#[=C^PH9(O+\G_7[XPF<[OEQC/>L>V^&]]8
M7[1:?XOU&ST!KDW1TR"-5;>6W%1./F"$_P /ZU>G-]_Y]?D3KR^>GY:_C8Y+
M5_CJVG^)KN")=,_LZSNC;/;2"?[7-M;:SHP3RP.O!.3CWKK!XL\3ZAX_U'1-
M)L]*;3;!;:>6:X,@E,4BY95 ."Y[= ,<YS3F^'%Y!K%S)I?BS4=.T:[N_MES
MIUN@#-(3EMDV=R*2.0/>M[3_  P+'Q7KFMF\9QJL4$?DA"IB\M2N=^><Y]!B
MHC\*OOK]]E^MRWN_ZZ_Y'#>%/BAKFN^)K>TNK?0X[>XG>%K!;AHKZT*YY=9<
M!^G1!GGV-=A\0/$E_P"%?#2ZCIMO!<7)NH85BGSM8.X4C((P>>OZ&L1/AC>S
M:W87&J>++S4M-T^X6YM;6>W3SE=3E=]Q]]P,G@UT_BOPY_PD^E0V7VK[-Y=W
M#<[_ "]^?+<-MQD=<8S3TLOZTNO^"2]W_7?_ (!PWB_XDZYX.M=.L-3_ +"M
MM:O/,E:9_M#VD,8;Y1A%,C,1QT R*Y3Q=XJU3XB^$?#GV./3EM;K6!8W<+R3
M!)IA]SD;6\H@Y/1@<>E>L>*O"$^N7]EJVE:S-H^L6:O'%=)"LRF-L;E9&X8<
M<>E5+GP#+=:9H%K<:_=W,^EZDFH27-V#*]PPR2OWAL'/&,X Z41L_B[K\_\
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M444 %%%% !1110 4444 %%%% !1110!RU_\ \E1T/_L%7O\ Z,MZZFN6O_\
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MB^(KRUN] FM=FL!+;S'R/W0\L8A4CIN&2<FE_E^-F_T&U;?O_E_G^!ZKX?\
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MCX<Z?JD7Q!U;4KZT\0K#>Z="8[C6(U#N0V"#L^5".R'D#GO1'7[OTN$M/O\
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M4 %%%% !1110 4444 %%%% !7*^/?^09I'_8<T[_ -*4KJJY7Q[_ ,@S2/\
ML.:=_P"E*4 =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB>4*K29P%5LC#9X&#G->=V=_X@U#4_"27MY%'J6HZ/>SFY>RA9X&8*4V_*"
MH(R 1NQSFN6TNUU6#X+Z%*VHI<B76[<V<+P!%MR)V!!8<L"W//3.*.7H^_\
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M?A&UU&VGTO5,W%[<)+;E"AB4QHY1NQ>16 /I525F[='_ )_Y$1E>*;[?HO\
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M%% !1110 4444 %%%% !1110 4444 %<KX]_Y!FD?]AS3O\ TI2NJKE?'O\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 <M?_P#)4=#_ .P5>_\
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MZ9%=E;2>7.=[QXY.0#U XI-6^%6@ZOJ&I7,MWJT$6I+_ *3:6UX8X'?&!(4
MY88'7*^U=S11TL.^MS!L?"5C8Z]!K*7%U)=0Z<NF@2,NUHU;=N("CYL]\X]J
MY[4O ACTG1O#NF":33!JOVZ]FG="50,TNW'&<N0!@' ZUW]%.[O?^M[_ )ZB
MMI;^MK?EH%%%%( HHHH *Y7XB_\ (G/_ -?UC_Z5PUU5<K\1?^1.?_K^L?\
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M_L.:=_Z4I755ROCW_D&:1_V'-._]*4H ZJBBB@ HHHH **** "BBB@ HHHH
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M5- T6VUBWUI(0ZR7:P-:R(NW)W#YDQS@<UZ/11?2W];6'>^YY?I?@+5-&G\
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M]QHKMCCJL4DK?<;JO-*R/#O^%1>(_P#GMI__ '];_P")H_X5%XC_ .>VG_\
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MG]?K>7W!]8F>=1_"'Q 9%$D]@J$C<1*Q('?C;7M%G:0V%E!:6Z[888UC0>@
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M .I"\<_^"?\ ^SKT"B@#S_\ X6G_ -2%XY_\$_\ ]G1_PM/_ *D+QS_X)_\
M[.O0** //_\ A:?_ %(7CG_P3_\ V='_  M/_J0O'/\ X)__ +.O0** //\
M_A:?_4A>.?\ P3__ &='_"T_^I"\<_\ @G_^SKT"B@#S_P#X6G_U(7CG_P $
M_P#]G1_PM/\ ZD+QS_X)_P#[.O0** //_P#A:?\ U(7CG_P3_P#V='_"T_\
MJ0O'/_@G_P#LZ] HH \__P"%I_\ 4A>.?_!/_P#9T?\ "T_^I"\<_P#@G_\
MLZ] HH \@N_B-YGCW2K[_A#/%Z^5I]U%]G;2\2ON>$[E7=RHVX)[%E]:W_\
MA:?_ %(7CG_P3_\ V=:]_P#\E1T/_L%7O_HRWKJ: //_ /A:?_4A>.?_  3_
M /V='_"T_P#J0O'/_@G_ /LZ] HH \__ .%I_P#4A>.?_!/_ /9T?\+3_P"I
M"\<_^"?_ .SKT"B@#S__ (6G_P!2%XY_\$__ -G1_P +3_ZD+QS_ ."?_P"S
MKT"B@#S_ /X6G_U(7CG_ ,$__P!G1_PM/_J0O'/_ ()__LZ] HH \_\ ^%I_
M]2%XY_\ !/\ _9T?\+3_ .I"\<_^"?\ ^SKT"B@#S_\ X6G_ -2%XY_\$_\
M]G1_PM/_ *D+QS_X)_\ [.O0** //_\ A:?_ %(7CG_P3_\ V='_  M/_J0O
M'/\ X)__ +.O0** /()OB-N^(5E?_P#"&>+QLTJXA^SG2_WS;I83O"[N5&W!
M/8LOK6__ ,+3_P"I"\<_^"?_ .SK6N/^2L:=_P!@.Z_]'V]=50!Y_P#\+3_Z
MD+QS_P""?_[.C_A:?_4A>.?_  3_ /V=>@44 >?_ /"T_P#J0O'/_@G_ /LZ
M/^%I_P#4A>.?_!/_ /9UZ!10!Y__ ,+3_P"I"\<_^"?_ .SH_P"%I_\ 4A>.
M?_!/_P#9UZ!10!Y__P +3_ZD+QS_ ."?_P"SH_X6G_U(7CG_ ,$__P!G7H%%
M 'G_ /PM/_J0O'/_ ()__LZ/^%I_]2%XY_\ !/\ _9UZ!10!Y_\ \+3_ .I"
M\<_^"?\ ^SH_X6G_ -2%XY_\$_\ ]G7H%% 'G_\ PM/_ *D+QS_X)_\ [.C_
M (6G_P!2%XY_\$__ -G7H%% 'G__  M/_J0O'/\ X)__ +.C_A:?_4A>.?\
MP3__ &=>@44 >?\ _"T_^I"\<_\ @G_^SH_X6G_U(7CG_P $_P#]G7H%% 'G
M_P#PM/\ ZD+QS_X)_P#[.C_A:?\ U(7CG_P3_P#V=>@44 >?_P#"T_\ J0O'
M/_@G_P#LZ/\ A:?_ %(7CG_P3_\ V=>@44 >?_\ "T_^I"\<_P#@G_\ LZ/^
M%I_]2%XY_P#!/_\ 9UZ!10!Y_P#\+3_ZD+QS_P""?_[.C_A:?_4A>.?_  3_
M /V=>@44 >?_ /"T_P#J0O'/_@G_ /LZ/^%I_P#4A>.?_!/_ /9UZ!10!Y__
M ,+3_P"I"\<_^"?_ .SH_P"%I_\ 4A>.?_!/_P#9UZ!10!Y__P +3_ZD+QS_
M ."?_P"SH_X6G_U(7CG_ ,$__P!G7H%% 'G_ /PM/_J0O'/_ ()__LZ/^%I_
M]2%XY_\ !/\ _9UZ!10!Y_\ \+3_ .I"\<_^"?\ ^SH_X6G_ -2%XY_\$_\
M]G7H%% 'G_\ PM/_ *D+QS_X)_\ [.C_ (6G_P!2%XY_\$__ -G7H%% 'G__
M  M/_J0O'/\ X)__ +.C_A:?_4A>.?\ P3__ &=>@44 >?\ _"T_^I"\<_\
M@G_^SH_X6G_U(7CG_P $_P#]G7H%% 'G_P#PM/\ ZD+QS_X)_P#[.C_A:?\
MU(7CG_P3_P#V=>@44 >?_P#"T_\ J0O'/_@G_P#LZ/\ A:?_ %(7CG_P3_\
MV=>@44 >?_\ "T_^I"\<_P#@G_\ LZ/^%I_]2%XY_P#!/_\ 9UZ!10!Y_P#\
M+3_ZD+QS_P""?_[.L#QI\1O[1\--;?\ "&>+[7-W:/YMSI>Q/EN(VQG=U.W:
M!W) [UZ_7*_$7_D3G_Z_K'_TKAH R?\ A:?_ %(7CG_P3_\ V='_  M/_J0O
M'/\ X)__ +.O0** //\ _A:?_4A>.?\ P3__ &='_"T_^I"\<_\ @G_^SKT"
MB@#S_P#X6G_U(7CG_P $_P#]G1_PM/\ ZD+QS_X)_P#[.O0** //_P#A:?\
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M]2%XY_\ !/\ _9T?\+3_ .I"\<_^"?\ ^SKT"B@#S_\ X6G_ -2%XY_\$_\
M]G1_PM/_ *D+QS_X)_\ [.O0** //_\ A:?_ %(7CG_P3_\ V='_  M/_J0O
M'/\ X)__ +.O0** //\ _A:?_4A>.?\ P3__ &='_"T_^I"\<_\ @G_^SKT"
MB@#S_P#X6G_U(7CG_P $_P#]G1_PM/\ ZD+QS_X)_P#[.O0** //_P#A:?\
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M\$__ -G7H%% 'G__  M/_J0O'/\ X)__ +.C_A:?_4A>.?\ P3__ &=>@44
M>?\ _"T_^I"\<_\ @G_^SH_X6G_U(7CG_P $_P#]G7H%% 'G_P#PM/\ ZD+Q
MS_X)_P#[.C_A:?\ U(7CG_P3_P#V=>@44 >?_P#"T_\ J0O'/_@G_P#LZ/\
MA:?_ %(7CG_P3_\ V=>@44 >?_\ "T_^I"\<_P#@G_\ LZ/^%I_]2%XY_P#!
M/_\ 9UZ!10!Y_P#\+3_ZD+QS_P""?_[.C_A:?_4A>.?_  3_ /V=>@44 >?_
M /"T_P#J0O'/_@G_ /LZ/^%I_P#4A>.?_!/_ /9UZ!10!Y__ ,+3_P"I"\<_
M^"?_ .SK \7?$;[?8Z<G_"&>+[?RM5LYMUQI>P/LG1MB_-RS8PH[D@5Z_7*^
M/?\ D&:1_P!AS3O_ $I2@#)_X6G_ -2%XY_\$_\ ]G1_PM/_ *D+QS_X)_\
M[.O0** //_\ A:?_ %(7CG_P3_\ V='_  M/_J0O'/\ X)__ +.O0** //\
M_A:?_4A>.?\ P3__ &='_"T_^I"\<_\ @G_^SKT"B@#S_P#X6G_U(7CG_P $
M_P#]G1_PM/\ ZD+QS_X)_P#[.O0** //_P#A:?\ U(7CG_P3_P#V='_"T_\
MJ0O'/_@G_P#LZ] HH \__P"%I_\ 4A>.?_!/_P#9T?\ "T_^I"\<_P#@G_\
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M -2%XY_\$_\ ]G1_PM/_ *D+QS_X)_\ [.O0** //_\ A:?_ %(7CG_P3_\
MV='_  M/_J0O'/\ X)__ +.O0** //\ _A:?_4A>.?\ P3__ &='_"T_^I"\
M<_\ @G_^SKT"B@#S_P#X6G_U(7CG_P $_P#]G1_PM/\ ZD+QS_X)_P#[.O0*
M* //_P#A:?\ U(7CG_P3_P#V='_"T_\ J0O'/_@G_P#LZ] HH \__P"%I_\
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M5S>W-I9M)#:G&0)''3Z]!W(H>FX+78[.BLKPWK]KXH\/VFM64<T=M=*619E
M< $CD D=O6M6FTT[,2::N@HHHI#"N=\)?\QW_L+W'_LM=%7.^$O^8[_V%[C_
M -EH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N5\>_
M\@S2/^PYIW_I2E=57*^/?^09I'_8<T[_ -*4H ZJBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N5\>_P#(,TC_ +#FG?\ I2E=57*^/?\
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M7\&F7BW,EA-Y%SL5@$?TR1@_AFCK8+Z7-2BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#E=1.SXG^'R>DFF7RCZA[<UU5<KJW_ "4SPQ_UXZA_.WKJ
MJ /G_P"(EYKOB?XQV=CX8TZ'5)_#L0F\B9PL?F9!)8EEZ?(,9ZBLGQ'J7CO0
MO'6A^-_%F@6FFI#(MJ\EFX99$.[(8"1SG:6QTKK[#5]9\.:[JM_I/PBOQ<WL
MK&>Y.INQF^8G=AD.W.<X']*?KWBCQ)XGTI],UCX07UU9NRLT9U(IR#D'*Q@C
M\Z(WBHVW6OW[_AH.5I-WV>G^7XE7QS=V-E\=/">KZQ)&-$>S_=32_P"J5_GP
MV3P,%D.>W!JGXUUK0-9^-G@N31KNTO)HYD%S/:N'4_.-@++P2/F^F:NZAJ^L
MZKH%OHE_\&+NYT^W0)#'+J)9HP!@8?9N!QQG.:S[6.XL9].FM?@=<PRZ=)YM
ML\>IN"K<<L=GSG@?>S51LFNR;?WW(FG*+[M6-/6=4L=$_:5MKO5+N&SMGTL(
M)IW"("0V,L>!T[U%IFMZ=KW[2XN=+NXKJWCTYHO.B;<C,%YP>A'/44GB34M5
M\7>2==^"UW=M#_JW_M)D=1Z;E0''MG%,T^^U+2=8@U;3_@I=6M[!"8(WBU%E
M54.<C8$V]SSC-3#2U^E_QO\ YCFKWMUM^%O\C0^&?/Q1^(X'_/S_ .SO4/[/
M6HV4>@:GIKWD"W[:A)(MJT@$I4(@+!>N.#S1I>OZ_HNK:CJFG_!Z_AO-1??=
M2?VHS>8<DYP4(')/0"K'@V.1?'L>H'X43Z'/=[Q/J)OF=8\J23Y>T*,D <8Z
MTX.R2?\ *E]VI4W>]N]_PL>PT444A!1110 4444 <K<?\E8T[_L!W7_H^WKJ
MJY6X_P"2L:=_V [K_P!'V]=50!PL_@V+5?B??ZKK&BV=[I;:9%# ]U''*!*'
M8L K9(.".<59\;>')[_0=*L-%L(MEKJ=K,88MD:QQ(^6(!P, =A78T4+2WE_
MG<.[[_Y6.#U+P_K\GC7Q#J>F!;?[5H:6MG=NZX$X9CTSD8R#G&*Y#PQX'\3P
M>,?#^MZAH9@DMXIX;RXN-6-Y+(Q0@2,"<!22?E4D_,<U[710M/Z]?\V#UOY_
M\#_(\8T?P;XLL?%-C]AT2'088;OSKV\LM59K2ZCS\RK:L25+#'7@8^E9\?PD
MNXO$,MM-X3TZ_BEOFN/[;FU*9 L)?.PP(ZDN!T(X]<U[O133LT^W]?H#UOY_
M\'_, ,  =!7)>$](U+2-0\5W%S:[1>ZF]S:CS%/FIL4 \$[>01SBNMHI!TL4
M=(NK^\TF"XU/3?[.O74F2T\]9O+.3QO7@\8/XUYG8?"N\U\ZSJGB#5]=TJ\U
M:YD,ME8WJ+$8?NQJX 8-\OOT.*]:HH=F[@KI6/(;7PMXPLO#?AFX&G176K^&
M;N9([:6X11=V[ JI5\D*=N,;O2M?PQX<UV]\2>,+WQ/I,%G;:U;P1)'#<+,I
M4(RLI(P20",D@<],BO1Z*;=[WZW_ !M?[[#3MM_5FVONN>5^$/!GBK3-&U^:
M\GCBUQK4:;I<S,&"P1*1&^03C).3GGCI65X5\$>);;QKX=UW4M#>!K:.:&]N
M)M8-W-(Q0@2$,<*I).%7)^8YKVFBB[O?^NOYW=_,EK2W]=/\D>4'P;KW_"JA
MHHL/^)C_ &O]I,/G1_ZO[3OW;MV/N\XSFM"^TSQ=X;\;:UK'A[1K76(-:2$'
MS;L0&UD12N6!^^O?"\UZ/12_K\$OT0^M_P"MV_U/'/&WP_UC6-=L=>O?#MCX
MDF?3UMKJRBOGLUBF!)\Q&+<KR1@G-7(_!FO^%H_#&JZ%HNGW5YIT,T%UID%R
MT:8E.XF.25F(P>N3SSCTKU>BFG;;^M_\V)J^_P#7]6/,=%/B;PAIGB[7M4T*
M"2[NM06YCM8;Q%1XR%4D/CJ!V(!8C@<UUGCK3;S6_ >L:=80>;=W-JR11;@N
MYCVR2 /QK?DACF4++&DBA@P#*" 0<@_4&GTFDXV&G9W/-_'_ ('N_$7AC08X
M=/AOI-+9'ETV6X,(N%V;602*?E/3!SBL*/X>:C%\,?$EE8^&;32]0U-H_)T^
M"^>9@B," \DCE"WWONX&*]EHIWW\_P#-/] CI;R.+AT#45^)NGZPUM_H,.AF
MT:7>ORR^8#MQG/3/.,>]>>>*O 7C77I]96ZTO^T9/MHN+*\?5RL8AW#$4=OP
MH8+D$M@<G&3S7N]%%]4^W^=_S#I;T_!6/-KK3/%WAOQEK&K^']%MM6AUJ. ,
M)KQ83:2(NW+ _?7OA3FK=[I?B>+QMX<U[^SK6^<6366I>1.(4@+LK&1 ^2P&
M#QDD^U=]12[>7_!T_$'_ %^'^2/'W\*>,[?P[>^ [;2K*32;J:0KK3W8'EQ/
M(7(:+&XN.F1QTKK?#GAZ^TOQ]XCU"6 BQN;:SBMIBZDR>6A#< Y&#CJ!79T4
MT[?UY6_)#;O?^NM_S/'/#VG)J7Q=O[2POK>\\.Z=<-JZBW<.J7<HV;"02,@A
MVQVS7H'CC2+K6_"UQ8VNGV&H.[*6M;XLJ2J#R RD%&]&[&MFRTRPTQ)$L+&V
MM%D<R.((EC#L>K' Y/O5JE]E1[?U_E\D%_><OZ_K]6>1Z#X*\37^D^(M/U"&
M?1=,O[+[-;:?<ZD;\QR\_O _9>@P*NV6C^,->U+P[:Z]HMII=EH$RSFZBNUE
M-VZ(578H&47N=U>GT4[ZW_K2_P#F3RJUOZUM_D>4+X-U\>$Q8_8/])_X2C^T
M-GG1_P"H\[=OSNQTYQU]J35/#_C'2W\7Z9HNBV>H6.O-+<1W<EVL1A=TVLA0
MC+'TZ#U(KUBBIMI;^MDOT12=G=?UJW^K.?\ #.DW-IX!TS2+Y#!<QZ>EO,H8
M-L;9M/(.#CV-<IX0M/'OA^UTWPO_ &+IJ:=8N5DU=[G>)H<DX2($,K\]6XX-
M>ET5;E>3D^O]?J3;2QX1/X#\:W^H6ESJFE&\O++5X[EM0?6"PFA\S)$4!(5
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M[O\ $V:***104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RNK?\E,\,?\
M7CJ'\[>NJKE=6_Y*9X8_Z\=0_G;UU5 !1110 4444 %%%% !1110 4444 %%
M%% !1110!RMQ_P E8T[_ + =U_Z/MZZJN5N/^2L:=_V [K_T?;UU5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7*_$7_D3G_P"OZQ_]*X:ZJN5^(O\ R)S_ /7]8_\ I7#0!U5%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^$O^8[_P!A>X_]
MEKHJYWPE_P QW_L+W'_LM '14444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5RWQ _Y%ZU_["NG_ /I5%74URWQ _P"1>M?^PKI__I5%0!U-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\0/^1>M?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^)/#>GZQ NU+N%9-O]T]Q^!R/PK5IM-.S)3NKH****0PHHHH **** "BBB@
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M_%'P)=W,JPV\,HDDD<X"J)5))_"NKT?XW>#=:UY=)AN+J%Y'"0W%Q"$BE8]
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MFET0"6_N'S@,[]<<#)'4GWK9\&^,]7TGPKK]YXHL-=^Q:4X>UFU"S\JYG@/
M!!(#,,<G/>MO5_A_?:A>:=K-GXEGL/$MI;"VDU)+1&6X7OOA/R]<D 'C/? K
M=\,:!<Z!821WNMW^KW<TGF2W%VYQGT1,X1?]D4UL]==?SW^[T![KY?D4_!'C
MS2_'MA<WFE07D,=O*(G%TBJ2<9XVLW%=1110[=!(****0SEK_P#Y*CH?_8*O
M?_1EO71W=K%>V<]I.I:&>-HW .,J1@\_C7.7_P#R5'0_^P5>_P#HRWKJ:35U
M9@G;4YWP;X*TKP-I,FG:2;AHI9C,[W#AF+$ =@!@  =*Z*BBJ;;W X;QSI,^
MK>)O"2+:336JW%PMRZ1EEC1H67+$= <XYKSK2_"_B,:39W&I:=>27L'B"QM5
M @?(M+;*B3'/R\D[NG>O?J*(OE=_ZW3_ $L-N_\ 7DU^OX'S[KW@[5AXD\06
M5S8^+[Q=5OC-;#2[Q8K&6-L?Z]BK!"O3D'. />NOU;2-:M_$WB-].TM[QCX;
MAMK<W,6^*>0,V4)("N<<D=_3FO4Z*FWN\O\ 6U@>LN;^M[GB'@_3]:E\>Z)J
MMYI_B58!IL]NTFIVR1)&X'W$CC'[M/3=C=QCI4UCX>U"+X1>%[0Z/=+>PZU%
M/-";9A(@\]LNRXR!MQR>U>TT5?-_7SN3;2W];6/(KU-4\.ZCXNTZ7PEJ.M-K
M\[R6EU;1+)$59 H29B?D"GUJUHGAC4=,\;>#H[VUDG73M!>"6Y$9:..7(&W?
MC .,@>U>IT5*TM_71K]1O6_]=O\ (\6C\-WT7PU6V31KE;K_ (243^4+9M_E
MBXX?&,[=O?IBJ/CW3O$VIZIXKL$T?7!'.BR6O]E6L*V]TBJ.9Y<;W;@C8,GL
M!7N]%*VEOZV2_0=];_UNW^IR&NV5Q>_".\LHDE2X?1R@212KAO*Z$=0>V*Y2
M"TEU?4OA3J%M933V,%I(TTJQ%DA/D*%W$#"_,.,]Q7K1Y&#533-,L]'L4LK"
M'R;9"Q2,,2%W$DXR3@9)XZ#M5\WO.7G?\_\ ,E*T4O)K\O\ (\@U'PW?GP)\
M18(M&N3<W>LM);1K;,7F3?&0R#&6'WCD>]5O&?AG5H?&>HZ@]KXMN+34K.&*
MW'A^<("ZIM,<^0=J9YSC R>M>YT5/2W];6+<K_UYI_H>5?V3?^%];\ W":/J
M=U:VEG+8SK!BY>V:39MWLH4%1R"V ,"N.UO3/%&HRW<-QHNOQO;:TERT%C:1
M1V)C\S_6#8-\SD<DC..IZ5]#455_>YO._P"*?Z&?*K-?ULU^IXAXTTW5H/$&
MM+I>@^(EN=1=61;:.*]TV\( P\RR+^Z/8CGI732Q:OIGQ/TG4IM&N9TN]$%C
M))9Q;H;></N.\_PI[_SKTFBI6BM_6S7ZE/=O^MT_T/GFSTOQ/>:CX<DOM&\0
M0OI^M(]S!'9Q0V$"ES\T21C<XZ9?H.>><UT]_9ZI#:?$K1O[$U-WU 2WEI<1
MVY:*8-&JA%(ZOG/R@=J]?HH>JMZ_C;_(.M_ZZ_YGDLD>I>%/%5GK\_AK4]7L
M[G0X+'98VXEE@D7DJR'!"GN:[#1M:73H= TJX\,RZ1+J*R[+:U57M[4J"^UV
M 4!B,G '7/IFNJJ"2SMY;R&[DC#3PAEC8D_+NQG Z9XZU7-=Z_UN_P V2HV5
ME_6B7Y(Y;QWI6I3RZ)KFDVQO+K1[OSVM P5IHV4JX4GC=@Y'TI-!\7:SXBUQ
M8XO"FI:;I"1-Y]QJT?D2^9_"$3)W#W_PP>QHJ5V_K4IZGD?@7X5>'+S2O[3\
M0>'7.JF]G8_:FE7*^8VTF,D*1C';FNF33[I/C1]M6SF6Q&@B$3B(B(/YV=F[
M&,XYQZ5VU%-.UK=/\K ];^?^=SB/$6ESW?Q3\'W@LYI;6UBO#),(RR1,44+N
M;& 3SC->=>*O"6J)XM\0QS6'BZ[AU>57M5T6Z6.TE7: 5N"5(3'3)!&.U>^4
M4NWS_%W#O\OP/.K31+RQ^*>C.+6[>SM?#IM6N7!=0X<?*T@ !; SVSUQ69H.
MDZUI_P #+VUM-%WZN[7#"TO+89?,IY*.,-\O(!&#@5ZQ10]4_/\ SN-.UO*W
MX*QX9X=T37=1\8O>36OB.**\T">TCN=7A2/RY,@!0D8Q$OH&P3R:W_!5U?06
MOA_PU=> ;Q;K2ALFU"[B1((, YEADP=['T7'7K7JE%._]?-O]63;3^NR7Z'B
M<&BZW<^ [K0UT&_^U:1K0O6AGC"17\7G,^V-B<-QC\<5M6:ZCXJ\677B.+P[
MJ.CV<&CS616_@$4]S(W( 0$DJN.#[UZE14M75OZVY?R*OK?^M[_F>;:9X4DO
M?@5;:'+;M9WOV .JS(8VBG4[U+ \@[@*;\-KFYU;0]5\;ZP@CN-038JYR(X(
M5*\'W;>WXUW.NZ#IGB72I-+U>U^TV<A5GCWLF2#D<J0>H]:<^B:<^A-HGV8)
MIS0_9_(B8Q@1XQM!4@CCT-5)N7,^_P#7_ %%)<J[?U_P3F/A%:RVGPOT99<@
MR(\R@]E=V9?T(KMZ9##';P1P0HJ11J$1%& H P *?3D[R;$KVU"BBBI&%%%%
M !1110 4444 %<[X[_Y$S4/^V?\ Z,6NBKG?'?\ R)FH?]L__1BT =%1110
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MD'M7N6N^$M!\2Z7%INKZ;#<6D1!BC!*>7C@;2I!'''!J+3O!/AO2&NC8:3#
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MW_["M?[2W;_-P<;\YW;,[=V>=V,^]=-5.5U_79?\.*VO]=_Z04445(PHHHH
M**** "BBB@ HHHH **** *.L:7!K>BWNE7+R)!>0M#(T9 8*PP<$@C/X5Y;_
M ,,X^#_^@EKG_?\ A_\ C5>P44K=1WZ'"^#OA3H7@B>^ETV[U&5KV#R)/M,B
M, N>VU!S^=3Z%\--&\/^$-3\,VES?O9:CO\ .>61#(NY IVD( .!W!KLZ*;U
M_(2TV]3$\*>%[+P?X>AT73Y;B6VA9F5KAE9SN))R0 ._I7-R?"'P[_:]W?VM
MWK%C%>$FZLK*],4$^<YW #..3P"!7?T4/5W8+16.,\/^ =+\"IK5UH,=U/\
M;5+_ &":5?+RN2J*=N1UQR37A]W=?"[3O$37-YX1\46]\&+#29EC$&_/'!;?
MC/;IVP:^HZ*6M[CZ6/'_ (/>#;I?A[K5MK-I-8)K4C@1;=DB1%-N<$<=3C(_
M"N\T#P/H_A_PB_AB,37>FR;PZW;*S.'Z@[0!^E=)15-W_!?<)7_%O[SR^S^
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MB-FUYJ_X7!JR?D[?C8]<HHHI %%%% !1110 4444 <M?_P#)4=#_ .P5>_\
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M+G2$0QMTQN^\Q'\(JIXD^*4&A0Z9'#I3/J-];_:?LFH7<=AY*9P0[2D -G(
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M:1[(L ;GE88+$^W)]*J7O@?Q _\ PFEE;76F'3=?C>2'S/,66.=E5?F(!&S
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M7;ZC%7K_ .(%WINOV'AVP\/7.JWEQI:WD)6Z569NFURP  XR7)_"EY?UM?\
M(JVE_P"M&E^;._HKA]+^)=I<^$=7US4].N-.DT>9X+RT+B1ED7'RJPP&R2 .
MG-48_B;JD5[H5MJ?@Z[T_P#MBZ6&WDENT9?+(R&.T$AN1\A ^IYIVN[>GX[$
MMV5W_5MST:BBBD,**** "N=\)?\ ,=_["]Q_[+715SOA+_F._P#87N/_ &6@
M#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;X@?\B]:
M_P#85T__ -*HJZFN6^('_(O6O_85T_\ ]*HJ .IHHHH **** "BBB@ HHHH
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MWYLO_D>@#H**Y_\ X1[5/^ASUS_OS9?_ "/1_P (]JG_ $.>N?\ ?FR_^1Z
M.@HKG_\ A'M4_P"ASUS_ +\V7_R/1_PCVJ?]#GKG_?FR_P#D>@#H**PHM U!
M'S)XLUJ9?[CQVBC\U@!_6I_[%N/^@[JGYQ?_ !N@#6HK)_L6X_Z#NJ?G%_\
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MNE_\_6N?^#V]_P#CU '045S_ /PANE_\_6N?^#V]_P#CU'_"&Z7_ ,_6N?\
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M")XHT5W8X54OXB2?0 -R:L_\)/H7_06M/^_HK6HH R?^$GT+_H+6G_?T4?\
M"3Z%_P!!:T_[^BM:B@#)_P"$GT+_ *"UI_W]%'_"3Z%_T%K3_OZ*UJ* ,G_A
M)]"_Z"UI_P!_12CQ+H[<I?QR#UC!8?F!6K10!E_\)'I/_/W_ .0W_P */^$C
MTG_G[_\ (;_X5J44 9?_  D>D_\ /W_Y#?\ PH_X2/2?^?O_ ,AO_A6I10!E
M_P#"1Z3_ ,_?_D-_\*0^(]* _P"/HGV$3DG\,5JT4 9/_"2:;ZW?_@%-_P#$
M4?\ "2:;ZW?_ (!3?_$5K44 9/\ PDFF^MW_ . 4W_Q%'_"2:;ZW?_@%-_\
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M.-_Z36]=57*^#O\ D)^+_P#L.-_Z36] '54444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5RWQ _Y%ZU_P"PKI__ *515U-<K\1?^1.?_K_L
M?_2N&@#JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;X
M@?\ (O6O_85T_P#]*HJZFN5^(?R^%%E'WH]1L''N?M<7^- '54444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!SNL?\CGX:_[>O\ T6*Z*N=UC_D<_#7_ &]?^BQ714 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '+7_ /R5'0_^P5>_^C+>NIKEK_\
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M#@]=2WH<CS>']-EE=GD>UB9F8Y+$H,DGN:OU4TNU>QTBRM)2ID@@2-BO0E5
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M;@VUP-C+LD'5>0,]>HR*JVGS?Z?AJ#Z?UU?^03:[I%O>&SFU6QCN@Z1F%[A
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M5T=W_P (/XD\,>*!X-\/R,_]DMON(;-HK<NO*H$.,R@\Y"9_VJ);-KM^E_\
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MH\N!]2,_C5<KNT_/\+?YBOI=>7XW_P CO:***D84444 %%%% !1110 4444
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M_P"0GXO_ .PXW_I-;UU5<KX._P"0GXO_ .PXW_I-;T =51110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7*_$7_D3G_Z_K'_ -*X:ZJN5^(O
M_(G/_P!?UC_Z5PT =51110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7*_$7_ )$Y_P#K^L?_ $KAKJJY7XB_\B<__7]8_P#I7#0!U5%%% $<
M\$-U;R6]Q$DT,JE)(Y%#*ZG@@@\$4R"RM+:R6R@M88K1$V+!'&%0+Z!1QCVJ
M>B@#!3P/X2CD5X_"VB*ZG*LNGQ @^H^6M#4=%TK6(8X=3TRRO8HSF-+F!9%0
MXQD!@<5>HH H:;HFDZ,CII>EV5BKG++:VZ1!C[[0,U?HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G=8_Y'/PU_
MV]?^BQ6_+#%.FR:))%SG:Z@C]:P-8_Y'/PU_V]?^BQ714 5?[,L/^?&V_P"_
M2_X4?V98?\^-M_WZ7_"K5% %7^S+#_GQMO\ OTO^%']F6'_/C;?]^E_PJU10
M!5_LRP_Y\;;_ +]+_A1_9EA_SXVW_?I?\*M44 5?[,L/^?&V_P"_2_X4?V98
M?\^-M_WZ7_"K5% %7^S+#_GQMO\ OTO^%']F6'_/C;?]^E_PJU10!5_LRP_Y
M\;;_ +]+_A1_9EA_SXVW_?I?\*M44 10VT%N"((8X@W78@7/Y5+110!RNK?\
ME,\,?]>.H?SMZZJN5U;_ )*9X8_Z\=0_G;UU5 !1110 5RWC70[S58=)O=.3
MS+[2]0BNTCW!?,3.UUR2 /E8GKVKJ:*.J8>1Q.L?"_1=9U*YNVO=7LX[UM][
M9V=X8H+LX S(F.<@<XQ5K7?A[I&MRVL\5SJ.DW5M"+:.YTNY,$GDCI&3@@K^
M%=911TL'6YS*> ]%@M=$MK99X(='NOM<"HX)>3!!+E@2V=Q)Z&H[CX?Z+>6.
MM6=S]IEBU:[^V2DN T4H  ,9 &W&T$9S7544/7^O3_)?<"T_KU_S?WG(:!\.
M],\/>(!KD6HZO>WYM3:O+?W7G%UW Y)(SG@#@@8[5:\2>"-.\3:C9:A-=ZC9
M7EH"B3Z?<F%WC/5&(_A/M@^]=+10W>WD!Q]A\-]&TV#3H+>XOQ#I^HMJ-NCR
MJV'8$%22N2O)ZG/O5]O!>DRWNOW%P)9QKJ1QW<,C#8 B[1MP 1P?4\],5T-%
M'E_73_)?<"TV_K^KLX?2OA;I&E:UIFJKJ>M75SIN\6_VR\\U51EV[,$<* >
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M^1.?_K^L?_2N&NJKE?B+_P B<_\ U_6/_I7#0!U5%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<K\1?^1.?_K^L?\ TKAKJJY7XB_\B<__
M %_6/_I7#0!U5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>??\+A\/\
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MU'_\71]6K?RL;QF'7VU_7R/0:*\^_P"%P^'_ /GSU/\ []1__%T?\+A\/_\
M/GJ?_?J/_P"+H^JUOY6+Z[A_YU_7R/0:*\^_X7#X?_Y\]3_[]1__ !='_"X?
M#_\ SYZG_P!^H_\ XNCZK6_E8?7</_.OZ^1Z#17GW_"X?#__ #YZG_WZC_\
MBZ/^%P^'_P#GSU/_ +]1_P#Q='U6M_*P^NX?^=?U\CT&BO/O^%P^'_\ GSU/
M_OU'_P#%T?\ "X?#_P#SYZG_ -^H_P#XNCZK6_E8?7</_.OZ^1Z#17GW_"X?
M#_\ SYZG_P!^H_\ XNC_ (7#X?\ ^?/4_P#OU'_\71]5K?RL/KN'_G7]?(]!
MHKS[_A</A_\ Y\]3_P"_4?\ \71_PN'P_P#\^>I_]^H__BZ/JM;^5A]=P_\
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MA_\ Y\]3_P"_4?\ \71]5K?RL/KN'_G7]?(]!HKS[_A</A__ )\]3_[]1_\
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MOY6'UW#_ ,Z_KY'H-%>??\+A\/\ _/GJ?_?J/_XNC_A</A__ )\]3_[]1_\
MQ='U6M_*P^NX?^=?U\CT&BO/O^%P^'_^?/4_^_4?_P 71_PN'P__ ,^>I_\
M?J/_ .+H^JUOY6'UW#_SK^OD>@T5Y]_PN'P__P ^>I_]^H__ (NC_A</A_\
MY\]3_P"_4?\ \71]5K?RL/KN'_G7]?(]!HKS[_A</A__ )\]3_[]1_\ Q='_
M  N'P_\ \^>I_P#?J/\ ^+H^JUOY6'UW#_SK^OD>@T5Y]_PN'P__ ,^>I_\
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M4?\ \71]5K?RL/KN'_G7]?(]!HKS[_A</A__ )\]3_[]1_\ Q='_  N'P_\
M\^>I_P#?J/\ ^+H^JUOY6'UW#_SK^OD>@T5Y]_PN'P__ ,^>I_\ ?J/_ .+H
M_P"%P^'_ /GSU/\ []1__%T?5:W\K#Z[A_YU_7R/0:*\^_X7#X?_ .?/4_\
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MY6'UW#_SK^OD>@T5Y]_PN'P__P ^>I_]^H__ (NC_A</A_\ Y\]3_P"_4?\
M\71]5K?RL/KN'_G7]?(]!HKS[_A</A__ )\]3_[]1_\ Q='_  N'P_\ \^>I
M_P#?J/\ ^+H^JUOY6'UW#_SK^OD>@URO@[_D)^+_ /L.-_Z36]9'_"X?#_\
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M7GW_  N'P_\ \^>I_P#?J/\ ^+H_X7#X?_Y\]3_[]1__ !='U6M_*P^NX?\
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M7#X?_P"?/4_^_4?_ ,71]5K?RL/KN'_G7]?(]!HKS[_A</A__GSU/_OU'_\
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M'_\ %T?\+A\/_P#/GJ?_ 'ZC_P#BZ/JM;^5A]=P_\Z_KY'H-%>??\+A\/_\
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M7#X?_P"?/4_^_4?_ ,71]5K?RL/KN'_G7]?(]!HKS[_A</A__GSU/_OU'_\
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M1SS[O[V'LH?RK[E_D9/_  B_A_\ Z 6F?^ D?^%'_"+^'_\ H!:9_P" D?\
MA6M11SS[O[V'LH?RK[E_D9/_  B_A_\ Z 6F?^ D?^%'_"+^'_\ H!:9_P"
MD?\ A6M11SS[O[V'LH?RK[E_D9/_  B_A_\ Z 6F?^ D?^%'_"+^'_\ H!:9
M_P" D?\ A6M11SS[O[V'LH?RK[E_D9/_  B_A_\ Z 6F?^ D?^%'_"+^'_\
MH!:9_P" D?\ A6M11SS[O[V'LH?RK[E_D9/_  BWA[_H!:9_X"1_X4?\(OX?
M_P"@%IG_ ("1_P"%:U%'//N_O8>SA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\
M(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_
MX4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_
MX"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H
M!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'
M_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\
M"+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1
MD_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*O
MN7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>R
MA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_
MO8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'
M//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%
M:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1
M_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_
M ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@
M%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?
M_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\
M(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_
MX4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_
MX"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H
M!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'
M_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\
M"+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1
MD_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*O
MN7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>R
MA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_
MO8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'
M//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%
M:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1
M_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_
M ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@
M%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?
M_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\
M(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_
MX4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_
MX"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H
M!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'
M_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\
M"+^'_P#H!:9_X"1_X4?\(MX>_P"@%IG_ ("1_P"%:U%'//N_O8>SA_*ON7^1
MD_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*O
MN7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_O8>R
MA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'//N_
MO8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%:U%'
M//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1_P"%
M:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_ ("1
M_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@%IG_
M ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?_P"@
M%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\(OX?
M_P"@%IG_ ("1_P"%:U%'//N_O8>RA_*ON7^1D_\ "+^'_P#H!:9_X"1_X4?\
M(MX>/70M,_\  2/_  K6HHYY]W][#V</Y5]R_P C)_X1?P__ - +3/\ P$C_
M ,*/^$7\/_\ 0"TS_P !(_\ "M:BCGGW?WL/90_E7W+_ ",G_A%_#_\ T M,
M_P# 2/\ PH_X1?P__P! +3/_  $C_P *UJ*.>?=_>P]E#^5?<O\ (R?^$7\/
M_P#0"TS_ ,!(_P#"C_A%_#__ $ M,_\  2/_  K6HHYY]W][#V4/Y5]R_P C
M)_X1?P__ - +3/\ P$C_ ,*/^$7\/_\ 0"TS_P !(_\ "M:BCGGW?WL/90_E
M7W+_ ",G_A%_#_\ T M,_P# 2/\ PH_X1?P__P! +3/_  $C_P *UJ*.>?=_
M>P]E#^5?<O\ (R?^$7\/_P#0"TS_ ,!(_P#"C_A%_#__ $ M,_\  2/_  K6
MHHYY]W][#V4/Y5]R_P C)_X1?P__ - +3/\ P$C_ ,*/^$7\/_\ 0"TS_P !
M(_\ "M:BCGGW?WL/90_E7W+_ ",G_A%_#_\ T M,_P# 2/\ PH_X1?P__P!
M+3/_  $C_P *UJ*.>?=_>P]E#^5?<O\ (R?^$7\/_P#0"TS_ ,!(_P#"C_A%
M_#__ $ M,_\  2/_  K6HHYY]W][#V4/Y5]R_P C)_X1?P__ - +3/\ P$C_
M ,*/^$7\/_\ 0"TS_P !(_\ "M:BCGGW?WL/90_E7W+_ ",G_A%_#_\ T M,
M_P# 2/\ PH_X1?P__P! +3/_  $C_P *UJ*.>?=_>P]E#^5?<O\ (R?^$7\/
M_P#0"TS_ ,!(_P#"C_A%_#__ $ M,_\  2/_  K6HHYY]W][#V4/Y5]R_P C
M)_X1?P__ - +3/\ P$C_ ,*/^$7\/_\ 0"TS_P !(_\ "M:BCGGW?WL/90_E
M7W+_ ",G_A%_#_\ T M,_P# 2/\ PH_X1?P__P! +3/_  $C_P *UJ*.>?=_
M>P]E#^5?<O\ (R?^$7\/_P#0"TS_ ,!(_P#"C_A%_#__ $ M,_\  2/_  K6
MHHYY]W][#V4/Y5]R_P C)_X1?P__ - +3/\ P$C_ ,*/^$7\/_\ 0"TS_P !
M(_\ "M:BCGGW?WL/90_E7W+_ ",G_A%_#_\ T M,_P# 2/\ PH_X1?P__P!
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M(_\ "M:BCGGW?WL/90_E7W+_ ",G_A%_#_\ T M,_P# 2/\ PH_X1?P__P!
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M!DLL<$3RRR+'&BEG=S@*!R23V%9O_"3Z!_T'-,_\"X_\:/$__(IZS_UXS_\
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M!'0@BM.BETL/K<X[1_AOI6ERW4]QJ&KZM=7%NUJ;C4[PS.D3=44X&!^M1/\
M##2WT32M-_M;7%;2W9K2\2\VW$:MP4#A>%Q@8 X KMJ* .)7X7:&GA[^QX[K
M4XU2]>^@NTN<7$$K=2DF,^W.3ZDU7O/ \&A^#]>TS2+74M7FUDL7%Q=1EED9
M-H<NY4X! )^\V>@KOJ*3U37]=/\ )#3L[_U_6IC>$]#'AOPKIVDE@\EO"!*X
M.=\AY=OQ8DULT453=W=DI65@HHHI#*]_9QZAI]S92EECN(FB<H<$!@0<>_-<
M;_PJG1/^?[4_^_D?_P 17=45O2Q%6C?V<FK]AJ36SL<+_P *IT3_ )_M3_[^
M1_\ Q%'_  JG1/\ G^U/_OY'_P#$5W5%:_7\5_S\?WE>TG_,_O9PO_"J=$_Y
M_M3_ ._D?_Q%=E86<>GZ=;6419HK>)8D+G)(4 #/OQ5BBLJN(JUK>TDW;N2Y
M-[NY1BT328&@:+3+*-K>1Y(2ENH\MV^\R\<$Y.2.M)_8>DG.=+LN;C[4?]'3
M_7?\].GW_P#:ZU?HK 1G2^']&GEN)9M(L))+DJT[O;(3*5.5+$CYL$<9Z4L^
M@Z/=7$UQ<:38S3S*JRR26Z,S@'(#$C) (!&?2M"B@#/N-"T>[N)KBYTJQFFG
MB\F622W1FDCZ[&)&2O X/%2?V3INZX;^S[3=<QB*<^2N94 P%;CY@ 2,'BKE
M% '#^*?A]-K5_I]YH^MG1GLH3!'#]CCN($3U2-L+&^.-R\XXKIO#^BV_AS0+
M+1[5G:&TB$:L^,MZDX[DY-:5%.^E@>NH4444@"BBB@ HHHH 9-#%<0O#/$DL
M3C#(ZAE8>A!JC9^']%TZUFM;'2+"UMYP1+#!;(B2 C!W #!XXYK1HH K'3K%
MFC8V=N6BB,,9,2Y2,XR@XX4X''3@5-%%'!"D,,:1Q1J%1$4!5 X  '04^B@"
M*WM;>T1UMH(H5=VD81H%#,QR6..I)Y)KE8_!!?Q#%J=Y=V4WDW'VE7BTY(;F
M5@"%$LJGYU7/ "KT&2>_7T4+1W!ZZ%%-$TF/5&U1-,LEU!AAKL6Z"4CW?&?U
MIZ:7I\:P*EC:JL$C2PA85 C<YRR\<$[FR1SR?6K=% %&?1-)NK26TN-,LIK:
M:0RRPR6Z,CN3DLRD8)SW/-/&E:<J(BV%J%2$VZ 0KA8CC*#CA3@<=.!5NB@#
M*/AG0&:!CH>FEK>/RH2;2/,2?W5XX')X'K3I/#FAS2122:+ISO#L\IFM4)38
M,+M..,#ICI6G10!5ETRPGG,TUC;22DHQ=XE+$H24.2.JDDCTSQ1)IMC*+H26
M5LXNP!<;HE/G # W\?-QQS5JB@"C9Z+I6GQ0Q66F65M'"Y>)(8%0(Q!!*@#@
MD$C(]:>^EZ?)%/$]C:M'<2"69#"I$CC&&88Y/RCD^@]*MT4 9DGAW0Y;R6\D
MT;3GNIL>;,UJA=\$$;FQDX('7T%/30M(COQ?II5BMX"S"X6W02 L<L=V,\GK
MZUH44 9'B30E\1:2M@\PB47$,Q)CW@B.17VXR.NW'X]ZF3P_HL>F/IB:18+I
M[G+6JVR")CUY3&#^5:-%'2P%"#1-)M8)8+?2[**&5!')'';HJN@& I '( )P
M*+;0](LX((+72[*"&W<R0QQ6Z*L;D$%E & 2"1D>IJ_10!0_L32<P'^R[+-O
M&883]G3]TA&"J\<*1U XJ&'PQX?MX?*@T+3(HMC)L2TC4;6(+# '0D D=\"M
M6B@"M)IUC++)+)9V[R21>2[M$I+1]=A..5Y/'2J]OH&C6=E]BMM(L(+7S!+Y
M$5LBIO!!#;0,9! .?:M&B@ HHHH *S])T>WT=+M;=Y6%U=273^80<.YR0, <
M>E:%% %"PTF#3KS4;F%Y&>_G%Q*'((#!%3"X'3"#KGG-(-'MQXA;6M\OVEK4
M6I7(V; Q;.,9SD^M:%% &+JWAW^T]4M-2AU6_P!/N[:*2%7M1"=R.5+ B2-Q
MU1>F*?9>'XK"WNO(O;O[;=LKSW[E&F=@ !U78!@8P% &3@"M>B@'J9^LZ/;Z
MY8+9W3RI&L\4X,9 .Z-PXZ@\949]J75])@UJQ%G<O(D8FBFS&0#F-U<=0>,J
M,^U7Z* ,"/PK!;:8;*SU+4;0_:Y+Q9X)5#AW9F8$%2K+EC\K*1T[C-1P^#;.
M![6>.^O1>07;7CW68]\[LNQMXV;<%<#Y5&,<8KHZ* >NYR&I>&K[4?'C:BEW
M>6-I_9:V_P!HM9(PS-YI)0A@W8CG''8@U,W@/3DREE>:A86\EHEG/#;2KMFC
M4$*&9E+ C<W*E2<\YKJ:*5M+?U_6H[ZW.3_X0#3A;);K?7ZQ"QAL74-'^]2)
MMT9;Y.&&3TP#GD=*NKX4ABU&:XMM4U*UMYY_M,UE!*JQ/)U+9V[UR0"0K 'N
M.3G?HJKN]R;'/KX/T]=-CL1-=>4FI?VD#N7=YOFF7'W?N[CC'7'?O5S2=#AT
M?3Y[&&YN);>2221%E*GR@Y)*J0H.,DGYLGGK6I12Z6'UN<G_ ,*]TG['8VOV
MB]V64$%O&=Z9*Q2K(I/R]2RC/3CTZU>UCPO'K,DXFU74XK2Z01W-G'*AAF7I
MC#*2F1UV%<UO44[L#,TO0X-(N[^:VGG,5Y*)6MWVE(WVA25^7=R ,@DCCC%9
M/_""6'VJT<7^HBTL[O[9;V/F)Y,<AW9Q\FXJ=QX+$#MBNIHI!Y'-6O@FPM9K
M8?;+^2SLW+V=D\J^5;,01E"%#G 8XW,=N>,<4QO MC= KJFH:CJD8@>WA2\D
M0^2CXW;6558G@?,Q8\=>M=110!E:5HTFFR-)-J^I:@Y0(OVN1,(OH%154G_:
M(+>]:M%% !7+OX+AD\*IH[W;+<0RR3VU]&FV2"5G9PR\]MV#SR,@]:ZBB@#&
MT_19K77;C5KB\6>:XLX+:14AV#=&7)8?,>N_IVQU-5/%'A[5->FM5MM6MK>R
MBR9[.XLVFCN3VW[94)4?W>A[YKI**;=P.9O-!URYNM+OTUC38]0L5F0L=-<P
MR+)MZ)YX*D!1_$<^@JS8Z%>6DU_J,FH13ZS>1I']H:V(AC5,[56(/G;EF)R^
M23UZ5NT4@,S7=(.MZ.]@9Q"6DB<R!-WW'5^F1UVXZ]ZJZCX:2ZUVWU:UN!;2
M[#!>IY>Y;N$@_*PR.0>0W..1T-;M%']?H!S6D^&M1TZU@TR76EFT>WB,,5N+
M0+*T>TJ%DD+'< .FU5/ R3SFDG@B];1H]&N=?9M-M8XTLTBM521&C96C>1R6
MWE=HZ!0><@UV5%.[W XZ\\$W>K-)=:IK"2WS-;!7AM#'$D<,HEVA"['+$<L6
M/; XQ4^I^#?[1A\31_;_ "_[;6-<^3GR=B!?[WS9QGM7544K_P!?=_D!R<_@
MKSK+4;?^T,?;-5BU+=Y/W-AC.S[W.?+Z\=>G%)>^"GGUVZUJVU(07[W,5S;,
MT&]8BD1B*L-PWJP)S@J?>NMHHO\ U^'Z!TL<[_PCM_<:CI-_J.KK<3V%Q).0
MEJ(T(>,Q[%&XE0,Y^8L??TI1^"I[.[?4-/U5(=1^UW,Z2RVOF1^7.5+1L@<$
MXVJ00PY'X5U]% '%V'@:]TH6]U9:VG]JPR7):YGL]\<J3R>8RM&'4\$#!##I
M[XJW+X7U,77V^VUX)J$UO]FNYI;-765 S,NU59=C+N8 DMQU#'FNIHH>N@7U
MN<VGA,K\//\ A%#?9/V V?VKRO\ 9V[MN?QQG\:V[BT\_3);/?MWPF+?C.,C
M&<59HHE[UT^H+2UNAQ]QX$6YTS1K)M3D1=.TZ6P,D4>UI \2Q[P<_*1MSCGK
M45GX'U"VOK2\_MNV@EM+*6SA%CIJPJ@;9APK,XW#8,YR#V KM:*;;NWW_K]0
MZ6.)/P_:ZEO+R^O[8:C.(=D]A9?9U1XGWH[(7;>V>I)Z<8%=+I=KJL!E?5-3
MBO)'P%2"U\B- ,\@%G8D]\L1P, 5HT47 Y*Q\->(+379]3EUW3KMYI",SZ8Y
MDBASGRD83A5'OMY/)S6EKVC7NI7NF7NGW]O:7-A([K]HM6G1PR%2"!(A'7UK
M;HI=O(-[^9REQX+;5$NY]6U(S:E.L2I<6\/E);^4_F)L0LW\6"=S'..PIZ^&
MM6>>YU";7H_[6EA2".6*Q @2-6+%3$SL3N)^8[P?0K7444 <1;^ );2Z.J6V
MHVMOK/VHW(E@L=EMRFQE\GS,X8 $G?DL <]JZS3;>\M[7;?WPO+AF+-(L(B4
M>RJ"2 /<L?<U;HH#S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm247121d1_drs-sp1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d1_drs-sp1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W +0# 2(  A$! Q$!_\0
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MK5K6/$6D^'XXI-5OH[5)25C+Y^8CKTKS#5O@-9&U9M'U:X6X RJW85E8^F5
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M3PO#(NZ.12K#U!X-%% &?9:+':7,<[75U<-#&8X1.P(C4XSC 'H.3DUIT44
M5X+..WN+J=&8M<N'<'H"%"\?@HJ66,30O$Q(5U*G'7FBB@!MM;K:VD-NA)2)
M%12W4@#'-4[O2$N+LW4-U<VD[*$=X&7YP.F0P(XR>>O-%% %^-/+C5-S-M &
FYCR?<U1N=*%W/ODN[GR2RNUN"NPE2".V1R!P"*** -"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm247121d1_drsimg007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d1_drsimg007.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  _ ,L# 2(  A$! Q$!_\0
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MX7<(7T4YI4[P@W;GFDKN,.>2ZQ1^U"#Y/H@/_H0_K7\#?_!,@C_B) _:5)(
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MF$T=W+J&MZ?,\0N_&WVTQMY]O;:M>Z[I>HZHLC6UMK%C/I\\R7MM-$G[.?\
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M*7QW\.7OPQ^.TGP7^(OA2+5!-J/@SQUJO@W6=.76=,/[I+W2-8N9$CN[3S9
MRR^1+"7VNIW_ "])\#/@1\"_@1X"3PE\ ?AOX)^'OPXU64:[;:'\/]+L;#PW
MJ#ZE&L[7UK9Z5#_9]Q;7]J4,<\$DL%S%.=@*LC/U9IQ52SCA+)<ES*E4J\09
M)B7+*L9=3HPP7UFI4G0G.5VFZ<DE=JSC:[YF<>6\/XC+,]Q^,PDXQPV9TK.-
MU[D_9*#?1)^T3DKVW/XC?^"+)5O^"_G[4$88%QX[_;&8H""VU?''B*(G;G.!
M*#$3T\T&/[_%?WSD#]P00?WG!!R#F&4Y!]#U!Z8KY,\!_LB?LB?"+XO7WQ4^
M'WP0^$OA#XT>+)/$&K:AXMT3P]H>F^-M9?Q'J%YJ_B"^BN9;B.\E2YO9;JYO
M)HHW3ER2 &V_6"JV(_\ 6!H71_G!8LFR5,$H!&7.]N(R>0H8YP*YN-^),+Q7
MG."S#"4*E"E3R[ 824)I)_6,OP-/"XFIHM(UL3"K4BY6;4T]4[G3P[DLLBP<
MZ$Y*=2KB,75E*+NG]8QE>O&_7:HKG\5O_!VU*O\ :7[)DL:1W*Q6OC"9T0N9
M""UT(?+D4?9X_.>2*)#<N@E>>)8BVYA4GP0_X.F?@[\)_@[\*_AC=_LS_$K4
M+SX=?#KP9X!N]1L]4\%1VU]-X.T"RT#[1 C>(K*81RQV,;KYL9R#E0I+[OZI
M?V@?V<OV/_VBM6\,Z5^T?\,?@Y\4]6T4-;>$M-^).G:#K5]I\-T8[AWT.SU1
MFN(TO2MJ;E[6,K</;V9?<(HZ\=3_ ()+_P#!-; !_8B_9ORJ!6'_  K'PYG<
MI9I&;_0S\Q+@L2>FW('?ZS*.,.!J_#65</<3<.YUF%7*)8Q/$87&QH4*BQ6,
MKXE>QA.<5']U5A3J))J4XR>NAY&)R'B6&;8[,LISC*,'2QGL7"CB<OE6KP]G
M0ITI>TJJ-Y7G"4HZZ1DHWLK'X()_P=K?!*>>!)/V7?BE$%DA9IGU?P3Y:QO=
MVML5=!XBO;EV,UQ!(HMD#CRF+;OEV_UM>"]>A\6^#_"WBE+.>QC\1^']'UN.
MSGD!FMHM3L(+R*&4Q_(9(XYE5]A*[@<$CFOS[O/^"7O_  2_TK4]+LIOV0/V
M8M,U2]DBDL;;_A!?"5GJ-U&;NWMU:SC+VEU(/MLMLBR0)/\ OPD:J9FC5OT7
MTNUL-&TVPTK2],%EINGV=M:6%G96@AM+6SAA1+>WMXHF,<<<,06,(A*KMP">
MM?+\49CP7CGAEPAE&,RFG2YEB(8^HJM:>BBKU5=33FG*/\L&DM$>KE&%S_#>
MV_UAQN'S'G:^KSPE)TZ,=6VE1UE3LM'?XI)RZW/'OVE/ W@_QC\(OB!<^*M
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M=4MI+/4K&\3S;2YMI2NZ.>($/(K,JX"D8.267K7*7?PW\$:B/!QO?"VC3_\
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D(#Z@SVXV;XG+>5"28IIH(^8D("1++MC4 @! 3@#&2>2 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm247121d1_drssplit2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d1_drssplit2img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (? MD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HI[F&VA::>18XU&2S' %2USJ*NN:G+-.H:SM',<*'E7?^)CZXZ"FE<3)_\
MA(?/)-CIUW<+_?V[%/XF@>(HH6 OK.YM,_QNFY/S%5O$OBW1O"-BEUK%WY*R
M$B*-4+/(0,D*!Z>O2K^G7UOK.D6U_$A-O=PK*BR 9VL,C(SZ&JT["U-*.1)4
M#HP9&&00<@T^N=@']AZI%;Q\6%XQ")G_ %4G7 ]C_.NBJ6K#3"BBBD,****
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M7 XBD[@^@/K51ZH3[E7Q['&W@379&52ZV$P5B.5!7G!J7P1_R(>@?]>$/_H
MK9DC@N[=XY4CF@D7:RL RN#V(Z$4T"VL+55416]M$H554!%11T '0"F!0U[_
M %%F%_UANXMGUS6_7/6@?6]2BOMK+86Q)@W#!D?'+8]!VKH:4NP(****D844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>(_%&F^%]/\
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M2'IG'8FN_P#A?:75AX%L[2[@G@>&69%CG5E94\UMHPW.,8Q[5V.** "BBB@
MHHHH *@NK.WO8&@NH(IX7&&CE0,I_ U/10!S?A_P/HWA?5+R^TB)[?[6JK)#
MOW(,$D%<\CJ>]=)110 4444 %%%% !1110!YC\2O^0_IW_7K)_Z&M<>.M=A\
M2O\ D/Z=_P!>LG_H:UQ_>N^C\"/GL9_&9LZI_P BAX8^MS_Z%6-6SJG_ "*'
MACZW/_H=8U.ELR<5\:]%^1ZC\.?^11C_ .OB;_T,UUM<G\.?^11C_P"OB;_T
M,UUE<,OB9[U'^''T"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYJ&R\2:O-]MS&)#%&6P$QY9SW]>_'M1R,.9';45PL?B76&TB6?8#ME"^?LZ
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MV Z[F(!;\!G]*[(>7O/WMVV/\L\?K7 H5\3?& D(6LO#D#K\W(-S)_4#]12
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MP^,;@6)_X$U6#L\]>N[S?UV_RQ4;"(0-RV#$<XZXI -BC"V9CP,;UX^NVFS
M&VMUP#M&[IZ5.?+R?O8\Q?IG Q_2D;R\<[L>6^/IGFG< D ^W(>XVC/UW5'
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M<#K]?RK<S'U^;=L3'Y\?K7=3BXQLSEQ=6%6IS05D 4?V@6[G*Y_ 5'",0W1
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M)9ZB+73].EF,CZK+#8(5?H6(W\>F >?>NCTW0-6L[^5$810I&T:2!AM88PH
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M5A\"[1<?W?Y-7(76BZVVF6<63(4+9C$@RF>G.:EET;6SK%M+YI95"9E$G"X
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MSHLNX7.OF/\ I: ]]OZ;JCB/_$RD7/ W-^86N9N-&UMM5MI//WA53]Z).$P
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M>YK6%1QBTNI#C=IFK1116184444 <'\-_P#D!:]_V%[K_P!EJU\+/^1 L_\
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MUKI+K6-1T[5X=*DN/,:]6#[%*Z+N.&Q/D  '"_-^- '74444#"BBB@ HHHH
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M84444 %4Q_R&F_Z]A_Z$:N53'_(:;_KV'_H1JHDLN=Z*.]%24%%%% !1110
M44A. 2!D^E>(^,?B]XBTZ_N]*M]*CTN>)BOF3'S7QV9>-O/T(H ]OHKS'X/2
MZQK%EJ&OZQJ-S=M,XMX1*_RJ%Y8@=!DD#@=J].H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@">/[@IU-C^X*=4@-D^X:@J
M>3[AJ"F@"N(^&*C^R=:D_B?6;HG_ +Z%=O7$?#$_\2K6U]-:NOYBF([>BBB@
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!3U73+?6=+N-.N_,^SW";'\MRAQZ9%36EI;V-G#:6L2PV\*!(XU& JCH
M!4U% '':UX1N(-1?7O"LZV.K'F>!O]1>#.<..Q_VA_\ 7K0\-^*X-<,MG<Q&
MQUFWXNK"4_,A]5_O*>Q%=#7/^(_"5EX@\NY$CV>J6_-M?P<21'_V8>QH$=!1
M7%Z7XMO-+U&+0_%T4=M>.=MM?H"+>['U_A;CD'].*[0=*!A1110 4444 %%%
M% &==_\ (:T[Z2?^@UHUG7?_ "&M.^DG_H-:-5+H2NH4445)04444 %%%1W$
MRVUM+.^=D:%VQUP!F@"2BJ]A>PZEIUM?6^[R;B)94W#!VL,C/YU8H **** "
MBBB@ JF/^0TW_7L/_0C5RJ8_Y#3?]>P_]"-5$EESO11WHJ2@HHHH ***H:QK
M%IHFGM>7;-M!"I&@R\KG@*H[DT -UO6[/0-.:\O&;&0D<:#+RN>B*.Y-<%K?
MP]U#QII=UJ>LS"WUJ10;*W#?N[5!R(V(^\3GD]CTKI]&T2[O-17Q!KZK]OP1
M:6@.Y+%#V'JY[M^ XKIZ!&+X2T-?#GA73]*"@/#$/-QWD/+'\R:VJ**!A111
M0 4444 %%%% !1144]Q%:PM--(J1J,EF- $M%9 UMYQFRTVZN%_O,!&I^F>:
M7^W! 0+ZRN;4'^-EWH/J1TJN5BNC6HIJNKJ&1@RD9!!R#^-.J1A1110 4444
M %%%% !1110 4444 3Q_<%.IL?W!3JD!LGW#4%3R?<-04T 5PWPSXLO$"_W=
M;N1^HKN:X;X=Y2^\818P$UZ? ]B :8CN:***!A1110 4444 %%%-D=(HVD<A
M54$DGL!0 /(D:%W8*HZEC@"LMO$FE*S*+DOM."4C9A^8%0VULVMC[9J )M6.
M;>V/"A>S-ZDU#JGC/PMX;NX].U'5[2SGVC;"<_*.V<#Y1]<56BW)NS7L]2L[
M\9M;A)/4 X(_ \U;K.N--L=25+J/:)2 T=S"<-[$$=12:5>32--979!NK; 9
MAP)%/(8"BRZ#N:5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"EJNDV&MZ?)8ZE:QW-M(,%''ZCT/O7%BYUCX>,$O#/JWAD8"W."UQ9#T<?
MQ(/7M^0/H-! (P>E BO97UKJ-G'=V5Q'/;RC*21L""*L5Q-_X6U#P_(^H^#'
M6++&2XTF4Y@N/]S/^K;Z8'2MKPYXGL_$=O+Y<<EM>V[;+FRG&)86]QW'H: -
MRBC.:*!A1110!G7?_(:T[Z2?^@UHUG7?_(:T[Z2?^@UHU4NA*ZA1114E!111
M0 5G:^VSP[J;_P!VTE/_ (X:T:R/%;^7X/UM_P"[83G_ ,AM0 >%1CPCHP]+
M&$?^."M>LSPXNWPQI*^EG%_Z *TZ "BBB@ HHHH *IC_ )#3?]>P_P#0C5RJ
M8_Y#3?\ 7L/_ $(U4267.]%'>BI*"BBJFHZC;Z7:&XN"V"0B(HRTCGHJCN2:
M $U34[;2+%[N[8A!PJJ,L['HJCN3V%9.EZ3=7FHKKFMH!> $6EH#N2S4_P W
M(ZGMT%3Z=ID]S=IJVL ->+DV]N#E+12,8'9GQU;\!@5MT""BBB@84444 %%%
M% !1110 4444 %8=O$-:U"2[G^>SMW*6\79F'5SZ^U;;9*G:<-CCZUE^'"IT
M*W"]1N#?7)S5+:Y+W(?$GBC3?"]G#/?><\D\GE6]O;QF269_15'6KNEWO]L:
M1%=2V%S:>>IW6UVFV11G&&'.*\[^)$4,'CCPSJFK7EW9:+''/$]Y;,5,$I'&
M6 )7(XR.>*U_A??ZAJ&EZH\]Y=WVFI?.FG75WDR20CN2>2,]S4]1G06RG1]5
M2R4G[%<Y,(/_ "R<=5'L>M;=9&N8+:<B_P"M-VA7Z '/Z5KU3$@HHHJ2@HHH
MH **** "BBB@ HHHH GC^X*=38_N"G5(#9/N&H*GD^X:@IH KB/!^;;QMXUL
MCT%Y%<X_ZZ1@_P!*[>N&T/,/Q>\6Q-_R\6=E,GT52A_6F([FBBB@84444 %%
M%% !65XD9E\/7I7KY?\ 45JU#=VR7EI+;2?<D4J::W$Q\("01JOW0H KS;QA
M;:=%=ZCH&@:='=^)/$(S<LY+B"+&TRN3]T '@#J?U[?1[YF4Z?=_)>6XVL#_
M !J.C#VK#U3X7>%-8U>XU6\L9WO+DAI9$NI4SP!T# =J&M1(Z'0M*70]!L-*
M21I%M($A#MU;:,9JO-\OBVUV_P 5HX;'H&&*L6-E8>'=%AM(,P65JFU?,<M@
M9[DDD]:KZ6KWUY+JTBE4=1';*W41CN?J::[@S8HHHJ2@HHHH **** "L.]\7
MZ+97+6INS/<J<&"VC:5Q_P!\@X_&J/B6ZO-0U.'P]83-;^9'YUW<(?F2+.-H
M]"W//I5W3M,L]+M5M[.!8HU'8?,WN3U)H(<BM_PFMM_T"-:_\ C_ (T?\)K;
M?] ?6O\ P"/^-:9D4, 7 )Z GK2Y^M%Q<S,O_A-;;_H#ZU_X!'_&C_A-;;_H
M#ZU_X!'_ !K0GN(;:!YYYDCA099W;"@>YI4FCD9U216,;;7 .=IZX/IU%%PY
MF9W_  FMM_T!]:_\ C_C1_PFMM_T!]:_\ C_ (UJ$X&2<"FI(DB[D=6'JIS1
M<.9F:/&MIGYM*UE%[L;)L#\JT=,\1Z1J\IALKU'G R86!1QZ_*V#3\\D9SC@
MUEZQH5KJ\/S9AND.Z&YB^5XV[<^GM1<.9G345A>%]6N-0M)[6_Q_:%A)Y%PR
M]).,AQ[$?UK=H+04444#"N;\1>$HM7NHM4L;AM/UNW'[F\C_ (A_==>C+]?_
M *U=)10!S&C>)Y_M:Z/XA@6RU8#",#^ZNA_>C/\ 0\UT]4=5TBRUFS-M>PB1
M,Y5APR'U4]0:QK>[U#PVZVNJNUWIV=L5]CYHQV$G^- CIZ*:CK+&LB,&1AD$
M'((IU S.N_\ D-:=])/_ $&M&LZ[_P"0UIWTD_\ 0:T:J70E=0HHHJ2@HHHH
M *PO&AV^!=?/_4.G'_D-JW:XSQIK$LNB:SHUOHNLSSRVSPQRPV3O$S,G&&';
MF@#H]"&WP_IJ^EK%_P"@"M"N<\/:]'<PV>G-INK6\R0*I:YL9(T!50"-Q&*Z
M.@ HHHH **** "J8_P"0TW_7L/\ T(U<JF/^0TW_ %[#_P!"-5$EESO10:BN
M;B.U@::4D(/09)/8 =R>F*DH9>7D%A:M<7#%8U(& I8L2<!0!R22< "J%A97
M%U=KJFI*5F (M[;.5MU.,Y]7/<]AP.Y,EM9275TFH7ZCS$_X]X#@B 'N?5SW
M/;H.Y.G0 4444 %%%% !1110 4444 %%%% !1110 5A;FT*_E9U)TVX;>749
M\ESUS[&MVD8*RE6 *GJ".#33$R/]Q>0#_5S1.,]F4TDTUO8VQDE=(88QWX '
MI5"3P]8,Y>,36Y;DB"4H/RZ4L&@6$,HE99)W7H9Y"^/P/%.R%J0V*RZGJ0U2
M:-HX(U*VT;#!.>KGZ]JVJ**38T@HHHI#"BBB@ HHHH **** "BBB@">/[@IU
M-C^X*=4@-D^X:@J>3[AJ"F@"N&7%I\;6!'_']HHQ_P  DKN:X7Q)BQ^*'A"^
M'_+VES9-_P!\AQ^N:8CNJ***!A1167::_97FOW^BQ>9]LLD1YLKA</TP>] &
MI16;K^MV_AW0[K5KJ.22"V7<Z1 %B,@<9('>I-1U2'3-(FU*:.:2&*/S"D$9
M=R/91U- %ZBL:P\26FH>(KS18HIUN+2WBN':10%*R= .<Y'?(%%_XFT[3+F_
MBO/M,26-J+J><P,8Q&<]& .3QT% %Z^TVWOU7S599$.4EC.UU^AJE]AUF/Y8
MM6C9!P#+ "P'N0>:EAUVTN+^TM(5N'-W;?:8I1"WE[..K'H>>AK3S5)LEHR8
M]%,LBRZE=/>.IRJ%=L8_X#W_ !K5  & ,"EHI-W&@HK$UWQ-;:%>:?9-:W5Y
M>:A(R006RJ6.T99B6(  'O6WVI#"BBL75/$UII.N6&E30SM->Q2RQL@&T"-=
MQSD^G3B@#:HK-T#6H/$6A6FK6L<D<%TF]$E # 9QS@D=O6M*@#D-,Y\7^)"_
M^L$L*C_=\OBMVL+Q#'-HFM+XBAA:6S>(0W\<0)8 'Y9 .^.A]JUK.\MK^U2X
MM)DFA<95U.:3,GN<KY>DS7OB-]<,&^*8 /,1OBA\M=I3/(YSC;_%[U-)JVH+
MKO\ 9-O([O'_ *8=Z?,]L(\!>G4R\'O722V5I/,DLUK!++']QWB#,OT)'%0P
MZ<(]6N-0>9I))$6)%*@")!S@>I)))/T]* .2U.ZDN?!]S*^LK=O<:>)GMRJ9
M5MR\KM ( )(P<_7BKLM]?RZU'9PWK6\<FI/$S1QIG8+<,!RI[]^:Z1=/LD$P
M6RME$W^MQ"HW_P"]QS^-2?9X-X?R(MX;<&V#(;&,Y]<<9]* ,"*ZN+OP3J#W
M4OFRI'<Q&0J%+!2R@D 8S@#I5+3(;6/6=)MM/1(TETQ_MJ6V% !";"VW&&SO
MP>O7%=<(81$T0A01MG<@4;3GKD>]1VUE:62%+2U@MT/)6&((#^  H$8GA6VB
MLY=;MH%*Q1ZB54%BV!Y4?<\GZFNAI%CCC9RD:H7;<Q5<;CTR?? %4=7UFST6
MT\^[DP3PD:\O(W8*.YH @TKY?'>IK%C8UE"TI']_<P'Z5U-<[X5TVZMX[S4[
M]!'>ZC()6B_YY(!A4/N!G/UK=%S ;HVPFC-P$WF(,-P7.,XZXS3-%L2T444%
M!1110 4CHLB%'4,I&"",@BEHH Q5L)]'D,FG@R6K'+VI/W?=#_2M2VNHKN(2
M1-QW!ZJ?0U-5>2U_>^="0DG?T;ZTQ%:[_P"0UIWTD_\ 0:T:S+ABVM:=D8($
MF1_P&M.JET$NH5G:KK=II")YQ:2:3B*"(;G?Z#T]ZNSS);P232MMCC4NQ] !
MDURVBQR7F_6;Q0US=<QY'^JB_A4>G')KDKU>166YK"-]63C6/$%R-T&E6MLO
M874Y+'\%''YT?;_$_P#SPTG_ +[DK1HKB]K4[FMH]C.^W^)_^>&D_P#?<E'V
M_P 3_P#/#2?^^Y*T:*/:U.X[1[&=]O\ $_\ SPTK_ON2C[?XG_YX:3_WW)6C
M11[6IW"T>QG?;_$__/#2?^^Y*7^V-?M1ON-+M;I.XM9B&'X,.?SK0HH]K4[B
MM'L/TK6[/5T<0,R31G$L$HVO&?<5I5R6LVSP,FL60"WMJ"Q(_P"6L?\ $I]>
M.E=/:745[:174))BF0.N>N",UVT*KFK/<RG&VJ)JIC_D--_U[#_T(U<JB6"Z
MRQ/_ #[#_P!"-=2,F7))%B3>YPHQVJK%;M-.MS<@;E_U4741^Y_VOY=!W)G$
M9>022=1]Q>R^_P!:EJ1A1110,**** "BBB@ HJ*"Y@ND9[>:.558HQC8, PZ
MCCN*EH **** "BBB@#SZ#XA#3;WQ VMB1[6TUB/3[86T.Y@'7(R,Y//IS[&E
MU?X@PW&D"YTPWEE/::M:VMY#<VV)51VY&S!^\O3'-5[WX>:G<W6HRI=68%UX
M@M]40%FXCCZJ?E^]Z=O>K5WX&U&XUO5KU;BU$=YJEC>H"S95(/O _+U/;^E
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M]S&<KZ+8*IC_ )#3?]>P_P#0C5RJ8_Y#3?\ 7L/_ $(UTHR9<HHHJ2@HHHH
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MFB))J>GR8@6QT]2UO L?S+)@KG/3 4D 8[TS[)XG_P"?_3?^_+4?9/$__/\
MZ;_WY:BT_P"5CLNY>_LC3_[1^W_8X?M?_/7;SG&,_7'&>M7JP_LGB?\ Y_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1113$%0WC^793O_=C8_I4U
M9OB"7R/#>J39QY=I*WY(30!-I3^;I-I)_?A5OS%7*S/#K;_#.EO_ 'K2(_\
MCHK3H **** "BBB@ HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ9/)IV%<EHJC_:#2C_1K:1_]IAM7]:BEFN<9GNXK<>B<G\S3Y6+F1I$@#)(
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M (5NZ7JEKK&FPW]G)O@E7(/<'N#[@\4"+M%%% PHHHH **** "BBB@ HHHH
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M!_,?Y'9T$9&#@@T 5K"_M=3LXKNRF6:"095E.?P^O^%6:Y.]T*^T.]EU3PT
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M?NZ9<-_P./\ ^*J!%VBLQM1U ?=T2Y/_ &VB_P#BJ@?5M6'W?#ERW_;S#_\
M%4 ;5!X&3P!WKGVUK71]WPI=-_V]PC_V:LW6==U]M%OT;PE=1HUO(#(;V#Y1
MM.3C=DXI7'8[*BOGCP3XV\76MU%I^G1RZM%G)M9 7*K[-U4?7@>E?0%E-//9
MQ2W-L;:9U!>$N'V'TR.#^%"=P:L3T444Q!55M0LAJ T\W4 O6C\T6_F#>4SC
M=MZXSWJT>AKPR;69+KQF?&4>GZF8X-36W6[6+-L+-<Q/EMW4L2W2DW8:5SVL
MP/"YDMF",>J'[K4D;%IF>V_<7(Y>%ONM_GUKRO5/%&OVI\2ZE%X@VC2]62W@
ML&AC*RHQ7Y2<;NYQ@]C^#M<\2ZTR>(M4CUA+3^QK];:WT[RD/FKQRQ/S9;/&
M#V[T7'8];VV>J Q7=JAE0<I(H)'N#Z4R#1-'AN"([2#S5YVM\Q'X'I7DNI>(
MO$,=_P"+;\>(_L;:*(7MK1X(B'W(&*'(SR>..Y_"B_UC4-(\4>*/$-O>2K>+
MHUM<+;2A"@+\8(VY*IG/7/')-3=]"T>V  # P!Z"HKN[M["TEN[N>."WB7=)
M+*P54'J2>E>9)XBUW3-1O=/'B.UU(/HAOX[JY2.-;:7( W% !L.>,_G67+XE
MUL>&O$MMJ=W=&\AT@72VVH6EO(I)(!='3*/'_LLOXFI&>RHZR1K(C!D895E.
M01ZTZO(=<\4>(+"Y>=-1F@TNUL;5V>PB@E%NS*-QN(FP^T]MA'%>M02"6WBD
M#!PR!MP& <CK0,DHHHH **** "BBB@ HHHH **** "BBB@">/[@IU-C^X*=4
M@-D^X:@J>3[AJ"F@"BBBF 4444 %%%% !1110 5B:SX9L]7=;E6>TU"/F*[@
M.UU/;/J/8UMT4 <@->UGPZWE>(;5KFT! &HVJ< ?[:]O\]:Z:QO[34K5;BSN
M(YX3_$AS^!]#5@J&!! (/!!KG[CP?8-=->:?+<:;=,=Q>T?:K'W7H1[4".AH
MKFI+GQ3I9)>VMM6MU_CA_=2GZKR/RJ6U\9:3-*(;AIK&<\>7=Q&/GZ]*!G04
M4R*6.9-\4B2*>C(P8?F*?0 4444 %%%% $4\,-U;2V\Z++#*I1T;D,I'(/MB
MJ9T'23!8P'3X/+L&#6B[/]20,#;Z5P^KS:G:_%NXEBU+$4>@27"0&,%>&/R]
M>3N&<]>U-L/&VK7-KX,D:6 OJUG<S76$'+)&67'IR*!';KX;T-=6.K+I-F-0
M/)N1$-^?7/K[U&/"N@)J?]I+H]DM[YOG?:%B ??C&[/KUK@-'\6>+M1C\).V
MHZ<!KT<H;-D?W)09W##\D_@/:K5MXRU^]&B:4MQ90WM]?7EK-?- =H6 D JF
M[&YN.^* .SC\(^'8=0%]'HEBEV)O/$RP@,)/[V?6I5\/Z%::E)K(TRQBO,%G
MNA$JL/4Y_F:\^/CGQ+=PZ;96T]A%?2:[+I,ESY!>*157(<+NSGVSVK8^*L5[
M_P *QND-XH<"%+DK$,39=0<#/R@GGOZ4 :L%OX'GMKK5[?\ L5[=+A;FXNHW
M0HLJ]'9@< C/7WK270- ;4AKBZ98F\(WB\$2[CQ][=_6O,/%$\FG:7XN\.1Q
M6:6L&@PW):WM4A+R,V"3M]J37?%GB+0M.GL#=V5V8M*@OX9(X-@CRX38PW'(
M[B@#OY]&TB[M9HCI]O#IKW'VJ7*X\V7.=_UR!S4]WIUKK-I]DO;.-]/XQ;R)
MG=CH3Z5QLFJ^)I]?TK1+B_T^"XN+.2]:<6I** 0%15+<D9Y))X]*JIXU\0WV
MAZ9>10QHK^>MY)9P">3,;%0R1%P2AQR1DBM+HSLV=R/#VBKI@TI=,M%LMP<6
MRQ@*2""#CU! K4KS&'7Y;_Q-HVHP&PN;F70;F6.XVM$A8.,##-\HR,'/3GFM
MGP7XDU'5=2N+#5I@MW';),UL]H860DX)5@S*Z>A'-%Q-':T444Q%'5-'T[6K
M1K74;.&YB/:1<D>X/4'Z5)IFG6^D:;;Z?:!A;P+LC#-D@>F>]6J* "BBB@ H
MIID1>KJ/J:9]IBS@-N/L,T 2T5%YI/W8G/UXI09B?NJ/QS0!)7FOC3P[=66I
M2ZSI]NTUE/\ -=QQC+1N/^6@'<$8SCOS7H-Y:+>V%Q:SR%8IXFC<KP0K#!P?
MQKS[_A([[P=]I\/7OFWUZNTZ7*<GS48X ?W!_/I71AW-2O#<I*^QRL-U!<+N
MBE1A['I4NY3W'-:>O>'-,TS38X[VV&H^*M3?"KO8!&8\G"XX&>_\AQ%I7@_2
M-,U=]$\36J^==(&M+U)652<<J.<9SZC^=>JL2FFUK_70KD[,H[EQU'YT;AZC
M\ZORP:9X,NKO1]7T2VOV*;]-N&@4M+DX"O\ 0]_;W%)J?A?3-&T1#?V"77B+
M5&VV]I$2B0L?15(X&?S_ !I?6M+M"Y-+E'*^HJ&6\MX2%>5=QX"CEB?0 5J:
M9X0TC2M7_L;Q/:*7NXU:UO$D9%#8Y3KC(/K_ %JY;W<'PXU"ZTVZT^&XW1F7
M3;M8 ))"3]QV')P>_P#B,$L0T[15^P^36Q:\/Z$UE;SZSK>RTG>%XK*UF8!U
M!'+$?WCTQV%;W@Z:.QTZ2*ZD2!Y)OD64[2WRCIGK7-:OIMI9Z.VJ>)D;4->O
M^+:T#L I/W5 4@X'?\JI:?X4M=/U>&S\7PB5;Z!5MKGS7"PR#_EGG.._?T'K
M7'.*FF^:[_K8KE5K)GK]0SW=M:[?M%Q%%O.%\QPN3[9KS[^W;KX>SR:/J)EO
MK)XFDTV8G+_]<V_$U5U73K2UT=]9\5(U]K5]Q;60D9=A/W550<X'&?3IUY.$
M:*WD].GF0H]6>E37MK;;!/<PQ>8<)O<#<?;UJ>O'++PS:Z/J=I;^,+430WL(
M6*X$S[;=_P"X2#COU_\ KU[&/2HJTU!JSNF*4;!1116)(4444 %17%O'=6LM
MO*"8Y4*. <<$8-2T4 4=+T;3M$M!;:;9PVT0[(O)]R>I/UJ]110 45DVGB&R
MO+J*!$N$,Q<0R20E4E*]=I[]":TTECD *2*P.>ASTH <Z+(C(XRK#!'J*I)H
MVF1Z0=)2Q@73RA0VP7Y"IY(Q5OS8RP4.NXC<!GMZ_2D\^+Y?WJ?,=J_,.3Z4
M <MI'@'2[#5=1O[NVM+N6>\-S;,\'S6XP %!.<XQUK:N/#NC7>I)J-QI=G+>
MI@K.\0+ CH<U<FNX((9Y7D&V!"\@')4 9Z5)YT8B65V"*V,;N.O;ZTM!ZG+6
MW@73CXEUC5]2M[2^-[/%- LL )@*)MZG.<]:V;[3-.>Y&HRV-J]XJ>2+B2(,
M5C;@CW&">*L-J=LNIKIP<O<E/,94&0B^K'MGM2WM_;65K//<./+A0O(JC<P7
MZ=?PHT"[*NDZ-I&B^;:Q:78PPW?#210*%ES_  L/Z=*MP>$_#UK9W5K!HUE'
M!=KMN(TB $@]#ZCVJ%I(;>W)=D>P;[V6_P!7_P#6S^56X;Y+22.WN)U:)_\
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JKT58VK_='Y4;5_NC\J+@5Z*L;5_NC\J-J_W1^5%P$C^X*=1C'2BD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm247121d3_s1aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $# E$# 2(  A$! Q$!_\0
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M:U% &3_PDFF^MW_X!3?_ !%'_"2:;ZW?_@%-_P#$5K44 9/_  DFF^MW_P"
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M 9/_  DFF^MW_P" 4W_Q%'_"2:;ZW?\ X!3?_$5K44 9/_"2:;ZW?_@%-_\
M$4?\))IOK=_^ 4W_ ,16M10!D_\ "2:;ZW?_ (!3?_$4?\))IOK=_P#@%-_\
M16M10!D_\))IOK=_^ 4W_P 11_PDFF^MW_X!3?\ Q%:U% &3_P ))IOK=_\
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M257,2[=PV'@UUE $%]_R#[G_ *Y-_(UE^$/^13TO_KUB_P#1:UJ7W_(/N?\
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M^S1]F3^])_WV: )J*A^S)_>D_P"^S1]F3^])_P!]F@#'UG_D8O#_ /UVE_\
M19K>KG=6B6/Q'H!!8_OI>K$_\LS714 07W_(/N?^N3?R-9?A#_D4]+_Z]8O_
M $6M:E]_R#[G_KDW\C67X0_Y%/2_^O6+_P!%K0!MT444 9WB#_D6M5_Z\YO_
M $ U'X9_Y%?3/^O:/_T$5)X@_P"1:U7_ *\YO_0#4?AG_D5],_Z]H_\ T$4
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M*F_Y[G_OD4>5-_SW/_?(H FHJ'RIO^>Y_P"^11Y4W_/<_P#?(H FHJ'RIO\
MGN?^^11Y4W_/<_\ ?(H FHJ'RIO^>Y_[Y%'E3?\ /<_]\B@":BH?*F_Y[G_O
MD4>5-_SW/_?(H Q]9_Y&+P__ -=I?_19K>KGM65U\1>']S[OWTW;_IF:Z&@"
M"^_Y!]S_ -<F_D:R_"'_ "*>E_\ 7K%_Z+6M2^_Y!]S_ -<F_D:R_"'_ "*>
ME_\ 7K%_Z+6@#;HHHH SO$'_ "+6J_\ 7G-_Z :C\,_\BOIG_7M'_P"@BI/$
M'_(M:K_UYS?^@&H_#/\ R*^F?]>T?_H(H U:P/&=G87WA>ZAU*Y%M:AD<R'D
M!E<%1COD@#'>M^L'Q9H][KNB2V-C=1P/(1N\P'# $'JI!!XZB@#G/#.A2W.N
MPZHVIW$PLUV!9;8Q':V\[03_  _-T_V5KO#-$LRPF5!(P+*A8;B!U(%<IX0T
M+Q/I;NVM:O#/&V,0H\DO0$???D=>@%4=:N8(/BEHT@L;YPEM/%//':R-&#)L
MV@L!CL?IB@#MOMMILED%U#LA.)6\P8C_ -X]OQI?MEMB$_:8<3_ZKYQ^\[_+
MZ_A7G]M>07[W5_:Z9>6EO;21K-:R6,BF6W1FR=I'SL3@\9.,5-)9WQ=46-PE
MZ/\ B7?Z*?\ 13YK/\W]SY"H[=,4 >@'I7@WBRZ>PO/%#W$<L>ZXTX,KS^<Q
M7<['!]PIXKW>3=Y;;<;L'&[IFOFS6TD?Q]+9VUUIMK;OJ5D)! ^^-G =M_S=
M0.010!Z!X0\07-AXU\0PW4,8M[[4(6"1L2T32Q!E/3D8&#[UZM7E/@W28X/'
MXO7MC$]]H\5U'%*[$0NK;6"@]!AACT!KU']]_L?K0!7UC_D"W_\ U[R?^@FK
ME4-6\W^QK[.S'V>3IG^Z:T* $HQ2T4 )BBEHH 3%&*6B@!,44M% "48I:*
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M^>FYHNBVFAV*VUJG7F21OO2-ZDTS1],M-%L5M;6-P.KN5^9V]2:T?-']U_\
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M1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T
M245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS
M1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T
M245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS
M1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T 245'YP_NO_WS1YP_NO\ ]\T
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MNBBB@#.\0?\ (M:K_P!><W_H!J/PS_R*^F?]>T?_ *"*D\0?\BUJO_7G-_Z
M:C\,_P#(KZ9_U[1_^@B@#5K&\5/J$?AVZ;2[RWL[OY0MQ.0%C&X;CSQG&<>^
M*V:YCX@VMU>^"=0M[*W>>X<)L1(A(V=PY53QD=10!0^'UW?W!U:.]UX:P(9@
ML<P:,@+EL8" =5V]>X-=HZ+(C(X!5A@@]Q7+^";NYNK>Z%S#JT;1E%_XF,2(
M2<'.W:3GWS75$XH YZ/PC:0VTL4-Q-&^%6VD4+NM47E53C& 2>N>M3-X9MFD
MMW,\N4&+CA?]*Y+?/Q_>);C')J(^)U-YJ%K':,9;>2**'=(%%PS@D 'M]T_E
M2-XIC4)F!0T?_'X/.'^CC>4]/F^8$=NE &](0(WR,C!R/6O"/"^LW#_$C5=9
M=HIT-I &@EMA$X5I=H5?5E]<<\^E>\$_+GVKRGPIIUI'\9M?DGM!'(MC#*GF
MS"4[F<Y8'MGTH ]6"@]A7 ?%27['IVDZA;QR27FGWR7BI$N28UXDR>PPV,GU
M%>@9'J*Q/$.AMK,(\BZ6VF"/$S-&'62)P-R,#V.!0!Q#>+(9(WCN]1O[?4;A
MKK9%YJA8"@)56P<<\8QUKT+2M-LK&SC-K:0PED!8H@!)QW-?/BV$>AW^N:<Y
M2^A6-H[>^NXB#F/:65".-R]<'J!7KGA/Q!JM_/:PZA+%YC+(D]N8]CQ.H!!^
MA!!_&O8Q-%.BI4^F_P!WE_5R-+ZG;[1Z#\J-H]!^5&1ZBC(]17CEAM'H/RHV
MCT'Y49'J*,CU% !M'H/RHVCT'Y49'J*,CU% !M'H/RHVCT'Y49'J*,CU% !M
M'H/RHVCT'Y49'J*,CU% !M'H/RHVCT'Y49'J*,CU% !M'H/RHVCT'Y49'J*,
MCU% !M'H/RHVCT'Y49'J*,CU% &+J"*?%.C@J#^YN>WM'4NLZUIN@Q0O?!@)
MG\N,1Q%RS8SC !]*COSGQ5H__7&Y_P#:=9WB_2[C4[S0TA2?RX[S=+)"Q5HU
MVD9R.E1-M*Z.C#0A.JHU'9:_DS9L-3L=0LENXE*1,Q4>=&8SGZ, :N,UNCJC
M>6&;[H.,FN%\;Z->2Z;9V%G9SWT8CF!E91-('(^4$N?E!Y^;DC  ZUC+HFKQ
MWNC7*:=<RW0M[99%NHEDBW)C.&SNB(Y.>Y]:S=22=K';#!4IQYU.U[Z>GS_,
M]+M]0TZZEN8X987:V?9-C'R-C.#^=3/);1Q^8WE!3T/'/TKRO5_#6IO=:NMO
MI4G.HK=.ZQJ1/#C[H!(W8;YMIX_&KAT2[@TO2#=:/<ZC;(LZ_8V10T+.04.W
M.   1UX!I*K+6Z-'@*%DU4WZ:7V3[V_KN=Y9ZSI=_HO]KPNGV':S^:Z;<!<@
MGGZ&J=EXKT*^2=DG6/R(S*ZSQF-@@_BPP!(]ZR_#>EWEO\-$T^XT_?<^5(K6
MDYV;\L?E)[9%8,>D:Q?6^I6L%CJ,6F-8R(+?4G5SYW5-AR6QD=SBAU)JVA,,
M)AY.:<MG9.ZV_KY'I$=Q:2)&RM$1(,IR/FID-[83M.(I8&,#[)<$?*< X/YU
MY-K6D:G>6R"Q\-W%H$@B,"I;)O!5R6RV<IW("]<Y/I6CJGA^\V:I#;:+(6-^
MET\BQ*PGB*_= )&XACNP:7MI=BUEU'K4W]._J>GGR1'O(CV8SNXQBC, (&(\
MD9'3IZUS7A'1I(?"LEEJ$<QCN'<^1<(H*(W\. 2 .IQVS7/1:!J5_I&JKJ5E
M=&6W@33[41,JR21HV2X+<$-\N1W"XJW.5EH<L<+3<I)ST3MZW[:_>>C(T$B;
MXQ&Z^JX(K-L=?TG4;B*"W<&26$SQAHRNY Q4D9'J.E8G@*SOK.QOENK)8$:4
M&-S;+ \GRX)9%) [<]ZQ;O0=8@\*Z/?Z?;2+J]CYD?E8^8I(2#^60:3J2LFD
M:0PE%U)4Y3ZI)]-4WK^3.^L[^QOH9IH-IBBE:)G*X&Y3@X)ZC/>IXY;65ML;
M0N>N%(-8]KX>\GP9'H7F*K?9_*>0H'&X\LVUN#SD\U2\,>"_^$=U*2[-[%/O
MB,>U;..(C)!SE1D].E6G+30Y94Z%IM2VV\S;DU33H]1_L\O&;KRFF,2C)"KC
M)..G4?6LN#QGH-Q),@\Z-H8C,XEM73Y00,C(YY(&.]*=(6W\<6][;62I'):S
M>?,BXW2%H\;CZX!_*HM)T);EM9N]5MV:2^N&3;)D$0H<(!Z#C=QZU-YWLC=4
M\,H\TKO1=5>[>O\ 7H;&GZKINJ%?L;I+F)9LA> I) S[Y4\>U1ZSK>F:#%"]
M\"!,^R,1Q%RS8SC !KEO#LFJ6>O6MM;Z4;;2KJ,R%6B8&-1N"@L>A&U#M/>0
M^E7/'MI=7 T>6WM+RX6"[\R06G$@7:1D'M1SRY&UN4L+36)C3;]U^:\]^FZ-
MJS\0:3>Z;<7\3XAM@3,)(BC)@9Y4C/3\ZLZ5J-AK6GQWUB5DMW) 8I@Y!P00
M>1R*\_33=<NM-OX;:SNH8M0O(57[=\TJJHRYD(.=GR@ 9[GUKI/"MMJFEZEJ
M=A?VZ>5(_P!JCG@4B(EL!E&>0<C/XFE&I)M)HJOA*,*<I1GJGHK]-+_B^_0Z
MGRX_[B_E2^5'_<7\J4=*6MSRAOE1_P!Q?RH\J/\ N+^5.HH ;Y4?]Q?RH\J/
M^XOY4ZB@!OE1_P!Q?RH\J/\ N+^5.HH HZI&@TF\PBC]P_0?[)J[M7T%5=4_
MY!-Y_P!<'_\ 035K(]10 ;1Z#\J-H]!^5&1ZBC(]10 ;1Z#\J-H]!^5&1ZBC
M(]10 ;1Z#\J-H]!^5&1ZBC(]10 ;1Z#\J-H]!^5&1ZBC(]10!@ZR /$7A_ _
MY;2_^BS6_6!K)_XJ+P__ -=I?_19K?H @OO^0?<_]<F_D:R_"'_(IZ7_ ->L
M7_HM:U+[_D'W/_7)OY&LOPA_R*>E_P#7K%_Z+6@#;HHHH SO$'_(M:K_ -><
MW_H!J/PS_P BOIG_ %[1_P#H(J3Q!_R+6J_]><W_ * :C\,_\BOIG_7M'_Z"
M* -6L'QC/9VWAFYEOI+N. ,G-H,R%MXV@#ODX'/'K6]7+^,;^\MELK;3IW%U
M<,Y$*PI)YB*,L?G( P.?4T 4OA\=,8ZH=/M+VVD,B_:1=E-TD@+AGPK'!+!L
M]!P,5V<D8EC9&SM8$'!Q6%X6MY5LVOWU"*]6^5)TD2U6$D$=3CJ2"*WF8*"3
MT R: ..@\!1Z=+=S:?>S&5C"]H+N1YEA>,, 2"<D?-[5:?PD7E1S+!_I QJ.
M8S^^^<R?)S\OSL>N>#5]?$MHXN (;H2Q*&6(Q8>52<*4'<$@CMTIY\0V@6V8
MQSXF^]^[_P!3SC]Y_=YX^M &E+&LD+QNH9&4A@>A![5XYX/\/:+>?%?6T?2]
M.\JTLX'A2V<ND;[SSD]&XKV8]#7F?A"=KCXO>)G:>6<BPMUW20B(\,W&!V]^
M] 'H_P!EA)SY:UD:UJ,&DJ^VQ>9U@>=BI4!%7N<D5N9KB?'%I=ZGJ>F:9I\_
MER7@>.YRN0+<$%C[<X'OFNC#0C.JE+;_ "$SC9/"8U/X>75Y.UQ#JEI+_:#P
MO(!$[GY^!VRAV]JU;)=*U%X/%/A.6>\U!$'FVMTS SP]& #8Y'8CC(Q78S>'
M9[C1[^VFNUDN+ATD5Q'M52F-H(]/E&:XA;'5O ^M+KUU8A/#<9E:6TMF\U[1
MY<;Y%P 3&2,[>HSFMIXJ2JRE!Z/ITUW06/0+#5]#U&SAN8;BW"R#[CN%93W!
M!Z$'C%:8M8#_ ,LUKQU[7?ICS:"$GFOW,TMM+;[EERY(D1^JY&/;Z5Z!:^,K
M2VGAL-:MYM*NV "BX \MST^5QQ^>*JO@[+FI:KMU!,Z/[)!_SR6C[)!_SR6I
M%<,H92"",@CH:7->>,B^R0?\\EH^R0?\\EJ7--DE2)2TCJBCJ6.!0 S[)!_S
MR6C[)!_SR6LZY\3Z-:9\W4(21V0[S^F:HGQQI+-M@2ZG;TBA)_GBK5.3V1//
M'N;_ -D@_P">2TGV6#_GDM81U[6+D?Z#H$P'9KEPGZ5%GQE<'[NG6P_%B/YT
M_9OJT+G70Z+[+!_SR6FM!;(,LJ*/4G%8BZ)KER,7VOR*#U6VC"?K2?\ "$:6
M[;KB6\N&[F6;_ 4<L>K"\NB-&:^T6W!,MW:+CL91G^=9S^)_#RMMC=IF](HF
M/]*NVWA;1;4@QZ?$2.[Y?^=:D<,4*[8HT1?11BCW%W#WSFSK\4W%GH.H3GU:
M+8OYFHWD\27'^HT6SMU/0S2[C^AKJ\4M',EL@Y7W.-L[?6(?%NF-JCVA5H+@
M(ENN,']WR3BNQK'O_P#D:M'_ .N-S_[)6S4-W=RDK!1112&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/50
M#I%Z#T,#_P#H)J;[+!_SR6HM4_Y!-Y_UP?\ ]!-6Z (?LD'_ #R6C[)!_P \
MEJ:B@"'[)!_SR6C[)!_SR6IJ* (?LD'_ #R6C[)!_P \EJ:B@"'[)!_SR6C[
M)!_SR6IJ* .=U:&./Q'H!1 #YLO3_KF:Z*L'6?\ D8O#_P#UVE_]%FMZ@""^
M_P"0?<_]<F_D:R_"'_(IZ7_UZQ?^BUK4OO\ D'W/_7)OY&LOPA_R*>E_]>L7
M_HM: -NBBB@#.\0?\BUJO_7G-_Z :C\,_P#(KZ9_U[1_^@BI/$'_ "+6J_\
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MCJ5^#/'>>%7N!]VYM99+24'Z@D?GFN!OM4UZVU"Y-U?BXFBD8'R]18KN'/(
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M>_\ ?2__ !-6([NVESY5Q$^.NUP<4_S8R0 ZY/H:5F!5_LY_^@C>_P#?2_\
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M_H(WO_?2_P#Q-7:B^TPBY%MYJ^>4W^7GG;G&<>F: *_]G/\ ]!&]_P"^E_\
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M8T^([DXPW\Z]8I"0 2>E3=KK^+_S)^M5OYF>/W'PAE?6H(!JK?9F@=FE6QC
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M,<?EJH9L< \U-'\$@55F\37X; ) 0<'\Z]<JCJVJVFBV$E[>NRQ(,D*I9C]
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MY4G@[6X/O6U52QU=N]_R_P A2J-NYY3-\,-834[:&/Q1JCVCHYFF,AS&PQM
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M;_T U'X9_P"17TS_ *]H_P#T$5)X@_Y%K5?^O.;_ - -1^&?^17TS_KVC_\
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M8U/1)+V.Z@MH%VQ+ ZL8@&;)EW$X+*5!VYKTVFK(DFX(ZL5.&P<X/I0!YO\
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M(&?;FL33K/Q3I^FVUF&T8B",1@YEYP,4 =/16%CQ5_U!O_(M&/%7_4&_\BT
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MK]EJFK#PDFL6,8N&O7%VEJ2\<8,4@SNQTY'-=%CQ5_U!O_(M&/%7_4&_\BT
M8G@FUO$O&M[NVEBCT6$Z? [])?FSN&>ORJG/N:P;$ZO<^*_%"BYN[=X9;B0?
M9Q]X((O)4DCIM+<=\FNYQXJ_Z@W_ )%J-;?Q(D[S)%H:R2 !W"R!FQTR>^*
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm247121d3_s1aimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $3 K8# 2(  A$! Q$!_\0
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M'N_]LZ9_T$K3_O\ +_C3AJVGLCNM_;%$QN82KA<],\UX-@>E:=C_ ,@'5_\
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M_P :\3N,?V78_P#;3_T*JG%..!3ZB>+:Z'N_]LZ9_P!!*T_[_+_C1_;.F?\
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M5I_W^7_&O",#THP/2CZA'^8/K;['N_\ ;.F?]!*T_P"_R_XT?VSIG_02M/\
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M2.))RZK@8PJ\<9YYS7/5I3<W'W]S.:BG[I>OQF6S'K;0_P#H(KJ-6\)V-O\
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M@OT]2<5:'B(&9)7MW)74?MG^L)., !<G)[=:5-<L98F6_P!-:Y\N>6: >;M
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M+_Z U>(5[?XH_P"19U'_ *]I?_0&KQ"O6P/P,\W%_$A<48HHS7><8449HS0
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M<?\ /9_SH^MU.R#ZK'N>8?\ "-ZW_P! F[_[]FC_ (1O6_\ H$W?_?LUZ?\
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M60/#1[GF'_"-ZW_T";O_ +]FC_A&]<_Z!5W_ -^C7I_VNX_Y[/\ G1]KN?\
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M10 5/%_Q[3_\!_G4%3Q?\>T__ ?YT 04444 %%%% !1110 4AZ'Z4M(>A^E
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MK,)2P&7*C;MV/NX/3(SFM+0]8EU2.[BNK3[)?64Y@N(1)O4' 8,K8&5*L".
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M?VU=_P#/.S_\ XO_ (FB\NWXA9=S.S1FM'^VKO\ YYV?_@'%_P#$T?VU=?\
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M11S!8S6_U,7X_P ZCS6NP78OR1_]\BDPO_/./_OD4<P[&3FC-:V%_P"><?\
MWR*,+_SSC_[Y%',*QDYHS6MA?^><?_?(HPO_ #SC_P"^11S!8R<U*W_'FG_7
M1OY"M'"_\\X_^^13L+Y0^1/O'^$4G(=C'S1FM;"_\\X_^^11A?\ GG'_ -\B
MGS"L9.:,UK87_GG'_P!\BC"_\\X_^^11S!8R<T9K6PO_ #SC_P"^11A?^><?
M_?(HY@L9.:FN?]=_P%?_ $$5H87_ )YQ_P#?(ISA=_\ JTZ#^$>E+F"QCYHS
M6MA?^><?_?(HPO\ SSC_ .^13Y@L9.:,UK87_GG'_P!\BC"_\\X_^^11S!8R
M<T9K6PO_ #SC_P"^11A?^><?_?(HY@L9.:>/]0?]\?RK3PO_ #SC_P"^12X7
M8?DCZ_W12<@L9&:,UK87_GG'_P!\BC"_\\X_^^13Y@L9.:,UK87_ )YQ_P#?
M(HPO_/./_OD4<P6,G-&:UL+_ ,\X_P#OD487_GG'_P!\BCF"QDYHS6MA?^><
M?_?(HPO_ #SC_P"^11S!8R<T9K6PO_/./_OD487_ )YQ_P#?(HY@L9\7^IG_
M -T?S%0YK84+M?Y$Z?W1ZTW"_P#/./\ [Y%+F"QDYHS6MA?^><?_ 'R*,+_S
MSC_[Y%/F"QDYHS6MA?\ GG'_ -\BC"_\\X_^^11S!8R<T9K6PO\ SSC_ .^1
M1A?^><?_ 'R*.8+&3FC-:V%_YYQ_]\BC"_\ /./_ +Y%',%C)S5BP_X_HOK5
M["_\\X_^^14D 7ST^1!SV44G+0+%^BBBL30R/%'_ "+.H_\ 7M+_ .@-7B%>
MW^*/^19U'_KVE_\ 0&KQ"O6P'P,\W&?$A:*2C-=YQBT4F:,T +24M)0!Z]X9
M_P"19TW_ *X+6K65X9_Y%G3?^N"UJUX,_B9[,/A04445)04444 %/7_5O^%,
MIZ_ZM_PH 91110 4444 %%%% !0:*#0 K??/UI*5OOGZTE !1110 4444 %%
M%% "GM]!24I[?04E !1110 4444 %%%% #F^X*;3F^X*;0 4444 %%%% !3O
M^6(_WC_2FT[_ )8C_>/]*3!#:***8!1110 4444 %.D^_P#@/Y4VG2??_ ?R
MH ;1110 4444 %%%% !2_P 'XTE+_!^- "4444 %%%% !1110 4444 %%%%
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MX4 ,HHHH *,T44 %%%% !0:*0T .;[Y^M)2M]\_6DH **** #M1110 4444
M*>WT%)2GM]!_*DH **** "BBB@ HHHH <WW!3:<WW!3: "BBB@ HHHH *=_R
MQ'^\?Z4VG?\ +$?[Q_I28(;1113 **** "BBB@ ITGW_ ,!_*FTZ3[_X#^5
M#:*** $"@,6QR>">Y'I2T44 %%%% !2_P?C24O\ !^- "4444 %%%% "%5)!
M(!(Z>U+110 4=Z** "BBB@!R?=?Z?UIM.3[K_3^M-I %%%%, IAAC:9)F0&5
M%95?N <9 ^N!^0I]% !0>3FBB@ I@BC69Y@BB5U"L^.2!G ^@R?S-/HH *D@
M_P!>GUJ.I(/]>GUH OT445D69'BC_D6=1_Z]I?\ T!J\0S7N7B-UC\/7[O$L
MJB"0E&) 8;#QQS7CW]HV?_0%L_\ OY-_\77J8)M1>AY^+7O+4SLBC(K1_M*S
M_P"@+:?]_)O_ (NC^TK/_H"VG_?R;_XNN_F?;\CCLNYG9%&16C_:5G_T!;3_
M +^3?_%T?VE9_P#0%M/^_DW_ ,71S/M^067<SLBC(K1_M*S_ .@+:?\ ?R;_
M .+H_M*S_P"@+:?]_)O_ (NCF?;\@LNYZ;X9_P"18TW_ *X+6K6+HMZ!H=AL
MMHD4P*0@+$+[#)S5_P"W-_SQC_7_ !KQ))\S/6@_=1;HJI]N;_GBGZ_XT?;F
M_P">*?K_ (U-F5<MT54^W-_SQ3]?\:/MS?\ /%/U_P :+,+ENGK_ *M_PJC]
MN;_GBGZ_XU*EXQAE;RT&-O'/K]:+,+DU%5/MS?\ /%/U_P :/MS?\\4_7_&B
MS"Y;HJI]N;_GBGZ_XT?;F_YXI^O^-%F%RW153[<W_/%/U_QH^W-_SQ3]?\:+
M,+EN@U4^W-_SQ3]?\:#?L!_J8_U_QHLPN7&^^WUI*K27S"1AY2<$^O\ C3?M
MS?\ /%/U_P :+,=RW153[<W_ #Q3]?\ &C[<W_/%/U_QHLQ7+=%5/MS?\\4_
M7_&C[<W_ #Q3]?\ &BS"Y;HJI]N;_GBGZ_XT?;F_YXQ_F?\ &BS"Y</]!_*D
MJJ]ZRD#RD/ [GT'O2?;F_P">*?K_ (T),+ENBJGVYO\ GBGZ_P"-'VYO^>*?
MK_C19A<MT54^W-_SQ3]?\:/MS?\ /%/U_P :+,+ENBJGVYO^>*?K_C1]N;_G
MBGZ_XT687+K?<6F_A59KTB)#Y2<Y]?\ &F_;F_YXI^O^-%F!;HJI]N;_ )XI
M^O\ C1]N;_GBGZ_XT687+=%5/MS?\\4_7_&C[<W_ #Q3]?\ &BS"Y;IY_P!2
M/]X_TJC]N;_GBGZ_XU(;UOLZMY2<N1CGT'O2LQW)Z*J?;F_YY1_K_C1]N;_G
MBGZ_XT[,5RW153[<W_/%/U_QH^W-_P \4_7_ !HLPN6Z*J?;F_YXI^O^-'VY
MO^>*?K_C19A<MTZ3[_X#^54OMS?\\4_7_&I)KPI)CRD/RCU]/K19A<GHJI]N
M;_GBGZ_XT?;F_P">*?K_ (T687+=%5/MS?\ /%/U_P :/MS?\\4_7_&BS"Y;
MHJI]N;_GBGZ_XT?;F_YXI^O^-%F%RW2_P'ZU3^W-_P \4_7_ !IWVUO*)\I/
MO8[^GUHLQW+-%5/MS?\ /%/U_P :/MS?\\4_7_&BS%<MT54^W-_SQ3]?\:/M
MS?\ /%/U_P :+,+ENBJGVYO^>*?K_C1]N;_GBGZ_XT687+=%5/MS?\\4_7_&
MC[<W_/%/U_QHLPN6Z*J?;F_YXI^O^-'VYO\ GBGZ_P"-%F%RZOW7^G]:;4$=
MXS1RGRD&U1QSSR/>H_MS?\\4_,_XTK,=RW153[<W_/%/U_QH^W-_SQ3]?\:=
MF*Y;HJI]N;_GBGZ_XT?;F_YXI^O^-%F%RW153[<W_/%/U_QH^W-_SQ3]?\:+
M,+ENBJGVYO\ GBGZ_P"-'VYO^>*?K_C19A<MU)!_KTJA]N;_ )XI^O\ C4UI
M>-)=1IY2#)ZC/^-)IC3-BBBBLBS(\4?\BSJ/_7M+_P"@-7B%>W^*/^19U'_K
MVE_] :O$*]; ? SS<9\2"BEHKO.,2BEHH 2BEHH ].T3_D :=_U[K5ZJ.B?\
M@#3O^O=:O5XLOB9Z\/A04445)04444 %3Q?\>L__  '^=05/%_Q[3_\  ?YT
M 04444 %%%% !1110 4AZ'Z4M(>A^E $DW^ND_WC_.F4^;_7R?[Q_G3* "BB
MB@ HHHH **** 'R=1_NK_(4RGR=1_NK_ "%,I(&%%%%, HHHH **** )&_U,
M7X_SJ.I&_P!3%^/\ZCH0PHHHH$%%%% !4Q_X\T_ZZ-_(5#4Q_P"/-/\ KHW\
MA28R&BBBF(**** "BBB@ J:Y_P!=_P !7_T$5#4US_KA_NK_ .@BEU AHHHI
M@%%%% !1110 4\?ZAO\ >%,IX_U#?[PI,!E%%%, HHHH **** "BBB@ HHHH
M FB_U,_^Z/YBH:FA_P!3/_NC^8J&D 4444P"BBB@ HHHH **** "K%A_Q_1?
M6J]6+#_C^B^II/8#H:***YS4R/%'_(LZC_U[2_\ H#5XA7M_BC_D6=1_Z]I?
M_0&KQ"O6P'P,\W&?$@JY%I6H3637D5G.]LN29%7CCK5,Y(('7M7=PVVH3ZUI
M&H69<:0D,1#!]J1HH^<,/7.:ZJM1PM8YX14MSA <BI(()KJ988(VDD;.%49)
MQ7:ZC#97$.F#3[*R8ZC=S+YLJ$942\<@@@8X]<<5?&G16M_I$WV6.&<S31,T
M<'DA@$;&%R>..">363Q*2V+5'7<\W!S]*6FI]T?2G5U&!Z=HG_( T[_KW6DU
M'6]*T=HUU/4K6S,N=@GE";L=<9ZTNB?\B_IW_7!:Y;Q-+I]IXCN[Z76'L]1@
MTD_9X)(4,<@WDC!=3N);:"JX/3GFO$GNSUX?"CJWU;3H]3BTQ[ZW%],F^.W,
M@WLO/('X'\CZ41ZMITNIRZ9'>P-?Q+ODMA("ZCCDC\1^8KAO$LXET?6K M''
MKUQJ%H]O;JX\T,5@V%>Y VOST&UJMZ'<6V[2+ 2QC5(M9NWN(LCS N9R[$==
MI#)SWW+[5-RSNJ*YC7(I;_Q5INFF]O+>VDL;J61;6<Q%F5X0IR.>-Q__ %9%
M8#ZE>V%K:ROJMXRWVC1WEW*[[C%^]A$DB#&$PDDG &. >HHN!Z-4\7_'M/\
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M_P"Z^7/KM !X&.>!3-.OM/EM[K5-0U#39+B]O(U4VA2:*P;:PAWL#C=R<N<
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MLB'^_)^8_P *.=!9F-16S_9$/]^3\Q_A1_9$/]^3\Q_A1SH+,QJFN?\ 6_\
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm247121d3_s1aimg004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &4 FT# 2(  A$! Q$!_\0
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M?^^J/-C_ +Z_]]4[ ]*,#TH ;YL?]]?^^J/-C_OK_P!]4[ ]*,#TH ;YL?\
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MH ;YL?\ ?7_OJCS8_P"^O_?5.P/2C ]* &^;'_?7_OJCS8_[Z_\ ?5.P/2C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,_V'_*@!]%,\S_8?\J/,_P!A_P J 'T4SS/]A_RH\S_8?\J 'T4SS/\ 8?\
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MN46WN&DRZ_-+F/;G!)Q@X'7M1%X:>))T8),"K+&TC29P7#] V%Z=1WP?J =
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MY!5G_P!<$_\ 015J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (I?]9#_OG_T$U+44O^LA_P!\_P#H)J6@ J.+^/\ WS4E1Q?Q_P"^
M: )**** "BBB@#E?$7_(37_KF/YFLS1/^1:U7_L)O_):T_$7_(37_KF/YFLS
M1/\ D6M5_P"PF_\ ): (]-_Y'/2O]R7_ -!JOKO_ !X7WT;^=6--_P"1STK_
M ')?_0:KZ[_QX7WT;^= &Y?W-U%9:=';W4D"_9D8^6!DG'N*F\'WUW>?VDMU
M</-Y,X1"^,@8]JJZC_Q[Z=_UZ1_RI_@?[^L?]?7]* .NHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HZQ:7%]I%S:VER;:>5"J3*2"A]0000??\
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MBB@"*7_60_[Y_P#034M12_ZR'_?/_H)J6@ J.+^/_?-25'%_'_OF@"2BBB@
MHHHH Y7Q%_R$U_ZYC^9K,T3_ )%K5?\ L)O_ "6M/Q%_R$U_ZYC^9K,T3_D6
MM5_[";_R6@"/3?\ D<]*_P!R7_T&J^N_\>%]]&_G5C3?^1STK_<E_P#0:KZ[
M_P >%]]&_G0!L:C_ ,>^G?\ 7I'_ "JEH)(TKQ!M8J3<@94X.#BKNH_\>^G?
M]>D?\JI:%_R"M?\ ^OI?Z4 5;"%+?Q5HXB!4.\FX9/.%KTBO.[;_ )&S1?\
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M%RS8_A%7TE,F=AB;'7#YKCKJ-)M!T1)%#J+.,[6&1G:*E\#*J7VM*H 421@
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M $4O^LA_WS_Z":EJ*7_60_[Y_P#034M !4<7\?\ OFI*CB_C_P!\T 24444
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M5RC7=N'!P5,HSFK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY@4= .._X4U="N#K%E=M(B);;R0.22PP*OW[HKWM!]]XAELS.RV.^*($EC*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQG!]:  R*IP6 /UI/-C_ +Z_G2J@4<?B?6G4 ,\V/^^OYT>;'_?7\Z?29!-
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MYL?]]?SI])F@!OFQ_P!]?SH\V/\ OK^=/SQ10 SS8_[Z_G1YL?\ ?7\Z?10
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M9?WBY0[94  !)RRN#TQZ[GC>=K3P?>7*"X+P-%*GV< L&612#@_P@@%O]G-
M$'@=Y3X&M&C^RR28EV>2V(F(D?&"!TZ9(!'<9&*Q_!5Y]O\ $]],I9H,7!B
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M/H><UG:)=R7?Q GW@#8\GFQ13RM''.(U5V :!1C@*/GQW R:VO >H3:KX?\
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M.?UKT0=*\S\)3F[^(>IO;?)91AU$)MA&T9X&TC^$<9![]:],'2@ H/%%!Z4
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MBC\+7:R%-S@;%:4H20P.5P021C< ""<<5RGBR<O\0M+L[,>5*&1I@UL/W@+
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M6]S:G'[F:(.G'3@\<5<HH A@M+>UM$M;:&.&WC78D4:A55?0 =!69HWA?2]
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MZ?K%K]FU*RMKR#<&\NXB$BY'0X/>K$,$5M"D,,:1Q1J%1$4*J@=  .@J2B@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (W4M)$0.%;)_(C^M2444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm247121d3_s1aimg005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &H MD# 2(  A$! Q$!_\0
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M)B]NG_Q- MO$O'^E1?DO_P 31[-?S(?.^QTM%<U]F\2?\_4?Y+_A1]G\2?\
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MO$,5T+Y/WMTYC1)0_EX0#[P++GDC&1C@5Z*+9%Z-+^,K?XTOV=/[TG_?QO\
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MU7_OH4>WI_R,+S_I$9\6<9\D\]L?_7H/BS!(\DY'H.#^M2?8=9_YZK_WT/\
M"C[#K/\ SU7_ +Z'^%'MZ?\ (PO,C_X2T=?);'?Y?_KT?\):<?ZH_39_]>I/
ML6L_\]5_[Z'^%'V'6?\ GHO_ 'T*/;T_Y&%YD?\ PE9S@1CZ[?\ Z]'_  E9
MS_JA@=3M_P#KU)]AUG_GHO\ WT*3[#K&<^8O_?0H]O3_ )&%YC[/Q&]Y=1VZ
MQA6D. 2O3]:W=MQ_STC_ ._9_P :P!8ZR#Q* ?\ >%.^R:[_ ,]__(E9RK)O
MW8M%*3ZHW@)^\D?_ 'P?\:,3?\]$_P"^/_KUA?9=>'_+?_Q\4?9M>_Y[_P#C
MXJ?:_P!U_<5S>3-W$W_/1/\ OC_Z]&)O^>B?]\?_ %ZPOLVO?\]__'Q1]FU[
M_GO_ ./BCVO]UAS>3-W$W_/1/^^/_KTN)N[I_P!\?_7K!^S:]_SW_P#'Q1]F
MU[_GN/\ OH4>U_NO[@YO)F]B7^^G_?/_ ->C$O\ ?3_OG_Z]87V?7O\ GN/^
M^A_A1]GU[_GN/^^A_A1[7^Z_N#F?8W<2_P!]/^^?_KT8E_OI_P!\_P#UZPOL
M^O?\]Q_WT/\ "C[/KW_/<?\ ?0_PH]K_ '7]P<S[&[B7^^G_ 'S_ /7IV)/[
MR_E_]>L#[/KP_P"6X_[Z'^%+Y&O?\]E_-?\ "CVO]UAS>3-[$G]Y?R_^O1B3
M^\OY?_7K!\C7O^>R_FO^%'D:]_SV7\U_PH]K_=8<WDS>Q)_>7\O_ *]&)/[R
M_E_]>L'R->_Y[+^:_P"%'D:__P ]E_-?\*/:_P!UAS>1O?-ZC\J,-ZC\JP?)
MU_\ Y[+^:_X4>3K_ /SV7\U_PI>U_NL?/Y&]AO4?E1AO4?E6#Y.O_P#/9?S7
M_"CR=?\ ^>R_FO\ A1[7^ZPY_(WOF]1^5)A_[R_E6%Y.O_\ /9?S7_"CR->_
MY[C\U_PH]K_=8<_D;N)/[R_]\_\ UZ,2?WE_[Y_^O6#Y&O?\]Q^8_P */(U[
M_GN/S'^%'M7_ "L7-Y,WL2?WE_[Y_P#KT8D_O+_WS_\ 7K!\C7O^>X_,?X4>
M1KW_ #W'YC_"CVK_ )6'-Y,WB)>S+_WS_P#7I,3?WT_[Y_\ KUA&WUX_\MQ_
MWT/\*/L^O?\ /?\ \>%/VO\ =8<WDS=Q-_?3_OG_ .O1B;^^G_?/_P!>L+[/
MKW_/?_QX4?9]>_Y[_P#CPH]K_=8<WDS=Q-_?3_OG_P"O01-CAT_[X/\ C6%]
MGU[_ )[_ /CPI#;:\?\ EO\ ^/BCVO\ =8<WDS<Q/_STC_[X/^-+B?\ YZ1_
M]\'_ !K!^S:[_P ]_P#Q\4?9M=_Y[_\ CXH]K_=8<S[,WL3_ //2/_O@_P"-
M&)_^>D?_ 'P?\:P?LVN_\]__ !\4?9M=_P">_P#X^*/:_P!UAS>3-[$__/2/
M_O@_XTFVY_YZQ?\ ?L__ !587V;7?^>__CXH^R:Y_P _!_[^4>U_NL.9]F;N
MVY_YZ1?]^S_\51MN?^>D7_?L_P#Q587V37/^?@_]_*/LFN?\_!_[^4>U_NL.
M9]F;NVY_YZ1?]^S_ /%4;;G_ )ZQ?]^S_P#%5A?9-<_Y^#_W\H^R:Y_S\'_O
MY1[7^ZPYGV9NXG[R1_\ ?!_QI<3_ -^/_O@_XUA"UUW_ )[_ /CXH^RZ[_SW
M_P#'Q1[7^ZPYO)F[B?\ OQ_]\'_&C$_]^/\ [X/^-87V77?^>_\ X^*/LNN_
M\]__ !\4>U_NL.;R9NXG_P">D?\ WP?\:4";NZ?]\G_&L'[+KO\ SW_\?% M
MM>'_ "\#_OH?X4>U_NL.;R9OXE_O)_WS_P#7HQ+_ 'D_[Y_^O6#]GU[_ )^!
M_P!]#_"C[/KW_/P/^^A_A1[7^ZQ\_D;V)?[R?]\__7HQ+_>3_OG_ .O6#]GU
M[_GX'_?0_P */L^O?\_ _P"^A_A1[7^ZPY_(WL2_WE_+_P"O1^\_V:PXH-<$
MJ%YQLW#=R.G?M6YL_P!IOSJXRYNEAIW#]Y_LT?O/]FC9_M-^=&S_ &F_.J&'
M[S_9H^?_ &:-G^TWYT;/]IOSH&.^;T'YT?-Z#\Z3;_M&C;_M&@!?F]!^='S>
M@_.DV_[1HV_[1H 7YO0?G3<R?W5_[Z_^M2[3_>--*-_SU?\ (?X4 +F7^ZO_
M 'U_]:C,O]U?^^O_ *U)Y;?\]7_(?X4>6W_/5_R'^% A<R_W5_[Z_P#K49E_
MNK_WU_\ 6I/+;_GJ_P"0_P */+;_ )ZO^0_PH (LYDW #YNQSV%25'$""X+%
MOFZGZ"I*!A4.90[[$1AGJS$=A[5-4:L SY(^]_04 -W7'_/*+_OX?\*QQX9T
MTZD-1.G0O>!MWG/.[,2"",D]<8&/3H.*W=R^H_.N3B\(W-N+MH/$%VLES<3S
MG);:OF2JX4!6!PJ@IUS\V>, 4"+C>%-+DA,+Z;$\90QE7N)"-I7:1ST^4 ?0
M*.@&)K;1+32Q?3V-E#;R70!G=96.[ .#R.V367_PBNL"=91XLNMWF!GW*W*A
MRVT .%'7&<=!BK^D:/>Z1#>?:M9GU)9(T6-)LXCVK@X)))+'DY- &%]C@W9^
MWC&.FQO\*/L5OC_D(#V^1N*M_P"E8_Y B9[\-_C1_I6?^0(F.W#?XUK?%=XG
M+;^M2F;&W(Q_: _[X:@V,''_ !,OK\C<U<S==]#3VX;_ !HS=<?\2-/?AO\
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M/\:?10(9O;_GDWYC_&C>W_/)OS'^-/HH 9O;_GDWYC_&C>W_ #R;\Q_C3Z*
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MG_?(J2B@"/[/#_SR3_OD4?9X?^>2?]\BI** (_L\/_/)/^^11]GA_P">2?\
M?(J2B@"/[/#_ ,\D_P"^11]GA_YY)_WR*DHH C^SP_\ /)/^^11Y$7_/-/\
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M44 -V+_=%&Q?[HIU% #=B_W11L7^Z*=10 R, &3 Q\W]!3Z8GWG_ -[^@I]
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MIQT5[^IK&-]69^GV%];7)DN;LRIMQM+L>?QK5HHI1BHJR-4K!1115#"BBB@
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M<OH__?!_PH\Y?1_^^#_A7GO_  M:+_H$/_W_ /\ [&C_ (6M%_T"'_[_ /\
M]C1]2K_R_B@^L4^YZ%YR^C_]\'_"CSE]'_[X/^%>>_\ "UHO^@0__?\ _P#L
M:/\ A:T7_0(?_O\ _P#V-'U*O_+^*#ZQ3[GH7G+Z/_WP?\*3SU]'_P"_;?X5
MY]_PM:+_ *!#_P#?\?\ Q-+_ ,+5@_Z!,G_?\?\ Q-'U*O\ R_D'MZ?<] \]
M?1_^_;?X4>>OH_\ W[;_  KS_P#X6M!_T"9/^_X_^)H_X6M!_P! F3_O^/\
MXFCZG7_E_(/;T^YZ!YZ^C_\ ?MO\*//7T?\ []M_A7G_ /PM:#_H$R?]_P ?
M_$T?\+5@_P"@3)_W_'_Q-'U.O_+^0>WI]ST#ST]'_P"^#_A2^>GH_P#WP?\
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M_P"_X_\ B:/J=?\ E_(/;T^YZ%YH]&_[X-'FCT;_ +X->>_\+6@_Z!,G_?\
M'_Q-'_"UH/\ H$R?]_Q_\31]3K_R_D'MZ?<]"\T>C?\ ?!H\T>C?]\&O/?\
MA:T'_0)D_P"_X_\ B:/^%K0?] F3_O\ C_XFCZG7_E_(/;T^YZ%Y@]&_[Y-'
MF#T;_ODURGASQNOB+47LXM/,+)$9-SS9!P0,=/>NHS/_ ,\H_P#OL_X5SU*<
MJ;Y9+4UC)25T/\P>C?\ ?)H\P>C?]\FF9G_YY1_]]G_"C,__ #RC_P"^S_A4
M%#_,'HW_ 'R:/-'HW_?)IF9O^>4?_?9_PI<S?\\T_P"^S_A0(=YH]&_[Y-'F
MCT;_ +Y--W3?\\T_[[/^%&Z;_GFG_?9_PH =YH]&_P"^31Y@]&_[Y--W3?\
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MCS!_A1YNC_\ /O=E2>GF#D?E1]2CWD'-Y_B;'VS4/^@K9?\ ?Q/\*/MFH?\
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M--SWW#_"C_A%=/\ [TV?7</\*/84?YI!RS_IE/[9J'_05LO^_B?X4"\U _\
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MF%]GU_\ Y^(__'?\*/L^O_\ /Q'_ .._X5NT4>R7=_>'(NYA?9]?_P"?B/\
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M&/*3_OFI:*@HC\B+.?+3/TJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP(F@D+!I$+JIP",D D8/..*FMO$FD:K*+.SO));F6U:Y2)HW4F,-M).X#')
MP>>_2M3[';^8K_8XMZC"MM7(Z?X#\A39+6"-))$M(T?RBF]54$+UQD=L\XH
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M[MG.?VAK^[_CU?;_ -<Z0:AX@[VC?]^ZZ3S7_P">$@_%?\:7S'_YXO\ F/\
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M_P#S\2?DO^%'E/\ \]Y/R7_"CS7_ .>$GYK_ (T>:_\ SQ?_ ,=_QH /*?\
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MX1N\_P"@K+^1_P#BJCVD._YCY9=OR,[,V1_Q3X_[]/Q1F;&/^$>'U\MZT/\
MA&KS_H*R?D?_ (JC_A&KO_H*R?D?_BJ/:0[_ )ARR[?D9^Z7K_PCO'_7)^:,
MR_\ 0O?3]T_%=5IUK)96:PR3&9@2=Y&,U;K-UM=OQ9:I^?Y'%?OL?\B\,_\
M7-Z,S?\ 0OC'IY;\^U=K12]OY?BQ^S\SBLS?]"\/^_3\5+;(TMS%%+H(1'<
MOY;C:/K7844G6\OQ8>S\S/\ [$TW_GSB_*KZJ$4*HP , 4M%8MM[FB26P444
M4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGQ3:<?(>?<_X4A\56@_A/Z_X4<LOY NOYAOV_6O^?5/^_P"E'V_6?^?5.?\
MING%6;7Q!!>72VT* R-G&20.!GTK3S<=HX_^_A_PJ9/E=G$:5]F87V_6?^?:
M,?\ ;9*UH9"T$;2W.R0J"RAE.#W'2I\W'_/./_OX?_B:,W'_ #SC_P"_A_\
MB:AROTL4E;J,W+_S^'\U_P *-R_\_A_-?\*?FX_YYQ_]_#_\31FX_P"><?\
MW\/_ ,34E#-R_P#/X?S7_"C*_P#/V?S7_"GYN/\ GG'_ -_#_A1FX_YYQ_\
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MYBC,O]Q?^^__ *U&9?[B_P#??_UJ #S$_P">X_,4F]/^?@?F*7,O]Q?^^_\
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MPHRO_/U^J_X4_>W_ #R?\Q_C1O;_ )Y/^8_QH 9E?^?K]5_PHRO_ #]?JO\
MA3][?\\G_,?XTN]O^>3_ )C_ !H 9Q_S\G_QW_"@$#_EX_/%/WM_SR?\Q_C1
MO;_GD_YC_&D S=_T\#]*-W_3P/TI^]O^>3_F/\:-[?\ /)_S'^- #<_]/ _2
MC/\ T\#]*=O;_GD_YC_&C>W_ #R?\Q_C0 W=_P!-P?RHW?\ 39?TIV]O^>3_
M )C_ !HWM_SR?\Q_C0 W=_TV7]*-W_3=?TIV]O\ GD_YC_&DWM_SR;\Q_C0
MF\?\]U_2C>/^>RT[>W_/)_S'^-&]O^>3_F/\: $\S_IK'_G\:/,'_/6/_/XT
MN]O^>3_F/\:3>W_/)OT_QH 3S5_Y[1_Y_&CS5_Y[1?Y_&EWG_GDWZ?XT;S_S
MR;]/\: $\T?\]HO\_C2>;_TWA_+_ .O3MY_YY-^G^-&\_P#/)OT_QH ;YO\
MTWA_+_Z])YH_Y^(?R_\ KT_>?^>3?I_C2[S_ ,\F_3_&@"/S1_S\0_E_]>CS
M1_S\0_E_]>I-Y_YY-^G^-&\_\\F_3_&@!(&#;R'5OFZKTZ"I:CB)._((^;H?
MH*DH&%1JRAGRP!W>OL*D[57)G$C^7'&RYZM(0>@]C0!-O3^\OYUD:]HD&N_V
M?YEP8_L5VMVN "'8*R[6!_A.[FM'==_\\8?^_I_^)HWW8_Y8P_\ ?T__ !-
MCE;3P4+2]ENO^$AU N\4,.[SB"%C=F'.>?OL,8QCMG)-[2M'ET@W#2:O<7R-
M;JBK<3L^'&=S<D]1LX[8/J:H:]X4UO6+F:2'6VMHI) X@+,44 1X V[6^]'D
M\_Q'&T\U>TG2-4TK^T)+W4C>K< LH9CB([G8[>O'SCCMCTP P,_-WC_D#6GO
M^[_^RH_TO(_XDUGCM^[Z?^/4SS;?_H*_^.2?X4>9;\?\37K_ +$G^%:>UK?\
M^_Q_X)R_UT';KO!!T>Q^FW_[*@M=_P#0(L3Z_)_]ES3?-@ S_:O_ (Y)_A3A
M);Y.=6Z>B.?Z4_:UO^??XA_707==9!_LBQ]CLZ?^/<4ADN0<'2;$'_<XS_WU
M2[[3(_XG!Y_Z9O1YEIG']L-_W[>E[6M_S[#^NA+9$S7<:7&FV4<).)'VX./^
M^O6MS[#HPQB.U&/0BN>\RTY_XF[<=?W3T![0D?\ $W;_ +]/42G7;T@U\RU*
MW3\CI8;;2[>420BV1QT*D#%6_M$'_/:/_OH5R.ZQQG^V7ZX_U+_XT;K'!/\
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M6JU6I:8[S$_OK^=+N7^\/SIF]O\ GD_YC_&C>W_/)_S'^-,!^Y?[P_.C<O\
M>'YU&9'!_P!2Y_$?XTGFO_SPD_-?\: )-Z#JR_G1YB?WU_.H_,?_ )X2?FO^
M-'FO_P \)/S7_&F!)YB?WU_.CS$'\:_G41F<?\N\A_%?\:3SI/\ GUE_-/\
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M/_+)?R%)Y,7_ #Q7_OD4 2\4<5%Y,7_/%?\ OD4GEQ?\\!^0H$34<5!Y,/\
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M?UJ?9R[%<Z[FMYD?]]?SH\R/^^OYUD_\)'I^2/FX_P!W_&C_ (2.PR1A^/\
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M[]'_  HV6_\ SP'_ 'Z/^% $J?>?_>_H*?44 0!]B!1NZ;<=A4M PIB?>?\
MWOZ"GTQ/O/\ [W]!0 ^BBB@ J*Y_X]I.-WRGCUXJ6HKC_CWDYV_*>?2@#B\1
M<?\ $@DZ?WY.*,19_P"0#)['?)3M]Y@'^W(<GMYSX'Z4![O<!_;L7/4^<_\
MA7H?UU.3^NA'MBVG_B0R8YYWR4$187_B0.,?[<E/#WA!/]NQ C_IJ_\ A2[K
ML_\ ,>C'I^^?_"G_ %]H/ZZ#<19/_$A?Z;Y.:,1;2/[!DZ?WY*=NN^O]O1>X
M\Y_\*-UWDC^WHMN.OG/G^5+^NH?UT&GRNO\ 8$OTWR<4F(LC_B0R'C^_)3_,
MO,9_MR'/8><_^%!>[&/^)[$<]?WK_P"%']?:#^NA'B+)_P")$_UWR4H$6T?\
M2%Q[[Y.*?NN\D'7HL^OG/_A1NN\?\AZ+/;]\_7\J?]?:#^N@W$>[/]@2?3?)
MS0!%S_Q(9/KODI^Z[S_R'HO?]\_^%)OO,@#78NF2?.?_  I?UU#^NA&1%C_D
M 2#V+R<4$1<?\2"3.>F^3FK-M#J5W(8X-9C=@,@"9^GJ>*M?V/KO4ZD.>H$K
M_IQ2<HK=_BQV;_I&;B($XT)SQUWR4 1;?^0"_7^_)Q6G_8VN=]3_ !\UO\*/
M['UW'.IX^DK?X4N>/=?>Q\K[?D4H(X);J&-M#D568*6+R< GK6__ ,(YI1Y^
MS?\ D1O\:HV^E:U'<Q22WX9%=2Z^:Q!&>>U=&.E8U)N_NO\ ,TA'NC)_X1O2
ML8^S'_OXW^-!\-Z4?^78_P#?QO\ &M:BLO:3[E\L>QE?\(YI>XG[-S_OM_C1
M_P (YI>"/LW7_IHW^-:M%'M)]PY8]C*_X1S2S_R[?^1&_P :/^$;TK_GV/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 8GWG_WOZ"GTQ/O/_O?T%/H
M*8GWG_WOZ"GTQ/O/_O?T% $&H:?!J5NL,^\!9%D1HV*LK*<@@CW%8G_"!Z"9
M$<V\I9) XS,W4#;CZ8X_^OS72T4 <R_@+P\[LQLR"R+&Q5L$J(_*P3UQMX_7
MK5BQ\,:7H1OKJSBD$MSO>9FD)W$XS].@K>J.XR+>0@@':<$_2@#A?/TG=C[%
M-G_KM_\ 6H^T:3S_ *#/[_OO_K5?\_5^/]/L_P#ON/G]*/.U?.?M]EV_BC_P
MKT.;S_%_Y');^K%#[1I'7[!/_P!_A3?M&C\?Z#/[?OJT/-UGD#4;+)']Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #$^\_^]_04^F)]Y_\
M>_H*?0 4Q/O/_O?T%/J)4!9R2WWO4^@H EHIOECU;_OHT>6/5O\ OHT .J*Y
MQ]EEW9QL.<?2G^6OJW_?1J*X3_1Y-I.=IQEO:@1Q&-"R1G4/_'*UK+P]IU_9
MI<12701\X#,N1@D>GM5/['J^=NVWQ](JF1=?CCVQS(JKT :,"NZ3=O=E^/\
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M5%]G3^])_P!_&_QH^SI_>D_[^-_C0(EHJ+[.G]Z3_OXW^-'V=/[TG_?QO\:
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MC0 ZBFA .A/YFEQ0 M%)BC% "T4F*,4 +128HQ0 M%)BC% "T4F*38/4_F:
M'44W8/5O^^C1L'JW_?1H =13=@]6_P"^C1L'JW_?1H 1/O/_ +W]!3ZCC&"_
M7[W<^PJ2@ IB?>?_ 'OZ"GU$)8T=PSJ#NZ$^PH EHJ/SX?\ GJG_ 'T*3[3!
MG'G1Y]-PH"YBZ^VN^=$FD[U1HVS(BQL%?*@;PY'&"Q&WN.?>+29-=DDU'^V8
MC' T:F';LPAP=RC:26['<<=< <$GH//A_P">J?\ ?0J.>:(V\FV2,G:<<BF(
MXSRM%X_TJYZ'C8.*3R=%W'_2KK.!SL%3[[[K_9=ESU'DK_C1NON!_9=EM/\
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MSH =13/-C_OK^='FQ_\ /1?SH ?13/-C_P">B_G1YL?_ #T7\Z 'T4SS8_\
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M][_WQ_\ 7K)V7??P_#GO^[/^/-&R[_Z%^'V_=G_&CV4/Z:#GE_2-;_A*-/\
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M>$GYK_C4U%240^8__/"3\U_QI?,;_GC)^:_XU+10(B\QO^>,GYC_ !H\QO\
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MS_\ 7H DHI@$G]Y?^^?_ *]+B3^\O_?/_P!>@!U%-Q)_>7_OG_Z]&)/[R_\
M?/\ ]>@!U%-Q)_>7_OG_ .O1B3^\O_?/_P!>@!U%-Q)_>7_OG_Z]&)/[R_\
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MZ77_ 'ZE_P *3[3!Z77_ 'ZE_P *O8HQ1<+%+[3!_=NO^_4O^%'VF#^[=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm247121d3_s1aimg007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &, F@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T?4/B(EAJ
M-S:'3W<PR%-V\<X-5O\ A9Z?] Q_^_@KC/$/_(QZE_U\/_.LVO;CA:3BG8\J
M6(J)M7/1?^%GI_T#'_[^"C_A9Z?] Q_^_@KSJBJ^J4>Q/UBIW/1?^%GI_P!
MQ_\ OX*/^%GI_P! Q_\ OX*\ZHH^J4>P?6*G<]%_X6>G_0,?_OX*/^%GI_T#
M'_[^"O.J*/JE'L'UBIW/1?\ A9Z?] Q_^_@H_P"%GI_T#'_[^"O.J*/JE'L'
MUBIW/1?^%GI_T#'_ ._@H_X6>G_0,?\ [^"O.J*/JE'L'UBIW/1?^%GI_P!
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M?_OX*\^^SS_\\)O^_9_PH^SS_P#/";_OV?\ "CZK1[?B'UBKW/0?^%GI_P!
MQ_\ OX*/^%GI_P! Q_\ OX*\^^SS_P#/";_OV?\ "C[//_SPF_[]G_"CZK1[
M?B'UBKW/0?\ A9Z?] Q_^_@H_P"%GI_T#'_[^"O/OL\__/";_OV?\*/L\_\
MSPF_[]G_  H^JT>WXA]8J]ST'_A9Z?\ 0,?_ +^"C_A9Z?\ 0,?_ +^"O/OL
M\_\ SPF_[]G_  H^SS_\\)O^_9_PH^JT>WXA]8J]ST'_ (6>G_0,?_OX*/\
MA9Z?] Q_^_@KS[[//_SPF_[]G_"C[//_ ,\)O^_9_P */JM'M^(?6*O<]!_X
M6>G_ $#'_P"_@H_X6>G_ $#'_P"_@KS[[//_ ,\)O^_9_P */L\__/";_OV?
M\*/JM'M^(?6*O<]!_P"%GI_T#'_[^"C_ (6>G_0,?_OX*\^^SS_\\)O^_9_P
MH^SS_P#/";_OV?\ "CZK1[?B'UBKW/0?^%GI_P! Q_\ OX*/^%GI_P! Q_\
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M@I*Q[+;+G]J77]Y?^^:/[4NO[R_]\U3HI\J"[+G]J77]Y?\ OFC^U+K^\O\
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M>>XQZYK#D\)QM@"\E52KJXV [@TWG?A@\?2KDV@PSP:I$\L@&H2B5F7 ,;
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MM))")(Q91B64B5L22R9V@C.,  G'J153==6>B^))&OIYY[*[,T<LAYRJ(VT
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MTH_C_P  ETX+=_@<IM;^ZWY4;6_NM^5=7_PL#4_^?2Q_[]4?\+ U/_GTL?\
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ME0.A]01FI*H:)92:=H=E:2G,D<8W^S$Y(_ G%7Z8@HHHH **** )6_X]H_\
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M>P_[Y-'V$?\ /8?]\FBZ"Q3HJY]A'_/8?]\FC["/^>P_[Y-%T%BG15S["/\
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MEU;Z24O7!SEVD4H">YPK?KZT =/1113 **** "G/_#]*;3G_ (?I0 VBBB@
MHHHH *S].UO3]7+BQG>4(,EC"Z*1G&0S* WX9J]("T3JHRQ4@9..<5S'A:QN
M[*^*K97UAIR6PC:WN[GS@9@WWH_F.%VY';.1Q0!KWNOZ9IY?[3<,-C;'\N"2
M3:<9P=BG'!I[:UIRZ.FK&Y'V&159)0C'<&.%PN-QR2.,5ST5K>W/AV\TN%7^
MT2ZI)'>L&P1$TFXM]#'M'X^U:VOVXN=/^R+I=S=0PR12>7!((BP!_@((.Y<
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M4?\ "O-3_P"?RS_-O\*[M-2L9-/-^EW"UF 6,^\; !UR>U323Q11"22150D
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M@^5'P?N#^5+@^AKYX]L**,'T-&#Z&@ KA9+;4Y]9:;1--FLKB.UF@9+M%2&
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MDD%E!=^-C/;M<Q1VD"W$X,S8>64?*I7.  HR1ZD>E5_$UPD&HPWUKJA,\$\
MEMUN<,D;-C"1]'+YYR>@XZ5N#6=,.JS:>JQF^>+S9HU;+%!A<MQ[@<U4N-9\
M/VNJVUO/:Q"[B"I$_EY$.[[H+8PN><4687+>BSR-<:M:2,SK9WK1QLQR=I57
MQGVW$?0"M:LG2[FRBMI3:([AYY&E=G^8R;OFSQV/'T J[]N3_GB?^^__ *U.
MS LT56^W)_SQ/_??_P!:C[<G_/$_]]__ %J+,"S3G_A^E5/MR?\ /$_]]_\
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M0DPN6:*K?;D_YXG_ +[_ /K4?;D_YXG_ +[_ /K4[,"S15;[<G_/$_\ ??\
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MG9@6:*K?;D_YXG_OO_ZU'VY/^>)_[[_^M19@6:</]6WU%5/MR?\ /$_]]_\
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M48  SZ'TKNM$O7U'0M/O95VR7%NDC#T)4$UB'5] NH]36*TDA#*ZW5U%%LW
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M',%C&HK7S]/RHS]/RHY@L9%%:^?I^5&?I^5',%C(KD-6T*_EUZ\N;6"1VNS
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M;ZU- UP)&EN5"&1I';+..P[C XY]JK#P_+%I=II1U"&>U2YCE8^5'#L1#NP
MO4E@.3[UQ^E7=W<7R6OVFZ,UQ;W+74YN \>]3\CQ@'Y0#QV]#78Z1>/J&BV-
M[(NUYX$D8>A(!HY0N=$70G_6Q_\ ?8HWI_SUC_[[%95%/E%<U=Z?\]8_^^Q1
MO3_GK'_WV*RJ*.4+FY:,IF.'0G'0,#15'2O^/S_@)HK*2LRT>::Z=*_M_4/-
M2]\SSWW;67&<]N*S\Z-_<O\ _OI/\*=XA_Y&/4O^OA_YUFU[\(^ZM3QI2]YZ
M&M;0Z=<3A+:#47E +@(R9 ')/X5-]HM[?9J&[5X_M&X+.)5!DQUY[U%X:O+>
MPUD7%RZ+&()5^?H24( /U-;EAK>EO!IAG%K;2QQW"A(P0D+L1M)SNQG!YYJ)
MMI[-HN%FM[&$M]IR* LNI@#=C]ZO?K^=2PRVUT72'^U9/+C#L%D7Y43H?H*Z
M"RU72%U6:XDO+6,-*@E53\DJA<%L[,MSU' [U#;:KIL6DM$E_;11?8I86M_+
M^=I23ALXZ$>]0Y/L_P"OD4HKNOZ^9A-J5E(2S7&J,><DRJ>O!_.M#2=7M;03
MW,-I>W2QHH=Y''[M0>.01QGM6F^IZ&@M!+=P7*PW0*,1DJGEX!*A0  V/EYZ
M53765M&O97U6TN;MK9$26*' +!\D=.3CO2;YE;E?]?(:T=[_ -?>8MU=Z5>7
M<MS,+XRS.78[D&2?PJ+.C?W+_P#[Z3_"NL_MC14_M#R9+3YYW=U?(6=2HP!A
M3WSQQS7!Y&>.!Z5K3?-T:,YZ=F:&=&_N7_\ WTG^%&=&_N7_ /WTG^%9]%:\
MOFS/F\C0SHW]R_\ ^^D_PHSHW]R__P"^D_PK/HHY?-AS>1H9T;^Y?_\ ?2?X
M49T;^Y?_ /?2?X5GT4<OFPYO(]L%K"ZJVY^5'IZ4?8X?[S_I4L?^JC_W!_*G
M5X-V>P0?8X?[S_I1]CA_O/\ I4]%%V,@^QP_WG_2J3KHZSWH>YB$T$2FZRPR
MB8.-_H,9K4KC-9\.7$Q\11Z=:^2+R"W=&3"^;(LA9QD_Q$<<^HI78'0:9)I&
MI6F[3;E9H(SY>$& N!]T@@$<5B/9^#+,6\%W<6TC99(6F 8A0Q^7('"AB0">
M.V:M:!:WJ0:PXAO8(YR/LJW[;I\A,$L<DXW8QDFL3=/<:#I.F1:3?/9S62)?
MW=K )'8J<-".1@[@Q)/3/')I786.BBC\-MKDMM%);G5-I60*@WD8Y&<<G'49
MSBI9IM"M;VVTN>[CCN,JT,#?PG^$CC [XS67-!=S^)[&:'2KNW6SFD=V.TV[
MQLA&]>_FG('J.<U2UO3=5OM4N(["WNHK?4OLTDK/"I4%&!.Y]V8R /NX.<\$
M<T[L+'3:;INGQV\C6L[RK),[O)D$L^?FS],8]L5<^QP_WG_2LW0=S76MRK_Q
M[2:BYA]#A5#$?\##?CFMFB[ @^QP_P!Y_P!*/L</]Y_TJ>BG=@0?8X?[S_I3
MY+2([,L_"@=JDIS_ ,/TI78%;['#_>?]*/L</]Y_TJ>BG=@0?8X?[S_I1]CA
M_O/^E3T478$'V.'^\_Z4U=.M4=W0,K.<N0!ECTYJS11=@85W;:'HEO<R7]UY
M5K=REF2494L1R  ,\XR:NG2],OH"Y1)XIT7)(#+(O4?4>E4M<2XAU33-3ALI
M[V.V6>.2*!0SC>H 8 D9'&#]:M>';*;3_#UC:7 "S1Q8=0<A223M_#./PI78
M"C0-/6XM945D6U5EAB0 (N[J<>N./Q-6_L</]Y_TJ>BG=@0?8X?[S_I1]CA_
MO/\ I4]%%V!!]CA_O/\ I1]CA_O/^E3T478$9M(O)5=SX!/I3/L</]Y_TJR?
M]6OU--I78$'V.'^\_P"E'V.'^\_Z5/13NP(/L</]Y_TK/OKG1+:Z@L;Z]1)I
M6#112=SG@],#GH3CFM>N6\4V]W>$VEMIEU))(8GCN82OE.RMG9/G^ =>^<TK
ML+&E!<:&^JSV$%Y&;_):6)?O$@8.3C!(&/<55U/3_#D%Q<3ZI.@#1HTL4P#*
M<$A&QC.[D@8Z_A6/H.CZG8:U:QRPWI,%Q<27$\K@VSH^XJ8QGALD9X!ZY)JW
M=W-W8:CKTL&F2:A?F:W>VC50VU-F ^..%;>>.>?>E=A8T;9/#<&FV]Y;S6\=
MD9-L$@PJ^8QVX&>=Q/&.M6K_ $S1UL[B745B%M_K)FG"[>.YSZ5@2:(+KPM$
M%L+J6_2\2<M=PB.7>9E:1PN2%&,_@*W-?M$U?1M2LVLFF=8V\I9$&UWVG:5]
M<?SIW8!#INE-J4<T,Q,J6H$42X 2)C]Y1CO@?D*O_8X?[S_I6*L<B^(-"C4$
M206$GV@?W5(0*#_P(''T-=#1=@0?8X?[S_I1]CA_O/\ I4]%.[ @^QP_WG_2
MGK:1")QN?!(]*DIP_P!6WU%*[ K?8X?[S_I1]CA_O/\ I4]%.[ @^QP_WG_2
MC['#_>?]*GHHNP(/L</]Y_TJC=V.BK?VC7?D_;'8I;&0+O8@$D+WX )]JU:Q
M-7TP7&M:+?16BO-!<GS)@!N2/RW'7TR1^=*[ EU'2M*EGM7O)2K NBAB,2*5
M.Y#GJ,#)^E5M'L_#%Y'*VC_9W1'7S/)7&"/NG!'Y'I5?Q':37FKQ6ZG N--N
MH("3@><=IQ]2H;\,T:*MW_:4E]-I=W:1_8[>R$;(-Q==V6P#]P9ZT78#B/"T
M[:G;07L$,[(?M;P@*^W.&.['/7!(SBMR+3[:*%(X]RQHH50,8  XKAM%TJ[T
MF%$O[>]6WL[&XCOI+IP\,F?N^0,\9[X SWR:[+08[B+P[IL=YG[2MK&)<]=V
MT9H38%G['#_>?]*/L</]Y_TJ>BG=@0?8X?[S_I1]CA_O/^E3T478#K&VCBG+
M*6)V]Z*EM?\ 6G_=HK.6Y2/)->U6ZBU_4$7R-JSN!FWC)Z^I%9_]L7G_ $[_
M /@-'_\ $T_Q#_R,>I?]?#_SK-KZ"$8\JT/&E)\SU-K3+J^U+48;17MD#DEG
M-K&0B@9)^[V K3^P:B]WJ%O%<V;?98TEC<V\2K*C8P<D8'!K"TC56TB6>:.%
M7FDA,<;/R$SU.._''XUIGQ3'<0-'>Z<DOF6XMY?+;RPRALC  XQTK*<97]U:
M%QE&VKU+%EINO75]]GECMH%681.[P1=2,_+Q\W'/%5W@UP6TERL5LT*[B/W$
M09E!P6"XSCWJ1?%X>Y$USIR2^5<">W59"OED*%P?7@#\:KGQ-F#/V)?M8A>W
M2?><"-CDC;Z\XS22J7^%#O"VY<.D^)5./L]F3DC CAZXSCIU([5%';:S<)"T
M"VQ\R 3L9((D"J6V]2/6F_\ "6'[6T_V,?-=BZV[_1-F/ZU7?Q$7L?LWV8?\
M>RV^[=Z2;\_TH4:G5(+P[DRV^O-+/$(;42P,RM&88@Q*C)P,<\5#J-S>6 M#
MYEN_VBV2?_CUC&W=GC[OM5U/& 6XGF^P /*[,2LF,AEVX;CG'45AZC?_ &\6
M@\O9]GMD@ZYW;<\_K51C)OWEH*3BEHS6FMM>ALUNFAM3&51_EAA+!6^Z2,9
M/K3A;ZRLBK*MML=)&5XX(F!*#+#IVJ6]\1V<*1+:6J3R/:P0SR.QVD)@E-OU
M&,U'/XM$ICVV94()@ 9,_P"L&,#C@#L*E*;^R5[BZD5U#KMG8_;)HK00X5B5
MAB) ;[I(QD UF_VQ>?\ 3O\ ^ T?_P 35N[\0&ZMKN'[.%^T0P19W?=\KO\
MC6+6L(Z>\C*4M?=9?_MB\_Z=_P#P&C_^)H_MB\_Z=_\ P&C_ /B:H45?)'L3
MS/N>RF[F& '&,#^$>E)]LG_OC_OD5$W4?[H_E3:\.R/7)_MD_P#?'_?(H^V3
M_P!\?]\BH**+("?[9/\ WQ_WR*/MD_\ ?'_?(J"L2+4M4N-2U:RCLH(Y+>.-
MK422$[]Q(W/CH.,X%%D!T7VR?^^/^^12+<RH"$*J"<G" 9/KTK!T;5)[J&_-
MV\$J6DI07-NI"2@+EL ]P>#VJL^N:@+#2+I+.(QW\\8D=GQY4;M\H ZEB"#[
M4:#U.H^V3_WQ_P!\BC[9/_?'_?(KG#=ZJ/%$=@EQ:R6VPSS+Y)#1Q]%&[/))
MS^ -4]6\33Z;JMQ&7M([>V,(,,N?-N/,."4[8&?S!HT ZY;J5%"H551T 4 ?
MRI?MD_\ ?'_?(K+TZ]:Z:\AE"B:TN&@?;T/ 93^*L/QS5VBR$3_;)_[X_P"^
M11]LG_OC_OD5!119 3_;)_[X_P"^14DMU,!'AQR@/W152I9ND?\ N"BR&.^V
M3_WQ_P!\BC[9/_?'_?(J"BBR$3_;)_[X_P"^11]LG_OC_OD5!119 3_;)_[X
M_P"^11]LG_OC_OD57.<':,G' SC)K$T?4]0GUB[TW45@$L42R@Q(R $G!4;O
MO@<?,.*+(9T?VR?^^/\ OD4?;)_[X_[Y%<I>^)I(-*O+N"%))C-+#90DX\SR
M\AF8_P!T$'\ /6K=_J5['X<@O;. RW4PAX2(R!=V-QVCD@ FC0-3H/MD_P#?
M'_?(H^V3_P!\?]\BN;L-;DD_L\2RI,+F62W=A$8FCE4%@I4]. 0?PK=HLA$_
MVR?^^/\ OD4?;)_[X_[Y%04460$_VR?^^/\ OD4?;)_[X_[Y%04460%MKN86
MZ'?R6/\ "/:H_MD_]\?]\BFM_P >T?\ O'^E1460R?[9/_?'_?(H^V3_ -\?
M]\BH**+(1/\ ;)_[X_[Y%'VR?^^/^^14%86OZIJ.DO%<11P&SW(A#*Q9R6P<
ML.(P!SD]319#.D^V3_WQ_P!\BD^TR[]^5WXQNVC./3I7(Z?XDN[KQ.^GND7V
M<RS1+A&&T1]"'/RN3W4<C\*T)K^_N+N^M]/%L@M3&CRW&=JEAN8\=<+CCOGV
MHT#4W_MD_P#?'_?(H^V3_P!\?]\BN-?7M6;0/[31M/CAB\S,KAB+DJV$$:]0
M']>?:MJ_GOETZ*>W:UM3MWW$ET25A7&3P.ISQ1H!KBZE#EP5W$8)VC)'Y4OV
MR?\ OC_OD5SFEZU<73::+N!8C?6SR(%R,,AYZ]BI#"MRBR G^V3_ -\?]\BC
M[9/_ 'Q_WR*@HHLA$_VR?^^/^^14BW<Q@D._D$?PCWJI4J?\>TOU7^M%D,=]
MLG_OC_OD4?;)_P"^/^^14%%%D(G^V3_WQ_WR*/MD_P#?'_?(J"BBR G^V3_W
MQ_WR*/MD_P#?'_?(J"N6U3Q-=6NNS6=ND0@M6A$[2QN0?,YY<<( /7//7BC0
M9U[7,K%2Q4[3D94<'UZ4OVR?^^/^^161>WTT>IV]A:QH\TD4DQ#G VK@ 9[9
M9E_#-5=#U.]N[Z^L;\0^=:[#NC1HP=P.0 W) (P&Z'\*+(#H&N974JY5E/4%
M01_*E^V3_P!\?]\BN0LM<U.XGNXYE$,^R62UM9K5HRX0\?.>O&,_7-=#8W<=
M_86]Y%_JYXUD7Z$9HT O?;)_[X_[Y%'VR?\ OC_OD5!119")_MD_]\?]\BC[
M9/\ WQ_WR*@HHL@-+3KB66ZVNV1M/845'I7_ !^?\!-%93W+CL>3>(?^1CU+
M_KX?^=9M;^O)IAU_4#)<78?SWW!8%(!SV.ZL_P O2?\ GZO?_ =?_BZ]^$O=
M1X\H^\RA16E%:Z=<2>7#-?R/@G:MLI.!U_BI&MM-2))6FOA&^=K&W7#8ZX^:
MJYD3RLSJ*O>7I/\ S]7G_?A?_BZ<8=+"!S<7P5NA-NN#_P"/4<WD'*9]%7MF
MD_\ /U>?]^%_^+IR0Z7(ZHEQ>LS' 46ZY)_[[HYO(.4SZ*TA:Z<96B$U^9%S
MN7[.N1CK_'226VFPL%DFOT) 8!K=1D'H?O4<R#E9G45>V:3_ ,_5Y_WX7_XN
MCR])_P"?J\_[\+_\71S>0<I1HJ]LTG_GZO/^_"__ !=.:'2TQNN+Y<C(S;J,
MCU^]1S!RF?15_P O2?\ GZO?_ =?_BZ/+TG_ )^KW_P'7_XNCF\@Y3U!NH_W
M1_*FU=^QQNJMYC<J/X?;ZT?84_YZM_WS_P#7KP[H]>Q2HJ[]A3_GJW_?/_UZ
M/L*?\]6_[Y_^O1=#L4JS;W1HKS[>PN)X)+V%('DB;#*JY^[Z'DUO_84_YZM_
MWS_]>C["G_/5O^^?_KT706,+3M*73]/:Q-S+/ 5V*'51L7&,# %16ND$:/8V
M-V^392(T;(?O",_)G\ ,UT7V%/\ GJW_ 'S_ /7H^PI_SU;_ +Y_^O1=!8R(
M["**^N[Q6?SKI45B3]T*,#'ZGZU1N?#MM>7L5S<7-S)M"!XRPV2%3D$C''/4
M#&<#-=+]A3_GJW_?/_UZ/L*?\]6_[Y_^O1=!8Q--LGM&O)IF4SW=PTS[>@X"
MJ/\ OE1^.:O5=^PI_P ]6_[Y_P#KT?84_P">K?\ ?/\ ]>BZ"Q2HJ[]A3_GJ
MW_?/_P!>C["G_/5O^^?_ *]%T%BE4LW2/_<%6/L*?\]6_P"^?_KU))9HVS]X
MW"@?=_\ KTKH+&=15W["G_/5O^^?_KT?84_YZM_WS_\ 7IW06*5%7?L*?\]6
M_P"^?_KT?84_YZM_WS_]>BZ"Q190Z,K=&!!YQQ6;IVBQ:=<FX^U75U*(_)C:
MXDW&./.=H_'')YXKH/L*?\]6_P"^?_KT?84_YZM_WS_]>BZ"QRG_  B]E<6U
MS:WUO%/"996MW.=\:R<L/^^B:MG18A8164-U<V\4*H(?)?:8RG0CUSW!X-=!
M]A3_ )ZM_P!\_P#UZ/L*?\]6_P"^?_KTKH-3F8=!6"YL=DC/%;RR7,CRMF26
M9AMW'\"?TK9J[]A3_GJW_?/_ ->C["G_ #U;_OG_ .O3N@L4J*N_84_YZM_W
MS_\ 7H^PI_SU;_OG_P"O1=!8I45=^PI_SU;_ +Y_^O1]A3_GJW_?/_UZ+H+%
M=O\ CVC_ -X_TJ*M$V:>2J^8W#$_=_\ KU']A3_GJW_?/_UZ5T%BE15W["G_
M #U;_OG_ .O1]A3_ )ZM_P!\_P#UZ=T%BE67J&APZE.7ENKM(I%5)H(Y,1RJ
M#D CM^&,UT/V%/\ GJW_ 'S_ /7H^PI_SU;_ +Y_^O1=!8YNV\/6MK?I<I-<
M-'%(\L-LS_NXG?.XJ.O<_3-0W_AW^T);^)KF2&TO3'+)Y1PV]."#G@J0%R/;
MWKJOL*?\]6_[Y_\ KT?84_YZM_WS_P#7I70:G*S^&C<26<KZO>^9:;O*.$P"
M>^W&,@< ]JFU301JT$<,^H72I'(L@"[<,0,#((P1GG'K72?84_YZM_WS_P#7
MH^PI_P ]6_[Y_P#KT70:G/QZ9*-3M+B>X:=;2!T1WQO=W(R3@8X  'U-:=7?
ML*?\]6_[Y_\ KT?84_YZM_WS_P#7IW06*5%7?L*?\]6_[Y_^O1]A3_GJW_?/
M_P!>BZ"Q2J5/^/:7ZK_6K'V%/^>K?]\__7J1;-!"Z^8W)'\/_P!>E=!8SJ*N
M_84_YZM_WS_]>C["G_/5O^^?_KT[H+%*BKOV%/\ GJW_ 'S_ /7H^PI_SU;_
M +Y_^O1=!8I5DWWAZUO[R2X>:XC6;9]HAC?"3[/N[A^G'45T?V%/^>K?]\__
M %Z/L*?\]6_[Y_\ KT706,&^TTW>I6]V&X$4EO,-Q4F-\'((Z$%1^M,LM$6R
MD:;[==SW#!$,TS!F\M<X3ITY.3U-=#]A3_GJW_?/_P!>C["G_/5O^^?_ *]*
MZ"QR_P#8'V?S9[>[N)KA8I([474NY(-_7'<_CV&*T[&TCL-/MK.+/EP1+&N?
M0#%:OV%/^>K?]\__ %Z/L*?\]6_[Y_\ KT[H+%*BKOV%/^>K?]\__7H^PI_S
MU;_OG_Z]%T%BE15W["G_ #U;_OG_ .O1]A3_ )ZM_P!\_P#UZ+H+"Z5_Q^?\
M!-%6;&V6*X+!R3M/!&**RF]2H['COB'_ )&/4O\ KX?^=9M;&L6TUYXMOK:W
MC,DTETX51W.:DF\+7\8M538\DT;2, XVQJ#C);.,5[T9QC%)OH>.XMMM(3PI
M=I8Z^ER\B)LAE*ESQNV' _.NC%YHEQ_9CJT*AHKB1(I2-L,S;3@YXZYQFN4C
M\.ZK*9U%H08&*.'8*2P&<#)Y..>*5?#FINL!$"?Z0F] 9%!VXSN// ]S6<XP
ME*_,7"4XJUCHE72KFYG0&P@=+RWD?=(NUE ^?:1QR>PJRM_9/##E[%[>W^UX
MB<+][)*<>AKDT\/:E)<R6PMP)4(&UG W$C(V^N1Z5"VCWJ6@N7A54(#!2P#$
M$X!"]<9I>SB_M#YY+[)T5O<:=-HJRSFP$;P2F[4J!,9_X-@[#ITXK1O18VDD
M0G^PQ;6M'MQ& )5;@N6QVQZUQM_H]]IB(]W!L5R5!#!L'NIQT/M56:>6YD\R
M>1I'P%W.<G X I^R4M4]!>T:T:U.TDO--NKL7$OV-9,WJ$H N5V_)GUYZ&L;
M4I[.;7].>>19+58;=9BISP -PK Q15QI*/4EU&^AVC-:_P!J$SR:,9?*E^QF
M,#8#GY/,[=.F?QIQ72;F::))K".99+:25B0L9(SYNSV]A7$XHQ2]CYC]KY'<
MI<:2/W!6Q,4TUYYA91D*!F/![#/2L3Q+="\_LV5)8'3[(B_N\;E8#D-BL' H
MIQI*+O<4JC:M8****V,CW&/_ %4?^X/Y4ZFQ_P"JC_W!_*G5\\>V%%%% !11
M10!FWVOZ9IMXEK=7.R9@"0$)" G +$#"@GUJY<W<%IY?GR!/,;:N>YP2?R )
M_"N>\0C4KS48[!=+N)=(*J]S);LH:=@>(SD\*.I[GI5O5ED3Q'I%QM5HO*N(
M5#G"B5@I3/L0K#/O[T@)[7Q+I-Y&\D-UE4*!BR,O#G"MR/ND]#TK5KA+RTOC
M;:Y>W.GR6GVVSCMO(DG$QDN-V%\O^Z@SP.!WP*[B%72"-)&W2*BAF]2!R?SH
M ?1113 **** "G/_  _2FTY_X?I0 VBBB@ HHHH *H:GK5AI C^VS%&DR51$
M+L0.IP!T'<U?K \32:J8X+73;*:2.<,MS<P%?,B3^ZF[NWKVH UY+ZUCLEO#
M,IMV"E77D-NP%QZYR,?6J4?B329;B>!+K<\*NS80X8)]_:<8;;WQTJEJL"VV
ME:(4@:"SL[N!I86.3'& 5&?7!*Y^F:JRP7I\0#4[NP^R06<$Z3R&X#PRQ$?*
M(U_A)X).!Z'-(#JD=9$5T8,C ,K Y!!Z&G5E^&H)K;PSIT-P")5@&5/50>0/
MP! _"M2F 4444 %%%% #C_JU^IIM./\ JU^IIM !1110 55O=1M-.6 W<ZQ>
M?,L$6[J[MT45:KD?$N@:QJ.K6U]:S6LD4,T!BBE0[H@'#.P.<9./R&* -ZWU
MJRNM2EL(3,\T3,CL(FV!EZC=TS2WVLZ?II=;JXV,@4E0I8_,<* !U)(.![&L
M.PTN]@\2K-#I\EE$)YI+J879DBN58';A">#N(/08Q274VI6&HZ]_9]D+K4)I
M()+<-C"Q;-N[GKM(;C_:'K2 TY?%6BPVD5T]Y^[EW$!8V+*%.&+*!E0IZYZ5
M<OM6L=.M8[FXF_=RD+%L4N9"1D;0.3QS7%3^'+PF*ZBTW4)F>UE@=&NQ%+Y[
M/O\ .8@X()_+'2NFN3J,6DPV[:?)>NB+%</#,(I&!3#/$1C!SQU'6@9HVFIV
M5\4^S7"R^9$)DQ_$A.,C\01[5;KD=&L+NSO]!M)5"RV=I<&95(.Q'8>6I(ZG
MCKW()KKJ8@HHHH *</\ 5M]13:</]6WU% #:*** "BBB@"EJ6K66DQ1O>2E/
M,;:BJA=F(&3@#G@<FJTOB;1X9;>-KU3YZHZ,JDJ%?A2S 87/;-+KPN6LQ%#I
M\EY%*&2807'DRH"."C<=^#R.*XZ'PKK5JP'D.]U-';"*XBN0L5J8^"'3HWRX
M['-(9WUW?6MB$-U,L0?=@MZ*"Q/T !-4[7Q'I-W:W%REXJ0VRAYFF4Q[%(R&
M^;'!QP>]5-7,MOXFLKL6YN$-G<10Q9 W2DJP7G@9"GGVJII%C>7UKJ4^LZ;(
MNH748#><%,8P#LCC )X4D\GJ3F@1TEO=07-G'=Q2*;>1!(LAX!4C.>?:J]KK
M.G7L%O/;722PW$C10R+]UW7.0#^!^N*BTBWD@T;3].N[8G;:JDV<%00 "I]:
MPI-/GM/#]IIWE".ZDU?S(%7'RKYYDSQT&S/YXH ["BE/4TE, HHHH GM?]:?
M]VBBU_UI_P!VBHEN4CR^YAU+3_&5UJ$-A),JW$A QPRG(//T-6HM1N[>.*V@
MT*Y2S2%H2GF9<@MN!#8ZY]JY[Q"3_P )'J7)_P"/A^_O6;D^I_.O<5/FBF^Q
MY#GRMI'62W-W=QR1WVAW-PHF,T.92"I*XPQ'4<"DAO-3AOH)_P"R)C&ED+-T
MZ%E]0>U9GA>V@O=<2&Z1)(O*D;;(2%R%)&<=LUK&TTBZWB"*V:Y2PD>5;5G:
M)7R-I7/).*B247RV+C=J]R>UU6_MKMKC^Q;EF$BLC%_FV@8V$XZ=^*K+>ZFF
MFFU72;AR.4,Q#JAW;MR\9![8SBI;/PM9+>6)N);ETDG:&6%BN[<$W?PGCZ'F
MJ4_AVTBTP78OW65T\Z..0J R;L!>N=V/;%2G3O\ \.5[]O\ AA^MRZEJZ*JZ
M7=0YD,LBE]RECZ#'%8O]C:E_SY3?]\UTNH>%K+[3>R_:_L<9G>.W3<NQ=J@_
M-N.>2>U9.KZ;:QWVF6MB94:Y@B+F0\;F[UI3FK)1(G!WO(H?V-J7_/E-_P!\
MT?V-J7_/E-_WS6O_ ,(_8OJ$EO%>7NRW$IN2\.#\@YV>N?0TDWAR%;5KF&ZN
M'C98)(E9 &VR,1\P]1CM5>U7?\"?9^1D_P!C:E_SY3?]\T?V-J7_ #Y3?]\U
MOIX4LS*T+WURLK74UM#A 02B[LM_]:LO7;.SLH].^R><'EM5DEWG@D]Q1&KS
M.R_('3LKLJ?V-J7_ #Y3?]\T?V-J7_/E-_WS5+)]3^=&3ZG\ZU]XS]TN_P!C
M:E_SY3?]\T?V-J7_ #Y3?]\U2R?4_G1D^I_.CW@T/<D1A&@(Y"C^5+M;TK*;
MJ/H/Y4VO"Y3V+FOM;THVMZ5D44<H7-?:WI1M;TK(HHY0N:^UO2C83U%9'(I>
M?>CE"YK;">U&UO2LD L< $_2@Y'7-'*%S6VMZ4;6]*R**.4+FOM;THVMZ5D4
M4<H7-?:WI3G4_+QVK&J6;I'_ +@HY0N:6UO2C:WI6111RA<U]K>E&UO2LBBC
ME"YK[6]*-K>E9%%'*%S7V$C!&104)&",BLD DX&324<H7-?:WI1M;TK(HHY0
MN:^UO2C:WI6111RA<U]K>E&UO2LBBCE"YLE3Y:\=S3=K>E9K?\>T?^\?Z5%1
MRA<U]K>E&UO2LBBCE"YK[6]*-K>E9%* QZ GZ4<H7-;:WI1L.<XYK)P<9P<>
MM !/3)HY0N:VUO2C:WI63ALD8.1UH ).!DFCE"YK;#Z4;6]*R>?>DHY0N:^U
MO2C:WI6111RA<U]K>E."GRVX[BL:I4_X]I?JO]:.4+FEM;THVMZ5D44<H7-?
M:WI1M;TK(HHY0N:^UO2C:WI62 2> 3]*4*Q&0"1]*.4+FKL)[4;6]*R.:4 D
MX .:.4+FMM;THV'TK)((.#G/I001U!%'*%S6VMZ4;6]*R**.4+FOM;THVMZ5
MD44<H7-ZU4B4Y':BL_2O^/S_ ("?Z45E)69:/)O$7_(QZE_U\/\ SJ@\,L4,
M<TD;+%*"8W(X8#@XKH7EM(?B!/)?;?LZW<FXN,J#S@D>F<5MIJ>GDVJW5]82
MWB6SJ)H]HB5R^>ZD D=\5[GM'%))7T/)Y%)MM]3A+>ZFM)?-MY3'(5*[AZ$8
M(_*BWNYK0R?9YC$70H^T]5]*Z_[=I[)>?8YM,M)&N&,PF7S%D3;QL^7IG/ Q
MUHM]5TX7>GP/):B&.P&U]B@+<8(RQ(/./4'%#J/^7^ON%[/^\<X_B#5':)GU
M"4F-_,0\<-C&>G7%-DUK49;=[5[Z1H7;<T9(P3G/\^:ZVRO='&JSS27%E&C2
MHLJ!EV.NWE@2O()[#'/-4C<Z6V@B&6:WC" ?NX2K&7#]"I&X''<'%)37\O\
M7W%<K_F, :[JF+@"_E_T@YEY'S'&/PX]*@FOKJXC@2:=W6!=L0/\ ]!70>*[
MS3[B&%;,VLF)"8WA8;DCQPI 48_$DUR]:T[-<UK&<[IVO<T7U[5I)H97U"<R
M0Y\MMWW<]?K^-(FN:K'=2W*7\PFE 5WSRP'05GT57)'L3S2[E[^V=2\U9/MD
MN]9&E#<9#L,,?J14$U[<W,$,,TS210 B)6_A'M4%%/E2Z"YGW"BBBF(****
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MP\L=B" 03G&*OZ7I%OI"7 AEN)GN)?.EDN)-[N^ ,YP.P%&HB_1113 *<_\
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M?>;_ +_-1]>I>8?5*GD>0T5Z]_PK_P /_P#/O-_W^:C_ (5_X?\ ^?>;_O\
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..%64A2,Y4<T5+=QH__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm247121d3_s1aimg008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ', M8# 2(  A$! Q$!_\0
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M^-OQ5O/C#X5^ ?A3XE^%K'3_ ($ZOXKTR7P-^S]=^*KG4=,^*_Q?L[>[\'>
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M!,9!%K%W(8G2*7;#I)\J5R (9"-(PDZ[E,D+8EB5XVE1%D0M(+-R PU6]*D
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MKX'?$G3/ _CGQ/8_%[]E^T_:VOM$OO&_P4^''C'P?\,)/&6H^ ?^$=TKP_\
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M% &5_9T__03O?^_.D?\ RIH_LZ?_ *"=[_WYTC_Y4UJT4 97]G3_ /03O?\
MOSI'_P J:/[.G_Z"=[_WYTC_ .5-:M% &5_9T_\ T$[W_OSI'_RIH_LZ?_H)
MWO\ WYTC_P"5-:M% &5_9T__ $$[W_OSI'_RIH_LZ?\ Z"=[_P!^=(_^5-:M
M% &5_9T__03O?^_.D?\ RIH_LZ?_ *"=[_WYTC_Y4UJT4 97]G3_ /03O?\
MOSI'_P J:/[.G_Z"=[_WYTC_ .5-:M% &5_9T_\ T$[W_OSI'_RIH_LZ?_H)
MWO\ WYTC_P"5-:M% &5_9T__ $$[W_OSI'_RIH_LZ?\ Z"=[_P!^=(_^5-:M
M% &5_9T__03O?^_.D?\ RIH_LZ?_ *"=[_WYTC_Y4UJT4 97]G3_ /03O?\
MOSI'_P J:/[.G_Z"=[_WYTC_ .5-:M% &5_9T_\ T$[W_OSI'_RIH_LZ?_H)
MWO\ WYTC_P"5-:M% &5_9T__ $$[W_OSI'_RIK+U."ZM-+OKF#4KB&6WL)IU
MS!I+*LD"%I,@:2RL%P ,*0Q^ZN.:ZFL+7_\ D":Q_P!@K5?_ $4U &[1110!
MR^J3PQ:UH'FS11_-J9^>1%XV(,\D=P1]01U%:_\ ;&D_]!33O_ VV_\ CM9.
MI)OUC0<^6>=3&)X4D/\ JT'!&<'H!T&,'AB<=%Y?T_)/_C= $7VZS_Y^8?\
MOXO^-(]_91_?N85_X&#_ "S3_)C_ .?>/_OU%_\ %4K00O\ >@C/UCB/\P:
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M7_GXB_[[%?*'_#:W[+__ $/<W_A!^.O_ )E:?_PVQ^S%_P!#^_\ X0GQ _\
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M/_"#\>__ #)U)_PVO^R__P!#])_X0?C[_P"92C^P,]_Z$V:_^$&*_P#E9/\
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M?'?BBW6R?PE<:8MMJ!BV@HLX]Z_X;"_96_Z'*'_PW7C[_P"9JG_\-C?LK?\
M0Y#_ ,-]X\_^9FI_L7./^A5F/_A'7_\ D#/Z_@?^@S"_^#Z?_P D>4?M9?\
M!.7X4?M@ZO\ LX^*?'_Q2_:!\&^,/V5M3UWQ!\)O%7PI^(6C>%-9MO%VO:;H
M&A/XXUH7OA#6-*U3QCI.CZ'Y7AW7)M-$_AR?5M=FTM5EO!*_V)\./A_'\/?
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M=<U*QTC3;>;P)XTL(IM0U+_CR@EO=0T*UL;)9N]Q>W-M;1?\MIHZ^D_[)T[
M/V&PP>G^A)_\=KAJT*]!J->C5HR>J56G*FW;LI)7-Z5>C65Z-6G57>G.,_\
MTEL_,-/^"3'P T/P!^RGX/\ ACX]_: ^"6O?L;^#/&_P]^#OQ/\ A5\2K/2O
MB3/X.^)"VTGQ T+Q]J>K>'-4T/QE;>.-4T^Q\4ZVUSH5K>67BV)-1TC4;=?,
M<]//_P $POV=-9N?VH[SQ=K7Q/\ &>H?MC?LW_#S]E_X[:UXK\>IJNN^)/A_
M\-_!/C/X<Z-K46KR:?)JD/Q#U/PEXSU2#QAXOO\ 4-8;Q1?/;W#:;IL<+PM^
MCG]FVO\ SZ6?_@*G_P =J?[#:?\ /!/_ ![_ !K(U/QLT3_@BC^RW9W?B/6_
M$?C_ /:!\?\ B_QE\:OV3OCQXJ\:^/OB7X?UWQ)K'C3]C%=4A^#4,DT/A"TT
MBT\.BQUV_L/$/AVQT.&":PC72-$OM$@2'4G^L]#_ &&/AEX+_9NU7]E_X>>.
MOC5\//"&L?$#QY\4(_'O@;XI7?AOXN>'/%WQ%^.&N_'OQ-+H'CFTT[SXK&_\
M:>)=5L9[:XTV07OA*1](ULZY)*YD^X/L-I_SP3_Q[_&J?]C:?_SX6'_@&G_Q
MV@#\@+S_ ((E?LJW/A#1+&#QG^TII7Q7TO\ :0O/VLK_ /::T7XWW%E^TIXE
M^.>M>'KWP/K?B'6_B0GAV*T@T2]\%ZA<^'9] \-^'_#V@OH)2V7PT+B(I/[=
M\*/^"9/[./P5\+?LG^!_!$WCP^&OV,_B5XM^*?P5MM;\>W6NW-KXF\::;^T#
MI.H+XMU*^ACO?$UAI>G?M(?$""PEN OB+49[?PO/K'B*X;3)WF_13^S+/_GQ
MM?\ P'C_ /CU6?L-I_SP3_Q[_&@#\\H/^":_[,L/[<'Q _X* 1:5XJB^//Q'
M^#US\'/$&_Q5;GP0VA:MI&AZ!?>(+;PI' %C\?'P_P"%="\*7VOMJ!6X\*V-
MA80O*\=TK^76?_!';]C:#Q9^P/XSET[XA7.N?\$Y?!ND?#_X#3WGCJ$QZUX;
M\/3>'M3\)6_Q.@@M/*\;1^#]?T"R\4:1'.NFK;>+;=]4AB>)TW?J]]AM/^>"
M?^/?XT?8;3_G@G_CW^- 'X]^#_\ @BG^ROX \7WOB?P_XN_:"N](6+]JR#PM
M\--9^)]CJ'PR\ 0?MK:?K.G?'N+P9X>'A>QN()->N=8;5;?4/$=]XEN]$2U@
ML](61-\!]V^+7_!-[]G_ .,_[+'[/_['OBG5OB9I'PI_9IO/@;JGPJU;P7X\
ME\&_$70]1_9]\)?\(Q\-=17QOI,$]_8ZSHS6UM?3WWAVUT(-.8C:D(DT;?H/
M_9MK_P ^EG_X"I_\=J;[';?\^L?Z4 ?SN?MD?\$*/ _Q._87U[]CGX"^)M8U
M+7/B_P#MK^#/VJ?C?\>_VA/B5XD\4_%S5]?UC6$TOXO?$Q/$.BZ9!!K_ ,0+
MKX:OJ/@;1O#%OI_@GPE-X;UK5(S<0^(9#K4WZI_M3?L*? +]K_\ 9UT[]E[X
ML:!K=K\.O#NI^!-?\&:GX#\7WO@;QK\/O$OPQ:W;X?\ B?P!XOTD/J&A^(/#
M,%A#817;6.QK>\G*JXW*?M;[/!_SQC_[X'^%'D1?\\H_R_\ L: /S6^$G_!-
M'X5_#'XM_"3XX:[\9?VF?C;\4O@G??&B[\&>,_CU\9W^(]\\'QQ\%?#WP!XJ
MT273Y=$TS3M&T'3-'^%WA?5O#%CX5C\/_8_$=[XFOKH&/4DCKRWPY_P1V_9]
M\!Z1\%[3X1?&+]J+X%>(/@G\#]7_ &;-)\<_";XS:9H?C#QI\&-3\<:E\18_
M"/Q(EU'P=K7A/Q#!H7C/Q!XHUOPMJ>F>#M UVQ.M.DFHVS#9!^O/V2V_YX1_
M]\BF?8;3_G@G_CW^- 'YOWW_  3&_9TU'7/B9XBU&Z^(UYJ/Q:_:L_9X_;%\
M7C_A--(:W3XR_LSP> -/^&5SHL(\-6:VOA=+3X?:"WBC29#YVI"TN$MBYN@H
M\BUG_@C'^RI>:QXA\9^&?%'QY^''Q8U;]KOXZ_ML>'/C+\/OB]-H'Q#^&GQF
M_:5\*:)X/^,-GX"O/[$N?#=EX%\0^&_#.DZ,NC>)?"/C&X5B\S-Y<>Y_U_\
ML=K_ ,\4_(_XT_[/!_SQC_[X'^% 'QE\/?V&_P!F[X;?LAR_L*Z9X)?Q#^S=
MJ/@KQ1X$\4>%/%VOZEXAU;QKH_Q%O=6OO'=UXH\4W.LV^MZCKWB+5M<UK7O$
M6MM)'>7=WJ9FL7-U%MKX>T?_ ((6?LJPO=_\)C\5/VM/BQ:1_LT?%[]D?P+8
M_%OXZ7/C,?![X%_&SPO>^$_&?AGX<SOHEI/%J$FB7%MIMIJ/C&X\;B"&QMU
MDC1-G[4_8;3_ )X)_P"/?XU!_9MK_P ^EG_X"I_\=H _+SXY?\$G/V?_ (ZR
M?"[4Y_&?[0/P@\3?#3]G"\_9%;Q;\#OBM-X#\2>//V<-1&G_ &_X2?$R[%CJ
MD/BGPE?/IMMJ,]O&MC?Z7KZ?;M&U$1GS%\X^/?\ P1!_8S^.MA=>&I-;^/\
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M0!=\^'_GHG_?0I^]?7]#_A4?V>#_ )XQ_P#? _PJG_9MK_SZ6?\ X"I_\=H
MT-Z^OZ'_  HWKZ_H?\*S_P"S;7_GTL__  %3_P".T?V;:_\ /I9_^ J?_':
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M0!H;U]?T/^%,\^'_ )Z)_P!]"J7]FVO_ #Z6?_@*G_QVHO[&T_\ Y\+#_P
MT_\ CM &MD>H_,5S^OS1?V)J^)8S_P 2G5#PZG@Q$=B>Y ]CP><U=_LRS_Y\
M;7_P'C_^/5F:[96JZ+J_EPQ1_P#$IU0$D$CA"QR!G@D$\9ZX/&: .GHHHH Y
MS4/^0UH'^_J?_H$=='7.:A_R&M _W]3_ /0(ZZ.@ HJ!KF% 2SD89%(*/E2Z
M[QN7;E%"9=V8!8D5FD**C$5K;5M,O5=K.^MKQ8Y;F!S:RK<XGLW2.[M\0ER;
MBUD=8KB!<RPRDQ2(L@*@ T**SUU;3&N#:"_M/M2BW)MC/&)]MXLKVC"(L)&6
M[6"X-JRJ1<?9[GR2YMYMFA0!\G?M=1Z;'\);B74=2_LR$:]H)-V9M/M[A4MY
M\G;>7_C7X>2@A<EW'BF*8] CAFV?EO\ 9O!O_0W2_P#@R\#_ /T45?J?^UB)
M$^$]TT=_J=EC5=)!N=(N]6L;D,'8%O-T;4-)U< [>1%K49X&XL<!?R\^VM_T
M,OB?_P *+X@__/8K]<\/J%>IE$N2O+233Y))](ZZQE?RV1^?\2SA]=6L5HM&
M]MO,I?9O!W_0W2?^#/P/_P#10T?9O!W_ $-TG_@S\#__ $4-7_M4G_0R>)__
M  H_B!_\]FC[5)_T,GB?_P */X@?_/9K[GEQO_/^M]\?_E9\[SP_FA]Z_P R
MA]F\'?\ 0W2?^#/P/_\ 10T?9O!W_0W2?^#/P/\ _10U?^U2?]#)XG_\*/X@
M?_/9H^U2?]#)XG_\*/X@?_/9I^SQ_P#S]K_^2_\ RL.>'\T/O7^90^S>#O\
MH;I/_!GX'_\ HH:/LW@[_H;I/_!GX'_^BAJ_]JD_Z&3Q/_X4?Q _^>S1]JD_
MZ&3Q/_X4?Q _^>S4\N,_Y_U?_ H__*PYX?S0^]?YE#[-X._Z&Z3_ ,&?@?\
M^BAH^S>#O^AND_\ !GX'_P#HH:O_ &J3_H9/$_\ X4?Q _\ GLTTWC*2K^)O
M$T3]HIO$GQ AG?\ ZY6\OQ92:7_ME&]6J.8-753$-=U:WW^S#G@W92@WVOK]
MURE]F\'?]#=)_P"#/P/_ /10T?9O!W_0W2?^#/P/_P#10U=-ZP 8^)O$H4MM
MW?\ "2>/]H/J3_PMK"K_ +1(7WH^VM_T,OB?_P *+X@__/8I3IXZG_$K5J?^
M-QC^<$7"]3^&N?\ P)R_*Y2^S>#O^AND_P#!GX'_ /HH:/LW@[_H;I/_  9^
M!_\ Z*&K_P!JD_Z&3Q/_ .%'\0/_ )[-=)HGA?QGXFMY+OPW%\2O$-K%.;:2
MYT*X^*>KP1S#DH\VG_%"YC4#NY8)_M5SUJ]3#J^(QRH);NM7HTDO5S44OFT7
M##^U_AI5/\%Y?^DMG&+!X)8D+XSSAXHRPU?P'M$D_P#JH]__  U+M\QO[F=R
M_P 0%+]F\&?]#@__ (-/ O\ ]%)7V)X/_93^(FM+H.M:WXRU6ST748-/?4+(
M>,_B?;>+;?2XE!>!XGUS^STUU&.QKTN(-PW)(Z,K-] #]C_P'CGQC\8<_P#9
M4O$?'M_K/UKY7$<7Y-AG;ZYCL7O=T9>T2:=M^7[K*6FM['I87AG%5OXRG#9_
MO(RC^=C\N3#X(569O&@"H(BY.K^ AY8FSY0ES^U+^Z9L?=DVL.K 4?9_!'_0
MY)_X.O!O_P!%'7ZHZ/\ LH^"]'U;3=6@\3?%FZFTR[M+];?5?B7K=UI^H/;D
M?Z-JMNLI-S& "6 PI)7:^ U?1!\,:$!@:-IY_P"W6WR?_(8^O]..?+Q7'6#H
MN/U=YE633N^>,>5JUKI1G>Z>Z>C5CT,/PM.JG[>HJ=MKIK[MF?A*(?!??QEC
MZ:MX%/\ []&*[3PM\*M5\;V$NJ>#M,\:^*M-AG-M)J'AZS\+ZQ9+..=@NK#]
MIR>%^.=R.R?[5?M3_P (UH7?1=-_"TMQ^NS^=36&DVVEQ&"RM(8;<N9?*MX[
M:T42, #BWLH+6V); W,PRV.2:Y,3XBXJLO\ 9J5:D_\ IZ]//X*4'MMK^!T4
M.$HP?O58+T?^;_KR/SQA_81U=H[>4_$RRM)L SPGPSXRD /INC^,CH?^ L1T
MR>N+'_#".J_]%4LO_"6\:_\ SXJ_1O#?W%_(?XTN7]!_G\:^<_UOXD_Z&-5?
M]O\ ^<>AZ_\ J_EW_/K\C\X?^&#=0_Z*E9?^$OXT_7_B\7^->S>'OV-_A!8:
M/I\?B#1K[5_$4%HJW^MV/BOQYH+7EQC+-_9UKXTN[6-LY7_6R)C:1U./K=5(
MZKD?AQ_6D9222!U]Q_\ 6_K]:PQ/$O$&)2C5S&L[--.-647==W3<;KNG=/JG
M8NCD>50VPD?^WH6^ZZ_&Y\S_ /#(WP'_ .A6UG_PO_B)_P#-71_PR-\!_P#H
M5M9_\+_XB?\ S5U],^7[_I_]>CR_?]/_ *]<G]KYS_T.<Q_\'U?_ ):=?]FY
M;_T"T_\ P!?Y'S8/V2/@-V\*ZL2.W_">?$ 9/_A4?E@FOH86L2# A@)_ZY("
M>G4C//'3\>*N[?4-^:G_  I=@]2/KC_/ZUS8C&8S&<KK8_&5.6_+[5SGRWM>
MW/*5KV5^]D72PU'#_P /!86/^"%-?CR_UW*WDQ?\\H_^^%_PH\F+_GE'_P!\
M+_A5G8/4_I_A1L'J?T_PKEM4_P"@NM_X#_P33DC_ - M#_P&G_\ (%;R8O\
MGE'_ -\+_A1Y,7_/*/\ [X7_  JSL'J?T_PHV#U/Z?X46J?]!=;_ ,!_X(<D
M?^@6A_X#3_\ D"@EI%OW-&F69&9@,-YD+9BD'7'& 5.< [22,YT"H( Z8Z?Y
MYZ_G2#=_< ^F./UY_,?6GC/?_P#7[TY3KO\ BM32VY;NVW37\NW8=.%*%_94
ME2\N5Q_.WSL%%%%4:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %86O_P#($UC_ +!6J_\ HIJW:PM?_P"0)K'_ &"M
M5_\ 134 ;M%%% '.:A_R&M _W]3_ /0(ZZ.N<U#_ )#6@?[^I_\ H$=='0!X
MA^T%X&UOXL_ ?XR?#/P?XRE\">*OB3\)?B%X(\'^.K4G[;X5U_Q9X/UWPYI/
MBZQ>,EKB71KG5(-3MS;AY4:&&:(9DB(_GE\,_L _\%"=1\'^-O#.BZ'\/_V.
MO#>H:]H%KX9\$?LM_%KPY\.?$HL?AY^QC^U+X$\/0Z_\7?@M\._@OXU^(?PT
M;]JSQG\!_$G@'PK\7-6\5^+M!?1_$O\ PETM[:S:Q-XA_2;]O+]O7XJ?LG_%
MSX*> _A[\(/"OQ&T#QOX+\=?$[XE:[XB\6^(/#NH:%H/@#XO_LI_"N:P\+P>
M'-!U[3M8\3WMA^T-=Z[%I>NW.@Z;/:>#[V[6:2T@N\?2\WQM^.:_M1VGPAC^
M#7A8_ ^\T5M9D^-/_"7?'<^(X=0'A)M772CH _98?]G\JTR?8=@_:;8?9\W9
MMQXCSH@ /C+]C[_@G9XL^&W[7?QO_;,^+?BBWB\?>*OB+\5&\'>&? ]CX6L=
M!U/PM\3O#'P M?$-[XT\1:5HEOX]\4W&G^*/A"]EX:\.>(?%]UX6\%--XANM
M*\,VZ>);Z9_V4CGAE57CE1U=69&1@P=%;:SJ1G=&&('F#*<J=V&!/\O?Q<_X
M*-?'#2]<_P""@LWPM_;?^!.H^ ?V>_B9\+M \,1^+;SX(?"'XF>']4M_$GC^
M'X\> _!\/B[P_P"*-*N_"^FV%[\,_A%\&_%OQ0\"ZL/B3\7-!\1VNB7FM2WM
MNUU_1G\)?&%SX[^%OP\\;SZ5XHTB3QAX$\)>*I-&\<:7;:'X[T]=<\-6>H?8
M/%.D6N++3?%T-U));ZGIMIBRM+B&>)&4A20#S3]J;P_J7BGX72Z7IC7GG/JN
MFYDTW3=8UFZ#)+C(L=#\!?$74&4[P"PTQ4#8#RY*[OS<'P9\>'_EY\8?^$G\
M;/Z?LJU^A?[8]W<Z;\'KF:WM]*O9QKVD!(M8M?"=]:_>8'-OXR\+>,]$W#"D
M%O#\K 'Y3'N;S/RC_P"$DU[K_P (O\/O_"%^ O\ +_A26*_5^!*'$%;*&\!7
MRW#Q]I44_;5:4&Y7C?E]HFW':S6F]M$?!<25*'UQ7HR;LK>[O]W_  _<]8_X
M4UX[_P"?GQC_ .$C\;?_ *%6C_A37CO_ )^?&/\ X2/QM_\ H5:\G_X277_^
MA7^'W_A"_ 7_ .<E1_PDNO\ _0K_  ^_\(7X"_\ SDJ^M>#XLC\6.RA>N(PR
M_.!X//1_Z!ZG_@,CUC_A37CO_GY\8_\ A(_&W_Z%6C_A37CO_GY\8_\ A(_&
MW_Z%6O)_^$EU_P#Z%?X??^$+\!?_ )R51'Q9K W'_A'?AUA7\LG_ (0CX!GY
M_;'P3Y7_ &QE/]JA8?C!JZQN6M=U6PUO_22)5\-'XJ4H_P")-?F>N?\ "G/'
M7_/UXP_\)+XV?_0JTW_A3WCC_G[\8?\ A)?&W_Z%2O*#XGUW.!X7^'[$+N*I
MX#^ [L!Z,J?!%F5_]@@/_LU[/H'P6_:&\4:+IWB'0_A#X%O-(U:UBO;"Z;P]
M^S%9M/;3C,4AM;[X56UY"6'_ "SGMXI5_B05SXG$Y_@[?7,RR/"W=E]8Q&"H
MW>]E[3EULC>E%5_X&"KUO^O5*K/_ -)BR_X=_9Z^)/BF_;3M+U'58)TMOMC3
M:];_ !*\*Z;Y!8ID:OXG_9ITC26DR#_HZWIN-H+^5L!:OJ3PO^Q)I9T6PD\7
M^-_&]KXB9/\ B<0^&M;T2YT;S.>-)GU3P<FH6Z8QEY$1LDC;C!KT+]EGX??$
M3P1X;\0Q?$+P5H?A+69O$#2Z:FBQ?#2-;C1VTBWQ^Z^'?AGPSIL*)J?G1^1<
M S.P$H,,.6F^M$5P.5'7I\O3\.G>OS7.>*<XEB94<+F"]E!_Q*%1<LM%?EE3
M;C):Z6MK&^FB7VF7Y+@YX6-6MAW3K2O[E2#A-6[QDDU<^8? O[*7P_\ !&M7
M&LSZGK_C4W5BM@VG>-QX<U[3HE!R9TC'AVQ(D. ,YR,]&&:]A'PK^& X/P[\
M#'W_ .$3T$?K_9_3VKO]O^R?^^A_A1M(_AS[$C/\Q7S5?,<QQ;4JN8XQR2M=
MUYIV3=M'4CU;UY7ZGK4<#@,,K0PJ7^&GS?C8X,?"[X8_]$Z\#=."?"F@G![?
M\P_G]:W-(\,Z'X<ADM?#FAZ+H-K*_FS6NCZ;I^EVL\I&"\D5G;Q[CCC++NP3
M@\FM[9SS'@?5?\2:>$'HP^A7_P"M7-4K59?QL7BZJ>MI5*E1=_YY[/7U[FU.
ME['X,-AE_AC#](K2V_Z$*1E6+"/#,Q21Y)"96C P"C*6"C)SM#+P,X#8JU11
M69N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M86O_ /($UC_L%:K_ .BFK=K"U_\ Y FL?]@K5?\ T4U &[1110!SFH?\AK0/
M]_4__0(ZZ.N<OP3K.@G& &U,_-\O\$9_BQGCG YQ@]"*Z'>G]Y?^^A_C0!FM
M8!YTG>)&FACDMHKAR3.D%U)!-?1PS2/<2I;70@MQ+;ED5KBQMI %$<,T<WV=
MT^<-,S)ED3S6&?G,@CV^>+<+M_T<'R00O.X 9JWYD?\ ST3_ +Z7_&CS(_\
MGHG_ 'TO^- &,^E"X\Q9X@5-PMQ'NFW-$R3;8I(;EDDN+>XAL]R1&U%L+-Y6
M%K,TY^WI;$$@.#"23*TCE9$:.0-.D44CRR_Z7]JM[-%<%=L88%%D<K'MO[T_
MO+_WT/\ &ER/4?F* /E+]KN?[)\(KB472PLNM:4P>?6K;P^A'F$LK7DWB?P?
M =O7:U\S'_GEP6'Y3?VLO_01TS_PN_!O_P ^^OUI_:FUE]"^%UUJ$5S):.NL
MZ5'YR3ZY9D,Q.T?:= \=_#74AG#?<\31KURIP GYF_\ "T1_T')O_"N\6?\
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MVNM>,=5M]$\*11^)-7NX[J6UT_1/&7A+4KFYCL^;EH([3XVRF81C_GGN+_\
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M?F* %HI,CU'YBC(]1^8H 6BBDR/4?F* %HI,CU'YBEH **3(]1^8HR/4?F*
M%HHHH **3(]_R/\ A1D>_P"1_P * %HHI,CU'YB@!:*3(]1^8I: "BDR/?\
M(_X4M !129'J/S%(70=64?5@/ZT .HHI,CU'YB@!:*3(]1^8HR/4?F* %HI,
MCU'YBC(]1^8H 6BDR/4?F*3>G]Y?^^A_C0 ZBBB@ HIN]/[R_P#?0_QI<CW_
M "/^% "T4F1[_D?\*6@ HIN]/[R_]]#_ !HWI_>7_OH?XT .HI,CW_(_X4M
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M^AYL.(,?!6PU+ 45YSI1_P O+\C] /\ AK/PMYF?^$/^(FWU_P"%:?$3./\
MPD^O?ICOUJ[_ ,-8>"O^A9^)G_AK?B#_ /,K7YY?VI\*?^B._#;_ +^^&O\
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M (DN5_\ R8?VYC/^?Z^]?YGZ%_\ #67@K_H5_B=_X:SX@_\ S+4W_AJ_PO\
M]"?\1O\ PVOQ"_\ F3K\]O[4^%O_ $2'X:?]]^'?_F3J3^V?A9_T1WX;?]_O
M#?\ \R58_P"KT/\ HC<^_P#$ERS_ .3#^W,9_P _E]Z_S/T$B_:P\*G_ %G@
MSXEI_P!TW^(#?^ZNW/YBG_\ #67@O_H5OB=_X:[Q_P#_ #,5^?']L_"S_HCO
MPV_[_>&__F2J-M5^%"E0?@_\,_F7<,7'A=ACW*^$R%/LQ!]J/]7XO?@W/O\
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M^A_[^0__ !50^???\^)_[_0?_':OT4 4//OO^?$_]_H/_CM'GWW_ #XG_O\
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MG>?>?\^=W_WWIW_R12?:[S_H%WG_ '_TW_Y+K2HH S?M=Y_T"[S_ +_Z;_\
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M ._EA_\ )58VO7,XT?5V-A/@:3JG_+>U&2(R,?ZXXX^;.. -O.<CIJPM?_Y
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MQMS6A_PSC\=_^A!\4_\ A0)_]$%7[,K D<0BCC152(0QJ59H1&",!K6-;:$
M 8 0*0. =O%6<K_</_?<G_Q-<+\2LXN^7"X!+6R<&W:^EVJB5[::*VE^MEU?
MZI93_P _L9_X%+_Y$_%__AF_X\_]"!XI_P#"AC_^B"H_X9O^//\ T('BG_PH
M8_\ Z(*OVDX_N'\S_A29'_/-OR?_  H_XB1G?_0)@/\ P7+_ .6!_JGE'_/[
M&?\ @;_^1/Q<_P"&;_CS_P!"!XI_\*&/_P"B"H_X9O\ CS_T('BG_P *&/\
M^B"K]I./[A_,_P"%+M_V/_'J/^(D9W_T"8#_ ,%R_P#E@_\ 5+*?^?N-_P#
MG_\ (GXM?\,W_'G_ *$#Q3_X4,?_ -$%4UO^SE\<I9((IO /B.SAGOO]*F.N
MF4VUKW<+%\?W=QQ]R-6?G[M?L[E?[O\ X\:9E?[A_P"^Y/\ XFC_ (B/GG_0
M'@?_  7/_P"6$_ZJ91_S_P 7_P"!_P#VI^;_ /PPIK?_ $4K3O\ P0>/_P#Y
M\=3_ /#"NM?]%+TW_P $/C__ .?'7Z,Y'O\ D?\ "EKPO]=N+?\ H(I?=2_^
M4'I_V#E?\L?OC_\ )'Q=\*_V2KGP%XSL?%6M^,SXBM])5IK'3K8^/;",ZJ1C
M^T)$UWXF>,8GCY.(I%8<89,'G[.6",C! ]@1_P#J_F35@,,?,>?I_D4@=!TR
M/^ M_05XN/S7-<UKK$XNK*I4Y>6]1/FMOLK)7>KLEKTV.RA@L%AE^[A!7?1I
M_A_FR#RT_P"><7_?'_V5'EI_SSB_[X_^RI^$_N_R/\EI2J@X*_J/_B:\]SC'
MXL577JDOSB=7LI?\^,-_Y)_\@0/$Y.Z$(& W,3%O:0 DB($3V_OC>3'TR>]7
MJK*7!Y&/<'_ZYS4X/ R1GZC_ !K2U1JU6<9KI9?I_7D:^SC3OR*_^%W_ ,QU
M%-+*OWF ^IHWKZ_H?\*:UVU]-2K/LQU%-WKZ_H?\*-Z^OZ'_  J/:4_YX?\
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M[\;2_P C3Z_Q3_T T_\ P3+_ .1/>?\ AN?X8_\ 0L?$K_PBKNE_X;F^%_\
MT*OQ%_\ "*O_ /"O!/\ AE#XC?\ 1*/"/_@P^#O_ ,ZBC_AE#XC?]$H\(_\
M@P^#O_SJ*/[&X!_Z&,?_  NI?HD/Z]Q1_P! ,/\ P1+_ "/>Q^W'\+&^_P"&
M/B6.!][P3>-S]1Z4L?[<?PODW!/"GQ1.T;B#X"U$''MNB!/T7)]J\#_X90^(
MW_1*/"/_ (,/@Y_\Z>N^\'?L51:O:S3>-=%\.>$;V"]/V6"T\(_!GQ<MQ:X/
MSL\WPSMT0'IM=A(,YV&N;$Y=P!A$W+$U<2^U#%0J?C"$[?<^^QKA<9Q;6_C4
M*$/\<.7\['?_ /#<7PR_Z$_XF_\ A#ZI_P#&Z@_X;I\ ?]"9\3O_  D]4_\
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M *%'XD?^$S??_(E,_P"&[?AY_P!"A\2__"5U+_Y!KV?_ (9<_9]_Z([X)_\
M!-:?_%4G_#+7[/G_ $1[P9_X*;/_ !K/Z[P/_P!"K-?P_P#DRO8<2_\ 03@?
M_)?_ )$\=_X;K^''_0G?%'_PA[__  JS_P -P_"__H5/B=_X14O_ ,57K/\
MPRQ^SS_T1[P9_P""N'_XJF_\,L?L^?\ 1'_!'_@EM?\ XJH^M\$/_F6YPOG#
M7\'^@_8\3?\ 03@?O1Y)+^W/\-A_JO!_Q58^W@:\'X?./\^_>'_ANWX;?]"A
M\3O_  BKVO8_^&6OV>_^B/>#O_!9!_\ '*/^&6OV?/\ HCW@S_P4V?\ C0L9
MP1_T+,X^;B_RL'L>)O\ H)P/WH\@_P"&ZOAE_P!"7\6/_"$O:/\ ANGX6?\
M0H?%+_PAKG_XJO8/^&6OV?/^B0>"_P#P50?_ !=)_P ,M?L^?]$>\&?^"FS_
M ,:7UK@C_H6YQ\I1_P @]CQ-_P!!.!^]'DW_  W#\+_^A4^)W_A%2_\ Q55O
M^&Z_AQ_T)WQ1_P#"'O\ _"O8/^&6/V?/^B/^"/\ P2VO_P 53O\ AEC]GG_H
MCW@S_P %</\ \53^M\$+_F6YP_G#3\%^H>QXF_Z"<#]Z/(/^&ZOAC_T)GQ6_
M\(:[_P :/^&ZOAE_T)?Q8_\ "$O:]?\ ^&6/V>?^B/>#/_!7#_\ %4O_  RU
M^SY_T2#P7_X*H/\ XNE];X(_Z%N<?^!1#V/$W_03@?O_ . >1_\ #<?PO_Z%
M#XJ?^$'=_P#Q-1_\-U?#'_H3/BM_X0UW_C7K_P#PRU^SW_T1[P=_X+(/_CE'
M_#+'[//_ $1[P9_X*X?_ (JCZWP1_P!"W.?_  *'Z)!['B;_ *"<#]__  #R
M#_ANKX9?]"7\6/\ PA+VG?\ #=/PT_Z$WXL?^$;'_P#)E>O?\,M?L^?]$@\%
M_P#@J@_^+IG_  RQ^SY_T1_P1_X);7_XJG]:X(_Z%V<+_MZ'_P BP]CQ-_T$
M8%_,\C_X;E^%7_0I_&'_ ,(&;_Y*I#^W-\)U^[X5^+K?3P)(OKZW?^<UZ[_P
MRS^SW_T1[P9_X*H/_CM'_#+?[/O_ $1WP9_X*+/_ .+K?ZWP-_T+N*/_  LR
MS_Y ?L>)_P#H+P/WK_Y \E_X;I^&?_0G?%G_ ,(R/_Y-IO\ PW7\,?\ H3_B
MS_X1:?\ R;7K?_#*_P"S]_T2#P/_ ."2V_\ BZ7_ (98_9\_Z(_X(_\ !+:_
M_%5S?6>$/^@+-?\ P.G_ )"]CQ-_T$X#[_\ @'DO_#=/PS_Z$[XL_P#A&1__
M ";5BS_;A^&NI72V.F>#/C#J=\_*66F?#^;4;MQZI;65Q/.__ 4->H_\,K_L
M_?\ 1(/ _P#X)+;_ .+K;\/?L^_!_P *:O::]X;^'7AO0]8L59;74=/L+>.Y
MC# @Y8J><'J#N'!# \U,L3PCROEP6:N7++E3G!1<K/E4FHMJ+E9-I-I-M)M)
M![#B;KB<#;U5_EH>6_\ #6OAW_HE7Q]_\-;K'_Q=:/A_]I[0O$.NZ5X=M?AC
M\;K2;5KPV$-]J?PXU"PT>TE5<_Z3J%Q)'!!" .9)#Y8 ^^>!7U#Y3>A_\=_^
M*IGD,1@H1C@Y" ,>#O0"0E>22,G=GJ> 3XSK9)9\O#-5.SLWG,FDVFDVO9JZ
M3:;5U>UKK<]'ZKC5_P Q<?N_^W?Y:;]"'^T+C_H&W'_?^S_^2*L?:9?^?.;_
M +^6W_QZK'E)Z?H/\*?@>@_(5PG>9WG7/_0,N/\ P*M?_DFF_:9_^@;<?^!-
MM_\ )%:E0[&]/U'^- %/[;<?] Z\_P"_NG?_ "73!>3-]_3[A?\ MXMS_*?_
M #Q^%_8WI^H_QIWE)Z?H/\* (?/G_P"?*;_O[;?_ !^J?]H7'_0,O/\ O]IW
M_P E5K5'Y2>GZ#_"@#-_M&Z_Z!=Q_P"!%E_\?H_M&Z_Z!=Q_X$67_P ?K2\I
M/3]!_A1Y2>GZ#_"@"F)[@C)L+@]>3/:#'YW%9S:^L8D+VDD:PMLF=[JQ1(7,
M4,P29WG"Q/Y5S"X20JV'  R& W"V4&WKUZ8[$]L#T/ZFO\ZG_@J;K6NP_P#!
M0G]J>&'5]15+3XDK]E6UN]3>:*'^P_#^;:S%K=V-NJYZ1IIK$=,GK7VW G!5
M3CW-JF64<;1R]TJ<:LIXB7)",93Y&FG.%I+1V<EH[M6/E^)L_I\,Y=]=JTG5
M=[-):Z:]FS_0W_MM 8E^S@-,XCA4WVG;II#)Y>V)#=;I&W_(0H."#GO4_P#:
MDN,C3;T[RRKB;3,L0^PE5%^2RAA]Y05(^;=L.3_G0_\ !-?5M>F_;S_91@FU
MC5);>Z^-GA"TGMY[_4K=+JTN-9/]H6\FE7=Y>Z?<P)_STC+Q/SY;N<$?Z!7Q
MX^,/AK]GCX+_ !-^-WC8S#PM\*/ 7BCQQKEO:JJ:AJUIX5\/W6J#1M%1<R/J
M6JSVQL]+MHXI;FZOY8K:U@F>YA1Z\0N ZW 6;97E=?&4L?4G2=5O#WDN5SE1
MBG:=1N2:N]4[.ZBD'#'$;XFR[ZY2P]2DV^5*49*[^*R32\[:'JYU7 !^S7)R
MP0!;C2&)8H\F JWQ8GRXI93@<1122'"1NRC:I*H4MI]^N_A09-,#,V"1&%-W
MN,IVN%B \UF1U"%D<#^:;X7_ +??[1'C+P#'\,?BKXT\::5\<M"_;._X)F^)
M9M;B^&OC;X(W&K?!G]J[]H#X8Z7\0OA18>&O%/@WX8:WK/A;X1_$#2/C7^SE
MJ>L:?I][J/B'X8:/X7U/Q@OB76]7U7S/I'X1?\%.?B"VG_!3X=:Y\);O7OB)
M\?+7X'ZG\ KB3QG;ZU??$GPWXH\;?$2Q_:$UK7KWP_X+\*1'4/V:_#/PYUCQ
MMXMOM&\&);^,K7Q%\.M+UI]%UWQ0UG7PY]0?N0FK2R*K1:;>RHV0KQ3:7(C$
M.T9"NE\R,RNCAE!)4(S, JDB/^U[K<5_L;4"1YNXBXTDJAAV^8)'%\4B*AU(
M$C*7!!3<.:_,O]@K]O'XB_MIKIOBZ_\ V=O$/PS^&OCGX4Z/\6? 7BG6HO%E
MN]M9:SK8TRQ\'>(9/$?AWP]8^(O$,^C3:1JSZOX(DUW0HKNQ\4Z5?7]G?Z!X
M=C\3?(OQ&_X*H?&CQ+X=^.]C\$_!_P -;6_\+^$/ GQ3^$GQ5UD?$Y_ /C;X
M;:I^TF_P2UF71X?'?PF\)3^,;2]TUXM2T?QOX9AU7PCX@LK_ ,3:KX=U?4-/
MM?#UY=@'[Y0ZG/.I+:7J,1 C+(9--,J>8@=%>);WS4D*$,8G02*I!9%S3WU&
M9%+/IVI*!O&#_9^YC&)681H+K=(VV&1E6-6+J%9 RNA;\W/VI/CIXO\ @W\0
M_P!EOQ!KOBS1/#V@6OPY_:I\<_%>TL-9URR^'%]>_"SX!+XZMGUB?2M(USQ-
M?>'-.E6;5K6&PTW4?$US90B]TW2-056BKYH\*?\ !5OXD:QX5\4Z[XC_ &>C
MX0TSX4?M'7GP3^-GC#6[/XK1Z1\.O#I^$'PM^+^D_$?7/AW'\)G^,.@^%(;7
MXJZ5X1\::SK7@:WTSX9_V9)K7Q&U#PUI=[:W<8!^W/\ :<_'_$KOQN9E4&73
M 6*Y)V WP+*?X64%7RNPMO7,"ZS<OL":/?L9/N 7&DDNI+!9%'V[)A?8Q2?_
M %+C#([*RD_ GP!^,W[1'C_X6?M3>)?'%W\(HM;^'WQ5_:6\&?"B7PTNM%;*
MQ^&GQ ^)WAKPJ_Q&34K>,P?V0NA^%UNY-(2?S;2SDU$.;:XAN9OS=_93_;O_
M &@OAU^RKX9OO%NE^$_BYXQ^&O["G[//[>WQ_P#%7Q-^.?CB7QM\1M&_:*L?
MBGJMUX=^%FDZMX-\2?V7XKL;;X1^)[VZ\-R)IGPT\*ZEXI\(_#OPGI7AWP_!
M+K=N ?T-G6YU<1MI-ZCG<-KW6D(0R(92K;K\;',2O,B/M>2".69%:**1UF76
M-RJRV=V02X;]Y8YA\M'DE^TC[3FU$01DE-R(A'-MMW*SND;?@%X=_;1^*GPB
M\3>,/&_B;6O%/Q!TW0/B!_P4)\#:/X#\2>-+G1/")U1O^"E_[,W[-GP'U'Q1
MJE_I7B.;PG\/?ACI_P 1-0L[KQ-%!JG_  A?P[_X2N]\,P^)=-5KB'Z!^)G_
M  4J\;?!.;Q[X8^)OPC\"7GC;P9XF^)_P@\*IX.^(FL:OX3^)G[2NF? OX1_
MM!?L\?"_0;K6?!.E7OA_4_BUX;^(7B+0]6T:[CU"\\)^(O %YJ.BMKNE7EI?
M3 'Z\'6641F#3M1NTD(1'ADTZ6,L7BC"F2.]9$;,Z,59@5B669@(;>=XU;5[
MM02VBZDJA9&+M-I:H$B#%W:0WH18P%)WE@C J58ATW?FO^SG_P %$K7]I'0=
M$\>>'_@[\1]2^'OB[6OA)X+T'5? WA?5/'%QX7\?^-/A7\.O'_Q&TGXN2P6T
M&C^$]"^&NH_%'3?A]XANYI8=6TWQ5X/\=Z->VT6IZ;=65I\]I_P5HU.\_9]^
M#_Q@TKX4> V\2?%/]GCP[\>-:\'W7Q/ET:Q\(ZGK/[2OP,_9YO-.UK7+;P=J
M.IV'@^.7XO7OB^3QQ=:3'J,-MX3N89="5KB!) #]HUUR5R0GA[67*C)"_P!@
M,>!*2 %ULDL##*A0982QO"1YJE!9&J7C??T+41];G1S_ .@ZB/\ ./P^:?V:
M_C=XO^*\OQL\-^/=!\(:%XT^!7Q@C^%_B2_\"^)-9\5_#[Q(;WX;?##XI6VO
M^';[5M,TR]MK:'P]\1K/P[?V]TA>Q\9^'O%*WR0;0DOUAY2>GZ#_  H QY-2
MOH_]5H.HS>N+K1T'_C^HC\?ZU#_:US_T*NM?]]^&_P#Y?UT.!Z#\A2T 8/\
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M%7Q!XX\(Z%JWB.&[TW5=4CLM2MXM&T&![E)AF(1RKHT;1%NF[>I7D$K7U/\
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M&F:!XW\/7*S7_A_Q'I4%EJ5A?7"ZLT[ZP@N(OHNB@#SWP+\,? _PQT>Y\/\
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MDVI_!AOL$-Q?-)KGAR6*"STR'6;B:)IRPDCLI/#GBF>3*Y.Y+(L >9/F._\
M*+_A#O%__0L>+O\ PCO$?_SFJ_7+]H9O#'@[X.PVVL:'I6L^'M.F\/:5;Z1K
M,DK6BF!FC2::>'PWXPBE>.-",CPS+D[R"H9$3\]/^%A_!O\ Z)#\+O\ P!T_
M_P"AGK]8X%SC-,MRF6'HY5''495)N4Z5"56*E[JE%-1>BLK;Z/1GY_Q%2HU\
MW2J3A!62]^45IKW?]>IXY_PB?BK_ *%OQ9_X1_B+_P"<U1_PB?BK_H6_%G_A
M'^(O_G-5[%_PL/X-_P#1'_A?_P" .G?_ $,]'_"P_@W_ -$?^%__ ( Z=_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6S9RWF:?_P!!,_\ @X\+_P#SP:/,T_\ Z"9_\''A?_YX-=3_ &!9?]#'H/\
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MVO?[_ 9)@\!'WJ:JR6SY>;\OZ\]K4X+7R@VPJ,^02-D.,QD;BVR"#(QD Y(
M^9%7[AOE<C!/X^_^>U0;9?[H_,?AW]?\BI<-MQ[^HZ8Z?Y]*\!NJUSU9*I-+
MX8=-.RW]>A[2IQI_#:S\[LDHHHIC"BBB@ HHHH **** "BBB@ HHHH ****
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M)?\ !=GX>>-?!OQH\+_%_P 5_P#!/[]G34[JUU7Q/X4^*D=UXHU+X@:%./\
M2XK#]E_6;F]T^#4KN-=EYKOQ#A^&GB;2PSOX>OILLC_V\?\ !1_P;XQ\>?\
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M\'ALI<:U2AAY.<FHUIPA)Q?+:RG9NW=7[=#X/B*$YXQ<D)3T6L$Y?BKGEO\
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MIZ7D/_?1_P *3^V-,_Y_8?S/^%1[.I_S[J?^"ZG_ ,K#ZWA?^@FA_P"#J?\
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MT[_GZ3_OF3_XBD_MC3?^?N/\G_\ B*SOY2_\ J__ "D?UK#?]!-#_P '4_\
MY,TJ*SO[7TW_ )_8/^^__K4O]JZ=_P _D/\ WT?\*T]E5_Y]U/\ P74_^5B^
MM87_ *":'_@ZG_\ )&A15+^T;+_GX3\F_P#B:C_M?3?^?V#_ +[_ /K4*G4>
MU.H_2G4?Y08?6L+_ -!-#_P=3_\ DC1HJA_:FG_\_47YG_"E_M*P_P"?F/\
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MNQ8W&JRZ=:F:WEDQ*]S;:QX;;R4!D)B.JH9"Q95/W5_"/_AFW]G#_HG.D?\
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M -#*O_?SQ#_]%E3?[/\ #G_0Q?\ D;Q!_P#19TWG%",N25>@I_RO(*"E_P"
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MX6\4_P"!;MGOS4P_9P_9I*AU^'&G.A,JJ\?Q#CD1S#_K?+=/BVRR;?5"P/\
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M+^</_P <HV2^DOYP_P#QRC_B(O&__0WQ'_A-DO\ \Q!_JED?_0NK?^'6O_\
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M/PXT'Q#;^&/#/P)\7?&GXH>//B9=_#OPY\/M _:'^)GBSX3_  ST/P[:Z/\
M#SXBW/B?QKXE\3>!M>G6#58_ '@'3&C\/Z?XC\<:3J/BWPI;:L ?J$&4@$'A
MN0<'D>O3I[].1SR,QK<0NJ/&XD210R/$&E1U*R,"CQAE;*QOC:3SM'5T#?D[
MH7_!:;_@G]XI\%MX[\(?%3Q3XWT :IXBM(Y?"/PG^(_B;4&TSPEX%U#XF>)_
M%@T/0_#-YK4?@[0? >DW_B;5+][ 265A;A)E%S-!#)M:A_P5+_9[U;2/&?\
MPK;_ (2_5O&GP[2P3QWI'CGX8?%?P99_#34=1^-7C[X':=X0^*>LGP%XIO\
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MPB0K+XA^.+HXRLD>D>))(_QDC\!,BGV9@?:NK_X8Z^.?_0O^!/\ PH?AI_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC_A1D>_Y'_"@!:*3(]_R/^%&1[_D?\* %HHI,CW_ "/^% "UA:__ ,@36/\
ML%:K_P"BFK<R/?\ (_X5A^(,C1=7&"3_ &5JAX4GK$V.@/7.<=<9/0&@#=HH
MHH YC5(()]8T%9XXYAG4@/.AC?I&@Z]L#@<8QR<,3CXG\0_MT? WP=\:?$'P
MD\;>'/&/A#3]"^)47P6O_C7XBTCPS9?!N#XI7/P$T?\ ::MOA[K'C!]<D\1Z
M')=?"?7D\467B'6_#=AX3N;YY/#%MXCE\7[O#Z?;FH?\AK0/]_4__0(Z^"_B
M/_P36^!WQC\??%#QE\3M:^*WB;P]\8O$&N>-/&?P@N/&NF:?\)YO'>N_LZ6O
M[)UUXV;1/#GAK0?$FJ:W+\#-/M-#&D^(O%^O^"]$\2*/&6A^&?\ A+E7Q)$
M>E6G[=_[%UZWAM(?VA/A/'/XP\12^$?#%I>>)(=/O];\5P:C\/=-E\,V.GWZ
M6U[)KZ-\6?AEJ7]D&!=0;PYX\\*^+%MSX8UFRU>6M9_MY_L2ZOH6E^)]/_:/
M^#6H:%K?B[2/ >BZA9^)=-N(]8\6:_X;E\9Z%I&E10L]QJ#:SX.M[[QAI5W9
MQ3:?J'A32M9\26MU+HNB:M?67S]XI_X)1_ 7QW>^#==\>?$O]HGQGX@\#_%6
M]^.L'B36/'GA[25\1?%&X\,?"OX;)XL\4:7X-\#^#_">I.?@O\(M/^!Y2S\/
M:9;)\-?%WQ,N7'_":^/KCX@UK?!O_@EE^SE\(X?!LMAJOQ$\8:OX%TSPSX6T
MW7?%WB72+K6(_A_X+^ OCK]F[P%\,M5_X1SPCX7AU/PU\/\ X5?$3Q18:#>W
MNG6GBK5_%&KW_B[QSK?B2^2WLE .M^(/_!1_]C?X;Z_\,-.U?XO^"Y-!^)]U
MJDMMXZTS6=!N/!?A#3H_@]IWQ\LM3\;:O+*\VFZ3XV\!ZM9:_I-_90W-A)HM
MR-0GN+*VM9Y*T[_]OG]EW2+;XG6^H^-O"MMXK^'UG\<-0UOP$WB[X52^,M3\
M._LYWOBNQ\:>));B/QK-X:T71UNO!7B6T\-ZC\4-:\!V-I<Z/>0>+KC1;F.1
M1\A3?\$COV1/#O@W6/AQK/QT^.]O;^%?"6?%NL:W\7OATOB#3_@?J/P _P"&
M4I?!_B2XU7X;1?V-\,;SX >'I_ >HZS>:=;>(]*L;'4?$^D?$)/'EG<^)(O6
M=,_X)5_LIZGJ?QB\9^"?%_Q2T?2OVI/A]\8O GQ@@\'>.O#USX3^)'PV^.OB
MCXL^-=0TB\BN/#>HMI]AX2\0_&CQ_/\ #2?1M3C.E6]U;6^I2:X;+8@!VWQ4
M_:\_9^\6:-\0/AO\"?B_\.O&WQ8^&WB(VOCOP+X)\6ZM!XH\+)H/CK4OAIK\
MFK:;\,XSXFM[;0O'FE7WA;6+E+1[;2M6@,&H26ZRVSR?*(^.7Q*9=C1:H8O[
MDWCO]IQG_P"^D@/?'?M^->Y:Y_P3<_9^^%WBG6OC?H5[XS@\::Q:_'30+R[U
M>]T;Q)H3:=^TG^TM>?M6?$%I=%NO ^IZ?]HE^*^HWDNC3S:3JHTS2'BT]6 W
ML>;_ .%&^"_^@Q%_X2_@S_YP5?<\-<3<%Y)E_P!3S3+,SS7'MJV.HX+%8F"T
M6CJ4<)7CIOO?74^$XHEBH8Q?5*GLM%UM^5CR_P#X71\0?^>5[_X5O[2W_P C
MU(OQN^(:?=CU/'MXO_:3_K#_ (UZ=_PHKP9_T%XO_"8\%_\ S@Z8_P #_!,:
M[Y-9AB7&?WWACP7$<>PD^ :D].@&?:OH%XA^'<ML1FLO^[6QC_\ ><>#_P *
M_P#T,H?^#%_\D>7_ /"[?B%_=U+_ ,+3]IO_ .1J=_PNWXD_W=0_\+3]IK_Y
M&KU'_A1?@7_H,P?^$QX*_P#G!4W_ (4;X*/*ZS"X]4\,>"W'YI\ V'ZU/_$1
M/#G_ *",T_\ $5QW_P ZR>?-/^AI3_\ !B_^2/+_ /A=/Q#_ .>>H_\ A:?M
M,_\ R/1_PNGXA_\ //4?_"T_:9_^1Z]/_P"%'>"?^@S#_P"$QX,_^<'1_P *
M.\$_]!F'_P )CP9_\X.M?]?O#_\ Y^YM_P"(MBO_ )A'[?'?]!L?_!B/,/\
MA=WQ'_YY:K_X7O[3W_R/3A\<?B81N":SCU/B_P#:>'Z&W!KTW_A1W@G_ *#,
M/_A,>#/_ )P=>BZ)^QK9>(=,M=2L)K"6SO8O/M)1HWPAA,\).WS4AG_9WBFV
M$GAB@!X(R#43X^\/:>DJF9Q[\_"^)A;_ ,"P'^7S-:-'/<1_ QKK?]>FY_\
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M=2_^)V?Y6_RZETJ"I]%?RV_$H_V9;?\ /K9_^ H_^/U7_P"$?TC_ * ^D_\
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M\\?O_P" %GV,^/3;9?\ ED<_]?$Q_J/?N?3FC^S;;_GD?_ F?_&M#(]_R/\
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MQ.\0Z1K/]L>+M4BU71/C'X/\$:,->C TV+^V_A5XX,40 ^2$ #[PV#^ZG_?
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M=7_HKJ'_ (:W_P#+2_\ B(#_ .A?6_\ !%3_ .1/[]?[8T[_ )_+3_P*@_\
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M_P _]C_X&VW_ ,=K^ _^U_%7_14+7_Q(W1__ *;K1_:GB3_HIMK_ .)&Z/\
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M\%766'_MJ4IOP3JQ^+BRBO7*9K\YE/Q"2WP%5>M&I_\ (G]_GVRT_P"?E/\
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MM37_ /HI6G?^)-^'O_IK=/\ X@E#_HL:W_ACQ'^0?\1"C_T+ZW_@JI_\B?Z
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MFD[15TE=VLG)Q5VKR2U1]?X@=E_JI12T7_(WA;Y^\]/0_>3[=;_\]!_WS_\
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MEQX:U_PUJH;'79J.",;N%4#\[/\ A#6_Z'2U_P# OXB?_/'K]!?VH[/PY/\
M"NZA\2B]_L:35M)5SINBP^(FR&8#-G=>&?&5B8\D@22>'90I&T$')/YK_P!@
M?!C_ )Z>,?\ PS?A_P#^AQKZSA6OGE' .A@,VSFG3<Y.3P_!65XVDM59^WE7
MC9M6O3Y5&&B5[W/@^)Z5)XU-.-K+3\][O<Z3_A"C_P!#=;?^!WQ$_P#GDT?\
M(4?^ANMO_ [XB?\ SR:Y_P#L/X)_\_'B_P#\,_X?_P#H<Z/[#^"?_/QXO_\
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MEW_RX/:/_H&R_P"^E_F=!_PA1_Z&ZV_\#OB)_P#/)H_X0H_]#=;?^!WQ$_\
MGDUS_P#8?P3_ .?CQ?\ ^&?\/_\ T.=']A_!/_GX\7_^&?\ #_\ ]#G1[;/?
M^AGQE_XKO+O_ )<'M'_T#9?]]+_,Z#_A"C_T-UM_X'?$3_YY-'_"%'_H;K;_
M ,#OB)_\\FN?_L/X)_\ /QXO_P##/^'_ /Z'.C^P_@G_ ,_'B_\ \,_X?_\
MH<Z/;9[_ -#/C+_Q7>7?_+@]H_\ H&R_[Z7^9T'_  A1_P"ANMO_  .^(G_S
MR:/^$*/_ $-UM_X'?$3_ .>37/\ ]A_!/_GX\7_^&?\ #_\ ]#G1_8?P3_Y^
M/%__ (9_P_\ _0YT>VSW_H9\9?\ BN\N_P#EP>T?_0-E_P!]+_,Z#_A"C_T-
MUM_X'?$3_P">31_PA1_Z&ZV_\#OB)_\ /)KG_P"P_@G_ ,_'B_\ \,_X?_\
MH<Z/[#^"?_/QXO\ _#/^'_\ Z'.CVV>_]#/C+_Q7>7?_ "XSY<)_(ON7^9T'
M_"%'_H;K;_P.^(G_ ,\FC_A"C_T-UM_X'?$3_P">37/_ -A_!/\ Y^/%_P#X
M9_P__P#0YT?V'\$_^?CQ?_X9_P /_P#T.='ML]_Z&?&7_BN\N_\ EQI[1_\
M0-E_WTO\SH/^$*/_ $-UM_X'?$3_ .>31_PA1_Z&ZV_\#OB)_P#/)KG_ .P_
M@G_S\>+_ /PS_A__ .ASH_L/X)_\_'B__P ,_P"'_P#Z'.E[?._^AIQC_P"*
M\RW_ .7$<F%_Y]_A_P $Z#_A"C_T-UM_X'?$3_YY-'_"%'_H;K;_ ,#OB)_\
M\FN?_L/X)_\ /QXO_P##/^'_ /Z'.C^P_@G_ ,_'B_\ \,_X?_\ H<Z%B,[>
MV:\8OT\/,N?_ +E'[=?\^,M_\"I'0?\ "%'_ *&ZV_\  [XB?_/)H_X0H_\
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M4?\ ##Y_Y_--_P# /X7?_.(H_P!;W_T5O$'_ (A&2_\ S8']DYK_ - &'_\
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MPDW-OEJU84I;1Z3E%].W<^'XCO\ 6X^B.V_X0"]_Y\/&_P#X-_'O_P DT?\
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M ".U_P"$ O?^?#QO_P"#?Q[_ /)-'_" 7O\ SX>-_P#P;^/?_DFN*_LO5/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^:/_ (%'_P"2(_\ A"_%/_0^^(/_  !^/'_S=T?\(7XI_P"A]\0?^ /QX_\
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MSA>&L16_C.4%UYXN+^5['Y;>$?V9?C'XPDOXXO%NK:*^G8\O_A-+'X]>'UN
MW0QO>^/;1)0>N8V<8R:]Q^''[(WQ5\,>.?#/B+Q3X^TK6-#T/4H=5FTVQ\1_
M%"XOKB6S@,UI TOBCQ3KT+QKJ&&),F!'AAD\#]$HXY57Y]KL!\F 8P!C&'9I
M9V8GU (Z9]:E8.3PGY%1_7_"ODL;QQG^-4HIX6C"<'"4%"*34H2A/WDG-<RD
M[=5T/I,/P[E\-725T[ZI+SZI+1]O(2%)8TQ(XD8="!C/YX%3T45\B>^%%%%
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M3PAS>$/_  .7%ZC^)Y$,/A:G\.K1G_@E3E^39X@/@+\0&WA?"7AYV3[RI?\
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M,\00S6NYVMFN]2TO6;>#<KJS+-8;B#&HQAJ^6Q^P'I?\7[1G[10/_8:^&_\
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M2X>PAY?A_P#)GV!_PKGQO_T77XB?^$_\&/\ YU='_"N?&_\ T77XB?\ A/\
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M<-7X?>,WSM^.WQ%.!EC_ ,([\&@%QC*NQ^%0".,@M&Q$BCDJ!7SI^U1^W1X
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MX3_P8_\ G5U[!M_V/_'J-O\ L?\ CU+ZWC/^?6%^ZG_\K#V%/S^Y?_)GC_\
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M%VOV$/AGQ]X1@N-<L+26XCUFWCM;VSU[3='NK&XB7[]V_P"Q_P"/4GBL:O\
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MJ.J^$(/&%SHEEIG@K3M"UCQGXEUJ'Q$NDV6B6"L;Y)98H9G]:QO_ #ZPF_\
MTZ_^0_'8/80_JW_R9^BJ_#[QFV[;\=_B&=O#'_A'_@SA3TVLW_"J\!Q_$A(=
M<@LHR,O_ .%<^-_^BZ_$3_PG_@Q_\ZNOBCP/_P %1/V?/'7[9$_[%.G:!\7;
M+QM-XM^)/PZ\'_%35_ .SX'_ !#^*WP6\):7XX^-_P )? GCBV\0RZK=>-?A
MKX1UW3-:UN[U;0]/T&X@FU"#0]8U>YT?4[>']-]O^Q_X]0\5C5O2POR]F_RI
ML/80Z_A;_P"3/'_^%<^-_P#HNOQ$_P#"?^#'_P ZNC_A7/C?_HNOQ$_\)_X,
M?_.KKV#;_L?^/4;?]C_QZE];QG_/K"_=3_\ E8>PI^?W+_Y,\?\ ^%<^-_\
MHNOQ$_\ "?\ @Q_\ZNC_ (5SXW_Z+K\1/_"?^#'_ ,ZNO8-O^Q_X]1M_V/\
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MFP]A#_AK?_)GD_\ PKGQO_T77XB?^$_\&/\ YU='_"N?&_\ T77XB?\ A/\
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M&JW\-E#?W<@^8*T%DHLXI"" (SM<#),>/F$^N_/HVKH =QTW4XQD%1N:V:4
MLV% * G<2%&"I.[BOQV/_!:OX"0_#_4=<O?V>_VQ],^+.F>.D^'TG[)-W\'O
M#4/[3=S9S_!W4?C_ !?$9? [_$?_ (11/AK+\)=)U3Q VNOXICU!=0M/^$/-
MJ/&<D?AN3]/?AY\6/ _QV^!WA#XT?#+6E\1?#OXN_#32OB%X'UV.&[ABU[PQ
MXQ\*0:YX=U&TM;VWMM1C_M#2KNWN1975I;ZE;EWAO+.UNDD@2#0]IHHHH YS
M4/\ D-:!_OZG_P"@1UT=<YJ'_(:T#_?U/_T".NCH **** "BBB@#\.OV]?\
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M_BIX#\/^'(/!OB'0GTK2=4\9>#;72?&$MY;WAN?#EY+>:7+'J*L\GY^^/?\
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M\P/PF_X($_%OX/\ B+P+X0TG]J+PMXE_9\U_5_\ @G_\0_VC--\2_#OQ#?\
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M++BYBT#PW%&@']0FG:?#I=A:6-JC>190B"V5V#.L:C #OG#$#K@G@=S6C10
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M_0_X5'OF_P">7_CR_P#Q5&^;_GE_X\O_ ,50!)O7U_0_X4;U]?T/^%1[YO\
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MY\"O#_Q6^//@OQ9;:U'8_$*;XV^-_&&O:U<Z''J6C:EH^N:WJGB1OW\WS?\
M/+_QY?\ XJC?-_SR_P#'E_\ BJ /R$\-?\$MC\-?'OP=^.WA+XZ_%#XA_%W]
MEK]GWX@?!/X!:;\5W^$%C9ZS9ZUHGQ!T7PEH/Q>^,'@SX&0_&;Q1X%T.T\96
M%JFCWFN:SI+ZGX=TCXE7WA*\^(-N\[_<?['GP%?]F#]EC]F_]G>ZU&#7+[X(
M_!+X=?#+4]?T]'M].UK6?!WAG2-+UO68+:8QSPIK^M6MWJD4;0'RHF,4AA+!
M)/IC?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\
M'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O
M_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ
M_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_
M  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\
M'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O
M_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ
M_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_
M  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\
M'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O
M_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ
M_H?\*-Z^OZ'_  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_
M  J/?-_SR_\ 'E_^*HWS?\\O_'E_^*H DWKZ_H?\*-Z^OZ'_  J/?-_SR_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm247121d3_s1aimg009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 I0# 2(  A$! Q$!_\0
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MQ2YP59.H(]L^V: .QHK,T/6#K5DUR=.OK !]HCO8A&[# (8 $\<UIT %%%%
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M;S7>FZ1;RP^4E\;:X)?&#Y@ R/;(K>\$:-K^F7>I2ZI<3+8S%/L=C/=FZ>#
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MNVED5H9VBL'"E3U4N$QCVSBK4OCGX87>E1Z4]Q97&G1J EN+&1XE Z #80*
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MK'S<V$G^NM?7_>7WJG:ZM=Z1<&ZM%8C/[U#]UQ_C796VHB<1>(-$F,5PH_>
M=#ZJP[T >+8.?>ESV->F>,/#ECKNER>(]#M3;W4?.H6*CY5/=T]O4=J\RH ^
MS/A3_P DO\/_ /7J/YFNQ/2N.^%/_)+_  __ ->H_F:[$T ?'OQC./BKK?\
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MW#SJ09HWX5P.^/:@#D_#?A6[U_6(=/A.))3@>@'=CZ "NTT7X8^(-4OI+:2
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MZXKR/6M1\2:_<3:QJ-])<!"?+B3*!5]%4< ?J>^:QTOM)^U17MW!=S(!S&A
M7/O0!NMX?GFQ<#48&$K?,N[)]R>]3ZGH:JD=LUS(5VEXHG/48Y(J/0?$OA^.
M>[*V$T7R@IYK%@&] M=#':?;PNI21R1*4**,?,!]!TS^= 'FMW;_ &%L[20>
MF.,5##-D,Y4=2>!7<ZIIL<FY?*8H1P"IS^=<_%HRM<[(XR^WL!_.@#&P\Y)5
M2".GO77:';Z'L*WY$DZ*"R99?U%7AX6$EJ"C+"^,KE2>?2N:U&QO;*5-MNL1
M! 954@MCN30!7U:2XTN:6>6U06KO^Y(DSD=@*J#4$EC$^THA_P!K./PJQ?21
M:C>PQ7D$HV1]?0]CCO6-,X6$QVXW*<@G&#B@#334;4D#SU!]^]+)J=M&O#[C
MZ 9KFW0JY.W ]*O:98VFH2B)[TPL>@=?O?CF@#<T4FZANKQ@2SR")/IZ"NEB
MLTL;26YD>(R1G:$#_/O/?CH!2VEA'8Z"EI;6]NO)S<2+\[>X/KVJKJEE+<$8
MNH8;>- '<G+ >E 'I_PM6VN-86_;(OVLGCD Z,H=#GZUZZ.@KY_^">J)J'CJ
M^@@8M;VVG%$)_B/F+DU] #I0!Y%J^H&Q_:-L$!&;C2A&H/0G<YQ^E=#JDEIJ
M,=UI.J6XMY8[R,AHUW(-_1B??I]:\Y^)=^=-_:!\/W0_@A@!QZ%W!_G7K>JV
M"0WB:HBK)%*!%=1.?OH3QM]P>W?- '@GC/0?L6EVNN0$D6%Y+8SD'GR]QV-^
M!R/RK'2^B6T,KC"J.6/0BND^*'@W6;2>*VT&UF;0[I][I&20DNXYW9Y4#.?2
MNIT#X?Z#\.M)2_\ %<HUG4B-\%C#%YJJ1V13RQ_VFPO\Z +?PI\.W4RS7^J:
M7;2Z=-'F%[F,,<]BF1TQWZ?E72_$+4['P]H#6%C;PPWFH*T0$,84JF/F/'Y?
MC[5XOXW^*OBG5YIH9;-])TS[L=H=RO)[LV/F^G3V[U@S?$J^N-;@U&Z3[4Z0
M)"RW(# !1CC\R3ZDT 2"]M]-N$MI$$*GF,#I6/K>O^;$]M;)MC8;2P'49Y%:
M5UX"\::R5U:#29;N";YHWM\8Q[#.16=XNT36]"CTZ#6;9[61XMZ0ELX&>_H:
M .@T]E;2[1D&!LQZ5='W 3D@>W6N-TCQ+/;J\5P?,4XVY'3C&!^%:X\1VK$#
M>,'@GT]J -@PCRG) Q@_,2.*YW3-6:RLA)+"L=L9/+#+T/OC_"JFN>(#/!]C
MMCA<_O&SR?:LK2M+O-9N!:VV2>H!S@&@#J[W7;-)=B;.@._&.".U+:7&G+:F
M_EO(2[MC:7^8>G%9OB/P8?#MC%--JUK-<.!FV3=O7USQVKE: /0H]1C9PZ2J
MZ-]W!R*=+.LL!D+ @=5R,9^M<!$LT[+#&68DX5=W>K3:1JN<&QNSS_SS8T ;
MFBPIJ?B>VMXA'Y-JKOO50"0,MDGOSW->L?"V$#6Q>;'<VZEG<#Y0K'U/%<=X
M+\()IFFWFK:Y>R6,LL9AM[5(2\LF?ITS7=S:T_ASP\FBSQVT44RJS21H4ED;
MCY0,G/UH [+P3I[V'CWQL&7"SW$$R'LP9#S_ #KT#M7-:%=6USK%WY.6E6TM
MO,;USO(_2NE[4 ?&_P 7?^2JZ]_UV7_T!:[FU2"YT**5_P"&WC#>X(QBN&^+
MW_)4]>_Z[+_Z M=+IEM=ZEX/L9K6Z6$>5Y<P8D;@#UH XW7IO[+\1>5(C'RE
M"L1W':M31%F\17\5CI%O-=W+_P#+)$Y4>K'H /4G%=-I/@W2/&&NQ6NJZB;>
M0K@2+@,X4=/3..YKJ[_QKX<\ 6#^'_ MG"UQTFO6&Y=W3);K(W_CH[<<4 >A
M^#;-O"FCV.A:MJUO)?S,[6\&\ A<9*KGE@.3G'>O(?BOXWMM5\2RV$4S-:Z<
M#& HX9_XF_I^'O7GNJ:MK/\ :_\ :MS//+?,0PNVE(=6!X(/;'8#BJ.G6UK'
M=V][=7*QH7^=#\V1WS0 )K"7%RR(_EAN 6X%/\Z*VU"-]S[ WS'%>A1VG@Z0
M*PT:-[@KN18RPW_@#BL._P#!NH7;SW2VJP1N,QP[@30!62<3*KKD@\T[(*$\
M "L+S;NS MF5D9.FY:2&]=T PSR'^$'O0!8U"^_>I%'@A3EF_I71:+86=UI\
M\S*&N&4B/+D*I/3ZU%I'@NYN+,7LJA2[;A&3U%6-0BN+ JD1X4D?*P &* .1
MOKG4M&N1:W0A9_16SQ3SJ+0X:9-RL?E9.15_4%M;H7D\]FR2K@++_$2,=1TK
M$AMIKMBR,#&F< @<>^* +YURT*?>*GTVU1N-32]NH(U0^67&>>M/?3[88656
MP><C@UTNG:!I>GFWO0'DFQO5788!H U=.M$MK>:2YG\F1$++&5/SD]!GZ5%#
M.+GQMX'<'.+M%SGMY@J:TL!?22+=WYC#,6 "G+$]LUD6-W!+\6?#UG:@BWL[
MZ&)<]SO&30!]<#I2T@Z4M !1110 4444 >%_M)';H_A\^EQ*?_'5J#PW,^H>
M'[1HV3?@#<_8$?SJ?]I3_D#:!_U\2_\ H*U@^ ;ICX;A!_@*CG\J -;Q?H"W
M6DLT;CS O#XQD]C]0:X_19)_$%B[RE5\F58Y.<'?C&?TKTLE;D2).WF1*-I!
M.<?2O/\ 2K>UM_'&HZ7>A4M+N,3HY&-K*<@KCH30!U6AZ$P<RQQ@01DA9)),
M"0]S576H8K[4$NH &*#8V,<CU K.UK6K^*^D>*>4*IV+'N.T =.*K^']/MDB
MFOGFE>ZE4@(\AQD^@H I>)F7R[,00".8-M=0G)/8^^:T_#GABYOPLMQ"\"8X
M8';N/MBJGV75+NX2>_2&)XF&S:V2%'K78VR3RVH>.78%&Y6R<YQ[=J *EU8:
ME;2%(;YO) SLD3E1]:FL[::X :XNE(Q\T:)W]*X37_&&MI?+8+<$[,D@C(Y]
M*;H?B/4;JZ%J2Q?J020"* /1+O3F2W,EFL*L.2/+&3^-<E?:?<332S2EE^7#
M*>H/K74II@,:RW+;I"N>&("^W7-9=Z\=I=$R?<VX.3QB@#EK^RM]1AAM]OEP
MHP!=>P JWX:T*QU"YEB@@=;6(XE>5LY-3Q6R3-MW;4:4UU&DV46F:6L,9 ,C
M-)(W<F@# G\ 61NYI8)083@*C#.T_6L&]\'V^GW:7-T^[RV^4QCY6],UZ5'&
M"K$,#N]*Q];C1X[:W:(2-*Y"KW/TH \RO-8:SU&ZMYYCL3A% SD8KCG8-(S8
MZDFO6_%*Z#X7MLRV<5UJ3KM!<#KC]<>M>22R>;*\A4+N). .!0!]D_"G'_"L
M/#__ %[#^9KLS7&?"G_DF'A__KV'\S79&@#Y<\8W7V7X]:D<X#NJ_P#D-:[[
M:UPRP11-(LH#'Y00!_O>M>7?$Z7R?C5J$G3%Q%_Z M>GZ;=_Z+ 1R/+'!/7!
MH XGQ+:2>&]134(4Q 6"S+C 9"<'(]C42^=JT5O';+F(;@A*\'GK7::_8KK>
MF7$<@VC:?D0]1]2*Y+P)%->:8;1)BO\ 9EPPG0KD&,]\CD&@#<T&QR#&6,L0
M^4[8SR?K6=JFD6MOK<K6R(L,PY11D;O>KMSXSDLHYK>&".&VVE4\LG.#GKD\
MUG:0=7DL9[G498/LZKF-57)S[_A0!B>(;"QL#:3VP9O,Y+ X.>X]JU-"N=8O
MO+AM+QV1!G;(-P450GN+;6;R*6V@8P(X#(00"<<XXKO-.E-E;JEG;Q@K\WRQ
M]1[F@"K<WVIVR?9Y[$2HV,2Q$ &F6L;W3+)#IVTDX+D]ZSM:\>VMJ54V/[]B
M1N5B"!]#5'3O&T4KD! IS@*V<X^E '57.G2B%V9KB0=UC8*"?YUS&K,]PBQP
MPMY><2 DDX]373VU[?7D0DMF$<9XWO%U/H.:I7ZM"ZR-L,F?F8)MR* ./?3(
M$M[F23_7/PN.BJ!@"L:T\.&!HI+NYB#GE(1]XY]:ZV[MTCOW\L[T,9.VK&B:
M*\VN0WUT,Q6T1< \Y;M0!BZE\/;MK6.Y@7S#(R[H^AQZUD7W@>Y@CVB%P/\
MGJ1\JGW->NL\K2+RW7H>13)E+L5<_)C) % 'E2B[\/Z(B74AN-S %=^Y03TP
M:Q_$]\TUI;PARHR24!Z^YKMYO#!UU+FWCG*PL=[OP-A!ZX]#7">*M)TG1G2U
ML[V2ZN5/[PGH* /0?V<1CQIJ?_7A_P"SK7TS7S+^SC_R.FI_]>'_ +.M?35
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MR1;-N%60C#!> #TQ70Q7UGI]NJW%QM&T8##DMC]:X:#5?M'A;33(2LJ-Y>X
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M:_\ D'^(/^NL/\FKWGM7@O[-?_(/\0?]=8?Y-7O5 'QO\7O^2J:]_P!=E_\
M0%KF=#O#8:S:S@XPX#?0UTWQ=_Y*IKW_ %V7_P! 6N8T2U^V:M!#@G+9P.]
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M/XDCA76%A5HY6M'D81DG&&53WSQ567XR_#:=0LNI;P. &LI3C_QVO)?VA_\
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MC:!699%9HY5^[*APPH [S4+?1/$ZB#Q;:);W1&V/5K1-C _]-!T(]Z\Q\8>
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M'Q!T'6%CM_%&GV43L-HOX(LQM]3U4_6NSM?#ESID8U'PIJCK:R?, KB2%_\
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M Z!KK3[]DBU"$6EP>CDX#>ZOT-:._4["V,$FS5=-;AK:Y ;CV/\ A7)+!')
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MVK7?2VMIH[K3\1MTDC/1A]/6@! D]N%6*+:O1@6P![U*E@);A)[D"1U^XI'
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MYWD9%4L<E5&!^5-5 IXP![4 9\-M<3R^;>'"GE80>!]:M):0+N9(U#'N!5C
MZX)Q2\?I0!GR6;Q2?:+5@C_Q(?NM4\=_Y\<:I\CL.=QZ'^M6L9'0\>U1&!6S
MO4'ZT .WJA 9R2:%L[<3^>L2B3KD4S84/RGGT/-*9RBJ2K @?.<Y'X4 3DJX
M*YYJ"1GC/'(J/SXIID$4B;VZ L!4D]PL4>YV48&>6% #/*ENUP[*D1(5E/WC
MZX/TK2\#SG5O&SWA4"+S%*C_ &(UXKE9M;$D-S#%\DL@$:$]E/WC7:_#ZU6V
M75;O&$B@\F,>I(Y- &S\)-3DU7XO>(KAV+#[*P7/8>8M>]#I7S?\ =W_  L7
M7-W)^ROG_OXM?2 Z4 ?-?QST34M9^)*?8+.>X6+3XC(T:%M@+OUQ6OXMNX;_
M ,+>'[FV9FD@C^PRAT*LCICJ#TKJ/'6O,?'=CX7LMD-[>-!-)/) LBB)=^>O
M?@C\:SQ;Z?XF\6^)= MV"2Q-'(@(P"X ^8?4<4 >&W<877+QKA0EO>320+*>
MB,&'/\OSJRD<]E+]GF@DCN%ZJ1^H]JQ=;>ZMYYM*N@5:TN9?E(Y!)Y_E3+76
M[FW5%9BZKP,GG'I0!V[7@LK+?)R>^*L1S;H0T@VLZ\5R4OB2WD:+?9R.BD,R
ME]N<=.15B"]N+S&^ZCA1N0JCGZ9- &K>00G,BWC0'J2#G/M5:WN-265XT43(
M3A))!L__ %_A4MK91PDR$F5CT<G)K2$:\?*,YH R;72D2Y>ZG8S7/7>PPJ_0
M5=9)78'"848&5R:GG801/)C"]36/'>:Q/+));0QQ1#A4E^\WO0!=>SCN+9XI
MX58<GU_+TK.^R7L*0QLZ7,2N6"29Z#H":M6&K^;,;2\7R;I>,=F^E;!097*A
ML<X(H RA>322@RO]C11]W;D'\>E:\,Q18CG<DGW&_A./0U"\*M'S&5!&"<FL
MF_6"-B+>*0W&./*&W\<_SH O2Z@]E>@./W3C'/--U&VMKE%ED;:IQC%8ZQZD
MMS [7$,YCC;=]H0%-W]T^OM4NLSP77@ZUO;>\BBG,YAN+(XWAAR'4_W?Y4 6
M(=5M=/TF[DMBN^+=#;E?OM))U;/H /UKT7X-6<EMX:US56POV6!X$+=W(W,?
MY"O"K&'[3>6T"E]\DH!].O6OIO3TB\*_"*\\N++WAE,:D<ONX'Z"@##_ &<V
M:2#Q*[?>:XB)_)J]U[5XE^S[I]WIL/B"&\A:*5G@DVMP0"&(KVWM0!\H>-+:
MWO/COJ,-UN\HW*EMIP3A%JQXF+FW)W.Z0H1&6ZA3V)]JS_B#<FT^-FJS!-Y6
MY7"^^Q:W;:U74+4VD[Y>:)NO8DT <+]KBT_5P<;[66)0ZYZG';\:U()H7VLC
M[@>1DUR^HQW%G?/:3\- VS(/:EL+9;VY:)&(9C\F#F@#K"Q\S>Q&Q>IS3GO5
M8?N\M]!6,MA<0W!3 +)UR:T8YYXRJ2VK;3QE1F@"R1-+\I^48Y [U)';1QX*
MK@XZGK3T'RC 8'W[4,0ISVH ANI8XHF=^@XQZFJ$%^AF0,A 8X.>U69XENL;
MB?+!SQQ59+&-^&R,'ALT :N%8=.*C\L(<JN&/<<4Y<)B/DDCK3E'&: (R[H<
MGY_IP:A^U1K*&G;RV[ U/+O16,2!VQTS63/;7ETVZ122.BG'% &G=W$-LJM)
M/"-PSPX)Q6'?:R-K) P(/&^A[)WL[J212/LZA@?0D]*PX8V+E<EAGI@YH W=
M M!.]H-I\Z>5PK9Y*X_QKT*".XNO$OAE4 $%E?0*,<Y 8 G\ZYKP;I32VD^K
MRDB)-T5NO\S77:%.T7BC3U/^J6>W0#U9I!_2@#Z&4Y%+2+TI: "BBB@ HHHH
M \2_:(A^TVGAJ'(&^[D7GI]U:\66Q;2O$EF95!C9MO\ 2O:/VBI&BLO#4BXW
M+=R$;AQT7K6.^CZ*VD?;;VX62ZDVBW2$9"O^/- '">)8FLVLY'8-FW*PL!QE
M3R#^%<[;61U.^5(9$&[G81QFO3M?TA;K2DB=7^TV-RLA95(^4X# 'H3R#7/2
M>!+F-WU)+N.2V1\E81M?KSQV(]* ,KP\@AU-].O7CC8/C/ 4#USWKJ+OPAJD
M9,^GPK=P/R C8(_.F?V-I=S>V-Y+?/ T6!^[@+"0YS\Y'3CO7=Z9>Z1JDRI#
MJ[S2;23'%$4R/^!=?PH \QGBGM'$5U"89/1N_P!*C.Q3S\P([5T=[I%G-J86
M^:11]H8&:X!1@.H R>1TK U>TFTV]DE>-19R-^[*2;\'V/IWH SYIXG<@%E#
M#HPP*KI++(Y$C$IP-O8XZ4D]V)\*K ^@'6H'9HXE( R3DL>,T ;,:!5X[#.#
M0#SG'X54T_[;?72V=E;&>=ONKGK76V'@?5-0,?DM\P3=.K$?*?[H SDT <\
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M* (W8A3%NVLO2HH97N&<, $!XQV-+?21QF-H_G)(!7O3[C$%H\BF).,X)ZT
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M<[KLR6P*Z>^U"QNU>/3-+NKF-1\TUR^!]< 9K(M]/F9P8;4"5N5<9(3W&<T
M9@L;Z>46\=N[3R1&2-/N@+TW'-6%\/ZIIFFN;^1(XY#G:&R2?I7:>'O"[K%=
M:EK-T\D#XWR2C+/MZ*G^/2L;5[EM8U$+&@2%#MC0>E $_AK18+/3$U2*9I'W
M'=&5^Z?K6!<ZVG_"1S^9C:R;V!]SQ7H0L[;3- =88PA$6]_<D=?:OGW5;YYM
M8NYE8X9R!]!TH ]F^"5^=2^)NM3_ ,/V':OT#K7T,.E?,O[.1SXTU3_KP/\
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M?SKT7P1,D7C[QCX8FM=]@\WFB' *INZ\>AKS3X%^&+K4O%G]L,C)96"DF0\
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MMR)%.>3V^M6/"GB![_5[JWD9=JC?$5&  >HKA=7N+F;98.#^YD,CMVQVKH_
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M'A<Y_&M^_P#"&NS>'(K.&U3S4"'9YJX) ^OK7I'FW/\ S[?^1!1YMS_SZ_\
MD04 ?*4OP0\?RS.[:7$2S$D_:X_\:9_PHWQ]_P! F'_P*C_QKZP\VY_Y]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm247121d3_s1aimg010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "S M,# 2(  A$! Q$!_\0
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M/_\ ':/)UC_G^L?_  "?_P".T :%%9_DZQ_S_6/_ (!/_P#':/)UC_G^L?\
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M>5JG_/Y9_P#@*W_QR@"]15'RM4_Y_+/_ ,!6_P#CE'E:I_S^6?\ X"M_\<H
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M^_T?_P 52_;[_P#Z \__ '^C_P#BJ -&BL[[??\ _0'G_P"_T?\ \51]OO\
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ME>6'P^T<CA5=T>(%@HP 3GG Z5/]OO\ _H#S_P#?Z/\ ^*H T:*SOM]__P!
M>?\ [_1__%4?;[__ * \_P#W^C_^*H T:*SOM]__ - >?_O]'_\ %4?;[_\
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MCDC-WI=I' TBHSQWA=EW$ $ QC/)'>K5[_R$=-_ZZO\ ^BVH OT444 %%%%
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MJ:'.C7?^]<?^AO5RT_X\X/\ KFO\J )J*** "BBB@ K.MO\ D.W_ /URA_\
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M_P#/)OS'^-(9)14>]_\ GDWYC_&C>_\ SR;\Q_C0!)14>]_^>3?F/\:-[_\
M/)OS'^- $E%1[W_YY-^8_P :-[_\\F_,?XT 245'O?\ YY-^8_QHWO\ \\F_
M,?XT 245'O?_ )Y-^8_QHWO_ ,\F_,?XT 245'O?_GDWYC_&C>__ #R;\Q_C
M0!)14>]_^>3?F/\ &C>__/)OS'^- $&H_P#'LG_7>'_T8M1WO_(1TW_KJ_\
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MJZY.6 \Q@3TR=JX+$<YIO_"P]+$4CM;7BF-Q&5PARQXX(;!&2HSG!W C(R:
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M7HG,244SS/\ 8?\ *CS/]A_RH ?13/,_V'_*CS/]A_RH ?13/,_V'_*CS/\
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MA)3BI(F4>5V'T4SS!Z-_WR?\*/,'HW_?)_PJR1]%,\P>C?\ ?)_PH\P>C?\
M?)_PH ?13/,'HW_?)_PH\P>C?]\G_"@!]%,\P>C?]\G_  H\P>C?]\G_  H
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MG5I62)9@I-_9.MR).^^.XC4AP.202,GW]ZZ"N?U^P-_<V30W"QN"Z9/(;C<
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M_?1H\E/]K_OHTD5Q#.NZ&5' Z[3G%29KI(&>2G^U_P!]&CR4_P!K_OHT^EH
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M$"(\#GYOIM#-]%-4/$"I)XVTE04WB!@V'^8 R)U'8<'GOSZ5AB/X;1I2^([
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MLK>\5PC?H<&MHXBFU>_Y_P"1GR2V.CHK&C\263CYX[B/W,>1^:YJPNNZ6_\
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M3\/_ -VY@/JI(_D:9_:ND_\ +/6[Z/V;>1_*E[::WC]S0_9^OW,R?^%FW_\
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M\26>LV&^*&ZMUB80$W<!AW.,@A=W4@@CBETZ[>[T;4"\)BV/,,$YZY;],XK
MG\+ZI<:9I\<'V4[+^6[8LP!"M)O4@E&YQP<;3G&&QG-7N([47=N>D\1X)X<=
M!U/Z&J5YK]C:6US,&>X-MY8>.V0R/F0@( !USD5Y^?!E]&EMH\5K$DB6D>;Q
M4("%82C1*^PC8[<G/.7)VD<UT.G>$[F#3+BTD"0_:&MI&:"<AUV2[F7>JKT
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M7TNFZ%=7<)(FC4>7B$R_,2 ,JO.,D9]!S3= U"?4;>[EF8$)=21Q?N6C.P'
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M2HSW&1G^=/G\-^'XX;B:73;*-""\CM&H"C9M)]OE']:LVNDK::Q?ZBMQ,QO
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MY(+O(S,>69F+,3]230!9HHHH R_$?_(!N?\ @/\ Z$*U*R_$?_(!N?\ @/\
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MCBFR> [*.,&TN)DE,B-*[[?WB@Q[@< 9.(ACL"<^U '6"EQ2"C- "XHI,TM
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M7WB"Z&CRWUK)$[W,BW<<2#:B")L;N3_'CH:ZA]WEMLQNQQGIFLK_ (1?1O\
MGS_\BO\ XT?\(OHW_/G_ .17_P :35T _.J_;L;8O*V?\!S_ #S6#K.I>(-/
MNYQ96D\TDTJQ)^[#QHGE%RR#(R<HXP2,EE[5M_\ "+Z-_P ^?_D5_P#&C_A%
M]&_Y\_\ R*_^-84:'LVWS-W[LN4^;HD9\\VJ"XUA0NH%#%%Y CC4= -YC)[G
M=C![H3WK,L]3\7N+JQOK/;-]CE>*9$&?,5%&.#@Y=R1TX4UT?_"+Z-_SY_\
MD5_\:/\ A%]&_P"?/_R*_P#C70026OVH^&(OMJN+LV8\X/@MOV<YQQG-7;3_
M (\X/^N:_P JS&\*Z*ZE6LL@C!_>O_C6NB+&BHHPJC 'M0 ZBBB@ HHHH *S
MK;_D.7__ %RA_P#9ZT:S;O0=,O[HW-S;;YBH0MYC#@9P, X[F@"S=F\"K]D6
M$MGYO-) Q[8%9&FOXC,UU]JCMM@FPF]B/E_V<#D?7FK/_"+Z-_SY_P#D5_\
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MJ&O7;6#7%O+&4U22*<0H-IA$; %LYXW[>GI75G...M9/_"+Z-_SY_P#D5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm247121d3_s1aimg011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X M4# 2(  A$! Q$!_\0
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M7Y2,$D,3NW9RH^7H2>*[:RMWM;*""2=YY(XU1I9/O2$#!8^YZT 2?O/[R_\
M?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[
MR_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &
M?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3
MZ* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_
M .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7
M_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]
MY_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\
M]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\
M?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[R_\ ?/\ ]>C]Y_>7_OG_ .O3Z* &?O/[
MR_\ ?/\ ]>C]Y_>7_OG_ .O5+7M0?2?#^HZC'#YSVEK+.L7]\JI8#\<5P</C
M75M%O+5M1NK75;.YTV*_FDAC$/V56FCC)&,ADQ(6YYQ&>: /2?WG]Y?^^?\
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MH_>?WE_[Y_\ KT^B@!G[S^\O_?/_ ->C]Y_>7_OG_P"O3Z* &?O/[R_]\_\
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M '\;_P"+H]JNS^X?.NQT&?<49]Q7/>;K'_/H/^_C?_%TOFZQ_P ^@_[^-_\
M%T>U79_<'.NQT&?<49]Q7/>=K'_/H/\ OXW_ ,72^;K'_/H/^_C?_%T>U79_
M<'.NQT&?<49]Q7/^;K/_ #Z#_OXW_P 71YNL_P#/H/\ OXW_ ,71[5=G]P<Z
M['09]Q1GW%<_YNL?\^@_[^-_\71YNL?\^@_[^-_\71[5=G]P<Z['0YHKGO-U
MG_GT'_?QO_BZ5;C6E&!9I^+'_P"*H]JNS^X.==CH,T9K ^U:U_SZ)^9_^*H^
MTZU_SYI^9_\ BJ/:KL_N#G1OYHS6!]IUK_GT3_OH_P#Q5'VG6O\ GT3\S_\
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M*D^VZY_SYQ?E_P#94>U79_<'.B]_8FE?9I[;^S;/R+A52:+R%VR*JA5##&"
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M&VGVK( 0 85( SG'3U)-8NNB_@N"EAX8M=3MC$"V7C1B=S%D^;CN&&>/O=Z
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MUKH1116$I.3NS5)+8****D84444 %%%% !1110 4444 %%%% !1110 4444
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M=1\T:O?E-'%T/,4&38QS^[3CC@XJN3./^9<!SG/[IS]?K_6NV+]U?\ YGO\
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M444 %%%% !1110 4444 %%%% !1110 4444 %,D^Z/\ >'\Z?3)/NC_>'\Z
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MLGA:RB9&M%:+=/#)*'E=QMC<R*J@DA0'YP,#^5;]%  .E%%% !1110 4444
M%%%% !1110 4444 %%%% !3)/NC_ 'A_.GTR3[H_WA_.@!]%%% $;_ZQ/QJ2
MHW_UD?XU)0 4444 %8.K'6/[0C.F:A81*JJ&MKI<[R6.3D<CY00/?MQ6]6)K
M'A72-=G\Z_@=Y/+$89)70@ DC[I'/)Y]SZT 5$_X3!UC(GT X;#E8YB#A@"!
M\W!QN'?G%3:8OBA;D'59=*>$D;A;+(I VG.-V?XL=2>,U6N?"&@6,=S?R6]P
MVQ&D?$\C< '.%SCD9X[]ZS-&;PT?$%L;.SO8;QI'9&:;*,=L@).'(88#@'D9
MH T;J35EU>]%I>010B13L9D#9V+ZCI48FU_!SJ5KQ_M1]NN>*IZO_9W]N7YN
M4NFD#KGRV4+C8G/()JF3HP!_=7W?JZ<8_P" \?TKMC&Z6GX?\$YF]?\ @FP9
MM?Q@:E:YYZM'_A^=*LNOR2 )?VK9Z*KQG.?P_P ^]5-*TS2M5FDAB^VQ[%W9
M,B__ !-;EMX6LK:ZCN$FN"T;!@&88X_"IDXQT>_H4DW_ ,.:.F"[6R07S*UQ
MSO*].IQ^F*N4E+7(;(****!A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %1SQ>?!)$6*AU*DCMD5)10!R__  A5MS_I
M4GL-HK<T[3TTZQ2U1V=4S\S=3DY_K5RBJ<Y/1LE)+8RT\.:0@G"Z?;CS\^9\
MF=V6W?A\W/UYI6\/:2\B2/86[LB% 73=\N&7'/7AF'T8^M:=%245+'3;/3(W
M2RMXX%D;>X08W-@#)]3A0/PJW110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !111F@ IDGW1_O#^=/S3)/NC_ 'A_.@!]%%% $4L4<K)YB*V,
MXW#-84VNZ3 \RO9R8@ODL)6\@?+(_E[?<@^:G(SUST%;['#H/7-<C):^##J<
MTKZI +U+IKN0?VNX9)54JS$>9QA5*D= %QC Q0!MQ7NF3:S+I20J;F*/S'_=
M#:.G&?7#*<>C#UJ_]DM_^>$7_? KEH[[PEINO6US"EL+NZ@6-=25E821LKLN
M^4G+9%NV"2?NCGFNFLM1LM161K*[@N5C;8YAD#A6P#@XZ'!!Q[B@"3[);_\
M/"+_ +X%5[VSS8SBSB@6Z,;"%G0;0^.">.F<5>J"]NTL;*>[D#,D,;2,%ZD
M9X]^* .;FM/$T<2QP1Z'*PB(::6-U)?) .T9&,;2?<D5+90:^=1B^W6>BBS8
MOYODERZ==FW*X.?ESG&.<9JK?^*?"NNZ9-97-[+Y#\2!8Y4(VL3C<!ZH>AY
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MJ/LGB3KN@'_ (_\ "NMHJ/:OLON'R>9R7V/Q)_>MSG_8C_P_Q_&E%IXE'&^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHKDN;6"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)?\ XFIJ* L0^0__ #\R_DO_ ,31Y#_\_,OY+_\ $U-10!#Y#_\ /S+^2_\
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MWJ+=K''_ !)K8Y_Z8#_//^<5!JT5@^NWYGNI8Y2RY58]PV^6GO53[/I7S?\
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M84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJD#-AFVMD ^^[_\ 771?V;H9^;R[7USN'^-<Y]DT7<6SJ'/NG^%(++1 ,9U
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M+8]+B+_OL5QGV31#U.H'G)Y3FD^QZ*2I+ZB<#C)3_"CVE#^?\ ]H=I]KM_\
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M444 %%%% !1110 4444 %%%&: "BC-% !1110 4444 %%%% !11FB@ HHHH
M***,T %,D^Z/]X?SI^:9)]T?[P_G0 ^BBB@"*5=TD?)'7I2^6/\ GHWYT/\
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MKV/]YGFWVCXC_P#/#_QV&C[1\1_^>'_CL->DT4?6E_)'[@]C_>9YM]H^(_\
MSP_\=AH^T?$?_GA_X[#7I-%'UI?R1^X/8_WF>;?:/B/_ ,\/_'8:/M'Q'_YX
M?^.PUZ311]:7\D?N#V/]YGFWVCXC_P#/#_QV&C[1\1_^>'_CL->DT4?6E_)'
M[@]C_>9YM]H^(_\ SP_\=AI#/\2#TA(^BPUZ511]:7\D?N#V/]YGFGG?$G_G
MF?\ OF"CSOB3_P \S_WS!7I=%'UI?R1^X7L/[S/-/.^)/_/,_P#?,%'G?$G_
M )YG_OF"O2Z*/K2_DC]P>P_O,\T\[XD_\\S_ -\P4>=\2?\ GF?^^8*]+HH^
MM+^2/W![#^\SS3SOB3_SS/\ WS!1YWQ)_P">9_[Y@KTNBCZTOY(_<'L/[S/-
M/.^)/_/,_P#?,%'G?$G_ )YG_OF"O2Z*/K2_DC]P>P_O,\T\[XD_\\S_ -\P
M4>?\2/\ GF?^^(*]+HH^M+^2/W![#^\SS;[1\2/^>/\ X[#1]H^)'_/'_P =
MAKTFBCZTOY(_</V/]YGFWVCXD?\ /'_QV&C[1\2/^>/_ ([#7I-%'UI?R1^X
M/8_WF>;?:/B1_P \?_'8:/M'Q(_YX_\ CL->DT4?6E_)'[@]C_>9YM]H^)'_
M #Q_\=AH^T?$C_GC_P".PUZ311]:7\D?N#V/]YGFWVCXD?\ /'_QV&C[1\2/
M^>/_ ([#7I-%'UI?R1^X/8_WF>;?:/B1_P \?_'8:/M'Q(_YX_\ CL->DT4?
M6E_)'[@]C_>9YO\ :?B/_P ^X_[YA_QH^T_$?_GW'_?,/^->D44OK*_DC]P>
MQ_O,\W^T_$?_ )]Q_P!\Q?XT?:?B/_S[C_OF+_&O2**/K*_DC]P>Q_O,\W^T
M_$?_ )]Q_P!\Q?XT?:?B/_S[C_OF+_&O2**/K*_DC]P>Q_O,\W^T_$?_ )]Q
M_P!\Q?XT?:?B/_S[C_OF+_&O2**/K*_DC]P>Q_O,\W^T_$?_ )]Q_P!\Q?XT
M?:?B/_S[C_OF+_&O2**/K*_DC]P>Q_O,\W^T_$?_ )]Q_P!\Q?XT?:?B/_S[
MC_OF+_&O2**/K*_DC]P>Q_O,\W%U\1A_R[*?^ Q?XTOVOXC?\^J_]\Q?XUZ/
M11]97\D?N#V/]YGG'VOXC?\ /JO_ 'S%_C1]K^(W_/JO_?,7^->CT4?65_)'
M[@]C_>9YQ]K^(W_/JO\ WS%_C1]K^(W_ #ZK_P!\Q?XUZ/11]97\D?N#V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWB/?C[  /4JQ_P#9O\]LTHU#Q)C)L!VXVG_&NKHQ1[1?RH7(^YRAO_$@ Q8
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M3\[WDMT\MF(PHY'R@$]JDTR*=-9@2Y\9)?/$S;K$")2S$-Q\N&. >A'\.3[
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MRV'6XA'_  ,5-BC% $'VZT_Y^H?^_@H^W6G_ #]0_P#?P5/BC% M2#[=:?\
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MYZI_WT*//A_YZI_WT*?M'I1M'I0 SSX?^>J?]]"CSX?^>J?]]"G[1Z4;1Z4
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MI_U:\\'_ #[U&--ON_B#IC_ENW^-=<6K+_@G.[W_ .&*OSXP?#/R^FQ_\/\
M]=*?-SC_ (1LY['8Y_6KRZ)JSH&36I"".")6(KIXE*Q(K,6(4 D]ZF51+;7[
MRE%O^D<3F4]/#1'_ &R<?7_/\Z!YA_YEGCT$<@Y[=O\ /M7<XHJ?;>7XL?)Y
MG#8E_P"A:)QT^1^/T_\ U^U+^]!/_%-'/KY;UW%&*/;>7XL.3S.5TFSBOIW2
MZT-;:-5R"R,N3D>O'^>];']@:7_SYQ_K6E16<IMO0I12,W^P-+SG[(F?QK0C
MC6*-8T&%4  >@%.HJ6V]RDD@HHHI#"BBB@ HHHH **,T9H **,T9H **,T9H
M **,T9H **,T9H **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !3)/NC_>'\Z?3)/NC_ 'A_.@!]
M%%% $,PD,D>QE'7JN?ZTFVX_YZ1_]\'_ !I[_P"L3\:R-2U^+3=<L[*X>VB@
MG@FE>:6<*4\L G@C&,$G.>QH U=MQ_STC_[X/^-&VX_YZ1_]\'_&L/PWXE?7
M=0U*W-M'$MH1ADEW]9)4V.,#:X\K)'. Z_CT5 $.VX_YZ1_]\'_&J.J:FND0
M137<R*DLRPJ0G<]SEN@ )/L*U*Q=4771>12Z6]F8% $D-QD;LMR<@9! Z>_Y
M@ P;OQ;X>UVS-JNJRLK.OS064^X$98<[>.%/_P"LBJFBRZ)?>*8I]/U>[:ZC
M9U\N6)@EPQ3D\CC: >FW\1BMU1XLB5-EOHG4;U!D4$9 R.O.W/'L*GTUO$QN
M0VJ)IBPDKE;=G)7Y.<9 S\W?T[4 <_JXMAK=]]I,Q<.F?+ "_<7!YY%4L:<.
MOVH<''W?EQU^E;]['J;:M?&TDMUB\Q>) F?N+GJ,U%Y6N<GSK/\ */CTQQ7;
M&HDDK_B<KCJ%IXGCM(([:.-BL8V@L!^'.?2IAXR0KN$)Q_N__95#Y6N9QYUH
M%^D7^'^?:D\O7NIGM<^XB_GBH:I>7WE7D3_\)@,9\AL<?P__ &7YTX^,$'6W
M(QD\CTZ\YQ5?RM<_Y[6F?<1_X4>5KF/]=:?4"+/MVHM2\OO#FD3_ /"8IS^X
M/!QTZ_3G_/M1_P )E'@$6[8/3C\N]0>5KO\ SWM,]L"+_#_/M4GV/Q)_>@R>
MOR1_X?G1:EY?>.\OZ1)_PF"9 ^S,,XZ@=_QQ1_PF"#K;D8!R".>.O>NABM8_
M*3S(HR^T;CL')QS3_LD'_/&/_O@5GS4_Y?Q+Y9=SFCXQ0=8#UQ@#G\L_Y]J/
M^$Q0D 6Y)/3&/\:Z7[+!_P \H_\ OD4?98/^>4?_ 'R*7-3_ )?Q#EEW.;_X
M3%#_ ,N[#IU _P :#XP0#)MV[Y&.1CKQFND^RP?\\8_^^!1]D@_YY1_]\"CF
MI_R_B'++N<T?&* @>02?;Z9]?\^U \8H6P+=B?;&/YUTOV2#&/*CQ_NBC[+#
MC!BCQ_NBCFI_R_B'++N<T/&*$9^SMCCDC_Z]+_PF,8'-LW?//IU^E=(;2 _\
MLH_^^11]E@_YY1_]\"GS4_Y?Q#EEW.<_X3&(MM^S-GV84@\9Q,,BUD(^HYKI
M/LL&,>3'C_=%!M83UBC_ .^11S4_Y?Q#EEW.<_X3&/&?LCXX[^O^>:/^$RB!
M.;9AC/)8=NO/2NC^R09SY4?_ 'P*/LD'_/&/C_8%'-3_ )?Q#EEW.<_X3*+!
M_P!%?CWZ_3_/Y4G_  F41 (M7P>G(KI/LL'_ #RC_P"^11]EA_YY1_\ ?(HY
MJ?\ +^(<LNYSG_"8QY_X]'&<'DCO^E'_  F,0ZVK#&>IQTZUT?V2#_GC'_WR
M*/LD'_/*/_O@4<U/^7\0Y9=SFSXSB !^ROR<8!YS]*7_ (3&+< +5R3TP171
M_981TBC_ .^11]E@QCRH_P#O@4<U/^7\0Y9=SG!XRC/_ "ZN.G4BC_A,XE&6
MM'[\;L$8Z\5T?V2#_GC'_P!\"C[+!_SQC_[Y%'-3_E_$.67<YW_A-( VW[&Y
M/LX_S_GM2CQG"6P+*0_1Q70_98/^>4?_ 'R*/LL&,>5'_P!\BCFI_P OXA:?
M<YT>,X2,BSDQQSO'?CTI3XSA'6SD'7^,<8Z]JZ'[)!_SQC_[X%'V6 ?\LH_^
M^!1S4_Y?Q"T^YSH\9PEBHLW)'7#B@>-(2,BRE(]=XKHOLL&,>3'CTV"@VL!Z
MPQG_ ( *.:G_ "_B%I]SGO\ A,XL9^Q2= ?OCOQZ4?\ "9P\_P"B.,>K_P#U
MJZ'[+!WAC_[X%'V6#_GC'_WP*.:G_+^(6GW.=_X32 Y_T.3 ZY<4?\)I#M#?
M8I<'_:&:Z+[+"?\ EE'Q_LBC[+#G/E1_]\BCFI_R_B%I]SGO^$RBR!]BDY./
MOC'YXI/^$T@P3]D<#&>7QG]*Z'[)!_SQC_[X%+]E@_YY1_\ ? HYJ?\ +^(6
MGW.</C6$#)LFQ_UT'^%!\:1@\V$F>>-X_P *Z3[-#U\I,_[HI/LL':*/_OD4
M<U/^7\0M/N<[_P )DF<?87SG'^L_'TI/^$UAQG[&V, _?YY]L5T7V2#_ )XQ
M_P#? I?LL'_/*/\ [Y%'-3_E_$+3[G.'QK$" ;)LG_IH./KQ1_PFD>2/L,F0
M,D>8/\*Z/[+#S^ZCY_V11]E@X_<Q\?[(HYJ?\OXA:?<YW_A,XSTL7/./]9U_
M2D_X36+C_0VY /\ K/7UXKH_LEO_ ,\8_P#O@4?98/\ GE'S_LBCFI_R_B%I
M=SG/^$UBW%?L39'7]X,?GB@>-(R"18R<9S\X[?A71_9H<8\J/_OD4?98"?\
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M2@'RYXWQY85@3[Y)(Z G&>@!-=567JO]K!X6TP0, &WB4XR>,?48W<9!SMY
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M!D8L ZE@-ZDJPW+D<5LUI[237+T(Y%>Y5W7O_/*W_P"_C?\ Q-&Z]_YY6_\
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M_P#?QO\ XFC=>_\ /*W_ ._C?_$U:HH"Q5W7O_/*W_[^-_\ $T;KW_GE;_\
M?QO_ (FK54=4U6ST:T%S>NRH76-0D;2.[L<!5502Q/H!0%B3=>_\\K?_ +^-
M_P#$T;KW_GE;_P#?QO\ XFLP>+]&_M.WTYIIDNK@)M22VE4*SJ65')7".0I.
MUB#QTK=H"Q5W7O\ SRM_^_C?_$T;KW_GE;_]_&_^)JU10%BKNO?^>5O_ -_&
M_P#B:-U[_P \K?\ [^-_\35JB@+%7=>_\\K?_OXW_P 31NO?^>5O_P!_&_\
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M-6JS;C7M.M=;M=&EGQ?W2L\,01CN"@DDD# X4]3S@XH"Q8W7O_/*W_[^-_\
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M0(O4DY/)/UQVS72T44 %%8_BC4[S1?#M[J=E;07,EI$T[QSRF,%%4LV"%;G
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MLL6EF92\C,3UPN,8[FNEQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@
MHHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1
MB@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ IDGW1_O#^=/Q2%01@^N: %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm247121d3_s1aimg012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S @ # 2(  A$! Q$!_\0
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M03MYYQ@UZN0""",@]:YY/ ?AB.TEM4TB%8I71V 9@04SMVG.5 R<!2 ,GUH
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M #-K?WS^0HVM_?/Y"GT4 ,VM_?/Y"C:W]\_D*?10 S:W]\_D*-K?WS^0I]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 1S_ .J:I*CG_P!4U24 1S_ZEJDJ.?\ U+5)0!YO\4+G1KPVVE7\
M]RT\:F1;>&TDG#O(K1PYVX ;?R 3S@_6NC^'\,,'@?34@D5X\.WRQ&((3(Q*
M;221M)*\DGY:SO&FE^$H[F+5/$-Q>6\TQ2%/LUS.AD*%G7Y(CR5RQSCBM[PM
M'I<7ARU713*=/^<Q&7?O.6)8G?\ -G<3UH U965(79WV*%)+9Q@>M>(6/B".
M>.XE@\57AT"YU>")S+J!,\$ 20-([YW1+)(% Z8'IFO<J888BI4QK@]1CK0!
MXQ#JOB6UT33M8&K7%P[6<[K"2S,+>,RCSF4_*V5:)@QY+!1T)(]1\*7\.H^&
M[2> 3>6NZ$&:7S68HQ0MO_B!*DANX.:U_+0'.P9QC..WI2JH50J@ #H!0!7O
M\FQGP<#RVS^5<38C.IWF?^? _P#H8KM[[_CPN/\ KFW\JXBQ_P"0G>_]>!_]
M#% $^B7*VFHZI.R,^RWBPJG&3N:MJR\017<=TS6LJ&W95*A]Q8L,\=*YVQ_U
M^K?]<(/_ $-JGT;_ )BW_76+_P!!-3)V38F[*YU6GW\&HQRO&LJ>5)Y;!S@Y
MP#V)]:N!%/0G_OHUR%FBR65ZKJ&4WIX(R/N+6MX4 &D2 < 7,H _X$:F$[NQ
M*E?0VMB^_P"9HV+[_F:=16A8W8OO^9HV+[_F:=10 W8OO^9HV+[_ )FG44 -
MV+[_ )FC8OO^9IU% #=B^_YFC8OO^9IU% #=B^_YFC8OO^9IU% #=B^_YFC8
MOO\ F:=10 W8OO\ F:-B^_YFG44 -V+[_F:-B^_YFG44 -V+[_F:-B^_YFG4
M4 -V+[_F:-B^_P"9IU% #=B^_P"9HV+[_F:=10 W8OO^9HV+[_F:=10 W8OO
M^9HV+[_F:=10 W8OO^9HV+[_ )FG44 -V+[_ )FC8OO^9IU% #=B^_YFC8OO
M^9IU% #=B^_YFC8OO^9IU% #=B^_YFC8OO\ F:=10 W8OO\ F:-B^_YFG44
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MOS&8PQ;L>W\JO>8G]]?SH\Q/[Z_G2Y4*R.<CTVXMKB\NI558V@2,<Y.0Q/\
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M9F_Z\6_]#%):?\A#4O\ KA#_ .A-1;D#69LG_EQ;_P!#%):$?VAJ(SU@A_\
M0FK%="%T'6/^LU7_ *ZQ?^@46'_'I>_]?I_]%K261'FZJ,\^;%_Z!18$?9;X
M9Y^VGC_@"T=/D :=_P @QO\ K[F_]"IMC_R+]K_VU_\ 0VIVG$?V:PSS]KF_
M]"IMB1_8%J/3S?\ T-J'U^0=R.3_ )%>V_Z\/Z&C6/\ D7S_ ->2?^@BASGP
MO;XY_P! _H:-7(/A\X.?]"3_ -!%#Z@RQKWW'_WXO_0EKSS4?^2F)_V&$_\
M1@KT+7B#&YSQOBY_X$M>>:B1_P ++0YX_M=.?^V@J*FZ]1/?YAI/_)3;/_L(
M2_R>NP'_ "$X_P#KWN?_ $77'Z40/B99$GC^T).?P>NOR!J<>3C_ $>Y_P#1
M=:8?X'\RJ?PLX?PO_P A#5?^P-<?S2DT#_CV\0_]@Y?_ $:M'A<@:AJN?^@/
M<?S2C0"!;^(,]].7_P!&K7)'9>C,5T^8[2?^19\2?[UI_P"A-3;/_D2M1_["
MD?\ Z*-+I)'_  C7B,9YW6G_ *$U-LR/^$+U 9Y_M2/_ -%&CI\A_P"0\?\
M(@0?]A6;_P! 6G7G_(B>'/\ KI>?^C::"/\ A 8!GG^U9O\ T!:=><^!?#@[
MB2[_ /1M#V?HA/KZ$&J_\BQX=_Z\7_\ 1C4OBG_D':1_V!H/_032:J1_PC'A
M[_KQ?_T8U'BD@Z=I&#_S!H/_ $$TY?:^0WU)O&W_ "'S_P!<K;_T!*L:_P#\
ME%_[B</_ *&M5_&Q!UXD'(\JV_\ 0$J?7R/^%B9SQ_:<//\ P-:;W^8W^I(?
M^2J1?]AAO_0VJ#0?^2@VG_7:X_\ 1;U,2/\ A:<1R,?VNW/_  )JAT$@?$&T
M.>/.N/\ T6]"W7JP6Z]2'PK_ ,AV?_L'77_H%'AW[NN_]@MO_1BT>%B!KL^3
MC_B777_H%)X>(QKO_8+;_P!&+4QVC\Q+I\Q=$_Y 7BC_ *XVO_HTUU_PBZZW
M_OP_^@M7(:(0-#\3C/)AMO\ T::Z[X1D!M:!(R7A_P#06K6A\<?0JGNCTJ?_
M %35)4<_^J:I*]$Z2.?_ %+5(*CG_P!2U24 <3\2'U".PTY[2:>.V%S_ *4(
M+N&V=EV-MP\O ^;' ZUL>#DC_P"$9M)$60-(&+-+/',['<1EI(_E8X ''8 =
MJPOB5!I]Y#IEK=6EU>W$LLL=O;VZ1-EC"_S'S"%!4?,#GMCN:W/!=D^G>$K&
MVDBFB==[-',L:LI9V8C$9*@<\ '@8% %_4QJ6Z$V8M6MADW4<J,SNGHF" #U
MZ\=*\HL]!NY8;C46\,75J)=7M;JZTM+=5C%M&K(JHN<.PR';@9/3I7L]&!0!
MXM%X'U>WT:":TL[N+43!<2O 74)''NE\N $<AV67:0&P!D]0IKU/PVUVV@6W
MVVU2UF7<@BCC\L!%8A#MR=N5"G;GC..U:N!2T -90Q&>GI2[5]!2T4 )M'H*
M-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4
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M1!@_["LW_H"TZ\_Y$3PY_P!=+S_T;0]GZ('U]"#5?^18\._]>+?^C&H\4_\
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M%#XSGN_$GAN2^LYK2+[-<06#7!,JEPZN4!(.W9CMUKJ? MO-:^#=/BGLOL3
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MCD%I+_I#,2%$7R_O,D'[N: .CHKF[;QUX=O'C$.HKB2$S;VC9550&)#,1A6
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MWZ?XT^B@!F]O^>;?I_C1O;_GFWZ?XT^B@!F]O^>;?I_C1O;_ )YM^G^-/HH
M9O;_ )YM^G^-&]O^>;?I_C3Z* &;V_YYM^G^-&]O^>;?I_C3Z* &;V_YYM^G
M^-&]O^>;?I_C3Z* &;V_YYM^G^-&]O\ GFWZ?XT^B@!F]O\ GFWZ?XT;V_YY
MM^G^-/HH 9O;_GFWZ?XT;V_YYM^G^-/HH 9O;_GFWZ?XT;V_YYM^G^-/HH 9
MO;_GFWZ?XT;V_P">;?I_C3Z* &;V_P">;?I_C1O;_GFWZ?XT^B@!F]O^>;?I
M_C0&)/W&'Y4^B@".?_5-4E1S_P"J:I* (Y_]2U2"HY_]2U2"@ HHI"0!R<4
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M_<'_ 'U1E_[@_P"^J '44W+_ -P?]]49?^X/^^J '44W+_W!_P!]49?^X/\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm247121d3_s1aimg013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %' ?D# 2(  A$! Q$!_\0
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MT[+OGGD4C)P !V&  !74X%% 'AVF^#/%PTJ\2SM[^TF;0%L2VH7,3.9@P.R
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MU244 1YE_N+_ -]?_6HS+_<7_OK_ .M4E% $>9?[B_\ ?7_UJ,R_W%_[Z_\
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M6_[Z-'ECU;_OHT .HIOECU;_ +Z-'ECU;_OHT .HIOECU;_OHT>6/5O^^C0
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MFCS1Z/\ ]\F@!]%,\T>C_P#?)H\T>C_]\F@!]%,\T>C_ /?)H\T>C_\ ?)H
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MG_X]Y/\ =/\ *E\T>C?]\FDG_P"/>3_=/\J )**** &3?ZHT_M3)O]4:?VH
M*#THHH \TU^*0?$.[DTVSU'[7/HEQ:_:5@E,0G;88@'QM7A3R"!GKR:Y.ST:
M9%@N%T*^3P^DNG#4;-K-P99$BE$K&+&7 =HMQ .XC/.*]VP*,"@#Q&V\,:S9
MZ-9W=M#J(U$6<TCPE<&&W!D"1*V-P9E8#8.1C=U !]6\*S33^&K-IK%;(H&C
M2%49 $5BJD*W*@J <'D9Q6Q@4M #67=UZ>GK7$W_ /R$+C_KHW\Z[BN'O_\
MD(7/_71OYT 7OA__ ,BU_P!O#_TKJJY7X?\ _(M?]O$G]*ZJ@ HHHH ****
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MS T[)@ \>6X;(R<+T;->G^%[^'4O#MM/";E@FZ%C<N&D+QL48LP)!Y4\@X-
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M_<'_ 'U_]:C+_P!P?]]?_6H ?13,O_<'_?7_ -:C+_W!_P!]?_6H ?13,O\
MW!_WU_\ 6HR_]P?]]?\ UJ 'T4S+_P!P?]]?_6HR_P#<'_?7_P!:@!]%,R_]
MP?\ ?7_UJ,O_ '!_WU_]:@!]%,R_]P?]]?\ UJ,O_<'_ 'U_]:@!]%,R_P#<
M'_?7_P!:C+_W!_WU_P#6H ?4<_\ Q[R?[I_E2Y?^X/\ OJDG_P"/>3_=/\J
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M.D?]?T7\ZO\ A[_D17_Z^F_F*H7G_(1TC_K^B_G0!L^(HEN=6=92[*@ 5=Y
M&0.U5_"4TEM::\T9YBE 3=R!P:N:W_R%YO\ @/\ (50\,_\ 'CXB_P"NP_K0
M!5U/6-9L[-ITU24MN QL7')^E>CQG,:D]2*\MU__ )!+_P"^O\Z]2C_U2_04
M .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/\ C1Y2^K_]]G_&@S1B/S#(H3^]GC\Z:ES!(VU)HV;T5@30 [RE]7_[[/\
MC1Y2^K_]]G_&G9'K2Y% #/*7U?\ [[/^-'E+ZO\ ]]G_ !I^:,T ,\I?5_\
MOL_XT>4OJ_\ WV?\:?10 SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_X
MT>4OJ_\ WV?\:?10 SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4O
MJ_\ WV?\:?10 SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\
MWV?\:?10 SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\ WV?\
M:?10 SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\ WV?\:?10
M SRE]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\ WV?\:?10 SRE
M]7_[[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\ WV?\:?10 SRE]7_[
M[/\ C1Y2^K_]]G_&GT4 ,\I?5_\ OL_XT>4OJ_\ WV?\:?10 SRE]7_[[/\
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MG1+R>=Y+B1+AE3>W; P,T3^)M1M7@$MK;E99EB^5B3R:Z9;2WCMQ D*+$/X
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M'KD4:C:6[6]U,T2F78S;SUSBAU;).P<^ESLQ.C+N4Y'J!40U&T9@JW$1).
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M13-K_P!_]*-K_P!_]* 'T4S:_P#?_2C:_P#?_2@!]%,VO_?_ $HVO_?_ $H
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MWPX_Y"GB/_L'UR%W_P ><O\ NFNN^'()U3Q%@X_XE]<A=_\ 'G+_ +AHG\,
M>T3MO%'_ ")GA#_KR_\ 94K/^'G_ "46T_Z]I/Y&K_B@'_A#?".3G_0^./\
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M/SH =13=Z?WA^=&]/[P_.@!U%-WI_>'YT;T_O#\Z '44W>G]X?G1O3^\/SH
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ML)TG3I-,B4.6&I3^''_(4\1_]@^N/N_^/.7_ '#77_#D@:GXCR?^8?7(7?\
MQYR_[IK*?PP(>T3MO%'_ ")GA#_KR_\ 94K/^'G_ "46T_Z]I/Y&M#Q00?!O
MA'!_Y<__ &5*S_AZ0/B+:9./]'D_D:U_Y?KY%_\ +PQM4_X_;S_KI)_,UTK?
M\D:T/_K\?^<M<UJ?_'[>?]=)/YFND8C_ (4WH@SS]L?C\9:SA\,R([,P_#G_
M "/.@_\ 7S_2KWC'_D;M3_Z[?T%4?#G'CG03_P!//]*N^,#GQ=J>/^>W]!4O
M^"O4'\!VGP<_Y%F__P"O]_\ T%:]!G_X]Y/]T_RKSWX.L!X9O\D#_3W_ /05
MKT*?_CWD_P!T_P J]2E\".J'PHDHHHK0H9-_JC3^U,F_U1I_:@ HHHH R=9U
M>XTM5,&CWU^&1W)M@A";1D @L#D]!@&O);+Q+K$IN;35M3U.TBFUFV6\GE5K
M?[+')"7:-&8#8N\!0>#@@]Z]PQ43VT$JNLD,;K)]\,H(;Z^M 'B]MKGB>VTF
MRU9M7DN%DM)RJDEG6"-I%\]DP%/'EL')R6VCH21ZMX8U"'4O#UK/;_:/+7=#
MFX<.Y,;%"2P)#9*DY!YZUI_9X<Y\I,[=GW1]WT^GM3HXTB14C1411@*HP *
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M .M3Z* &9D_NK_WU_P#6HS)_=7_OK_ZU/HH 9F3^ZO\ WU_]:C,G]U?^^O\
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MZ*9YGLW_ 'S1YGLW_?- #Z*9YGLW_?-'F>S?]\T /HIGF>S?]\T>9[-_WS0
M^BF>9[-_WS1YGLW_ 'S0 ^BF>9[-_P!\T>9[-_WS0 ^BF>9[-_WS1YGLW_?-
M #Z*9YGLW_?-'F>S?]\T /HIGF>S?]\T>9[-_P!\T /HIGF>S?\ ?-'F>S?]
M\T /HIGF>S?]\T>9[-_WS0 ^BF>9[-_WS1YGLW_?- #Z*9YGLW_?-'F>S?\
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MG\Q9$:1F5D^8X^4C/0DY)R>:[*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "HY_\ CWD_W34E1S_\>\G^Z?Y4 24444 ,
MF_U1IP-*0",$9%&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $XHXI:* &A$#EPJACP3CDTO
M%+10 G%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4<_\ Q[R?[I_E4E(0""" 0>U "T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm247121d3_s1aimg014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %% @D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WUY%C +'
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M,9 P!&7(/X[_ -*D\.:+'X=\/66D13-,EK'L$C#!;DGI^-4?^*D]3_W[C_\
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MNX\8SG';KGBM..19(U<9 8 @,,'\1V->>MX5UU();(K#-%"U\;>6/$8*SQ9
M"EB5Q(S+UZ8J8^%=:.H26\3K!8& W<<HDR8[TP^3C']T?ZS/]ZN8U.^!!Z$&
MEKC_  /X?N=%%P]Q!<6[2111M&YA$;,N[+*(AR3GEF^8\9Z5V% !1110 444
M4 %%%% !1110 4444 -;[R_7^E.IK?>7Z_TIU #9/]6WT--F_P"/=_\ =/\
M*G2?ZMOH:;-_Q[O_ +I_E0 L/^HC_P!T?RI],A_U$?\ NC^5/H 9)_#_ +PK
M@/B8E\[:;]BO'ML"3?MEV;ONX[C-=_)_#_O"N0\<6$UZUEY6GO=[ ^=LRQ[<
M[?7KT_2MZ#M43,ZJO%GF'DZ[_P!!B?\ \"A_\51Y.N_]!B?_ ,"A_P#%5T/]
MA7?_ $+\W_@9'_A0="N\?\B_-_X&1_X5ZGM%_5CBY6<]Y.N_]!B?_P "A_\
M%4>3KO\ T&)__ H?_%5T/]@W?_0OS?\ @9'_ (4?V%=_]"_-_P"!D?\ A1[1
M?U8.5G/>3KO_ $&)_P#P*'_Q5'DZ[_T&)_\ P*'_ ,570#0KO_H7YO\ P,C_
M ,*7^PKO_H7YO_ R/_"CVB_JP<K.>\G7<_\ (8G_ / H?_%4>3KO_08G_P#
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M]YJ '4U^J?[W]#3J:_5/][^AH 9<PPW%M+#<(KPR*5=6Z%2.0:P/^$0\)_\
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MSSN.O_/5J7[=K'_/.?\ [^M1<#*WVV?^/Z3\Z-]M_P _\GYUJ_;M8R/W<_\
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M(DV?(S?W<]/PKMY/X?\ >%<EXVM);I[+RIA%M#Y^0-GIZD5M0TJ(SJ?">?\
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MZ&G4 %(.K?6EIHZM]: '4UNJ_7^E.IK=5^O]* '4444 (GW%^E+35^XOTIU
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MK'K;_P#@5/\ _%4?5H_S![9]CU1[ZU*,!,G3UIWV^U_Y[I^=>4_V1K'K;?\
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MPYXAD<(L,63ZW-P/_9J7U>'\P>UEV/3FOK7'^N3J.]+]OM?^>Z?G7GT?@KQ
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M&_<1]/[HI?LMO_SPC_[X%'NAJ,^WVO\ SW3\Z07UKN/[]/SJ3[+;_P#/"/\
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M[02<>WR5K?\ ",+_ -!*\_,?X5OT5FZTV6J<49VFZ5'8H2999V;^*7!Q]*T
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MWDG\/^\*Y7QG;07#V?G(S;0^,6[2^GITK:@[5$9U%>+/,OLJ_P#/_9?E)_\
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MI&4,I4C((P: &P_ZB/\ W1_*GTBJ%4*. !@4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm247121d3_s1aimg015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ EH# 2(  A$! Q$!_\0
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M_P! Z[_[\M1]6H?T_P#@A[>M_2.Z_P"%H0?] N;_ +^C_"C_ (6A!_T"YO\
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MT#KO_ORU'U:A_3_X(>WK?TCNO^%H0?\ 0+F_[^C_  H_X6A!_P! N;_OZ/\
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MN);/UHL%Q+CQV/LT<UI)--NB,@3RA\W[EI N<\'"\U#8^/;F:XV7=O<PQO\
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MPU\\!BN984@DF,T40Y*RM'M"YSVZ_P A49^($DEU;I;6]Y,&::.:%(E:5'0
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M61<@=",U-]ONO^>Q_(50M+:.RLH+6+_5PQK&N>X Q4U.R"Y<AOKEIXU,I(+
M'@>M;E<W!_Q\Q?[X_G725G-%1/#/$7_(R:E_U\/_ #K,K3\1?\C)J7_7P_\
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M4*1SCYMN6!..N,TN4=S2A\!ZE::5-9P7ME(US;M;S//&6POFM(&7GK\V"#Z
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M7%VE[/:3W!9D&%(4;E4>W:LJ]U35X9X98[R9HK>WM9;APRA(S*_S;D(S(".
M!C&*5@N=.?"5_!I\T%IJ"B9[B"7SGR&=8XPF"PY4G&<CG\ZH0^ ]2M=,N+:&
M^LY)+J"6WF:>-F 5I"X9><YRQ!SUP#VJ2PBG?Q5>^5J%X]G:*$>.60,KRO\
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MY [9Q4,&J6MI:&V@U34X[=LY153!SP:5I]&%X=2:^\/6UGIMW*+B=KFU2%I
M4 C8R#/RGVKG:["?5[6_T4:;%#J(B*!BRKNRD?7 )X [USX712,B>^(_ZYI_
MC5TY2L^8F<8W]TSZ*T=FC?\ />__ ._:?XT;-&_Y[W__ '[3_&M>;R,^7S,Z
MBM'9HW_/>_\ ^_:?XT;-&_Y[W_\ W[3_ !HYO(.7S,ZGP_\ 'Q%_UT7^8J]L
MT;_GO?\ _?M/\:=$FC>?%B>^SO7'[M?7ZTG+R#E/3I?]:WUIE:#V<;.3YC\^
MPIOV*+_GH_Y"O#YD>Q8HT5>^Q1?\]'_(4?8HO^>C_D*?,@L4:*G<6$9G#WJ*
M;=0\P+ >6I&06].E%F+'4+=;BRO!<0MP'C((-+F06(**5KO1UN((&U2$33Y\
MI"XR^#CC\>*LW$5I:0//<W(AA09:23"JOU-',@L5:*MI;VTC.J3EC&VUP,?*
M?0T_[%%_ST?\A3YD%BC15[[%%_ST?\A1]BB_YZ/^0HYD%BL/^/9O]\5%6B+.
M/R67S'QN!Z"F?8HO^>C_ )"ES(+%&BKWV*+_ )Z/^0H^Q1?\]'_(4^9!8HT5
M>^Q1?\]'_(4?8HO^>C_D*.9!8HT5=:SA169I655!))   ]:IS76D6Z6SS:G#
M&ESCR&9P!)GIM]:7,@L)15N2WMH5#2SE 6"@M@9)Z#ZU!9RZ9J#2K9ZA'<-"
MVV01,&V'T-',@L1T5/*+""4Q37BQR",RE6(!V X+8],D<U.+*(@$2,0>0<"C
MF06*-%7OL47_ #T?\A1]BB_YZ/\ D*?,@L4:*O?8HO\ GH_Y"C[%%_ST?\A1
MS(+%&I9ONP_[G]35G[%%_P ]'_(4][.,K'EVX7'3W-+F06,ZBKWV*+_GH_Y"
MC[%%_P ]'_(4^9!8HT5>^Q1?\]'_ "%'V*+_ )Z/^0HYD%BC15[[%%_ST?\
M(55NYM+L)(8[S4([=YCMB65@I<^U+F06(Z*MR6]M"%,DY3<P1=V!ECT ]ZAF
MDTV"*XEFOXTCMCMF9F&(SC.&]#@CCWHYD%B*BIX?L%Q9B\AO5DM2I;SE(V8'
M4YJ.UGTN^BCEM-1CGCE8JC1L"&8#) ]\<T<R"PRBKWV*+_GH_P"0H^Q1?\]'
M_(4^9!8HT5>^Q1?\]'_(4?8HO^>C_D*.9!8HTY/OK]15S[%%_P ]'_(4JV48
M8'S'Z^@I<R"Q3F_US_[QIE:#V<9D8F1^3Z"F_8HO^>C_ )"CF06*-%7OL47_
M #T?\A55YM+CU!-/?4(UO'&Y8"PWD?2CF06(Z*MM;VRRI$TY$DF=B'&6QUP*
MJSW>CVMH+J?5(8[<N8Q*SC:6!P0#ZC!HYD%A**GN/L%I9F\N+U(K8 ,9G("X
M/0YH@%C=!#;WBRB1/,380=R],CVHYD%B"BKWV*+_ )Z/^0H^Q1?\]'_(4^9!
M8JP?\?,7^^/YUTE9$5G&LR$2/D,#T]ZUZRF[E1/'_M$-K\1)IIY5BB6[DW.Q
MX'6GZ(MAIMY=-<7MA)-(F8)/,#(OS<@DJ0"1[56U[5KN+Q!J$:^1M6=@,P(3
MU]2*S_[9O/\ IW_\!X_\*]I0<HKT1Y7,HR^;.DM[K1?(OLS6:1S>?^XR,*<?
M)@E<MD].F*G&IZ6MD8UN[$6S&U\J%4PZA6!??QSW/-<I_;-Y_P!._P#X#Q_X
M4?VS>?\ 3O\ ^ \?^%)T6Q^U1TAU/2OLS6V^R,4B7A<[!NW;B8L'&1[5)K<<
M(\-WDD<=NMN#;K; 0[)$&/F#$CDYSZUR_P#;-Y_T[_\ @/'_ (5-+XEU6>)(
MI;A)(T^XC0H0OT&*/8R330>U333-K2]3LCHFF6]U<VBM TP"3*#L<C]VQ&.5
MZ_I65J]Q82ZQ9/NAE"I']M>W7"2/GYBH^E5/[:O/^G?_ ,!X_P#"C^VKS_IW
M_P# >/\ PJU3:E<ES35CL'U32#)"EQ=V$L8NY'A6)0%C79B,N,=OH:@M;W2/
M[8DGDN+&,9B64*5*2CG<V2OY@ 9KEO[9O/\ IW_\!X_\*/[9O/\ IW_\!X_\
M*S]@R_;(ZF#6[2&UM0MY:!;>"[C$9 R&)/E]N017-:_/;7.HQSVQB.^WB,GE
M !?,V_-P.G-1_P!LWG_3O_X#Q_X4?VU>?].__@/'_A6D*;B[HB5125F9]%:'
M]M7G_3O_ . \?^%']M7G_3O_ . \?^%:WEV,[+N9]%:']M7G_3O_ . \?^%'
M]M7G_3O_ . \?^%%Y=@LNYGT^$_Z1%_OK_,5=_MJ\_Z=_P#P'C_PH&M7H((^
MSY'/_'O'_A1>78-.Y[*>M)7E'_"8Z_\ ]!!O^_:_X4?\)CK_ /T$&_[]K_A7
MF?4JG='?]:AV/5Z*\H_X3'7_ /H(-_W[7_"C_A,=?_Z"#?\ ?M?\*/J53N@^
MM0['8#2TL-4\03QZ0UQ;W$=O)Y2@'[0XW%\9ZD<<?04S2+:_BT7Q"\<5TDER
M\LMJUT@2=V,?5E'3YAA?;%<C_P )CK__ $$&_P"_:_X4O_"8Z_\ ]!!O^_:_
MX4?4I]T'UJ'8T;G3KVXMK>/2;>1H=0L;.,R_9PZJ8VR?WF1Y9').0<GIS6GX
MWT_6-;TUX["TCGM8D?-O,[1R23 X5@-I#*.2.1SSVKF(_%NMQ)LCO=BY)PL2
M ?RK8T+7]2U6Y:VN=9N8)2"R>7;HP( ).<_2IE@YQ5VREB8MV2.GL#*WBS5&
M  C^RVXF"G*B?YLX/?Y=GZ5MUQMM=7LNFKJ%OJFI/%/))_JK*,GY>,M[FJ<>
MIZ])X>EU(:NXF7<\<!B3YXE8*6SCU-0L.^Y3K+L=]17%WMYJ]IIL=P-3U"21
M[=)05M(_*RP'!;\:RM1UOQ/I9"W.I1[\E61 I92.Q&/_ *U..&<MFA.NENF>
ME_\ +,_6FUP<=WXKN!&8-2C56ABE8S%%'SYQCBJ$7B/71J3V5WJCP.K&,E8%
M?##C& ,X^E-863V:$\0ENF>ET5Q-O=:XNI_V?J&N-%<.5$*00+(7W?Q'@;0.
M^>:5;K6S:Y;7R+K89MODKY?E!]N=V.O?Z5/L'W7XE>V78[6BO/M9UC6M*8A-
M9:8%]L9\I.0!R3@>O%1:;JWBG5(9)8-2A1(W6,F8HGS-T X[XJOJLN7FNK$^
MW5[6=SO-1LX=0TZXM;B$312(08ST;T'YUQ^H6%Q_PA]AIQTJ^-V^FI!YMM$K
M%6 '[J3/W4)QD^U54U+Q:\4[_;XU: MYD9V;U"G!)&.QJ]=R^*()Y;>#5!<R
MK+'&#&J8RPSSQQTI/#.]N9#5==F:VJQRMJ'AU+D!8B\B2A#\HE,)"8/USBL?
MPM:ZE:7\4UW:7$=K96(LU3[)Y;L=_ X8[\#DL,#GI5=Y?%DLS0R7]L42,3^:
MY3RRN[&X-CL:L;_%IM\_VI%]I^TFW\C"9X&2<XYXY^E'U?\ O(/;^3'VNF:M
M;^,)M3UBVM'M9;.Y6>YCF9@L65*1[2HQA0>,\_,:Z#PP+A?"VEBZSY_V==V>
MOM^F*X.]\0>(8IA:2ZA%-Y@ PBJRMGH#Q^AK3>]\3-?W-I::JDCVYV%65%9F
M"Y8*,=!SUQ3>%DNJ%]83Z,[ZBO.=4UKQ#I<=FS:NDIN81+A%7*Y['C]:F6\\
M7R/;K'J,+B=BBLI0J& R03CT_"CZL[7N@]NKVLST"BO/Y;SQA%C%_%("8]IC
M*,&#G"D<=,C!JM;ZWXHN=0FLH]13S(=QD=M@10O4EL=*%A6]>9![==F>DTYN
MB?[M>?R77BZ%)WEU.V1(41W=F3&&!*X..<XIHO?%\GV;R]0BD6=BBLA0JI W
M'<<<8'.>:7U9_P R'[==F>@45Q$LOBD&V6#5HI#)!YTDAV"-,L5 #8YSBL^\
MUOQ'96"W$FH.)%N'MYHS&GR.HR.W.0::PS>S0.NENF>CT5Y1_P )CK__ $$&
M_P"_:_X4?\)CK_\ T$&_[]K_ (5?U*IW1'UJ'8]7KA_&NEWM]J+-!;7KI)8-
M;H;2,,)7+[O+ES]U.!R,=^:P/^$QU_\ Z"#?]^U_PH_X3'7_ /H(-_W[7_"C
MZE/N@^M0['=ZCY@U[P^TP BW2@@'Y1,8_E_3?BLMK,Z##KDMKH,EVK7T4UK;
MQINW/Y:#S/4@-DD]>*Y5_%NN2 ![W<%8,,Q(<$=#TZT__A,=?_Z"#?\ ?M?\
M*/J4^Z#ZU#L=2EB9_!=[8"WU![F\6:63?;>46E)R<*> "<  ]<&L](=4>.>^
MN8VBN;O4;,6J&W\@DH &;9DD#&<Y/0>E8W_"8Z__ -!!O^_:_P"%-;Q;KC,K
M->Y9#E28DRIQCCBCZE/N@^M0['K1QDXZ4E>4?\)CK_\ T$&_[]K_ (4?\)CK
M_P#T$&_[]K_A1]2J=T'UJ'8]7HKRC_A,=?\ ^@@W_?M?\*/^$QU__H(-_P!^
MU_PH^I5.Z#ZU#L>KTHZCZUY/_P )CK__ $$&_P"_:_X4?\)CK_\ T$&_[]K_
M (4?4JG=!]:AV/6&^\?K25Y1_P )CKY_YB#?]^U_PH_X3'7_ /H(-_W[7_"C
MZE4[H/K4.QZO7"ZAI=_)XP>9+6[*M?6\R!$'V9T1<%W?J'&6P/9?>L+_ (3'
M7_\ H(-_W[7_  H_X3'7_P#H(-_W[7_"CZE/N@^M0['=R0I/XRGBN@6AETU5
MB!. 1YC>8![\IG\*PQ%=:)X=M+6UT29KDW-PD4D=MYHLXF9OGVCKE3@#OGGB
MN=/BW7&=7:]RZ9VL8DR,]<<4_P#X3'7_ /H(-_W[7_"CZE/N@^M0['5W]F8_
M#.G6VG6E\6TUK>6(26V]L+D?,F1N(!)*@@CC'2JVCVM];7FB_:%*74UW>7,J
M;-A2!U/!4?=^;R^/6N=_X3'7_P#H(-_W[7_"F_\ "6ZYYGF?;?GQMW>4F<>G
M2CZE/N@^M0['K-%>4?\ "8Z__P!!!O\ OVO^%'_"8Z__ -!!O^_:_P"%'U*I
MW0?6H=CUF/\ UJ?[PK0KQVQ\7:[)J-K&]^2KS(K#8O(+ 'M7L5<U>C*E:_4W
MI554O8\:U[2;B77]0D66T :=R UR@/7N">*S_P"Q;G_GM9?^!:?XUHSRV\/C
MVY:[C22W:[=) XR,,<9_#.:T&T>WL;J'1I$1KA+>XN9I  3]T[%S]!G\:]53
M<4EY'G\BDV_,Y[^Q;G_GM9?^!2?XT?V+<_\ /:R_\"D_QK>3PSI\LMAY7FF"
M25(Y69]KJ67."I'!SZ9J.'PQ$L5J]Q!,"T+23*S;=O[S:.,$].V*?MEW_#_@
MB]D^WXF+_8MS_P ]K+_P+3_&C^Q;G_GM9?\ @6G^-:>NZ7;:;I,\429,6IO$
MLC#YBOE@@$UJ#PYI<UQ&LZS[I9(H5,;!0N8MV<8YYI>VLKW_  _X(>SUL<Q_
M8MS_ ,]K+_P*3_&C^Q;G_GM9?^!2?XUNIX>TU[<W<5M>3(;1)U@1QOR9"AYQ
M[9Z5)_PB5FLUY$WFE%\WR9-XR-B;L$ =CP<X]J/;+O\ A_P0]D^WX_\  .>_
ML6Y_Y[67_@6G^-']BW/_ #VLO_ I/\:VKK2=.ATPWD\<KLL%J%5&"#=(IR3Q
M[5<?PSHOVJ2W5+L,MP]L&\P'D1[PW3\,4>V\_P /^"'LOZN<S_8MS_SVLO\
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M )\T_P"_R?XUZJ>M)7E_7:G9'?\ 58>9Y7_PA.O_ //FG_?Y/\:/^$(\0?\
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M[U$VD^)3IC6:Z5;*3$8!-YX++$6W;>N/QKO:*/K$NR_'_,/8+N_Z^1P@T?Q
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M //FG_?Y/\:]5;[Q^M)1]=J=D'U6'F>5_P#"$Z__ ,^:?]_D_P :/^$)U_\
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M?]]4?VSJ7_/]-_WU2_V='_T$K+_OIO\ XFC^SH_^@E9?]]-_\36ON=OP_P"
M9>\)_;.I?\_TW_?5']LZE_S_ $W_ 'U2_P!G1_\ 02LO^^F_^)H_LZ/_ *"5
ME_WTW_Q-'N=OP_X >\)_;.I?\_TW_?5']LZE_P _TW_?5+_9T?\ T$K+_OIO
M_B:/[.C_ .@E9?\ ?3?_ !-'N=OP_P" 'O"?VSJ7_/\ 3?\ ?5']LZE_S_3?
M]]4O]G1_]!*R_P"^F_\ B:/[.C_Z"5E_WTW_ ,31[G;\/^ 'O"?VSJ7_ #_3
M?]]4?VSJ7_/]-_WU2_V='_T$K+_OIO\ XFC^SH_^@E9?]]-_\31[G;\/^ 'O
M"?VSJ7_/]-_WU3XM8U(SQ WLV"Z_Q>]-_LZ/_H)67_?3?_$TZ+3HQ/%_Q,K/
M[Z_Q-Z_[M#Y.WX?\ />/92QSUI-Q]:8TL08@RKG\:3SH?^>J_K7@V/8)-Q]:
M-Q]:C\Z'_GJOZT>=#_SU7]:+ <M/XLO%\2RVD:QI8VUVEG,\D+8+,H.3)G"G
MY@ ,'/<CBKVC>(I=9UV_MTCC%A%#'):R9RTN692_L,KQ^=/N- TNYU%[N2>;
M;)(LTML)/W,LBC"NRXY/ []A4FGZ%H6E:E+?V%M;6TTL*PMY2!5V@D\ #W_0
M468S/U#Q9-;:5J%U;QQRSK--!8PL<>88@=[L?[H(8_0#UJDWC*^;4XXXTB%M
M";9+ES"Q4M* 3\X.$QD8X.3UQ6F?#>E7,-[:ZA#:W-M+-++ 73+Q"7EP"1Q\
MV2"/;TI1X6T598O+EFAA41![:*3;%-Y?W"ZXY(P.F,]Z+,#1TK4)+U;J.8*+
MBTN7@DVC@XY!'IE2*T-Q]:S-*MDLDNI)IXVN+JX>XE*YQSP /8  5?\ .A_Y
MZK^M%A$FX^M&X^M1^=#_ ,]5_6CSH?\ GJOZT6 FW'RSSWINX^M-\V+RB?-7
M&1ZTWSH?^>J_K18"3<?6C<?6H_.A_P">J_K1YT/_ #U7]:+ 2;CZT;CZU'YT
M/_/5?UH\Z'_GJOZT6 S=0U2^M==TFSCMX_L=W*4EG9_F!VD@*OX<DU0T37-0
MO-7DM]1+6WF>:;>W>S,995;&1(6.[C!(P/O"MFXM[.ZN+2>27Y[60RQX) W%
M2O/KP35.RT6PLK\78O+F9T#K"D\Q=80YRP08[X[YXXHLP*M]KU_'I^NWEA:1
M3FP+11B1MH)1-SLQ[@$XP/0^M5]1\2:E!]HGMEM_L^GVD-U=*ZDM+OY*H<_+
M@ G///%:,6FP*-8MY)U-GJ#,Y"DAE+KM<?U!]S4=YH&E7TL;O<S*JQI#+''+
MA)T0Y59!CD#\*+,95\7>([W1&MDLPA+Q2S,3 TQ.P#"[5Y4'/+G@8K2T[5I+
MK4);658U8V\5U&8SD%'&",]\,.OH146H:)9:BXDEU"[CE"NADBEVL8WQF,\?
M=X&._O3[#3K>RU&>Y62-4\B*UMXUS\D2#O[DG]!19@:^X^M&X^M1^=#_ ,]5
M_6CSH?\ GJOZT6$2;CZT;CZU'YT/_/5?UH\Z'_GJOZT6 DW'UIS,<+SVJ'SH
M?^>J_K3GEB 3,J\K_6BP#MQ]:-Q]:C\Z'_GJOZT>=#_SU7]:+ 2;CZT;CZU'
MYT/_ #U7]:/.A_YZK^M%@)-Q]:H:U?7EAH]S=65NEQ<1H65'?8HP,Y)]!Z"K
M?G0_\]5_6H[@6UU;2V\DHV2H4;&0<$8-%@.2U?QCJ-A)8>2D)$EG#<RCR6<,
MSL 5+#B( <AFZ_A71ZAJ,\&I6=A91QO/.LLIW\+L0>O;+%1FJ5WX;TF[\L-=
M7$:"W2VD2*4JL\:?=5^.>_3'6K&HV$=W?6ES#=")HDD@<J2I\IUP=IQPP(!%
M%F,PYO$^K6GVJWGGT]C%/#"]^L;""V9\[E?GG;@<Y'WAG%7](\32W\EDDI@D
MCN)I[3S8@=KRQ<[AG^%E!_+WI;7PQ86>E_V='JVH& %6CS,-T3 YR"%Y)[YS
MFIK?1;2UNM/\J<?9K(2RKO8L\DS\%V./0M^?M19@;NX^M&X^M1^=#_SU7]:/
M.A_YZK^M%A$FX^M&X^M1^=#_ ,]5_6CSH?\ GJOZT6 DW'UI0QR.>]1>=#_S
MU7]:430[A^]7K[T6 D9CN//>DW'UIKS1!VS*N<^]-\Z'_GJOZT6 DW'UJAK-
M[>6&D7-U96Z7%Q&A94=]B\#.2?0>@JWYT/\ SU7]:CN!;75M+;R2C9*A1L9!
MP1@T6 H76LRVWA>+4BBO/+#%LCQ\IDDP /IDTBZGJ"^*H]*F@B6U-FTRS!LM
M(ZLH.%_A7YN_-+J&G6]UH/\ 9L-PJ>6B"!VR=K)@J3^0JRUO;37T6H22A;I(
M&A^1CM 8@G''J!@T6 P-0\5WD'B.6S@1!:6DT$-P[PL03)ZN.$QD8X.3UQ6[
MI>H27JW<<X43VER\$FT<''*L/J"*I3>'M,N+L7$MY<G=Y9GC$N$N#'RK2#')
M''3&>]6M*MDL4NGFGC:XNKAYY2N< G@ >P %%F,T]Q]:-Q]:C\Z'_GJOZT>=
M#_SU7]:+")HV/F)SW%7ZS(YHC*@$JD[A6G4R*1Y'#M_X65)N"E1=R$ANAZUI
M3:?I]_9V+VB1&"YN9IS$Q(*$)RG')Y!P.]9>H)!?>+KNSBTY6N)+EU#M<LH)
MSUZ<5%-I:P-#C3H98Y2P26"]9UW*,D9 X->PU>SO9V1YB=KZ7U-.7PY8RS2Q
MVUOF3_19-A?&U&SYG4]/Y5%<:)IOV*^\F 1R1/-B24MMVJW&U@<9 [$<UB83
M9')_8<^V4[8V\Y\.?0<<U(+9B2I\/W*C(W;I7 &>YXJN62^U_7WBNNW]?<;U
MUX>TP2V<<$ P\@V2-(VR==F3D^N?3Z5@^);"VL+RV%M&8UEMED9>>&YSP2<=
M.E+=VOV&\^R3:'+YH<HFV=R'(_N\<_A4819)9(AH-PTD?WU\UR5^O'%."::=
M[_UZDRL]+6_KT,BBKWVNP_Z!?_DRW^%'VNP_Z!?_ ),M_A6]WV,K+N4:*O?:
M[#_H%_\ DRW^%'VNP_Z!?_DRW^%%WV"R[E&BKWVNP_Z!?_DRW^%'VNP_Z!?_
M ),M_A1=]@LNY1HJ]]KL/^@7_P"3+?X4?:[#_H%_^3+?X47?8++N4:*O?:[#
M_H%_^3+?X4?:[#_H%_\ DRW^%%WV"R[E&GP_\?$7_71?YBK?VNP_Z!?_ ),M
M_A3X;NP\^+_B5X^=?^7AO7Z4-OL%EW/4)?\ 6M]:96DUO 6)*')_VJ3[-!_<
M/_?5>%S(]BQG5SOC'S6T^R02)%:O>(MU)(I*+'@\L 0=N<9Y ]:[/[-!_</_
M 'U0;6W((,9(/4%NM',@L>;PPO)X=TF5)IEC@U)4C6)V$<R^;@/@Y.W'0$X'
MY5OZQ-(FK:5$$=XRTTQC0X,CHF43\\G\*UGU"Q&L-I<=C=S2QA3(\84QQ[@2
M,DD'H.PXJO;7FG:OJHL)=+U""YM56Z!G4*%Y(!RK'D\\=QFES(+'%6%P9KG7
M#K\5_ LZ6TDPF1A'&27 7Y3]P<9]<$FKEF[?\(+J-K'=;74W @ECW8D0'.Z,
M?>V<XXSC'>NRN]2T>SL]1N[@E;>Q^6X<\C.,[1_>/(&/4XI/[2T9;W3K+)%S
M?)N@B'4+MW9/]T8%%T.QP=A<.EM<75E EO;17]J+6*&8R(68!9%5NA!SSCO[
MUWYX)Q3X+?3-3BBG2$D6\S;5)V^7(N5.1ZC_ .O5W[-!_</_ 'U0I(5C.HK1
M^S0?W#_WU1]F@_N'_OJGS(+%,?\ 'LW^^/Y5%6F+>'RB-AQN'\5-^S0?W#_W
MU1S(+&=16C]F@_N'_OJC[-!_</\ WU1S(+&=16C]F@_N'_OJC[-!_</_ 'U1
MS(+&)J,!N=-N(1-+#NC/SQ-AAQV/:N'N?(.CZ;_:+R;1HBFS)9LFY]L=7^YC
M\?>O3K@65I;27%P1%#&NYW9\ "LM-=T&6#2Y S'^TG"VB%3N/)&<?PCCK2;0
M6,N[:>2[\.VESD"8LUP/[TBQ9"G_ (%G\JK>'K*QM[W4]6CACM8FG-K"N2%"
M(<$\GJSY_(5U&I1Z:C6B7$$DLK2[K=(SERZ@G(^@S^=0:9J-CJMY=6:Z=>VT
MML%:5;E%4#=R!D$C/&<4<R"QQ]@-(U'Q)<K97"1QQK/%<.UP3+<N?O?*3]U,
M<'U'' KHO#US-=^'-.N+C/G20*6)[]LT\:MH%[#= VEP(?*D82^5M$\:G:Y0
M]2!GGIQ6[%:V@@C$*?N@@V;6XVXXQ[8H4D%BC16C]F@_N'_OJC[-!_</_?5/
MF06,ZBM'[-!_</\ WU1]F@_N'_OJCF06,ZI9ONP_[G]35S[-!_</_?5/>WA(
M3*'A<#YO>CF06,NBM'[-!_</_?5'V:#^X?\ OJCF06,ZBM'[-!_</_?5'V:#
M^X?^^J.9!8SJXO4[>6&3Q2HN[APT-M*3(S$ 9;<@V_=7 QQTZUZ+]E@_N'_O
MJLAM<T)3J>)&?^SMJW!0$_,W 4?WCGC [\4<R"QS.@W4T>B:[<VD"Q6\3.]E
M%'(9$&(LG:>XW9Z<>E9^I+91VFEO#.YU...UD57+[YE+ D1'.,DD[N#QP<=:
M] TZXL+^WD:."6 P-LEAG&QHCC.&'3&.?2LR'5M!LHK2&&VNA;D)LE\LE(0[
M%4RQY&X],9]\4KH=CF-'DABUFUE\QEOP]V=4+,?E0-\F_/ '3;[5!$7;QHTL
M[QR7)U,QQP .)/LQ7AP0<>6!VQ@^N:[FTU72+W46LXH9@[%U25TQ'.8SAPK?
MQ;3Q_*FOJVD_VL=.6&X:;<83*B?('QGR]WK^F>^:+H+&?X;E>31PKL7$4\T,
M;DY+(LC*ISWX K6J;2X--DTNV:PC(M=G[L9(P/0^]6_LT']P_P#?5/F0K&=1
M6C]F@_N'_OJC[-!_</\ WU1S(+&=3D^^OU%7_LT']P_]]4JVT 8?(>O]ZCF0
M6*$O^N?_ 'C3*TWMH"[$H<Y_O4W[-!_</_?5',@L9U9VO0&YT*]C6>:']RQ+
M0MM8X!XSVS[5T7V:#^X?^^JIZC/9Z=#&\EM<3/*_EQQ0+O=VQG '3H#U-',@
ML<SJ$TL7@BV9'9&DAMXWD[JK;0Q_(FI'M_LWC>&03S&)M/D C9_W<85T P/S
MYZUMO<:-?>'9+Z12VGO$V\/D' ."I'8Y&,>M,AU32VU*/3OL]TLA/E))(A",
MX7)3=W8#KV]Z7,@L<-JDKR>*IKEIHG=)K4V$.'WS1DC)C8' &<D\'ISQ74:&
M[;M3M\EH;>^DCB).<+P2OX$D5I76J:59:BEI);7&59(VG6/,43.<(I;MD\<?
MCBK.EP::]F?L<3K&LKJZLQW!]QW;O?/]*+H+$5%:/V:#^X?^^J/LT']P_P#?
M5/F06*4'_'S%_OC^==)67%;0B5"$.0PQ\WO6I6<W<J)Y#*9;'QW<7LMK<M"E
MTY)CB))!R.*FLK^'3$M[>WM-0EA6:2>21[<J=S(5  ].:IZB;V]\9W-E#<S*
M9;PQ@"0X W5=O]%G.KPP6=_=P6LT$DH>Y9LKY>=P/Y9_&O7=K)2['F*]VX]R
M:'5K>WM8(H[&_&R:WE(,!)'E_>^;//MP*H3:E=RV,T)AOR\NH_:6)1N8_P"Z
M?\.E2Q>'=2FE;;K#&#;$8Y@7(?S!E>.HZ<DTU-!OOLPEFUOR7$;2LA9SM17V
M$Y'7FA>S3W_,;YWT_(T!XA)O7FDLK^13=S2*6A),<;IM&/<'M3;?68DU'[3-
M:7[F-H?+?[*1E4!R"N>O/!.>*H2:-?Q Q/J,OF+=M 75W;("!LA1]:BN;5=-
M:Y@U#5KL7 B22W\LG#AAGG)X-+D@]%^H^::W,BYM;F6[FD2TN-KR,PS$W0G/
MI47V*[_Y]+C_ +]-_A5[4[F.*>,:=J5Y-&4!<R,00W<=:H_;KS_G[G_[^&NI
M.37_  YSNUP^Q7?_ #Z7'_?IO\*/L5W_ ,^EQ_WZ;_"C[=>?\_<__?PT?;KS
M_G[G_P"_AI^\+W0^Q7?_ #Z7'_?IO\*/L5W_ ,^EQ_WZ;_"C[=>?\_<__?PT
M?;KS_G[G_P"_AH]X/=#[%=_\^EQ_WZ;_  H^Q7?_ #Z7'_?IO\*/MUY_S]S_
M /?PT?;KS_G[G_[^&CW@]T/L5W_SZ7'_ 'Z;_"C[%=_\^EQ_WZ;_  H^W7G_
M #]S_P#?PT?;KS_G[G_[^&CW@]T/L5W_ ,^EQ_WZ;_"GPV5WY\7^B3_?7_ED
MWK]*9]NO/^?N?_OX:?#>W9N(O]*G^^O_ "T/K0^8/=/;"K9Z'\J3:W]T_E6;
M+(_FM\[=?6F>8_\ ?;\Z\'E/8N:NUO[I_*C:W]T_E65YC_WV_.J6J:K_ &99
M&8L7E=A'#%OQYDAZ#^I/8 T<H7(M0\/W=UKZW,5E91+]HBG^WJS"<*OWDQC!
MSC'4#!Z5JZ1IT]G-J-S<X:XO+MI25R<1@ (OX 5Q7_"2:W)I>FWI9XX&M3->
M7%O;><B,&QC&X$ #)SS717FJ3)>:=;6S[FNBS[F)QY:KD_F2H_&ERCN9\WAF
M^U*POK);N2UF@N[J55:$/'.9<E&.1V#8R.ASZ5M)HMV%\/AW222P/[^3;MW_
M +LKQ@>IKGX-5UYKR^TZ>\MHIXHDF6>6%D15)(<J-WSJ..<CD\U=TO7)6\/R
M:EJ4X$4;.1.JE!+&#\KA2>,]A_C1RA<UM MYE_M.Z>-T2[OI)8E88.T87./<
M@FMC:W]T_E7!67B?49;*6\NQ'&L6HBWDB5LE(FP%R<_>&03^(KJ3)(#C>WYT
M^45S4VM_=/Y4;6_NG\JRO,?^^WYT>8_]]OSHY0N:^UO+/!Z^E-VM_=/Y5GB1
M_LS'>WWQWJ+S'_OM^='*%S5VM_=/Y4;6_NG\JRO,?^^WYT>8_P#?;\Z.4+FK
MM;^Z?RHVM_=/Y5E>8_\ ?;\Z/,?^^WYT<H7-1D+*05R".XKGH- NXM%T:T;R
M_.LKI)I6&<%0[-@''O5J:2Y\F3R'S-M.S>QV[NV<=JY8ZUX@,-W#:R"_DBGB
MB%U;6_ )YD4*6PVWUSW]J.4=SJ;^WE3Q-I%[Y;-"%FMVP"=C. 5/X[2/QIVC
MZ?=Z;8R>;&DUW<73SW!#$ [F[''.$VC'M6*-?EC\+-J(G>>=?W7S1F,^:7V;
M67)QACR,]J=-JNIVVOI9S>2MI]CDE\PN=SNF,D]E7GZT<H7*T'AR^TR2YO+E
M2UM:V]REM;QS-*',IX"H1\@]LGKZ"NKTBSFL=&L;2;+2PP(CGW YK@M-\6ZO
M+87ES<]8+:&["O"8BRL3O"Y)W+@</Q]*[03,RAED8JP!!SU!I*(7-7:W]T_E
M1M;^Z?RK*\Q_[[?G1YC_ -]OSI\HKFKM;^Z?RHVM_=/Y5E>8_P#?;\Z/,?\
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M?**YKQJ?,3@]1VJ_7.P2.;B+YV^^._O715$E8J)Y#J$D=AXKOKN#4HH[@32
M!H6;;G(/X\]:8FH742+;OJXD9 ^/.MW9PKKAN3SC%))!!<>/[A;IT2W2[>20
MN<#:ISC\<5LR7=E?7T.JQWR2LUI<P2LZ^6Q.TE.#[''X5Z[:25U?0\U*[?J8
MT.L/"-HU6U=/*2+9):%EP@PIP>XSUJ+^T/W A_M:WV" P?\ 'LWW"VX_K6RE
MGH[M:(L5DT#S6ZVIC;,LF<>8)!^?6I#::0M[&ES%I\=YB<1QQ$&,@$>7NYQG
M&[J12YX]OR#EEW,D:W,)&?\ M>V)>1I&!M6PQ9=A'TP*I:BT>H3I/=:E"&$:
MHNVV91M' K;\C3&DO/L5MIOG"8"6.ZE&Q(]G)0@_WL].:=86^FR?8GD-FX6V
MB$B.0QY<[B-QP..O>FI1CJD'*WHV<O\ 8[+_ *"D?_?EJ/L=E_T%(_\ ORU1
MZE'%%JEW'!CR5F<)M.1MSQC\*JUU)-J]SG;2=K%[['9?]!2/_ORU'V.R_P"@
MI'_WY:J-%%GW"Z[%[['9?]!2/_ORU'V.R_Z"D?\ WY:J-%%GW"Z[%[['9?\
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M2V6I+>3M"$BTR;F6>,K@A0=ZYYQAOQIEYI5TFIZ1<P6\CQ6Q>%U R55UP&_
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M>2-KN[>58V'*KPHS[D#/XT: ;'VZ3^XGY&C[=)_<3\C47V>;_GD_Y4?9YO\
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M7!ZO^5'VN#U?\J+,":G-T7Z57^UP>K_E3WNH0$R6Y7(X]S19@/HJ'[7!ZO\
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MHM8BFD:2/4)0BJ/M<BM*$^Z"-_S8]\UH:6+2TMY6CF:9KB9YY)0H^=F/UZ#
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M '/ZFM#;'_SRC_[Y%.94PG[M/N_W12Y@L9%%:NV/_GE'_P!\BC;'_P \H_\
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M/B"P_M%$-S$D*6*)!(5PL<V!N)X)R<8S5J4N6]G_ %;R):5[7_K[SG-VB_\
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M#%QN) )Y)/?FJC4A?WK6^0I0E;2]SFO[=U+_ )^?_'%_PH_MW4O^?G_QQ?\
M"M;_ (0'Q!_S[Q?]_11_P@/B#_GWB_[^BM?:4>Z,N2KV9D_V[J7_ #\_^.+_
M (4?V[J7_/S_ ..+_A6M_P (#X@_Y]XO^_HH_P"$!\0?\^\7_?T4>TH]T')5
M[,R?[=U+_GY_\<7_  H_MW4O^?G_ ,<7_"M;_A ?$'_/O%_W]%'_  @/B#_G
MWB_[^BCVE'N@Y*O9F3_;NI?\_'_CB_X4?V[J7_/S_P".+_A6M_P@/B#_ )]X
MO^_HH_X0'Q!_S[Q?]_11[2CW0<E7LS)_MW4O^?G_ ,<7_"C^W=2_Y^?_ !Q?
M\*UO^$!\0?\ /O%_W]%'_" ^(/\ GWB_[^BCVE'N@Y*O9F3_ &[J7_/S_P".
M+_A3X=<U(SQ W'!=1]Q?7Z5I_P#" ^(/^?>+_OZ*=%X"U]9HV-O%@."?WH]:
M/:4>Z'R5>S.^DNYQ(P$AP#3?MEQ_ST-3R:=<-(Q"C!/K3?[,N?[H_.O(O$]/
M4B^V7'_/0U5OM0U.* ?842:=G"XE?8B#NS$ G ]A5_\ LRY_NC\ZSM;\,WNK
MZ<;..\:T5F!=D4-O4=4()Z'O1>(:G,W?Q$N[:UM)C! #*DCL&F.)-DFS;$0O
M)/4%L#!'-=)?ZS/;3V=LJ^=-<N=J'' 5=Q/UX 'N15*X\"WES&%?42C-;&TG
M,5O&JR0YR%"]$(Z9%7;[PY>O=Z=<6N%:V+Q'+ X1UVY&>I!"GWQ2NAZF0_B_
M5[>:6TN;2 7I\KR8XIRRAI&("R''RD8)XSP.*U--UV\O+.X>="ES:S/#-%"=
MX++@_*3C(((QGUJE:^ [Z"PDM9=5:9FD6=9_LZ+()@<B1CD[SVP>,5J:;X;O
M-.7'VDS-)(\T[,B@RR-CYN/N@ 8P*+H-3,M?%=U/IT%]<VQMU-ZUJZLP9HOF
MVANGKC/IFMW[7<?\]#63/X1NC8QV,1WPR7WVJ=V(!"[MY4?B *VSIMR3G:/S
MIW0M2+[9<?\ /0T?;+C_ )Z&I?[,N?[H_.C^S+G^Z/SHO$-1HNI_L[-YASN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm247121d3_s1aimg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg1.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &O R # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@#Y
MF_:V_:'\'?LC_LV?'K]IWQ]'%)X3^!/PL\<?$[5+%;VUL;OQ!+X4T2ZU/2O"
MFFW%Y(EL-;\8ZU#IOA70X)6 N]8UBQM=K^<%;\#/^"-OQ,_:_P#@-^TL_P"R
M5^WQ\9OBK\6O'/[:?[&WP?\ ^"BWP9U#XR^*-7URY^&GQ U2Y;0_VIOV7_";
MZ_J-V^BZ?\/=0UKP+K?AOX;>'D32O"OAG2M;NTCDAGEEA]!_X+X'XN_M8>(O
MV//^"2G[-^M^#-)^*?[7'Q$UKXZ?%74_'VEW?B/X=^&OV>OV4HH_B&J?%+P]
M8VUU<ZCX4\?_ !6M?!NE66GF%[;Q#J'A:Y\.7&(M0=T_.W]O_P""'_!:+]E:
M]_9R_P""J7[6?[4'[+W[2/AG_@FO\5='^(&J^#/@;\$]8^'?Q+NO@O\ &;Q#
MX1^$W[0&B:=JD?ARPL[_ $/4_ 6J>9K=GJ5Q%;Z98:;-XC1UFT40S9X2G&==
MU,3*G1IXG%PROVM5Q]E#"34*=3$.<XR5*-/B'$Y3"K/W*<,-@<PQ%6HZ$9^R
M5>+5!TJ;4ZRHU<:H12E-XA5X_5,,DEK]8RNCF,Y:R<I8O!*,&XRD_P"HG]K3
M]O/]FO\ 8FM/A_;_ !L\2^))?''QBU/6=!^"OP=^%WP_\;_&#XW?&CQ%X?TQ
M=6UK1OAE\*OAOH7B3Q9K[:3:7%@=9UN:QT_PMH,VL:';ZYKVFRZOIZW/YK?M
M8_\ !:?X077_  3Q_;6^.O[*D?QW'[0W[//@SQ9X%\0_"W6OV8O'\7QM_94^
M-FO_  Q\3>*OAUXP_:-^"7Q \+65QX$^%FC7&CMJ6L_%#Q)8ZS\);9M/O+"?
M5M:O;#5=#BXGQ9\0OAY9?\'"O[+'Q=\8^)=%M_A9^T5_P2'U_P &_L;?$#6[
M^"/P?XP^+[_M%3_$;QSH'P_O+MXK,>//$'P3\1^"]7C%L(K_ %7PW)#I=M-,
MUU%9W7/_ /!2GXW_ +'WCOP#_P %M?@_\&_A4==_:P^'/_!*SXCZQ^T[^T5X
M.\,>$)_"^EZ)>>"O&MK\._@)\0?B)I7BJZ\777Q0TW1].U+Q?9^#]0\)/I&D
M^#-.G-SXEM;NV_LA.:NO88&JY)RK1H8YU*>&DZ4J%3!XV>'^J591UHU<-3H5
M_K,.:C.G2Q%"5&I.3G26E+E^LQI1I35**PT_:U8TW#$0QF'A4IXBG%5)*5"M
M.LJ%*I)R=>MAL1&KAJ-.I9?9'[(7_!3+X:^-O@U_P3MTGXJ^'OVB/#?Q@_;(
MTL_"OP@_Q<^"FO?#K6_&/Q+^%?P1TOXF?$7Q[JEKKUOHA_X0#Q?I\%[KG@WQ
MQHVGW7A_Q8UPLFCPP6OF"U^W?'/[6?PA^&G[3?[/W[)GB67Q''\7OVF?"OQ>
M\7_#"WLM$>^\.7.C_!+3=)U?QP-;UZ.X5-&NX['7K.32('M;@:DQEA$D$RHC
M_@G\;_&'A/P?XB_X-;OB9XI\2:)X?^'.D>)K'P9K'CO5=2M;/PCIGB[XE?L%
M+H/@#P_J.O2R#3K'5?&>M[],\.VEU/%)J5TLJ0Y6.5E]W_:<^*/P\\6_\'$'
M_!*WX8>&O%6B:WX\^%W[-/[=VK?$/P_I5_9:A=^#8OB+X \)7/@ZT\1):S3G
M3=4UBS\-:IJ]OH]Z;74!I#Z;K!B_L_5;&:Y]2K2]IF^*PM*<(TX\0\38+$1I
M4XN$:6683-,7AY4XTX0C#V]7!*4>5>RIQJPPU#_9\+A[>=.?LLLP^+2C*=7*
M,IQC4FY<E7'9O@LOJTW-MN4L/#&251M<\Y+VE11J59GVE\9?^"OO[)/P?^(W
MCWX6:5H?[2_[0/BCX-:O_8?Q^N?V4_V6?CC^T5X._9[ODTZ#69K3XO\ C_X=
M>#=4\%>'M4T_2I;J^USP[IVNZWXG\/)I>IP:]HFFW<$4$_Q+_P %<O\ @KCI
MOP^_X).6W[8?[ OCCQSXU;X_W'@;3/@C^T+\+?@QKOQ%\#^"])G^+?@SPOX^
MU'XCS>)/#;6/PCUR;2+SQ7X!\+6?Q'T&R\1Q?%F.'PG!H%OXJL9(K+P?]F;X
MQ?M'_M!_"S]J_P#:&_9[_:G_ &&O^"17['O@C]KO]HJZ\=V=E^SMH/Q?_:$N
M];\%>,]:\/\ Q8^*W[4GBGXG_%?P/\*OAE\4/BGJ&F)XW%M<?#?Q7J6F:9_P
MABWFK>)-.-Q:ZW^7-OK^F>)?^#0KXQZWI>O7?B+3'_:TU+4AXDU+2['PY=:M
M8:A_P4[\)ZW!KNHZ-I,-OI/AN74K+4[75+S3-/MK33-)N+M[2S@AABA2L<-0
MG4^K^T2YHU>'YU*LW%1FL?FN38::J5'%4:=.7]H.I*-2I;V4:BG:,IRI]DWR
MS481O>MF>$]E"_N/#99FV*I6BE>4[Y>J,'!-*K4IV<E"U3^LSX@_\%.?V9?@
MY\$/@W\9OBUIGQU^&NK_ +0^K>)= ^"7[-_B;]GWXKM^U]\1O%GAA]6_M7PE
MH/[,FC^&M8^*:ZG#%I27MS?ZCHNG^&=(TW7O"FH:_KVD6OB?1Y+KT']D_P#;
M^_9U_;&NO'GACX77GQ \)_%?X3G1%^+WP#^./PK\?_ KX]?"O_A);*34?#5W
MXS^%WQ-T'P[K\>BZ_9)YVD>*=$36O"=[(SV<6N'4+:]L[7\,_P#@H!I'QTO_
M /@O+^RAK?PV_;#^'O[&EK\4/^"=GCWX8_LY?&7XH? 3PG^TAX&\5_&?1_C]
M?>(/C#\)O ^D^+/B;\.="\)_%/Q'X U/P#J(\2V&LW&JZWX=T<>![6SN#J[Q
M3^O_ +-7PD^(&C_\%EM"UKX]?\%./!'[6_[5/PN_8A^(GA7QU\+OA3^PKH_P
M0A\._ ;QU\2_!>J^'M.^+WQ9\%_'+XB>'-$UNS^)&G:9XJ\ _#WQ)I3>*-2L
M;K5M:TZVLM%U(ZG<S2Y:L%4G&=.,WC+*5.%.IAOJU?%4&Y0@W-:X.<W[6-*I
MRUJ,W%1<G)3CR1I^S<)ITL)67*^:->.+ITZB3LN523J^S:YYI.$M8MQ@ONC_
M (+;^/\ Q[\)_P#@E+^W-\1?A7XY\8?#3XA^$/@A?:OX3\=^ /$VL^#O&/AC
M5(]?T"%=2\/>)O#UYI^MZ)J @::".^TV]MKJ.*>6-9D61Q7YR_#;_@B5^TEJ
M/PH\ ?%KX??\%V_^"O6@?%#Q'\./#/C#P_+\3/VB+SXR?"W2?$_B?PE:7Y;Q
M-\+O$IT_3O%_ANTN]2D(T74-8@G\F.$P:A_:,-O=5]T?\%[R&_X(V_\ !03=
MU_X4)JP!8@'">)/#H7DD9)W<#))) &20#ZQ\+O\ @H=^P'X _9F^%E]XV_;9
M_90T"W\(?!+X?GQ-!=?M"?":6_THZ1X'TE-4MY='MO%EQJ=S?VSPRVXTJTLK
MK4;FZ46=K97-T\=N_/AX<D\XG>*G2K92HRNWRJMEV=5ZM1TU[W+/$0I2[V5K
MW"7M%4R^+TH5:.8.HDKI2IX[**5./M-$Y4\-4JPM>S;NE8\"_P""97_!1#QI
MX]_9:_:7N?\ @H/K_P ./AK\??\ @G)\9/B;^S[^U_\ $6UN;'PQ\,O$*?#.
MQL];TKX\:;;_ &>QM="\/?$#PIJ$=VEI;6.GVM]KFGZO=^'_  [HUAJND>'+
M#UCX,_\ !9/]BKXT?$/X;_#O3YOCS\+Q\>-9M-!_9L^(O[0?[,GQV^ 7P<_:
M;U6]TZYU*QL/@?\ $_XI>!/#GA?Q)J6IVD$#Z%H6LW?ASQ%XGFOM/L/"^D:W
MJMU%I[?RQ_%W1OBA\>_^"7/_  4U_P""A.DV>L?#[]GO]L[_ (*S_ W]H"PG
M\1_#"]\8S77["OP7^*/@/P7I7QN\3_!Z]N]'NO'/A5]:T[3/'/B7P/JEUIMC
MJ^B^"=1OKC4K+1+P:Q!^@W_!0SX.?M%?$']E?X>V/[3W_!>GX'^*OA#\=_BO
M\ %_9YD^"G_!,7P+XE^)/Q&^+;_$?PGXE^"FH?LYR?"_]JS5O&&N>(?[>LM-
MO8]2\$QW)@\)-K(U26/1K^Y%STQA"<Z4\0GAFX970Q,877L*V+RC"9EC:D>5
MSDZN'^L7;2C3LL=0C-5E['#U-*$'&FU*,9YE.E-^]R4\'C*N&IV=E%TY0IN4
M))MQH3IR<9-7K?TF_"3]KOX/_&?X[_M/_LW^$I_$-C\8/V2-<^'VC_%[POXE
MT1M':*S^*O@T>.?A]XL\,70N;J#Q!X0\3:&EX+35XC!)#?Z?>65Y9VTRP>?Y
MC<?\%(OV3=,MOVT->\4_$$>!_A[^P-XIT7P+^T;\6?&=B^C_  ST3QGJ_A;2
M/%$WA/PMXABEOKGQGXFT3_A(?#?AO6/#6AZ9<>(6\:^)- \(Z+I>M:[J]E9R
M_EW_ ,%*OB]X9_X)@?\ !0?X,_\ !3WQ2ILO@7\;_P!E_P"._P"R+^TH9+F2
MRTL_$;X/^#O$W[4'[)VH)%;07$NK>-_'^K>"_'?P/T&YN4:)'U_1;*!XQ=8D
M_+/]J']F[XR? 7_@BA_P3O\ 'OQ"\<V/PS\>_$G_ (*C?L[_ +?7_!0KXU^*
M?AA:_$#PQ\/?$?[27B/QYXKF^(OQL^%VK:YX=TOQWX/^$WCOQE\#/"WB_P +
M:]KEIIVJS>$-%M9+F"WMX[=<TX5::G&7)3A5PN7XBK.4[T\TQ&9XG"<L'%6J
M4?[-HTLSA+FA[/V]-3?O0DB=Z4Z<(Q<U6]IB:.T6\)3RRAC*EXVE*+CCJTL%
M%RBO:UE*<%+EJ4X_TD_ S_@K1^R3\>/BUX2^"-M:_M ?!?X@_%&+6+WX#V7[
M3W[-'QN_9QT;]HS1= LHM5U/6?@;XE^*W@KP]H7C80://::W'X>^VZ?XUN]%
MN3J=EX7GMK/47L? /V0_C;XUE_X*Q?\ !<'PM\1OBGXJNO@[\#="_P""<6M^
M!?"GC;Q[J,GPS^#>F^+/V:/'7BGXFZSX5TG7=5;PI\/=.\07UFOB;X@:CHT.
MEVNK3:9_;>MO>7%FLQ_/S]LKX&?M&:_??L+Z/^UQ_P %N?@_\3K3QM^VC^S3
M\0_V5O!'PD_X)I^")/B3\1/C!X,\76_B;P9XB^'6N_#K]I[Q'K>A^$(-*:^B
M\9?%2.QG\$^%_">NR2>)=0^PZM!8ZCXG^V'X6^)?C?XC_P#!W=X9^$,&IW?C
MG5?V8_\ @G8;;3=%2XEUC6?#%C^RKXRU/XA:%IUK:AKO4+K6_AW9>*M)32[6
M.>XU1;MM.BM[B2Y$#J3C"AB9R2FZ> S9VJWG%+!SX;DJS?*O?3Q,J4W#F2DE
M534)N)5.*G)TXR7[ZMEJ<[6Y%7QU>,FFTVO:>PMIRR][D::W_9G1_P#@NS_P
M3UU35-(U";Q7\:]!^!7B3Q3:>!O"G[9/BK]F3X]^%?V*_%OCB]UUO#5MX7T;
M]I37O -A\/XW?6X-0LE\6:Q>:3\/9?[)U&ZMO&,]@MK>7?T#^U7_ ,%/OV1_
MV+/BI\-/@W^T'XJ\2^&?'/QA\%>)_&7PTTO0O!>N^.+SQO+X;\5>&/!L'@3P
M?H'@ZVUOQCXQ^)_BWQ!XMTFQ\%> O"/A?7=:UTB_N1':V>F7]S;?#'[8?[2W
M["NL?\$#/BGXYTGQG\-=6_9@\<?L'ZG\-O@WH>CZOH<EIJWBS4/A(?!WPH^$
MGAC1$F\^T^(^@>.;71?#T'A5+&#7_!?B?0YVU*RTF;PYJ,EA\->"]4\+? O_
M (*$?\&X^@?MH7VE>$/C#IW_  2J\<?"S3K_ .*.H6MC=:+^U3=_#;X&^&KS
M0;W6=9N8[.W\?ZPJ>/O MBLMRE_KGBK78?#NFO>:QK6FVMQTJ%..+K82<:MJ
M>->#A6E%..,@L-FE>#A44YQYV\N4H*+K+EQ5*-[P<JV$9<U%8AQ<'4P-;$_5
MK-3HXBG7R:C!NG924*7]I8F%32-ZF#Q,TU#DO^ZW[-O_  4N_9?_ &HX_B[I
M7@F?XH>!OBA\ ?#B^*_C7\ /CK\(/B#\#_V@/AQX=O+'4-4T36M9^%_Q&T30
MM8U#1?$.EV(O=)UOPU)KFC_Z=IMAJ-_I^JWT6GGY'T?_ (.#/^";>L^!? _Q
M8M?%?QN/P1\5?\(Q8^+?V@;7]F[XSZW^SY\"_%7C+3= O?#'@#X[_&_PQX1U
M[X9^!O'=[<^)]$T?5O#EEXE\0W/@K5[U+'QY)X7ECN!#X%^TYKOA?XD_\%L?
M#J_!/4-.UGQ7\ ?^"3_[7>B_MEZYX<9+^+P_X+^)6O\ @W4OV>?A1XXU^P^T
M66F>+[OQ?IWB7XC^'?!.J7,/B$^&UO/%4&E_V3*;NOC[P5X<T+3_ /@SKO\
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M"0Z^MKITWB_1[[5_AW:/J%K<7OC&UM8M0GL>?_;&^+GC2P_X*;?\$/\ PIX
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MHM/Q$\.W#V;XUX,=/3W'Q-D3AI4A67NO%\NE:G3J[/\ >PA4^.,9KZ&\3?\
M!+W_ ()T^-/CJW[3'B[]B;]FGQ+\=9=3_M^[^(VN?"/P?J>KZGXG%X-0C\9:
MS:W>F2Z1K7CB'4%COK;QOJVG7OBRVO(+:ZM]9BGMK>2+UFS_ &-_V6++X4_%
M/X%I\!OAK=?!GXV^+_&OC[XK?"[5?#EIK7@3QOXP^(FJ0Z[XSUW6/#.L"^TH
MW>MZ[;V^N2K:VUM;VNM00ZM80VFH1I<K\0?\/R_^"7O_ $=;9?\ AF_V@O\
MYT-*O_!<O_@EZ2!_PU99<GM\&_V@LGV_Y)$/YU#X&XT<90?!_$W).$:<X_V#
MF?+*G&4)QA*/U*SA&=.$XQ:Y5.$)I*4(RC?_ !$G@"ZE_KUP?>,N=2_UIR6Z
MERRASI_7&U+DE*/-?FY92C?EDXOZH;_@G?\ L-S_ +-'A_\ 8XU#]ECX+ZY^
MS!X2FUJ\\)_!;Q+X+TWQ1X,\*ZGX@U?Q%K^JZYX9M?$*:G=^'_$<VM^+?$NJ
MV_B72+RSU[3K[6K^XTW4;228D=U^S9^QU^RO^QWX1O\ P+^RW^S_ /"GX$>&
M-7NH+[7['X;>#M(\.77BC4+07*66H^+M8M+<:WXMU*PAO+FUT[4/$NHZK>:?
M8RFPLIX+-4@7XC/_  7(_P""7@S_ ,95V>>?^:._M ?_ #I3UZC@Y!##(()@
M_P"'Y?\ P2]_Z.MLO_#-_M!?_.AIO@;C-N;_ -4.)9.HW*HUD.:/GDTDY3O@
M5S2:BDV[MJ*3;LDI7B/X>V2CQQP;9--6XGR31WNGKBEJFKIW=NC6Q^D_Q@^#
M'PM^/WPQ\8_!GXR>"=&^(/PN^(.DMH7C3P5K\<\NC>(=(:X@NFL-02WGMYVA
M-Q:V\W[J>-P\2$,,<_G9X8_X(5?\$??".O6'B/2O^"=_[,5UJ.FO/);6_B;X
M?VOC70I&N+:>TD^W>%_&4^O>&=458KB1[=-3TB[2TNE@O;58;VVMKB++_P"'
MY?\ P2]_Z.MLO_#-_M!?_.AH_P"'Y?\ P2]_Z.MLO_#-_M!?_.AJ5P+QFI3F
MN#>)5.HH*I-9!F2E45-2C34Y+ \TE",YJ"E)J*E)1Y5*5Z_XB1P XJ'^O/!_
M)%R<8_ZTY)RQ<W%S<8_7+)R<(N327-RQO?E5OU7?PMX9ET!O"DGA_19/"SZ.
M?#S^&GTRS;P^^@&Q?3#H3:*83IK:,=-=]/.EFV-B;%C:&#[/^[KXM^"W_!+O
M_@G3^SE\5KCXX_ K]BG]F[X5?%F2>XN+#QQX+^%/A71M8\+RWEE>Z9??\(']
MGT\6GP[CU#3-1OM-U&'P);>'8=0TZZFL;R.>T<PU\]?\/R_^"7O_ $=;9?\
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M\T<_:"['(_YI%ZTW_A^1_P $NL@_\-5V60<_\D<_:#ZAMW_1(O[W/Z=.*F/
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MMD?\*B.#CJ,G'J:3_A^7_P $O?\ HZVR_P##-_M!?_.AJ_\ 4?C7_HC^)_\
MPQ9I_P#,9@_$?P_3:_UXX.T;7_)49)T;77%WZ==>Y^NM%?D5_P /R_\ @E[_
M -'6V7_AF_V@O_G0T?\ #\O_ ()>_P#1UME_X9O]H+_YT-'^H_&O_1'\3_\
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M,6:?_,8?\1'\/_\ HN.#O_$HR3_YL/UUHK\BO^'Y?_!+W_HZVR_\,W^T%_\
M.AH_X?E_\$O?^CK;+_PS?[07_P Z&C_4?C7_ *(_B?\ \,6:?_,8?\1'\/\
M_HN.#O\ Q*,D_P#FP_76BOR*_P"'Y?\ P2]_Z.MLO_#-_M!?_.AH_P"'Y?\
MP2]_Z.MLO_#-_M!?_.AH_P!1^-?^B/XG_P##%FG_ ,QA_P 1'\/_ /HN.#O_
M !*,D_\ FP_76BOR*_X?E_\ !+W_ *.MLO\ PS?[07_SH:/^'Y?_  2]_P"C
MK;+_ ,,W^T%_\Z&C_4?C7_HC^)__  Q9I_\ ,8?\1'\/_P#HN.#O_$HR3_YL
M/UUHK\BO^'Y?_!+W_HZVR_\ #-_M!?\ SH:/^'Y?_!+W_HZVR_\ #-_M!?\
MSH:/]1^-?^B/XG_\,6:?_,8?\1'\/_\ HN.#O_$HR3_YL/UUHK\BO^'Y?_!+
MW_HZVR_\,W^T%_\ .AH_X?E_\$O?^CK;+_PS?[07_P Z&C_4?C7_ *(_B?\
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M"?\ H4O#/_A/:-_\@T?\(#X)_P"A2\,_^$]HW_R#7744_:U?^?M7_P &U?\
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M_:3NR_\ 6 /V_:_3NCVM7_G[5TV_>U=.NG[[34?U/"-)/"X>RO;]Q1TN[O\
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M\!-U%#"T)>RDXSMAH:.,XTVU>@N:*E.*YHWC:2=];+ZH_P"$!\$_]"EX9_\
M">T;_P"0:/\ A ?!/_0I>&?_  GM&_\ D&OC/P'_ ,%-/V.?B-X;\=^-M#^)
MVLZ'X$^'7PGF^/.N^/\ XH?![X[_  5\ ZQ\#X2X'QA^''C?XQ?"_P "^%?C
M#\,)E6*:U\=_"/5_'/AF\M=0T.\M=2FMO$6@R:CZU\ ?VO?@G^TW%XR_X5'X
M@UN\U;X<ZQHV@_$+P3X_^&_Q8^"/Q3\!ZCXFT:T\3>%7\:?"'XX^!/AS\4?#
M&E>,/#%[%K_@[7=7\(VNB^+=-2>Z\-ZAJD%M/)&1KU9.:C/$2=.G"K-1E7<H
MTZG,HRE'VJ<4^5_$HM:)I2:BZ>&P"WH85+VDJ7,Z5!1]I"5.$HI^SUY9U:5.
M3BI)5*E.FVISC%^Y?\(#X)_Z%+PS_P"$]HW_ ,@T?\(#X)_Z%+PS_P"$]HW_
M ,@U^85O_P %#?CWX-_;6^!/[,G[0?[*7A3X1^"?VM/'/[1?@G]FW7=)_:&T
MGXE?&[4+#]G7PE>^.[SXH_%7X1>&? 2^#O!OPQ^(7A:VM+C0[[PK\9/'WB/P
M5J_B#POX?^(V@:!JFL7,.D?K)%*[JI957<2" 6/&2 1E%.#C))4 >I')(UYS
MI4ZT:\Y4ZL7*$HUJKNE[)M27M;QG%5Z+E3E[\/:QC.,*BJ4J0\+@54G1>'PW
MM:?LW*G["ES<M53=.:7L?>IS5.I::=O<EI:SES'_  @/@G_H4O#/_A/:-_\
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MF#2?#D?A'2+;6]<TCPYI=\UU;.G.O5CSTYUY1YIP3]I53DX2QD).*=9.4.?
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M>+/!OPJ^"6K_  S\=--9?&'PQXO\1:G<:%H8L-5^']]\3]4U?3O#<WRE<?\
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MVY/^CBOV4?\ Q#/XP?\ T>E 'UA17R?_ ,(;^W)_T<5^RC_XAG\8/_H]*/\
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M?@Q\'?VC/VB_VBO@]XQ\8?M Z=/I?@'XG?#W]FKX\>!?"FE?L:P^!K_5]?\
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MYX>D^+?A?Q'X7UV?Q7H_@FV\<ZQXL\*:/IVJ^'K:#QM::+K&L_VU9Z8FEO\
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M'<>^+'_"(_MQX##]HC]E,@@'_DS'XP=#_P!WZ>AS]*N#=&+IPE*"LE;5M/\
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MQ&DFGFUK2M1NO#NB^';JX\/>%_AS8Z?9:-9:;^A3>&/VX%)4_M$?LJY'&/\
MAC'XO]< X_Y/U]"/:FGPO^V\=Q/[0W[*9(W*2?V+_B^20@.1G_AO3IAFP/\
M:/3)K&I[*K"I2G+W:E.5%I-Q<:4Z5'"SI4VHWI0G1P]"A*,.52A2IJ7,XQFJ
MC55.K&KSWJ0DJG-4O-N5.;KQ<^9/F5.I*5:,;J,9MS4;MI_$-K_P1A^ WBCX
M?^/]&^*7Q4_:(\=_$OX@?#;]G?X7V?Q>UCXG:'JWCWX$>#_V8O&^@?%_X.^
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M):QC*4JE2;459)<U:O*RND\1B+7^L5E5^%M _P""(/[-G@;X;_"KX?\ PO\
MC'^U5\*-1^&/@?XT?"&_^*/PY^*7@_PW\5?BE\"?CU\:O%/Q^\?_  4^)'B9
M/A3=6*^$A\1/%VKW?A+Q3\.M$^'GQ?\  EI/,?"/Q-TG5-1UO4]6]T^,W_!,
M#X.?'GQMX.UGXB?%3]H75?A3X/\ %'PB\;1_LOWOC[P[XH^ >I^+?@4VA3_#
M+6[:/Q]X$\7_ !@^';:9J'A?P[JOB;2O@O\ %[X8Z!\2-2TZZN/B5I/BY/$?
MBN'7?;F\,_MPHYC/[0W[*V1CYO\ AC#XO[<G'&3^WL#D9&>./Q&7#PO^W"1D
M?M$?LJ'UQ^QC\7^,<<_\9Z^M"2IR51RDFY*2E*3LY1INE"]E&_+"\8*3:CJX
MQ4W*<KJ3=>I4JU9RJU9^T56I-N52<IU9U:DI2<;RE*I*3<DMK13Y5&*^LXHS
M&&W'<S,68\<L2>20JY.,+G &U5   J6ODD>%/VXF)'_#1/[*8( .#^QC\8!]
MXX_Z/TZ@]1VIZ>$?VXW) _:)_92X //[&7Q@[E@/^;]#S\I_3UIQE&2O%W3]
MZ^OVKR6Z6COIV6FEK#^&R>FRUWU3M]ZC)^=G\_K.BBBJ **** "BBB@ HHHH
M *:_W&_W6_D:=37^XW^ZW\C0!^8W_!,W_CX_X*'?]I._VH__ $U_#.OT[K\Q
M/^"9O_'Q_P %#O\ M)W^U'_Z:_AG7Z=T %%%% !1110 4444 ?,O[:O_ "9U
M^UA_V;3\>/\ U57BS_/-<=^R)XW\&>"?V(/V.;[QGXL\-^$;&Y_9E_9_LK>]
M\3ZWIN@V4]X?A#X5N!:0W>JW-I;RW/V>*6?R$D:7R8I9=FR-V7L?VU/^3._V
MK^,_\8T_'CW_ .:5>+.#]?PZ5^1'QF_8U\:?MH?LD?\ !&?P9X?T_P .1^$/
M!.G_  Z\=_%#Q=XR^%/P>^.WA3P1X7;_ ()Y?%7PCH6KZU\'OC7;:GX/\;#5
MOB!XD\(>&--C_L#7M2\/ZKJUKXGMK>SCTJ34]/B<G'DLE9S@IN4DE"#=7GF[
MM-V5.,4E=N52*492<82=XI2<FXJ*3NDY7;J4H?#%2E9*I*3M%MJ#LGH?T )J
MVGR)')'<;XY462*18IS')&Y55D1_+VO&V]"KJ2A5T<'8RL7G4[$$ S_,<$IY
M<ID52VP2/&(RZ1;LJ9758U*N&<;&Q_,/XU_9=_X*3_L_?'3X0?!K]D/_ (:;
MN_V1OV>OV6Y/@/X9\07?Q7^#]UX,^(MHG[(O[0UKHWBK5/#R?$WX67_@CXJZ
M1^T\OP1TVWBA^ WCZ72[&RT37_ OQJ^$/PR@U?X2ZY]C?L!_LJ?'?X ?M8^-
M?'_Q:U+]JKXDK\4/V#OV4='U[XI_&#XZZ;\2O!1^/'@KQ;\3=2^./@;Q!X5D
M\;-J&C^.K#5/&VAZQ\.[CPK\/I?A;HWA6[^(>B>'/$NC2ZC/H&JZ<MYJ<*U*
M6'E4Q:C+6%10PZJ1IQJ0J3@Z<JU2FW&=1<C4N6'M%%5)R[QA!R:=27U5.DOB
M4JU:,*D$USP<J5-N4G"4XQ;=Y+V%:,?VNM]8TN[DO8;6_MKB73;A;348H9!)
M+I]V]K;7Z6M]&F7M+E[&\L[Y;>X6.9K.\M+H(8+F"22P;RV4$F0@ 9.8Y0>A
M( &S)+;3M !+\;0<C/Y:_LV?L^_$S]F?P_\ \%-X_AQ\/?$[:K\1_P!HWQM\
M9/V>XO$_Q3CUOQ+\7-9U3]CW]G?0(?$5[\3/B%<_%*_T:Y\2_&SPAXM\/C5?
MB/I.K6WAB73S.O@^Y\!Z=HNFW_Y(_#C]G_\ X+'^*?@5J7A+XA>./VUO!&MV
M/C#]JOQIX2U9/C/\,?#/Q=N;#5OV&/@WJWP'\'>+=>TGX]?'RUO=)3]M=/BI
M!I5NWQ#MK*.XMB\OA7X._!7Q#:?"+P_RTJTIPC>TW]6PM>=2$;)3KT_:U,/&
MBY.I*K3Y*E&RD_WLJ2DDG(:C)R@^>GR5,6L+&[Y;<WU=*M5FVU3H*=?WJO*X
MJ$*M1R4:4F_ZJKCQ!HEG<V=G=ZI9VMWJ4TMOIMM<S+!/J4\%M->SPZ=%*5>_
ME@LK>YO9X[19GAL[>XNI MO!+(A#XAT*XU.\T6#5]/GUG3;>QO-1TB&ZAEU3
M3K34VN5TRZU#3T9KNRMM1:RO%L)[J&**\-G="V>4V\VS^=#X<_ G_@H%XH_X
M**_LP?%G]HCP)^T7X@\-?#+XV>-/B!J7Q NOB?\  *X_9.\$?"SQM_P3C\:_
M"KPOHG@SX0:/XN3XM:!\;-+^/7B_QCX:^)FLZ=X)7PQK-[XENM<E\2^*O"E]
MX#@^'_2Z7^SQXEB_X*%?M@_' ?L(?M0?"+P]'\,_BAX)\&?&3X ^,/@;I7Q'
M_:YUGXD^//V?O$?Q"^(GB;XP:K^U;H_Q7T35[:_^%&@>&/V8?@]J?A?P=\._
MA7\*=%^*7B*Z\7:=K/Q4T7X7> ^B25.O[*=:G.#CC>6K0CSTY/#8EX>B^=U(
MQC2Q$:<\12G-QE6HU*#IT^64JL<8SG.A.K!+FC#+ZBIS<8R4<72C4K4W&_M)
MUJ#G&%2$(<M*<*RJS7(E4_??6/'?@GP[=Z58>(?%WAK0+_7;A;30[#6]<TW2
M;W6KIIX;9;72+34+FWN-3N6N;FVMU@LHYY6N+B"$(9)HU;H3>VRN4:3#*')R
MD@4!,;P7*;,KD97=NZ\<''X??\%(/V>G^*/[2/P<\=>*O^"=NJ?\%"/AA;_L
MG?M3_!L>%=*TW]F;5+#P#\6/BG\0/@%K'@CQ)J=[^TC\5?AD?!>E7WA_P7XR
MLY?B%\.D\1>+?#:3.\&G'SXU;Y\TSX$_\%;?!7Q$^'O@H>./VCO%VO\ @WX+
M> OA[<?''P]\6?@;??LJ:MX \-_\$^V\"?$)[SX:?$358?B9KW[9GB3]O^"7
MXE^"/B;XU^&VK>&Y/!LWA!_$WQ$TOX>P?$+X6:MC1J2JTZDFZ5&<)XM1C.3<
M*D,+&K+GBTO:<E1PII2]DY.-7GA3JS@Z+UJ/D]G;WN=T;JUG#VU2E!IZJSI\
MU5-M*,IP@I.E"<JE/^D'^T+3<5,K!@2"&AF7D,RX&Z, DE6*@9W(-ZY3YJY+
MQ'\4/AOX.DMHO&'CWP?X2DO5DDLD\4>(])\/->1PN$FDM!J]W9FYBA=E2:2'
M>D3,JR,I90?Y6-6^#G_!=B\_9Y^"WA3P3XS_ &KO!>I>&_CC\9AJ?B'QC/\
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MA#3/C#-??$GP[I.D>'[>^B\ ^&M)T;Q U_JOB#2_L/XA_P#!,[]B?XJC7_\
MA-_@K/J)\6?$+XF?$SQDVE_$KXP^$Y/&^N_&6#P=!\6_#_C>3PC\0-"D\9_"
MGXG1?#_P./'OP,\3MJOP4\5OX1\/2:U\/KR72;)X?11^Q7^S1#XDM_%D'PGT
MZ/6K/X\ZW^TW;S)K/BP62?&[Q%\%)/V=-9\:?V+_ &\=$DCO_@I<W7@)_"DV
MG/X*BL9/[2MO#<&OG^UCSSCB(T:<:?(ZZ@\-4G.,I0E4JX?#T5B$HSC./L\2
MI54KRBHJHY.]1\N3Y8<[<'*"KJK"*TG##4<0ZTJ+=ZD7.>%G.CS6DE-4N2,_
M9.-3\N?@;_P74\(?M&^$=#N?A%^S#\1_%?Q6^(7Q;^#'PW^#GPQ7XB_#6TT/
MQGI?QR^''Q2^-'A_Q#XF^+=S>P^$/!.O_#[X5_!?XD:E\9_ $$'BO6/"/B_1
M]'\)>%-1^(T/B[P]XCN^T\*?\%%OV@[K_@E7I?[7VI>"_AM8_M(^-_CS>?L\
M>%?"WCR:Z\&_";P-XW\>?M_:W^QI\--1^+U[X6\0>-WM_#'PTMK_ ,-^(/B?
M<>$/%VJ1>+;KP_K=KX2UVRM]>TJZB^OM+_X)??L.:7\,M4^$6G_!"ZL/!.H^
M-/ /CZP6#XI?&A/&'@GQ+\*('LOA1)\*/B:?B*?B9\&="^%.CS7GAKX8>#_A
M+XO\%^$/AYX1U/6?!_@[0M%\+ZUJND7OK/A/]BC]ECP5^S-=?L;:%\$?"+_L
MOWNE^,-#O/@OKT6I^+/"%UI'COQ-K7C3Q-I]Q'XMU#6]2FM;SQ5XAU;7+%)-
M0;^PKZ>W.@'3$TW2XK/HK?5T\1.C&K!3J8.HE)SJ.,:<?WRIVTC&K1IRYH*+
MM74)6BGR3JFY)*$DIVKU'*6B:@J=:"4F[*7-5=*7NJRC'235FOS^\2_MN?M>
M_L;?"#QRO[6EC^S!^U9\<=/^.'A3X9_"OP]^R7XLUSX5^)/%FF>,?A=?_$YK
M/XC? WQI/\6OBGI7C+1(/#OB?_A&O"_P+TSX\^/?B)X0D\/^-H_AMX:\(Z5X
MZ\7Z1Q>J?\%MK"3X:^/OC=X#_93^)OC3X1_#O]E?]CC]J'5];O?B)\/O"OBF
MYLOVX[/1;SX.?##3/"%U%J<5Y\0;/[??P>)KL>(E\$6!LX9AXGN5U2S2U^M_
M _\ P2%_X)S?#7X2^'_@CX _9BT'P=X!\,?%=?CAI7_"/^-?BKIWC@_%!-'U
M;PS)XEU7XLV_CM/BOXA2]\'Z_KG@74] U_QMJ?AG6/A]JVI> -4T>[\&W<^A
MR>C:;_P3A_8RT;X9>*_@UIGP5AM_AKXX\ _ +X6^*?"Y\=?$^>'4O '[+OD_
M\*$\-KJEQXUEUO3K3X<I;00:?-I6IV%]JMK##:>([K6;:..)72Y'4<JW-*DI
M)1C%2A--*A0KM:N*2A#%5:/,G>O*C-N5-2A-3OR0A#^*JE24W+6FX2A-P6EF
MY1J*GU^!2C9R::_.7XQ?\%W/"'P+T;4="^*'[,/Q%\/?''P[\>?CM\&/%GP?
MD^*/PIO;2VTW]GSX8_!+XW>+/%GA7XBZ?J%SH'B_7?$_PZ_:0^"UAX ^'<6G
MZ5JVM?$[Q+J?@O5=3\,^'O#>I>/Y.[TO_@J5XSU3XXZ[\,/AW\(]4^.$_P 1
M/VGOA+\$?@+X=DO-)^"-WX>T?QS_ ,$V/!G[>FH^(?B!XD\6W/B1[ZPATVY\
M3+J=O_PCN@>+?#PG7P_8>%_%-YI&G3^(?MOXE_\ !.7]CKXMR>-;GQY\'KK4
M]0^(/Q9UKXW>,M8TCXC_ !=\'Z_KGQ!\5?#'P+\%O&$C^(O!GCSP_KEGX-\;
M_"OX:^"O!'C_ .%>F:A9_"KQWH>AQ1>+O!>LS7>HS7G;Z7^QA^S3HGQ6M_C9
MI/PEL]/^)EE\3[+XQ6/B.SUSQ?:V^G_$73_V;XOV1[#Q#IOAR#Q GA73H;/]
MG6&+X8PZ#9:);^'([%/[>72!XL>37FUM3DW-TYIS5.R52/+&4:>$=5<KO[L\
M1'&*,KMQH3IIISYIM8A1E7INA*K&C["W+4LYNM-UW&3E!**A%5,.VFD]*JDW
M[B7S9^RK_P %,-'_ &G_ (D^ O"7_"C?B'\-/ /[0WPH^*WQT_9%^+OB#Q)X
M!\0:1\>/A-\%?&GP^\$>.->U?PCX:URZ\7?"/7KJ;XJ> O&/@SPQXLTR\;7_
M  )KOVC6]5\*^-=+UKP)8?"O[0/_  7FT;PLO[>/@7X$?!>Y\4?$S]E;X8_M
M4:I\//$?C3Q-IK^"_%_Q)_9%LO.^,%E\1/"OAQH_$GP_\)6,,/B36OA==:GK
M=G??&NU^&/C_ $$/\,M3O/ -YXU_6[X+?L/?LL_L\?$?QC\7/@U\%]*\#>/_
M !S8Z]INIZM9ZQXOU33_  _HGBSQ3;^._&'A;X:^%M>\0:MX3^#_ (0\9^.K
M2U\;^,_!WPFT3P5X7\7>,[6U\5>)-)U37H(=03.O/^"??['VH^,?C5XXU#X*
M:?J&L?M"^%/B)X*^+6G7_B3Q[>>"=?T+XP:?I>F_&%]&^&USXKE^'7@3Q!\7
M[;1=&/Q7\8?#_P *^%?%WQ*NM'TK4/&VN:[?Z=9W,.2J\UFERKV#O'E:<L14
MBIT]7=1I4H24:T;2E.HI.$Z:_=K2-2/,W&'-%U:3@IW5J/.W5C)62=25-QC"
M5XPC--SA.+Y5Y9^U!^W/XN_97_9I^$'Q;\3_  )NO&'QD^*+>&-!_P"%!^&_
MB;H$FIZ;XSOOAYK?Q$\8Z)X?U73="UKQW\73X3T[PKX@L[73?@;\'?B7XXUL
MK:>))_!.B> =/\8>-?"O(_L2?MWZ[^V+\7/C%<Z/I2:)\%/^&5/^">O[1WP:
MT?5M&6R^(^EP_M@^!?C'XV\0:3\0;_3M=UK0KN]TR#PAX4L;2#2%CL],NTUK
M&JZW97FG7D/T_P#$#]B+]FCXJ_#'X,_"'XB?#[5/%O@C]G^Y\+7OPGCU?XC?
M%27Q=X;N?"7@^^^'MDU]\2X_&\?Q+\71:YX#U76?!?Q!M/&GB_Q%:_%+PKKN
MOZ!\2X?%NEZ]JUM><=X'_P""<7[&OPXNO 5WX+^#C:%<?"^W_9RL_ TL?C_X
MJWK:+9_LE>%?'O@;]GJV<ZEXYO%U>#X<^$OB?XYT.VBUM=1C\16NM1R>,%\0
MW.C:#/I43BYQKQDN55:F,A0J0M>AA,1AE2HQA#3]]AZMZJG-R3J/W4H*QS35
M5X>A%2BZ\*=#VDG%J+KT:D:DFESN7L:ZYTXMNHH.*G*4H^]\V?';]J+]K'X?
M?\%!/V>O@-X)UG]G_P 8_#KXOZOX?0_L\^'_  9\0?%G[1$'P,T[P_KE[\=/
MVN/BA\54\4>'? /P#^'OPR\8V_AWX?\ PY\-WG@;XAV7QF\1:K;^&-,\:Z7X
MUU]-"\'_ !3\+O\ @I=^V3\0O@QXI\9>*OBA^Q=\$8O&O[&_[(/_  4:T7XT
M_$SX?_$6V^'/[*W[,O[3OB;XQ:?XY\">+O"ND_%34-0_:-^+7PM\/_"[1[?X
M?ZC%XD^ FB?$KQCXMU"VU;1]#70=,\/^(?UZUW_@G[^R]XA_:AD_;)O/"OQ*
MLOVB+A/ ,&I^,O#/[1O[27@SP_X@T_X7Q3KX$T/Q5\*_"'Q;T3X1>+?#6@/=
MZA<IX8\3>!-5\.W^H:OKFH:II=]?ZYJ]S>>4Z[_P26_8&UGP'X\^%K_ 6ZTS
MP+\3?B%X#^)WBW2?"WQ>^//@R=O%'PJUC6/$WPLLO#NN^#?B?H/B+P+X ^&?
MBC7]:\2?#SX4>!-6\-?"OP1XEU6]\0>&?!NEZO.]Z:]JXT%3E3IJJXU$ZOL7
M)1Q57'TW">DH\U"C@%4E.+4%6J*5.56G[6G.G2IN-6E-3J5*-.,5[)1I*=2G
M3H)SYW.$FJTZM.I3ISA**4IT:KA)Q]G/\OO%7_!;3XC?#Q/^"</PN^+#_L__
M  6_:%^/'Q$^!NO?M<Z#\9-?L_A/JG@C]FCXP_$WQE\//AOXE\"?!GQMX^@\
M<:#\1?C!HGAA/BEXE\.ZCKGC6#]E'P]:7OAKXURIXC\:?"X>*?Z9HG#%L @@
M#(((((9N"& .<$<'D=#S7RI:_L7_ +.__"!?"#X;:OX&UWQ=X8^!'Q(\+_%S
MX7W'Q$^*'Q;^)GC31/B)X+\1ZQXM\*^)-8^)OQ#\<^)OB5XWET+7==U.YL--
M\=>+?$NC1V\MOIC:<^DV&FV-I]5Q9R^5*_=Z@\\'IG'3H>.O3W4*T:D*2A[3
MFC4K3YZE)TW5P]:%!TE."TA6IJA.ZNHJ=6O[J4Z5.CIR<LKR48IQBE&+<OWJ
MJ5ZDG%W?+22K\E*,FY1HT:$9SE456=2:BBBM2@HHHH **** "BBB@ IK_<;_
M '6_D:=37^XW^ZW\C0!^8W_!,W_CX_X*'?\ :3O]J/\ ]-?PSK].Z_,/_@F=
MQ/\ \%#SZ?\ !3K]J/\ ]-?PSK[G^+'QO^#_ ,!_#^G^+?C9\5/AG\'O"FJZ
MYIWA73/%'Q5\?>%/AUX>U'Q5K,=S-HWAFPUKQCJVC:9>:_J\=E?2:;HUO=R:
ME?+973VMK+'!/)"F[<J_FDH1\Y/9>GF*^K2Z1<W_ (4[-^IZK143-M4?+P3A
M@ 2P.,G 4-DX!QC/.T#KD<9X)^(W@/XCV^L7WP^\:>#O'6F^'O%/BGP)K^H>
M#/$^B^*+30_''@C6+CP_XS\&ZS<Z)>7T&F^*_"6NVEUHOBCP[>2P:QX=U>VN
M-,U>QM+R)X55YVVCS13E.-WI'5)IVUUW6@I2C'E3NG)\JT=KVOJ^E_/3SN=Q
M17#>)/B3X#\':]X+\+^+/&W@SPOXE^)6MWOAKX:^'?$?BO1-#U_XA^(=+T'4
M?%&J:#X(T;4KNVO_ !5KFG>'-(U37[W2-!@U"_M=$TS4=7N8(=/LY[A.FTG5
M].UNUEO-+O[#4;>"_P!4TN>?3;V"^@@U+1=1NM(U?3II8&98=0TK5+*\TW5+
M&79=:;J5I=6%W%%<VTJ*T[I/ND_O5RC3HHHI@?,O[:?_ "9W^U=T_P"3:?CP
M?R^%?BS_ !Y__77XZ_M"_'']H;X._L6?\$>-"_9XU?\ :(M]2^,.B^ /"7Q
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M@/QUX\^'?C;P8W[*FL6VO^%=1\%G3=>GUZ]\/Z!KD>L^#/$[6?W=_P $^?\
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M***I7ZN[N];6TO=+Y=QK1)=%HO)!1113 **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !37^XW^ZW\C3J:_W&_P!UOY&@#\PO^":7W_\
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MG?[5X]?V:?CR!_X:OQ9_G/\ C7Y.?M ?LO\ C;]K?_@G7_P2?^%?@WPM\/\
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M/XQT2S\?_M"?#[5_B9\(-6\4?!7POX<U'X&^$/\ A6?CGXAZ=X.NG?#W0/\
M@LY/X$^%FM^.O'_[5.D>.?A#H?@PZIX3&B_ 0V?QAO[7_@J+\2/!=Q9_%A;;
M2?%\&NW%C_P3YE\+>(=<'@7QWIIUK3[BS\4ZOXN\1>-M)MM4&U"FZU>.&4Z<
M7[;#4)5ZDU2H/ZQ&I+ZPY2]Z-&G[/DJN44X5&H6<HSY*J\U.'.H.;E4E3ITH
MN/M'-5)TXP>KC&,G!25234(PJ1E-Q49,_J%IK,$5F/15+'D#A02>6(4<#J2
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M_CKX'\4_!?2?"O[7'PL\<Z5K_P -=1^%C7/B/Q5X:MO#6A:5XQX?]H[X8_\
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M&O\ \\:OB# ]!^0HP/0?D*?_ !&SQ9_Z+_B?_P +<O\ _H;#_6_B7_H=8O\
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M7*RDG*:2YG-I\JG[*IR32Y'RM.;=)5N51:4D^5NS:M*SL[^ZOT\HKX%\+_\
M!3+]A'XB:M+X1^%O[4_P=^)?C^71/BSK&D^ /"7Q!\/2^*]:G^"MI>ZK\0=
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MDTTFM4]4^C6MFFFTT[73ZK4<7S1C*S7-%.S5FKI.TETDKVDNC370^9?VU/\
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M_P!HE.<HWO44ZKE*]5V_$KX@_P#!:OQA\+?&G@GX5>,?V+=1U[XIP_%_XO\
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M;K/Q=^(.N7MGJ5YK,<5_I_C"V\>65[I]A9:?/:^*+32-&T*"^@:WM\!8=/\
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ME6E>/+;G.]_8\_Y-+_9<_P"S<?@?_P"JT\-U]'5\X_L>?\FE_LN?]FX_ _\
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MT$Y<W-)/>6+Q4XN$ZC<9.<I6C3BG*HJJG)I0C>4E6FV]'[TTI1YVU_/3H?\
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M7+322Q6%IQIRHPBH49QITYPO*7-3IT?JZ3?,Y.;H-TG4<E)JTGJM?E+]E/\
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M 6#_  2\&_!:3XGMXV^"G@_XZ^![?P7XTO/BQX,^&7@[X">(_%_[5O@[X/?
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MU/!K\/?"G_!9/P;\0?'ROHWPK\3>"O@"?%W[*AT/X^>./[+N](\>?#']I/\
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MMKW5*<4Y*ZO^L]!( ))P!R2>@'J:_&#XJ_\ !<G]ESX :1\$;W]HCX2_M-_
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M;RUU7?7]#O)7_.?\:/)7_.?\:X+_ (6S\,O^BB^ /_"S\/\ _P G?X_4T?\
M"V?AE_T47P!_X6?A_P#^3:Y?[8R'_H;Y-_X=LK_^>I'ML+_S_P )_P"#L-_\
ML.]\E?\ .?\ &CR5_P Y_P :X+_A;/PR_P"BB^ /_"S\/_\ R;1_PMGX9?\
M11? '_A9^'__ )-H_MC(O^AODW_AVRO_ .>H>VPO_/\ PG_@[#?_ "P[WR5_
MSG_&CR5_SG_&N"_X6S\,O^BB^ /_  L_#_\ \FT?\+9^&7_11? '_A9^'_\
MY-H_MC(O^AODW_AVRO\ ^>H>VPO_ #_PG_@[#?\ RP[WR5_SG_&CR5_SG_&N
M"_X6S\,O^BB^ /\ PL_#_P#\FT?\+9^&7_11? '_ (6?A_\ ^3:/[8R+_H;Y
M-_X=LK_^>H>VPO\ S_PG_@[#?_+#O?)7_.?\:/)7_.?\:X+_ (6S\,O^BB^
M/_"S\/\ _P FT?\ "V?AE_T47P!_X6?A_P#^3:/[8R+_ *&^3?\ AVRO_P">
MH>VPO_/_  G_ (.PW_RP^!/^"AB!/C3_ ,$C@/XO^"G=B#^'[ /[?IXY.#GN
M*_3CR5]?Y_XU^3__  4=\6:+J$O[ _Q.\"^+O"GB;5O@7_P4F_9B\6:KX6TN
M[M_$K:MX)^+]K\0?V0O'^M7\^B:S#<^%M+^&/@S]I?6_C'?>*+NQU?1K2/X=
MKINN6VG:3JUWXBT3](A\6?AF  ?B+X!R ,Y\:>'R<]\XO0,^N !3><9%9?\
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M_&CR5_SG_&GJY)QM &.N<_I@4^O04*;VC%V];=]'S6?9]G=.S32UY5_+'O\
M#'\=-/1D(A4'(/(Y'7_&OE+]O;_DQK]L_P#[-,_:._\ 50>+J^LZ^3/V]O\
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M.O!G@O\ :A^--QH?B>XT?X/?#?\ 9E_:@63X<?#[XPV_PS\"?$(?"'QC\*O
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MRODJ2C&5-W7ZX?#_ /8E_83^$?Q/\'^%_!7@V30OBKX=UY/VB_AQX#O?C?\
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M/'?A_P *_%?2?#?COX<_%'QA\.O!.I^)_A/XXTG7?A9=6^@0Z&GA"WT6YO\
M2K[K-=_X)\_LF^)4\8V6K_!S4+J'QQH?QT\)>+&M_B-\7+"/4-%_:6^/UO\
MM/?&NWADM?'EF; ^,_CA;0>-'U'1WL;WPOY3>%O"%[H/@OS/#R_FEKO_  2=
M_:"OS^UK:1^'/V2]<O?C5\5-7^)&I_%+Q!X_^-]I\1/VU? M]^USH'[16C?L
MR?MG:-IWP^D\+>#OA'X9^$ECK?[*MMKNDM^TEJS_  [U&P3P[X7\$_#R3QM\
M&O'',:9_P1=^+#W/P[\8:[I_[-"^.?A/I7P0OO@;9Z=XI^(=UHG[+FH>#_\
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M(/'^J^"?&=[XM\'Z)+J'AKX=>,]7\/>)KNXTC-\7?\$:_P!I7Q1\#?B1\/\
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MGR<T:DKO]X]U&ZHU';1MM\I/[J_]\)_\31Y2?W5_[X3_ .)J2BOE^2/\L/\
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M.M>'?$MA+H_B[PSHFK!-/UBVAO?L1T_4XKW3+N\L;GQOQ?\ \$^?V2_&]O\
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MM/AI\1O&OPXO9/B1X[\.:5XO_;RAO&\(:EK_ (-L[7P;\)-.^SIJ\<46M?T
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M:E<06%KE;73X)[V>::&PME)6ULD=;6U629((HUGF#_TB_P#""^#/^A/\,?\
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M?LYQ:[\2]<T3XRVWACXD:]J?C?\ ::\6^"M=\,7-E'X)^&'PYUKPS>V_B/\
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MW*K!(K(L[3@3A1/&@AEA=_T!_P"%I?M,?]&M:5_X?[PG_P#,M0!]0T5\O?\
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M8;I]/G\,R36;S1@.UO))(T1)0NV-Q /TQHKY>_X6E^TQ_P!&M:5_X?[PG_\
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M:?&#_P"CSH_X0O\ ;A_Z.(_92_\ $-/C!_\ 1YT ?6&1ZC\Q1D>H_,5\G_\
M"%_MP_\ 1Q'[*7_B&GQ@_P#H\Z/^$+_;A_Z.(_92_P#$-/C!_P#1YT ?.O\
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MY$'\:^CLCU'YBOSA_92^!_Q1U']EW]FN_M?VQOVA]%MKS]GSX+7,&DZ;X/\
MV1'L=.BF^''AMTLK234_V7-1U![6V!,5O]LO;JY6)4$US/(&D;W[_A07Q9_Z
M/:_:5_\ "-_8W_\ H3Z /J#(]1^8HR/4?F*^7_\ A07Q9_Z/:_:5_P#"-_8W
M_P#H3Z/^%!?%G_H]K]I7_P (W]C?_P"A/H ^H,CU'YBC(]1^8KY?_P"%!?%G
M_H]K]I7_ ,(W]C?_ .A/H_X4%\6?^CVOVE?_  C?V-__ *$^@#Z@R/4?F*,C
MU'YBOE__ (4%\6?^CVOVE?\ PC?V-_\ Z$^C_A07Q9_Z/:_:5_\ "-_8W_\
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M"#P1[4ZFO]QO]UOY&@#\Q?\ @F@<S_\ !0\M\V/^"G/[48^8]ETKX9 #)Z
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M:I0J2JR5HU*T(-1G>:I8ZO@(JR@VG.M0<ES;4I*;<HTZTJ/]ESLBMC:2Q1B
MB@G"D<X!W=2!D#:.A(R,RA5R2 .0#T^N/SK^-NS_ &A?VS_VH/V"_P!F3]JS
M]JWXJ_"CXH^"?BO_ ,%8_P!C[X6_"GX0:#\$Y?A]J?P[C^$W_!2+7OAU)\2/
M$GQ \.>/WF\;^+M?@\+V,6F>&[?PQH/A'0=,T;2KNZM/$FJZCKTE[^@?P)_;
M7_;5^/7[1?B_XMG]J?\ 8E^#'[-/@?\ X*._%/\ X)Z7O[&GQ<\+7WASXI^*
M+#X;7>H:9:>+O#/QUF\<OK6H?M6?$2_TR/7?AS\!T^'NG> =3^'FK1:F^LZA
MK,,?VW*BXUYOV3O4A&E+$1<91]A0KX?+L3AY/FTJ3J/-,+3E"C&52E)SE52H
MP=156O05YV::Q*@X24E.IA,;F&!Q%--)J*A6RO%M59\M*<(1Y)RE4IQG^Q/[
M:@ _8Z_:PP /^,:?CQV'_1*O%E>/?!/QI?\ PV_X)A_!;XCZ3:6=_JGP^_84
M^'?CG3K#497AT^_O_"/[/.E^(+*QU&>.XM'BT^[NM.AM[V5;NU=+:25DN;>0
M),GK?[9Y)_8Y_:P)+'=^S/\ '<X;JO\ Q:KQ6<8).#U!Y..F>Y\__9NT_P (
M:M_P3D_9XTKXA?8_^%?ZG^Q;\)K#QW_:-]=Z9IW_  AEW\"=#@\4K?ZC87%I
M?Z?:/H4E_'/?6-S#>62.;JVD26%&"K.7L*LH3C3DJ56<)S?+"$H0JRC.;::C
M"$J?/-M-1A&;:=FG5/WJE+EC*HU5HODBFYSM5H3=.$='*<U>$(KXYSC&+O)'
MY1? _P#X*J_MHZOX#^%OC7XB_LUP?%#3_BC\5_V6_"'@S4?AA^S[^T5^RYJ7
MQ!D^/'PG_:#\;_$/X3_"WP7^W)XN^&UEXM\9_"6[^%'PYU:T_:!D^)%A^SGX
MS\'_ !F2*VU+1M0\$^)+R3ZTT[_@M)^S%J7C']GOP39?#GX^7NI?M)_!.R^,
M_@:/2-&^$7B/Q1IC:E\%_BG\=M/^%VN_!SPU\:-9^/\ J'Q#N_!_P?\ %FBZ
M=J/@;X2^,OA3JOC^70/ VF?$Z^\0ZQ%:Q]#\$OVF_P#@G;^TC\'?"'B+1=37
MP5\)?V+U^"/Q7\!:I^T!H/Q2_9STSX?^#M9\$^*?"G[.GQITC4OC0O@>3Q7\
M*/'?@:X\5Z=\._'.KZAKWAGQBMOJD-Z9_$.G7*67F^D?LT_\$H+?]H/PU\+=
M%^"MKJ_Q-\&Z5\%/AMI>FV^M?&/Q#\-KO1/&/[,_[2,'PPN=?M+CQM?_  U\
M>C5OV;_#/QL^&VJ^-?$VE^*-9U3P-?>'OAYXIUF_T&Y\)Z?8ZUJD7&O".%E3
MJ4/KU:%64:FM*.#JRPLJD?>IMTJ]+VE?V<YQ<8UZ,'*4.8YJ=.LI0O).%*EA
MZ5>*A)6KT\12CB)\[Y7R5:*M1:C%\TZ=2=.,)\JYKQ%_P7Y_8[\+?"#X;?%S
M7/AQ^T )?B3X[^(?@NS^&?A]OV</'GQ!\-V/PM\&_#GQS\0_&?B*?X>_M'^*
M_AU>6/A;0OBU\.8KGX=^#?B#XL^/-WKWBB'PSIGPAOO$&D>(=.TC[3_:2_:E
M^('PG^,'[#/@GP5\.-+\0_#7]IWX\+\*O''Q5UWQ'_9R^%+35/@Y\6?B5X:T
MSPAX2L[E=?UKQ-K;_#HWUSJWB*SMO".AZ-#-8LFK>)=5M;?0?ESX0?LK_P#!
M)KXX?\+!^"?PG\(:/\4(?@;XZ\._$_QUXTT_XQ?&KQM>:MX@^+7A >'1IVM?
MM$S?%'6O%OQ?\":QX'^&6G^ ?'_PF\1>/_%/PNB\.^!?#O@+Q9X-?1O#6C:1
MI_W'XV\9?L9?%33?V=_B-XD^*/P+\0Z'I?QRMM4_9M\8I\8/#-KX:UKX^VGA
M[Q[\+[#3/ &J:+XML=$^(GC&'2/%/CWPHG@6VG\0[[NYU%7T0ZSHEL]@-X9U
M8)PG)4\51G.E/1SP3I5(S@U%INK5Q#QBI)J+E&DURJ2Y:;C*LFVN3V2P^)@N
M>_-&NISE0J>[9*%.G6P\ZK;:Y*D?>UN_,OVN/VC_ (W?#']FWPYX_P#A'\/=
M!^'?QF\??M-?L]?LY^'?#W[15II_C'P_X>A^-O[5/@C]G:'Q_P")-,^ _P 6
MKB+7=(O/#7B1?B1X3T?1?B=IVO0Z/J6B6?C:P\+>)+7Q'X3TCYAT7_@J]<?"
MO3_B=X+_ &DO@SXN\:?&O]G3Q7\?[3]H"\_94L]#U;X7^'O@Q^SGX-_9^^(W
MQ$_:=ALOC5\1_ OBBR\"Z3X,_:>^$SZK\)/"6H?%SXV#Q2OC;1OA_P"&_B9I
MG@[5->D^HOB#\._V%?C;\'OB!^S?XS^(GA/Q9\.OAWXCN?C!\1=*L?VJ_&^F
M^._ACXC^'WQMUWQU<>--<^*/A;XNZ=\9?AE#\._C?X-\0P6NH7'C;0-+\!:C
MX,U+P#;II&B>$_\ A&]*\NOOV-O^"6/CCPA^SG\,;G1O@UXDT/4$^(?C7X#P
MM\??$^I>+?C?I/BE="\7?&._O_%\7Q1E\=?M8^!?'QT+PGXG^-NE?$;Q'\5?
M!/C\>&O">M?$G3=>.@Z-=:?C2BU"I&K9R?L9N:4DK2H8"\E&<HMJ^&QDW%:J
M#]HKRIR2N;2C>$6I?OUR]U1JXNK9-\TDI*OA80<K)SE%<W)).?&?$?\ X+4?
MLL?#'6_VEM*\9^!OCEHLW[-USX>T^X6^B^"6E:I\7[SQ=\2_ /PC\(R?#'P5
MK?QRTOXA:#X9\7^,?B=X'D\&?$SX[^$/@I\)?&O@_6X/B/X1\>:U\/MWB6L;
M]H__ (*:ZXG[#7[._P"UY^RQX>GL'_:(^/GPR^#ECHOQL^#'Q;^*OB/P+%XH
M\7>+O"7C$7WP._9G\1ZG\2/B;XP\.:UX1O=,T72O@]KWC#1_&,<D6O\ A/4_
M%7A&\L-=G[M_V:_^"3OQ9\<^(-?M[WX!>/O'7[5B^+-+T=-%_:/U'5;KQ1?Z
M=XE\*?&?Q_JO[.?AO0?BL]A\,/'*>.=&\!_&OQ_XR_9LTOP-XWN/'VD^#OBG
MXIUJ?Q18:1X@A[_XO_ 7_@GAJGP<TS]DGXJ^(_ /A3X;?L^V6B?&RV\(+^TW
MXT^$WQ"^%&G?#BY36;/XR:W\1O#/Q:\'?&O0_P"R=7\7)X@\1_%#Q%XTBEUG
M6/%D>M>)]?U'4=>%U>;*<)4^6JI1FI8><6VN54Z=;FK1:?*YU)I4%",&E!5(
M^ULY6>E)PIXB$ZE*I5A3AB_:TXI*2=7!UOJ=2%I2<HT\8Z3F[.;C2K*"ERPO
MYO\ #G_@I;I_A'Q+^RI\$?VBO"OCJ]^,7[2^G275I\3-!^!7BW]DWX.65]K'
MQ-\=> _"GAV#X/?MJ_$[P;^U5=>+M_A:P3Q=X2\"_#WXIZ_X.T_7O"7Q*\;:
M?X+^&7Q'\#Z]JN/X[_X++?!+X>_LS0?M9>+?V>_VH="^$7B:#0O$?P>O]=7]
MF;PI=_'[X8>*/ 'CSXJ:-\4_A/=>,?VFO#OAJ>POO 7P\UG7;;X3^./$?@C]
MI)VU/PGI47P1?6?%6B:?=^?V_AS_ ((_^'OVC_A[\)M1\1Z9JOQ8_9B^#7PX
M_:0T[QQ\1OVD/C;X_P# GASP%KOQ9UWQ+\!-5^-'QE^)?Q@U[P3\7O%%I\1_
M&6M?$/\ 9U\*_&W7OB#XA^'5CKB>./A99^$M(UK0M0O^T?\ 84_X(ZWVE_$[
M13X=^!=QIOPNOM/^)_Q3@L_VC/%*-\&O#?B/X<>,].TO1]>O++XN+=_!3]G[
M6_A1\5?B-'8_!>*;PE^SWJ?@?Q]XHN(? =QHNLWKS95)PC!MPJP3]O-VC45X
MJO27[OE]Y7CAJD7>%USMJ,N:",4Z<YTU*<Y1<\-&<N1WFIX>HWR2OR*\L30<
M7)NZJ0@^5PDY<=XV_P""T?P<^"&F?%?QU\8?"^O:G\.=*^/&B>!OAEJ'PWNO
MAUI7BF?X1ZK^R_\ LF?'VY^)/B_PO\9?C#\.=9\7:KI%_P#M.Q0ZCX%^"FE^
M./B/)X<M$U+2_AG?IHOBS5H9-/\ ^"N%QX?\1ZO=?&+X,>-OAOX3T/Q?_P %
M#/!FD^%=(T_P3\2_'/Q=O_V1_P!IW]F#]F+X6#X>ZYX:^-;Z-X9\0_%;XA?M
M"VO@-_!OCOPS:V]WX]\ZYN?&?@#X=>&-/\9?$O0\5?L^?\$9/BAXD\4_"+Q7
M?_!K5=9^'OP)TK]H?QG:2?M$_$/1+:#]G/XJ_#'X?? :T\>^(?&]A\5](T[Q
M9\)-<\ ?LY?!U-3AU'Q%K7A/0]6\$?!GXN>(;;2/'>K^ /&NJ^P>(/@#_P $
MK[K7]2@\9ZA^SO>Z]^TAI/Q)\3KX>\4_']KRR^)>D?MG7_PK'COQ-X!\'ZS\
M2WT9=.^-OB[]G'X?^)=#USX>:%I]O>?$KP5K?CCP-<V7CW7O'.NZYM)8:*J\
MM/$U(SKXB.&51TY-4J4'2PLYRC&WM%[*M&M-+E]M=-2BI4VH\TO9*:M.-*G+
M$U(.2BZU2%+GE!2DI0CS5U6C3E*ZH;3A5E&=/C?&'_!8KX/^!](N[[5_V;_V
ML3KO@OP_^TSXL^/O@6VT;X ?\)1^S3H/[(NM_!^R^-^I_%2:Z_:$MO"OBFWT
M?P_\</A]X\\+K\ ?%'QJG\=^#]6DE\)0:KKZVVAW'ZXV]VD\K1KN#1R^4<EL
MG(5PV#_"R,K <$*<, P*C\P?&_[-?_!-[X4_!S4-#U_P7H.H^ ;V;QE^Q'X@
MCT_X@?$_X@^,_$OB/]N_XR?"3P9\1_AWX[\7VGC?6?B+XH^*7Q@^*]S\,I_'
M7Q!\=:_JWQ7TEE?Q-J7BO1-*36+MOI/X=>-_V=O@]X9^.>IM^T7X!O\ PYX#
M^+WQ(\6?&GQ'XN^-6AZQI?P6\6^/_$EQXTU'P9XUUKQ'XLU!?A98:+_;4-OH
MG@WQ%J>CV&@:;-:V&A:9I&B/I>E6G/-1M+W)0M5;^L6J.[=3#Q]ERW:BE.K&
MK&<5.+HU8JJ_;<\ZD)UHSIRA94[<KI.+<E3C2KS<U*T4K.FZ4HO3GC=<L;1C
M]AT5X-KG[2W[//AG4Y-%\2?M ?!/P]K$'AJ?QE-I.N_%;P-H^I1>#[7P_<^+
M;GQ;+8:CX@M[M/#-OX3M+OQ1+K[0C2T\.6EQKC78TV"2Z'-:+^V%^SGX@^)_
MBWX-:9\4_#,WQ(\):/X=U]?##ZM90W_C/1O$OP_;XIZ?JGPQCEN%;XF6%OX$
M \0ZQ=^"AK,&CV$D4VHR6\4J/5>U2C.4HR@H<S?,G%\L+\\O>C'2'++FZQLT
M[/0ZE&;:7LYW<HP7NO6<WRPBK)MRG+2*LFW\[?3U%?/?@#]IKX&?%$>!K3PC
M\4?"%QXJ^(?@S1O'_AOX<WGBO0--^*$OAO6?"'A7QW'<WWP[GU'_ (2RQGT_
MPGXV\):WK-K-I8?2;#Q'HUW?&*UU2QGN,'QK^V5^R_\ #OX-:_\ 'SQ#\=_A
M?/\ "GPZ/'%H_BW0O'WA3Q-8Z[XC^'6G>)-2\6^!?"4FBZO>)XN^(NE1^$O$
MEI)X"\/O?^*FU31=1TQ=,-Y9W,,52GR-J:<'%7FI:<B3E%N6FRG"<-.L).]H
MNT1DIJ#BU+VDN2%G?FD[-*-MV[JW=-6ZV^H< G) R.0<#(/3/Y4M>+V7Q\^$
M-UH7A3Q#=?$/PMH-CXU\(>$/'7AZW\5>(=(\+ZK=^%_'FI>'M#\)ZI+I.N7U
MAJ%O%KGB3Q;X:\)V/G6RFY\6:YI7AF RZY?VMC+X]XZ_;R_95^&GC&W\%^._
MC#X<\,WUYXG^#7@?2=7O;M)/">M^/_CK\1OCA\)_!/@#3?%%D]WI,WC"S\<?
ML[?%K1_&6B37%O/X)E\+R_\ "2MI[R"-*?,I.+A--2G'X9-7IU/8S3?*HIQK
M-4I)N\9OEE:SLHSC4INK3?M(*FJO-'6]%J$_:Q6K=-4YJK=1=X:Z)W/LFBOG
M;]GO]J+X(?M0^$4\9?!CQ]I?BNT2%9M7T'SXK/QGX56XU#5M/TT>,?!EQ*/$
MGA)]:?1=2NM"BU[3K%]9TRV_M'3A<6K"2N9\:?MJ?LO>!QX)N];^.GPY&@^-
M_BMXY^"$'C'3?&7AW5? GA?XF?#;X8?$7XP^./#/Q#\9V&J3^&_AY>^&?!7P
MJ\7S:PGB_4=*>PU6#3]"NU@U35K&WE3ER3=.:<*BY+P:;:=3F]FFTK7J.$U%
M;MQ>B+=U*491DG"<Z<E;WE5A5E2E3<5[W,IQFFNCA)6;5CZOHKQK5?CI\&O#
MFJ:]HGB+XQ?#+0==\*_#]OBSXHT37/B#X4TS5?#7PJ6:>"3XG>(-+O-8@OM%
M^'D,]I=VTGC;58+7PS'-:W"MJ:^1(RQ>'/V@/@GXUO3I7@CXT?"CQEJ_]B>(
M_$JZ5X5^(GA#Q%J3^'O"'B>Y\%^+->6RTC6KVX_L3PMXQL[SPEXEU8Q#3]!\
M36=WH>IW%IJ5M-;+,ZL*<93F^6G&,YSJ-2]G"--5'6E.?+:,:*HUG4<K<JHU
M)6M%VB,U.,9P3E&;@HM*R?M'!4]_Y^>-O)];,]JHKYQ\/_M3? WQ9XO^#WA'
MP?\ $SPMXWD^//ACXG^+/A-XE\$:O8^,/ 7C;3O@[J?A#3O']EHWCWP[=:EX
M3O/$&E?\)IIUW;:!!JLFJ:EI^D>,M0L+:>V\%^)9--^CJTM)?%%Q=Y)J2::E
M"3IU(ZI:TZD94Y6O:<6G;K2DI;7VA)733<:D%4IRLTG:<'=>C5[HAE21\&-E
M5E!VEP[*&)!5F163<%8!BH9&< QB1%=C7\\W[''[5=]^SY^RG^SU\$_@]%X9
M^(/PK^&OPE\%>&/AUXX\3P:[!XA\6^"K/1X#X<\0ZU:6$NAVMEJFJ:>8[N[L
MGT?1KJSDD%O+I-MLW-_0_7\@?[(/@U_"O[#?[".JQVYCT_QY^R)\&O%MK.D(
MCAEOFT!--UV#>J1HUXFI6?\ :U^&:9G&O6D_G>9).H_GCZ2&<\9\,\)Y-Q'P
MCGF89/#!9['!9W3P4,OG'%8+,<'76$]LL=E^.:FLQPM##8=TO9+GQ4E4YTX.
M/QG'&*S7+\MH8[*\95PCHXFG2Q'LX4Y\]/$2C"+E[2$DN246E:S]\_7+_AX;
M\6/^A)^'O_?'B?\ ^: ?R'TH_P"'AOQ8_P"A)^'O_?/B?_YH:^ Y&\N-Y-@D
M\M'?8S%<[%+'E!NS[=V(!&#FOLSXA?LL6_AF_P##7AOP]/XRGUSQ3K5II6E:
M]XR7P;IW@2]5/#&J^*=1%O=>&M5UKQA;W,=IIK6MNVH^$K*!YXYS-*R&&X?^
M4LE\0O'KB'+LTS3*>,,]Q>%R>KEF'QSA7R:%18O-XXF6!PV'HOA:;JSJSH0@
MFZN&H4XUE*>*C'"UX5/@,)GW&&.CBI87-*U2.#6'E6YHX.F[8F<H4U!3@O:3
M3C%RA'WG&7-&Z3.P_P"'AOQ8_P"A)^'O_?/B?_YH:/\ AX;\6/\ H2?A[_WS
MXG_^:&OGWPC\$WUKP\FOZWJZ6,.IZ)\//$&AQ:47N9)-/\8_%.Y^&M^=7CO[
M2V6QO;&XL;Z]LH=/N]3L[JWBMYI;J+SV@CJ>+_@;XC\-W7BZZ@U'1KGPQX8L
M?%NKC7+J>[A62T\,_$:Y^&QT2Z\C1Q;KXRN->AMXGTB/R])9;I)X=4MK7;G2
MKQW](2G@89C'B7B6OA94*^*J/#U\@K5L'@Z.6ULXCC<QH4^'I/ X3$991EC,
M/B*E6M3J4I1^";5.5K.>-I488B./Q$J,N9RDHX/FIPA3=2=25-P]HX4XI\[2
M]W1NR9]&_P##PWXL?]"3\/?^^?$__P T-'_#PWXL?]"3\/?^^?$__P T-?,6
MF_ _Q]J_@(_$6SMM-&@_8=1UB.&1M6.IS>'](UBTT35=<BCAT2;1H;+3[Z[9
MI[6^U^#Q%=65I?W^DZ)=6MJTR]9=?LR^.[;Q!:^'(M?^'M[>3^)?$'@^]N[3
MQ!K4EAH/B'PQX8E\8:CI^M37'A>"6!VT"-[NWEMK/6HVD ANS8SIY#52XW^D
M95CAJD<XXV5#%T<OQ5#$RAPW3HRP6;4:6(RS%6K8+#UN7%T*KJNC&C/$8-03
MS"G@Z=?"8C%.EG/'-:%&I3Q.82CB*5*K2DL-A>2:K2<*,5-I*]249*/NVNGI
M;WCW'_AX;\6/^A)^'O\ WSXG_P#FAH_X>&_%C_H2?A[_ -\^)_\ YH:^7[CX
M->)$\.W'B*SUWP3JD0\.ZUXQTS2]/U;5SKGB'P5H%Y-IVI^,-%L-0T6RCDT2
M.:*^>)=1N].UN:STVZU*VT*=+=;UO4?$G[,EY;ZE?Z1X0UB;5+K3_&7BW1+V
MYUV%DLK'PWX2\%>!_%<^NSP>']+U76+FZFN?&8TH6&D:7J%U=2IIT-G922RL
MXZ,+Q?\ 2-Q=#V]+B#B;EME\H4I8OAA8C$QS&-*5.6!A#*\10QD<-&K&ICYQ
MQ^'A@:$J6(Q4Z6'Q&'K5%3SGC>JFX8[$M.A2KTGRX+]^J\DJ,*5HN\JL9TZD
M+Z.%2+5UJ_3_ /AX;\6/^A)^'O\ WSXG_P#FAH_X>&_%CMX)^'N>WR>)SSVX
M_P"$AYYZ X!Z9&<CQWPI^S+XEOO&UIX9\<:[X<\(V+^-[/P.]Q_:-TVJ:[J5
MYX>L/%:IX-MIM$>WNB/#VI:1J);Q#'X?VMJ<>G+ VLLUI7S/\I PS' ()PJ,
M'0E& *<$817#Y#$NQ8 @X\;-O$WQXR/"8/%YQQ3Q/E<<=5QM"CA\=4X?I9A3
MK8&IA*->&+RZ&2XG%81NIBXJ@\2J,<72HU<7@WBLOJ83,,9GB,^XTPE*-7$X
M_$T(RJ5:2YX8/F52G0^L<K@H<WO1T3M:]^FK^R?VP_B_/\;/V4/V6?%VH6ME
M8ZY;?\%4/^"9.AZ_9::DJ:;;ZA8_M[_ :ZMC9+/>7\_E7&BWVD7+K-/O2>>4
M!0JH6_;I?NKWX'/X5_+3X]\6BU^'WPE\!2(##J__  4C_P""5'B^P\I"!#>:
M1^WS\!M)U82#:%9;F#4],,.&1;=-/;B>2X*0?U*J,*H/4* <'(Z=C@9^N!GT
MK^\_![BVMQKX<\.9[B\2L7F;IXS+,YQ'L_9NKFN3XFG@L35E%)0;JQG2FW37
M(YNHUHXGZOPUF4\VR3+\;6DJF)G1=+%35ES8FA4G1K.RT2E*GSQ5E:,TFKJR
M=1117Z8>Z%%%% !1110 4444 %?)G[>W_)C7[9__ &:9^T=_ZJ#Q=7UG7R9^
MWM_R8U^V?_V:9^T=_P"J@\74 =+^QY_R:7^RY_V;C\#_ /U6GANOHZOG']CS
M_DTO]ES_ +-Q^!__ *K3PW7T=0 4444 %%%% !1110 4444 ?GS_ ,%:O^45
MW_!2K_LP?]K_ /\ 6?OB#7Z"CI^+?S-?GU_P5J_Y17?\%*O^S!_VO_\ UG[X
M@U\%_P#!>CXO^/?AE\,_V=],\(?MAR_LJ:1XK^)'C6Y\8Z3I'[0>D_L7^-_C
M5I_@_P (MK>C>#_A[^VAX^^!?QV^#GPE\3Z+KS:?KDWPW^)FD^"++XY>'AK6
MA:=\0]%A\.ZMI^LQ*?+*G'E;]I-0O=)15KN4F]+**D[)\SM:*>O+48J3?O*-
MH3EK=WY(N5DDF[NUET3=WH?OU17\BWA?_@JW^U!X5\.W?QZT_P#: \+^*?AM
M:_\ !-#_ ()X?'7PK\,_VH?@]IOA?XD:S:>/OVW?&_[//[4/[1/BB^^%OQO\
M(>&]9/A/P-HMSXZ\9^-? O@U?A9_PC?BOX':Q86'@;2-/UBY^.?TAXW_ ."Q
MGQ(USQ!XGT'P#\9OV)?AE\*;S]L#]KOX)>$/VM_BTOC/7?@=)\._V<_V<?@W
M\5_"7@J+5O#GQN\$:/K/QM^,/BGXG>*K?P]X^T[QM8^%K#P=\.]<U;PS\*/B
M#K-C;:9?Z5U+#QJ3E%RC2IUJDW&SY8TJDZ>J3FTYR@U%<KG=2A&G4K*G0KO"
MTYXMQ5&*;DTESMP3;E2B[2E3C&23K1NZ;J)Q4FF^5I?TLT5_-1^Q%_P40_:X
MUO3O^"<W[*?B*+P=XZ^)W[1O[._[!?[0FA?&'QG8>/\ Q'JWB7]DG6OV4=;\
M6_M@?$#XB:O:^,H(=5^.OAGX\?#&/P!I?BAKO1M!\[]J3X%Z[?>!O%XT'QH+
M_-_X*5?M(6GAG]K_ .*?@G]H+_@J)\;_ /@F+X/^"?[/WP1^+/[(-M\)K7P1
M?Z5^TC\1?%NI_&73?BIXA\6> M=^&GCOQ1^U6/ VO>'_ (;>$3^S%X0O]"F-
MG=0ZT]E/>>.[+5--FI^[G24G!TZM?%T54A4C/3 RA#$R5.*<I5*5:;PTL.I*
MLL33JTI.*INH84JBJTO:I<J]CAZW))I32Q2FZ%XKWDJD8.K&?*XO#N-=+E?(
M?TTT5^!][_P5%^,5M^V3+\#8K[X"OIMK^UK8_LHG]F"^\-^,=+_;-N_ UY^R
M_:_'R;]N:6:Z^+,-CI?P+LM8O#9W?@6Z^ IL+3P/9:AJ]W\>['QG;GX?VGRK
M\+/^"L__  4$U7P-\+/B;X^C_8[U;P]XE^"/_!(7]I+QAH'@WX0_'#PKJ[>#
M/^"FO[36H_LUZS\+_#NO:Y^TSXPL-)\1?#R33)?B/I?Q8U30=8TJZ51\/;GX
M37BW+_$*"H*=2K1HQBXU,345'#QJOV4JM=U:=-4N1QJU:=U6HU%.K2C%PJQL
MYSA5C2C$8BGADO:WNTFHP_>:3I8>I2?/34J=JCQ,8)J<DG&4W>%F?U-45_(S
M\:?^"M_[3GC[]GW]LWPS8_%?]GT^+!^S!_P6/U/3]&_9EL_'_@?]H[]C/6/V
M%/BGXI^%?P:^)GQ7\1WGQV^(H$'QHT>#3M0T"\C\%?!K4-'\82Z-J?@^?QAH
M6H:M;^%.U^.G_!7W]M#Q)\2_^"D?[/?PL\'^!?AK/\$/@]_P4%LOAEKK6WPS
MU7XU_#/6_P!E'X5Q^(_!OQPO/"MQ^UYJGQ8^(^@_&>XVS^!++4?V,/A7X*\!
MWWQ#^%'B&V\>?'OP]IWB+3?$64:BJ4:=:"NJN$J8ZE&3C3<L/2PBQDY2]I**
M@XTG:SYE*:E"G.K4BZ9VPP]2:A*R498RC@9-M-PKXG'T,NH)P4N:4:F)K6<E
MRQI0C[2O*C3J0FOZL:*_EG\)_P#!3+XZ>"_$NKZ:W[1'[--U8_$*^_X)I_#Z
M;]KSXM1?$C5OV5_A98_&C]DC]HSXU^,/C+K'PXA_:BM_"MKIWQ!\0_![0OA+
MX7L?#7QT^&>DZS\4/'ND:QXP\:>);ZRTGP_K,>M?\%DOVU+WX?:Y\7O"N@_L
MJZ/X&^#7[(WPC_:=^)=AK?@GXS>*KCXYV6O?MV?M'_LE:SX@^!/C"#XP> K+
MX??"CXU?#KX(:%\>O@7XG\9>%?BA>Z'H_C#2]+U*R^)6F:Z/$GASMJ86M3KS
MH24.:DZGMY.;4:,:=7ZNY23IN<F\1*E24%"$G[5U8>TPU.>(ES1ESTJ=>,7*
MG6P]+$TG\$YTZU#!XF"]E55&JINAC:,G!P<H2YZ<U3J4ZD8?U.45XK\=?BI=
M?!'X2^/_ (KV_P ./BU\8W\!:%<ZZGPN^!GA2W\>_%WQJ+:6"W_L;P!X1NM:
M\/V_B#Q%+),9H=.GUO3XWMHI)'N8Y(FBE_(;_@J[^U7H?A?]D'X!?%/6/C/^
MTC^R;XV^-5U8Q?!S]G+3/B!\-_V7?C1\3/C3X\^'LE_\/? GQR^*_C+4;_1O
M@#X&^ FMWR>/OV@-3D\5MX+L[;PV?#?B]_B!9ZEIOPX\<<4IR@H-P;4JBI2M
M.G[LI^T=/>4>?G5-VY6E%RC&<HRNC6$93?*E:\92BVU:2@H.5]?<LYI>]O9M
M)QU7[QT5_&?^T'^W%_P4L^'_ (;_ ."@?AWP=>1?'SX:>!]7_P"":=EXW_;I
M^'/[5OACX<Z)\%M=\>_LU?L8Z_\ $+7/V?\ X(6G@[5[_P 7^ /C5XD\5ZYX
MZ27P;XQ\)Z1J-I\3M06QL;@VUS-J'TG\0/VE?%FO?M._\%+?"'[/'_!2RRMV
M^%_[/'[8O@SXM^)_VD?VA/ ?@'X2?!K]H[5=3\!0?!#0_@)\,?"NCZYXW^&/
MA/\ 82\&:GXHMOCI^T+I?@34=,\5>-=<T;0O'E[X^^(.B:Y?_#7IKTU051N:
MJ.$\7!1IQFI3^IX>6(E->W6&5.%2,5&G]8>'F^>,N1I58T9IJ<X4Y^SDE.G@
MZC]ZG*,?KD\'"$/:1FZ<JE.6+<:D8-^]1FE)J=.3_J=HK\D?^"0'Q'U;QO\
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M[2BU-)R]XJ-2I3DY0BXWC2C[1/EE#V595X--:QDJJ4E))MM15[))?BU\ /\
M@D[XF^'_ ,#?VX/@W\3_ (O?".1_VS?@'X'^ 5SJW[+_ .S5_P ,W>'_ (>:
M%X*^!_B;X#V_BBR\$W_Q4^*=KXC\9:GH&N:=K.IZE=:KI6GW%QI2Z!::5IOA
MNVTNST[YX^/_ /P1#^+7[0WPR\&^!]=^-W[(/PWU32M1^+.H>*K?X$?L+:]\
M%/ ^H7WC'0_V:M)\"^)/#5O\.OVI-"^(P\9:(/V:M"MOB$_Q3^(_Q8^%_P 1
M]"\1:7I&M_".>+X,_"!O#?\ 1OF/H9!QR077@9QR.PS@4AD7G$@W#&03P-W
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M?_LE?&CXMZYX3\2:9\'M9^(WPS\ ?".P\*Z7\1_AYJ'QD\:?'C7_ !G;+?\
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M?@?PYXQLO"OA?Q5\+OA+\1-0EU[QO=^#/&7]B7,GPZ\'^()-,N=(5%+$4/\
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M;_$_P-X^T;2_@]^S3X6_:GT3Q3X(^'#^$+W5O%>F?$OX6>._!/B3PI:>(/\
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M_P %F?@-\'_#'QPU+P;\+?CA\6O$GPDNO$^E>#K72O .K^'O!7[0&O\ PO\
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M(_BUX1^,G_!?K2)OVR/'-C\0/&W_  3D_9E^*L/QV\<P^(-+TCX'^&KGQO\
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M^@6<C?!_2OVH-5_X1^SN=1\?V>IR2Q>.OB)\&OB#\"?^"2_P;^+?Q3T/P?\
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M3BJN$BI\D*?U9\TE>.'G0Q$,/1<'S*26&PV%PDJ<DWRT</33<E'#QI_KQ/\
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M_OH4;SZ#_OH5_1K_ ,0TO[67_1??V=?^_7Q*_P#F2H_XAI?VLO\ HOO[.O\
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M#\2_^"63?JW_  4F8G'8GDX&:D_X;(_:/_Z1.?M^_P#ARO\ @EE_],FK[_\
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M8ZLK_P#!)O\ ;]97X93\2?\ @ED59>ZL/^'D^"I&0RD89<AL@FF+^V'^T8H
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M>[U:T7*[O;1ZZ.R335TTUW337WIM?B? 7_#9'[1__2)S]OW_ ,.5_P $LO\
MZ9/1_P -D?M'_P#2)S]OW_PY7_!++_Z9/7W[]HM\A?/AW$X"^:F2<9P!NR3C
MG [<]*7SX<$^=%@=3YB8'3KS[C\Q3\NM[6ZW[6WOH]+7T>FC&]-]-]]-FD][
M;-I/LVD[-I/X!_X;(_:/_P"D3G[?O_ARO^"67_TR>C_ALC]H_P#Z1.?M^_\
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MW].]'GP\'SHL-PI\Q.3Z#GG\*5T]FGZ-/R[]]/73?0+WO;6V_EZ]OG8^ ?\
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M]=O.R;=O1)M^2;V3:^ /^&R/VC_^D3G[?O\ X<K_ ()9?_3)Z/\ ALC]H_\
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M:/\ ^D3G[?O_ (<K_@EE_P#3)Z/^&R/VC_\ I$Y^W[_X<K_@EE_],GK] Z*
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MH_X;(_:/_P"D3G[?O_ARO^"67_TR>OT#HI@?GY_PV1^T?_TB<_;]_P##E?\
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MB-\=_ GP=_9A\0_\$3_BE\<-8L?B'/\ "WPAX=U#XS?#CXD_#_3_  ]K\'Q
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ME-5)52FO9\[:4IU*U>K*=Y)OVM/!PA!:NRIO".=U[TY5IW=K(_F[^)G[</\
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MZ_X);?\ K>?P&K].J_,7_@JQ_P D:_9A_P"TG7_!+;_UO/X#5^G52:A1110
M4444 %%%% !1110 5\F?M[?\F-?MG_\ 9IG[1W_JH/%U?6=?)G[>W_)C7[9_
M_9IG[1W_ *J#Q=0!TO['G_)I?[+G_9N/P/\ _5:>&Z^CJ^<?V//^32_V7/\
MLW'X'_\ JM/#=?1U !1110 4444 %%%% !1110!^?/\ P5J_Y17?\%*O^S!_
MVO\ _P!9^^(-?H*.GXM_,U\ ?\%7;6\U/_@E_P#\%'=(TVQO=2U/4OV#_P!K
M:ST_3]/M+B^O;Z]O/@+X^MK6SL[2UBEGNKFXF=4B@MXY)"2,J 5+?<7AGQ+H
M?C#0='\4>&-5L-=\.>(M+T[7O#^N:5=17VE:WH6M64.J:-K&F7UNSV]YI^J:
M;=6M]97,#O%/;7$4B.RL"0#\*?\ @L3_ ,%$OVEOV'OB7^R=\//V>-8_9B\-
M#X[^"/VEO%GBSQ-^TI\ OVSOC_8V]Q\$]9_9VTGPWH/A;PY^Q'9^(OB%H\FM
M1_&GQ)J&K:UXF\&ZGX7C_L+3K8Z]H>JW-A9Z[\YW_P#P5>_;VTC_ (*:1?L>
M6O@;]F7XC>!/"_QD_9"^$7CSP)X _9^_;NG^..H:3\</@+^SQ\0_C1\;O#/Q
MJL-*\6_LM^"_A]\'M7^,7C7QN?"_QFOO!?C0?"WX?RZ1KEC%K6K:;XIU3]^O
M&?@SX.V_QB^&WQS\:ZGI.@_$[X>^ /BS\,?A]K.L>-/^$>LD\%?%[7?A)K_Q
M/TY-"NM5L]+UQ[W6_@[\,KI-0N+2[N]%.E1QZ?<6::K>+?L\)^#/@O\ "CXB
M_%GQ#H.J:3X?^('[27CWPO\ %#X@66I>,@][XQ\7Z/\ #CX>_ [PSJ^B^'M6
MU9Q86[^ _A)X)T&*V\.V$%AJ=UI,]^T5SJ]WJ,US-"4*?)S1IUM<0Y*]E4J2
M@G2PZJIW:A:<Y247I&+Y$FY&;4DW*,^6/L8J7,DG3BZCYZTH7U4(N"LY1OS+
MWFDX/^9?X._\%KOVZ_B#\.OV\OBWJY_8>O=-_9J^!O[47Q#^&WPS\._LY?M\
M>&/&%MXU^#_QA/PS^'K_ !+^+'C[4K/]FCXB>$-5L[:_N_&'A_X)_%:Z\<27
ME_9+I$>E+X?\76FD?LK^Q-^TA^VCJ'QZ^+_[(W[?7AG]ER/XW>!O@S\(_P!I
M+P;XY_8\NOBZOPL\3?"KXL^-?B_\-XO#GB/PM\:5N?&/A;Q]X4\5?!S4+@3V
MFMZSX>\5Z#XELGTZWTC4?#NJ6TGOD_[(/[*MI^RC\0_V%KC1U@_9\\0>%?B3
M;>._ -[\2/$46N6OA#XO>+_%_CCQQ?WOBR?Q"WC30-,U7Q'XC\1WMEJRZI9Q
M:- 9++2)K*RTRWMH*/[&7[%_[)O[)UCX^U/]F#3M2U#4?B3?>'[;X@?$?Q7\
M:/B%\?O&_B(>#;:^B\*^%]0^(OQ+\;>/?$L7A_P?;>)-5GT'PA9:O9:#HUYX
MDUS5K?3H;_7-0O[@@J=-590BI+V.&C&K&E!NO5IX=PQ59P4ER.KB^7$R;E4<
M?9JDY-<M2&M=0G?V=J4IXW$349S3]GAI5*7U:BG;WK8:E4I-I)U%6Y]'!QET
MNO\ [2.F_%_X#_%'X@_L+_$3]F;]H7QMX0EU7P=H^J-\;-&U;X(>&/B1I)T>
M?7]-^*GCCX8/XQN=$?P#H&MQ>,?$WA*U%CXDOM.@LM(>[\-_V]9Z]:_D9X-_
MX+77/@C4/V7-:_:>M_"D_P $/C=<_M\^'K'X]?L^_ #]H[X@:;\=E_9?^(/[
M/'A;X,_&KX&_"_P/=_&OQUX*^#7Q2L/B5\3/[0N_% ^)NE:O>>$?"OB'PG\2
MQX4\0Z1<>(OV(^+W[)/[-_Q'^ 'Q7_9J\4^ ]%\#? WXV6U[IGQ1\._"R_F^
M!T'BB+Q9=Z?;:];ZCX@^&MUX0U1+GQJ+.S\/>)9H[Z.Y\5Z+=R>%M7?4]-U&
MXM)N$^$G[('[.'P$U_X<^+/#WBGXI>)/$/P+T;XI_#;P/XG^-'[2?Q=^-FN>
M#]#^/5S\%+KQIX#EUOXM>/\ Q9J TO4I_@U\)I?"7A?4KMK3PSY4Q\(6%B?%
M>H+?Q&#O75N9S5!4I*,)2<_JM>%76'*X7Q-2E3BIN;A[92NY1Y91/D5/X&[N
MK>,7[*RE4INE%7C4YE1I4\0Y6BHU(\Z_=IWC^7G@#_@IY^U[XW^$/_!-GXZI
MX9_94DTS]M"?X/>&U^">F:=\6I?C[\;_ !=\0?C!J_AKXN2? ?P^_C62T^$?
MP]_9;^!=AI7[07Q)^('Q.LOBWI>NZ<^L^%]9'PJAT[1O$.N?7G[$7_!2O2_V
MS?VS?VI?@YX%'PQN/@)\+/A9\)/'7P"\;:'XNL]<^(/QEL]<^('QM^&OQ2^(
M5]I-AXBN[#1/AU;^+OAIIMK\.+.+0XM7U7P;JWAGXHZGJTWA[XM>"=.T_7T/
M_@ES^PUX'\8_"OQ]X'U'XU_#?Q3^RO\ "C1O@YX8G^'W[8?[0/P^MO"WPDM/
M'VH?&<^"?B7I/A?XJZ/IWBKPGXE\67 \1>*]/^(UKK-AXUTK3-$A\01ZII.@
MZ1;67TS\"_V3_P!C_P"&GQ<\8?M&_L_?"OX2>$_'GQ"^'_AOX3^(_%GPIT?P
MSI&A7_@_P+XB\2>(K+2K#3?"4$'AS3K^;Q%XGU*Y\5ZCID$.J^)&T[PK8^)[
MK4H/!GA6WT7IJ5,)/%U*]"G;#U98RI15XWITL135+!3NF^;VDJ;4?BJ*2F_:
M2A[AG)MPY%)^T56@O:<J@ZKCBJV)Q%&4+NRAAI44FIR7L[Q2]I>JOL:BBBLS
M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z'Z'^5+2-T/T/\
MJ /SW_8P_P"3C_\ @K)_V?K\+O\ UUI_P3<K]":_/;]C#_DX_P#X*R?]GZ_"
M[_UUI_P3<K]": # ZXY]:3:O]T=2>@ZGJ?J>YI:*/^&^7;T\@_K[]_OZ]^MQ
M JCH /H /Y4N .@Q110 4444 ?,O[:O_ "9S^UA_V;3\>/\ U57BRJ7[$3^7
M^Q1^Q^Q!('[+O[/V0" 3_P 6G\)<9) Y^O7WJ[^VK_R9S^UA_P!FT_'C_P!5
M5XLK\[/CE\'_ !M\?O\ @AO\,O@]\._"UOXT\8>.OV8OV*=,TKPY>^&--\;Z
M9>PVNH_ S5=7N=;\%:S>Z=I/C'P]H^AZ?J6M>(O"FI:A8V/B+0].U#2+J[MX
M+R29%)M+1)MRA%7O9<]2E3<I6UY8*K*I*VO)2G9-V3F4E&,YN+DH0G-QCK*7
M)"<^6/\ >DX*,?[THG[1B=#*B;7)?.TY4IPI)PP8[P,,#MR4(^<+NC+VJ_EU
M^)O_  3#_:._9GM?"]Q^REXZ\8V'Q!\-?!C_ (*8?&+1O%G[*/P1^"/[/OPR
M\#_&[Q?\./V,-.^!GP#^$/P+OM+^(W@SX8?#3XKZ_P#L_6FO^)_#&G2ZOJWQ
M"^(@^)_BC7_&&D+X^U?3I+/Q)U3_ (+-^(/C[^V9+X8M_P!KGX>_"K7/@[\2
M_#7PT30O#/[,?Q(TS2O&OA;QM^S1<_#KQE\"+:\\:_#!].?QM\(=?^/%[J'A
MS5]:'C/1+LZMHT?Q"\=?''PGX,\*^'*A&FU&,*BZ\RFW'D2HJOS7E9NFVYTH
MR>KJP:2Y)4Y,DW&35U)<E*I%I-657%?57!MIWG2=Z]2R]VA:5G)V/Z@3P"?2
MJAN(_++D-M4.S9(!58P-S$,00H# DXV@,#D C/\ ,7\+;O\ X+@:Q\=_^"?M
MSXMN_CKX$^!]CX<\,6WQ6TSQ7X0_9Y^*6I>+8=/^.OQIMOBI>_M.^*="\>_!
M"?X9:GK_ .S7:_ >^^'<-G\//BIXPT76=:O[%;?5_C'X?^(.H>)OHO\ :$^$
MTGBS_@K7\'_B+I?[)7[1.E6OPW\#OXB\1_MM_#_1+KQ;KGC/7A\'/C1X)\'_
M +-?@OQ1KWQ"ATOX'_ #PAIWQ*\0_$+XG:1X8\+S67QL_:(O_AFFN^&47P;X
MC\7:QG.48O#MRC^_6+]WFY:M-X6BZWOJ2=.,:BBXQDY2<7>3C)1<9U>\9\M^
M>,*,T]'']]4J4U%V;3E%TW*2MLXI-W;7[Z Y /J,T5YQ\)9+A_AI\._M)\?&
M=? 7A%9_^%J'3S\31.N@:<)1\2!I.=,'Q!#[U\:?V<1I_P#PD:ZD+$&W";?1
MAR!]!6DERSG![PDXM][7UM=]N[WW>[F,N9)KJK_<VOT%HHHI%!1110 4444
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MIUVG4]I7JPE^[Y;?D/\ \%*_V>_B/^T%^R9\(;[Q!X>\8>(OC3\+_C-^QO\
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M/&WA#6/#-KJ5W:V\D$]U:V,^J1W5S;PS0RS0Q.D4B2%&7P;_ ()O>+%\??\
M!/#]@WQPNG-I*>,OV,_V8/%*:5)?#4WTU-?^"?@C54L)-1%GIPOY+1;H0/>"
MPLA<M&9A:VX<1(-*2::NG;\'&2^YQB_EZIM-IW6Z_K]3ZUTZSNXM(LH;Z_2^
MOH[2UCOK^*R6RBO;V.-4O+N&Q^T7BV<5W<>;-#:"YNQ:JZ0B>X$>]_PNA^!^
ML:-^W?\ %CQM\3/V%OB1\</VC/$7[3#_ !*_9?\ V\--N_!6F?#GX._L\P?
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M5:CS/WGRP]FKM]/-GYB_\%6/^2-?LP_]I.O^"6W_ *WG\!J_3JOS%_X*L?\
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M%X<U7PWJVEZDR7V@RWEO:7UIR7A/_@C1^QYX'MM%T[PY'\:/[*\/_M^^&/\
M@I?I]MXF^-OC#Q_JLW[5GAOPE=^$)_%.M^-?B$WBOX@^*M&\56^HW^N>,M-\
M5^+-<U#7O$DK:DVL6D<L]K+^LM%;1J58S=55JJJ2:E.HI>_.:E&7/*5KN=X0
MNU9>Y!<MHHEP@X1IN$73@K1IN*<$OWFG*]++VU5)*UE4G:W,[^6_%GX6Z%\9
MOA9\2_@_XR2[E\(?%?P!XW^&WBR/3+]M/U&7PUX^\/:EX7UV/3K[R9S87ITG
M5+E;*[$4YM)_+D".(\/\A^/O^":?[._Q&_9>_9L_93UE/B)I/@[]CT_!6_\
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M #75]244 ?+?_#<?[%?_ $=]^R[_ .) ?"7_ .:ZC_AN/]BO_H[[]EW_ ,2
M^$O_ ,UU?4E% 'RV/VW?V+YVCCA_:[_9@ED>:%52/X_?"=W9GD5$557Q:69G
M=E1%4%G=E5020*^$O^"6_P"V)^R/X5_X)E_\$Z_#/B;]J;]G'P[XC\/_ +"_
M[)6BZ_H&N?'#X8Z3K>AZSI?P$\ V.IZ1K&E:AXHM[[3-4TV]@GL]0T^]@@N[
M*[AFMKF&*>*2-?V-D_@/<2)C_@1VG\U)'T)K\_\ _@DTV/\ @E?_ ,$U"Q_Y
ML$_8\&3D\#]GGX>8'X 8'L,4!_7W:_DF>P?\-Q_L5_\ 1WW[+O\ XD!\)?\
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M^S5_X?+X9?\ S3T?\-N?L9_]':?LU?\ A\OAE_\ -/7T]@>_YG_&C ]_S/\
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M1U%-_P"&I_"&03\*?VG"<MR?V8?C63A@N1D^#2<$JN>N2JYZ U].B*,  +P
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MJKPE_P!$K_:=_P#$8_C;_P#,97TUY:?W11Y:?W10!\R_\-5>$O\ HE?[3O\
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M^RG_ .)F_%S_ .@,H_X2S]N/_HWC]E/_ ,3-^+G_ - 97UE10 4444 %%%%
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MP;X<\7^$/@[I7B'Q3;7F@7&D?\)CXM7Q-H$1D_0/]DS]O+]MS]K+XKZ=\2O
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M_J_))7VDG]G7\@OA9^S-\9?A=\+_ /@J9\&[/3OB/KG@#XE^+?&&J?L?Z?\
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M_P %$;+X3?$GP[XQ_P"%^R:G^R1\7-7U7Q/^TMX7^(W[46E:?^SWXITKX>>
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MAI\/O&-CXL\ >#?A3X(T/2[WX\N_CC4/"^J>)[JX@\*1^$]*:\BU[4?$,']
M5I"(($B!R%W?ADDD=3W)/;KSSDF<(@QA5&!@84# '0# Z#TIU;.<Y1IQG)S]
MG%I.6K]Z.&@VW9-N4,'A5)MN[I7TYF1"A2A4G5C",9S<KN*:]UU,16:LVU=U
M<9BIMJR;K/HDD4445)L%%%% !1110 4444 %%%% !1110 4444 %%?C7_P /
MF? O_1B/_!3K_P 12M?_ )Y='_#YGP+_ -&(_P#!3K_Q%*U_^>77V'^H'&/_
M $(<1_X6Y!_]%)\+_P 1,X$_Z*3"_P#A#Q!_]"I^RE%?C7_P^9\"_P#1B/\
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M?IJK7OCJRM8]37QW\%O&L21:5=ZSI[:9'IEPNIO>W-Y8:?\ 6?\ P^9\"_\
M1B/_  4Z_P#$4K3_ .>765+@?BRNG*EDE>:BW%M8S)%9WE%K]YQ'2>\9*Z33
M2WLUS:UO$;@BA-4ZO$6%A-PA4Y7@L^;]G6IPJ4Y7APQ.-JE*I&5N;F2;A4A"
M:G3A^R>!Z#CIQT^GI2;$_N+Z_='7UZ5^-O\ P^9\"_\ 1B/_  4Z_P#$4K7_
M .>71_P^9\"_]&(_\%.O_$4K7_YY=:/P_P",'OP_7=MKXSA]V]+\4.WR,EXF
M<"+;B3"KTP7$"_+A4_9'RHR<F-,Y!SL7.1R#TZ@\BE"(!@(H'H% ' P. ,<
M ?@/05^-O_#YGP+_ -&(_P#!3K_Q%*U_^>71_P /F? O_1B/_!3K_P 12M?_
M )Y=5_J!QC9+^P<19;+Z[D%EZ+_6FR^20O\ B)? ?_11X37?_8<_ULFE?_C%
M>B;2\FULVG^R)CC8Y:-"1T)53WSW'KS]:3R8<8\J/!&"-BX(QC!&.1@ 8/'
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M?,^!?^C$?^"G7_B*5K_\\NG_ *@<8_\ 0AQ'_A;D'_T4A_Q$S@3_ **3"_\
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MN!'%R_UDPEDTG_L6?WU3:LO]5KVT=W:R=DVFTG_2W17XUC_@LSX%_P"C$?\
M@IU^/[*5I_3XEXH_X?,^!?\ HQ'_ (*=?^(I6O\ \\NG_J!QC_T(<1_X6Y!_
M]%)/_$3.!/\ HI,+_P"$7$'_ -"I^RE%?C7_ ,/F? O_ $8C_P %.O\ Q%*U
M_P#GET?\/F? O_1B/_!3K_Q%*U_^>71_J!QC_P!"'$?^%N0?_12'_$3.!/\
MHI,+_P"$/$'_ -"I^RE%?C7_ ,/F? O_ $8C_P %.O\ Q%*U_P#GET?\/F?
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M53K.HJ<_J>?-2=)P4U9<+N<>5U(?'""E>\'-*3C^RE%?C7_P^9\"_P#1B/\
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M_P#A\SX%_P"C$?\ @IU_XBE:_P#SRZ/^'S/@7_HQ'_@IU_XBE:__ #RZV_U
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M6M]/IDEW;PW#&6*":*-_WJR$K_4'C'_H0XC_ ,+<A_/_ %IM\OF'_$3.!/\
MHI,+_P"$/$'_ -"I^]5%?C7_ ,/F? O_ $8C_P %.O\ Q%*U_P#GET?\/F?
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M?#C_ (+*2^/_ (3>)OV@M4_X)_\ [<GPW_9]\-_L^>//VD[7XU>-_#?P:M_
M/BKP)X,\"R^/=/L] U'2/BSJ=])J_CG2HOL_@\7&GVEC=7TUN][?6=EYLZ_-
MW[$7C/QA\./V O\ @H[_ ,$W/B[J<FJ_%G_@FQ\/OCG\&M&U>Y4Q7/C?]FCQ
MK\(/%_CC]F3Q\ENTK1P6E[X!EE\,06%FI@T6R\-Z5ITA$YDSV^E,H_X-C8C,
MN8V_X(_7'FJLC1';_P ,VS"15D!S%D,1Y@RRD!LG:,TLDR;"RIX"OD\,75K<
M793D6'S7#9OF5-8S+<YP&$S'#9I0PWU:.&BZN&Q,)4HIJC1JJI0D^:E.R>88
M^JY5J>,=.*R3%9A/"?5,,ZF'QV%JU*#PW-.7-.FJE&HI^TLY2Y)2:C4B?2_P
M._X*C_$+XY>(_A-9:1_P3-_X*%^$/ WQ>U+P6-*^+_B[P3\'X_AKX?\ "GC8
MZ?+8?$'Q%J.C_&#6-4@\(6>DW\.N7UU8Z;=WPTS$L5C-*984_7K8/4_I_A7X
MS_\ !-+X??\ !1/2/AM^S#XC^-G[1/[.7C;]FN;]FWX;2:)\,?!'[/'B[P5\
M3M/L[[X:^&9/ -M?_$._^)>NZ5=7/ANT:WMO$LD7AVWCUV6*:6"UTM)/LT?[
M-U\MQ#A\MPV95,-EE+ QPV']I2<L'F&:YK3G5AB,1"?M<1G6$PV(AB8^SC&O
M1HTY82G.ZP]6K34)/W<ME7J895,1.I.53DFE5HX:BX<]"C.<8_5JDU)<TVWS
MV:=N6Z<K,V#U/Z?X4C*BXW-MR0HR0,LQP ,]23T Y-25\E?MP?%/XH_!W]FG
MQUXZ^"H^'W_"UX->^%?A7P"WQ6MM=N_ALGB7XC?&'P%\-M/;QM#X7N+;Q*?#
MJGQ:SZG+X?:?6K:%6N-+LM1OHH+"Y\)J*U<8VNDWR0LK]9/DT7=O1=3T8QYI
M**2N]KNR^;;LMSZM\RWP#YT>"NX'S$P5QG<#G!7!!)' !!Z$5(JHP#*VY3T*
MD$'!P<$9!P>/K7X?^"/^"K7BC7/B3\3_  GJGP@T;3+SP=\=[7X5:QX*\6^,
M+WP-\0/#&I:)X*_8GT'Q_P#"+PI90>'/%NG?'3XL^%_C1^TWXNU*TU3PQ<^%
M_ GBOX9V7P_U7P3J^M:=X_T_Q5#V'[+O_!1OXP?%O5OAY\._%/PG^&/]N:E\
M-=(O_'OQ<MOCI\-_"W@JV^(6I? O4/C4VL^&_AGXHUW3_C!XJ^$%@UK#\-/$
M?BWP=X7\37/AKXE:3\2M(FL)?#_PE\7Z]::^PES^SY*?-R.I:U*WLU:\[\MG
M'56<7)NZLG<324>9\MN9QW5W)0A-I+FNVHSCIWNNC/V//EAMI<!MI?:67=M!
MP6QUV@G!;&!W-.V#U/Z?X5^:?[3/[;.J?!;]IWX-?#>QTYIOA7IT_@^3]IKQ
M0OPP^)7BN#PA9_'CQ?-\*?@08_B9X:M9OAE\)5T'QQ%<^/?BAJ'Q=N],M8_A
MC:1WNB2K->QM<8/P\_X**Z[XP_9N\7_&76?AO\._#_CCPI\9?A'\'=;\&6?Q
MAN?$GP^\#ZA\9]0^$]IH6O>/?CIHWP_N/AY?>&O#=E\5;'Q!KGBWX.WOQ=\"
MWFAV=E'%XMTSQ3?^(O"G@?.,8SI*K!4YPE*$(<L8<TY3J>R2A&5*%[2<92=T
MH4YPJ2<8232E:$E"2LWR]-/?ISJ*[3TM&'O](2E"$GS327ZBDP$!O- 4,5W"
M0!=P8H58@@9#@J5)^^"N-P(I5\L%8Q*2V"0C2;F*C'.&RQ X^;U/7FOR#\ _
M\%%/$W_"*_MJ_M%_%K1?!N@_ 7]F#X+>$O&F@>%? >H:CXH\7>+?$6DZ?\49
M?'.H:'XLO]/TFS\9^&OB?J_@O1M._9UNM)TC2[KQWX4U_P *>)KC1;#4?%,&
MG0_"/@W_ (+I?$GX>^$/AWX*^-_PY^#>O?M!:3=?'Z'XX:;XOU7XZ?L*:_XC
MN?A=KW[,>L^ /!W[,_[,_P"T9\#==^,WQ!^,OQP^&O[4NC+\&OA5XXF^';_$
MKQ?\-/%Z:'XM72=0@OK%149U'3CRN4?8)Q3]V^)E7C25DE3O-X:JVI1345&;
M3C)-$DH\[DK.DZT7W_<I2JN"3?/%)QM**?,W:.MU'^FLF($J9!N499=R[@,
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MCSX/2:4>-LKES.*C)9=G?(^=I1?/+AV$5%N2]^;IP23<I047;YE<;<,M1?\
M:$O><(KFP6/@KSNHKGGA84G=I_#6DGO%S6I^P.P>I_3_  HV#U/Z?X5^1_AS
M_@IOXFU2[\0?$/7O@S\/O"?[+/PKMK/0_CS\5=6^/%S#\6?!7CU?V+/"_P"W
M#XBF\ _ 2Y^$]H/B]\-O#GP\\9:'X6-_X?\ B7IOQHUOQ#;^*/$.C_ >X^'_
M (9?Q5J>%XF_X+/_  G\&2Z5I/BC]EW]KW2?&MOK.J:7\4_AZ=!_9PO_ !5\
M"+*SD_9/ETOQ%\2;C2OVGK_PGKFD^*-%_;6_9^\0Z#9_!?Q/\6_$\=AXGU;3
MO$'AW0/$_A;7O#]G^NTTJR@Z5/VO.Y**A2C*7-&M]7Y914+PDZMHQC)WDI1F
MDH2NOIU4IN/,VHQ]FJRE-J$72=*-9SO*:7+"E.,YNZY/AE::Y'^QNP>I_3_"
MC8/4_I_A7Y2Z/_P5N^$.I^*?!OAN^^!G[2'ANRUD_#RQ^(_C+7M)^!*>$_V?
M/%'Q/_:J^*G[%?A;P=\7I-*_:$U;7K_5W_:-^$>O>!M1UKX.:#\6O VG6&L>
M'O'$_B[_ (0-M=\1Z'YIJ?\ P6^^!VCR7=OJW[-W[5NG7'AZ[^*=]\0I;:U_
M9;\6:+\./AE\(/ _[(GQ.\3_ !RUKQ;X(_:K\1>"?&/PHU+X<_ML?!;QEX6O
MO@_XG^)GC#7-+/BJWB\&1:OI.G:7K>D:,IN*A14G-\L5&%)WDZU+#QCLDG.M
M7H4H)M.<\1027[V%ZE.$55E)VC03=9M22I*,)U)NII>*A"E4G--<T53E[M[*
M7[2[!ZG]/\*-@]3^G^%?!7PU_;X\'_&,_M"V'PX^&GQ+U/Q+^S;X6\;ZGX]\
M/Z[%\//#2)X\\$_$[X\_">?X.1Z_<?$F[T2V\>ZGK_[/7BGQ!::A?7-OX"@^
M'WB_X:>-;OQA#IWBV*&W^%O!7_!;_2;#X5Q^)_CE^RO\4]'^+.FZU\6D^(?P
M2^"-])KOBWX.>$?@S\#O!O[0_CCQ)\5]$_;"\-_L)?$GP[?:/\-/%5[JUMX?
MTKX8>(I_'EMX;N-7^#UY\2]%\0>%;S6,TE*:IQIJ4G3P]6-J=/EE#%*3P\E)
MQC%^TC&<EJE%0GS.,H2BK49-V]G._-5BURWY71LZG-:;45%.#NW9JI3Y;\\3
M]WM@]3^G^%&P>I_3_"OR=\3_ /!7[X'Z!-J!T?X+?M(>/M.U?QI'\/\ X':S
MX/\ #_P?@T_]IWQ7IG[3GP@_8\^(FF?!N+QG\;?".KZ*/A/^T%\<OA_X+\97
M_P ?-)^!^F:U:WFI^*/A?>?$3POI-SJ]5M/_ ."Q7P!N+*P\0Z[\)_V@_ ?@
M"?\ 9Y^(?[0NJ?$KQYH7PAT'PMI4?P@T;XJZY\6O@QH>F1_&V]\??&3XY?#:
MQ^#/CR;QCX9_9Z\%?%WPIH5M86NJZAXX@\.W1UZ$M%0E-T^6,+\W/2C!I*%2
M;;C*GSVC&C5<FXI)TYPNZD?9M\K>T=+J-[.W-*5.,5>]KN56G%+=NI#36Z_6
MO8/4_I_A1L'J?T_PK\C?%7_!8GX.?#]/$EO\1_V>_P!J+X?:Y\,/ '[2?Q)_
M:#\.^(=(_9^O=2_9S\,_LQ^#_@1X[\2S?$B[\+?M%^(?#WBB\\?^&_VG/@)=
M?#*S^!>O?&)K^3XD6J>,9?!*>%/'\OA3D-)_X+.^ /B+:_!*;X+?L[_&KQ:/
MB;\3_P!G?P+\1M3\67OPH\)^&?V=M*_:#_:S\9_LD^'=0^(>MZ'\3/'$OCC7
MM6\9_"SXJ7_@.T^ ^F?%CP+XFM/"^BW?B7XD> ?#OC?PWXDN:4+S=-4TYJ<*
M<H*G!RC.I=PC)<NCDHMJW-HFR;Q]FJNCIN$IJ:^&4(M)N+O9ZR26J;;22=T?
MM#L'J?T_PHV#U/Z?X5^.G[4'_!5+QE^S#^T'\5?A;KW[+>IZS\-O 'PC\<>.
M/!GQ&F\=>)/#>I?''QOX%_9W\9_M&:SX$^&-UJ7P?G_9W6[T[P_X'USP]J_A
M'QE^TWX6_:,A?3M9^(>A?LZ^)?A%I</CK4^BUO\ X*_?!CP9I.M2^/\ X-?'
MSPKXL\*76OZ!XK\#+IGPEU_6=.\=>&?V4?V<_P!K2_\  ^G:CH'QAO\ P[KF
MIZEX:_:;^'_PW\/ZM8ZPWAJZ^)MIXA75]9T+X>6.G?$+6)7*X4YJ,&JKY8)1
MI2FY<THV<(Q<HOFA*-I<KNK).\7(E[KDI1:Y$W*5FX12=!-\R=G;ZS1NTI)<
MS4FG&45^M.P>I_3_  HV#U/Z?X5^2WP3_P""KWAWXD:]X=^'WQ!_9T^,?PD^
M,7CSXW^/_@]X ^%=U?\ PQ\:ZOK+?#S]H_XK? GQQ>ZAXA\,?$"7PA'K?P3\
M-?"ZX^-O[0^E>%]<\8>'?"/P]UO34^$_C3XX:U-;V%S^L<$S2DAD9<9ZHR=-
MHP<L><D]."!UXIM13BN2+YDI)QA3E&SA"HGS1C*-G&I3=[M7FE?F4XTQV4I1
M:UC*4'_BA*<)KXOLSIU(O1:TY6O9.<VP>I_S^%0LR!R@D^=<$K\N0#R">XR
M<$@ X..AJ25BH4@$DN!P,]F//MQSZ5_,Q^W]_P %8_VL_P!FK]L'XN_!#X:6
MOP7?P5X'_P"$"&A+XL\!>)-=\12/XG^%_@SQCJS7NIV/Q#T&SN4&K:_>FT6+
M3+=H;)(()?M$D7GO^A>&/A7QAXP<2U>$N!L'EV,SNCE.,SN=',<;ALKPSR_
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MU&XQL?T%;!ZG]/\ "C8/4_I_A7X">$_^"UOB7QWX@\-/8?LZV7@[P)JOAWX
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MG_&?Q+)I6M/\1-1\+6U]\*;!O$8L=.]+?]NCXR0P^'I1^SMX"U>2[^&7Q_\
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M^%WPF_9^^&?[5'Q<\8^ /AA:^'?C7\7?#7A#P9\0/%]EK.JW&GR> _@'\//
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MWA.\\ :SHFK:]<VS7VHVVI> -1U'P#=SWDLU_+X%U"]\'&\'AVYETYN3M?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm247121d3_s1aimg2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247121d3_s1aimg2.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &S R # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Z?XT?&7X
M:?L]_"CXB_&_XQ^+--\$?"SX4^#=>\>^//%>J?:9+;1?#/ARPFU#4[M+.Q@N
M]2U6\>*);;3='TFRO=8UC4KBSTK2+&_U.^L[.;\:/!'_  4#_P""L7[2'@;2
M_P!I#]EC_@EO\-;7]G#7=/N?%_PS\+_M0_M<V7P?_:=_:#^'U[IMOJ?@[Q+X
M<\&>'/ACXX^'GP0NO&%O*RZ+IWQ.\=ZY#=07.GZS<:CI^@WMKJ-QS?\ P<^?
M;3_P1U^/2R-?)X(;XE_LP)\6?[-:1+H?#-_VBOALNM!'C*RA&U,Z$K>6Z=@[
M["X/[Z62Z>EC;)IR6JZ6EM:IIZV"QI8)IXC3[&ME]G @2S2V\D0>3B&.$*(\
M1*F(<;TYU7.*M45"$+NRG'#QQ4JE1?:C*,E&DFN7EIU*B;FERG-&])<M[QJ5
M92[Q56.'C3IWMRR4I7K2B^9<U.&D)-O\1==_X+?_  WN?^";'CS]OKP+\#O%
M6I^-?@Y\</ _[-'QV_95^)'BF+X9?$/X+_'G6OC;X!^"GCOX?^-O$-OX5\;P
M077@BX\>V'B_3;NU\,RCQ1H$FEV=];^$=>O-8TSPU^H!^*'QQ3]JQ_@__P ,
MZ3']FU/@"WQ%/[6I^*/AH6Q^.*_$5?#*?LZ?\*3&E-XT$[^ 7;XE?\+576&\
M*A%_X1(Z8-69;D?BO_P7;\6?LZZU_P $POVO_#GP0\1_!O4_&'@[]JG]CFW^
M/.@?##5/!=SXE\,?%#6/VQ/@5J-Y_P +;TGPO*VJZ1X[UJ -J$[^,;>WU[5(
M UXS3PYD'JNMZGK#_P#!R2_A]=5U,>'C_P $+M>UE]$.H7?]A_VQ_P -S6>G
MC5WT?SC8-JOV4_9!J0M3>BT#6WG^2P2IYXRH2J1@KQQ&(G92;@Z6'X7CFCA!
MS]U4YXM5)X>HO>:E!U&HI\N"C-8KV:D^26%PLFN1<RG6SVG@95)6E%N<,/4C
M":UCRQ<E%S:1^\"2)M8EU^4G>=P 4@ MGGC Y.<8[U\Y_%/XG_&WPI\9_P!G
MKP-\.?V=I/BK\)OB9JOQ&L_CO\;HOBIX7\'P_LVZ=X8\)6VL> ]6F^'VK:;>
M>(/BROQ+\3O/X-6S\*7VF2^$'M6UO6'N;*181_'W^P'_ ,$L?V:/VO\ _@@Q
MX0_:[_:8C^*/Q;_:GM_V;/VE_$'P;^-7B'XV?%6+6?V;1\&?&?Q>M_A'HWP3
MT71_%ND^%_"FF>']9\%V7CO7C+H&JZAXT\::UXHN_%VIZ]IEYI^FV'V1\/OC
M/\3?B_X]_P"#2?XC_$#QGXA\0^,?BQ\+?VBM<^)^LWFKZBUQ\0?$2?L(:/+=
M>(O%R^?Y.NZSJ.J6[Z]>W>H1S,VLW=Y>V_D/.U=%2E*&*EA>>,ZM#$X.%2\9
MQISCBEB52DI<SUCB,,X5(Q;LESQ;3BBJCYL/4JWCRRP^95(3BI-IY?##SKRC
M&2C>,J&)A[)M7512A5C%)7_K*C<,BME>1C@Y&?0'OT[9]B1R4\V(OY8DC,G/
MR;UW\9S\N=W&UL\=CZ&OY5/V,?V OV:O^"P4?[67[:?_  4/\.^,/VC/'6M_
MME?M-?!+X%>$]?\ B?\ %#P=H'[*OP*^!WCVY^'/@/P#\,/"G@/QEX5TOPEX
MO9M&E\6>*/&$5JNO:OX@OK76G-OK-YKVIZ[4_;W^"/P/_9R^ W_!.O\ 8R_;
M9_:R_;N_;JT?PEK'QI:W_8V^ _PQ\6^._P!HW_@H_P"'/#^GRZEX(TSXEP?"
M;QGX?\4W?@S]EO1K[2KR[NM7\86>C>/K'36G\1)J&N6*76C<\9KEPZ3UK+#.
M"<9-\F(HJO%M0YI\\*$J=2<(TIJ3J.$94_J^)G3UE>,ZD-&Z3Q$:EKI<^&=6
ME*,>9I6GBJ-6A3G*5DJ:G+^-A_:?U9RS($!5D8M)%&HR&!9W0#@'YB%</M!!
M*X.0#FOA+_@G9^VE+^WM^SFOQ]F^&"?"8O\ %SXX?"W_ (1&+QFWCU0?@M\3
M_$OPS?7?^$A;PCX*W?\ "1R^&Y-833%T/;I$=T-/;4M3> W<O\Z7_!-S1? _
M[/?_  6>^$/@+]E_]AC]JK_@FY^SI^TE^QC\>=8\6? +]H'Q[9FP^*WC/X3^
M._!$WA[XNQ_ R+XN_&"\^&&O^'K&XE\,1ZMJFI:'-KEEJUX= TY8+SQ=J/B3
M]3/^#>7G_@G1'M_Z.W_;GQV_YNH^*9[XJHQE)NKJH_4Y5(P:Y9*O2S>A@:K=
MI2:]VI4IQC?F49?O$JBL8593@X14K3684Z$W#5>PJY+B<PBDFD[J<*=2;NXM
MT[TY2I2;/KG]O?\ ;XO/V0=1_9\^$_PK^!VM_M0?M9?M:?$#Q-X#_9T_9[T;
MQKHGPPL_$\'P]\,?\)O\6/B!XV^)WB;3=8T;P)\//AAX1:UU'Q)JD6B>)-9F
MN]8T2UT_0)K*?6=4T#Y$U?\ X*3_ +<?[(_CGX,V_P#P4N_8U^#?PY^ /QV^
M+GA_X+:?^T_^RU^T/J_Q<\*?!7XA?$"[BTOX7Z%\=/A]X[^&/@'Q/H_A3Q7J
MT=]IU]\7M$U6Z\)^&[U=.T_6]*M+S6-*2\]:_P""EG[)'PZ_;(\??LU:/\-_
MVR;#]CK_ (*._LZ:EXZ^-W['_P 0O#M]X%\7_$S2O#6OZ;9^#/C/%J'P"\5Z
MS87?Q1^"_B_2+?3M"\<FVAM]/LM2TS18-4U'4/#\GB7P=XI_.GXN?MB_\%??
M^"97AO1_B%_P5.^$'[''[;7[!FB>*?!WA[XJ?M+_ +,VF^)O"'QK^$6F:YXU
MTCP]X>^+7Q1^"OC/3U\&>)XK+6=4T;9X:^%7A2TCT[4I(_\ BK;:5[(W!#E]
MU2;7-B%'WWRPG3YH4X0I54I0HN\_92G4<90K\LW*--MFS@Y1;A%-^R;M!6J0
MJ>_)SE%RC.I'EBIQC3O.5/G<8R?*C]U++]L'P+?_ +<7B+]A"S\+^,&^)7A+
M]F'1/VJ?$'C&>TTJ#P##X-\5?$K4OA?X<\-:;=#5Y=?U#Q5<:MH'B#5-5$FA
M6.B:;I=KIZ6VL:KJ-]>V>D?77FQJ 7=(R1NP[*O!;&?F(ZDXSW)]Z_EJ\(_L
M%_LMW7_!RM\9/%DW@GQ?-KV@_L2?"+]LG2;]/C5\;ECB_:%\3?M1>.])U?Q<
MUC!\18-,OO#%UIVGV=I!\*M0M;KX1Z?&DKZ9X(L7N9RWU;_P0BUG6-5TC_@K
M1_;^M:KJTVE_\%QOV_=$TH:IJ%[J7]FZ-;3_  F33]%L/MDLYLM-LUD9;?3X
M/*M+4S3R10QB0N"FU*E0J\_-*>"J8JK&S7PYUB\LBH-Q3E)1P[C-MRA'ZO=3
MG*M.GA5)6J5XT]8T\10P\'R^[>MEM#&)-0>B<IN=HMM^U:Y8\D)U_P!Z3-$/
M^6D>2%VC>N6W_<VC.3O_ (<9W=LU\(?MB_MH3_LG>.?V)/!@^&,?C\_MA_M=
M>$?V6CJ,OC-O")^'*^*/"?C3Q<_CQ;0>$O$__"8'3X?!CV*^%S=>%_MLFH17
M'_"1VBVQAG_ET^%WC[XF>-_^"77[!?[*.D_%3XA_#W0/V\_^"S?[0/[-/QT^
M)OA#Q3JNB_$)_@"G[1G[1'C;QQ\/_"7CR"X;5/"VM_$:U\':/X-BU*VFF6X\
M,S^(?#MUIVIZ+K.HZ?/]7?MC_P#!+#]E3]@?]I/_ ((Z>-?V.= \3? OX>Z]
M_P %3/@KX(^('P+TOXC?$3Q9\,/'/BR\^$GQAU/P9\6[SP_\0O%?BL:=\2/!
M^B^$O$WA";Q-H\]AJ'B31?&\L7B<ZO<:1H4]G>"C]:GE%6K:%#&XC!+ECJYQ
MK9=E^88FA4=^:G"/]I8>A&LDE/EFXOFC42RQLI4*>8*$HNMA:>/C3T;BJF&S
M+,,NI5E*UI.<LMKUE22]Q24*DO@E+^LSSH<9\V+  8GS%P%;.ULYZ'!P>AP<
M=#0)8BXC$L9D*EP@=2Y0-L+A<[BH?Y2V,!OESGBOYS/@7\<=#_X)D_M@_P#!
M8#X&?&76]8C^!=IX UK_ (+(_ !K_4+K4KF/X7^+[*YT#]JWX?Z#)=DV&AV'
MA+X[>'-%M/ 7@?2\JMOX]M3:6,$U["+G[._X(L?"SXD> /V#OAO\2?CG?7NH
M_M!_M=Z[XU_;7^.LMY)JRIIOCO\ :?UE?B18^%;#2]8FFN?#-GX(\ 7O@GP9
M)X8MRMCI6I:!J*6Z*97 F*J2A&:4;/#8:I)OFM'$XBK6HRP=TY)5:,L!FE23
M<O>I8:BU%.OSFTVX24='>O5I1U^.C"G1K4L5"_+^ZKPQF!4+Q=JM2O1YG4H\
MB^R/VU/VI?!?[%'[*7Q^_:K\?PP7_AOX%?##Q1\0)-!EU5-$F\7ZWI=D8?"'
M@'3M6DL]0BTW6/B%XPO- \$:)?36-Y!;:QX@L9)K6>,-&?%?^":G[>#_ +?O
MP \1_$OQ5\'[_P#9Q^,OPN^-GQ7_ &>OC_\ L]:UXO3QWJ_P=^+?PLU_[+>^
M%K[Q@OA;P3#XAEU+PEJ7A+Q>M[:>&K"RMQXD;2K:;4TTQM4O/R4_X+X_M1_"
M]_CA_P $\OV$OB/#X_\ $OPM\8_&C3?VR/VP/"7PF^%WCCXV^+=0_9S_ &:=
M;@U'X=^!/%/PS\ :%K>MZEX#^.7QZBTCPUJ&L_9TM-%D\"7=Y/-'+';07'CG
M[&'[??P5M/\ @O!\5=#^$FB?&WP;\"_^"IOP1\,^+#:?&[X!?%;X#I8?MO?L
MOZ!J]AK-MX-T_P")7A7PKI=UIOC_ . %G'KOBO5](EU/4M;^(2:+::L4NKG3
M!>.C[_.W!RYWBJ>'2E"ZG@J5*I)R3FN1XNH\5A:2DF^?#0E:U6[=:+A",XSC
M&4*='$5E-2C&I0Q-2="$8OE]Z5&+P^,E)2Y51JU$[\EX_P!:X=&&Y65AG&0P
M(SZ9!QGVKY"_:_\ VQ_A]^QOI'P(U/QWX<\7^*+G]HK]J?X&?LB^ --\'6>G
M7,MM\1_CUX@NM'\/:QXEN-2U+3TTOPAHMGINK:KKE_:QZGJ7EVMO9Z?I5Y<7
MB>5^&OP?_8[^ W_!8K]L+_@IK\5/V_\ 0/$OQY^'_P"RM^U[K/[$W[,_[.7B
M#Q[\0/#/PK^#/AGX1_#KP5>^-/B7H7A/P3XF\*)J'CSXS>(_%MWK>J>,-?DU
M/5+>PL;?3M&O+71;72[+3?E'_@J#_P $L/A/\$/@)_P3*^$GQ(^)OQC_ &C_
M  W:?\%E/@#\"_A%J7Q!^(GQ$T3Q+\)_V1/VD/'GB"ZU?]F6#Q#X:\?Q7WC"
MW\%6OAC3]+\)_%[Q!-_PMGPK9%])\#ZYX'\-PV/AZU5)>U>%4K+V\L'[J3ES
MPQE>E15-:M*4H5H5?>DHJGS*3]I"5,<TH2Q-*3<9T*687:3]VI@L%B<5)J\7
M[J=#V>W-.I*E&*4*LJ^&_LT\V/!;S$VJQ1CO7"NIPRDYP&4@@J>01R*3SH<*
M?-CPWW3O7#?=^[SS]]>G]Y?49_G<^#_A#1_@]_P<+Z=\!? ,_B'1_A#\+?\
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MOC"[\ ^+/B!<_&"/1_&MGK/A6TT?X7M/I7B'Q/K'YC?'*2W^&W_!(+_@KO\
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M4E_;-;_@GS^Q-\>_VQHOALOQ@;X'Z#X:UUOAP?&9^'X\3)K_ (\\)^"Y(/\
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M]H\\I3?*M+.\W9ZV5E]E6)+G=VWS>[>2MS2Y(QBN9V=](J]K7;;W;O\ #/\
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MG!)4YQ]V=-1FJBY)+6-JBYUNU)N46G9K\;_VG?\ @E#<>,_V=OV%O@Y^QO\
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M?!/A+PMI'P0T/3?"7A#0(]5A\*V&J2?+'Q__ ."'G[>?[3'[*?BC]B;XS_\
M!7?Q%X^_9UT7PYX:T7X2:'=?LN>"/#GCK7Y? ^O^'M1^&P_:@^(^@^-AKOQH
MT?X<:5H<:VNG:''X U#Q[XZTWPE\2/'6MWU]X=N=!US^FNBFW)R<G*5W"A3=
MK13CAE..&NHI7E0C5J1I2^*,:DXMRBTHD8J*LK_'6J)M\SC+$<CK<M]$JDJ<
M)RC9J4US.[LU^ W_  7R^,7P$T3]B+QS^SIJWQ8T:S_;8\8-\$_%O[$?P:\
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M_<YPC_\ ,_=/[@]EXG_]!?AY_P"$W'/_ ,M.(_X>9?L ?]'C?LY_^'2\.?\
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M<_Z,T_92_P#$=O@__P#,=1;@#_GWQ[_X6<(__,X>R\3_ /H+\.__  FXY_\
MEIPW_#S+]@#_ */&_9S_ /#I>'/_ )*H_P"'F7[ '_1XW[.?_ATO#G_R57<_
M\,&_L.?]&:?LI?\ B.WP?_\ F.IK?L'_ +#BD#_AC/\ 94.XX&/V=/A 0/J1
MX-PH]S@>]%N /^??'O\ X6<(_P#S.'LO$_\ Z"_#O_PFXY_^6G$?\/,OV /^
MCQOV<_\ PZ7AS_Y*H_X>9?L ?]'C?LY_^'2\.?\ R57:M^PA^PTI4-^QK^RH
M-S!5_P",=/A!RQR0,_\ "&>BDGG^8S)_PP;^PY_T9I^RE_XCM\'_ /YCJ27
M#WI<?1]<9PA^E!C]EXG_ /09X=O_ +EN.?\ Y:<-_P /,OV /^CQOV<__#I>
M'/\ Y*H_X>9?L ?]'C?LY_\ ATO#G_R57<_\,&_L.?\ 1FG[*7_B.WP?_P#F
M.IC_ +"/[#4>-W[&G[*>6.%4?LZ_"!F8^@ \&DD\Y^F3T!IVX _Y]\>_^%G"
M/_S.+V7B?_T%^'?_ (3<<_\ RTXG_AYE^P!_T>-^SG_X=+PY_P#)5'_#S+]@
M#_H\;]G/_P .EX<_^2J[,?L*?L,EMH_8S_95W8SC_AG+X1#NPY)\&@#)1MI)
MVMM.TD8S*/V#OV&ST_8T_92/./\ DW;X/_\ S'>G/THMP!_S[X]_\+.$?_F<
M/9>)_P#T%^'?_A-QS_\ +3A_^'F7[ '_ $>-^SG_ .'2\.?_ "51_P /,OV
M/^CQOV<__#I>'/\ Y*KN?^&#?V'/^C-/V4O_ !';X/\ _P QU1C]A#]AL[L?
ML:_LJ?+U_P",=/@^>?3CP8>1Z=?P(RK>'_\ )QY_X6<(_P#S.'LO$_\ Z"_#
MO_PFXY_^6G%?\/,OV /^CQOV<_\ PZ7AS_Y*H_X>9?L ?]'C?LY_^'2\.?\
MR57:K^P=^P\?^;-?V4@ 0#G]G7X0 ] >_@T>N/K4G_#!O[#G_1FG[*7_ (CM
M\'__ )CJ=N /^??'O_A9PA_\SA[+Q/Z8SP[?IAN.?_EAPW_#S+]@#_H\;]G/
M_P .EX<_^2J/^'F7[ '_ $>-^SG_ .'2\.?_ "57<_\ #!O[#G_1FG[*7_B.
MWP?_ /F.J)_V$?V&U=4_X8U_93#-D@#]G3X0-QT)X\&]%.-Q[;ESP<A6\/\
M_GWQ[_X6<(__ #.#I>)__07X>/TPO'/_ ,M.+_X>9?L ?]'C?LY_^'2\.?\
MR51_P\R_8 _Z/&_9S_\ #I>'/_DJNU_X80_8<4X;]C/]E0\$@C]G/X0XXQQD
M>#<;B3P.K9XS@X<O[!_[#;#(_8T_93QDCG]G7X0 Y4E2.?!W8@C(X/4$@@DM
MX?\ _/OCW_PKX1M]_P!6L'LO$_\ Z"_#S_PFXY_^6G$?\/,OV /^CQOV<_\
MPZ7AS_Y*H_X>9?L ?]'C?LY_^'2\.?\ R57<_P##!O[#G_1FG[*7_B.WP?\
M_F.IA_81_8:$BQG]C3]E/>REP!^SK\(#\JE5)_Y$[L6 /89&<9%.W '_ #[X
M]_\ "SA'_P"9P]EXG_\ 07X=_P#A-QS_ /+3B?\ AYE^P!_T>-^SG_X=+PY_
M\E4?\/,OV /^CQOV<_\ PZ7AS_Y*KN?^&#?V'/\ HS3]E+_Q';X/_P#S'5')
M^PC^PU& 6_8S_94.Y@JA/V<_A"[%B"<87P:3C )+'"J 2Q !-%N /^??'O\
MX6<(_P#S.'LO$_\ Z"_#O_PFXY_^6G%?\/,OV /^CQOV<_\ PZ7AS_Y*H_X>
M9?L ?]'C?LY_^'2\.?\ R57;+^PA^PV_3]C/]E0< _-^SI\(5X.0",^#1GD$
M?AD?*5)&_81_8:0X/[&?[*A.,X7]G/X1.>=QZ)X,8YPK'&.<8&20"6X _P"?
M?'O_ (6<(_\ S.'LO$__ *"_#O\ \)N.?_EIQ/\ P\R_8 _Z/&_9S_\ #I>'
M/_DJC_AYE^P!_P!'C?LY_P#ATO#G_P E5VB?L)_L-2;"O[&?[*N)$WJ6_9S^
M$2@CT)/@W 8C) )R0-PRI!+V_8/_ &&UY/[&?[*?X?LZ_" X ZDX\&\ #G].
MN 2W '_/OCW_ ,+.$?\ YG#V7B?_ -!?AW_X3<<__+3B/^'F7[ '_1XW[.?_
M (=+PY_\E4?\/,OV /\ H\;]G/\ \.EX<_\ DJNR'["G[#)QC]C3]E7D!A_Q
MCG\(0<-RI /@S)R.F >X.&!%+_PPG^PRPRO[&G[*IP2&5?V<_A"64C.=P'@P
MD'((P<<@@<@BI_XU_P#\^^/7HFE]<X0U3V=WA[:]%>[L[(%2\3W?_:_#O1M/
M_9N.=&MU_%W6E_4XS_AYE^P!_P!'C?LY_P#ATO#G_P E4?\ #S+]@#_H\;]G
M/_PZ7AS_ .2J[=?V#OV'&&X?L:_LID<C!_9U^$"D$$@Y!\& \$$>G<9&#0W[
M!_[#:X!_8S_94).2,?LZ?"$].N3_ ,(;@=1C)&3P,TTN &OX7'R\GC.$+_A0
M8>R\3_\ H+\._P#PFXY_^6G$?\/,OV /^CQOV<__  Z7AS_Y*H_X>9?L ?\
M1XW[.?\ X=+PY_\ )5=I)^PE^PS%MW_L:?LIC>RHN/V=/A"068A5&1X-(!)/
M<C@$]!3?^&$_V&MCO_PQK^RDJHP5MW[.GPA4H>"=P;P:"  P8DC[OS=.:=N
M/^??'O\ X6<(_P#S.'LO$_\ Z"_#Q^2PO'-WY+][JSC?^'F7[ '_ $>-^SG_
M .'2\.?_ "51_P /,OV /^CQOV<__#I>'/\ Y*KL1^PI^PT,JW[&O[*N\8R#
M^SG\(5.#T8#_ (0S.TDA0<'YB%^]Q3Q^PC^PXPX_8S_94##&5/[.GP@! /0D
M'P9QGKC (SR!TI?\8!K^[X]=M?\ ?.$%UMK?#JR?1NR?1L%3\3W_ ,Q?AXO)
MX;CG3R;55JZZJ^G4XO\ X>9?L ?]'C?LY_\ ATO#G_R51_P\R_8 _P"CQOV<
M_P#PZ7AS_P"2J[G_ (8-_8<_Z,T_92_\1V^#_P#\QU'_  P;^PY_T9I^RE_X
MCM\'_P#YCJ=N /\ GWQ[_P"%G"/_ ,SA[+Q/_P"@OP[_ /";CG_Y:<-_P\R_
M8 _Z/&_9S_\ #I>'/_DJC_AYE^P!_P!'C?LY_P#ATO#G_P E5VI_81_8:&?^
M,,_V5#@X./V<_A$>AP2,>#3D \$C@<YX%2#]@W]AP@$?L:?LI<C/_)NWP?[_
M /<G46X _P"??'O_ (6<(_\ S.'LO$__ *"_#O\ \)N.?_EIPW_#S+]@#_H\
M;]G/_P .EX<_^2J/^'F7[ '_ $>-^SG_ .'2\.?_ "57<_\ #!O[#G_1FG[*
M7_B.WP?_ /F.H_X8-_8<_P"C-/V4O_$=O@__ /,=1;@#_GWQ[_X6<(__ #.'
MLO$__H+\._\ PFXY_P#EIPW_  \R_8 _Z/&_9S_\.EX<_P#DJC_AYE^P!_T>
M-^SG_P"'2\.?_)5=S_PP;^PY_P!&:?LI?^([?!__ .8ZC_A@W]AS_HS3]E+_
M ,1V^#__ ,QU%N /^??'O_A9PC_\SA[+Q/\ ^@OP[_\ ";CG_P"6G#?\/,OV
M /\ H\;]G/\ \.EX<_\ DJC_ (>9?L ?]'C?LY_^'2\.?_)5=H_["7[#:L4_
MX8S_ &52PV_=_9T^$)'S[R/F_P"$-*C[C9W$8RN<;URY?V$/V&V.!^QG^RKT
MS\W[.?PA4?P^O@P9/S<X/!!&.*5O#^]O9\>_^%G"/_S/IMN[+S#V7B?_ -!?
MAW_X3<<__+?PW\CB?^'F7[ '_1XW[.?_ (=+PY_\E4?\/,OV /\ H\;]G/\
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M_P#F</9>)_\ T%^'?_A-QS_\M.)_X>9?L ?]'C?LY_\ ATO#G_R51_P\R_8
M_P"CQOV<_P#PZ7AS_P"2J[9/V$/V&WSM_8S_ &5,#@D_LZ?"$#/((!/@WD@C
M!QT/!YIS?L'?L-J"3^QK^RD .2?^&=O@_P #U)/@[ 'J3P!R2!S2MX?_ //O
MCW_PLX1_^9P]EXG_ /07X=_^$W'/_P M.'_X>9?L ?\ 1XW[.?\ X=+PY_\
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M</9>)_\ T%^'?_A-QS_\M.'_ .'F7[ '_1XW[.?_ (=+PY_\E4?\/,OV /\
MH\;]G/\ \.EX<_\ DJNY_P"&#?V'/^C-/V4O_$=O@_\ _,=4)_84_89!Q_PQ
ME^RLQ.<;?V<?A&V=HRW3P9QC('S;1D@#)-%N /\ GWQ[_P"%G"/_ ,SA[+Q/
M_P"@OP[_ /";CG_Y:<9_P\R_8 _Z/&_9S_\ #I>'/_DJC_AYE^P!_P!'C?LY
M_P#ATO#G_P E5W/_  P;^PY_T9I^RE_XCM\'_P#YCJ/^&#?V'/\ HS3]E+_Q
M';X/_P#S'46X _Y]\>_^%G"/_P SA[+Q/_Z"_#O_ ,)N.?\ Y:<-_P /,OV
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M_P![L<7_ ,/,OV /^CQOV<__  Z7AS_Y*H_X>9?L ?\ 1XW[.?\ X=+PY_\
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MXW[.?_ATO#G_ ,E4?\/,OV /^CQOV<__  Z7AS_Y*KN?^&#?V'/^C-/V4O\
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MO&G[5_Q>^#7PLUV*Z\4&/QY\-M(\6V_P\^$^@^*M:7P[\,;?4[SXC:_JM_\
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M!?'7X+?%KXY1_ 3P'XB\>_$3]L']LO\ :KUS1?&4O[._[4'[8OA_X)_L]_\
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M?&*3>-/B#_Q4/[0OPHD^&4WPU\=ZH5\5I]JLO!LGP8^%$N@>!I ?AU:GX?\
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M'J7Q+@^'G[-=M\0O&?BWP_X,\#?!3]H+QC)\*_!7@339_B7:>&M%U[4OBY\
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MUO4]-TJT_:?X(_L2?LT_LZO\+Y?@]X(U3PZ?@KX$^+'PS^%2ZA\2OBOXZMO
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M6CY92G&-XT?:4W&46E4E1BJEW[SDG/EE"$[M0G.K*K9^SI(_/;QQ^W]^W/\
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M_P#11Y#_ .'C+O\ YK/O"BO@_P#X>;_L+?\ 1P6@_P#A+_$#_P"9*C_AYO\
ML+?]'!:#_P"$O\0/_F2H_P!4>+/^B8XA_P##+F?_ ,QA_K5PO_T4>0_^'C+O
M_FL^\**^#_\ AYO^PM_T<%H/_A+_ ! _^9*C_AYO^PM_T<%H/_A+_$#_ .9*
MC_5'BS_HF.(?_#+F?_S&'^M7"_\ T4>0_P#AXR[_ .:S[PHKX/\ ^'F_["W_
M $<%H/\ X2_Q _\ F2H_X>;_ +"W_1P6@_\ A+_$#_YDJ/\ 5'BS_HF.(?\
MPRYG_P#,8?ZU<+_]%'D/_AXR[_YK/O"BO@__ (>;_L+?]'!:#_X2_P 0/_F2
MH_X>;_L+?]'!:#_X2_Q _P#F2H_U1XL_Z)CB'_PRYG_\QA_K5PO_ -%'D/\
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M/Z5K/B2]\,>*-*LK;P?IVBZ3K\=]9:_I=IX3^V#:_MD_#3QM\>&_9UUKP?\
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M;\5OA%\'7?3M5N=&TN3PA<>,=1&L/K&F:/HNL^D_ ;]K_P#X)N?LV?!_X>_
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MJ^I>'_%7AU-8E\->)=,N(%UW1]1GTO29;'Q_P3\3_P#@G9X%^*/P+3PK\;/
M'A/]G7]E#3/&_C/X%?#NSA^-_B[Q7XA_:7^,D?C+0?B9\?\ XN^*O&GA._\
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MV1\#/A=XYTKXEWWQ%L;SX?:=X9_;6^"7P7^(=_X]^%$_@"UN/%WB/PO;^(O
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MZ."T'_PE_B!_\R5'_#S?]A;_ *."T'_PE_B!_P#,E1_JCQ9_T3'$/_AES/\
M^8P_UJX7_P"BCR'_ ,/&7?\ S6?>%%?!_P#P\W_86_Z."T'_ ,)?X@?_ #)4
M?\/-_P!A;_HX+0?_  E_B!_\R5'^J/%G_1,<0_\ AES/_P"8P_UJX7_Z*/(?
M_#QEW_S6?>%%?!__  \W_86_Z."T'_PE_B!_\R5'_#S?]A;_ *."T'_PE_B!
M_P#,E1_JCQ9_T3'$/_AES/\ ^8P_UJX7_P"BCR'_ ,/&7?\ S6?>%%?!_P#P
M\W_86_Z."T'_ ,)?X@?_ #)4?\/-_P!A;_HX+0?_  E_B!_\R5'^J/%G_1,<
M0_\ AES/_P"8P_UJX7_Z*/(?_#QEW_S6?>%%?!__  \W_86_Z."T'_PE_B!_
M\R5'_#S?]A;_ *."T'_PE_B!_P#,E1_JCQ9_T3'$/_AES/\ ^8P_UJX7_P"B
MCR'_ ,/&7?\ S6?>%%?!_P#P\W_86_Z."T'_ ,)?X@?_ #)4?\/-_P!A;_HX
M+0?_  E_B!_\R5'^J/%G_1,<0_\ AES/_P"8P_UJX7_Z*/(?_#QEW_S6?>%%
M?!Q_X*<?L*C.?V@M!X&3CPO\02>H7H/")).2!@<U]D>#?&OA?X@^%/#OCCP9
MK%MX@\)^+-%TWQ%X<URQWFTU;1=7MEO-/OK<2I%.B7%NRN8KB&&YA;,5Q#%,
MCQKP8_)<XRJG3JYGE.9Y=2K3=*E4Q^ Q>#IU:D:;JNG3GB,/2A4FJ495'"$I
M24$YN*CJ=N"SG*,RG.GEV:9=CZE.'M*D,%C<+BITX<\:?/.-"M5E"'M)QIJ4
ME&+G)13<G8ZFBBBO,/2"BBB@ HHHH **** /YSO^#C10W[/OPA# $#Q5XJQD
M9Q_H.A'CKCE5;ZJIZ@5_&6L:'/RC@D=/3_/_ -;U_LU_X.,_^3??A#_V-7BK
M_P!-^B5_&:O\7^\?Z5^MY;=<,<,)-J+PV=2:3:3E_K'CTI.SUDH^XI-74/<O
MRI(_/<3)O/<_3=^3$9;&-W)\L5D^$=DG)Q2O5J-VBKMWW5VGEI_=%'EI_=%/
MHK7[_P#P*15W_20SRT_NBCRT_NBGT4??_P"!2"[_ *2&>6G]T4>6G]T4^BC[
M_P#P*07?])#/+3^Z*/+3^Z*?11]__@4@N_Z2&>6G]T4>6G]T4^BC[_\ P*07
M?])#/+3^Z*/+3^Z*?11]_P#X%(+O^DAGEI_=%'EI_=%/HH^__P "D%W_ $D,
M\M/[HH\M/[HI]%'W_P#@4@N_Z2&>6G]T4>6G]T4^BC[_ /P*07?])#/+3^Z*
M/+3^Z*?11]__ (%(+O\ I(9Y:?W11Y:?W13Z*/O_ / I!=_TD,\M/[HH\M/[
MHI]%'W_^!2"[_I(9Y:?W11Y:?W13Z*/O_P# I!=_TD,\M/[HH\M/[HI]%'W_
M /@4@N_Z2&>6G]T4>6G]T4^BC[__  *07?\ 20SRT_NBCRT_NBGT4??_ .!2
M"[_I(9Y:?W11Y:?W13Z*/O\ _ I!=_TD,\M/[HH\M/[HI]%'W_\ @4@N_P"D
MAGEI_=%'EI_=%/HH^_\ \"D%W_20SRT_NB@QI_='^?2GTAY!QU[?7M35KJ][
M75_>DM/6^@7?])$!: .L9:)9&#,J%QN95(W,JYW%0",L!A20#BJXO+!HWE%S
M:&*,JKR">,QH[ X5G#E5)(. 2"1TZ<_IU\$OB1H>I_\ !/\ ^.WPJUB#X,^!
MX="_::_8IU(>)=5\-I)K_C6WUSQM\<+SQ9XE^*TIU5_$7Q"\(> -&@\/Z?\
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M?"WASXC?!RQ\5P>$I=1\'VGA/4Y-9^'#7WB:UO-0\ 6OB30]2%CX;TG2-/\
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M\Q1D>H_,4 +129'J/S%&1ZC\Q0 M%)D>H_,49'J/S% "T4F1ZC\Q1D>H_,4
M+129'J/S%&1ZC\Q0 M%)D>H_,49'J/S% "T4F1ZC\Q1D>H_,4 +129'J/S%&
M1ZC\Q0 M%)D>H_,49'J/S% "T4F1ZC\Q1D>H_,4 +129'J/S%&1ZC\Q0 M%)
MD>H_,49'J/S% "T4F1ZC\Q1D>H_,4 7]*_Y"VD_]A33_ /TKBK_26_8,_P"3
M,/V8_P#LB_@/_P!,T5?YM.E?\A;2?^PII_\ Z515_I+?L&?\F8?LQ_\ 9%_
M?_IFBKR^*O\ DE*?_944O_6:Q)MD_P#R/Y?]B&M_ZN\&?7E%%%?F9]T%%%%
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M,N(_^C0.3AK_ *+',?\ PKA_]"9^ _\ PX#_ &S?^?7PU_X5_AO_ .2Z/^'
M?[9O_/KX:_\ "O\ #?\ \EU^_'_#];]@O_H8_'O_ ((/#7_S;4?\/UOV"_\
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MQ^/?_!!X:_\ FVH_X?K?L%_]#'X]_P#!!X:_^;:CZUQQ_P!&^RG_ ,,N(_\
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M1W6@.'#3U?&.8-[7>+IMVO?=\)/KKZZ[ZGX#_P##@/\ ;-_Y]?#7_A7^&_\
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M#OUQ_P A;CG]23W->N^'_P#@A!^U[XFT;3M?TFW\/OIFJV_VJR>?Q5X=@G:
MNZ RP-=DQ.65CMW,,8(8Y./T+'_!3;]DPDJ/%6OEAG*BT\-$\<GC_A+L]!GC
MMSTK[0^'/_!;/]ACPIX'\.>'-0\2^-GOM*L!;7+6NB>&)H'F,\\Q,$G_  F@
M\R,B8;'"@,,8YS3QLN+J5.G.CP/E%5N;BT\HJM)6<FX_\9LOA=W*R:7,Y2Y=
MY%&?#DVXU.+\Q@M5%O%)*Z=I17/PA"+:NKI.Z;5TKJ_X>_\ #@/]LW_GU\-?
M^%?X;_\ DNC_ (<!_MF_\^OAK_PK_#?_ ,EU^_(_X+J_L&'IXC\>'L,:#X9.
M?ICQMSZ@C@@AAP02T?\ !=C]@EL;?$OCILC(VZ'X8;(]MOC<_P"<^AKS%BN.
M);>'V42W2MDN(>T7)I?\9H]HIR:Z13;22;71R<-+_FL<P5E?3%T]$VE?3A/2
M[DE?JVM6VK_@1_PX#_;-_P"?7PU_X5_AO_Y+H_X<!_MF_P#/KX:_\*_PW_\
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M\?\ #];]@O\ Z&/Q[_X(/#7_ ,VU'_#];]@O_H8_'O\ X(/#7_S;4?6>./\
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M^&__ )+H_P"' ?[9O_/KX:_\*_PW_P#)=?OQ_P /UOV"_P#H8_'O_@@\-?\
MS;4?\/UOV"_^AC\>_P#@@\-?_-M1]:XX_P"C?93_ .&7$?\ T:!R<-?]%CF/
M_A7#_P"A,_ ?_AP'^V;_ ,^OAK_PK_#?_P ET?\ #@/]LW_GU\-?^%?X;_\
MDNOWX_X?K?L%_P#0Q^/?_!!X:_\ FVH_X?K?L%_]#'X]_P#!!X:_^;:CZUQQ
M_P!&^RG_ ,,N(_\ HT#DX:_Z+',?_"N'_P!"9^ __#@/]LW_ )]?#7_A7^&_
M_DNC_AP'^V;_ ,^OAK_PK_#?_P EU^_'_#];]@O_ *&/Q[_X(/#7_P VU'_#
M];]@O_H8_'O_ ((/#7_S;4?6N./^C?93_P"&7$?_ $:!R<-?]%CF/_A7#_Z$
MS\!_^' ?[9O_ #Z^&O\ PK_#?_R71_PX#_;-_P"?7PU_X5_AO_Y+K]^/^'ZW
M[!?_ $,?CW_P0>&O_FVH_P"'ZW[!?_0Q^/?_  0>&O\ YMJ/K7''_1OLI_\
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M++7/!_\ :M]+YVM^&)]:MIAI>K6MDUS?V$]JG5:W^S9<W7B&W\&?!WX@:?\
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M1KQC.4H8A1IJ4INU=J$80G4FY6B[*,*523=GI%VOHG\Y[?\ 9_S_ -]T;?\
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MSR_FG_X,F1[?]G_/_?=&W_9_S_WW4E%'+'^2'_@/_P!N'/+^:?\ X,F1[?\
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MW_DF>%_^P7.O_6DQY^=XC_D?<0_]A67?^J; #J***U- HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *0G _,#W/' ]3\R\#GYAZC*GH:_1#_@GU\$_"WB
MC6OB5^T/\5U^""?"SX : \/AK1_VEO&'AKP)\$/BO^T7XST;7!\(_A9XRUCQ
M;<VVEZKX:L(-)U_XF>.]#M8M4NKG0_">E:5>:9-;^)K7?%2I"E"=2I*,805/
MF<Y.,;U:U.A23:A-I3K5(0O&$W%*I-QY:;;$I2E&$%S3DW:-[:13E.;;<4H0
MA&<IR<E9):/F1^=N[D*!EB2J@<EF'8 <D\KD $C<OJ,J#GM^/4?@1P:_IS\'
M?L=? 3P/^T-^T,WCKX4_";5/ACK7_!1LWGAO3]4\ >$M9T'PE^S3\"OV7O'O
M[<GBO3/ ]M>:5-9Z'\,O&5MXV^$OP]\1Z-H'E^&?$7A^.Q\+:C8WFAV45C'^
M4_['/[(_A7]ICP3XC^+7C[PU\=;^RUO]J/X!?L_>%O"_[.NG>$;9=+U3XWS>
M)]9\;^)?$<FO^#O%&D^'O!_PQT%/#6H6"6]II>DRRZC:>'=2U+PY8ZK;^(M#
M\^AFM#$QJRA1JQ5#!X+&5WS<WLY8M45+#JFXT6JM#$5:E!QYYMQHRGHT[]^(
MR^IAYQ@I<WM,3B:%)SC;VD*"K3A7C.,Y1<:U&A[2_L[*4U!)77+^<A./SQ^?
M_P!? KW?]F3XS6_[/GQQ\'?%Z]TCQ%K-MX8T[Q_ITEEX1\2Q^#?%4)\<_#3Q
ME\/(]8\-^*IM(UU-"UOPY-XNB\0Z;J']D7S17FF0".$/(DB?I=8_\$K?#]MX
M \5Z]K_B#XDZA>:?X[^'6G_#GQGX7\4_"Y?!OQF\#_%_]K?2OV;_ (0:CX4\
M*V/AWQYKGA@?%CP_<:KXR\.^-_%_C" :3J.FW5N?A-XH\-Z?/K5Y[3XO_80_
M9_\ ']Q\2-(\$:3J?P6^&6F_&;]LGQ]X4\.S:3H6N_$KQ)\)?V&_#'PQ^!]Q
MIW@_XOZS\+_$/Q6\.Z+\5/BI\0;GQ[J6F:];?$GP_H'A?2M9\<ZMX7\>>+M#
MAU%(GFN"E"M!2E5BZ4XXA<LH^RHU:=.@[)/GE*O#'N,%&+ES0FDZ;IRFHC@L
M2JL(.#A4C4I2C)\K4:E/$*=*2;;@TJV$IR;?-%4W!R3]I[*7Q+\+_P!O?PY\
M*?B=9?$E;3]J?XT7<=A\*M/N7_:-_:1TGXF:_96OPM_::^!O[1-I8^$]>C^&
MVES:3I.M+\)M9\.75BT5S$^I^)[/Q! 9XM,FL]5YW]G[]N3PY\"/@=9_"_2O
MACJL'BE?A5\5?AAJ/B32=?\  UKX&\2:E\0M>U_Q%X=^*7C[PU-\)M0^)_C/
M7/ 4^KZ=H-OX.E^,FG>!IO#.@Q7FD:!H?B:_OKZY^LM/_P""97[-MM\5-%^'
M'B3XH?'Z1OB-^T?XN^#O@8V6D>%O!VK>!_!GPW_9>\'?'[XN^,?BGIOCCP!'
MJVI7_P *-<\8+X2O4\/>'_#NG^-]-TIM9L8O"::G"]N[X?\ _!/[X"_%7PQ^
MRQX7;PG\;/!7C7Q-^RU\'_BOXO\ %-CK.H1>%_C)\9?VH/&T][\//AM+\3KK
MX)?$OP/\%M0T?X;:)J&I^ --\0Z&OA;QI=:SH'@/6_%'A;Q5IGC'XH^)>:6(
MRQ152^)J1@Z2E4]R'-2P]2IB%91MS)3E*45%2>O)=I)&E"CCE%1IQC02E&I%
M2FDFZE)8>,DYQDG%TX*"4FEI?E4FY'+_ !@_:G^ 'P@\)>*K'X*S:=\0_&7Q
MK^+O[4WQ=\3V^A?%+7O'/A3PM??&>;]GC4/#?B+^V=;^"'P=U+2]+U#5OA=X
M@M=-^&&HVFK_ !*T7P_;VFI_$7QYINH76D:7:^7-^W_\*M/OM=A\(_![XR^$
M] \:?$_]ICXO^,H'^,7PB\=7.K^(_P!I/5?@+K6K^';GPK\0OV:?$WP@\6_#
M3P]<?!-=-M?!WQ+^&OBFYO9+_2?&EGX@T3Q5X<LI)O!O@O\ L]_"77+_ /;#
M\4?''7?BWX7^$W[)OA8ZMJ'_  KFW^'FM_$77/%>H?'#PU\*?"?@.9K^]U/P
M"NJ>)8[[Q#:2:WH^M:CH&E:QIK^(;2Z\1^'=)EL-:_0J[_X)'?"F;7O!7A/2
M_C)\2TU:^\1>$IM?U:R\)W'CO2/''A36_P!G7QO^TWXF\-_"2'2/ASX9T63X
ME>&_!GA?3M!\)"[^('BVU^*USJEQXNL_"O@FQL)?# F5/*<)"E2K^UG'DPM2
M-6<9NFJ53"PQV&4_8I0<</@H4ZSC*G.=.$4Y*4[Q6G+C\1*I&C%1:JU*#ITY
M4XSE7IUJ>"KNG)\DKSQ-=46U4@G-RL_9KG?R#K?[:7P&\;^ ]9^%GB_]F/Q)
MX>^%^HW$5SHG@WX,?%O0_ UMX/M]-_:I^/W[2&@>'/#K:[\)_&%BOAFQTKXU
M0?#>73AH5D]E'H9\7:''HA&BZ%H_C>E_M+^&?$OQ&_;!\;_&?P1XDU6P_;%M
M?$#^*-+^%'BO1/!VJ^$=9\0_M(_#O]I,2>'M4\8^#_'VGW>EVVK?#R'PTEIJ
M>DO>7&D:C->B_&H(UR/LS6_^":WA37_A.OCOX6:9^TI!X]U_X'_LZ?$'PQ\&
MO'-IX5U;QII/CS]JC]I'5O@_\,/#7B=/#?P^T.6Z\-:5X!\"_$7XB^(M;?3?
M!TMQ8CPQJ+-X=LOMNG7OI7B?]@_]G7P9X%^(.C>*_'/CG3_A%X&\>_MZ?%-/
MB#I'@#X.:Y\;]:\!_L<>)?A+^S-H6CZ9XSN_".B:KJ6D?$/XZ>/-<M-,^'\/
MBS0_AK?&PTK6GM]&\36U_P"(5J%3**$*W)ST^:E4P]2G[1\U+#Q5"=>?\:LD
MX_5Z,:?)SSG5I*E!Q2J2".'S#%SH.$55E[>%:G))OV]=S4J*4.2DY1G+$ISE
M)0A&G5=6I^[C-P^*%_:[^$VK>']%^$7BGX)_$.[^ 7PYU+X&Z_\ "#PUX=^,
MWA[1/B9H^O\ P-UCXW^(#<>//B%J/P>US0_%4'Q-U[]HWXJ:QXGM]"\"^$I/
M!UW<^&;?P?<6\.DZI!J_L-G_ ,%.+7^V_"WQ$\3_  /A\>_%?3/&^J>)I]8\
M6Z]\.=1TCP/IGC+4_B#)\4]&^!.OZA\$[OXQ>#M.\9>'_B#JFBZ-X&^(OQ7^
M+7P7^'UYYNLZ'\,M6>+3M,T+UJY_X):_!_Q#X6^%DW@SXQ_$7P[XG^,^I_LE
M:MX'U'QUH*>)/!P\,_M<^,+R'1/ ^J7'A7X>Z%X?3Q]\//AK+9^)I/&B_$Z+
MPW\4O&/AWQSX)T+X?^"OL>E:M/X[^T]\#?A#\+?V</V:O!OPW^$_Q7L/%OQ_
M_:S^/-_#J_QP\.> _#G[1E[X!^$=SX ^!OAKP98>);'P?I\GA[P-X^\1Z_K'
MCK2O#FI:'J6D:+XUNKF"]/C-/"=EXAU>XO*\5B882-&M5Q-7&+#3P]24H57*
MK7EA,7]8<Y\J:J2G2K6DVJM&3M&E2C7F1CCZ-+ZU!PIX:EAY5(U*2@J<*5/#
MK$TZ=*+@M)0C3Y8I-/F2=1592IQ^>?$G[5NFZA^T3^S+\8M-\+>+;SPI^S+K
M_P *M4T3PCXP\0_#P^(?$=GX ^,=[\9=:LOMWPP^$GPM\ ^$H/$6K:OJ%C:6
M.B_#GR=-227Q+JDGB37]6UF:]]+'[;F@VGQ!TSQZGB7]NCQ7) OQ"T]].^*G
M[4O@?XG:9H&D_$+2[NTOK3PIX7\;_ KQ-X!U"RDNO[)LO$7A#X@^#?&'@;Q=
MX6M)])U31+;4[?0M<T3[@\=?\$WOV:?%_P ?=7\+>"-+_:"^'_@+6?VC_B9^
MR=X:N_"QT#Q/X1^"LO[-'P?\/:Q\2OVBOCWXJ\9Z&;V3PWXZ\0W:^*[#X=RZ
MYX.FG\-KXO\ &VB?$Y--N_#G@#3?BS]AOX._"#XB_"#]H:X^*_AG5O%EYX]^
M+/[&W[+?P;U/P1;^%H_&>F?$/XT_&#5-:U?6?A_XI\<^&?$>G>$;F?P7\.[J
MRU;68_#U]JUYX0UW5?#45M;1^))[R"*-;+*U&-2E&HYT:484X2J4>>=/'X["
M0E"?*Y+FG7S"AB4Y*A)4I.U65.%6-)588JG5<9RA::O4G!.<:<L)A:U?GCRQ
MB[4HX.M3G>59.<5)THN5-U>1^(O[6'P)^)%GIPU']E^\\/CX:ZW\2;KX*>$_
M WQ.TGP!\-;+2?BG#X0E\2P?%7PAX+^%NB2ZU>S>+?#^O^.-0M?A#J/P<\(Z
ME=>+9?!T?A+1O GA?3M'7WOQ/_P4U\#:MH=_X<@^ &OZQX>EU_XA:S;>&?&O
MQ ^'J^%[71?B%\9?V5/BS>_#6QT/X3? [X4Z/HWP]TZQ_9JF\&VEG96,_B'5
ME\=3^)M9U[^V+":RGO>)O^"<7PS^'WPC^.GQ8\?^*?BOI'A'X5ZQ>^(_"OCY
M-=^%XTCQ[\);K]JO3?V?O %W#\/M,T+Q+KVBZK\2?#\'BOQ!I7C#Q1XU\*6V
MF^)-$%I8_#'Q5X:M=0UI^WUG_@EG\)_!7Q4^+/PC\8?%GQO>^.OA+X6^-OQV
MU7PAX;U3PP^I2_L_Z-\5-%^$_P"S9IFLZEI'@'QW-X9^(?Q<36K;XN>.O%-K
MX5\5Z9\-OAC>^&(YOA5J&K^+(;O2%3J9,HPM5ERTOWE.,.><%&&'PV+J3BH3
MG']U0CAZM:3DG%.$>:527LE,H8YNI"23]JYX>H^2GRMNI#"R@Y<L5!RJSA2B
MTE+F:FN6*=6/BWC3_@HEX,\6>&(? C_";XC7?AZW\$?'?P?!>:Y\1?A5;:W:
M#XJ?%7]F'XQ^%!I>F> /@)\.OAWX>\+^ O$_[-]CH>H^#]&\'1QZ_P"&?$U[
MJ-EKVFZYNDGR?$/_  4%\%:[\2]<^.)^"'B:#XNWMC\4OA]HUTWQ3TJ3X?6?
MP:^*?[1_C7X]WMKJOA _##^V]1^)VD:-\0?$?P_@\16WB^R\)37/]D?$:^\%
M/KVF7FE:A0T3]B'X>ZO^VK^TM^S[I7B_XK^-_A%^SC\+?C3\6]5U_P +>#3H
M7QFU32?AA\/+'Q%:^#D\'^*?#0@C\;6?Q \0:)\,]=@N?#VFVNL:E::C?Z1!
MI%OJ%B++W;5/^"<O[//AF+P]J?CKXB?'CP2GQ:\:?L8_"+X6^"=3@^'<GBKX
M=_&S]JOX8^(/'GB'P+^T)KM]X?T"PTW3O@]9W?P[\;^)M>T#PKHVN)X'UUM"
MNO!$'B;7M/U;P_K2_LJ@\,J*JTW.E2JX=P55S<<1[.G33@ZC;E7]C!<LE+GY
M7)OFG-S56.+J/$>UG3JJ-2I"NY.G*$91A4K5';D24:<*E23E!)07NI*,(QC^
M=?Q>^/=I\3_#VG:%;^%+G0ELOVH/VI/VB);F;5X[]YXOVCIO@I)%X5FC32K(
MB]\*#X47!OM==FBUJ37X&_L_3/L;BY][^+O[<^G?%'QKX_\ %J?"[4-%;QE\
M%OVN?A/!93^+XKV72I?VGOVK/BK^TQ;Z[]J_X1NT2[M_!]K\2[7PA?:6L=FW
MB"XT=]:CU#1H;NUTM?KOQ+_P2D^&VH^.'^$/PJ^(_P 3IOB]X@\"_M(2_#/P
MY\1["U\.Z'XL\;?L]_%3X>>#?[>OO$^J_#/P7I=CX+\5>&=;^(U[X@\'Z/=:
M[K7PK\1^"$@U'XB>,-,EF$U&S_8F_9Z\0_!36]3^'OBSQ[XY^%MCXN_:Q^-W
MACQ3I/PX^&-Y\>OCS\+/V./!'PE^%^O1_"/Q:/ =UXI\,^&OB'\;_B-X@UG1
M?#MU)XC\$^&_ASH@\7^+O"_B;Q]HMYJ%UG+%Y4\/3482E2I*G4BG1J*:PV)H
M_5Y8B-KRG#V&!C&,$Y351*]*E4J5:BU5+'RKN4FW5E4C34XRA&,L11QE;&QH
M2UA#F>)KUJDG+W'2E95*E&%.DOSN\%?&?X/7/PZ^&_P^^/GPE\=_$F#X*^(_
M%NL_#NZ\ _%;1OAM;ZKX8\<:S8>*?$?PQ^(UKK7PU^(,]_X7E\9VMWK6G:]X
M/N_#'BW3[3Q;XPTJ2ZOEG\-7?AWZ!^'O[>?@CP)XL\#?%A/@1?Q_%SPYX1^$
MWP>UI= ^(MKIGP=?X+_"?]H+P-\;+#3/!WP\U+P%K'BS0O'$^@_#[PW\-+75
M]9^)/B?PYIBC4?'<_A_4]>NDB@^B;?\ X)/Z=K'BK0-$T'4OC1++XX^._P"Q
MC\*+#PE)H^A:AXX^"]I\=_@_??'O]H'2_CN-/\+)90>*?@1\-(]-N;;6M/TW
MPOH$]UJEG=:WHJB:;2;',\/?\$U?AYXN\&?#;Q9X&U#XRZS=^,_CC\$O"VIV
MGC7^R_ K^#_AI\>_VA;KP#\*=>U;P1XD^&?A>X^)/A?QQ\)TTWQAI?QA^"_Q
M1\5Z7>>([G5].O?A9X;\-Z)J>N6O3/%Y8ZRA5K.$JV+3E!5)QA&O5K1IU)RA
M3<Z=*G&I43JN,71C%\\%.FE)X/#XNG1514J<X0PZG!J-.<Y4?9SQU.G"3BJD
MN?E]I3I-\WM_9WA"JH\OREX+_;-TOPA8>!K5OAK>7TO@SX9?M$_#UKI/%EG;
MMJ-U\=OV@K;XWKK7ER>&IFME\-I;GPU?:?,+F;Q#=RMJGG:>5;2F]7T[_@H+
M\//"&O\ BR3X?_ _QKIGA'QS\6/''QX\1Z1XM^+FB>+/$"_$WXD?M!_LM_&/
M6K72/$%A\,?#%M:^"M,\._LQ:;X/T33+K3=8\476J^,KWQ5XG\2ZQ'H>G:0?
M2OVG?V4OV?=3\,?&G]MO0]8N/ 'P)U+QA^TEX \#?#GX=:9\/O"FE77[1'AS
M]H;QO\,/V??A3\._#VG>'+?3M!^'%]\&/"]I\;OBA*NFZEKFG:+H^O#2+F"Z
M\5:1)IK?@/\ LY>!?'7[''P2\/6OP>U77O'_ ,=]>_:B^.7Q3^*=G?\ [/MC
MXM\+?L\?LOZA\/\ P/#:^#O&7QB^&.LZ_P#"OPMKGQ#U@63:C\.?$DOBNZUB
MW\:7&MZ!\4?#6M6_@3P]Q0JY;4PU+%1P^)4:2PL)455]G&C*O35>G&3G%.4Z
M5'"4J\X*,Y)QI1D[U6EM5^M*I*E.JO9U_K52,VE.57ZNZE&M[L;\JG6QV(PT
M7SJ-YU7%MTHM^ _#W]N'PGX1\,:CX;U;X3^)+C4)O&7[1/CS1?'/A7QCX M?
M&WA'4OC=\1O@7X[5/#$_Q%^$'Q3\.Z1<VEK\'KSPOK7BY/#+>+GMO$UOK7@S
M4O"TVG7T.M^L:K_P4_L9O&_BCXG:!\&+W3O'=UX_^*OC7PC'JOCVTU?PII:_
M$K]I[]EK]J:*Q\26,?@JRUK7+G1O%/[.<_AF>_LM5T9=6T/Q9;7SZ?I^JZ2%
MG^Q_A'^P3\%?@;\6/$VF^.;?3/B3\/?!_P"U!X1LO%N@_%#X>_#;QQJUAX*^
M W[#6M_MI_&+PQJ'B;6/ UAJG]F0^+_$_@#X4>*?^$5LO N@?$6Q<VGCKPC=
MVMK;Z5:>4:;_ ,$F?AYXJOOACH+?&/Q9I_C[QGJ_PKUCQ7?^&/ ]UKOPY\3Z
M;\1O@'XX_:<\<>#_ ():5HWP]TK0]&\4>#O _AC^SOAS'JOQ+\5V'Q*EFN[B
MV\,>"X]+_P"$?85;)8M5N2*H0I4Z=.M><Z;A"FZS34.>,'36 A%7;DY2LDXU
MYR5..8U_:1<I*<ZCKU*=1*C4YN6I[WO1IQE#_:9Q2A3@G>-TW34E\!>,/VH_
MAPOP,^*O[.OPG^$OC'PI\/\ XF:'\09#=_$'XFZ%X_\ %>E^-OB7\;?V5OB?
MKMX^HZ%\-OA_877A#2/#7[+'AKP7H>AQ:;_PD%[J7B+5_&'B#Q!?-'!H\%0?
MM;VJ_MB>-?VH9OAO::YX9\=Z_P"(K[Q1\'/$6N)>:9KWAW7](@M4\-Z]K=OI
MD4%W::7KMAH'B^WN1I"1_P!K>'M%4V\<D6:]^^.?P*^%<&F?\$SO@?\ #[X3
M_$7P+XE_:(GUGXB>,4^(UCX)T;]HW4/#WQT^-FD?#+X;>&_%/C.P\#6-A?6&
MBZ#X&U[4O 5UJ7@F71].L/%SZS)X5D:\U*VN/KKXA?LN?L:>(=-\2_#32OAK
MX\^#6E>+OVI/V]?$GPS\;:*?"NO>*O"'P7_8-_9ST[1+^]\4>+_'/A"[^(NM
M?"[QG\0-%UWQ#8?#..^LM4U;6?%2^(M8^)EQK_A&PE\1[JO@,-2E%4,2XKV^
M"NZD95:>'HPHY>ZBFI*47+V'L<.J4IR@L%[M95'*=2(TL77J^R]K3YU[&M-*
M*Y/;U<76K15DHN3=2*K5G.3A)580]G[%N,/CGPC_ ,%,-=T;Q5\/O%WB7X:R
M^(]5\'_\,I:QK[1^+#I\WQ!^(WP&^*UC\2_BC\3_ !-/_8&I2?\ "<?'J32]
M)L]=OTCN/[$U+1=/U&\3Q#%&;1?GSQ)^TSX8O_"GC/P5X9\ :_I^A:]^R-\(
M?V4?#MWKOC#2M5UG1])^$GQ]\&?&.Q\6:W<:?X8T2PU*[UW3_!\?A^^T;3;'
M1+5=9U&;Q E\;2-]-'OW[5/[!O@#]F[]GNT^(2?$KQ1XB^)&E7/P$L]9G31[
MZ^^$WCO4?C/\+[WXFZSHWP_U2R\ Z;8>'9O >F#3+G2[W7/B=XRF^)GAYM6U
MK3M$\(76FG29>V\)_P#!.3P1XC\0?L]_"._UO]H31/B)\;-._9JUZZ^.Z> /
M"FH?LEZ-)\?_  MK/Q+O/AG9ZI=WNB>)K[QSH7PTTV(^"M=T7Q3XJM?B5\3%
MO_!5QX'\#:-!#XMEVY\LY9U>2T7BJN$DXPJ13JT\/'&5N6.C]E3PL85VXJ/[
MI1C3I3J)43.7UY<L9SYFZ,*Z4I0G:G4G[*DY-QDN:K6K>Q7,_>JS?M90@W67
MSG\"_P!KGPQ\%_A]%H%MX'^*4FNIX9\<>%_%'A/PU\;E\._LU_'V'Q;;^(K+
M1M7_ &D?@/JO@'Q3'X^U7PE9^(UT6XF\/>*/#'_"4>%?!O@C2"/#.LZ==^)M
M1][^$/\ P4A\ _"WQ;X#^($7P,\<'QAX43]EVZU_5- ^)7PXTN3QO/\ L\_!
M+P5\"+KPG?ZUXB^ _C/Q5X;^&OB?1?A_HGC2/P_X,\1>&]<OO$6H^*]"\8^*
M?$OA>Y\,#P[LI^P-\#G^&=C\>+M_VH_#'@O5?@]J_C6R^!GBH_#;2_VA(?&F
MH_M5^"?V:_@I::UJESX)M- T/P3\=SXB\1:WHEW=> )=8\+S^#/$\VG/\2M'
MT>VN_$7T=\-?V"/V;OAI^T1::]HUE\5_CKX,^#7Q8_X*"^#?'7@+XE>"_AWX
MXM/BEX9_9*_9\M]1;Q+X2\#6/AZ&POM0TCXW_$;PGX!T_P />))M?TSQUXA\
M,6_B-+/PG%JD'A.PY:]?*JU+$U)T\3-2I5ZM>"IU4E[*C7YH5*JE*,).-.K3
MC",JCYN2C3M*I1INL/2Q<YT*5*I3]]TJ5).<;SC5FFO9P?LIRY92@VW&"4JM
M.4I./M*E+X&\!?MWV'@?Q/K^OI\*;G5[/Q-\%/V3O@;JVF3^,XM+GF\*_ #X
M26WP;\;3V.KP^%KM]*U?XA^&)/$%]X0NA9W,7P_U^]T^\O[/Q4-/O+*^[CX;
M_M^?"3X2P_"W3/ OP+^)FG:=\%_"/PJ\/>!_$=W\6?ACJ?Q+O5^''QE_:&^+
MFL^'];\8ZS^SIK5EX<\#_$V\^/4%MXE/PJ\-> _B!I?_  @>@Z=8>-;K0M1N
M88?I/X=_\$WOAM=0:=X:M]7\=Z7;?M"#_@GYX0L/#WQ(\(_"OQ)\9O@AK7Q\
MN?'_ ,8/CEX7U'Q=J7@FTC\*^//A]\!OA4?'%CK_ (8\-^ _$.J>&/&^F:%X
MT\-KIMQ?V.H^:_#/_@G/\*OC+;_!GQ[\+A^T)X@^%OQ&\#WFN>(K#Q!XR^"O
M@KQCX<U/Q'^TMX@_9^^">L3Z[+X0\00P:3\6+?P1XY\36_@SPS\-?B;K^BWV
MA)I5UXH?2+U?%$-UJN73G5]O[:G&\')RE&FI5%+%>TC.\U2]RL\1"ERN4:JG
M>+E!)TW)8R5*3C.4HSC5G45)5)+V#HT94ZL(QIRJQIU,/2IR:<(2IS@DHQG*
M+J?-?CK]L7P+\3_$7C>T\9_"7Q9_PJ[XF? 36?@=XLT3PS\0]#T'QQ:6Y_:U
M\2_M9^%_$OA?Q1J_P]\0^'M-_LGQ)?>'/"VN^']4\(:IIFM:39ZY=PW-A>WV
MD7&BX-]^U9X(\1_M.?'OXW>)/AGXP@\$_';X9^/?A?>>"?#WQ!T9?&/AC2O&
M_P /=&\"?;K+QUKW@?4M$U>\TI-,6\2:]\&16]_-(T<BV4LKB3]"?"_['7P!
M^$V@Z9JD7A;7O'^L^ ?%W_!3?XQ^(_C'XPT?P7XX\%>(O@3^PMIWBOX3>"-"
MO?@YXX\">*/AM>V_Q%^)ETNI6EOJ4E_J46LZ'JVNO>7NGW?@71?!O*6/_!)[
MP/)\1])^#\WB[XV:3J_@S]HO]G/X$>/OB-XDTKP]IGP]^.=K\4_AOKOQ9^+>
MO?LS)=^&!J.G_P#"EO /AVZ\27&L>+-:^(NF^(O#6IZ7XKO+70H)XM(NHHXS
M*J<E&%.I0C.C*C3J-M0JTY4J4JKC&,G&FZ4*E"#E.ISN4H1I0<:4YTG7I8Z;
MJ.JXSJQK2G7C;E<9PJUI+FA.R2YJ->3C"FH-1GS\JG"$_B\_M1_!FY^&-W^S
M1?\ P;^)TG[,4OAW36CTNR^,7A6#XW3_ !0M_B+-X_U;XC:AX]N?@Q>>!KFT
MU^SEL_ %WX%@^&-O8:=X:\->$]?BU27Q=IESJ>N^Y0?\%+/#FK>(+3QMXZ^!
M%]XR\2Z7\=+7XP^%=$U;QC\/M8\%?#-[?]H[P[\>!J/PLUO7_@MJ/QQ\ >,6
MT/2]6^&^JP>%?C%IGPM\=ZCK^M?$WQG\-_$/B/7];T/6?#?'7[,'PMUCQ/\
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M<FF>$M)O-?\ #%SJ*>(])3Q)?Z=;Z7>\3^T5\1/A5\+V_8U\+?LO>)EU._\
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M-EJ?A_4/$T7BKX;0:]\0?$*?$#2=4\ ^/-%M+2S\'>%=1%[;^(?%WB7@)/\
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ML_:4ZLI0]U4W3K2YJD8SFHTO90K34HN,J="22JPJQIXK\AHU$4<<:* B(J*
M<@!% P"220H!Y)R0-Q/4AX;/09Y(ST'!(/<G@@@\=01Q@X_?OX8?\$[?@+\,
M_CYX9\0^,4^)GB#P#^S[^TU\:/AW\9/#O[0/A#P<GA+]H'P;^S=^SAXN^-_C
M;XJ_#KP1'I,,]K\)5\:^&=&\#:EX=\477Q-T;6=#\;^$+V?QJ;_4=3\-65S6
M?V"_@5\2]?\ V=_!OBO0/%GPS\3BS_8G_9@\1Z9\$-&^&?@Q]=^/'QL^"/Q
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M !1110 4444 %%%% %[2O^0MI/\ V%-/_P#2N*O]);]@S_DS#]F/_LB_@/\
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M7?\ S7T?\0XVI?\ 19/#'_A/>+O_ )KZ_J\P/0?D*,#T'Y"C_7?B3_GYDO\
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M7?\ S7T?\0XVI?\ 19/#'_A/>+O_ )KZ_J\P/0?D*,#T'Y"C_7?B3_GYDO\
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M/K%U875O/JL[O-?R7$KLY_J)P/0?D*,#T'Y"F^->(GO+(WJWKPKPV]6K-_\
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MR7++6+24\PTYE=2LM4O,_$#6/^"47BOQ#JEMKGB'XM77B#7+)84LM;UWQ/\
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M=^).93]IDG,GS*7^J_#G,GR\EU+^SKI\ONW3ORI+9*R_U7RFSC?-.65^:/\
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MX8_\)[Q=_P#-?7]7F!Z#\A1@>@_(4?Z[\2?\_,E_\1?AW_YWB_U5RC_J9_\
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M_A/>+O\ YKZ_J\P/0?D*,#T'Y"C_ %WXD_Y^9+_XB_#O_P [P_U5RC_J9_\
MA^SS_P";C^4/_B'&U+_HLGAC_P )[Q=_\U]'_$.-J7_19/#'_A/>+O\ YKZ_
MJ\P/0?D*,#T'Y"C_ %WXD_Y^9+_XB_#O_P [P_U5RC_J9_\ A^SS_P";C^4/
M_B'&U+_HLGAC_P )[Q=_\U]'_$.-J7_19/#'_A/>+O\ YKZ_J\P/0?D*,#T'
MY"C_ %WXD_Y^9+_XB_#O_P [P_U5RC_J9_\ A^SS_P";C^4:'_@W,U2WGAN(
M_C-X666WFBN(RWASQ:X$D,BRH2C>, K?,HR&!##Y3@'(_I/_ &>/A;??!7X'
M?"GX27^L6_B&Z^'7@7P]X2N-<M;)],@U:?1M/2T>\ATZ2[OWLXY70R+"]_=,
MNX@R'  ]IVK_ '5_(?X4H '0 ?0 >W\N*X<UXES?.<+1P>/JX)X>CB%BHT\)
ME669:GB%1^K^TF\OP]!UG[!NDE6YE&#?+9MWZ\#D.79=7GB<+'%^WJ47AY3Q
M.8YACE[&515G""QN(KJFO:QC4_=J+<DN:]E9:***\(]@**** "BBB@ HHHH
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M,CU'YBOSD_X>>?LZ?]"Q^T5_XCI\4O\ Y24?\///V=/^A8_:*_\ $=/BE_\
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MYR?\///V=/\ H6/VBO\ Q'3XI?\ RDH_X>>?LY_]"Q^T5_XCI\4O_E)^M/\
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MTTU8G"YUD?\ $GFV7MVNH*KB&X_XE'+Y23VZ)/6S=K'Z-J%4!05 &  N
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M_P#?@?ZQ9'_T-\M_\'U?_F(_1O(]1^8HR/4?F*_./_AY[^SG_P!"Q^T5Z?\
M)NGQ2Z^F?[$QWI?^'GG[.?\ T+'[17_B.GQ2_P#E)0^%>*%OD&:K5+7"+=I2
M2_WW1M-.SL[-,/\ 63(EOG&6+UQ%3_YC/T;R/4?F*,CU'YBOSD_X>>?LY_\
M0L?M%?\ B.GQ2_\ E)1_P\\_9T_Z%C]HK_Q'3XI?_*2C_57BC_H09K_X1I_E
MC&'^L>1?]#C+?_!]7_YB/T;R/4?F*,CU'YBOSD_X>>?LZ?\ 0L?M%?\ B.GQ
M2_\ E)1_P\\_9T_Z%C]HK_Q'3XI?_*2C_57BC_H09M_X1_\ WX'^L61_]#?+
M?_!]7_YB/T;R/4?F*,CU'YBOS5O_ /@JC^R_I2VKZKI?QZTQ+_4++2;%M1^
M7Q(L5OM5U*XCM-.TNR-UI,0N]2U"ZECMK&QMS)=7EQ(D%O%)*P4W_P#AYY^S
MI_T+'[18Y(P?V<_BD#D'!X.A@_X]1Q3_ -5.*+)_ZOYM9WL_J3L[6O9_6[.U
MU>S=KJ]KJZ7$N0MN*SG+')6;BL34<DGS6;7U.Z3Y96;2ORRM?E=OT;R/4?F*
M,CU'YBOSD_X>>?LZ?]"Q^T5_XCI\4O\ Y24?\///V=/^A8_:*_\ $=/BE_\
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MDU%-/DE&3N5;-:=*K6G7FHT'+VL.>//R4X>TE*-J;C*_P)1;;>JO+W'^C_\
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M8UDVEQ\&(\E=V"2B<CE0>*_IR^+G_)*?B=_V3WQI_P"HWJ5?Y:6E?\@S3_\
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M)WLTW@\PQZA2J?69N%9-TY*-&2DE*<6_=@W&TJ<XOF46G%JUS_0O_P"":O\
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M7SU\3/\ @O=IGQ$^._[,_P :U_90O])'[.NH?%R_;PXWQJL[U_%A^*7PXO/
M*PQZL/A7:KHHT8W?]IRR/8:L+Y1]D6&U8_:*\.^*W[$'['_A7X_Z1\!/"VLK
M=ZA%:?%74O$4FC_ME^ _B%\7K*V\!_L>?%?X^647B_\ 9^L/@!X=U3X56ESX
MT\+^&+.\U74_'7BB"30@^DI9"Z\66.JZ'X%X-_X)A^*/&WQ>U7X(:)\<O"#^
M,_#_ (8^$]_KVHW7PU^)]KX&TCQG\:O =O\ $GP#X&O_ !R=-E\,6]U>^%+J
MWGO95U2?Q#)J;W.F^%?!OB]-$\37NA<>$7#^%=7$T*?U5O"9A1E6K3DT\-7P
MN*P&.Y%&M6Y9>PK5X1=6"J1E:=*,IQC?IQ-',:\*5.I4^LP]O@,0H*\%&K3K
MX;'8)R?+",E[:E0G.*J*'+S0J2C%R/US'_!S-I@ '_#%&H^^/VA+$#/X?!@#
MZ  #L!2_\1,^F?\ 1E.I?^)"6/\ \YBORG^#/_!-[2==\8?#JS^)7Q;T76(;
MK5_@18_%WX8^ K#Q-I7B_P &)^TG\ ?B-\??AE;:=X]U_P .W'@[7[B+PKX-
MT^3Q%)H%GJ]K;ZA>:EHD4ICLK?6=0\F\(_\ !/S7M?;1AK7QV^$7@+3M0F_9
M.M[WQ)X^N+CPOX;TN3]K#]G7Q9^T/X7@N]:U2]M]+@U#2--\)/X$M+;4+[3K
M#Q1XUUO1+:/6-%L[BXNH%_9?#L>=/#Q;I\W-S5,9S-\\DTESJ4Y<SDDH1DWR
MOE4N65B6(S5;SJ1LM8\E%<BBFO>C]A6I->]:[M;XHW_;#_B)HTS./^&*=2[_
M /-PEEVSG_FC';'-+_Q$SZ9_T93J7_B0EC_\YBOS \%?\$X/"^E6/QU@^-/B
MS4-)C^%UO\</L7CO3+?Q?H(3_A!/V2+7]H[PCXBO?AYK'@2]U+7_  M9?;8I
MM9F\*:]JR^+H[.XL_ &LZOX?GTOQQ??-GA+]BF]UO]LKX=?LGZS\8?AEI&F?
M$#4?@OJFE?%;4-5N_"FC>)?A_P#&G3? /BGPO/X,TCQ=IUCJE[\4-=\(>/\
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M+;XG7#>#/%FBV?BS7+.PN=K3?^"EW[1VA?#V]\$^'].^%^@>(]:\&?"_X?\
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M%_M ^)_A_/H/BBR_8U\!?L;Z_K?CV+PQX#L]1^)_A37-!^'.A>.]-\!6.O\
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M;7],%?G^>?\ (UQG_7R'_IFB?599_N.'_P ,O_3E0*_@<_X+M_\ *3#XP_\
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M&D^)?#/2/^"C&IV[?#WQ1\=/B)^RIX6_9W^''@_XK:3+^U=XL^(_P \)^#O
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MN>A^A_E7]5'_  ;%?Z_]N+_<_9E_]!^/]99__P B?%>N'_\ 4JF7E.F8T?\
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M_P 4O\/[70H9-4M8/$G[<_Q8\7_##Q/\,O$.@_#O4+7QAX,^+GP]U3QQ??\
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M/_!/'_HT'X&_^$)H7_R#1_K5@WOA*[]:F%_^2'_8>(_Y_P!'YN;_ #;/\Z3
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M48'H/\__ *S^=?WQ?\.(O^"8?_1 -?\ _#]?M#?_ #TZ/^'$7_!,/_H@&O\
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MZW_@GM:WVNEE;M96M96/['QW_3G_ ,'2_P#D3^-+'?\ SZ4;1Z ?0"O[+?\
MB&U_95_Z+?\ M#?^#'X>_P#SN:/^(;7]E7_HM_[0W_@Q^'O_ ,[FC_6'+'>[
MK.Z:?[G=---/WM4TVFGHTVFFFTS^Q\?_ -.?_!TO_D3^-+ ]!^0I:_LL_P"(
M;7]E7_HM_P"T-_X,?A[_ /.YH_XAM?V5?^BW_M#?^#'X>_T^'-/_ %BRS^:N
M^O\ ";[OK)ZZO[WW=S^Q\=VH?^#7_P#(')_\&S__ "0W]J/_ ++1X5_]5[IM
M?TP5\&_L%?\ !/[X6?\ !/WP7X]\&?"_Q7X_\6P?$/Q79^+=>O?'NH:!?7%O
M?6&CP:):V^EC0?#?AU+>T-G;K).EVM_.]RSNMPD96)?O*OB\SQ%/%8_$XBES
M.G5G%P<ERNRITXZJ[MK%GT6"HSH86C1J<O/"+4N5WC=SG+1V5])+H%?P.?\
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M=_L,-&C'X(S%F7<Q_P"%M?'898LVYL+\4P/F.221N9LLQ9B33_\ AUS^PO\
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MB+_ZF?AROVO\(_\ !$O_ ()N>!O%OA7QOX<^!.MV?B/P7XET'QAX<O9OC?\
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M\#^!W ]!^5+7]\/_  XB_P""8?\ T0#7_P#P_7[0W_STZ/\ AQ%_P3#_ .B
M:_\ ^'Z_:&_^>G2_UIR[_GQC.K_@0W=DW_$W=E=];*][!_8N)O?VN'OWYI7^
M]QO^)_%_^PY_R>[^Q?\ ]G;_ +-G_JYO!=?Z7I^^O^ZW\TK\K_A__P $7?\
M@G/\+_'W@;XF^"_@;K6F^-/AOXP\->//!NJ7'QJ^/&JP:5XM\':S9>(?#FJR
MZ5JGQ+O-*U1=-UFPL[T:?JME>Z7>F 6^HV-W9R2V\GZG[3M4;B&"XW8!.=I7
M.",9R0V",9&"*^>SG,L/F5:A4PZJQC1HNE-58<DN>56=71)R3CRR5FF[OHGH
M>QEN$JX2E4A5<'*=3G2A)R7*H*";;2^*U_*]C_+M^-W_ "7#XU_]EC^*7_J=
M^(J](_8^^,OAK]GS]I;X4?&#QA8ZY>^&O".I^((M7F\+QV4WBO08/%7@OQ+X
M+B\9^$X=2N+6PF\5> [GQ'!XT\.07-U:)-K&@V<2WME(Z7D']I7B+_@A7_P3
MI\4^(?$'BC5_A;XOEU?Q-KNL>)-6FA^,7Q>MHIM6UW4;G5=3GCM[?QO%!;I/
M>W<TJV]O'%:VX80VL$$"1Q)D?\.#_P#@FS_T2GQIZ\_&GXR'D<@_\CWU!Y![
M'D<U] ^)<LG1="I1QDZ<Z,J%1>RY>:G/#QPTTI0K1G!N'.XRC)2C)Q:DG"[\
MEY1BN?VD:N'4E556/-*32E&K3K0NE'WDITH*2VE'FBU:33_G"_9\^-?[&'PD
M^*WAZ7XJ_M+_ !Q_:B\&?#[P9X4TK1+SXM_L_:#KOP_U"WO_ (SP^+/B=X$\
M->$OBEI_QS^(/A*RO/ ^V_:?0Y_ARWBOQA<:Y9ZQX\TSPQ?BPU35\,?ME?LZ
M^&?[;\$>!/$7A#X4>%-2_82U/X/:5XH_X95\+^,K&W_:5O\ ]I*P\80>(_&V
MAZEX)U#Q%\1/"MI\+_#7@F4W/BB#Q-IFARZ/#>Z5X1U/Q=;Q66H?T3_\.#_^
M";'_ $2GQGTQ_P EI^,G0YX_Y'OIR>.G)]31_P .#O\ @FQC'_"J/&>/0_&C
MXQD<<C'_ !7?&#T(Z=JX)9KDU11559I-<G).*A0I1J)UH5:DG"C&E34I6G%6
MIJ*3BFG%2C+K^I8Q*T98.,E-U8U).K4J0J*A[&#4Y\TN2/+3;AS):3<>6=1R
M?\Z7CO\ :?\ V"?$&C?&FU\!_#+P_P"#]"\5:G^TX;7X<W?[/7A";Q!\3/&G
MQ)B\$VO[-OQ1\,_%4Q7E]^S_ .$O@SXATO7_ !?J/PUT?7M)L-,L99M)TCPU
MXO7Q;J5EI/M/[2_[2?['/@WXA?M4?#.ROO#&I:CK:?M>?#'P_P",/@C^S]X%
M\!:5X3^%_P 0=9^ 5MX'^"D4_A&PTWP[\67L]9\ ?$KQGI'Q$UZYU'P_Y.JV
MD6KZ]9S^+-;TC0OW$_X<'_\ !-C_ *)3XS]/^2T_&3T _P"A[] /R'H*0?\
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MB9\3KJTO(M!\&Z!X=\*WS1?#/5/AUIJZYH^FQI<PZ;;Z==SW%]8W'D?V6_\
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M/0#M]2.O;UI1(I .#S]/\:+_ (.W]+?YVMY] _SM\[)_DU_6@^BF;QZ']/\
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M;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0?$[1+/]NCQQ\%DT?P1ID7PX\9?"_P#8&\9VWA/XBR>-[ZXUR3Q%X?\ '/Q
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M_P U!_Q&WQ7_ .BZSW_PHI?_ #,?N%_Q$ ?M[_\ 0V:7_P"$S\+/_G3T?\1
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M** "BBB@ HHHH **** "BBB@ HHHH **** /C/\ X*$_\F6?M*_]DMU__P!
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M^S9KW@^W?0OC1?\ PUU(ZMJGB%-3_MG1OB%J%IX<OK.^L9CK7V,3:K+\0_\
M@E9X=^'UW\;]<D^-NIZU\-_V7M3^/%C^T)XI'@O2])U#PI+X1^&_P\^)'[/%
MAH.BOXNO3K&I_'^;XG:#X$6&\FTN#0O%/A[QI+ICZII6G1R"Z7BWP155%_7<
MQI+$13H2KY%G%"-:K+$0PM/"4O:895:F/K8BKA\/0P,,/+$5L5B\'@X)8G%T
M8/*IX.\=TW5C_9V#J2HR2J1I9OEM6<8\BJRKRC3J-1PM*DJ]:OBI35*EA\+B
ML0^>C0J2C^--*&*D%25=2&5UR'0J0058?=.<<CGCBOVW_P"";'P4^!WCOX.J
MWQ.^ OASQ?XT^)_[1-A\(/!GQ/\ B?\ #GXT?$_X.^+EG\(:"P^!%CXI^ 'C
MW3O&/[+GQ1N=8\2#Q+_PNCQ9\-_%GAB+P]=V-Q:B_30=5BTOR_4?^";?AVW\
M"/<3_$7Q=H'Q>N?@+^UU\=H?"UWX0T#5O@MH-O\ LA?%GQ?\/?&G@K5?C;'X
MSLM0O;S6[3PL3H_B^#P N@Z?J=UHL^N6\.G^,-)CMM*WB?P]A,^S7(<QACL!
M5RW'1P-+&*BL?0S!QBGB\;A8Y4\57HY?@)K_ &G'UIIX5*$Z^$P>(E3PQ5#P
MFXDQF2Y9GF5U\OQ]/'X>KB:N'56>#J8"*K5J6%H8FICH4Z%3%9@J-26&PL(1
MC5BIQCBZ\:.+GA/G?PU^WW\8=!O/#*ZKX(^!/C[PQH7[,?P__9-U/X=_$3P-
MXEU_X?\ CSX6_"_QU>?$CP5?^-M-L?'FCZ]<>.=(\9W":W'X@\.^(O#&GM)9
MV4#>'_)6Z2?H_$G_  4Q_:9\8^"OBYX0\3GX4ZUJ/Q>N?C-'??$BZ^'S1_$[
MP#X5_:'U7PWJOQM^'7PMURUURWT+PQX%^(I\*Z=9:U9:CX9\0Z_;V4^IG2/$
MNF7M\]XOU9I'_!)[P3K/Q7UOX5P_'+Q]I[?##XX>)/V?OC1XCUWX,Z?I=@OC
M'1?V9OBW^T/:>(O@Y9?\+,E?QOX>>3X2:GH%YH?B:Y\#^)!X8\0>$_B"DS:3
MK]O:P4/AO_P3#^$GQ*UWP9<6G[1WB7PYX.^+'P4_9V^*7PQC\6?#KP;X6\4:
MCK?[0'C_ .*_PU3P+?:]XA^*VE?!\^*= UGX3WU]X9\&P_$VV\5_%6#719^"
MM.:\\.ZBD_Q>(XC\$X-X_$Y;'VE"A@LT^L?V#G]6<(4ZU7/<!7A4HU*T%6Q4
M\3'-Z=6EA_:9ME];#U\RJ?5L'ALMP_V5/AOQMH16!I9I5HJ=3$X+ZM'/LBIO
MVE7"4\LQM&2JPNJ>'H8..75'4K*&!Q-)K!VJU9X^K^6_C[XQ^*_B+\/?@G\,
MM=L_#</AGX">$O%W@SP5/I.GW]KK&H:1XV^(GBCXFZS+XKN+K5]0LM1U!/$7
MBW5;:RFTG3M M(M%6ULKJPO+J.XU*]]$\+_MB?M!:'\>OA-^TCXF\?:[\9/B
M?\%=2TC4/ U]\;_$7C+XBV=K:Z'>WNHV&@737WBFQUU?#4=]J5_=_P!D:3KV
MCQK<7EQ+#<0,[+)]6I_P3DL+/P3=V6O?$CQ7I?QQ@_9P^.7[4K^''^&NF'X3
MZ-X%^ ?Q0\0_#+Q7X"\3?$6/Q])KVE_%*YG\*:O<W$(\$7'A;PQXCO\ PQX
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M5?\ A>>)?_DBOWS_ (G$X#_Z)WBK_P $8/\ ^7'X5_Q*#QA_T5'#O_@G,O\
MY6?YYN]/[R_]]#_&C>G]Y?\ OH?XU_H9?\.7OV"/^B<>*O\ PO/$O_R11_PY
M>_8(_P"B<>*O_"\\2_\ R11_Q.)P'_T3O%7_ ((P?_RX/^)0>,/^BHX=_P#!
M.9?_ "L_SS=Z?WE_[Z'^-&]/[R_]]#_&O]#+_AR]^P1_T3CQ5_X7GB7_ .2*
M/^'+W[!'_1./%7_A>>)?_DBC_B<3@/\ Z)WBK_P1@_\ Y<'_ !*#QA_T5'#O
M_@G,O_E9_GF[T_O+_P!]#_&C>G]Y?^^A_C7^AE_PY>_8(_Z)QXJ_\+SQ+_\
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M.-73/V@OCOHFN>.O%&B?'?XVZ'XJ^)Z/#\2_$^B?&#XA:3XA^(]O)')"]O\
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M3?%MO?\ B?5=$TNRL=*T?4]=N-0O--TVQLK&QEMK:VBC7*T3]H;X^^&9?/\
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M-?Z&7_#E[]@C_HG'BK_PO/$O_P D4?\ #E[]@C_HG'BK_P +SQ+_ /)%=/\
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M1110 4444 %%%% !1110 4444 %%%% !114<LBPQM(P)"@<#&3D@ #.,DD@
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M<QK5?91O[.<TU)-QM[MU9-W:ZOHGUN>,0_ZJ/M\@Z]LLYP?<9P1V(([5+35
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MG:FN=^T@I1IUWRSJRJQE"I&LY3BTJBJTO;S4$H3EAJ*DI0HTX+^.;]H#X?\
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MFM&-2O6<E3C*M6HPHTTW%KFJ3C%:;MV/Z'J*122 3U(!/U(I:_'#]@"BBB@
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M>./#7[:?CSXRO\/9-.\/?"WXZ^(=*TK]FW1/A5\<?C_K?A+X??#3P#8>+?\
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M4>:<IN5G3FW+F:E*<FK14$BBBBF:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6!XH4'0-:)&=ND:J1R<9^P3]1T..HR#@X(P0#6_6#XG
M_P"1?UO_ + ^J_\ I!/4S^%^G=KJNJ:?W- M7%-)IS@FFDTTY*Z::::?9IH_
MRA;0 6=FO4"U@ W?,0 @P,MD_7G)/)R>:L<?W5_[Y7_"H+7_ (]+3_KVA_\
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MM.=1-6T<ZE]4FO\ EYVE%Z-K71M:LX_NK_WRO^%'']U?^^5_PHHI\TOYI?\
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MFE-S2:[VOYG]Y@&  .@&!WZ>YY/XT445_D*?ZV!1110 4444 %%%% !1110
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M'3-.T?P?J%OHG]#/[,/[=WP*_:F\2>*? 7A;3?C3\+_C%X(\/:+XO\5_ O\
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M\1Z?8>-_AS\+]=_0_P#X(A?"_2?A[+^T;;>!]'^+6K_#:VM?A+I>B_M ^+_
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MPRJ2MSW2B^=.HXUJ;FJE2G.G%>UE*495W.=-PDG7O74N11Y/K5=PNG%'\/\
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M1?VG/CCXNO\ XV_"6"S\%^ /$7@OXI_%+X"^(I/B1^T'XM\*?#3X;?\ "/\
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MO9T5+_6[B9W5*"DFN(<^L[I73NDT[W32['^NG!<IK@OA!*<[/A7AV_*VDO\
MA!R2Z:CHUJ[W[ONV^G\'^+-4\$^)--\2Z45>ZL)&2XMG<10ZGIT^Q;_3;IPI
M*QW4:+Y<V6%K=1VU[Y,SVJ1O^%O_  <A^(=,\6?%7]DKQ'H\IET[5OA#X[N(
M"X EB=?%VD0W-I<*I98[NRN(I+6ZC!VI/&Z(65=U?M8>#GG #=/8 _AP#C/4
MX Y(!_G_ /\ @O!HNI:'XF_9174[2"W;6?A_\2/$-@Y>_-\=,O\ Q'X9@M8K
MF*6Z?3H8)!9MJ5HEM:17Q749&O;J6%K*QTW]"^CU2A_Q&3A.MM4^J<203O\
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M5C%\9?"/Q3\&^'6_:"\)_"3P!X)\0?$0Z-X+U_X<:+J\'Q0\ Z1\*_$/Q/\
M@3+8W'PSUN&#PIXKTSPMX>T_6VFU7\JKN<W=S<76V*-KBXFN)8;:!;2SADN)
M'E,-I:1DQ6MK%DQV]K'MCMX42*,"-0J_OOK/[3G_  3^UOX:WO@G4-;^$>H_
M#O3->^*WB;5?A-=?LZ^-Y?&/B;4O%W[ O[/?PY\.W/P,\<3_  B&F?"/QNG[
M5?@#5]8U[Q>WB7X:75[%H5]XFOO$E_H5_9Z;XT_ %48)&'<%]D2%L;(Y953;
M*ZL0$"JX(4;V"*0FY\;S^B>&ZPRAG,:7!^-X.EA*V%PSIU*F:4LJQ6'=2O\
M5UE^"S7$PP^75*#PL?[0^H4<1AJM.KDV&AF+>&H82E^>>)<,9.ED=6KQ;@N+
M7B:6(Q$_81RNMC\%B73PTL13Q.*R^E/%8S#SGB*E/ +&5*&(I3I9G5> C[6K
MBJJ44X*6) P2 Y.&7I&C.Y!S@@*K$$$AB,+EL"@J1G...N&4CJ!P02&Y8=,\
M9/0$C]1335TTTY.*::=Y*S<59N[LT[*^C7='Y*X32NXR2LG=Q:T<N5-W6B<D
MXZVUT&U^XG_!O9_RD8T;_LAOQ6_]'^&Z_#L@CK7[B?\ !O9_RD8T;_LAOQ6_
M]'^&Z_,?&K_DTOB'_P!DKF??MA.Z3_!'Z3X.JWBAP.G_ -%'E_\ Z56/[S**
M**_R&/\ 6T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9(
MNZ-EXY&.>!^-?EG^V_#XJ^&G[1/[%G[6.L?"[XD?&7X+?L_ZA^T'X=^(GASX
M,>!_%7Q6^(OPN\5_'7P5X/\ !_P]_:3TOX3^"]+U;QOX\TKX=^'=%^)OPI\6
M0?#SP_XH\=Z!X9^/NK>(].\.ZAX=TKQ9+9_J<PW CU]1GWZ4SRP"#QE=VTXY
M ;!QGKC*@^^ #T%3[T9TYQ47R3Y[37-'2GB:3BU=64H8NI[T)1G&<*4TTX*X
MG;VFC?M*,J+V249RA)RB]6IPE3C)-IIK1J2<HO\ FO\ VL],^-'[=5_\:/C)
M\,_@K\;?AA\(?$7[*EY_P3$^$^N_$KX+>+_A_P#&GXMW'_!0_P#:D_9O\+?'
M_P"/=O\ "/QKI5E\3O!7P-_9S^%_@?2/$6BZ[\8?!G@J;6[W5/B=XFDT72?!
M'AFT\3^(?B__ (*Q_LSR>&O$GQI^$OPC_9*\6:WX3^%_[/WB#XV?L]6*_LI_
MM_?MP7W[3'[3?Q/_ .%C^)/C#\6H?BU\*OVC_A;\&_@G^T/X+U/PQX L;SXV
M?M#W7Q2_:&E34-/OOAG#?Z=J-AX$\;?V0>6,DG:2>,[<''.1D'N#@Y_^M33%
MCA"L8.20$ZDDG)^8<Y))XY))ZFL73:=H1<8N4>:<9S]K-PIU(TYRJ.JI.=&M
M7Q5>E)*G)5:W/*\Z<)E<S;YIOGFDE%R^&/+.$HM)*ZO""HR5VO95*\(1@JMX
M_E5^P3\+/BAH?QF_:X\:_%2^\:^(-?\ #FG?L>_L=^'_ !_XZM?$=OJ/Q6\%
M?LQ?LR>&OB#KOQ0TS5O$.GV=YXLL_$W[0W[3_P"T%87GBJ-[NSUC7O#VJR"\
MENHKF.*[\8=&\?\ B?\ X*.?#_Q7HOPO\3>+_#'[)_["/[1'CSPSYB7N@>%/
M'GQ[_:1^(WPY\(^!/ V@>.=2L&\*Q>,]*\ _L_\ Q-TS6X3=2W_A30_B[H&H
MZU;0:+XELY;O]25C('+ GGG;C@]NIZ$DCW)-*(EP 0IYS]TXSS@XW=1D\^Y]
MZJI[:HW5C:A6M7G2=)1I_5ZU>AF4(UHPII4U*A4S2M4A3O4I<].$O>]G3,H4
MX*#I3C[:G*G2HSC4;DZE*DLOBZ<[<G/"LLO2JN7OSC7KQDU[64H?Q*_LV^&/
MVF?!7QRU3]K?P!\(?C/:_&"R_8&_;<^.OQKETO\ 8@_X*"? GQM\3OVG(_ W
M@&Q^'/[(OQ*^+7[6OQ[^*6K_ +7GBCPW\3?B#+J_P_G\/?#7P#X \/7/PYB/
MP:OE\,:?J_@SP-ZUX;_9A/@+X.?$KP_^P[^SS^V=\/D@_P""6U]^P'^T#XW^
M-G@?]H7P=XN^.?[5OQO\1?LU_L[_  "UB/P)\0'E?QZ_[&OA+3OC?K7C/XW?
M##0I/@C\*_ASX\TOPQ\)O'NJ_##3-0L?"']AYC)_B&/]T$\9QR3VR..G!]>
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M7-)N4INHHHI%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5@^)_^1?UO_L#ZK_Z03UO5@^)_^1?UO_L#ZK_Z
M03U,_A?]=4-?%#_'#_TN)_E#6O\ QZ6G_7M#_P"@"IZ@M?\ CTM/^O:'_P!
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M_N#_ .(<O]AO.?\ A)OC?GV\:6 ![<@:%@_B#BE_XAS/V&_^AF^-W_A9Z?\
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M?L.?]#-\;O\ PL]/_P#E#1_Q-SX4?] _&G_B,T__ *(0_P")4?%#_H)X/_\
M$@K_ /S@/L7_ ((X?\HS?V4/^Q2\4_\ JT/&U?J/7@W[-OP \$_LQ?!3P%\!
MOA]+K,_@KX<Z;>:9H$OB&_34M9D@OM:U+7KF34+Z*WM$GFEU'5;N1=EM!'#
M8+:-/W+/)[S7^>?%69X;.^+.*L[P2JK!9QQ'G6:815X>SK+#8_-,PQM!5J:E
M-0JJEBZ2J1C.<8U%.*G-14I?Z \*Y9B<FX:X>RC&.F\7E6191EN*=&?M*3Q&
M!P&%PM9TYN,7*FZE";A)QC*4'%N$6W%07'W!_OK_ %K^-[_@YH_Y+E^RY_V2
MOQ]_ZEFB5_9)*H90"<?,#^0..I'?K[5^:_[<'_!,']G_ /;T\5>!_%GQDU3Q
M]IVI?#[0]6\/:$/!VO6^DVLFG:S?VVI77VZ*XT^^,]P+BUA\F5&A"1ET9920
MT?V/@WQCE' /B-DW%6?1QLLKR["9Q1KQR[#1QF,E/,,JQ&"H>QPTL1A544:U
M2+JWQ%-QI\TX\[CR/Y+Q@X1S;CK@'.>&<DE@XYCF%7*YT9X_$2PN$C'!9C2Q
M=7VV(CA\2X<U*#C3Y:%3FJ6C)03YE_G-T5_<)_Q#F?L-_P#0S?&[_P +/3__
M )0T?\0YG[#?_0S?&[_PL]/_ /E#7]M_\3<^%'_0/QI_XC-/_P"B$_BO_B5'
MQ0_Z">#_ /Q(*_\ \X#^'NBO[A/^(<S]AO\ Z&;XW?\ A9Z?_P#*&C_B',_8
M;_Z&;XW?^%GI_P#\H:/^)N?"C_H'XT_\1FG_ /1"'_$J/BA_T$\'_P#B05__
M )P'\1VB:QJ?AW6M&\0Z)+'!K.@:MINN:1-*N^*'5-(O8-0T^65,C?&EW;0L
MZ$J&4%20#D?H3\;_ /@H3XG\=W/[0/ACP)X+\-Z?\)_CCJG[5]P;3QKIFKR?
M$+1-/_;+^(GP5^+WQ5M#J?A_QT/#LMWX7\;_  5T#1_AUJJ:2D(\)W.IW/B'
M0KC6=5LXO#?]-!_X-S/V&R"/^$F^-W/''C33P?S&A9'U'-!_X-S/V'"2W_"3
M?&[) !_XK/3\8'3C^P<9]\9/<UXF9?25\#LXQF#Q^9Y7QCC*V I2I8>G6X:C
M+#K_ &[!9G2JU*,>)J4:E7"X[ 4*^'=1U*<7.LJE"M";@_?RGZ/'C9D6&Q6%
MRC..$\##%UZ5>M4HY]/VSE3PV)P;A&=3ARM&-.MA\74IUH^R;ER4FIQE3C*/
M\X0_X*W?M(-XMUKQF_@_X2P:OX@UKX[:AJ<N@W'QV\#77]B_M$ZM\/\ Q+\0
M_!^F^(/AY\=?"/B_0='7Q?\ "[P1XJ\.ZYH/B/3/B#HU_I$VE?\ ":W7A75]
M9\/7_B^L_M]_&?7KWPMJ&HZ'X$N[SPEX-_:W\"V-WJ;_ !,\1ZEJ.B?ME/XQ
M'Q'E\0:[XM^)GB#Q%KVK^%+3QMJ5A\.]6U+6)[RTM;+2W\:R>.KZ*\O;[^J7
M_B',_8;_ .AF^-W_ (6>G_\ RAH_XAS/V&_^AF^-W_A9Z?\ _*&O)PWCQ]'+
M!U?;X;A'B"C55*%#VBX6JRG["G2E0A1YJO&-9^R5&<J3I\W)*%HSA/E@X>Q4
M\&?I%U?XG&61R?MWB+_ZQ4E+VSQ>&QSJ<T>#H-N6-P>%Q4D[PGB,/2JSC.4=
M?YEM#_X*<_&_0?!?Q#\$6GP\^"1M/B9\.M.^%GB36X])^*6E>(9O!VE_LR^&
M?V5+/39[GP]\6]&TWQ##9^ ?"UEXGT>R\:Z5XITCPK\2]1\0>+?".F:"FN7V
MF.[6?^"G/QI\0ZCXLN=9^&?P+O\ 1_B-JOQ-U/XH>$I-(^*T7A_XC0_&'X/>
M /@S\0-)UJ:V^+\'B;0--UC1_AGX3\5VC?#WQ%X+U/0O'%I-J>AZE8://_8"
M?TS_ /$.9^PW_P!#-\;O_"ST_P#^4-'_ !#F?L-_]#-\;O\ PL]/_P#E#4_\
M1U^CA[:MB%PCQ$J^(FJE:M'AK%QJ5*D524)RDN.+J5/V%&5)Q]G[&=*E4HJE
M5IPJ1F'@M](BG3I4H\7</JG0I4Z-*+SW"S4*5**A3IISX)G)PC",::4IRO37
MLY.<&XO^776_^"C7QQUZ\@N;KPK\)+:'3KGXQ+H&FZ=X>\7V>G^&O#_QD_9;
M\)?L>WG@_157QX]XOA[P+\&_ _AN#P'+J5[J7B./Q/9S:_XR\0^,FO+FTDZG
MXF?\%/?C=\6/ ]U\.-;^'_P1\,^&;[X;?$_X4(O@[0/B=;Q^'/"WQ@\/?##P
MSXP?P;X9U;XQWO@WPH+2U^$WAG5/#7A3PSHWA[X?Z/K-SX@GM_#,,6NW0C_I
MA_XAS/V&_P#H9OC=_P"%GI__ ,H:#_P;E_L-D$'Q-\;L$$'_ (K33P<$8X(T
M'(/H1@CJ#FJ?CS]'13PU:/"?$2K8*<JN#FN&:\7AZKC3O4IWXSG34Y2HTIRG
M4HUG*JI5I^TJU<1/%4_!CZ14E.,^,<BE"K3I4*J?$%&2E0H\L:5-K_4V#Y*4
M(PA3A&<%&G2HTHM0HT%0_D"_:M^-&G_M"_M!?$WXN:)HVH^'_#/B36=*TOP9
MHNM-:/K^E^ / OA70?A[\/;3Q&VG3W.F_P#"1?\ "&>%=&F\0KIUS>:>-<EU
M 6-[>6@BNIOGBO[A6_X-SOV'79G;Q/\ &\L[*S8\::> 2BE5^4:"%  )R  "
M>2"0"$_XAS/V&_\ H9OC=_X6>G__ "AKZ3+OI4>#N49?@LKP&%XXC@LOPM#!
MX6-7AVG5J1H8:G&A14ZCX@CSS]E2ISJ3<5*=:MB)2;;BU\OF?T8?%C-LPQF9
MXK%<&/%8_$5<5B/9YY5I4E5K>R<H4H+(I<M*FJ5.E2BY-QI4:2NWS.?\/=%?
MW"?\0YG[#?\ T,WQN_\ "ST__P"4-'_$.9^PW_T,WQN_\+/3_P#Y0UV_\3<^
M%'_0/QI_XC-/_P"B$X/^)4?%#_H)X/\ _$@K_P#S@/X>Z_<3_@WL_P"4C&C?
M]D-^*W_H_P -U^X'_$.9^PW_ -#-\;O_  L]/_\ E#7U-^Q__P $@/V8OV+?
MC#%\;OA1JWQ-OO&5MX7UOPC;IXI\46>I:0FF>(7M&U&1["+1[-Y+@_88?(E^
MTXB)8E)% 0?&>(GTF/#?BO@3BWAO*Z7%4,QSK(\9E^#>.R&.%PJKXCV"@Z^(
MCF^+]E37LY.<W2=E:RD_=/L/#_Z-_B%POQKPSG^9XCAB6 RK-\+C<4L)G53$
M8ET:#J2FJ-"64X7VM1J2Y8JJKO>RU/UFHI!G SUP,XZ9[]A_(?2EK^"3^\0H
MHHH **** "BBB@ HHHH **** /QD_P"'S?@+_HQ;_@IS_P"(LZ9_\\^C_A\W
MX"_Z,6_X*<_^(LZ9_P#//K]FZ^)OV@_VG/'GA3XC_P##._P%^&MGXX^-US\.
M-/\ BSJGBCX@Z[!X.^!GPI^&^I:_XC\+P>-?B)XCM;FX\5ZJT>N>%]3C@\'^
M#]!O-3U&RM[BZGU72H(@TWUG]K<)?]$9B?+_ (S3/7JVDMLF;W:V3]-#X1Y'
MQRDV_$/#I)-MO@+A^R23;;_X7]DDV_)/L[?'W_#YKP&.O["W_!3H?]VLZ9_\
M\ZC_ (?-> ST_86_X*='_NUG3/\ YYU5OV-/^"D/CCXG_##X%?%;XC:9I'Q>
M^!/[2OCZ#X9?!S]I7X2:(WA"2S^(&H>/=8^'<?@CXV_!7Q1KT^L^!;B#QAH&
MMZ;I?BWP?J_C'1=0T>WT.[U&ST^ZU.[FA[+XU_\ !6SP%X0^.7CS]FW]G/\
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MX"_Z,6_X*<_^(LZ9_P#//H_X?-^ O^C%O^"G/_B+.F?_ #SZ_9NBC^UN$O\
MHC,3_P")IGG_ ,YP_L+CK_HX6'_\0+A__P"?Y^,G_#YOP%_T8M_P4Y_\19TS
M_P">?1_P^;\!?]&+?\%.?_$6=,_^>?7[-T4?VMPE_P!$9B?_ !-,\_\ G.']
MA<=?]'"P_P#X@7#_ /\ /\_&3_A\WX"_Z,6_X*<_^(LZ9_\ //H_X?-^ O\
MHQ;_ (*<_P#B+.F?_//K]FZ*/[6X2_Z(S$_^)IGG_P YP_L+CK_HX6'_ /$"
MX?\ _G^?C)_P^;\!?]&+?\%.?_$6=,_^>?1_P^;\!?\ 1BW_  4Y_P#$6=,_
M^>?7[-T4?VMPE_T1F)_\33//_G.']A<=?]'"P_\ X@7#_P#\_P _&3_A\WX"
M_P"C%O\ @IS_ .(LZ9_\\^C_ (?-^ O^C%O^"G/_ (BSIG_SSZ_9NBC^UN$O
M^B,Q/_B:9Y_\YP_L+CK_ *.%A_\ Q N'_P#Y_GXR?\/F_ 7_ $8M_P %.?\
MQ%G3/_GGT?\ #YOP%_T8M_P4Y_\ $6=,_P#GGU^S=%']K<)?]$9B?_$TSS_Y
MSA_87'7_ $<+#_\ B!</_P#S_/QD_P"'S?@+_HQ;_@IS_P"(LZ9_\\^C_A\W
MX"_Z,6_X*<_^(LZ9_P#//K]FZ*/[6X2_Z(S$_P#B:9Y_\YP_L+CK_HX6'_\
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MJOBGP9XFT[P7XCU2V^$OQ:;X<6GB[4?"&O\ CI_#EG\8&\$?\*HU?5-#\/\
MAVZ3Q=#I/C2]A\&>(]0\/>"/%5QI'C?Q1X9\.:PEF_!]U!<&UTVI-)<:YVE[
MK2EMDZ5TY)./Q7>JN]4\CXZU;\0:#2:BW_J%P^VVTVM/[?;::C+7;W7KH^7\
MVO\ A\O\/_\ HQ3_ (*<?^(LZ9_\\^C_ (?+_#__ *,4_P""G'_B+.F?_//K
M]7= ^)_@WQ+X_P#'WPRT;5C?>,?AC8>#=0\;Z='IVK1VVB1>/[76+_PK;/K,
M]C%HE[J=]IVAWFHW6D:;J-YJFCZ?/H]]K-I86GB#0I=0[X2(R[E=&&=H(8%2
MQ. N1D9)(&.3DXQFG_:_"%[?ZG5[VO\ \EMG>W?_ )%&WGMYC_L+CGKXA89>
MO /#Z[=\_6NJOZKNK_C)_P /E_A__P!&*?\ !3C_ ,19TS_YY]'_  ^7^'__
M $8I_P %./\ Q%G3/_GGU^K/ACXI>#O&?_"&3>$]7B\4:5\0?!][X^\'^)O#
M=GJVM>#-=\(V-SX;MFUBT\;V&G3^$8_[0_X2S1+OP]IUWK5OJOBG2I-1UGPU
M9:KI?A_Q%=:3/JGQ,\'Z-\1_!WPGU'4YH_'7C_PWXY\7>%=%@TO5[P7OAOX:
MW/@FQ\:ZM>:G9V$^C:-:Z/??$;P38H-9U&PN-3N_$%K!I=O>&&Z,+_M;A+;_
M %,Q-^W^NF>WVOM_8U]DWZ)O9-A_87'/_1PL-_X@7#W9/_H?]FGZ-/9IO\G_
M /A\O\/_ /HQ3_@IQ_XBSIG_ ,\^C_A\O\/_ /HQ3_@IQ_XBSIG_ ,\^OV>H
MH_M;A+_HC,3_ .)IGG_SG#^P>.?^CA8?_P 0'A__ .?Y^,/_  ^7^'__ $8I
M_P %./\ Q%G3/_GGT?\ #Y?X?_\ 1BG_  4X_P#$6=,_^>?7[/44?VMPE_T1
MF)_\33//_G.']@\<_P#1PL/_ .(#P_\ _/\ /QA_X?+_  __ .C%/^"G'_B+
M.F?_ #SZ/^'R_P /_P#HQ3_@IQ_XBSIG_P \^OV>HH_M;A+_ *(S$_\ B:9Y
M_P#.</[!XY_Z.%A__$!X?_\ G^?C#_P^7^'_ /T8I_P4X_\ $6=,_P#GGT?\
M/E_A_P#]&*?\%./_ !%G3/\ YY]?L]11_:W"7_1&8G_Q-,\_^<X?V#QS_P!'
M"P__ (@/#_\ \_S\8?\ A\O\/_\ HQ3_ (*<?^(LZ9_\\^C_ (?+_#__ *,4
M_P""G'_B+.F?_//K]GJ*/[6X2_Z(S$_^)IGG_P YP_L'CG_HX6'_ /$!X?\
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MC,3_ .)IGG_SG#^P>.?^CA8?_P 0'A__ .?Y^,/_  ^7^'__ $8I_P %./\
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MLZ9_\\^C_A\WX"_Z,6_X*<_^(LZ9_P#//K]F^O2BG_:W"7_1&8G_ ,33//\
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MS:5XAUBZUC2I_&7]B:E-?6=@GP]M_@=^QS^S5\&/!?[,/PVU"^^"FLZG</\
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MN<90P]>%&I)<TE]7A.-[._AW_!/?X3?\% /"/A[X1>*OVA?VO?A)\8O@?=?
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M9[:&6XL)+FW>TN)+*:1&DM7GM99+:9X&C:6WD>%RT;LIN444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
